TARGETID,GENENAME,,,Disease Entry, [ICD-11]
T00033,TGFA,TARGETID,T00033,,
T00033,TGFA,TARGNAME,Transforming growth factor alpha (TGFA),,
T00033,TGFA,INDICATI,Phase 1/2,Chronic kidney disease,[ICD-11: GB61]
,#N/A,,,,
T00039,CTGF,TARGETID,T00039,,
T00039,CTGF,TARGNAME,CTGF messenger RNA (CTGF mRNA),,
T00039,CTGF,INDICATI,Phase 2,Fibrosis,[ICD-11: GA14-GC01]
,#N/A,,,,
T00043,#N/A,TARGETID,T00043,,
T00043,#N/A,TARGNAME,HUMAN cyclin G-associated kinase (GAK),,
T00043,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T00043,#N/A,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T00099,#N/A,TARGETID,T00099,,
T00099,#N/A,TARGNAME,HUMAN calpain-1/calpain small subunit 1 heterodimer (CAPN1/CAPNS1),,
T00099,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T00100,#N/A,TARGETID,T00100,,
T00100,#N/A,TARGNAME,Ubiquitin-activating enzyme (UBA),,
T00100,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T00140,ALOX5,TARGETID,T00140,,
T00140,ALOX5,TARGNAME,Arachidonate 5-lipoxygenase (5-LOX),,
T00140,ALOX5,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T00140,ALOX5,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
T00140,ALOX5,INDICATI,Approved,Asthma,[ICD-11: CA23]
T00140,ALOX5,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T00140,ALOX5,INDICATI,Phase 2,Carcinoid syndrome,[ICD-11: 5B10]
T00140,ALOX5,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T00140,ALOX5,INDICATI,Discontinued in Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T00140,ALOX5,INDICATI,Discontinued in Phase 2,Eczema,[ICD-11: EA80-EA89]
T00140,ALOX5,INDICATI,Approved,Filariasis,[ICD-11: 1F66]
T00140,ALOX5,INDICATI,Phase 2,Fungal infection,[ICD-11: 1F29-1F2F]
T00140,ALOX5,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T00140,ALOX5,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T00140,ALOX5,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T00140,ALOX5,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T00140,ALOX5,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T00140,ALOX5,INDICATI,Discontinued in Phase 1,Osteoarthritis,[ICD-11: FA00-FA05]
T00140,ALOX5,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T00140,ALOX5,INDICATI,Phase 2,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T00140,ALOX5,INDICATI,Phase 3,Postoperative inflammation,[ICD-11: 1A00-CA43]
T00140,ALOX5,INDICATI,Discontinued in Phase 2,Pruritus,[ICD-11: EC90]
T00140,ALOX5,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T00140,ALOX5,INDICATI,Withdrawn from market,Respiratory system disease,[ICD-11: CB40-CB7Z]
T00140,ALOX5,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T00140,ALOX5,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T00140,ALOX5,INDICATI,Phase 4,Thrombocytopenia,[ICD-11: 3B64]
T00140,ALOX5,INDICATI,Discontinued in Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T00145,#N/A,TARGETID,T00145,,
T00145,#N/A,TARGNAME,HUMAN pH-dependent viral fusion/replication (pH-DVF/R),,
T00145,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T00145,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T00145,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T00145,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T00156,TRPC5,TARGETID,T00156,,
T00156,TRPC5,TARGNAME,Short transient receptor potential channel 5 (TRPC5),,
T00156,TRPC5,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T00156,TRPC5,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
,#N/A,,,,
T00158,#N/A,TARGETID,T00158,,
T00158,#N/A,TARGNAME,HUMAN glycosylation of host receptor (GHR),,
T00158,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T00158,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T00158,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T00158,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T00176,MDM2,TARGETID,T00176,,
T00176,MDM2,TARGNAME,Ubiquitin-protein ligase E3 Mdm2 (MDM2),,
T00176,MDM2,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T00176,MDM2,INDICATI,Investigative,Breast cancer,[ICD-11: 2C60-2C6Y]
T00176,MDM2,INDICATI,Phase 1,Liposarcoma,[ICD-11: 2B59]
T00176,MDM2,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T00176,MDM2,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T00176,MDM2,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T00176,MDM2,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T00176,MDM2,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T00176,MDM2,INDICATI,Phase 2,Neuroendocrine carcinoma,[ICD-11: 2C34]
T00176,MDM2,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T00176,MDM2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T00216,#N/A,TARGETID,T00216,,
T00216,#N/A,TARGNAME,HUAMN alpha-1 adrenergic receptor (ADRA1),,
T00216,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T00216,#N/A,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T00238,NFKB2,TARGETID,T00238,,
T00238,NFKB2,TARGNAME,NFKB messenger RNA (NFKB mRNA),,
T00238,NFKB2,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T00239,IL4,TARGETID,T00239,,
T00239,IL4,TARGNAME,Interleukin-4 (IL4),,
T00239,IL4,INDICATI,Investigative,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T00239,IL4,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T00239,IL4,INDICATI,Phase 1,Atopic eczema,[ICD-11: EA80]
T00239,IL4,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T00239,IL4,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T00239,IL4,INDICATI,Phase 3,Pulmonary eosinophilia,[ICD-11: CB02]
T00239,IL4,INDICATI,Phase 2,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T00254,NR1D1,TARGETID,T00254,,
T00254,NR1D1,TARGNAME,V-erbA-related protein 1 (NR1D1),,
T00254,NR1D1,INDICATI,Preclinical,Cardiomyopathy,[ICD-11: BC43]
T00254,NR1D1,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
T00254,NR1D1,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T00259,#N/A,TARGETID,T00259,,
T00259,#N/A,TARGNAME,HUAMN eIF4E-eIF4G interaction (eIF4E-eIF4G),,
T00259,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T00259,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T00419,TNNC2,TARGETID,T00419,,
T00419,TNNC2,TARGNAME,Fast skeletal muscle troponin complex (TNNC2),,
T00419,TNNC2,INDICATI,Phase 3,Motor neuron disease,[ICD-11: 8B60]
T00419,TNNC2,INDICATI,Phase 2,Muscle disorder,[ICD-11: FB32-FB3Z]
T00419,TNNC2,INDICATI,Phase 2,Muscular atrophy,[ICD-11: 8B61]
,#N/A,,,,
T00420,HIV rev,TARGETID,T00420,,
T00420,HIV rev,TARGNAME,Human immunodeficiency virus Rev protein (HIV rev),,
T00420,HIV rev,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T00477,SRR,TARGETID,T00477,,
T00477,SRR,TARGNAME,Serine Racemase (SRR),,
T00477,SRR,INDICATI,Investigative,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
,#N/A,,,,
T00484,IL23R,TARGETID,T00484,,
T00484,IL23R,TARGNAME,Interleukin 23 receptor (IL23R),,
T00484,IL23R,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T00484,IL23R,INDICATI,Investigative,Indeterminate colitis,[ICD-11: DD72]
T00484,IL23R,INDICATI,Phase 3,Postoperative inflammation,[ICD-11: 1A00-CA43]
T00484,IL23R,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T00494,ABCA1,TARGETID,T00494,,
T00494,ABCA1,TARGNAME,ATP-binding cassette transporter A1 (ABCA1),,
T00494,ABCA1,INDICATI,Approved,Coronary atherosclerosis,[ICD-11: BA80]
T00494,ABCA1,INDICATI,Investigative,Dyslipidemia,[ICD-11: 5C80-5C81]
T00494,ABCA1,INDICATI,Discontinued in Phase 1,Inborn lipid metabolism error,[ICD-11: 5C52]
,#N/A,,,,
T00496,PAWR,TARGETID,T00496,,
T00496,PAWR,TARGNAME,Prostate apoptosis response-4 (PAWR),,
T00496,PAWR,INDICATI,Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T00523,SLC2A9,TARGETID,T00523,,
T00523,SLC2A9,TARGNAME,Glucose transporter type 9 (GLUT9),,
T00523,SLC2A9,INDICATI,Phase 2,Gout,[ICD-11: FA25]
T00523,SLC2A9,INDICATI,Discontinued in Phase 2,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
,#N/A,,,,
T00663,MAPK10,TARGETID,T00663,,
T00663,MAPK10,TARGNAME,Stress-activated protein kinase JNK3 (JNK3),,
T00663,MAPK10,INDICATI,Investigative,CNS birth injury,[ICD-11: KA40]
,#N/A,,,,
T00749,MAP4K1,TARGETID,T00749,,
T00749,MAP4K1,TARGNAME,MEK kinase kinase 1 (MAP4K1),,
T00749,MAP4K1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T00750,FUT3,TARGETID,T00750,,
T00750,FUT3,TARGNAME,Galactoside 3(4)-L-fucosyltransferase (FUT3),,
T00750,FUT3,INDICATI,Phase 2,Fallopian tube cancer,[ICD-11: 2C74]
,#N/A,,,,
T00852,MAP3K8,TARGETID,T00852,,
T00852,MAP3K8,TARGNAME,Serine/threonine-protein kinase cot (COT),,
T00852,MAP3K8,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
,#N/A,,,,
T00884,CXCR1,TARGETID,T00884,,
T00884,CXCR1,TARGNAME,C-X-C chemokine receptor type 1 (CXCR1),,
T00884,CXCR1,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T00884,CXCR1,INDICATI,Withdrawn from market,Gout,[ICD-11: FA25]
T00884,CXCR1,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T00884,CXCR1,INDICATI,Phase 2,Liver vascular disorder,[ICD-11: DB98]
T00884,CXCR1,INDICATI,Phase 2,Medical/surgical procedure injury,[ICD-11: PK80-PK81]
T00884,CXCR1,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T00884,CXCR1,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T00884,CXCR1,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T00884,CXCR1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T00884,CXCR1,INDICATI,Phase 3,Transplant rejection,[ICD-11: NE84]
T00884,CXCR1,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T00890,HCAR3,TARGETID,T00890,,
T00890,HCAR3,TARGNAME,Hydroxycarboxylic acid receptor 3 (HCAR3),,
T00890,HCAR3,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T00890,HCAR3,INDICATI,Phase 2,Dyslipidemia,[ICD-11: 5C80-5C81]
T00890,HCAR3,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T00890,HCAR3,INDICATI,Clinical trial,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T00895,PRKCE,TARGETID,T00895,,
T00895,PRKCE,TARGNAME,Protein kinase C epsilon (PRKCE),,
T00895,PRKCE,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T00895,PRKCE,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T00895,PRKCE,INDICATI,Discontinued in Phase 1,Liver vascular disorder,[ICD-11: DB98]
T00895,PRKCE,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T00895,PRKCE,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T00902,NTF4,TARGETID,T00902,,
T00902,NTF4,TARGNAME,Neurotrophin-4 (NTF4),,
T00902,NTF4,INDICATI,Terminated,Central nervous system disease,[ICD-11: 8A04-8D87]
,#N/A,,,,
T00938,TYRP1,TARGETID,T00938,,
T00938,TYRP1,TARGNAME,Melanoma antigen gp75 (TYRP1),,
T00938,TYRP1,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T00938,TYRP1,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T00938,TYRP1,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T00938,TYRP1,INDICATI,Phase 2,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T00972,HIV gp120,TARGETID,T00972,,
T00972,HIV gp120,TARGNAME,Human immunodeficiency virus Envelope glycoprotein gp120 (HIV gp120),,
T00972,HIV gp120,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T01003,ERN1,TARGETID,T01003,,
T01003,ERN1,TARGNAME,Endoplasmic reticulum to nucleus signaling 1 (ERN1),,
T01003,ERN1,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T01003,ERN1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T01011,#N/A,TARGETID,T01011,,
T01011,#N/A,TARGNAME,Aurora kinase (AURK),,
T01011,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T01110,CSF1R,TARGETID,T01110,,
T01110,CSF1R,TARGNAME,Colony stimulating factor-1 receptor (CSF-1R),,
T01110,CSF1R,INDICATI,Phase 2,Bone/articular cartilage neoplasm,[ICD-11: 2F7B]
T01110,CSF1R,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T01110,CSF1R,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
T01110,CSF1R,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
T01110,CSF1R,INDICATI,Phase 1,Inflammatory arthropathy,[ICD-11: FA2Z]
T01110,CSF1R,INDICATI,Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T01110,CSF1R,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T01110,CSF1R,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T01141,#N/A,TARGETID,T01141,,
T01141,#N/A,TARGNAME,microRNA hsa-miR-191 (MIR191),,
T01141,#N/A,INDICATI,Investigative,Liver cancer,[ICD-11: 2C12]
,#N/A,,,,
T01232,#N/A,TARGETID,T01232,,
T01232,#N/A,TARGNAME,T-cells (T-cells),,
T01232,#N/A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T01232,#N/A,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T01232,#N/A,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T01232,#N/A,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T01232,#N/A,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
T01232,#N/A,INDICATI,Phase 1/2,Immunodeficiency,[ICD-11: 4A00-4A85]
T01232,#N/A,INDICATI,Phase 2,Immunoproliferative disorder,[ICD-11: 2B32]
T01232,#N/A,INDICATI,Phase 1/2,Low bone mass disorder,[ICD-11: FB83]
T01232,#N/A,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T01232,#N/A,INDICATI,Phase 1/2,Mature B-cell lymphoma,[ICD-11: 2A85]
T01232,#N/A,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T01232,#N/A,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T01232,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T01232,#N/A,INDICATI,Phase 3,Transplant rejection,[ICD-11: NE84]
T01232,#N/A,INDICATI,Phase 1/2,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T01271,BCR-ABL1,TARGETID,T01271,,
T01271,BCR-ABL1,TARGNAME,Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I),,
T01271,BCR-ABL1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T01280,BACE2,TARGETID,T01280,,
T01280,BACE2,TARGNAME,Beta-site APP-cleaving enzyme 2 (BACE2),,
T01280,BACE2,INDICATI,Clinical trial,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T01283,TSG101,TARGETID,T01283,,
T01283,TSG101,TARGNAME,Tumor susceptibility gene protein 101 (TSG101),,
T01283,TSG101,INDICATI,Phase 1,Influenza,[ICD-11: 1E30-1E32]
,#N/A,,,,
T01318,Malaria DHOdehase,TARGETID,T01318,,
T01318,Malaria DHOdehase,TARGNAME,Plasmodium Dihydroorotate dehydrogenase (Malaria DHOdehase),,
T01318,Malaria DHOdehase,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
T01318,Malaria DHOdehase,INDICATI,Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T01318,Malaria DHOdehase,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T01318,Malaria DHOdehase,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T01318,Malaria DHOdehase,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T01318,Malaria DHOdehase,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T01318,Malaria DHOdehase,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T01318,Malaria DHOdehase,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T01358,#N/A,TARGETID,T01358,,
T01358,#N/A,TARGNAME,Cell cycle (CC),,
T01358,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T01385,#N/A,TARGETID,T01385,,
T01385,#N/A,TARGNAME,HUMAN valosin-containing protein p97 (VCP),,
T01385,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T01447,NAE1; UBA3,TARGETID,T01447,,
T01447,NAE1; UBA3,TARGNAME,NEDD8-activating enzyme (NAE),,
T01447,NAE1; UBA3,INDICATI,Phase 2,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T01447,NAE1; UBA3,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T01447,NAE1; UBA3,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T01447,NAE1; UBA3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T01521,GSTO1,TARGETID,T01521,,
T01521,GSTO1,TARGNAME,Glutathione S-transferase omega-1 (GSTO-1),,
T01521,GSTO1,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T01575,SGPL1,TARGETID,T01575,,
T01575,SGPL1,TARGNAME,Sphingosine-1-phosphate lyase 1 (SGPL1),,
T01575,SGPL1,INDICATI,Phase 2,Congenital ichthyosis,[ICD-11: EC20]
T01575,SGPL1,INDICATI,Terminated,Diabetes mellitus,[ICD-11: 5A10]
T01575,SGPL1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T01597,CAT,TARGETID,T01597,,
T01597,CAT,TARGNAME,Catalase (CAT),,
T01597,CAT,INDICATI,Phase 1,Skin sensation disturbance,[ICD-11: ME65]
,#N/A,,,,
T01674,CEP290,TARGETID,T01674,,
T01674,CEP290,TARGNAME,CEP290 messenger RNA (CEP290 mRNA),,
T01674,CEP290,INDICATI,Phase 2/3,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T01777,ADRA2C,TARGETID,T01777,,
T01777,ADRA2C,TARGNAME,Adrenergic receptor alpha-2C (ADRA2C),,
T01777,ADRA2C,INDICATI,Discontinued in Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T01777,ADRA2C,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T01777,ADRA2C,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T01777,ADRA2C,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T01777,ADRA2C,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T01777,ADRA2C,INDICATI,Phase 3,Chronic pain,[ICD-11: MG30]
T01777,ADRA2C,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
T01777,ADRA2C,INDICATI,Investigative,Dementia,[ICD-11: 6D80-6D8Z]
T01777,ADRA2C,INDICATI,Discontinued in Phase 3,Depression,[ICD-11: 6A70-6A7Z]
T01777,ADRA2C,INDICATI,Phase 3,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T01777,ADRA2C,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T01777,ADRA2C,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T01777,ADRA2C,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T01777,ADRA2C,INDICATI,Discontinued in Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
T01777,ADRA2C,INDICATI,Approved,Herpes simplex infection,[ICD-11: 1F00]
T01777,ADRA2C,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T01777,ADRA2C,INDICATI,Approved,Hypotension,[ICD-11: BA20-BA21]
T01777,ADRA2C,INDICATI,Phase 2,Non-specific cutaneous vascular sympton,[ICD-11: ME64]
T01777,ADRA2C,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T01777,ADRA2C,INDICATI,Discontinued in Phase 3,Orgasmic dysfunction,[ICD-11: HA02]
T01777,ADRA2C,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T01777,ADRA2C,INDICATI,Discontinued in Preregistration,Peptic ulcer,[ICD-11: DA61]
T01777,ADRA2C,INDICATI,Phase 3,Post-traumatic stress disorder,[ICD-11: 6B40]
T01777,ADRA2C,INDICATI,Discontinued in Phase 2,Prostate disease,[ICD-11: GA91]
T01777,ADRA2C,INDICATI,Discontinued in Phase 2,Sexual dysfunction,[ICD-11: HA00-HA01]
T01777,ADRA2C,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
T01777,ADRA2C,INDICATI,Investigative,Unspecific body region injury,[ICD-11: ND56]
T01777,ADRA2C,INDICATI,Investigative,Unspecific substance harmful effect,[ICD-11: NE6Z]
T01777,ADRA2C,INDICATI,Phase 4,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T01788,#N/A,TARGETID,T01788,,
T01788,#N/A,TARGNAME,COVID-19 non-structural protein 14 (nsp14),,
T01788,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T01822,#N/A,TARGETID,T01822,,
T01822,#N/A,TARGNAME,Haematin (HA),,
T01822,#N/A,INDICATI,Phase 2,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T01840,#N/A,TARGETID,T01840,,
T01840,#N/A,TARGNAME,Protease unspecific (PRO),,
T01840,#N/A,INDICATI,Approved,Alpha-1-antitrypsin deficiency,[ICD-11: 5C5A]
T01840,#N/A,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T01840,#N/A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T01840,#N/A,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T01840,#N/A,INDICATI,Phase 2,Coagulation defect,[ICD-11: 3B10]
T01840,#N/A,INDICATI,Terminated,Cystic fibrosis,[ICD-11: CA25]
T01840,#N/A,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
T01840,#N/A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T01851,ITGB1,TARGETID,T01851,,
T01851,ITGB1,TARGNAME,Integrin beta-1 (ITGB1),,
T01851,ITGB1,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T01851,ITGB1,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T01851,ITGB1,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T01865,Malaria ht1,TARGETID,T01865,,
T01865,Malaria ht1,TARGNAME,Plasmodium Hexose transporter 1 (Malaria ht1),,
T01865,Malaria ht1,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T01908,KLK2,TARGETID,T01908,,
T01908,KLK2,TARGNAME,Tissue kallikrein (KLK2),,
T01908,KLK2,INDICATI,Discontinued in Phase 2,Atopic eczema,[ICD-11: EA80]
T01908,KLK2,INDICATI,Phase 2,Epidermal dysplasias,[ICD-11: EK90]
T01908,KLK2,INDICATI,Phase 2/3,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T01908,KLK2,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T01943,Malaria FabZ,TARGETID,T01943,,
T01943,Malaria FabZ,TARGNAME,Plasmodium Beta-hydroxyacyl-ACP dehydratase (Malaria FabZ),,
T01943,Malaria FabZ,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
,#N/A,,,,
T01973,MST1R,TARGETID,T01973,,
T01973,MST1R,TARGNAME,Macrophage-stimulating protein receptor (RON),,
T01973,MST1R,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T01973,MST1R,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T02001,PDE4D,TARGETID,T02001,,
T02001,PDE4D,TARGNAME,Phosphodiesterase 4D (PDE4D),,
T02001,PDE4D,INDICATI,Investigative,Acute upper respiratory infection,[ICD-11: CA07]
T02001,PDE4D,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T02001,PDE4D,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T02001,PDE4D,INDICATI,Terminated,Amyloidosis,[ICD-11: 5D00]
T02001,PDE4D,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T02001,PDE4D,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T02001,PDE4D,INDICATI,Phase 1,Choreiform disorder,[ICD-11: 8A01]
T02001,PDE4D,INDICATI,Terminated,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T02001,PDE4D,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T02001,PDE4D,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T02001,PDE4D,INDICATI,Investigative,Mature B-cell leukaemia,[ICD-11: 2A82]
T02001,PDE4D,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T02001,PDE4D,INDICATI,Phase 1,Mood disorder,[ICD-11: 6A60-6E23]
T02001,PDE4D,INDICATI,Discontinued in Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T02001,PDE4D,INDICATI,Discontinued in Phase 1,Mycosis fungoides,[ICD-11: 2B01]
T02001,PDE4D,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T02001,PDE4D,INDICATI,Investigative,Pneumonia,[ICD-11: CA40]
T02001,PDE4D,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T02001,PDE4D,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T02001,PDE4D,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T02001,PDE4D,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
T02001,PDE4D,INDICATI,Investigative,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T02024,#N/A,TARGETID,T02024,,
T02024,#N/A,TARGNAME,HUMAN inosine-5'-monophosphate dehydrogenase 1 (IMPDH1),,
T02024,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T02024,#N/A,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T02024,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T02024,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T02107,#N/A,TARGETID,T02107,,
T02107,#N/A,TARGNAME,COVID-19 replicase polyprotein 1ab (pp1ab),,
T02107,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02119,ARSB,TARGETID,T02119,,
T02119,ARSB,TARGNAME,N-acetylgalactosamine-4-sulfatase (G4S),,
T02119,ARSB,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T02122,#N/A,TARGETID,T02122,,
T02122,#N/A,TARGNAME,HUAMN monocyte differentiation antigen CD14 (CD14),,
T02122,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02134,GCLM,TARGETID,T02134,,
T02134,GCLM,TARGNAME,Glutamate--cysteine ligase modifier (GCLM),,
T02134,GCLM,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T02134,GCLM,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T02203,#N/A,TARGETID,T02203,,
T02203,#N/A,TARGNAME,HUAMN serine protease factor Xa (SERPINA5),,
T02203,#N/A,INDICATI,Preclinical,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02228,Stre-coc parC,TARGETID,T02228,,
T02228,Stre-coc parC,TARGNAME,Streptococcus Topoisomerase IV A (Stre-coc parC),,
T02228,Stre-coc parC,INDICATI,Investigative,Bacterial infection,[ICD-11: 1A00-1C4Z]
T02228,Stre-coc parC,INDICATI,Phase 3,Otitis externa,[ICD-11: AA00-AA13]
,#N/A,,,,
T02246,#N/A,TARGETID,T02246,,
T02246,#N/A,TARGNAME,Iron (Fe),,
T02246,#N/A,INDICATI,Phase 2,Anemia,[ICD-11: 3A00-3A9Z]
T02246,#N/A,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T02246,#N/A,INDICATI,Phase 3,Iron deficiency anaemia,[ICD-11: 3A00]
T02246,#N/A,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
T02246,#N/A,INDICATI,Approved,Mineral absorption/transport disorder,[ICD-11: 5C64]
T02246,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T02246,#N/A,INDICATI,Approved,Thalassaemia,[ICD-11: 3A50]
,#N/A,,,,
T02258,POLQ; POLN; POLB; POLG2; POLG; POLE2; POLD4; ;POLD1,TARGETID,T02258,,
T02258,POLQ; POLN; POLB; POLG2; POLG; POLE2; POLD4; ;POLD1,TARGNAME,DNA-dependent DNA polymerase (DPOL),,
T02258,POLQ; POLN; POLB; POLG2; POLG; POLE2; POLD4; ;POLD1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T02262,KCNT1,TARGETID,T02262,,
T02262,KCNT1,TARGNAME,Calcium-activated potassium channel KCa4.1 (KCNT1),,
T02262,KCNT1,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T02262,KCNT1,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
,#N/A,,,,
T02318,TNFSF13B,TARGETID,T02318,,
T02318,TNFSF13B,TARGNAME,B-cell-activating factor (TNFSF13B),,
T02318,TNFSF13B,INDICATI,Approved,Lupus erythematosus,[ICD-11: 4A40]
T02318,TNFSF13B,INDICATI,Discontinued in Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T02318,TNFSF13B,INDICATI,Phase 3,Multiple myeloma,[ICD-11: 2A83]
T02318,TNFSF13B,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T02318,TNFSF13B,INDICATI,Discontinued in Phase 2,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T02333,GHR,TARGETID,T02333,,
T02333,GHR,TARGNAME,Growth hormone receptor (GHR),,
T02333,GHR,INDICATI,Phase 1,Binge eating disorder,[ICD-11: 6B82]
T02333,GHR,INDICATI,Discontinued in Phase 2,Obesity,[ICD-11: 5B80-5B81]
T02333,GHR,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T02333,GHR,INDICATI,Phase 1,Short stature,[ICD-11: 5B11]
,#N/A,,,,
T02389,#N/A,TARGETID,T02389,,
T02389,#N/A,TARGNAME,HUMAN cysteinyl leukotriene receptor (CysLTR),,
T02389,#N/A,INDICATI,Phase 2/3,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02392,#N/A,TARGETID,T02392,,
T02392,#N/A,TARGNAME,HUMAN dipeptidyl peptidase 1 (CTSC),,
T02392,#N/A,INDICATI,Preclinical,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02469,PIKFYVE,TARGETID,T02469,,
T02469,PIKFYVE,TARGNAME,Phosphatidylinositol-3-phosphate 5-kinase (PIP5K3),,
T02469,PIKFYVE,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T02469,PIKFYVE,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T02506,#N/A,TARGETID,T02506,,
T02506,#N/A,TARGNAME,HUMAN estrogen receptor (ESR1),,
T02506,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02532,CD2,TARGETID,T02532,,
T02532,CD2,TARGNAME,T-cell surface antigen CD2 (CD2),,
T02532,CD2,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T02532,CD2,INDICATI,Discontinued in Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T02546,SCN4A,TARGETID,T02546,,
T02546,SCN4A,TARGNAME,Voltage-gated sodium channel alpha Nav1.4 (SCN4A),,
T02546,SCN4A,INDICATI,Discontinued in Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T02546,SCN4A,INDICATI,Phase 3,Musculoskeletal disorder,[ICD-11: FA00-FC0Z]
T02546,SCN4A,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T02551,DRD3,TARGETID,T02551,,
T02551,DRD3,TARGNAME,Dopamine D3 receptor (D3R),,
T02551,DRD3,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T02551,DRD3,INDICATI,Phase 1,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T02551,DRD3,INDICATI,Approved,Bipolar disorder,[ICD-11: 6A60]
T02551,DRD3,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T02551,DRD3,INDICATI,Discontinued in Phase 2,Cocaine use disorder,[ICD-11: 6C45]
T02551,DRD3,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T02551,DRD3,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T02551,DRD3,INDICATI,Phase 2,Gastroduodenal motor/secretory disorder,[ICD-11: DA41]
T02551,DRD3,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T02551,DRD3,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T02551,DRD3,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T02551,DRD3,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T02551,DRD3,INDICATI,Terminated,Nausea/vomiting,[ICD-11: MD90]
T02551,DRD3,INDICATI,Terminated,Nicotine use disorder,[ICD-11: 6C4A]
T02551,DRD3,INDICATI,Investigative,Oesophagus motility disorder,[ICD-11: DA21]
T02551,DRD3,INDICATI,Discontinued in Phase 3,Orgasmic dysfunction,[ICD-11: HA02]
T02551,DRD3,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T02551,DRD3,INDICATI,Phase 2,Psychoactive substances use disorder,[ICD-11: 6C4G]
T02551,DRD3,INDICATI,Discontinued in Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T02551,DRD3,INDICATI,Phase 2,Respiratory infection,[ICD-11: CA07-CA4Z]
T02551,DRD3,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
T02551,DRD3,INDICATI,Phase 1,Sexual dysfunction,[ICD-11: HA00-HA01]
T02551,DRD3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T02551,DRD3,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
T02551,DRD3,INDICATI,Terminated,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T02562,PTGES,TARGETID,T02562,,
T02562,PTGES,TARGNAME,Prostaglandin E synthase (PTGES),,
T02562,PTGES,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T02562,PTGES,INDICATI,Patented,Circulatory system disease,[ICD-11: BE2Z]
T02562,PTGES,INDICATI,Patented,Joint pain,[ICD-11: ME82]
T02562,PTGES,INDICATI,Patented,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T02584,MycB leuS,TARGETID,T02584,,
T02584,MycB leuS,TARGNAME,Mycobacterium Leucine-tRNA ligase (MycB leuS),,
T02584,MycB leuS,INDICATI,Phase 2,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
,#N/A,,,,
T02591,HIV env,TARGETID,T02591,,
T02591,HIV env,TARGNAME,Human immunodeficiency virus Envelope glycoprotein gp160 (HIV env),,
T02591,HIV env,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T02598,#N/A,TARGETID,T02598,,
T02598,#N/A,TARGNAME,Leukocyte (WBC),,
T02598,#N/A,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T02617,TF,TARGETID,T02617,,
T02617,TF,TARGNAME,Transferrin (TF),,
T02617,TF,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T02653,#N/A,TARGETID,T02653,,
T02653,#N/A,TARGNAME,HUMAN mineralocorticoid receptor (MR),,
T02653,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02677,BIRC5,TARGETID,T02677,,
T02677,BIRC5,TARGNAME,Apoptosis inhibitor survivin (BIRC5),,
T02677,BIRC5,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T02677,BIRC5,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T02677,BIRC5,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T02677,BIRC5,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T02702,Bact DHFR,TARGETID,T02702,,
T02702,Bact DHFR,TARGNAME,Bacterial Dihydrofolate reductase (Bact DHFR),,
T02702,Bact DHFR,INDICATI,Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
T02702,Bact DHFR,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T02703,NOS2,TARGETID,T02703,,
T02703,NOS2,TARGNAME,Nitric-oxide synthase inducible (NOS2),,
T02703,NOS2,INDICATI,Discontinued in Phase 1,Arteries/arterioles disorder,[ICD-11: BD52]
T02703,NOS2,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T02703,NOS2,INDICATI,Phase 2,Bowel habit change,[ICD-11: ME05]
T02703,NOS2,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T02703,NOS2,INDICATI,Phase 2/3,Chronic kidney disease,[ICD-11: GB61]
T02703,NOS2,INDICATI,Phase 1/2,Coronary atherosclerosis,[ICD-11: BA80]
T02703,NOS2,INDICATI,Discontinued in Phase 2,Insulin-resistance syndrome,[ICD-11: 5A44]
T02703,NOS2,INDICATI,Phase 3,Osteoarthritis,[ICD-11: FA00-FA05]
T02703,NOS2,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T02703,NOS2,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T02703,NOS2,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T02703,NOS2,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T02703,NOS2,INDICATI,Phase 3,Sepsis,[ICD-11: 1G40-1G41]
T02703,NOS2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T02719,GRM3,TARGETID,T02719,,
T02719,GRM3,TARGNAME,Metabotropic glutamate receptor 3 (mGluR3),,
T02719,GRM3,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T02719,GRM3,INDICATI,Discontinued in Phase 3,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T02719,GRM3,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T02719,GRM3,INDICATI,Discontinued in Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T02719,GRM3,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
T02719,GRM3,INDICATI,Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T02719,GRM3,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T02728,NTSR1,TARGETID,T02728,,
T02728,NTSR1,TARGNAME,Neurotensin receptor type 1 (NTSR1),,
T02728,NTSR1,INDICATI,Terminated,Acute/chronic pain,[ICD-11: MG30-MG31]
T02728,NTSR1,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T02728,NTSR1,INDICATI,Phase 2/3,Indeterminate colitis,[ICD-11: DD72]
T02728,NTSR1,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T02728,NTSR1,INDICATI,Investigative,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T02752,CCR3,TARGETID,T02752,,
T02752,CCR3,TARGNAME,C-C chemokine receptor type 3 (CCR3),,
T02752,CCR3,INDICATI,Discontinued in Phase 1,Asthma,[ICD-11: CA23]
T02752,CCR3,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T02752,CCR3,INDICATI,Discontinued in Phase 1,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T02777,ABCC9,TARGETID,T02777,,
T02777,ABCC9,TARGNAME,ATP-binding cassette transporter C9 (ABCC9),,
T02777,ABCC9,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T02777,ABCC9,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T02777,ABCC9,INDICATI,Discontinued in Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T02777,ABCC9,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T02779,DMD,TARGETID,T02779,,
T02779,DMD,TARGNAME,Dystrophin nonsense mutant (DMD),,
T02779,DMD,INDICATI,Phase 3,Cystic fibrosis,[ICD-11: CA25]
T02779,DMD,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T02779,DMD,INDICATI,Phase 1,Eye anterior segment structural developmental anomaly,[ICD-11: LA11]
T02779,DMD,INDICATI,Phase 1,Lysosomal disease,[ICD-11: 5C56]
T02779,DMD,INDICATI,Phase 2,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T02808,IFNB1,TARGETID,T02808,,
T02808,IFNB1,TARGNAME,Interferon-beta (IFNB1),,
T02808,IFNB1,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T02808,IFNB1,INDICATI,Terminated,Diabetes mellitus,[ICD-11: 5A10]
T02808,IFNB1,INDICATI,Phase 3,Intrathoracic organs injury,[ICD-11: NB32]
T02808,IFNB1,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T02808,IFNB1,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T02808,IFNB1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T02808,IFNB1,INDICATI,Phase 2,Skin fungal infection disorder,[ICD-11: EA60]
T02808,IFNB1,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T02918,#N/A,TARGETID,T02918,,
T02918,#N/A,TARGNAME,HUMAN phosphatidylinositol 3-phosphate 5-kinase (PIKfyve),,
T02918,#N/A,INDICATI,Preclinical,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02957,#N/A,TARGETID,T02957,,
T02957,#N/A,TARGNAME,HUMAN programmed cell death protein 1 (PD-1),,
T02957,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T02974,IL1RAP,TARGETID,T02974,,
T02974,IL1RAP,TARGNAME,Interleukin 1 receptor accessory protein (IL1RAP),,
T02974,IL1RAP,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T03006,#N/A,TARGETID,T03006,,
T03006,#N/A,TARGNAME,Acetylcholine release (Ach rele),,
T03006,#N/A,INDICATI,Approved,Cervical cancer,[ICD-11: 2C77]
T03006,#N/A,INDICATI,Discontinued in Phase 1,Mild neurocognitive disorder,[ICD-11: 6D71]
T03006,#N/A,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T03046,KRAS,TARGETID,T03046,,
T03046,KRAS,TARGNAME,Mutated KRAS (mKRAS),,
T03046,KRAS,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T03189,PRAME,TARGETID,T03189,,
T03189,PRAME,TARGNAME,Tumor expressed melanoma antigen (PRAME),,
T03189,PRAME,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T03189,PRAME,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T03279,RPS6KA3,TARGETID,T03279,,
T03279,RPS6KA3,TARGNAME,Ribosomal protein S6 kinase alpha-3 (RSK3),,
T03279,RPS6KA3,INDICATI,Preclinical,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T03313,IL2RA,TARGETID,T03313,,
T03313,IL2RA,TARGNAME,Interleukin 2 receptor alpha (IL2RA),,
T03313,IL2RA,INDICATI,Terminated,Diabetes mellitus,[ICD-11: 5A10]
T03313,IL2RA,INDICATI,Phase 1,Hodgkin lymphoma,[ICD-11: 2B30]
T03313,IL2RA,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T03313,IL2RA,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T03313,IL2RA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T03313,IL2RA,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T03346,IL4R,TARGETID,T03346,,
T03346,IL4R,TARGNAME,Interleukin 4 receptor alpha (IL4R),,
T03346,IL4R,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T03346,IL4R,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
T03346,IL4R,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T03346,IL4R,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T03346,IL4R,INDICATI,Phase 2,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T03403,PTGS1; PTGS2,TARGETID,T03403,,
T03403,PTGS1; PTGS2,TARGNAME,Prostaglandin G/H synthase (COX),,
T03403,PTGS1; PTGS2,INDICATI,Discontinued in Phase 1,Asthma,[ICD-11: CA23]
T03403,PTGS1; PTGS2,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T03403,PTGS1; PTGS2,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T03403,PTGS1; PTGS2,INDICATI,Approved,Cerebral ischaemia,[ICD-11: 8B1Z]
T03403,PTGS1; PTGS2,INDICATI,Discontinued in Phase 2,Chemotherapy/radiotherapy-induced mucositis,[ICD-11: DA42-DA60]
T03403,PTGS1; PTGS2,INDICATI,Discontinued in Phase 2,Female pelvic pain,[ICD-11: GA34]
T03403,PTGS1; PTGS2,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T03403,PTGS1; PTGS2,INDICATI,Discontinued in Phase 2,Immune system disease,[ICD-11: 4A01-4B41]
T03403,PTGS1; PTGS2,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T03403,PTGS1; PTGS2,INDICATI,Approved,Inflammatory spondyloarthritis,[ICD-11: FA92]
T03403,PTGS1; PTGS2,INDICATI,Approved,Inherited coagulation factor deficiency,[ICD-11: 3B14]
T03403,PTGS1; PTGS2,INDICATI,Approved,Joint pain,[ICD-11: ME82]
T03403,PTGS1; PTGS2,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T03403,PTGS1; PTGS2,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T03403,PTGS1; PTGS2,INDICATI,Approved,Osteoarthritis,[ICD-11: FA00-FA05]
T03403,PTGS1; PTGS2,INDICATI,Approved,Otitis media,[ICD-11: AA80-AB0Z]
T03403,PTGS1; PTGS2,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T03403,PTGS1; PTGS2,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T03403,PTGS1; PTGS2,INDICATI,Approved,Postoperative inflammation,[ICD-11: 1A00-CA43]
T03403,PTGS1; PTGS2,INDICATI,Discontinued in Phase 3,Qualitative platelet defect,[ICD-11: 3B62]
T03403,PTGS1; PTGS2,INDICATI,Discontinued in Phase 2,Reactive arthropathy,[ICD-11: FA11]
T03403,PTGS1; PTGS2,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T03403,PTGS1; PTGS2,INDICATI,Approved,Spinal pain,[ICD-11: ME84]
T03403,PTGS1; PTGS2,INDICATI,Discontinued in Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
T03403,PTGS1; PTGS2,INDICATI,Discontinued in Phase 2,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T03410,MycB mmpL3,TARGETID,T03410,,
T03410,MycB mmpL3,TARGNAME,Mycobacterium Membrane protein mmpL3 (MycB mmpL3),,
T03410,MycB mmpL3,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T03410,MycB mmpL3,INDICATI,Phase 2,Bacterial infection,[ICD-11: 1A00-1C4Z]
T03410,MycB mmpL3,INDICATI,Phase 2,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
,#N/A,,,,
T03485,CFB,TARGETID,T03485,,
T03485,CFB,TARGNAME,CFB messenger RNA (CFB mRNA),,
T03485,CFB,INDICATI,Phase 2,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T03500,MMP12,TARGETID,T03500,,
T03500,MMP12,TARGNAME,Matrix metalloproteinase-12 (MMP-12),,
T03500,MMP12,INDICATI,Investigative,Aneurysm/dissection,[ICD-11: BD50]
T03500,MMP12,INDICATI,Investigative,Arterial occlusive disease,[ICD-11: BD40]
T03500,MMP12,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T03500,MMP12,INDICATI,Discontinued in Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T03500,MMP12,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T03500,MMP12,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T03500,MMP12,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T03500,MMP12,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
,#N/A,,,,
T03513,#N/A,TARGETID,T03513,,
T03513,#N/A,TARGNAME,Dopamine receptor (DR),,
T03513,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T03513,#N/A,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T03513,#N/A,INDICATI,Phase 3,Gastroduodenal motor/secretory disorder,[ICD-11: DA41]
T03513,#N/A,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T03513,#N/A,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T03513,#N/A,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T03513,#N/A,INDICATI,Phase 3,Parkinsonism,[ICD-11: 8A00]
T03513,#N/A,INDICATI,Phase 2,Respiratory infection,[ICD-11: CA07-CA4Z]
T03513,#N/A,INDICATI,Phase 4,Restless legs syndrome,[ICD-11: 7A80]
T03513,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T03513,#N/A,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T03573,FCGR2B,TARGETID,T03573,,
T03573,FCGR2B,TARGNAME,Immunoglobulin gamma Fc receptor IIB (FCGR2B),,
T03573,FCGR2B,INDICATI,Phase 1,Autoimmune disease,[ICD-11: 4A40-4A45]
T03573,FCGR2B,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T03573,FCGR2B,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T03573,FCGR2B,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T03573,FCGR2B,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T03573,FCGR2B,INDICATI,Phase 1/2,Mature B-cell leukaemia,[ICD-11: 2A82]
T03573,FCGR2B,INDICATI,Phase 1/2,Rheumatoid arthritis,[ICD-11: FA20]
T03573,FCGR2B,INDICATI,Phase 2,Sjogren syndrome,[ICD-11: 4A43]
,#N/A,,,,
T03634,CREBBP,TARGETID,T03634,,
T03634,CREBBP,TARGNAME,CREB-binding protein (CREBBP),,
T03634,CREBBP,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T03634,CREBBP,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T03634,CREBBP,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T03634,CREBBP,INDICATI,Phase 1/2,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T03644,SNCA,TARGETID,T03644,,
T03644,SNCA,TARGNAME,Synuclein alpha (SNCA),,
T03644,SNCA,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T03644,SNCA,INDICATI,Phase 2,Autonomic nervous system disorder,[ICD-11: 8D87]
T03644,SNCA,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T03661,ADA,TARGETID,T03661,,
T03661,ADA,TARGNAME,Adenosine deaminase (ADA),,
T03661,ADA,INDICATI,Approved,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T03661,ADA,INDICATI,Preregistration,Chronic pain,[ICD-11: MG30]
T03661,ADA,INDICATI,Phase 3,Immunodeficiency,[ICD-11: 4A00-4A85]
T03661,ADA,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T03661,ADA,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T03661,ADA,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T03672,ADAM9,TARGETID,T03672,,
T03672,ADAM9,TARGNAME,Cellular disintegrin-related protein (ADAM9),,
T03672,ADAM9,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T03691,LTA4H,TARGETID,T03691,,
T03691,LTA4H,TARGNAME,Leukotriene A-4 hydrolase (LTA4H),,
T03691,LTA4H,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T03691,LTA4H,INDICATI,Phase 1,Chronic skin disorder,[ICD-11: ME63]
T03691,LTA4H,INDICATI,Discontinued in Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T03691,LTA4H,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T03691,LTA4H,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T03755,BCL2L2,TARGETID,T03755,,
T03755,BCL2L2,TARGNAME,Apoptosis regulator Bcl-W (BCL-W),,
T03755,BCL2L2,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T03755,BCL2L2,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T03755,BCL2L2,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T03818,PPARG,TARGETID,T03818,,
T03818,PPARG,TARGNAME,PPAR-gamma messenger RNA (PPARG mRNA),,
T03818,PPARG,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
T03818,PPARG,INDICATI,Phase 3,Sjogren syndrome,[ICD-11: 4A43]
T03818,PPARG,INDICATI,Terminated,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T03871,HRAS,TARGETID,T03871,,
T03871,HRAS,TARGNAME,H-ras messenger RNA (HRAS mRNA),,
T03871,HRAS,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T03896,HCV NS3/4A,TARGETID,T03896,,
T03896,HCV NS3/4A,TARGNAME,Hepatitis C virus Serine protease NS3/4A (HCV NS3/4A),,
T03896,HCV NS3/4A,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,TARGETID,T03917,,
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,TARGNAME,Sodium/potassium-transporting ATPase (SPT ATPase),,
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,INDICATI,Approved,Cardiac arrhythmia,[ICD-11: BC9Z]
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,INDICATI,Approved,Dental disease,[ICD-11: DA08]
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T03917,ATP1A1; ATP1A2; ATP1A3; ATP1B1; ATP1B2; ATP1B3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T03963,#N/A,TARGETID,T03963,,
T03963,#N/A,TARGNAME,Heat shock protein 90 (HSP90),,
T03963,#N/A,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T03963,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T03963,#N/A,INDICATI,Phase 1,COVID-19,[ICD-11: 1D6Y]
T03963,#N/A,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T03963,#N/A,INDICATI,Phase 1,Motor neuron disease,[ICD-11: 8B60]
T03963,#N/A,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T03963,#N/A,INDICATI,Phase 1,Neuropathy,[ICD-11: 8C0Z]
,#N/A,,,,
T03985,PJ top2,TARGETID,T03985,,
T03985,PJ top2,TARGNAME,Pneumocystis jirovecii DNA topoisomerase 2 (PJ top2),,
T03985,PJ top2,INDICATI,Discontinued in Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T04079,#N/A,TARGETID,T04079,,
T04079,#N/A,TARGNAME,Plasmodial phospholipid metabolism (PPP metab),,
T04079,#N/A,INDICATI,Phase 2,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T04084,ERBB3,TARGETID,T04084,,
T04084,ERBB3,TARGNAME,ERBB3 messenger RNA (ERBB3 mRNA),,
T04084,ERBB3,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T04321,Stap-coc hly,TARGETID,T04321,,
T04321,Stap-coc hly,TARGNAME,Staphylococcus Alpha-hemolysin (Stap-coc hly),,
T04321,Stap-coc hly,INDICATI,Phase 3,Medical/surgical procedure injury,[ICD-11: PK80-PK81]
T04321,Stap-coc hly,INDICATI,Phase 3,Phlegmy cough,[ICD-11: SA80-SA8Z]
T04321,Stap-coc hly,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T04361,MAP3K7,TARGETID,T04361,,
T04361,MAP3K7,TARGNAME,TGF-beta-activated kinase 1 (MAP3K7),,
T04361,MAP3K7,INDICATI,Investigative,Mature B-cell lymphoma,[ICD-11: 2A85]
,#N/A,,,,
T04388,KCNN3,TARGETID,T04388,,
T04388,KCNN3,TARGNAME,Calcium-activated potassium channel KCa2.3 (KCNN3),,
T04388,KCNN3,INDICATI,Clinical trial,Myelopathy,[ICD-11: 8B42]
,#N/A,,,,
T04389,#N/A,TARGETID,T04389,,
T04389,#N/A,TARGNAME,ATP phosphatase (ATPase),,
T04389,#N/A,INDICATI,Terminated,Angina pectoris,[ICD-11: BA40]
T04389,#N/A,INDICATI,Discontinued in Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T04389,#N/A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T04389,#N/A,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T04394,#N/A,TARGETID,T04394,,
T04394,#N/A,TARGNAME,Vasopressin receptor (VR),,
T04394,#N/A,INDICATI,Terminated,Abnormal micturition,[ICD-11: MF50]
T04394,#N/A,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T04394,#N/A,INDICATI,Phase 1,Essential hypertension,[ICD-11: BA00]
T04394,#N/A,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T04507,DLG4,TARGETID,T04507,,
T04507,DLG4,TARGNAME,Presynaptic density protein 95 (DLG4),,
T04507,DLG4,INDICATI,Phase 3,Cerebral ischaemia,[ICD-11: 8B1Z]
T04507,DLG4,INDICATI,Phase 3,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
,#N/A,,,,
T04689,CHRNA1,TARGETID,T04689,,
T04689,CHRNA1,TARGNAME,Neuronal acetylcholine receptor alpha-1 (CHRNA1),,
T04689,CHRNA1,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T04741,ATIC,TARGETID,T04741,,
T04741,ATIC,TARGNAME,Phosphoribosylaminoimidazolecarboxamide formyltransferase (ATIC),,
T04741,ATIC,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T04773,CXCL12,TARGETID,T04773,,
T04773,CXCL12,TARGNAME,Stromal cell-derived factor 1 (CXCL12),,
T04773,CXCL12,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T04773,CXCL12,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T04773,CXCL12,INDICATI,Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
T04773,CXCL12,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T04820,Malaria Pfmrk,TARGETID,T04820,,
T04820,Malaria Pfmrk,TARGNAME,Plasmodium CDK Pfmrk (Malaria Pfmrk),,
T04820,Malaria Pfmrk,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T04894,CCL20,TARGETID,T04894,,
T04894,CCL20,TARGNAME,Liver and activation-regulated chemokine (CCL20),,
T04894,CCL20,INDICATI,Phase 1,Psoriatic arthritis,[ICD-11: FA21]
,#N/A,,,,
T04902,CAPN2,TARGETID,T04902,,
T04902,CAPN2,TARGNAME,Calpain-2 (CAPN2),,
T04902,CAPN2,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T04902,CAPN2,INDICATI,Terminated,Cerebral ischaemic stroke,[ICD-11: 8B11]
T04902,CAPN2,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
T04902,CAPN2,INDICATI,Discontinued in Phase 3,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T04902,CAPN2,INDICATI,Withdrawn from market,Trematode disease,[ICD-11: 1F8Y]
,#N/A,,,,
T04911,HCV NS4B,TARGETID,T04911,,
T04911,HCV NS4B,TARGNAME,Hepatitis C virus Non-structural 4B (HCV NS4B),,
T04911,HCV NS4B,INDICATI,Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T04977,#N/A,TARGETID,T04977,,
T04977,#N/A,TARGNAME,Oxalate absorption (Oxalate absor),,
T04977,#N/A,INDICATI,Phase 3,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
,#N/A,,,,
T05031,PIK3CB,TARGETID,T05031,,
T05031,PIK3CB,TARGNAME,PI3-kinase beta (PIK3CB),,
T05031,PIK3CB,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T05031,PIK3CB,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T05031,PIK3CB,INDICATI,Phase 2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T05031,PIK3CB,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T05031,PIK3CB,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T05031,PIK3CB,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T05031,PIK3CB,INDICATI,Terminated,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T05034,#N/A,TARGETID,T05034,,
T05034,#N/A,TARGNAME,Fatty acid-binding protein (FABP),,
T05034,#N/A,INDICATI,Terminated,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T05089,ANO1,TARGETID,T05089,,
T05089,ANO1,TARGNAME,Calcium-dependent chloride channel anoctamin (ANO),,
T05089,ANO1,INDICATI,Approved,Gout,[ICD-11: FA25]
T05089,ANO1,INDICATI,Approved,Viral intestinal infection,[ICD-11: 1A2Z]
,#N/A,,,,
T05090,HDAC3,TARGETID,T05090,,
T05090,HDAC3,TARGNAME,Histone deacetylase 3 (HDAC3),,
T05090,HDAC3,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T05090,HDAC3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T05114,CMA1,TARGETID,T05114,,
T05114,CMA1,TARGNAME,Chymase (CYM),,
T05114,CMA1,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T05114,CMA1,INDICATI,Investigative,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T05114,CMA1,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T05114,CMA1,INDICATI,Phase 2,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T05114,CMA1,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
T05114,CMA1,INDICATI,Phase 2,Left ventricular failure,[ICD-11: BD11]
T05114,CMA1,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
,#N/A,,,,
T05152,HCV NS5B,TARGETID,T05152,,
T05152,HCV NS5B,TARGNAME,Hepatitis C virus RNA-directed RNA polymerase (HCV NS5B),,
T05152,HCV NS5B,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T05152,HCV NS5B,INDICATI,Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T05196,#N/A,TARGETID,T05196,,
T05196,#N/A,TARGNAME,Uric acid (URA),,
T05196,#N/A,INDICATI,Approved,Gout,[ICD-11: FA25]
,#N/A,,,,
T05351,MARCKS,TARGETID,T05351,,
T05351,MARCKS,TARGNAME,Myristoylated alanine-rich C-kinase substrate (MARCKS),,
T05351,MARCKS,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T05351,MARCKS,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T05387,TGM2,TARGETID,T05387,,
T05387,TGM2,TARGNAME,Tissue transglutaminase (TG2),,
T05387,TGM2,INDICATI,Phase 2,Coeliac disease,[ICD-11: DA95]
T05387,TGM2,INDICATI,Preclinical,Kidney fibrosis,[ICD-11: GC01]
T05387,TGM2,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
,#N/A,,,,
T05409,MME,TARGETID,T05409,,
T05409,MME,TARGNAME,Neutral endopeptidase (MME),,
T05409,MME,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T05409,MME,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T05409,MME,INDICATI,Phase 2,Choreiform disorder,[ICD-11: 8A01]
T05409,MME,INDICATI,Discontinued in Phase 2/3,Chronic kidney disease,[ICD-11: GB61]
T05409,MME,INDICATI,Phase 1,Chronic pain,[ICD-11: MG30]
T05409,MME,INDICATI,Terminated,Heart disease,[ICD-11: BA41-BA42]
T05409,MME,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T05409,MME,INDICATI,Phase 3,Hypertension,[ICD-11: BA00-BA04]
T05409,MME,INDICATI,Phase 2,Hypotension,[ICD-11: BA20-BA21]
T05409,MME,INDICATI,Phase 2,Intracranial injury,[ICD-11: NA07]
T05409,MME,INDICATI,Discontinued in Phase 2/3,Kidney failure,[ICD-11: GB60-GB6Z]
T05409,MME,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T05409,MME,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T05409,MME,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T05409,MME,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T05409,MME,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T05409,MME,INDICATI,Phase 1,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T05643,LINGO1,TARGETID,T05643,,
T05643,LINGO1,TARGNAME,Leucine-rich repeat neuronal protein 1 (LINGO1),,
T05643,LINGO1,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T05661,LCAT,TARGETID,T05661,,
T05661,LCAT,TARGNAME,Lecithin-cholesterol acyltransferase (LCAT),,
T05661,LCAT,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
T05661,LCAT,INDICATI,Phase 1,Myocardial infarction,[ICD-11: BA41-BA43]
,#N/A,,,,
T05849,CCKBR,TARGETID,T05849,,
T05849,CCKBR,TARGNAME,Gastrin/cholecystokinin type B receptor (CCKBR),,
T05849,CCKBR,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T05849,CCKBR,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T05849,CCKBR,INDICATI,Approved,Diagnostic imaging,[ICD-11: N.A.]
T05849,CCKBR,INDICATI,Terminated,Digestive system disease,[ICD-11: DE2Z]
T05849,CCKBR,INDICATI,Phase 3,Duodenal ulcer,[ICD-11: DA63]
T05849,CCKBR,INDICATI,Terminated,Dyspepsia,[ICD-11: MD92]
T05849,CCKBR,INDICATI,Phase 2,Gastric ulcer,[ICD-11: DA60]
T05849,CCKBR,INDICATI,Preclinical,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T05849,CCKBR,INDICATI,Discontinued in Phase 1,General pain disorder,[ICD-11: 8E43]
T05849,CCKBR,INDICATI,Discontinued in Phase 1,Malignant intestine neoplasm,[ICD-11: 2C0Z]
T05849,CCKBR,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
T05849,CCKBR,INDICATI,Approved,Pancreatic internal secretion disorder,[ICD-11: 5A4Y]
T05849,CCKBR,INDICATI,Phase 2,Pancreatic malfunction,[ICD-11: DC30-DC3Z]
T05849,CCKBR,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T05849,CCKBR,INDICATI,Phase 2,Stomach disease,[ICD-11: DA43-DA4Y]
T05849,CCKBR,INDICATI,Phase 1,Thyroid cancer,[ICD-11: 2D10]
T05849,CCKBR,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T05876,EV GP,TARGETID,T05876,,
T05876,EV GP,TARGNAME,Ebola virus Envelope glycoprotein (EV GP),,
T05876,EV GP,INDICATI,Approved,Filovirus disease,[ICD-11: 1D60]
,#N/A,,,,
T05880,APH1A-APH1B,TARGETID,T05880,,
T05880,APH1A-APH1B,TARGNAME,Gamma-secretase subunit APH-1A/1B (APH-1),,
T05880,APH1A-APH1B,INDICATI,Patented,Alzheimer disease,[ICD-11: 8A20]
T05880,APH1A-APH1B,INDICATI,Patented,Herpes simplex infection,[ICD-11: 1F00]
,#N/A,,,,
T05904,PDE8A,TARGETID,T05904,,
T05904,PDE8A,TARGNAME,Phosphodiesterase 8 (PDE8),,
T05904,PDE8A,INDICATI,Investigative,Itching,[ICD-11: 1F28-1G07]
T05904,PDE8A,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T05938,MUC16,TARGETID,T05938,,
T05938,MUC16,TARGNAME,Ovarian carcinoma antigen CA125 (MUC16),,
T05938,MUC16,INDICATI,Phase 1,Fallopian tube cancer,[ICD-11: 2C74]
T05938,MUC16,INDICATI,Phase 2,Malignant mesenchymal neoplasm,[ICD-11: 2B5D-2B5Y]
T05938,MUC16,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T05938,MUC16,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T05938,MUC16,INDICATI,Phase 1,Peritoneal cancer,[ICD-11: 2C51]
,#N/A,,,,
T06011,#N/A,TARGETID,T06011,,
T06011,#N/A,TARGNAME,Transforming growth factor beta (TGFB),,
T06011,#N/A,INDICATI,Phase 1,Anemia,[ICD-11: 3A00-3A9Z]
T06011,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T06011,#N/A,INDICATI,Preclinical,Cardiac arrest,[ICD-11: MC82]
T06011,#N/A,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T06011,#N/A,INDICATI,Phase 1/2,Myelodysplastic syndrome,[ICD-11: 2A37]
T06011,#N/A,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T06011,#N/A,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
T06011,#N/A,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T06011,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T06011,#N/A,INDICATI,Phase 2,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T06020,FCGRT,TARGETID,T06020,,
T06020,FCGRT,TARGNAME,Neonatal Fc receptor (FCGRT),,
T06020,FCGRT,INDICATI,Phase 3,Acquired haemolytic anaemia,ICD-11: 3A20
T06020,FCGRT,INDICATI,Phase 2,Idiopathic inflammatory myopathy,ICD-11: 4A41
T06020,FCGRT,INDICATI,Phase 3,Inflammatory polyneuropathy,[ICD-11: 8C01]
T06020,FCGRT,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T06020,FCGRT,INDICATI,Approved,Myasthenia gravis,[ICD-11: 8C6Y]
T06020,FCGRT,INDICATI,Phase 3,Myasthenia gravis,ICD-11: 8C60
T06020,FCGRT,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T06020,FCGRT,INDICATI,Phase 2,Sjogren syndrome,[ICD-11: 4A43]
,#N/A,,,,
T06037,MAPK9,TARGETID,T06037,,
T06037,MAPK9,TARGNAME,JNK2 messenger RNA (JNK2 mRNA),,
T06037,MAPK9,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T06042,#N/A,TARGETID,T06042,,
T06042,#N/A,TARGNAME,Sinus node I(f) channel (SA node IfC),,
T06042,#N/A,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
,#N/A,,,,
T06046,NOS3,TARGETID,T06046,,
T06046,NOS3,TARGNAME,Nitric-oxide synthase endothelial (NOS3),,
T06046,NOS3,INDICATI,Phase 2,Angina pectoris,[ICD-11: BA40]
T06046,NOS3,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
T06046,NOS3,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T06046,NOS3,INDICATI,Phase 2,Hypotension,[ICD-11: BA20-BA21]
T06046,NOS3,INDICATI,Phase 2,Intracranial injury,[ICD-11: NA07]
T06046,NOS3,INDICATI,Phase 3,Myocardial infarction,[ICD-11: BA41-BA43]
T06046,NOS3,INDICATI,Phase 1,Pulmonary hypertension,[ICD-11: BB01]
,#N/A,,,,
T06093,ROCK2,TARGETID,T06093,,
T06093,ROCK2,TARGNAME,Rho-associated protein kinase 2 (ROCK2),,
T06093,ROCK2,INDICATI,Investigative,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T06093,ROCK2,INDICATI,Phase 1,Glaucoma,[ICD-11: 9C61]
T06093,ROCK2,INDICATI,Approved,Graft-versus-host disease,[ICD-11: 4B24]
T06093,ROCK2,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T06093,ROCK2,INDICATI,Clinical trial,Postoperative inflammation,[ICD-11: 1A00-CA43]
T06093,ROCK2,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T06093,ROCK2,INDICATI,Phase 1,Psoriatic arthritis,[ICD-11: FA21]
T06093,ROCK2,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T06093,ROCK2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T06093,ROCK2,INDICATI,Phase 1,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T06128,IRS2,TARGETID,T06128,,
T06128,IRS2,TARGNAME,Insulin receptor substrate 2 (IRS2),,
T06128,IRS2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T06182,VIPR2,TARGETID,T06182,,
T06182,VIPR2,TARGNAME,Helodermin-preferring VIP receptor (VIPR2),,
T06182,VIPR2,INDICATI,Phase 1,Cardiomyopathy,[ICD-11: BC43]
T06182,VIPR2,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T06182,VIPR2,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T06182,VIPR2,INDICATI,Phase 1,Hypertension,[ICD-11: BA00-BA04]
T06182,VIPR2,INDICATI,Phase 1,Muscular dystrophy,[ICD-11: 8C70]
T06182,VIPR2,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
,#N/A,,,,
T06273,PARP1,TARGETID,T06273,,
T06273,PARP1,TARGNAME,Poly [ADP-ribose] polymerase 1 (PARP1),,
T06273,PARP1,INDICATI,Approved,Acquired cutaneous blood vessel malformation,[ICD-11: EF20]
T06273,PARP1,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T06273,PARP1,INDICATI,Investigative,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T06273,PARP1,INDICATI,Investigative,Cerebral ischaemia,[ICD-11: 8B1Z]
T06273,PARP1,INDICATI,Phase 3,Cerebrovascular disease,[ICD-11: 8B22-8B2Z]
T06273,PARP1,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
T06273,PARP1,INDICATI,Phase 1,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T06273,PARP1,INDICATI,Approved,Fallopian tube cancer,[ICD-11: 2C74]
T06273,PARP1,INDICATI,Investigative,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T06273,PARP1,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T06273,PARP1,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T06273,PARP1,INDICATI,Investigative,Myocardial infarction,[ICD-11: BA41-BA43]
T06273,PARP1,INDICATI,Approved,Ovarian cancer,[ICD-11: 2C73]
T06273,PARP1,INDICATI,Approved,Peritoneal cancer,[ICD-11: 2C51]
T06273,PARP1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T06273,PARP1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T06281,Klebsiella mrkA,TARGETID,T06281,,
T06281,Klebsiella mrkA,TARGNAME,Klebsiella Fimbrial subunit type 3 (Klebsiella mrkA),,
T06281,Klebsiella mrkA,INDICATI,Preclinical,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T06320,#N/A,TARGETID,T06320,,
T06320,#N/A,TARGNAME,Galectin (LGALS),,
T06320,#N/A,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
,#N/A,,,,
T06365,AGXT,TARGETID,T06365,,
T06365,AGXT,TARGNAME,Alanine glyoxylate aminotransferase (AGXT),,
T06365,AGXT,INDICATI,Terminated,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
,#N/A,,,,
T06413,PRKCA,TARGETID,T06413,,
T06413,PRKCA,TARGNAME,PKC-alpha messenger RNA (PRKCA mRNA),,
T06413,PRKCA,INDICATI,Investigative,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T06421,IFNAR2,TARGETID,T06421,,
T06421,IFNAR2,TARGNAME,Interferon alpha/beta receptor 2 (IFNAR2),,
T06421,IFNAR2,INDICATI,Phase 1,Endometriosis,[ICD-11: GA10]
T06421,IFNAR2,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T06421,IFNAR2,INDICATI,Approved,Lupus erythematosus,[ICD-11: 4A40]
T06421,IFNAR2,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T06421,IFNAR2,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T06421,IFNAR2,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T06421,IFNAR2,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
,#N/A,,,,
T06438,#N/A,TARGETID,T06438,,
T06438,#N/A,TARGNAME,Oxidoreductase unspecific (OR),,
T06438,#N/A,INDICATI,Phase 1/2,Ataxic disorder,[ICD-11: 8A03]
T06438,#N/A,INDICATI,Phase 1/2,Muscular dystrophy,[ICD-11: 8C70]
T06438,#N/A,INDICATI,Approved,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T06446,#N/A,TARGETID,T06446,,
T06446,#N/A,TARGNAME,Leukotriene biosynthesis (LT synth),,
T06446,#N/A,INDICATI,Investigative,Asthma,[ICD-11: CA23]
,#N/A,,,,
T06455,CYP2A6,TARGETID,T06455,,
T06455,CYP2A6,TARGNAME,Cytochrome P450 2A6 (CYP2A6),,
T06455,CYP2A6,INDICATI,Approved,Mycosis fungoides,[ICD-11: 2B01]
T06455,CYP2A6,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T06475,NCL,TARGETID,T06475,,
T06475,NCL,TARGNAME,Nucleolin (NCL),,
T06475,NCL,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
T06475,NCL,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T06542,IL17F,TARGETID,T06542,,
T06542,IL17F,TARGNAME,Cytokine ML-1 (IL17F),,
T06542,IL17F,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T06542,IL17F,INDICATI,Phase 2,Psoriatic arthritis,[ICD-11: FA21]
,#N/A,,,,
T06569,CA6,TARGETID,T06569,,
T06569,CA6,TARGNAME,Carbonic anhydrase VI (CA-VI),,
T06569,CA6,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T06569,CA6,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T06569,CA6,INDICATI,Approved,Seborrhoeic dermatitis,[ICD-11: EA81]
T06569,CA6,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T06575,CGB3,TARGETID,T06575,,
T06575,CGB3,TARGNAME,Choriogonadotropin beta (CG-beta),,
T06575,CGB3,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
,#N/A,,,,
T06671,IL18,TARGETID,T06671,,
T06671,IL18,TARGNAME,Interleukin-18 (IL18),,
T06671,IL18,INDICATI,Phase 3,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T06671,IL18,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T06671,IL18,INDICATI,Phase 1,Follicular lymphoma,[ICD-11: 2A80]
T06671,IL18,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T06671,IL18,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T06671,IL18,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T06671,IL18,INDICATI,Investigative,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T06671,IL18,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T06770,HIV gp41,TARGETID,T06770,,
T06770,HIV gp41,TARGNAME,Human immunodeficiency virus Glycoprotein 41 (HIV gp41),,
T06770,HIV gp41,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T06841,IL23A,TARGETID,T06841,,
T06841,IL23A,TARGNAME,Interleukin-23 (IL23),,
T06841,IL23A,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T06841,IL23A,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T06841,IL23A,INDICATI,Phase 2/3,Indeterminate colitis,[ICD-11: DD72]
T06841,IL23A,INDICATI,Phase 2,Inflammatory spondyloarthritis,[ICD-11: FA92]
T06841,IL23A,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T06841,IL23A,INDICATI,Phase 3,Mature B-cell leukaemia,[ICD-11: 2A82]
T06841,IL23A,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T06841,IL23A,INDICATI,Phase 3,Psoriatic arthritis,[ICD-11: FA21]
T06841,IL23A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T06841,IL23A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T06841,IL23A,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T06850,GHRL,TARGETID,T06850,,
T06850,GHRL,TARGNAME,Ghrelin (GHRL),,
T06850,GHRL,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T06869,PDGFA,TARGETID,T06869,,
T06869,PDGFA,TARGNAME,Platelet-derived growth factor A (PDGFA),,
T06869,PDGFA,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T06869,PDGFA,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T06955,CCR4,TARGETID,T06955,,
T06955,CCR4,TARGNAME,C-C chemokine receptor type 4 (CCR4),,
T06955,CCR4,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T06955,CCR4,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T06955,CCR4,INDICATI,Phase 1,Immune system disease,[ICD-11: 4A01-4B41]
T06955,CCR4,INDICATI,Phase 1,Immunoproliferative disorder,[ICD-11: 2B32]
T06955,CCR4,INDICATI,Phase 1,Lymphatic vessel/lymph nodes disorder,[ICD-11: BD9Z]
T06955,CCR4,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T06955,CCR4,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T06955,CCR4,INDICATI,Approved,Mycosis fungoides,[ICD-11: 2B01]
T06955,CCR4,INDICATI,Approved,Sezary syndrome,[ICD-11: 2B02]
T06955,CCR4,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T06958,POLB,TARGETID,T06958,,
T06958,POLB,TARGNAME,DNA polymerase beta (POLB),,
T06958,POLB,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T07035,CMV IE2 mRNA,TARGETID,T07035,,
T07035,CMV IE2 mRNA,TARGNAME,Cytomegalovirus IE2 region messenger RNA (CMV IE2 mRNA),,
T07035,CMV IE2 mRNA,INDICATI,Approved,Retinal inflammation,[ICD-11: 9B72]
T07035,CMV IE2 mRNA,INDICATI,Investigative,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T07045,ADCYAP1,TARGETID,T07045,,
T07045,ADCYAP1,TARGNAME,Pituitary adenylate cyclase-activating 38 (PACAP-38),,
T07045,ADCYAP1,INDICATI,Phase 1,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T07063,SLC5A5,TARGETID,T07063,,
T07063,SLC5A5,TARGNAME,Sodium/iodide cotransporter (SLC5A5),,
T07063,SLC5A5,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T07137,HPD,TARGETID,T07137,,
T07137,HPD,TARGNAME,Hydroxyphenylpyruvate dioxygenase (HPD),,
T07137,HPD,INDICATI,Approved,Metabolism inborn error,[ICD-11: 5C50]
T07137,HPD,INDICATI,Terminated,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T07173,NTRK1,TARGETID,T07173,,
T07173,NTRK1,TARGNAME,Tropomyosin-related kinase A (TrkA),,
T07173,NTRK1,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T07173,NTRK1,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T07173,NTRK1,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T07173,NTRK1,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
T07173,NTRK1,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T07173,NTRK1,INDICATI,Patented,General pain disorder,[ICD-11: 8E43]
T07173,NTRK1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T07173,NTRK1,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T07173,NTRK1,INDICATI,Preclinical,Pain,[ICD-11: MG30-MG3Z]
T07173,NTRK1,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T07173,NTRK1,INDICATI,Phase 2,Pruritus,[ICD-11: EC90]
T07173,NTRK1,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T07173,NTRK1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T07173,NTRK1,INDICATI,Patented,Thymoma,[ICD-11: 2C27]
,#N/A,,,,
T07191,MAP4K2,TARGETID,T07191,,
T07191,MAP4K2,TARGNAME,MEK kinase kinase 2 (MAP4K2),,
T07191,MAP4K2,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T07279,PIM2,TARGETID,T07279,,
T07279,PIM2,TARGNAME,Serine/threonine-protein kinase pim-2 (PIM2),,
T07279,PIM2,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T07279,PIM2,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T07279,PIM2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T07289,ACKR1,TARGETID,T07289,,
T07289,ACKR1,TARGNAME,Duffy antigen chemokine receptor (ACKR1),,
T07289,ACKR1,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T07303,FLT4,TARGETID,T07303,,
T07303,FLT4,TARGNAME,Vascular endothelial growth factor receptor 3 (FLT-4),,
T07303,FLT4,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T07303,FLT4,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T07303,FLT4,INDICATI,Phase 3,Circulatory system disease,[ICD-11: BE2Z]
T07303,FLT4,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T07303,FLT4,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T07303,FLT4,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T07303,FLT4,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T07303,FLT4,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T07303,FLT4,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T07341,#N/A,TARGETID,T07341,,
T07341,#N/A,TARGNAME,Dabigatran (Dabi),,
T07341,#N/A,INDICATI,Approved,Reversal of the anticoagulant effects of dabigatran,[ICD-11:N.A.]
,#N/A,,,,
T07374,MSMB,TARGETID,T07374,,
T07374,MSMB,TARGNAME,Beta-microseminoprotein (MSMB),,
T07374,MSMB,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T07394,NOTCH1,TARGETID,T07394,,
T07394,NOTCH1,TARGNAME,Notch-1 receptor (NOTCH1),,
T07394,NOTCH1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T07394,NOTCH1,INDICATI,Phase 1/2,Mature T-cell lymphoma,[ICD-11: 2A90]
T07394,NOTCH1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T07400,AGER,TARGETID,T07400,,
T07400,AGER,TARGNAME,Advanced glycosylation end product receptor (AGER),,
T07400,AGER,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T07400,AGER,INDICATI,Phase 3,Chronic kidney disease,[ICD-11: GB61]
T07400,AGER,INDICATI,Phase 3,Dementia,[ICD-11: 6D80-6D8Z]
T07400,AGER,INDICATI,Phase 2/3,Hypotension,[ICD-11: BA20-BA21]
,#N/A,,,,
T07403,ITGA4-ITGB7,TARGETID,T07403,,
T07403,ITGA4-ITGB7,TARGNAME,Integrin alpha-4/beta-7 (ITGA4/B7),,
T07403,ITGA4-ITGB7,INDICATI,Approved,Crohn disease,[ICD-11: DD70]
T07403,ITGA4-ITGB7,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T07403,ITGA4-ITGB7,INDICATI,Discontinued in Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T07403,ITGA4-ITGB7,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T07403,ITGA4-ITGB7,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T07403,ITGA4-ITGB7,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T07448,MASP2,TARGETID,T07448,,
T07448,MASP2,TARGNAME,Mannan-binding lectin serine protease-2 (MASP2),,
T07448,MASP2,INDICATI,Phase 2,Amyloidosis,[ICD-11: 5D00]
T07448,MASP2,INDICATI,Phase 3,Hereditary haemolytic anaemia,[ICD-11: 3A10]
T07448,MASP2,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T07448,MASP2,INDICATI,Phase 2,Thrombotic microangiopathy,[ICD-11: 3B65]
T07448,MASP2,INDICATI,Phase 3,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T07485,RSV F,TARGETID,T07485,,
T07485,RSV F,TARGNAME,Respiratory syncytial virus protein F (RSV F),,
T07485,RSV F,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
T07485,RSV F,INDICATI,Approved,Viral encephalitis,[ICD-11: 1C80]
T07485,RSV F,INDICATI,Discontinued in Phase 1,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T07507,MYH7,TARGETID,T07507,,
T07507,MYH7,TARGNAME,Myosin-7 (MYH7),,
T07507,MYH7,INDICATI,Phase 1/2,Deafness,[ICD-11: AB52]
T07507,MYH7,INDICATI,Phase 1,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T07533,APOB,TARGETID,T07533,,
T07533,APOB,TARGNAME,Apolipoprotein B-100 (APOB),,
T07533,APOB,INDICATI,Phase 1,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T07569,CYC1-MT-CYB,TARGETID,T07569,,
T07569,CYC1-MT-CYB,TARGNAME,Electron transport complex III (Complex III),,
T07569,CYC1-MT-CYB,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T07584,USP13,TARGETID,T07584,,
T07584,USP13,TARGNAME,Ubiquitin carboxyl-terminal hydrolase 13 (USP13),,
T07584,USP13,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T07601,CAMLG; CAML,TARGETID,T07601,,
T07601,CAMLG; CAML,TARGNAME,Calcium signal-modulating cyclophilin ligand (CAML),,
T07601,CAMLG; CAML,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T07601,CAMLG; CAML,INDICATI,Preclinical,Glaucoma,[ICD-11: 9C61]
T07601,CAMLG; CAML,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T07601,CAMLG; CAML,INDICATI,Phase 3,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T07663,PDE5A,TARGETID,T07663,,
T07663,PDE5A,TARGNAME,Phosphodiesterase 5A (PDE5A),,
T07663,PDE5A,INDICATI,Discontinued in Phase 2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T07663,PDE5A,INDICATI,Discontinued in Phase 2,Angina pectoris,[ICD-11: BA40]
T07663,PDE5A,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T07663,PDE5A,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T07663,PDE5A,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T07663,PDE5A,INDICATI,Phase 3,Colorectal cancer,[ICD-11: 2B91]
T07663,PDE5A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T07663,PDE5A,INDICATI,Approved,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T07663,PDE5A,INDICATI,Phase 2,Raynaud phenomenon,[ICD-11: BD42]
T07663,PDE5A,INDICATI,Approved,Sexual dysfunction,[ICD-11: HA00-HA01]
T07663,PDE5A,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T07806,HTR1B,TARGETID,T07806,,
T07806,HTR1B,TARGNAME,5-HT 1B receptor (HTR1B),,
T07806,HTR1B,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T07806,HTR1B,INDICATI,Terminated,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T07806,HTR1B,INDICATI,Phase 3,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T07806,HTR1B,INDICATI,Terminated,Depression,[ICD-11: 6A70-6A7Z]
T07806,HTR1B,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T07806,HTR1B,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T07806,HTR1B,INDICATI,Phase 1,Mood disorder,[ICD-11: 6A60-6E23]
T07806,HTR1B,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T07806,HTR1B,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T07806,HTR1B,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T07806,HTR1B,INDICATI,Approved,Psychotic disorder,[ICD-11: 6A20-6A25]
T07806,HTR1B,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T07806,HTR1B,INDICATI,Phase 2,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T07816,#N/A,TARGETID,T07816,,
T07816,#N/A,TARGNAME,Leishmania major Proteasome (Leishm Proteasome),,
T07816,#N/A,INDICATI,Phase 2,Leishmaniasis,[ICD-11: 1F54]
,#N/A,,,,
T07861,#N/A,TARGETID,T07861,,
T07861,#N/A,TARGNAME,IL-1 synthesis/release (IL-1 synth/rele),,
T07861,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T07893,#N/A,TARGETID,T07893,,
T07893,#N/A,TARGNAME,Polyamine transport (Poly trans),,
T07893,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T07931,LILRB2,TARGETID,T07931,,
T07931,LILRB2,TARGNAME,Leukocyte immunoglobulin-like receptor B2 (LILRB2),,
T07931,LILRB2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T07958,EPO,TARGETID,T07958,,
T07958,EPO,TARGNAME,Erythropoietin (EPO),,
T07958,EPO,INDICATI,Phase 2,Anemia,[ICD-11: 3A00-3A9Z]
T07958,EPO,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T07958,EPO,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T08014,TARDBP,TARGETID,T08014,,
T08014,TARDBP,TARGNAME,TAR DNA binding protein 43 (TARDBP),,
T08014,TARDBP,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T08014,TARDBP,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T08014,TARDBP,INDICATI,Phase 1,Cerebral ischaemic stroke,[ICD-11: 8B11]
,#N/A,,,,
T08029,CFP,TARGETID,T08029,,
T08029,CFP,TARGNAME,Complement factor P (CFP),,
T08029,CFP,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T08029,CFP,INDICATI,Phase 2,Sickle-cell disorder,[ICD-11: 3A51]
,#N/A,,,,
T08123,LRRK2,TARGETID,T08123,,
T08123,LRRK2,TARGNAME,Leucine-rich repeat kinase 2 (LRRK2),,
T08123,LRRK2,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T08133,TRPV6,TARGETID,T08133,,
T08133,TRPV6,TARGNAME,Transient receptor potential cation channel V6 (TRPV6),,
T08133,TRPV6,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T08133,TRPV6,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T08133,TRPV6,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T08139,FANCA,TARGETID,T08139,,
T08139,FANCA,TARGNAME,Fanconi anemia group A protein (FANCA),,
T08139,FANCA,INDICATI,Phase 2,Aplastic anaemia,[ICD-11: 3A70]
,#N/A,,,,
T08156,IFNA5,TARGETID,T08156,,
T08156,IFNA5,TARGNAME,Interferon-alpha 5 (IFNA5),,
T08156,IFNA5,INDICATI,Phase 1/2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T08156,IFNA5,INDICATI,Phase 1/2,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T08231,CD74,TARGETID,T08231,,
T08231,CD74,TARGNAME,HLA-DR antigens-associated invariant (CD74),,
T08231,CD74,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T08231,CD74,INDICATI,Phase 1/2,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T08298,GZMB,TARGETID,T08298,,
T08298,GZMB,TARGNAME,Granzyme B (GZMB),,
T08298,GZMB,INDICATI,Investigative,Aneurysm/dissection,[ICD-11: BD50]
,#N/A,,,,
T08306,CD79B,TARGETID,T08306,,
T08306,CD79B,TARGNAME,B-cell-specific glycoprotein B29 (CD79B),,
T08306,CD79B,INDICATI,Phase 1,Autoimmune disease,[ICD-11: 4A40-4A45]
T08306,CD79B,INDICATI,Approved,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T08306,CD79B,INDICATI,Phase 2,Follicular lymphoma,[ICD-11: 2A80]
T08306,CD79B,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T08306,CD79B,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
,#N/A,,,,
T08326,CDK12,TARGETID,T08326,,
T08326,CDK12,TARGNAME,Cyclin-dependent kinase 12 (CDK12),,
T08326,CDK12,INDICATI,Phase 1,Leishmaniasis,[ICD-11: 1F54]
T08326,CDK12,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T08378,SLC23A2,TARGETID,T08378,,
T08378,SLC23A2,TARGNAME,Solute carrier family 23 member 2 (SLC23A2),,
T08378,SLC23A2,INDICATI,Approved,Autoimmune liver disease,[ICD-11: DB96]
T08378,SLC23A2,INDICATI,Phase 2,Urinary tract infection,[ICD-11: GC08]
T08378,SLC23A2,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T08383,#N/A,TARGETID,T08383,,
T08383,#N/A,TARGNAME,Ketogenesis (KG),,
T08383,#N/A,INDICATI,Phase 2,Cognition symptoms/signs/clinical sympton,[ICD-11: MB21]
,#N/A,,,,
T08391,JAK2,TARGETID,T08391,,
T08391,JAK2,TARGNAME,Janus kinase 2 (JAK-2),,
T08391,JAK2,INDICATI,Phase 1/2,Acquired hypomelanotic disorder,[ICD-11: ED63]
T08391,JAK2,INDICATI,Phase 2,Alopecia,[ICD-11: ED70]
T08391,JAK2,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T08391,JAK2,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
T08391,JAK2,INDICATI,Phase 2,B-cell lymphoma,[ICD-11: 2A86]
T08391,JAK2,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T08391,JAK2,INDICATI,Investigative,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T08391,JAK2,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T08391,JAK2,INDICATI,Investigative,Liver cancer,[ICD-11: 2C12]
T08391,JAK2,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T08391,JAK2,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T08391,JAK2,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T08391,JAK2,INDICATI,Terminated,Multiple myeloma,[ICD-11: 2A83]
T08391,JAK2,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T08391,JAK2,INDICATI,Phase 3,Muscular dystrophy,[ICD-11: 8C70]
T08391,JAK2,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T08391,JAK2,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T08391,JAK2,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T08391,JAK2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T08391,JAK2,INDICATI,Approved,Thrombocytosis,[ICD-11: 3B63]
T08391,JAK2,INDICATI,Terminated,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T08441,#N/A,TARGETID,T08441,,
T08441,#N/A,TARGNAME,Viral Maturation (VM),,
T08441,#N/A,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T08499,NLRP3,TARGETID,T08499,,
T08499,NLRP3,TARGNAME,Caterpiller protein 1.1 (NLRP3),,
T08499,NLRP3,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T08499,NLRP3,INDICATI,Phase 2,Gout,[ICD-11: FA25]
T08499,NLRP3,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T08499,NLRP3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T08583,THBD,TARGETID,T08583,,
T08583,THBD,TARGNAME,Thrombomodulin (THBD),,
T08583,THBD,INDICATI,Discontinued in Phase 3,Disseminated intravascular coagulation,[ICD-11: 3B20]
,#N/A,,,,
T08735,Asperg M2DH,TARGETID,T08735,,
T08735,Asperg M2DH,TARGNAME,Aspergillus Mannitol 2-dehydrogenase (Asperg M2DH),,
T08735,Asperg M2DH,INDICATI,Approved,Bronchiectasis,[ICD-11: CA24]
T08735,Asperg M2DH,INDICATI,Approved,Kidney failure,[ICD-11: GB60-GB6Z]
,#N/A,,,,
T08743,#N/A,TARGETID,T08743,,
T08743,#N/A,TARGNAME,Aminopeptidase (AMP),,
T08743,#N/A,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T08743,#N/A,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T08743,#N/A,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T08856,MMP8,TARGETID,T08856,,
T08856,MMP8,TARGNAME,Matrix metalloproteinase-8 (MMP-8),,
T08856,MMP8,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T08856,MMP8,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
T08856,MMP8,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T08884,Plasm TRAP,TARGETID,T08884,,
T08884,Plasm TRAP,TARGNAME,Plasmodium Thrombospondin relate anonymous protein (Plasm TRAP),,
T08884,Plasm TRAP,INDICATI,Phase 2,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T08898,MC2R,TARGETID,T08898,,
T08898,MC2R,TARGNAME,Melanocortin receptor 2 (MC2R),,
T08898,MC2R,INDICATI,Approved,Adrenocortical insufficiency,[ICD-11: 5A74]
,#N/A,,,,
T08910,GABRG2,TARGETID,T08910,,
T08910,GABRG2,TARGNAME,GABA(A) receptor gamma-2 (GABRG2),,
T08910,GABRG2,INDICATI,Discontinued in Phase 1,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T08910,GABRG2,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T08910,GABRG2,INDICATI,Phase 3,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T08910,GABRG2,INDICATI,Discontinued in Phase 3,Female pelvic pain,[ICD-11: GA34]
T08910,GABRG2,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T08910,GABRG2,INDICATI,Approved,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T08910,GABRG2,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T08910,GABRG2,INDICATI,Phase 3,Status epilepticus,[ICD-11: 8A66]
T08910,GABRG2,INDICATI,Terminated,Substance abuse,[ICD-11: 6C40]
T08910,GABRG2,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
T08910,GABRG2,INDICATI,Phase 2,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T08922,ACACB,TARGETID,T08922,,
T08922,ACACB,TARGNAME,Acetyl-CoA carboxylase 2 (ACACB),,
T08922,ACACB,INDICATI,Discontinued in Phase 3,Obesity,[ICD-11: 5B80-5B81]
T08922,ACACB,INDICATI,Investigative,Parkinsonism,[ICD-11: 8A00]
T08922,ACACB,INDICATI,Investigative,Skin disease,[ICD-11: EA00-EM0Z]
T08922,ACACB,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T09005,Cory mTOX,TARGETID,T09005,,
T09005,Cory mTOX,TARGNAME,Corynebacterium Mutated CRM197 (Cory mTOX),,
T09005,Cory mTOX,INDICATI,Approved,Infectious meningitis,[ICD-11: 1D01]
T09005,Cory mTOX,INDICATI,Approved,Meningococcal disease,[ICD-11: 1C1C]
,#N/A,,,,
T09037,EV VP35 mRNA,TARGETID,T09037,,
T09037,EV VP35 mRNA,TARGNAME,Ebola virus VP35 messenger RNA (EV VP35 mRNA),,
T09037,EV VP35 mRNA,INDICATI,Phase 1,Filovirus disease,[ICD-11: 1D60]
,#N/A,,,,
T09058,TPBG,TARGETID,T09058,,
T09058,TPBG,TARGNAME,Oncotrophoblast glycoprotein 5T4 (TPBG),,
T09058,TPBG,INDICATI,Terminated,Breast cancer,[ICD-11: 2C60-2C6Y]
T09058,TPBG,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T09058,TPBG,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T09058,TPBG,INDICATI,Phase 2/3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T09092,IL10,TARGETID,T09092,,
T09092,IL10,TARGNAME,Interleukin-10 (IL10),,
T09092,IL10,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
T09092,IL10,INDICATI,Phase 2,Endometriosis,[ICD-11: GA10]
T09092,IL10,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T09092,IL10,INDICATI,Phase 2,Knee osteoarthritis,[ICD-11: FA01]
T09092,IL10,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T09092,IL10,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T09092,IL10,INDICATI,Investigative,Psoriasis,[ICD-11: EA90]
T09092,IL10,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
T09092,IL10,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T09092,IL10,INDICATI,Phase 2,Sarcoidosis,[ICD-11: 4B20]
T09092,IL10,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T09130,#N/A,TARGETID,T09130,,
T09130,#N/A,TARGNAME,Muscarinic acetylcholine receptor (CHRM),,
T09130,#N/A,INDICATI,Approved,Abnormal micturition,[ICD-11: MF50]
T09130,#N/A,INDICATI,Approved,Addictive disorder,[ICD-11: 6C50-6C5Z]
T09130,#N/A,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T09130,#N/A,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T09130,#N/A,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T09130,#N/A,INDICATI,Approved,Cataract,[ICD-11: 9B10]
T09130,#N/A,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T09130,#N/A,INDICATI,Terminated,Cognition symptoms/signs/clinical sympton,[ICD-11: MB21]
T09130,#N/A,INDICATI,Approved,Functional bladder disorder,[ICD-11: GC50]
T09130,#N/A,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T09130,#N/A,INDICATI,Phase 2,Lips/oral mucosa miscellaneous disorder,[ICD-11: DA02]
T09130,#N/A,INDICATI,Discontinued in Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T09130,#N/A,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T09130,#N/A,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T09130,#N/A,INDICATI,Approved,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T09227,#N/A,TARGETID,T09227,,
T09227,#N/A,TARGNAME,Protein tyrosine phosphatase (PTP),,
T09227,#N/A,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T09227,#N/A,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
T09227,#N/A,INDICATI,Phase 2a,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T09347,#N/A,TARGETID,T09347,,
T09347,#N/A,TARGNAME,Neurotransmitter release (NT rele),,
T09347,#N/A,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
,#N/A,,,,
T09423,KCNJ10,TARGETID,T09423,,
T09423,KCNJ10,TARGNAME,Inward rectifier potassium channel Kir1.2 (KCNJ10),,
T09423,KCNJ10,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T09423,KCNJ10,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T09483,EGR1,TARGETID,T09483,,
T09483,EGR1,TARGNAME,EGR1 messenger RNA (EGR1 mRNA),,
T09483,EGR1,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T09507,APOB,TARGETID,T09507,,
T09507,APOB,TARGNAME,APOB messenger RNA (APOB mRNA),,
T09507,APOB,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T09528,CXCR5,TARGETID,T09528,,
T09528,CXCR5,TARGNAME,C-X-C chemokine receptor type 5 (CXCR5),,
T09528,CXCR5,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T09528,CXCR5,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T09528,CXCR5,INDICATI,Phase 2,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T09538,ALPL,TARGETID,T09538,,
T09538,ALPL,TARGNAME,Alkaline phosphatase tissue-nonspecific (ALPL),,
T09538,ALPL,INDICATI,Withdrawn from market,Colon cancer,[ICD-11: 2B90]
T09538,ALPL,INDICATI,Approved,Genetic prion disease,[ICD-11: 8E02]
T09538,ALPL,INDICATI,Phase 1,Mineral absorption/transport disorder,[ICD-11: 5C64]
T09538,ALPL,INDICATI,Approved,Parasitic infection,[ICD-11: 1D0Y-1G2Z]
T09538,ALPL,INDICATI,Phase 2,Pseudoxanthoma elasticum,ICD-11: EC40
,#N/A,,,,
T09572,MCHR1,TARGETID,T09572,,
T09572,MCHR1,TARGNAME,Melanin-concentrating hormone receptor 1 (MCHR1),,
T09572,MCHR1,INDICATI,Preclinical,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T09572,MCHR1,INDICATI,Preclinical,Depression,[ICD-11: 6A70-6A7Z]
T09572,MCHR1,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T09572,MCHR1,INDICATI,Investigative,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T09756,#N/A,TARGETID,T09756,,
T09756,#N/A,TARGNAME,Polyamine unspecific (PLA),,
T09756,#N/A,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T09826,TOP1,TARGETID,T09826,,
T09826,TOP1,TARGNAME,DNA topoisomerase I (TOP1),,
T09826,TOP1,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T09826,TOP1,INDICATI,Clinical trial,Bladder cancer,[ICD-11: 2C94]
T09826,TOP1,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T09826,TOP1,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T09826,TOP1,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T09826,TOP1,INDICATI,Phase 2,Esophageal cancer,[ICD-11: 2B70]
T09826,TOP1,INDICATI,Phase 1,Gastrointestinal stromal tumour,[ICD-11: 2B5B]
T09826,TOP1,INDICATI,Phase 3,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T09826,TOP1,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T09826,TOP1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T09826,TOP1,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T09826,TOP1,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T09826,TOP1,INDICATI,Phase 3,Non-small-cell lung cancer,[ICD-11: 2C25]
T09826,TOP1,INDICATI,Approved,Ovarian cancer,[ICD-11: 2C73]
T09826,TOP1,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T09826,TOP1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T09826,TOP1,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T09909,AGTR2,TARGETID,T09909,,
T09909,AGTR2,TARGNAME,Angiotensin II receptor type-2 (AGTR2),,
T09909,AGTR2,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T09909,AGTR2,INDICATI,Phase 2,Neuropathy,[ICD-11: 8C0Z]
T09909,AGTR2,INDICATI,Approved,Secondary hypertension,[ICD-11: BA04]
T09909,AGTR2,INDICATI,Phase 2,Zoster,[ICD-11: 1E91]
,#N/A,,,,
T09937,#N/A,TARGETID,T09937,,
T09937,#N/A,TARGNAME,Receptor unspecific (Rec),,
T09937,#N/A,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T09937,#N/A,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T09937,#N/A,INDICATI,Phase 1,Oral mucositis,[ICD-11: DA01]
T09937,#N/A,INDICATI,Discontinued in Phase 2,Skin sensation disturbance,[ICD-11: ME65]
T09937,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T09960,CCR5,TARGETID,T09960,,
T09960,CCR5,TARGNAME,C-C chemokine receptor type 5 (CCR5),,
T09960,CCR5,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T09960,CCR5,INDICATI,Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T09960,CCR5,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T09960,CCR5,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T09960,CCR5,INDICATI,Phase 2a,Postoperative inflammation,[ICD-11: 1A00-CA43]
T09960,CCR5,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T09960,CCR5,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T09960,CCR5,INDICATI,Terminated,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T10052,CCNE1,TARGETID,T10052,,
T10052,CCNE1,TARGNAME,G1/S-specific cyclin-E1 (CCNE1),,
T10052,CCNE1,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
,#N/A,,,,
T10091,RHO,TARGETID,T10091,,
T10091,RHO,TARGNAME,Rhodopsin (RHO),,
T10091,RHO,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T10092,FSHB,TARGETID,T10092,,
T10092,FSHB,TARGNAME,Follicle stimulating hormone (FSHB),,
T10092,FSHB,INDICATI,Phase 1,Female infertility,[ICD-11: GA31]
T10092,FSHB,INDICATI,Phase 2,Male infertility,[ICD-11: GB04]
,#N/A,,,,
T10147,PTPRS,TARGETID,T10147,,
T10147,PTPRS,TARGNAME,Protein-tyrosine phosphatase sigma (R-PTP-sigma),,
T10147,PTPRS,INDICATI,Approved,Bone paget disease,[ICD-11: FB85]
,#N/A,,,,
T10191,CD4,TARGETID,T10191,,
T10191,CD4,TARGNAME,T-cell surface glycoprotein CD4 (CD4),,
T10191,CD4,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T10191,CD4,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T10191,CD4,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T10191,CD4,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T10191,CD4,INDICATI,Phase 3,Lymphoma,[ICD-11: 2A80-2A86]
T10191,CD4,INDICATI,Phase 1,Mature T-cell lymphoma,[ICD-11: 2A90]
T10191,CD4,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T10191,CD4,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T10191,CD4,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T10191,CD4,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T10249,#N/A,TARGETID,T10249,,
T10249,#N/A,TARGNAME,Histamine/peptide leukotriene release (His/p-LT rele),,
T10249,#N/A,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
,#N/A,,,,
T10265,PDE4B,TARGETID,T10265,,
T10265,PDE4B,TARGNAME,Phosphodiesterase 4B (PDE4B),,
T10265,PDE4B,INDICATI,Investigative,Acute upper respiratory infection,[ICD-11: CA07]
T10265,PDE4B,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T10265,PDE4B,INDICATI,Terminated,Amyloidosis,[ICD-11: 5D00]
T10265,PDE4B,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T10265,PDE4B,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T10265,PDE4B,INDICATI,Phase 1,Choreiform disorder,[ICD-11: 8A01]
T10265,PDE4B,INDICATI,Terminated,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T10265,PDE4B,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T10265,PDE4B,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T10265,PDE4B,INDICATI,Phase 3,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T10265,PDE4B,INDICATI,Investigative,Mature B-cell leukaemia,[ICD-11: 2A82]
T10265,PDE4B,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T10265,PDE4B,INDICATI,Phase 1,Mood disorder,[ICD-11: 6A60-6E23]
T10265,PDE4B,INDICATI,Discontinued in Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T10265,PDE4B,INDICATI,Discontinued in Phase 1,Mycosis fungoides,[ICD-11: 2B01]
T10265,PDE4B,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T10265,PDE4B,INDICATI,Investigative,Pneumonia,[ICD-11: CA40]
T10265,PDE4B,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T10265,PDE4B,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T10265,PDE4B,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T10265,PDE4B,INDICATI,Investigative,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T10339,#N/A,TARGETID,T10339,,
T10339,#N/A,TARGNAME,Lipoxygenase (ALOX),,
T10339,#N/A,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T10339,#N/A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T10362,#N/A,TARGETID,T10362,,
T10362,#N/A,TARGNAME,Enzyme unspecific (Enz),,
T10362,#N/A,INDICATI,Terminated,Acute diabete complication,[ICD-11: 5A2Y]
T10362,#N/A,INDICATI,Terminated,Bacterial infection,[ICD-11: 1A00-1C4Z]
T10362,#N/A,INDICATI,Terminated,Colorectal cancer,[ICD-11: 2B91]
T10362,#N/A,INDICATI,Approved,Female genital tract inflammatory disorder,[ICD-11: GA0Z]
T10362,#N/A,INDICATI,Terminated,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T10362,#N/A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T10362,#N/A,INDICATI,Phase 1,Infectious meningitis,[ICD-11: 1D01]
T10362,#N/A,INDICATI,Terminated,Lysosomal disease,[ICD-11: 5C56]
T10362,#N/A,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T10362,#N/A,INDICATI,Terminated,Mycobacterium infection,[ICD-11: 1B10-1B21]
T10362,#N/A,INDICATI,Phase 2,Nail/perionychium infection,[ICD-11: EE12]
T10362,#N/A,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
T10362,#N/A,INDICATI,Phase 2,Onchocerciasis,[ICD-11: 1F6A]
,#N/A,,,,
T10383,PLD2,TARGETID,T10383,,
T10383,PLD2,TARGNAME,Phospholipase D2 (PLD2),,
T10383,PLD2,INDICATI,Clinical trial,Coagulation defect,[ICD-11: 3B10]
,#N/A,,,,
T10445,#N/A,TARGETID,T10445,,
T10445,#N/A,TARGNAME,Lipase unspecific (LIP),,
T10445,#N/A,INDICATI,Discontinued in Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T10482,F12,TARGETID,T10482,,
T10482,F12,TARGNAME,Factor XII messenger RNA (FA12 mRNA),,
T10482,F12,INDICATI,Clinical trial,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T10491,ACKR3,TARGETID,T10491,,
T10491,ACKR3,TARGNAME,C-X-C chemokine receptor type 7 (ACKR3),,
T10491,ACKR3,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T10491,ACKR3,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T10513,ITGB2,TARGETID,T10513,,
T10513,ITGB2,TARGNAME,Integrin beta-2 (ITGB2),,
T10513,ITGB2,INDICATI,Discontinued in Phase 1,Cerebral ischaemia,[ICD-11: 8B1Z]
T10513,ITGB2,INDICATI,Phase 1/2,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T10513,ITGB2,INDICATI,Discontinued in Phase 2,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T10513,ITGB2,INDICATI,Discontinued in Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T10592,DNM2,TARGETID,T10592,,
T10592,DNM2,TARGNAME,DNM2 messenger RNA (DNM2 mRNA),,
T10592,DNM2,INDICATI,Phase 2,Congenital myopathy,[ICD-11: 8C72]
T10592,DNM2,INDICATI,Phase 1/2,Congenital myopathy,ICD-11: 8C72
,#N/A,,,,
T10670,NPY2R,TARGETID,T10670,,
T10670,NPY2R,TARGNAME,Neuropeptide Y receptor type 2 (NPY2R),,
T10670,NPY2R,INDICATI,Investigative,Acute diabete complication,[ICD-11: 5A2Y]
T10670,NPY2R,INDICATI,Investigative,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T10670,NPY2R,INDICATI,Discontinued in Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T10735,HDC,TARGETID,T10735,,
T10735,HDC,TARGNAME,Histidine decarboxylase (HDC),,
T10735,HDC,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T10735,HDC,INDICATI,Phase 3,Hypo-osmolality/hyponatraemia,[ICD-11: 5C72]
T10735,HDC,INDICATI,Phase 1,Pruritus,[ICD-11: EC90]
T10735,HDC,INDICATI,Phase 2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
,#N/A,,,,
T10762,BMP6,TARGETID,T10762,,
T10762,BMP6,TARGNAME,Bone morphogenetic protein 6 (BMP6),,
T10762,BMP6,INDICATI,Phase 2,Acute disease anaemia,[ICD-11: 3A90]
,#N/A,,,,
T10783,#N/A,TARGETID,T10783,,
T10783,#N/A,TARGNAME,MERS-CoV spike glycoprotein S2' HR1 region (S S2'HR1),,
T10783,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T10783,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T10822,CDK8,TARGETID,T10822,,
T10822,CDK8,TARGNAME,Cyclin-dependent kinase 8 (CDK8),,
T10822,CDK8,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T10822,CDK8,INDICATI,Preclinical,Colorectal cancer,[ICD-11: 2B91]
T10822,CDK8,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T10822,CDK8,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T10828,AFP,TARGETID,T10828,,
T10828,AFP,TARGNAME,Alpha-fetoprotein (AFP),,
T10828,AFP,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T10828,AFP,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
,#N/A,,,,
T10877,CD38,TARGETID,T10877,,
T10877,CD38,TARGNAME,Cyclic ADP-ribose hydrolase 1 (CD38),,
T10877,CD38,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T10877,CD38,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T10877,CD38,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T10877,CD38,INDICATI,Phase 1/2,Mature B-cell lymphoma,[ICD-11: 2A85]
T10877,CD38,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T10877,CD38,INDICATI,Phase 2,Myasthenia gravis,[ICD-11: 8C6Y]
T10877,CD38,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T10877,CD38,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T10877,CD38,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T10877,CD38,INDICATI,Phase 2,Thrombocytopenia,ICD-11: 3B64
T10877,CD38,INDICATI,Phase 1,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T10897,SCD,TARGETID,T10897,,
T10897,SCD,TARGNAME,Acyl-CoA desaturase (SCD),,
T10897,SCD,INDICATI,Investigative,Acute diabete complication,[ICD-11: 5A2Y]
T10897,SCD,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T10897,SCD,INDICATI,Phase 2/3,Inborn lipid metabolism error,[ICD-11: 5C52]
T10897,SCD,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T10937,MDM2,TARGETID,T10937,,
T10937,MDM2,TARGNAME,Mdm2 messenger RNA (MDM2 mRNA),,
T10937,MDM2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T10965,SELP,TARGETID,T10965,,
T10965,SELP,TARGNAME,P-selectin (SELP),,
T10965,SELP,INDICATI,Discontinued in Phase 1,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T10965,SELP,INDICATI,Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T10965,SELP,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T10965,SELP,INDICATI,Approved,Circulatory system disease,[ICD-11: BE2Z]
T10965,SELP,INDICATI,Phase 2,Graft-versus-host disease,[ICD-11: 4B24]
T10965,SELP,INDICATI,Phase 2/3,Hypertension,[ICD-11: BA00-BA04]
T10965,SELP,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T10965,SELP,INDICATI,Phase 4,Sickle-cell disorder,[ICD-11: 3A51]
T10965,SELP,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T10965,SELP,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T10988,IL1RL2,TARGETID,T10988,,
T10988,IL1RL2,TARGNAME,IL-1 receptor-like 2 (IL1RL2),,
T10988,IL1RL2,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T10988,IL1RL2,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T10988,IL1RL2,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T10988,IL1RL2,INDICATI,Phase 3,Psoriasis,ICD-11: EA90
,#N/A,,,,
T11005,IFNW1,TARGETID,T11005,,
T11005,IFNW1,TARGNAME,Interferon-omega (IFNW1),,
T11005,IFNW1,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T11011,CRHR2,TARGETID,T11011,,
T11011,CRHR2,TARGNAME,Corticotropin-releasing factor receptor 2 (CRHR2),,
T11011,CRHR2,INDICATI,Terminated,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T11011,CRHR2,INDICATI,Phase 1,Binge eating disorder,[ICD-11: 6B82]
T11011,CRHR2,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T11069,#N/A,TARGETID,T11069,,
T11069,#N/A,TARGNAME,Lyase unspecific (LYA),,
T11069,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T11072,HTR1D,TARGETID,T11072,,
T11072,HTR1D,TARGNAME,5-HT 1D receptor (HTR1D),,
T11072,HTR1D,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T11072,HTR1D,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T11072,HTR1D,INDICATI,Terminated,Depression,[ICD-11: 6A70-6A7Z]
T11072,HTR1D,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T11072,HTR1D,INDICATI,Phase 2,Insomnia,[ICD-11: 7A00-7A0Z]
T11072,HTR1D,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T11072,HTR1D,INDICATI,Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T11072,HTR1D,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T11164,#N/A,TARGETID,T11164,,
T11164,#N/A,TARGNAME,Secretory phospholipase A2 (sPLA2),,
T11164,#N/A,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T11211,AR,TARGETID,T11211,,
T11211,AR,TARGNAME,Androgen receptor (AR),,
T11211,AR,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T11211,AR,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T11211,AR,INDICATI,Approved,Alcoholic liver disease,[ICD-11: DB94]
T11211,AR,INDICATI,Phase 2,Alopecia,[ICD-11: ED70]
T11211,AR,INDICATI,Investigative,Bladder cancer,[ICD-11: 2C94]
T11211,AR,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T11211,AR,INDICATI,Discontinued in Phase 1,Cachexia,[ICD-11: MG20]
T11211,AR,INDICATI,Phase 4,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T11211,AR,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T11211,AR,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T11211,AR,INDICATI,Phase 1,Contraceptive management,[ICD-11: QA21]
T11211,AR,INDICATI,Discontinued in Phase 2,Cystic fibrosis,[ICD-11: CA25]
T11211,AR,INDICATI,Discontinued in Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T11211,AR,INDICATI,Approved,Female pelvic pain,[ICD-11: GA34]
T11211,AR,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
T11211,AR,INDICATI,Approved,Hypo-osmolality/hyponatraemia,[ICD-11: 5C72]
T11211,AR,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
T11211,AR,INDICATI,Approved,Mammary tumour,[ICD-11: 2C60-2C6Z]
T11211,AR,INDICATI,Phase 1,Muscle disorder,[ICD-11: FB32-FB3Z]
T11211,AR,INDICATI,Phase 1,Muscular dystrophy,[ICD-11: 8C70]
T11211,AR,INDICATI,Investigative,Oesophagitis,[ICD-11: DA24]
T11211,AR,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T11211,AR,INDICATI,Phase 2,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T11211,AR,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
T11211,AR,INDICATI,Phase 4,Prostate hyperplasia,[ICD-11: GA90]
T11211,AR,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T11211,AR,INDICATI,Approved,Testicular dysfunction,[ICD-11: 5A81]
T11211,AR,INDICATI,Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T11241,S1PR3,TARGETID,T11241,,
T11241,S1PR3,TARGNAME,Sphingosine-1-phosphate receptor 3 (S1PR3),,
T11241,S1PR3,INDICATI,Preclinical,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T11253,HSPB1,TARGETID,T11253,,
T11253,HSPB1,TARGNAME,HSPB1 messenger RNA (HSPB1 mRNA),,
T11253,HSPB1,INDICATI,Investigative,Bladder cancer,[ICD-11: 2C94]
T11253,HSPB1,INDICATI,Investigative,Breast cancer,[ICD-11: 2C60-2C6Y]
T11253,HSPB1,INDICATI,Investigative,Lung cancer,[ICD-11: 2C25]
T11253,HSPB1,INDICATI,Investigative,Ovarian cancer,[ICD-11: 2C73]
T11253,HSPB1,INDICATI,Investigative,Prostate cancer,[ICD-11: 2C82]
T11253,HSPB1,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T11283,HSPD1,TARGETID,T11283,,
T11283,HSPD1,TARGNAME,Mitochondrial matrix protein P1 (HSPD1),,
T11283,HSPD1,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T11288,ABCC1,TARGETID,T11288,,
T11288,ABCC1,TARGNAME,Multidrug resistance-associated protein 1 (ABCC1),,
T11288,ABCC1,INDICATI,Approved,Gout,[ICD-11: FA25]
,#N/A,,,,
T11309,CCL2,TARGETID,T11309,,
T11309,CCL2,TARGNAME,Monocyte chemotactic and activating factor (CCL2),,
T11309,CCL2,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T11309,CCL2,INDICATI,Discontinued in Phase 1,Asthma,[ICD-11: CA23]
T11309,CCL2,INDICATI,Preclinical,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T11309,CCL2,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T11309,CCL2,INDICATI,Phase 3,Nephritic syndrome,[ICD-11: GB40]
T11309,CCL2,INDICATI,Preclinical,Rheumatoid arthritis,[ICD-11: FA20]
T11309,CCL2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T11388,CTSK,TARGETID,T11388,,
T11388,CTSK,TARGNAME,Cathepsin K (CTSK),,
T11388,CTSK,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T11388,CTSK,INDICATI,Patented,Bone cancer,[ICD-11: 2B5Z]
T11388,CTSK,INDICATI,Patented,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T11388,CTSK,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
T11388,CTSK,INDICATI,Patented,Digestive system disease,[ICD-11: DE2Z]
T11388,CTSK,INDICATI,Patented,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T11388,CTSK,INDICATI,Phase 3,Low bone mass disorder,[ICD-11: FB83]
T11388,CTSK,INDICATI,Discontinued in Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T11388,CTSK,INDICATI,Patented,Multiple sclerosis,[ICD-11: 8A40]
T11388,CTSK,INDICATI,Investigative,Musculoskeletal system/connective tissue disease,[ICD-11: FC0Z]
T11388,CTSK,INDICATI,Preclinical,Osteoarthritis,[ICD-11: FA00-FA05]
T11388,CTSK,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T11388,CTSK,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T11388,CTSK,INDICATI,Patented,Psoriasis,[ICD-11: EA90]
T11388,CTSK,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T11448,ADRA2A,TARGETID,T11448,,
T11448,ADRA2A,TARGNAME,Adrenergic receptor alpha-2A (ADRA2A),,
T11448,ADRA2A,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T11448,ADRA2A,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T11448,ADRA2A,INDICATI,Investigative,Dementia,[ICD-11: 6D80-6D8Z]
T11448,ADRA2A,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T11448,ADRA2A,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T11448,ADRA2A,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T11448,ADRA2A,INDICATI,Approved,Opioid use disorder,[ICD-11: 6C43]
T11448,ADRA2A,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T11448,ADRA2A,INDICATI,Discontinued in Phase 2,Sexual dysfunction,[ICD-11: HA00-HA01]
T11448,ADRA2A,INDICATI,IND submitted,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T11448,ADRA2A,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T11451,TLR9,TARGETID,T11451,,
T11451,TLR9,TARGNAME,Toll-like receptor 9 (TLR9),,
T11451,TLR9,INDICATI,Preclinical,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T11451,TLR9,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T11451,TLR9,INDICATI,Phase 1,Autoimmune disease,[ICD-11: 4A40-4A45]
T11451,TLR9,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T11451,TLR9,INDICATI,Phase 3,Colorectal cancer,[ICD-11: 2B91]
T11451,TLR9,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T11451,TLR9,INDICATI,Discontinued in Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T11451,TLR9,INDICATI,Phase 3,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T11451,TLR9,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T11451,TLR9,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T11451,TLR9,INDICATI,Phase 1,Influenza,[ICD-11: 1E30-1E32]
T11451,TLR9,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
T11451,TLR9,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T11451,TLR9,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T11451,TLR9,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T11451,TLR9,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T11451,TLR9,INDICATI,Phase 1/2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T11451,TLR9,INDICATI,Investigative,Parkinsonism,[ICD-11: 8A00]
T11451,TLR9,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T11451,TLR9,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T11451,TLR9,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T11451,TLR9,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T11451,TLR9,INDICATI,Investigative,Sepsis,[ICD-11: 1G40-1G41]
T11451,TLR9,INDICATI,Phase 2,Skin disease,[ICD-11: EA00-EM0Z]
T11451,TLR9,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T11451,TLR9,INDICATI,Investigative,Spine/trunk injury,[ICD-11: ND51]
T11451,TLR9,INDICATI,Phase 1/2,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
T11451,TLR9,INDICATI,Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T11453,GIP,TARGETID,T11453,,
T11453,GIP,TARGNAME,Gastric inhibitory polypeptide (GIP),,
T11453,GIP,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T11487,ACAT1,TARGETID,T11487,,
T11487,ACAT1,TARGNAME,Acetoacetyl-CoA thiolase (ACAT1),,
T11487,ACAT1,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T11487,ACAT1,INDICATI,Withdrawn from market,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T11562,#N/A,TARGETID,T11562,,
T11562,#N/A,TARGNAME,SARS-CoV spike glycoprotein (S),,
T11562,#N/A,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T11562,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T11562,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T11566,#N/A,TARGETID,T11566,,
T11566,#N/A,TARGNAME,SARS-CoV envelope small membrane protein (E),,
T11566,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T11610,#N/A,TARGETID,T11610,,
T11610,#N/A,TARGNAME,SARS-CoV spike glycoprotein S2' HR1 region (S S2'HR1),,
T11610,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T11610,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T11615,SLC7A11,TARGETID,T11615,,
T11615,SLC7A11,TARGNAME,Cystine/glutamate transporter (SLC7A11),,
T11615,SLC7A11,INDICATI,Phase 2,Body-focused behaviour disorder,[ICD-11: 6B25]
,#N/A,,,,
T11701,IL31,TARGETID,T11701,,
T11701,IL31,TARGNAME,Interleukin-31 (IL31),,
T11701,IL31,INDICATI,Phase 1,Atopic eczema,[ICD-11: EA80]
T11701,IL31,INDICATI,Phase 1,Prurigo,[ICD-11: EC91]
,#N/A,,,,
T11754,#N/A,TARGETID,T11754,,
T11754,#N/A,TARGNAME,Fatty acid amide hydrolase (FAAH),,
T11754,#N/A,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T11754,#N/A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T11754,#N/A,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T11754,#N/A,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
T11754,#N/A,INDICATI,Phase 2,Liver disease,[ICD-11: DB90-DB9Z]
T11754,#N/A,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T11754,#N/A,INDICATI,Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
T11754,#N/A,INDICATI,Phase 2,Social anxiety disorder,[ICD-11: 6B04]
,#N/A,,,,
T11822,#N/A,TARGETID,T11822,,
T11822,#N/A,TARGNAME,Retinoic acid receptor (RAR),,
T11822,#N/A,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T11822,#N/A,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T11822,#N/A,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
T11822,#N/A,INDICATI,Terminated,Breast cancer,[ICD-11: 2C60-2C6Y]
T11822,#N/A,INDICATI,Investigative,Kinetoplastids,[ICD-11: 1F61-1G2Z]
T11822,#N/A,INDICATI,Approved,Light sensitivity impairment,[ICD-11: 9D45]
T11822,#N/A,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T11822,#N/A,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T11822,#N/A,INDICATI,Phase 2,Male infertility,[ICD-11: GB04]
T11822,#N/A,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T11822,#N/A,INDICATI,Discontinued in Phase 3,Psoriasis,[ICD-11: EA90]
T11822,#N/A,INDICATI,Phase 3,Retinopathy,[ICD-11: 9B71]
T11822,#N/A,INDICATI,Discontinued in Preregistration,Rosacea,[ICD-11: ED90]
T11822,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T11843,VKORC1,TARGETID,T11843,,
T11843,VKORC1,TARGNAME,Vitamin K epoxide reductase complex 1 (VKORC1),,
T11843,VKORC1,INDICATI,Approved,Bleeding disorder,[ICD-11: GA20-GA21]
T11843,VKORC1,INDICATI,Phase 3,Cerebral ischaemia,[ICD-11: 8B1Z]
T11843,VKORC1,INDICATI,Approved,Coagulation defect,[ICD-11: 3B10]
T11843,VKORC1,INDICATI,Approved,Pulmonary thromboembolism,[ICD-11: BB00]
T11843,VKORC1,INDICATI,Approved,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T11843,VKORC1,INDICATI,Approved,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T11911,KCNN1,TARGETID,T11911,,
T11911,KCNN1,TARGNAME,Calcium-activated potassium channel KCa2.1 (KCNN1),,
T11911,KCNN1,INDICATI,Clinical trial,Myelopathy,[ICD-11: 8B42]
,#N/A,,,,
T11947,F13B,TARGETID,T11947,,
T11947,F13B,TARGNAME,Coagulation factor XIII (F13B),,
T11947,F13B,INDICATI,Phase 3,Coagulation defect,[ICD-11: 3B10]
T11947,F13B,INDICATI,Phase 3,Graft-versus-host disease,[ICD-11: 4B24]
T11947,F13B,INDICATI,Terminated,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T12059,MAN2B1; MAN2B2; MAN2C1,TARGETID,T12059,,
T12059,MAN2B1; MAN2B2; MAN2C1,TARGNAME,Alpha-mannosidase (MANA),,
T12059,MAN2B1; MAN2B2; MAN2C1,INDICATI,Phase 3,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T12091,ACVR1,TARGETID,T12091,,
T12091,ACVR1,TARGNAME,Activin receptor-like kinase 2 (ALK-2),,
T12091,ACVR1,INDICATI,Phase 2,Anemia,[ICD-11: 3A00-3A9Z]
T12091,ACVR1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T12091,ACVR1,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T12091,ACVR1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T12097,MAGEA4,TARGETID,T12097,,
T12097,MAGEA4,TARGNAME,Melanoma-associated antigen 4 (MAGEA4),,
T12097,MAGEA4,INDICATI,Phase 2,Kaposi sarcoma,[ICD-11: 2B57]
T12097,MAGEA4,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T12097,MAGEA4,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T12097,MAGEA4,INDICATI,Phase 2,Synovial sarcoma,[ICD-11: 2B5A]
,#N/A,,,,
T12108,CRY1,TARGETID,T12108,,
T12108,CRY1,TARGNAME,Cryptochrome circadian clock 1 (CRY1),,
T12108,CRY1,INDICATI,Preclinical,Brain cancer,[ICD-11: 2A00]
T12108,CRY1,INDICATI,Preclinical,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T12119,SCN9A,TARGETID,T12119,,
T12119,SCN9A,TARGNAME,Voltage-gated sodium channel alpha Nav1.7 (SCN9A),,
T12119,SCN9A,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T12119,SCN9A,INDICATI,Phase 2,Bipolar disorder,[ICD-11: 6A60]
T12119,SCN9A,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T12119,SCN9A,INDICATI,Discontinued in Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T12119,SCN9A,INDICATI,Phase 2,Extremities vasodilatation,[ICD-11: EG00]
T12119,SCN9A,INDICATI,Phase 1,General pain disorder,[ICD-11: 8E43]
T12119,SCN9A,INDICATI,Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T12119,SCN9A,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T12119,SCN9A,INDICATI,Phase 2,Radiculopathy,[ICD-11: 8B93]
T12119,SCN9A,INDICATI,Phase 2,Trigeminal nerve disorder,[ICD-11: 8B82]
,#N/A,,,,
T12187,MycB ddl,TARGETID,T12187,,
T12187,MycB ddl,TARGNAME,Mycobacterium D-alanine-D-alanine ligase A (MycB ddl),,
T12187,MycB ddl,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T12187,MycB ddl,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T12187,MycB ddl,INDICATI,Phase 2,Obsessive-compulsive disorder,[ICD-11: 6B20]
,#N/A,,,,
T12189,#N/A,TARGETID,T12189,,
T12189,#N/A,TARGNAME,Telomerase messenger RNA (Telomerase mRNA),,
T12189,#N/A,INDICATI,Discontinued in Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
,#N/A,,,,
T12279,HPV E2 mRNA,TARGETID,T12279,,
T12279,HPV E2 mRNA,TARGNAME,Human papillomavirus E2 transactivator messenger RNA (HPV E2 mRNA),,
T12279,HPV E2 mRNA,INDICATI,Discontinued in Phase 2,Sexually transmitted infection,[ICD-11: 1A9Y-1A9Z]
,#N/A,,,,
T12355,CCND1,TARGETID,T12355,,
T12355,CCND1,TARGNAME,G1/S-specific cyclin-D1 (CCND1),,
T12355,CCND1,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T12355,CCND1,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T12355,CCND1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T12427,#N/A,TARGETID,T12427,,
T12427,#N/A,TARGNAME,Sodium pump (NaP),,
T12427,#N/A,INDICATI,Approved,Cardiovascular disease,[ICD-11: BA00-BE2Z]
,#N/A,,,,
T12475,GNRHR,TARGETID,T12475,,
T12475,GNRHR,TARGNAME,Gonadotropin-releasing hormone receptor (GNRHR),,
T12475,GNRHR,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
T12475,GNRHR,INDICATI,Approved,Endometriosis,[ICD-11: GA10]
T12475,GNRHR,INDICATI,Discontinued in Phase 1,Esophageal cancer,[ICD-11: 2B70]
T12475,GNRHR,INDICATI,Phase 3,Female infertility,[ICD-11: GA31]
T12475,GNRHR,INDICATI,Phase 3,Mature B-cell lymphoma,[ICD-11: 2A85]
T12475,GNRHR,INDICATI,Approved,Ovarian developmental anomaly,[ICD-11: LB45]
T12475,GNRHR,INDICATI,Approved,Ovarian dysfunction,[ICD-11: 5A80]
T12475,GNRHR,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T12475,GNRHR,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
T12475,GNRHR,INDICATI,Phase 2,Prostate disease,[ICD-11: GA91]
T12475,GNRHR,INDICATI,Discontinued in Phase 2,Prostate hyperplasia,[ICD-11: GA90]
T12475,GNRHR,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T12475,GNRHR,INDICATI,Phase 3,Uterine fibroid,[ICD-11: 2E86]
,#N/A,,,,
T12499,LCK,TARGETID,T12499,,
T12499,LCK,TARGNAME,LCK tyrosine protein kinase (LCK),,
T12499,LCK,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T12499,LCK,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T12499,LCK,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T12499,LCK,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T12499,LCK,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T12499,LCK,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T12541,PI4KB,TARGETID,T12541,,
T12541,PI4KB,TARGNAME,Phosphatidylinositol-4-kinase beta (PI4KB),,
T12541,PI4KB,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T12541,PI4KB,INDICATI,Phase 1,Zoonotic viral disease,ICD-11: 1D6Y
,#N/A,,,,
T12646,VCP,TARGETID,T12646,,
T12646,VCP,TARGNAME,Valosin-containing protein p97 (VCP),,
T12646,VCP,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T12646,VCP,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T12646,VCP,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T12646,VCP,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T12719,#N/A,TARGETID,T12719,,
T12719,#N/A,TARGNAME,Cytomegalovirus Replication (CMV replication),,
T12719,#N/A,INDICATI,Discontinued in Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T12808,PRKCA,TARGETID,T12808,,
T12808,PRKCA,TARGNAME,Protein kinase C alpha (PRKCA),,
T12808,PRKCA,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T12808,PRKCA,INDICATI,Approved,Muscular atrophy,[ICD-11: 8B61]
T12808,PRKCA,INDICATI,Terminated,Nephritic syndrome,[ICD-11: GB40]
T12808,PRKCA,INDICATI,Phase 2,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T12909,DMD,TARGETID,T12909,,
T12909,DMD,TARGNAME,Dystrophin (DMD),,
T12909,DMD,INDICATI,Phase 3,Muscular dystrophy,ICD-11: 8C70
T12909,DMD,INDICATI,Phase 2/3,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T12966,TNNC1,TARGETID,T12966,,
T12966,TNNC1,TARGNAME,Troponin C (TN-C),,
T12966,TNNC1,INDICATI,Approved,Acquired cutaneous blood vessel malformation,[ICD-11: EF20]
T12966,TNNC1,INDICATI,Phase 3,Cardiomyopathy,[ICD-11: BC43]
T12966,TNNC1,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T12966,TNNC1,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
,#N/A,,,,
T13017,SDC1,TARGETID,T13017,,
T13017,SDC1,TARGNAME,Syndecan-1 (SDC1),,
T13017,SDC1,INDICATI,Phase 1,Immune system disease,[ICD-11: 4A01-4B41]
T13017,SDC1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T13057,PTPN11,TARGETID,T13057,,
T13057,PTPN11,TARGNAME,Protein-tyrosine phosphatase SHP-2 (PTPN11),,
T13057,PTPN11,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T13075,CSNK1A1,TARGETID,T13075,,
T13075,CSNK1A1,TARGNAME,Casein kinase I alpha (CSNK1A1),,
T13075,CSNK1A1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T13075,CSNK1A1,INDICATI,Preclinical,Mature B-cell leukaemia,[ICD-11: 2A82]
T13075,CSNK1A1,INDICATI,Preclinical,Pancreatic cancer,[ICD-11: 2C10]
T13075,CSNK1A1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T13127,FNTB; FNTA,TARGETID,T13127,,
T13127,FNTB; FNTA,TARGNAME,Farnesyl protein transferase (Ftase),,
T13127,FNTB; FNTA,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T13127,FNTB; FNTA,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T13127,FNTB; FNTA,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T13127,FNTB; FNTA,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T13127,FNTB; FNTA,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T13127,FNTB; FNTA,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T13127,FNTB; FNTA,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T13127,FNTB; FNTA,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T13127,FNTB; FNTA,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
T13127,FNTB; FNTA,INDICATI,Approved,Premature ageing appearance,[ICD-11: LD2B]
T13127,FNTB; FNTA,INDICATI,Phase 2,Sexually transmitted infection,[ICD-11: 1A9Y-1A9Z]
T13127,FNTB; FNTA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T13176,EIF2AK3,TARGETID,T13176,,
T13176,EIF2AK3,TARGNAME,PRKR-like endoplasmic reticulum kinase (PERK),,
T13176,EIF2AK3,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T13201,CA1,TARGETID,T13201,,
T13201,CA1,TARGNAME,Carbonic anhydrase I (CA-I),,
T13201,CA1,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T13201,CA1,INDICATI,Withdrawn from market,Duodenal ulcer,[ICD-11: DA63]
T13201,CA1,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T13201,CA1,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T13201,CA1,INDICATI,Approved,Seborrhoeic dermatitis,[ICD-11: EA81]
T13201,CA1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T13209,#N/A,TARGETID,T13209,,
T13209,#N/A,TARGNAME,Activin receptor type II (ACVR2),,
T13209,#N/A,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T13251,IL12A,TARGETID,T13251,,
T13251,IL12A,TARGNAME,Interleukin-12 alpha (IL12A),,
T13251,IL12A,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T13251,IL12A,INDICATI,Phase 2/3,Indeterminate colitis,[ICD-11: DD72]
T13251,IL12A,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T13251,IL12A,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T13251,IL12A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T13251,IL12A,INDICATI,Approved,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T13259,ALDH5A1,TARGETID,T13259,,
T13259,ALDH5A1,TARGNAME,Succinate-semialdehyde dehydrogenase (ALDH5A1),,
T13259,ALDH5A1,INDICATI,Approved,Diagnostic imaging,[ICD-11: N.A.]
T13259,ALDH5A1,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
,#N/A,,,,
T13260,CYP19A1,TARGETID,T13260,,
T13260,CYP19A1,TARGNAME,Aromatase (CYP19A1),,
T13260,CYP19A1,INDICATI,Discontinued in Phase 2,Bladder cancer,[ICD-11: 2C94]
T13260,CYP19A1,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T13260,CYP19A1,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T13260,CYP19A1,INDICATI,Phase 2,Endometriosis,[ICD-11: GA10]
T13260,CYP19A1,INDICATI,Phase 2,Neuropathy,[ICD-11: 8C0Z]
T13260,CYP19A1,INDICATI,Phase 2/3,Oesophagitis,[ICD-11: DA24]
T13260,CYP19A1,INDICATI,Discontinued in Phase 2,Prostate disease,[ICD-11: GA91]
,#N/A,,,,
T13348,APEX1,TARGETID,T13348,,
T13348,APEX1,TARGNAME,AP endonuclease 1 (APEX1),,
T13348,APEX1,INDICATI,Investigative,Brain cancer,[ICD-11: 2A00]
T13348,APEX1,INDICATI,Investigative,Melanoma,[ICD-11: 2C30]
T13348,APEX1,INDICATI,Discontinued in Phase 2,Ocular cancer,[ICD-11: 2D00-2D07]
T13348,APEX1,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T13348,APEX1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T13409,HIV MA,TARGETID,T13409,,
T13409,HIV MA,TARGNAME,Human immunodeficiency virus Matrix p17 (HIV MA),,
T13409,HIV MA,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T13491,SLC29A1,TARGETID,T13491,,
T13491,SLC29A1,TARGNAME,Solute carrier family 29 member 1 (SLC29A1),,
T13491,SLC29A1,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
,#N/A,,,,
T13568,#N/A,TARGETID,T13568,,
T13568,#N/A,TARGNAME,Methamphetamine (Meth),,
T13568,#N/A,INDICATI,Phase 2,Stimulants use disorder,[ICD-11: 6C46]
,#N/A,,,,
T13616,ILK,TARGETID,T13616,,
T13616,ILK,TARGNAME,Integrin-linked protein kinase 1 (ILK),,
T13616,ILK,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T13629,PDCD1-CD274,TARGETID,T13629,,
T13629,PDCD1-CD274,TARGNAME,PD-1-PD-L1 interaction (PD-1/PD-L1 PPI),,
T13629,PDCD1-CD274,INDICATI,Patented,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T13629,PDCD1-CD274,INDICATI,Patented,Inflammatory liver disease,[ICD-11: DB97]
T13629,PDCD1-CD274,INDICATI,Patented,Postoperative inflammation,[ICD-11: 1A00-CA43]
T13629,PDCD1-CD274,INDICATI,Patented,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T13644,SSTR3,TARGETID,T13644,,
T13644,SSTR3,TARGNAME,Somatostatin receptor type 3 (SSTR3),,
T13644,SSTR3,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T13644,SSTR3,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T13644,SSTR3,INDICATI,Investigative,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T13712,#N/A,TARGETID,T13712,,
T13712,#N/A,TARGNAME,Cholesterol synthesis (Chole synth),,
T13712,#N/A,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T13712,#N/A,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T13714,NR1H2,TARGETID,T13714,,
T13714,NR1H2,TARGNAME,Oxysterols receptor LXR-beta (NR1H2),,
T13714,NR1H2,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T13714,NR1H2,INDICATI,Investigative,Depression,[ICD-11: 6A70-6A7Z]
,#N/A,,,,
T13726,RXRA,TARGETID,T13726,,
T13726,RXRA,TARGNAME,Retinoic acid receptor RXR-alpha (RXRA),,
T13726,RXRA,INDICATI,Approved,Kaposi sarcoma,[ICD-11: 2B57]
T13726,RXRA,INDICATI,Approved,Mycosis fungoides,[ICD-11: 2B01]
,#N/A,,,,
T13741,OGFR,TARGETID,T13741,,
T13741,OGFR,TARGNAME,Opioid receptor zeta (OGFR),,
T13741,OGFR,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T13741,OGFR,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T13852,S1PR1,TARGETID,T13852,,
T13852,S1PR1,TARGNAME,Sphingosine-1-phosphate receptor 1 (S1PR1),,
T13852,S1PR1,INDICATI,Phase 1,Acne vulgaris,[ICD-11: ED80]
T13852,S1PR1,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T13852,S1PR1,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T13852,S1PR1,INDICATI,Phase 2,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T13852,S1PR1,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T13852,S1PR1,INDICATI,Phase 1,Immune system disease,[ICD-11: 4A01-4B41]
T13852,S1PR1,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T13852,S1PR1,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T13852,S1PR1,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T13852,S1PR1,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T13852,S1PR1,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T13852,S1PR1,INDICATI,Phase 2,Pyoderma gangrenosum,[ICD-11: EB21]
T13852,S1PR1,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T13852,S1PR1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T13852,S1PR1,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T13852,S1PR1,INDICATI,Approved,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T13910,#N/A,TARGETID,T13910,,
T13910,#N/A,TARGNAME,Phosphofructokinase 2 (PFK2),,
T13910,#N/A,INDICATI,Phase 2,Type-1/2 diabete,[ICD-11: 5A10-5A11]
,#N/A,,,,
T14037,#N/A,TARGETID,T14037,,
T14037,#N/A,TARGNAME,RAC serine/threonine-protein kinase (AKT),,
T14037,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T14056,#N/A,TARGETID,T14056,,
T14056,#N/A,TARGNAME,Netrin (NET),,
T14056,#N/A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T14065,ITGB7,TARGETID,T14065,,
T14065,ITGB7,TARGNAME,Integrin beta-7 (ITGB7),,
T14065,ITGB7,INDICATI,Approved,Crohn disease,[ICD-11: DD70]
T14065,ITGB7,INDICATI,Approved,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T14110,KLB,TARGETID,T14110,,
T14110,KLB,TARGNAME,Beta-klotho (KLB),,
T14110,KLB,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T14110,KLB,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T14143,TGFB2,TARGETID,T14143,,
T14143,TGFB2,TARGNAME,Transforming growth factor beta 2 (TGFB2),,
T14143,TGFB2,INDICATI,Phase 3,Colorectal cancer,[ICD-11: 2B91]
,#N/A,,,,
T14231,LGR5,TARGETID,T14231,,
T14231,LGR5,TARGNAME,Leucine-rich repeat-containing GPCR 5 (LGR5),,
T14231,LGR5,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T14231,LGR5,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T14342,HIV RT,TARGETID,T14342,,
T14342,HIV RT,TARGNAME,Human immunodeficiency virus Reverse transcriptase (HIV RT),,
T14342,HIV RT,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T14342,HIV RT,INDICATI,Terminated,Cytomegaloviral disease,[ICD-11: 1D82]
T14342,HIV RT,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T14342,HIV RT,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T14342,HIV RT,INDICATI,Terminated,Herpes simplex infection,[ICD-11: 1F00]
T14342,HIV RT,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T14342,HIV RT,INDICATI,Phase 1,Mycobacterium infection,[ICD-11: 1B10-1B21]
T14342,HIV RT,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T14342,HIV RT,INDICATI,Phase 3,Sexually transmitted infection,[ICD-11: 1A9Y-1A9Z]
T14342,HIV RT,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T14342,HIV RT,INDICATI,Phase 2,Unspecific body region injury,[ICD-11: ND56]
T14342,HIV RT,INDICATI,Approved,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T14463,SOAT1; SOAT2,TARGETID,T14463,,
T14463,SOAT1; SOAT2,TARGNAME,Sterol O-acyltransferase (SOAT),,
T14463,SOAT1; SOAT2,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T14463,SOAT1; SOAT2,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
,#N/A,,,,
T14541,CD toxB,TARGETID,T14541,,
T14541,CD toxB,TARGNAME,Clostridium difficile Toxin B (CD toxB),,
T14541,CD toxB,INDICATI,Approved,Clostridium difficile enterocolitis,[ICD-11: 1A04]
T14541,CD toxB,INDICATI,Phase 3,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T14557,IL10RB,TARGETID,T14557,,
T14557,IL10RB,TARGNAME,Interleukin 10 receptor (IL10RB),,
T14557,IL10RB,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
T14557,IL10RB,INDICATI,Investigative,Indeterminate colitis,[ICD-11: DD72]
T14557,IL10RB,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T14558,TPSAB1,TARGETID,T14558,,
T14558,TPSAB1,TARGNAME,Tryptase alpha/beta-1 (Tryptase),,
T14558,TPSAB1,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T14558,TPSAB1,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
T14558,TPSAB1,INDICATI,Withdrawn from market,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T14558,TPSAB1,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
T14558,TPSAB1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T14582,MycB alr,TARGETID,T14582,,
T14582,MycB alr,TARGNAME,Mycobacterium Biosynthetic alanine racemase (MycB alr),,
T14582,MycB alr,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T14582,MycB alr,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T14582,MycB alr,INDICATI,Phase 2,Obsessive-compulsive disorder,[ICD-11: 6B20]
,#N/A,,,,
T14592,FAS,TARGETID,T14592,,
T14592,FAS,TARGNAME,Apoptosis mediating surface antigen FAS (FAS),,
T14592,FAS,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
T14592,FAS,INDICATI,Phase 2,Cerebral ischaemia,[ICD-11: 8B1Z]
T14592,FAS,INDICATI,Investigative,Mature T-cell lymphoma,[ICD-11: 2A90]
T14592,FAS,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T14592,FAS,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T14592,FAS,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T14592,FAS,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T14592,FAS,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T14597,ERBB2,TARGETID,T14597,,
T14597,ERBB2,TARGNAME,Erbb2 tyrosine kinase receptor (HER2),,
T14597,ERBB2,INDICATI,Phase 1/2,Bladder cancer,[ICD-11: 2C94]
T14597,ERBB2,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T14597,ERBB2,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T14597,ERBB2,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T14597,ERBB2,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T14597,ERBB2,INDICATI,Patented,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T14597,ERBB2,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T14597,ERBB2,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T14597,ERBB2,INDICATI,Phase 2,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T14597,ERBB2,INDICATI,Phase 3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T14597,ERBB2,INDICATI,Phase 1/2,Malignant mesenchymal neoplasm,[ICD-11: 2B5D-2B5Y]
T14597,ERBB2,INDICATI,Phase 2/3,Metastatic biliary tract neoplasms,[ICD-11: 2C14-2C17]
T14597,ERBB2,INDICATI,Phase 1,Metastatic malignant neoplasm,[ICD-11: 2D50-2E09]
T14597,ERBB2,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T14597,ERBB2,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T14597,ERBB2,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
T14597,ERBB2,INDICATI,Phase 1/2,Retinal vascular occlusion,[ICD-11: 9B74]
T14597,ERBB2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T14597,ERBB2,INDICATI,Phase 1,Spinal cord/cranial nerve neoplasm,[ICD-11: 2A02]
T14597,ERBB2,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T14597,ERBB2,INDICATI,Phase 1,Stomach cancer,ICD-11: 2B72
T14597,ERBB2,INDICATI,Phase 1,Testicular cancer,[ICD-11: 2C80]
T14597,ERBB2,INDICATI,Phase 2,Ureteral cancer,[ICD-11: 2C92]
T14597,ERBB2,INDICATI,Phase 2,Urogenital cancer,[ICD-11: 2C95-2C9Z]
,#N/A,,,,
T14602,F8,TARGETID,T14602,,
T14602,F8,TARGNAME,Coagulation factor VIII (F8),,
T14602,F8,INDICATI,Investigative,Angina pectoris,[ICD-11: BA40]
T14602,F8,INDICATI,Approved,Cerebral ischaemia,[ICD-11: 8B1Z]
T14602,F8,INDICATI,Approved,Coagulation defect,[ICD-11: 3B10]
T14602,F8,INDICATI,Phase 3,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T14602,F8,INDICATI,Phase 3,Liposarcoma,[ICD-11: 2B59]
T14602,F8,INDICATI,Approved,Sepsis,[ICD-11: 1G40-1G41]
T14602,F8,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T14602,F8,INDICATI,Phase 2,Venous thromboembolism,[ICD-11: BD72]
T14602,F8,INDICATI,Phase 3,Von Willebrand disease,[ICD-11: 3B12]
,#N/A,,,,
T14676,TNFSF13,TARGETID,T14676,,
T14676,TNFSF13,TARGNAME,A proliferation-inducing ligand (APRIL),,
T14676,TNFSF13,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T14676,TNFSF13,INDICATI,Phase 3,Lymphoma,[ICD-11: 2A80-2A86]
T14676,TNFSF13,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T14676,TNFSF13,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T14705,Bact uidA,TARGETID,T14705,,
T14705,Bact uidA,TARGNAME,Bacterial Beta-glucuronidase (Bact uidA),,
T14705,Bact uidA,INDICATI,Preclinical,Therapeutic intestinal toxicity,[ICD-11: DA94]
,#N/A,,,,
T14731,SIRT1,TARGETID,T14731,,
T14731,SIRT1,TARGNAME,NAD-dependent deacetylase sirtuin-1 (SIRT1),,
T14731,SIRT1,INDICATI,Phase 2,Choreiform disorder,[ICD-11: 8A01]
T14731,SIRT1,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T14731,SIRT1,INDICATI,Discontinued in Phase 2,Colon cancer,[ICD-11: 2B90]
T14731,SIRT1,INDICATI,Discontinued in Phase 2,Colorectal cancer,[ICD-11: 2B91]
T14731,SIRT1,INDICATI,Discontinued in Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T14731,SIRT1,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
T14731,SIRT1,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T14731,SIRT1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T14731,SIRT1,INDICATI,Phase 3,Systemic sclerosis,[ICD-11: 4A42]
T14731,SIRT1,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
T14731,SIRT1,INDICATI,Phase 3,Vasculitis,[ICD-11: 4A44]
,#N/A,,,,
T14755,CD40LG,TARGETID,T14755,,
T14755,CD40LG,TARGNAME,TNF related activation protein (CD40LG),,
T14755,CD40LG,INDICATI,Phase 1,B-cell lymphoma,[ICD-11: 2A86]
T14755,CD40LG,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T14755,CD40LG,INDICATI,Terminated,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T14755,CD40LG,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T14755,CD40LG,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T14755,CD40LG,INDICATI,Terminated,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T14755,CD40LG,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T14755,CD40LG,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
T14755,CD40LG,INDICATI,Investigative,Melanoma,[ICD-11: 2C30]
T14755,CD40LG,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T14755,CD40LG,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T14755,CD40LG,INDICATI,Phase 1,Sjogren syndrome,[ICD-11: 4A43]
T14755,CD40LG,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T14755,CD40LG,INDICATI,Phase 1,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T14825,KDR,TARGETID,T14825,,
T14825,KDR,TARGNAME,VEGFR2 messenger RNA (VEGFR2 mRNA),,
T14825,KDR,INDICATI,Discontinued in Phase 2,Degenerative high myopia,[ICD-11: 9B76]
,#N/A,,,,
T14834,PLA2G4A,TARGETID,T14834,,
T14834,PLA2G4A,TARGNAME,Cytosolic phospholipase A2 (GIVA cPLA2),,
T14834,PLA2G4A,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T14834,PLA2G4A,INDICATI,Phase 1/2,Atopic eczema,[ICD-11: EA80]
,#N/A,,,,
T14853,FGF23,TARGETID,T14853,,
T14853,FGF23,TARGNAME,Fibroblast growth factor-23 (FGF23),,
T14853,FGF23,INDICATI,Approved,Vitamin/non-protein cofactor absorption/transport disorder,[ICD-11: 5C63]
,#N/A,,,,
T14875,USP14,TARGETID,T14875,,
T14875,USP14,TARGNAME,Ubiquitin carboxyl-terminal hydrolase 14 (USP14),,
T14875,USP14,INDICATI,Preclinical,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T14875,USP14,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T14908,UGCG,TARGETID,T14908,,
T14908,UGCG,TARGNAME,Ceramide glucosyltransferase (UGCG),,
T14908,UGCG,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
T14908,UGCG,INDICATI,Approved,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T14908,UGCG,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T14912,MCL1,TARGETID,T14912,,
T14912,MCL1,TARGNAME,Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1),,
T14912,MCL1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T14912,MCL1,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T14912,MCL1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T14912,MCL1,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T14912,MCL1,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T14912,MCL1,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T14912,MCL1,INDICATI,Investigative,Rheumatoid arthritis,[ICD-11: FA20]
T14912,MCL1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T14912,MCL1,INDICATI,Withdrawn from market,Trematode disease,[ICD-11: 1F8Y]
,#N/A,,,,
T14945,CENPE,TARGETID,T14945,,
T14945,CENPE,TARGNAME,Centromeric protein E (CENPE),,
T14945,CENPE,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15000,CTLA4,TARGETID,T15000,,
T15000,CTLA4,TARGNAME,Cytotoxic T-lymphocyte protein 4 (CTLA-4),,
T15000,CTLA4,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T15000,CTLA4,INDICATI,Phase 2,Cervical cancer,[ICD-11: 2C77]
T15000,CTLA4,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T15000,CTLA4,INDICATI,Phase 3,Epidermal dysplasias,[ICD-11: EK90]
T15000,CTLA4,INDICATI,Approved,Liver cancer,[ICD-11: 2C12]
T15000,CTLA4,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T15000,CTLA4,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T15000,CTLA4,INDICATI,Phase 1,Non-small-cell lung cancer,[ICD-11: 2C25]
T15000,CTLA4,INDICATI,Phase 3,Pleural mesothelioma,[ICD-11: 2C26]
T15000,CTLA4,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T15000,CTLA4,INDICATI,Investigative,Rheumatoid arthritis,[ICD-11: FA20]
T15000,CTLA4,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15023,NRP1,TARGETID,T15023,,
T15023,NRP1,TARGNAME,Neuropilin-1 (NRP1),,
T15023,NRP1,INDICATI,Approved,Retinopathy,[ICD-11: 9B71]
T15023,NRP1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15068,PTK2,TARGETID,T15068,,
T15068,PTK2,TARGNAME,Focal adhesion kinase 1 (FAK),,
T15068,PTK2,INDICATI,Phase 1,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T15068,PTK2,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T15068,PTK2,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T15068,PTK2,INDICATI,Phase 2,Peritoneal cancer,[ICD-11: 2C51]
T15068,PTK2,INDICATI,Phase 1,Pulmonary hypertension,[ICD-11: BB01]
T15068,PTK2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15107,HIV p7,TARGETID,T15107,,
T15107,HIV p7,TARGNAME,Human immunodeficiency virus Nucleocapsid p7 (HIV p7),,
T15107,HIV p7,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T15117,#N/A,TARGETID,T15117,,
T15117,#N/A,TARGNAME,Adrenergic receptor (ADR),,
T15117,#N/A,INDICATI,Discontinued in Phase 1,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T15117,#N/A,INDICATI,Phase 2,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T15117,#N/A,INDICATI,Withdrawn from market,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T15117,#N/A,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T15117,#N/A,INDICATI,Approved,Diagnostic imaging,[ICD-11: N.A.]
T15117,#N/A,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T15117,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T15117,#N/A,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T15117,#N/A,INDICATI,Approved,Orthostatic hypotension,[ICD-11: BA21]
T15117,#N/A,INDICATI,Patented,Parkinsonism,[ICD-11: 8A00]
T15117,#N/A,INDICATI,Patented,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T15167,COL1A2,TARGETID,T15167,,
T15167,COL1A2,TARGNAME,Collagen I (COL1A2),,
T15167,COL1A2,INDICATI,Phase 2,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T15197,#N/A,TARGETID,T15197,,
T15197,#N/A,TARGNAME,Potential penetration (PP),,
T15197,#N/A,INDICATI,Investigative,Thyrotoxicosis,[ICD-11: 5A02]
,#N/A,,,,
T15334,CETP,TARGETID,T15334,,
T15334,CETP,TARGNAME,Cholesteryl ester transfer protein (CETP),,
T15334,CETP,INDICATI,Phase 3,Arterial occlusive disease,[ICD-11: BD40]
T15334,CETP,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T15334,CETP,INDICATI,Discontinued in Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T15334,CETP,INDICATI,Discontinued in Phase 1,Dyslipidemia,[ICD-11: 5C80-5C81]
T15334,CETP,INDICATI,Phase 3,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T15334,CETP,INDICATI,Phase 2,Inborn lipid metabolism error,[ICD-11: 5C52]
T15334,CETP,INDICATI,Phase 3,Myocardial infarction,[ICD-11: BA41-BA43]
,#N/A,,,,
T15344,TNFRSF18,TARGETID,T15344,,
T15344,TNFRSF18,TARGNAME,Activation-inducible TNFR family receptor (TNFRSF18),,
T15344,TNFRSF18,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T15344,TNFRSF18,INDICATI,Phase 1,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T15344,TNFRSF18,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15377,ATP2A2,TARGETID,T15377,,
T15377,ATP2A2,TARGNAME,Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (ATP2A2),,
T15377,ATP2A2,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T15377,ATP2A2,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T15377,ATP2A2,INDICATI,Discontinued in Phase 1,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T15439,C5AR1,TARGETID,T15439,,
T15439,C5AR1,TARGNAME,C5a anaphylatoxin chemotactic receptor (C5AR1),,
T15439,C5AR1,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T15439,C5AR1,INDICATI,Preclinical,Central nervous system disease,[ICD-11: 8A04-8D87]
T15439,C5AR1,INDICATI,Phase 2,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
T15439,C5AR1,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T15439,C5AR1,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T15439,C5AR1,INDICATI,Approved,Vasculitis,[ICD-11: 4A44]
,#N/A,,,,
T15494,GHR,TARGETID,T15494,,
T15494,GHR,TARGNAME,GHR messenger RNA (GHR mRNA),,
T15494,GHR,INDICATI,Phase 1,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T15497,PTGER1,TARGETID,T15497,,
T15497,PTGER1,TARGNAME,Prostaglandin E2 receptor EP1 (PTGER1),,
T15497,PTGER1,INDICATI,Terminated,Abnormal micturition,[ICD-11: MF50]
T15497,PTGER1,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T15497,PTGER1,INDICATI,Clinical trial,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T15497,PTGER1,INDICATI,Phase 3,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T15510,IRS1,TARGETID,T15510,,
T15510,IRS1,TARGNAME,Insulin receptor substrate-1 (IRS1),,
T15510,IRS1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15556,SERPINE1,TARGETID,T15556,,
T15556,SERPINE1,TARGNAME,Endothelial plasminogen activator inhibitor (SERPINE1),,
T15556,SERPINE1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T15556,SERPINE1,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T15556,SERPINE1,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T15569,MUT,TARGETID,T15569,,
T15569,MUT,TARGNAME,Methylmalonyl-CoA mutase (MMUT),,
T15569,MUT,INDICATI,Phase 2,Intrathoracic organs injury,[ICD-11: NB32]
T15569,MUT,INDICATI,Phase 1/2,Metabolism inborn error,[ICD-11: 5C50]
T15569,MUT,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T15571,HTR5A,TARGETID,T15571,,
T15571,HTR5A,TARGNAME,5-HT 5A receptor (HTR5A),,
T15571,HTR5A,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T15610,NPEPPS,TARGETID,T15610,,
T15610,NPEPPS,TARGNAME,Puromycin-sensitive aminopeptidase (NPEPPS),,
T15610,NPEPPS,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T15610,NPEPPS,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T15610,NPEPPS,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T15639,#N/A,TARGETID,T15639,,
T15639,#N/A,TARGNAME,Zinc finger protein (ZNF),,
T15639,#N/A,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
,#N/A,,,,
T15700,CASP8,TARGETID,T15700,,
T15700,CASP8,TARGNAME,Caspase-8 (CASP8),,
T15700,CASP8,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T15700,CASP8,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15739,TP53,TARGETID,T15739,,
T15739,TP53,TARGNAME,Cellular tumor antigen p53 (TP53),,
T15739,TP53,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T15739,TP53,INDICATI,Phase 1/2,Arterial occlusive disease,[ICD-11: BD40]
T15739,TP53,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T15739,TP53,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T15739,TP53,INDICATI,Phase 1,Cervical cancer,[ICD-11: 2C77]
T15739,TP53,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T15739,TP53,INDICATI,Phase 1,Endometrial cancer,[ICD-11: 2C76]
T15739,TP53,INDICATI,Phase 1,Esophageal cancer,[ICD-11: 2B70]
T15739,TP53,INDICATI,Phase 1,Fallopian tube cancer,[ICD-11: 2C74]
T15739,TP53,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T15739,TP53,INDICATI,Phase 3,Lip/oral cavity/pharynx neoplasm,[ICD-11: 2B6E]
T15739,TP53,INDICATI,Phase 1,Liposarcoma,[ICD-11: 2B59]
T15739,TP53,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T15739,TP53,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T15739,TP53,INDICATI,Phase 1,Metastatic liver/bile duct neoplasm,[ICD-11: 2D80]
T15739,TP53,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T15739,TP53,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T15739,TP53,INDICATI,Phase 2/3,Ovarian dysfunction,[ICD-11: 5A80]
T15739,TP53,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T15739,TP53,INDICATI,Phase 1,Peritoneal cancer,[ICD-11: 2C51]
T15739,TP53,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T15739,TP53,INDICATI,Phase 1/2,Stomach cancer,[ICD-11: 2B72]
T15739,TP53,INDICATI,Terminated,Toxicity,[ICD-11: N.A.]
T15739,TP53,INDICATI,Phase 3,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T15776,PDK1,TARGETID,T15776,,
T15776,PDK1,TARGNAME,Pyruvate dehydrogenase kinase 1 (PDHK1),,
T15776,PDK1,INDICATI,Phase 1,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T15776,PDK1,INDICATI,Phase 3,Inborn energy metabolism error,[ICD-11: 5C53]
T15776,PDK1,INDICATI,Phase 4,Insulin-resistance syndrome,[ICD-11: 5A44]
T15776,PDK1,INDICATI,Patented,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T15776,PDK1,INDICATI,Patented,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15783,KLRC1,TARGETID,T15783,,
T15783,KLRC1,TARGNAME,NKG2-A/B-activating NK receptor (NKG2A),,
T15783,KLRC1,INDICATI,Phase 1/2,Head and neck cancer,[ICD-11: 2D42]
T15783,KLRC1,INDICATI,Phase 1/2,Mature B-cell leukaemia,[ICD-11: 2A82]
T15783,KLRC1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T15783,KLRC1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15784,#N/A,TARGETID,T15784,,
T15784,#N/A,TARGNAME,Lipid peroxidation (LPO),,
T15784,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T15784,#N/A,INDICATI,Discontinued in Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T15784,#N/A,INDICATI,Investigative,Immune system disease,[ICD-11: 4A01-4B41]
T15784,#N/A,INDICATI,Phase 2,Ischemia,[ICD-11: 8B10-8B11]
,#N/A,,,,
T15795,KCNK3,TARGETID,T15795,,
T15795,KCNK3,TARGNAME,TWIK-related acid-sensitive potassium channel 1 (TASK1),,
T15795,KCNK3,INDICATI,Phase 2,Obstructive sleep apnoea,[ICD-11: 7A41]
,#N/A,,,,
T15797,SMYD2,TARGETID,T15797,,
T15797,SMYD2,TARGNAME,SET and MYND domain-containing protein 2 (SMYD2),,
T15797,SMYD2,INDICATI,Preclinical,Lung cancer,[ICD-11: 2C25]
T15797,SMYD2,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15803,F11,TARGETID,T15803,,
T15803,F11,TARGNAME,Factor XI messenger RNA (F11 mRNA),,
T15803,F11,INDICATI,Clinical trial,Alzheimer disease,[ICD-11: 8A20]
T15803,F11,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T15803,F11,INDICATI,Phase 2,Coagulation defect,[ICD-11: 3B10]
T15803,F11,INDICATI,Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T15855,DPP8,TARGETID,T15855,,
T15855,DPP8,TARGNAME,Dipeptidyl peptidase 8 (DPP-8),,
T15855,DPP8,INDICATI,Phase 3,Neutropenia,[ICD-11: 4B00]
T15855,DPP8,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T15855,DPP8,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T15867,#N/A,TARGETID,T15867,,
T15867,#N/A,TARGNAME,Gastric carcinoma-associated antigen MG7 (MG7),,
T15867,#N/A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T15882,PRTN3,TARGETID,T15882,,
T15882,PRTN3,TARGNAME,Leukocyte proteinase-3 (PRTN3),,
T15882,PRTN3,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T15882,PRTN3,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
,#N/A,,,,
T15894,CUL4A/CUL4B-DDB1-CRBN,TARGETID,T15894,,
T15894,CUL4A/CUL4B-DDB1-CRBN,TARGNAME,Cerebron E3 ubiquitin ligase complex (CRL4-CRBN E3 ubiquitin ligase),,
T15894,CUL4A/CUL4B-DDB1-CRBN,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T15894,CUL4A/CUL4B-DDB1-CRBN,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T16016,CCR1,TARGETID,T16016,,
T16016,CCR1,TARGNAME,C-C chemokine receptor type 1 (CCR1),,
T16016,CCR1,INDICATI,Discontinued in Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T16016,CCR1,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T16016,CCR1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T16047,Onchoc GluCl,TARGETID,T16047,,
T16047,Onchoc GluCl,TARGNAME,Onchocerca Glutamate-gated chloride channel (Onchoc GluCl),,
T16047,Onchoc GluCl,INDICATI,Approved,Onchocerciasis,[ICD-11: 1F6A]
T16047,Onchoc GluCl,INDICATI,Approved,Strongyloidiasis,[ICD-11: 1F6B]
,#N/A,,,,
T16087,TMPRSS6,TARGETID,T16087,,
T16087,TMPRSS6,TARGNAME,TMPRSS6 messenger RNA (TMPRSS6 mRNA),,
T16087,TMPRSS6,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T16087,TMPRSS6,INDICATI,Phase 2,Thalassaemia,[ICD-11: 3A50]
,#N/A,,,,
T16117,NOS1,TARGETID,T16117,,
T16117,NOS1,TARGNAME,Nitric-oxide synthase brain (NOS1),,
T16117,NOS1,INDICATI,Phase 2,Headache,[ICD-11: 8A80-8A84]
T16117,NOS1,INDICATI,Phase 2,Migraine,[ICD-11: 8A80]
,#N/A,,,,
T16128,GAST,TARGETID,T16128,,
T16128,GAST,TARGNAME,Gastrin (GAST),,
T16128,GAST,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T16144,ICOSLG,TARGETID,T16144,,
T16144,ICOSLG,TARGNAME,B7-related protein 1 (B7RP1),,
T16144,ICOSLG,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T16144,ICOSLG,INDICATI,Phase 2,Sjogren syndrome,[ICD-11: 4A43]
,#N/A,,,,
T16156,MPL,TARGETID,T16156,,
T16156,MPL,TARGNAME,Thrombopoietin receptor (MPL),,
T16156,MPL,INDICATI,Investigative,Acute myeloid leukaemia,[ICD-11: 2A60]
T16156,MPL,INDICATI,Phase 1,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T16156,MPL,INDICATI,Phase 3,Liver disease,[ICD-11: DB90-DB9Z]
T16156,MPL,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T16156,MPL,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T16156,MPL,INDICATI,Phase 1,Myocardial infarction,[ICD-11: BA41-BA43]
T16156,MPL,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T16156,MPL,INDICATI,Terminated,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T16263,CCL5,TARGETID,T16263,,
T16263,CCL5,TARGNAME,T-cell-specific protein RANTES (CCL5),,
T16263,CCL5,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T16308,PIN1,TARGETID,T16308,,
T16308,PIN1,TARGNAME,Rotamase Pin1 (PIN1),,
T16308,PIN1,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T16308,PIN1,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
,#N/A,,,,
T16340,IL1A,TARGETID,T16340,,
T16340,IL1A,TARGNAME,Interleukin-1 alpha (IL1A),,
T16340,IL1A,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
T16340,IL1A,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
T16340,IL1A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T16340,IL1A,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T16340,IL1A,INDICATI,Phase 3,Colorectal cancer,[ICD-11: 2B91]
T16340,IL1A,INDICATI,Phase 2,Hidradenitis suppurativa,[ICD-11: ED92]
T16340,IL1A,INDICATI,Phase 3,Influenza,[ICD-11: 1E30-1E32]
T16340,IL1A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T16340,IL1A,INDICATI,Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T16340,IL1A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T16340,IL1A,INDICATI,Phase 2,Pyoderma gangrenosum,[ICD-11: EB21]
T16340,IL1A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T16340,IL1A,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T16347,PTPN1,TARGETID,T16347,,
T16347,PTPN1,TARGNAME,Protein-tyrosine phosphatase 1B (PTP1B),,
T16347,PTPN1,INDICATI,Phase 1/2,Acute diabete complication,[ICD-11: 5A2Y]
T16347,PTPN1,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T16347,PTPN1,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T16347,PTPN1,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T16353,GJA8,TARGETID,T16353,,
T16353,GJA8,TARGNAME,Gap junction alpha-8 protein (Cx50),,
T16353,GJA8,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T16422,#N/A,TARGETID,T16422,,
T16422,#N/A,TARGNAME,Multidrug resistance protein (MDR),,
T16422,#N/A,INDICATI,Discontinued in Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T16422,#N/A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T16422,#N/A,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T16422,#N/A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T16422,#N/A,INDICATI,Preclinical,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T16486,TNF,TARGETID,T16486,,
T16486,TNF,TARGNAME,TNFA messenger RNA (TNF mRNA),,
T16486,TNF,INDICATI,Discontinued in Phase 2,Crohn disease,[ICD-11: DD70]
T16486,TNF,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T16486,TNF,INDICATI,Terminated,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T16514,FASN,TARGETID,T16514,,
T16514,FASN,TARGNAME,Fatty acid synthase (FASN),,
T16514,FASN,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T16514,FASN,INDICATI,Phase 2,Colon cancer,[ICD-11: 2B90]
T16514,FASN,INDICATI,Approved,concerning food/fluid intake symptom,[ICD-11: MG43]
T16514,FASN,INDICATI,Preclinical,Fungal infection,[ICD-11: 1F29-1F2F]
T16514,FASN,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T16514,FASN,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T16514,FASN,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T16514,FASN,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T16514,FASN,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T16538,EGFR,TARGETID,T16538,,
T16538,EGFR,TARGNAME,EGFR T790M mutant (EGFR T790M),,
T16538,EGFR,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T16538,EGFR,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
,#N/A,,,,
T16601,CEACAM5,TARGETID,T16601,,
T16601,CEACAM5,TARGNAME,Carcinoembryonic antigen CEA (CD66e),,
T16601,CEACAM5,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T16601,CEACAM5,INDICATI,Phase 1,Ascites,[ICD-11: ME04]
T16601,CEACAM5,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T16601,CEACAM5,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T16601,CEACAM5,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T16601,CEACAM5,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T16601,CEACAM5,INDICATI,Phase 1,Metastatic peritoneum neoplasm,[ICD-11: 2D91]
T16601,CEACAM5,INDICATI,Phase 3,Non-small-cell lung cancer,[ICD-11: 2C25]
T16601,CEACAM5,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T16601,CEACAM5,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T16601,CEACAM5,INDICATI,Phase 2,Stomach cancer,ICD-11: 2B72
T16601,CEACAM5,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
T16601,CEACAM5,INDICATI,Phase 2,Thyroid cancer,[ICD-11: 2D10]
,#N/A,,,,
T16605,MV NP mRNA,TARGETID,T16605,,
T16605,MV NP mRNA,TARGNAME,Marburg virus NP messenger RNA (MV NP mRNA),,
T16605,MV NP mRNA,INDICATI,Phase 1,Filovirus disease,[ICD-11: 1D60]
,#N/A,,,,
T16633,SSTR1,TARGETID,T16633,,
T16633,SSTR1,TARGNAME,Somatostatin receptor type 1 (SSTR1),,
T16633,SSTR1,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T16633,SSTR1,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T16633,SSTR1,INDICATI,Approved,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T16688,DGAT1,TARGETID,T16688,,
T16688,DGAT1,TARGNAME,Diacylglycerol acyltransferase 1 (DGAT1),,
T16688,DGAT1,INDICATI,Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
T16688,DGAT1,INDICATI,Phase 3,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T16688,DGAT1,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T16688,DGAT1,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T16688,DGAT1,INDICATI,Terminated,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T16691,HTR6,TARGETID,T16691,,
T16691,HTR6,TARGNAME,5-HT 6 receptor (HTR6),,
T16691,HTR6,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T16691,HTR6,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T16691,HTR6,INDICATI,Patented,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T16691,HTR6,INDICATI,Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T16691,HTR6,INDICATI,Investigative,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T16691,HTR6,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T16691,HTR6,INDICATI,Investigative,Nausea/vomiting,[ICD-11: MD90]
T16691,HTR6,INDICATI,Phase 1,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T16691,HTR6,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T16691,HTR6,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T16691,HTR6,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T16731,ATP6V1A,TARGETID,T16731,,
T16731,ATP6V1A,TARGNAME,Vacuolar-type proton ATPase catalytic A (v-ATPase-A),,
T16731,ATP6V1A,INDICATI,Preclinical,Fungal infection,[ICD-11: 1F29-1F2F]
,#N/A,,,,
T16738,DLK1,TARGETID,T16738,,
T16738,DLK1,TARGNAME,Protein delta homolog 1 (DLK1),,
T16738,DLK1,INDICATI,Phase 1,Motor neuron disease,[ICD-11: 8B60]
,#N/A,,,,
T16739,KDM1A,TARGETID,T16739,,
T16739,KDM1A,TARGNAME,Lysine-specific histone demethylase 1 (LSD),,
T16739,KDM1A,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T16739,KDM1A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T16739,KDM1A,INDICATI,Phase 1,Ewing sarcoma,[ICD-11: 2B52]
T16739,KDM1A,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T16739,KDM1A,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T16739,KDM1A,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T16739,KDM1A,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T16739,KDM1A,INDICATI,Phase 1/2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T16739,KDM1A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T16761,PC DHPS,TARGETID,T16761,,
T16761,PC DHPS,TARGNAME,Pneumocystis carinii Dihydropteroate synthase (PC DHPS),,
T16761,PC DHPS,INDICATI,Approved,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T16769,XIAP,TARGETID,T16769,,
T16769,XIAP,TARGNAME,X-linked inhibitor of apoptosis protein (XIAP),,
T16769,XIAP,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T16769,XIAP,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T16769,XIAP,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T16769,XIAP,INDICATI,Phase 3,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T16769,XIAP,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T16769,XIAP,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T16769,XIAP,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T16769,XIAP,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T16784,#N/A,TARGETID,T16784,,
T16784,#N/A,TARGNAME,Microtubule polymerization (MicroTu poly),,
T16784,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T16792,DIO1,TARGETID,T16792,,
T16792,DIO1,TARGNAME,Iodothyronine deiodinase type I (DIO1),,
T16792,DIO1,INDICATI,Approved,Thyrotoxicosis,[ICD-11: 5A02]
,#N/A,,,,
T16802,#N/A,TARGETID,T16802,,
T16802,#N/A,TARGNAME,Human immunodeficiency virus Attachment (HIV att),,
T16802,#N/A,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T16808,PRMT1,TARGETID,T16808,,
T16808,PRMT1,TARGNAME,Protein arginine methyltransferase 1 (PRMT1),,
T16808,PRMT1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T16868,CDH2,TARGETID,T16868,,
T16868,CDH2,TARGNAME,Neural cadherin (CDH2),,
T16868,CDH2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T16888,CCL11,TARGETID,T16888,,
T16888,CCL11,TARGNAME,Small-inducible cytokine A11 (CCL11),,
T16888,CCL11,INDICATI,Phase 2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T16888,CCL11,INDICATI,Phase 2,Pemphigoid,[ICD-11: EB41]
T16888,CCL11,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T16888,CCL11,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T16987,CA12,TARGETID,T16987,,
T16987,CA12,TARGNAME,Carbonic anhydrase XII (CA-XII),,
T16987,CA12,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T16987,CA12,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T16987,CA12,INDICATI,Approved,Seborrhoeic dermatitis,[ICD-11: EA81]
T16987,CA12,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T17003,#N/A,TARGETID,T17003,,
T17003,#N/A,TARGNAME,DNA-directed RNA polymerase (RNAP),,
T17003,#N/A,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T17003,#N/A,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T17003,#N/A,INDICATI,Approved,Mycobacterium infection,[ICD-11: 1B10-1B21]
T17003,#N/A,INDICATI,Investigative,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T17048,TOP2A,TARGETID,T17048,,
T17048,TOP2A,TARGNAME,DNA topoisomerase II alpha (TOP2A),,
T17048,TOP2A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T17048,TOP2A,INDICATI,Phase 2,Kaposi sarcoma,[ICD-11: 2B57]
T17048,TOP2A,INDICATI,Investigative,Mature T-cell lymphoma,[ICD-11: 2A90]
T17048,TOP2A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T17067,USP5,TARGETID,T17067,,
T17067,USP5,TARGNAME,Isopeptidase T (USP5),,
T17067,USP5,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
T17067,USP5,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T17140,P2RX3,TARGETID,T17140,,
T17140,P2RX3,TARGNAME,P2X purinoceptor 3 (P2RX3),,
T17140,P2RX3,INDICATI,Phase 3,Cough,[ICD-11: MD12]
T17140,P2RX3,INDICATI,Phase 1,Endometriosis,[ICD-11: GA10]
T17140,P2RX3,INDICATI,Phase 2,Functional bladder disorder,[ICD-11: GC50]
T17140,P2RX3,INDICATI,Phase 1,Hypertension,[ICD-11: BA00-BA04]
T17140,P2RX3,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T17163,LEPR,TARGETID,T17163,,
T17163,LEPR,TARGNAME,Leptin receptor (LEPR),,
T17163,LEPR,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T17163,LEPR,INDICATI,Investigative,Alzheimer disease,[ICD-11: 8A20]
T17163,LEPR,INDICATI,Investigative,Cachexia,[ICD-11: MG20]
T17163,LEPR,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T17163,LEPR,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T17234,CMV UL97,TARGETID,T17234,,
T17234,CMV UL97,TARGNAME,Cytomegalovirus Ganciclovir kinase (CMV UL97),,
T17234,CMV UL97,INDICATI,Approved,Cytomegaloviral disease,[ICD-11: 1D82]
,#N/A,,,,
T17248,MeV F,TARGETID,T17248,,
T17248,MeV F,TARGNAME,Measles virus Fusion glycoprotein (MeV F),,
T17248,MeV F,INDICATI,Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
T17248,MeV F,INDICATI,Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T17248,MeV F,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T17248,MeV F,INDICATI,Phase 2,Pregnancy/childbirth/puerperium maternal infection,[ICD-11: JB63]
T17248,MeV F,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
T17248,MeV F,INDICATI,Terminated,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T17345,DHFR,TARGETID,T17345,,
T17345,DHFR,TARGNAME,Dihydrofolate reductase (DHFR),,
T17345,DHFR,INDICATI,Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
T17345,DHFR,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T17345,DHFR,INDICATI,Approved,Indeterminate colitis,[ICD-11: DD72]
T17345,DHFR,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
T17345,DHFR,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T17345,DHFR,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T17345,DHFR,INDICATI,Phase 1,Toxoplasmosis,[ICD-11: 1F57]
T17345,DHFR,INDICATI,Approved,Tuberculosis,[ICD-11: 1B10-1B12]
T17345,DHFR,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T17367,SQSTM1,TARGETID,T17367,,
T17367,SQSTM1,TARGNAME,Sequestosome-1 p62 (SQSTM1),,
T17367,SQSTM1,INDICATI,Preclinical,Nasopharyngitis,[ICD-11: CA00]
,#N/A,,,,
T17427,GP1BA,TARGETID,T17427,,
T17427,GP1BA,TARGNAME,Platelet glycoprotein Ib alpha (CD42b),,
T17427,GP1BA,INDICATI,Phase 1/2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T17448,HNMT,TARGETID,T17448,,
T17448,HNMT,TARGNAME,Histamine N-methyltransferase (HNMT),,
T17448,HNMT,INDICATI,Approved,Episodic vestibular syndrome,[ICD-11: AB31]
T17448,HNMT,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T17448,HNMT,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T17485,MEN1-KMT2A,TARGETID,T17485,,
T17485,MEN1-KMT2A,TARGNAME,Menin-MLL1 interaction (MEN1-KMT2A PPI),,
T17485,MEN1-KMT2A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T17485,MEN1-KMT2A,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T17502,RPE65,TARGETID,T17502,,
T17502,RPE65,TARGNAME,Retinal pigment epithelium protein (RPE65),,
T17502,RPE65,INDICATI,Phase 3,Herpes simplex infection,[ICD-11: 1F00]
T17502,RPE65,INDICATI,Phase 1/2,Inherited retinal dystrophy,[ICD-11: 9B70]
T17502,RPE65,INDICATI,Phase 2/3,Macular degeneration,[ICD-11: 9B75]
T17502,RPE65,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T17502,RPE65,INDICATI,Phase 1/2,Vision impairment,[ICD-11: 9D90]
,#N/A,,,,
T17514,INHBA; INHBB; INHBC; INHBE,TARGETID,T17514,,
T17514,INHBA; INHBB; INHBC; INHBE,TARGNAME,Activin (ACT),,
T17514,INHBA; INHBB; INHBC; INHBE,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T17569,KCNA5,TARGETID,T17569,,
T17569,KCNA5,TARGNAME,Voltage-gated potassium channel Kv1.5 (KCNA5),,
T17569,KCNA5,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T17569,KCNA5,INDICATI,Phase 1,Cardiac arrhythmia,[ICD-11: BC9Z]
T17569,KCNA5,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
T17569,KCNA5,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T17569,KCNA5,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T17629,TACSTD2,TARGETID,T17629,,
T17629,TACSTD2,TARGNAME,Tumor associated calcium signal transducer 2 (TACSTD2),,
T17629,TACSTD2,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T17629,TACSTD2,INDICATI,Phase 3,Non-small-cell lung cancer,[ICD-11: 2C25]
T17629,TACSTD2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T17629,TACSTD2,INDICATI,Approved,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T17687,#N/A,TARGETID,T17687,,
T17687,#N/A,TARGNAME,Fibroblast growth factor receptor (FGFR),,
T17687,#N/A,INDICATI,Approved,Bladder cancer,[ICD-11: 2C94]
T17687,#N/A,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T17687,#N/A,INDICATI,Approved,Liver cancer,[ICD-11: 2C12]
T17687,#N/A,INDICATI,Phase 4,Lymphoma,[ICD-11: 2A80-2A86]
T17687,#N/A,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T17687,#N/A,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T17687,#N/A,INDICATI,Phase 2/3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T17687,#N/A,INDICATI,Phase 2,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T17710,HP,TARGETID,T17710,,
T17710,HP,TARGNAME,Haptoglobin (HP),,
T17710,HP,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T17758,PLAU,TARGETID,T17758,,
T17758,PLAU,TARGNAME,Urokinase-type plasminogen activator (PLAU),,
T17758,PLAU,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T17758,PLAU,INDICATI,Clinical trial,Cardiomegaly,[ICD-11: BC45]
T17758,PLAU,INDICATI,Phase 1/2,Cerebral ischaemia,[ICD-11: 8B1Z]
T17758,PLAU,INDICATI,Approved,Inherited coagulation factor deficiency,[ICD-11: 3B14]
T17758,PLAU,INDICATI,Clinical trial,Ischaemic heart disease,[ICD-11: BA6Z]
T17758,PLAU,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T17758,PLAU,INDICATI,Discontinued in Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T17758,PLAU,INDICATI,Phase 3,Thrombosis,[ICD-11: DB61-GB90]
T17758,PLAU,INDICATI,Clinical trial,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T17852,PDE9A,TARGETID,T17852,,
T17852,PDE9A,TARGNAME,Phosphodiesterase 9 (PDE9),,
T17852,PDE9A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T17852,PDE9A,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T17852,PDE9A,INDICATI,Phase 2,Genitourinary disease,[ICD-11: GA0Z-GC8Z]
T17852,PDE9A,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T17852,PDE9A,INDICATI,Phase 2,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T17852,PDE9A,INDICATI,Investigative,Mild neurocognitive disorder,[ICD-11: 6D71]
T17852,PDE9A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T17852,PDE9A,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T17852,PDE9A,INDICATI,Phase 2,Sickle-cell disorder,[ICD-11: 3A51]
,#N/A,,,,
T17967,PDK2,TARGETID,T17967,,
T17967,PDK2,TARGNAME,Pyruvate dehydrogenase kinase 2 (PDHK2),,
T17967,PDK2,INDICATI,Terminated,Acute diabete complication,[ICD-11: 5A2Y]
,#N/A,,,,
T17980,FYN,TARGETID,T17980,,
T17980,FYN,TARGNAME,Fyn tyrosine protein kinase (FYN),,
T17980,FYN,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T17980,FYN,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T17980,FYN,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T17986,EZH1,TARGETID,T17986,,
T17986,EZH1,TARGNAME,Enhancer of zeste homolog 1 (EZH1),,
T17986,EZH1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T17986,EZH1,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T17986,EZH1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T17986,EZH1,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T17986,EZH1,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T17986,EZH1,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
T17986,EZH1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T17986,EZH1,INDICATI,Phase 1,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T18059,CR2,TARGETID,T18059,,
T18059,CR2,TARGNAME,Complement receptor type 2 (CD21),,
T18059,CR2,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T18143,#N/A,TARGETID,T18143,,
T18143,#N/A,TARGNAME,MERS-CoV papain-like proteinase (PL-PRO),,
T18143,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T18143,#N/A,INDICATI,Approved,Crohn disease,[ICD-11: DD70]
T18143,#N/A,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T18143,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T18143,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
T18143,#N/A,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T18204,#N/A,TARGETID,T18204,,
T18204,#N/A,TARGNAME,Alpha-secretase (ASE),,
T18204,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T18226,#N/A,TARGETID,T18226,,
T18226,#N/A,TARGNAME,HUMAN clathrin-mediated endocytosis (RME),,
T18226,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T18226,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T18226,#N/A,INDICATI,Withdrawn from market,Schizophrenia,[ICD-11: 6A20]
T18226,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T18299,CAMK2A; CAMK2B; CAMK2D; CAMK2G,TARGETID,T18299,,
T18299,CAMK2A; CAMK2B; CAMK2D; CAMK2G,TARGNAME,CaM-kinase II (CAMK2),,
T18299,CAMK2A; CAMK2B; CAMK2D; CAMK2G,INDICATI,Investigative,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T18299,CAMK2A; CAMK2B; CAMK2D; CAMK2G,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T18356,LASV GPC,TARGETID,T18356,,
T18356,LASV GPC,TARGNAME,Lassa virus Pre-glycoprotein polyprotein GP complex (LASV GPC),,
T18356,LASV GPC,INDICATI,Phase 1,Arenavirus disease,[ICD-11: 1D61]
,#N/A,,,,
T18477,HSP90AA1,TARGETID,T18477,,
T18477,HSP90AA1,TARGNAME,Heat shock protein 90 alpha (HSP90A),,
T18477,HSP90AA1,INDICATI,Approved,Acute upper respiratory infection,[ICD-11: CA07]
T18477,HSP90AA1,INDICATI,Phase 0,Alzheimer disease,[ICD-11: 8A20]
T18477,HSP90AA1,INDICATI,Approved,Asthma,[ICD-11: CA23]
T18477,HSP90AA1,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T18477,HSP90AA1,INDICATI,Discontinued in Phase 3,Diabetes mellitus,[ICD-11: 5A10]
T18477,HSP90AA1,INDICATI,Phase 1,Encephalopathy,[ICD-11: 8E47]
T18477,HSP90AA1,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T18477,HSP90AA1,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T18477,HSP90AA1,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T18477,HSP90AA1,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T18477,HSP90AA1,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T18477,HSP90AA1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T18477,HSP90AA1,INDICATI,Phase 1,Neuropathy,[ICD-11: 8C0Z]
T18477,HSP90AA1,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T18477,HSP90AA1,INDICATI,Discontinued in Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T18477,HSP90AA1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T18477,HSP90AA1,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
T18477,HSP90AA1,INDICATI,Discontinued in Phase 2,Unspecific body region injury,[ICD-11: ND56]
T18477,HSP90AA1,INDICATI,Terminated,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T18551,CD80-CD274,TARGETID,T18551,,
T18551,CD80-CD274,TARGNAME,CD80-PD-L1 interaction (CD80/PD-L1 PPI),,
T18551,CD80-CD274,INDICATI,Patented,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T18551,CD80-CD274,INDICATI,Patented,Inflammatory liver disease,[ICD-11: DB97]
T18551,CD80-CD274,INDICATI,Patented,Postoperative inflammation,[ICD-11: 1A00-CA43]
T18551,CD80-CD274,INDICATI,Patented,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T18632,#N/A,TARGETID,T18632,,
T18632,#N/A,TARGNAME,Cholinergic receptor unspecific (CHR),,
T18632,#N/A,INDICATI,Phase 3,Hyperhidrosis,[ICD-11: EE00]
T18632,#N/A,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T18639,FGF1,TARGETID,T18639,,
T18639,FGF1,TARGNAME,Heparin-binding growth factor 1 (FGF1),,
T18639,FGF1,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T18639,FGF1,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
,#N/A,,,,
T18664,MGLL,TARGETID,T18664,,
T18664,MGLL,TARGNAME,Monoglyceride lipase (MAGL),,
T18664,MGLL,INDICATI,Phase 1,General pain disorder,[ICD-11: 8E43]
T18664,MGLL,INDICATI,Phase 1,Tic disorder,[ICD-11: 8A05]
,#N/A,,,,
T18779,MUC1,TARGETID,T18779,,
T18779,MUC1,TARGNAME,Mucin-1 (MUC1),,
T18779,MUC1,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T18779,MUC1,INDICATI,Phase 2/3,Bipolar disorder,[ICD-11: 6A60]
T18779,MUC1,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T18779,MUC1,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T18779,MUC1,INDICATI,Phase 1/2,Cervical cancer,[ICD-11: 2C77]
T18779,MUC1,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T18779,MUC1,INDICATI,Phase 1/2,Esophageal cancer,[ICD-11: 2B70]
T18779,MUC1,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T18779,MUC1,INDICATI,Phase 2/3,Lung cancer,[ICD-11: 2C25]
T18779,MUC1,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T18779,MUC1,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T18779,MUC1,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T18779,MUC1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T18779,MUC1,INDICATI,Phase 1/2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T18872,KISS1,TARGETID,T18872,,
T18872,KISS1,TARGNAME,Metastasis-suppressor KiSS-1 (KISS1),,
T18872,KISS1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T18876,PTGER4,TARGETID,T18876,,
T18876,PTGER4,TARGNAME,Prostaglandin E2 receptor EP4 (PTGER4),,
T18876,PTGER4,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T18876,PTGER4,INDICATI,Investigative,Glaucoma,[ICD-11: 9C61]
T18876,PTGER4,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
T18876,PTGER4,INDICATI,Phase 2,Migraine,[ICD-11: 8A80]
T18876,PTGER4,INDICATI,Phase 1/2,Non-small-cell lung cancer,[ICD-11: 2C25]
T18876,PTGER4,INDICATI,Investigative,Osteoarthritis,[ICD-11: FA00-FA05]
T18876,PTGER4,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T18876,PTGER4,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T18876,PTGER4,INDICATI,Phase 1,Rectum cancer,[ICD-11: 2B92]
T18876,PTGER4,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T18876,PTGER4,INDICATI,Phase 2,Transplanted organ/tissue,[ICD-11: QB63]
T18876,PTGER4,INDICATI,Investigative,Ulcerative colitis,[ICD-11: DD71]
T18876,PTGER4,INDICATI,Discontinued in Phase 2,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T18950,GNRH1,TARGETID,T18950,,
T18950,GNRH1,TARGNAME,Leutinizing-hormone-releasing hormone (GNRH1),,
T18950,GNRH1,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T18950,GNRH1,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
T18950,GNRH1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T18972,CD3G,TARGETID,T18972,,
T18972,CD3G,TARGNAME,T-cell surface glycoprotein CD3 gamma (CD3G),,
T18972,CD3G,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T18972,CD3G,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T18972,CD3G,INDICATI,Phase 1,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T18972,CD3G,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T18972,CD3G,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T19011,CDC25C,TARGETID,T19011,,
T19011,CDC25C,TARGNAME,M-phase inducer phosphatase 3 (MPIP3),,
T19011,CDC25C,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T19160,PLA2G2A,TARGETID,T19160,,
T19160,PLA2G2A,TARGNAME,Group IIA phospholipase A2 (GIIA sPLA2),,
T19160,PLA2G2A,INDICATI,Clinical trial,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T19229,SLC46A1,TARGETID,T19229,,
T19229,SLC46A1,TARGNAME,Proton-coupled folate transporter (SLC46A1),,
T19229,SLC46A1,INDICATI,Approved,Folate deficiency anaemia,[ICD-11: 3A02]
T19229,SLC46A1,INDICATI,Approved,Leukaemia,[ICD-11: 2A60-2B33]
T19229,SLC46A1,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T19229,SLC46A1,INDICATI,Investigative,Prostate cancer,[ICD-11: 2C82]
T19229,SLC46A1,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T19229,SLC46A1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T19229,SLC46A1,INDICATI,Phase 3,Vitreoretinopathy,[ICD-11: 9B78]
,#N/A,,,,
T19244,CYP2C9,TARGETID,T19244,,
T19244,CYP2C9,TARGNAME,S-mephenytoin 4-hydroxylase (CYP2C9),,
T19244,CYP2C9,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T19334,IL21R,TARGETID,T19334,,
T19334,IL21R,TARGNAME,Interleukin 21 receptor (IL21R),,
T19334,IL21R,INDICATI,Phase 1,Crohn disease,[ICD-11: DD70]
T19334,IL21R,INDICATI,Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
T19334,IL21R,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T19368,LIPG,TARGETID,T19368,,
T19368,LIPG,TARGNAME,Endothelial lipase (LIPG),,
T19368,LIPG,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T19368,LIPG,INDICATI,Clinical trial,Coagulation defect,[ICD-11: 3B10]
T19368,LIPG,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
,#N/A,,,,
T19414,FGA; FGB,TARGETID,T19414,,
T19414,FGA; FGB,TARGNAME,Fibrin (FG),,
T19414,FGA; FGB,INDICATI,Approved,Bleeding disorder,[ICD-11: GA20-GA21]
T19414,FGA; FGB,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T19414,FGA; FGB,INDICATI,Phase 3,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T19414,FGA; FGB,INDICATI,Preclinical,Dengue fever,[ICD-11: 1D2Z]
T19414,FGA; FGB,INDICATI,Phase 3,Injury,[ICD-11: NA00-ND5Z]
T19414,FGA; FGB,INDICATI,Phase 2,Pregnancy/childbirth/puerperium maternal infection,[ICD-11: JB63]
T19414,FGA; FGB,INDICATI,Approved,Skin postprocedural disorder,[ICD-11: EL8Y]
T19414,FGA; FGB,INDICATI,Phase 2,Ulcer,[ICD-11: CA02-CB40]
,#N/A,,,,
T19433,HPGDS,TARGETID,T19433,,
T19433,HPGDS,TARGNAME,Glutathione-dependent PGD synthase (HPGDS),,
T19433,HPGDS,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T19433,HPGDS,INDICATI,Approved,Flatworm infection,[ICD-11: 1F70-1F86]
,#N/A,,,,
T19556,OSM,TARGETID,T19556,,
T19556,OSM,TARGNAME,Oncostatin-M (OSM),,
T19556,OSM,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T19556,OSM,INDICATI,Investigative,Rheumatoid arthritis,[ICD-11: FA20]
T19556,OSM,INDICATI,Phase 2,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T19567,MGEA5,TARGETID,T19567,,
T19567,MGEA5,TARGNAME,Beta-N-acetylhexosaminidase (OGA),,
T19567,MGEA5,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T19567,MGEA5,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T19579,IL2RB,TARGETID,T19579,,
T19579,IL2RB,TARGNAME,Interleukin 2 receptor beta (IL2RB),,
T19579,IL2RB,INDICATI,Phase 1/2,Bladder cancer,[ICD-11: 2C94]
T19579,IL2RB,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T19579,IL2RB,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T19579,IL2RB,INDICATI,Phase 1,Head and neck cancer,[ICD-11: 2D42]
T19579,IL2RB,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T19579,IL2RB,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T19579,IL2RB,INDICATI,Phase 1/2,Renal cell carcinoma,[ICD-11: 2C90]
T19579,IL2RB,INDICATI,Phase 2,Sarcoma,[ICD-11: 2A60-2C35]
T19579,IL2RB,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T19615,CSF3,TARGETID,T19615,,
T19615,CSF3,TARGNAME,Granulocyte colony-stimulating factor (CSF3),,
T19615,CSF3,INDICATI,Approved,Aplastic anaemia,[ICD-11: 3A70]
T19615,CSF3,INDICATI,Approved,Neutropenia,[ICD-11: 4B00]
,#N/A,,,,
T19693,GUCY2D,TARGETID,T19693,,
T19693,GUCY2D,TARGNAME,Soluble guanylyl cyclase (GUCY2D),,
T19693,GUCY2D,INDICATI,Phase 2,Angina pectoris,[ICD-11: BA40]
T19693,GUCY2D,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T19693,GUCY2D,INDICATI,Approved,Pulmonary hypertension,[ICD-11: BB01]
,#N/A,,,,
T19760,MAP3K9,TARGETID,T19760,,
T19760,MAP3K9,TARGNAME,Mixed lineage kinase 1 (MAP3K9),,
T19760,MAP3K9,INDICATI,Phase 2/3,Asthma,[ICD-11: CA23]
,#N/A,,,,
T19784,GH1,TARGETID,T19784,,
T19784,GH1,TARGNAME,Somatotropin (GH1),,
T19784,GH1,INDICATI,Phase 3,Multiple structural anomalies syndrome,[ICD-11: LD2F]
T19784,GH1,INDICATI,Phase 3,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T19852,FGF7,TARGETID,T19852,,
T19852,FGF7,TARGNAME,Keratinocyte growth factor (FGF7),,
T19852,FGF7,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T19947,#N/A,TARGETID,T19947,,
T19947,#N/A,TARGNAME,Immunoproteasome complex (IP),,
T19947,#N/A,INDICATI,Phase 2,Idiopathic inflammatory myopathy,ICD-11: 4A41
,#N/A,,,,
T20017,CRTC1,TARGETID,T20017,,
T20017,CRTC1,TARGNAME,CREB-regulated transcription coactivator 1 (TORC1),,
T20017,CRTC1,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T20017,CRTC1,INDICATI,Phase 3,Respiratory infection,[ICD-11: CA07-CA4Z]
,#N/A,,,,
T20059,#N/A,TARGETID,T20059,,
T20059,#N/A,TARGNAME,TGF-beta receptor (TGFBR),,
T20059,#N/A,INDICATI,Phase 1,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T20059,#N/A,INDICATI,Investigative,Pleural effusion,[ICD-11: CB27]
,#N/A,,,,
T20089,#N/A,TARGETID,T20089,,
T20089,#N/A,TARGNAME,Plasmodium Deoxyribonucleic acid (Malaria DNA),,
T20089,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T20103,#N/A,TARGETID,T20103,,
T20103,#N/A,TARGNAME,Vacuolar-type proton ATPase (v-ATPase),,
T20103,#N/A,INDICATI,Preclinical,Arteries/arterioles disorder,[ICD-11: BD52]
T20103,#N/A,INDICATI,Discontinued in Phase 2,Low bone mass disorder,[ICD-11: FB83]
T20103,#N/A,INDICATI,Investigative,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T20103,#N/A,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T20178,TNF,TARGETID,T20178,,
T20178,TNF,TARGNAME,Tumor necrosis factor (TNF),,
T20178,TNF,INDICATI,Approved,Arterial occlusive disease,[ICD-11: BD40]
T20178,TNF,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T20178,TNF,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T20178,TNF,INDICATI,Phase 2,Bowel habit change,[ICD-11: ME05]
T20178,TNF,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T20178,TNF,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T20178,TNF,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T20178,TNF,INDICATI,Phase 3,Esophageal cancer,[ICD-11: 2B70]
T20178,TNF,INDICATI,Phase 2,Herpes simplex infection,[ICD-11: 1F00]
T20178,TNF,INDICATI,Phase 2/3,Indeterminate colitis,[ICD-11: DD72]
T20178,TNF,INDICATI,Terminated,Infectious gastroenteritis/colitis,[ICD-11: 1A40]
T20178,TNF,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T20178,TNF,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T20178,TNF,INDICATI,Preclinical,Motor neuron disease,[ICD-11: 8B60]
T20178,TNF,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T20178,TNF,INDICATI,Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T20178,TNF,INDICATI,Approved,Pancreatitis,[ICD-11: DC31-DC34]
T20178,TNF,INDICATI,Phase 2,Pemphigus,[ICD-11: EB40]
T20178,TNF,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
T20178,TNF,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T20178,TNF,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T20178,TNF,INDICATI,Phase 2,Psoriatic arthritis,[ICD-11: FA21]
T20178,TNF,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T20178,TNF,INDICATI,Phase 1/2,Sarcoidosis,[ICD-11: 4B20]
T20178,TNF,INDICATI,Discontinued in Phase 3,Sepsis,[ICD-11: 1G40-1G41]
T20178,TNF,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T20178,TNF,INDICATI,Phase 3,Spinal pain,[ICD-11: ME84]
T20178,TNF,INDICATI,Phase 3,Systemic sclerosis,[ICD-11: 4A42]
T20178,TNF,INDICATI,Preclinical,Transplant rejection,[ICD-11: NE84]
T20178,TNF,INDICATI,Phase 1,Ulcerative colitis,[ICD-11: DD71]
T20178,TNF,INDICATI,Discontinued in Phase 1/2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T20185,#N/A,TARGETID,T20185,,
T20185,#N/A,TARGNAME,Fucosyl GM1 (FucGM1),,
T20185,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T20185,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T20210,#N/A,TARGETID,T20210,,
T20210,#N/A,TARGNAME,Feto-acinar pancreatic protein (FAPP),,
T20210,#N/A,INDICATI,Terminated,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T20251,KCNH2,TARGETID,T20251,,
T20251,KCNH2,TARGNAME,Voltage-gated potassium channel Kv11.1 (KCNH2),,
T20251,KCNH2,INDICATI,Terminated,Angina pectoris,[ICD-11: BA40]
T20251,KCNH2,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T20251,KCNH2,INDICATI,Investigative,Genetic cardiac arrhythmia,[ICD-11: BC65]
T20251,KCNH2,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T20251,KCNH2,INDICATI,Phase 2,Malaria,[ICD-11: 1F40-1F45]
T20251,KCNH2,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T20251,KCNH2,INDICATI,Investigative,Ovarian cancer,[ICD-11: 2C73]
T20251,KCNH2,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T20251,KCNH2,INDICATI,Phase 3,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
,#N/A,,,,
T20278,#N/A,TARGETID,T20278,,
T20278,#N/A,TARGNAME,Major histocompatibility complex (MHC),,
T20278,#N/A,INDICATI,Discontinued in Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T20297,#N/A,TARGETID,T20297,,
T20297,#N/A,TARGNAME,Serine protease unspecific (SP),,
T20297,#N/A,INDICATI,Terminated,Arteries/arterioles disorder,[ICD-11: BD52]
T20297,#N/A,INDICATI,Approved,Bleeding disorder,[ICD-11: GA20-GA21]
T20297,#N/A,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T20297,#N/A,INDICATI,Phase 4,Intrathoracic organs injury,[ICD-11: NB32]
T20297,#N/A,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T20297,#N/A,INDICATI,Approved,Pancreatitis,[ICD-11: DC31-DC34]
T20297,#N/A,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
T20297,#N/A,INDICATI,Discontinued in Phase 2,Sepsis,[ICD-11: 1G40-1G41]
T20297,#N/A,INDICATI,Discontinued in Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T20297,#N/A,INDICATI,Terminated,Thrombosis,[ICD-11: DB61-GB90]
T20297,#N/A,INDICATI,Preclinical,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T20331,NPY5R,TARGETID,T20331,,
T20331,NPY5R,TARGNAME,Neuropeptide Y receptor type 5 (NPY5R),,
T20331,NPY5R,INDICATI,Preclinical,Acute diabete complication,[ICD-11: 5A2Y]
T20331,NPY5R,INDICATI,Discontinued in Phase 1,Binge eating disorder,[ICD-11: 6B82]
T20331,NPY5R,INDICATI,Investigative,Depression,[ICD-11: 6A70-6A7Z]
T20331,NPY5R,INDICATI,Terminated,Fungal infection,[ICD-11: 1F29-1F2F]
T20331,NPY5R,INDICATI,Discontinued in Phase 3,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T20333,CSF1R,TARGETID,T20333,,
T20333,CSF1R,TARGNAME,Macrophage colony-stimulating factor 1 receptor (CSF1R),,
T20333,CSF1R,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T20333,CSF1R,INDICATI,Approved,Bone/articular cartilage neoplasm,[ICD-11: 2F7B]
T20333,CSF1R,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
T20333,CSF1R,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T20333,CSF1R,INDICATI,Phase 3,Inflammatory arthropathy,[ICD-11: FA2Z]
T20333,CSF1R,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T20333,CSF1R,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T20333,CSF1R,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T20333,CSF1R,INDICATI,Phase 1/2,Phakomatoses/hamartoneoplastic syndrome,[ICD-11: LD2D]
T20333,CSF1R,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T20333,CSF1R,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T20401,CA2,TARGETID,T20401,,
T20401,CA2,TARGNAME,Carbonic anhydrase II (CA-II),,
T20401,CA2,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T20401,CA2,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T20401,CA2,INDICATI,Withdrawn from market,Duodenal ulcer,[ICD-11: DA63]
T20401,CA2,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T20401,CA2,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T20401,CA2,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T20401,CA2,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T20401,CA2,INDICATI,Phase 2,Low bone mass disorder,[ICD-11: FB83]
T20401,CA2,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T20401,CA2,INDICATI,Approved,Seborrhoeic dermatitis,[ICD-11: EA81]
T20401,CA2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T20474,#N/A,TARGETID,T20474,,
T20474,#N/A,TARGNAME,DNA topoisomerase (TOP),,
T20474,#N/A,INDICATI,Phase 2,Fungal infection,[ICD-11: 1F29-1F2F]
T20474,#N/A,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T20474,#N/A,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T20514,ALAD,TARGETID,T20514,,
T20514,ALAD,TARGNAME,Delta-aminolevulinic acid dehydratase (ALAD),,
T20514,ALAD,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T20514,ALAD,INDICATI,Approved,Epidermal dysplasias,[ICD-11: EK90]
,#N/A,,,,
T20534,Pseudo LasR,TARGETID,T20534,,
T20534,Pseudo LasR,TARGNAME,Pseudomonas Transcriptional activator protein LasR (Pseudo LasR),,
T20534,Pseudo LasR,INDICATI,Preclinical,Glanders,[ICD-11: 1B92]
,#N/A,,,,
T20563,EGFR,TARGETID,T20563,,
T20563,EGFR,TARGNAME,EGFR Exon20ins mutant (EGFR Exon20ins),,
T20563,EGFR,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T20575,CCR8,TARGETID,T20575,,
T20575,CCR8,TARGNAME,C-C chemokine receptor type 8 (CCR8),,
T20575,CCR8,INDICATI,Discontinued in Phase 1,Psoriasis,[ICD-11: EA90]
T20575,CCR8,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T20578,PDE7B,TARGETID,T20578,,
T20578,PDE7B,TARGNAME,Phosphodiesterase 7B (PDE7B),,
T20578,PDE7B,INDICATI,Discontinued in Phase 1,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T20593,#N/A,TARGETID,T20593,,
T20593,#N/A,TARGNAME,Tumor-associated glycan antigen (TAGA),,
T20593,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T20629,ADM,TARGETID,T20629,,
T20629,ADM,TARGNAME,Adrenomedullin (ADM),,
T20629,ADM,INDICATI,Phase 2,Acute respiratory distress syndrome,[ICD-11: CB00]
,#N/A,,,,
T20709,CHRM4,TARGETID,T20709,,
T20709,CHRM4,TARGNAME,Muscarinic acetylcholine receptor M4 (CHRM4),,
T20709,CHRM4,INDICATI,Approved,Asthma,[ICD-11: CA23]
T20709,CHRM4,INDICATI,Investigative,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T20709,CHRM4,INDICATI,Approved,Eye anterior segment structural developmental anomaly,[ICD-11: LA11]
T20709,CHRM4,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T20709,CHRM4,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T20709,CHRM4,INDICATI,Approved,Respiratory system disease,[ICD-11: CB40-CB7Z]
,#N/A,,,,
T20710,#N/A,TARGETID,T20710,,
T20710,#N/A,TARGNAME,Interleukin 2 receptor (IL2R),,
T20710,#N/A,INDICATI,Approved,Leukaemia,[ICD-11: 2A60-2B33]
T20710,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T20710,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T20741,SLC6A8,TARGETID,T20741,,
T20741,SLC6A8,TARGNAME,Solute carrier family 6 member 8 (SLC6A8),,
T20741,SLC6A8,INDICATI,Phase 1,Malignant digestive organ neoplasm,[ICD-11: 2C11]
,#N/A,,,,
T20761,VEGFA,TARGETID,T20761,,
T20761,VEGFA,TARGNAME,Vascular endothelial growth factor A (VEGFA),,
T20761,VEGFA,INDICATI,Patented,Bone growth disorder,[ICD-11: FB86]
T20761,VEGFA,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T20761,VEGFA,INDICATI,Patented,Circulatory system disease,[ICD-11: BE2Z]
T20761,VEGFA,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T20761,VEGFA,INDICATI,Patented,Corneal disease,[ICD-11: 9A76-9A78]
T20761,VEGFA,INDICATI,Phase 1,Fallopian tube cancer,[ICD-11: 2C74]
T20761,VEGFA,INDICATI,Patented,Fibrosis,[ICD-11: GA14-GC01]
T20761,VEGFA,INDICATI,Phase 1/2,Hypopharyngeal cancer,[ICD-11: 2B6D]
T20761,VEGFA,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T20761,VEGFA,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T20761,VEGFA,INDICATI,Phase 3,Lymphoma,[ICD-11: 2A80-2A86]
T20761,VEGFA,INDICATI,Patented,Macular degeneration,[ICD-11: 9B75]
T20761,VEGFA,INDICATI,Phase 3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T20761,VEGFA,INDICATI,Patented,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T20761,VEGFA,INDICATI,Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T20761,VEGFA,INDICATI,Phase 1/2,Muscular atrophy,[ICD-11: 8B61]
T20761,VEGFA,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T20761,VEGFA,INDICATI,Patented,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T20761,VEGFA,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T20761,VEGFA,INDICATI,Phase 1,Peritoneal cancer,[ICD-11: 2C51]
T20761,VEGFA,INDICATI,Approved,Retinopathy,[ICD-11: 9B71]
T20761,VEGFA,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T20761,VEGFA,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T20761,VEGFA,INDICATI,Patented,Stomach cancer,[ICD-11: 2B72]
T20761,VEGFA,INDICATI,Patented,Transient ischaemic attack,[ICD-11: 8B10]
T20761,VEGFA,INDICATI,Approved,Vascular system developmental anomaly,[ICD-11: LA90]
T20761,VEGFA,INDICATI,Patented,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T20796,#N/A,TARGETID,T20796,,
T20796,#N/A,TARGNAME,Reactive oxygen species (ROS),,
T20796,#N/A,INDICATI,Phase 1/2,Asthma,[ICD-11: CA23]
T20796,#N/A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T20796,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T20796,#N/A,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
,#N/A,,,,
T20808,IDH1; IDH2; IDH3A; IDH3B; IDH3G,TARGETID,T20808,,
T20808,IDH1; IDH2; IDH3A; IDH3B; IDH3G,TARGNAME,Isocitrate dehydrogenase (IDH),,
T20808,IDH1; IDH2; IDH3A; IDH3B; IDH3G,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T20808,IDH1; IDH2; IDH3A; IDH3B; IDH3G,INDICATI,Phase 3,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T20808,IDH1; IDH2; IDH3A; IDH3B; IDH3G,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
,#N/A,,,,
T20891,PDPK1,TARGETID,T20891,,
T20891,PDPK1,TARGNAME,Phosphoinositide dependent protein kinase-1 (PDPK1),,
T20891,PDPK1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T20891,PDPK1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T20973,CDK5,TARGETID,T20973,,
T20973,CDK5,TARGNAME,Cyclin-dependent kinase 5 (CDK5),,
T20973,CDK5,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T20978,CD8A; CD8B,TARGETID,T20978,,
T20978,CD8A; CD8B,TARGNAME,T-cell surface glycoprotein CD8 (CD8),,
T20978,CD8A; CD8B,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T20978,CD8A; CD8B,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T20978,CD8A; CD8B,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T21112,#N/A,TARGETID,T21112,,
T21112,#N/A,TARGNAME,DNA replication (DNA repli),,
T21112,#N/A,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T21112,#N/A,INDICATI,Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
T21112,#N/A,INDICATI,Approved,Impetigo,[ICD-11: 1B72]
T21112,#N/A,INDICATI,Approved,Kaposi sarcoma,[ICD-11: 2B57]
T21112,#N/A,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T21112,#N/A,INDICATI,Phase 1/2,Mature B-cell lymphoma,[ICD-11: 2A85]
T21112,#N/A,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T21123,EPAS1,TARGETID,T21123,,
T21123,EPAS1,TARGNAME,Hypoxia-inducible factor 2 alpha (HIF-2A),,
T21123,EPAS1,INDICATI,Approved,Adrenomedullary hyperfunction,[ICD-11: 5A75]
T21123,EPAS1,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T21123,EPAS1,INDICATI,Phase 3,Renal cell carcinoma,[ICD-11: 2C90]
T21123,EPAS1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T21291,Malaria AMA-1,TARGETID,T21291,,
T21291,Malaria AMA-1,TARGNAME,Plasmodium Apical membrane protein (Malaria AMA-1),,
T21291,Malaria AMA-1,INDICATI,Phase 1/2,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T21307,MAPKAPK2,TARGETID,T21307,,
T21307,MAPKAPK2,TARGNAME,MAPK-activated protein kinase 2 (MAPKAPK2),,
T21307,MAPKAPK2,INDICATI,Phase 1,Acute laryngitis/tracheitis,[ICD-11: CA05]
T21307,MAPKAPK2,INDICATI,Investigative,Fibrosis,[ICD-11: GA14-GC01]
T21307,MAPKAPK2,INDICATI,Phase 2,Hidradenitis suppurativa,[ICD-11: ED92]
T21307,MAPKAPK2,INDICATI,Phase 2,Monogenic autoinflammatory syndrome,ICD-11: 4A60
T21307,MAPKAPK2,INDICATI,Phase 1/2,Peritoneal cancer,[ICD-11: 2C51]
T21307,MAPKAPK2,INDICATI,Phase 2,Psoriatic arthritis,[ICD-11: FA21]
T21307,MAPKAPK2,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T21307,MAPKAPK2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T21312,#N/A,TARGETID,T21312,,
T21312,#N/A,TARGNAME,Immune checkpoint (ICH),,
T21312,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T21324,#N/A,TARGETID,T21324,,
T21324,#N/A,TARGNAME,Isomerase unspecific (IsoM),,
T21324,#N/A,INDICATI,Discontinued in Preregistration,Angina pectoris,[ICD-11: BA40]
T21324,#N/A,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T21334,TNFSF11,TARGETID,T21334,,
T21334,TNFSF11,TARGNAME,Osteoclast differentiation factor (ODF),,
T21334,TNFSF11,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
T21334,TNFSF11,INDICATI,Phase 1,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T21334,TNFSF11,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T21334,TNFSF11,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T21351,#N/A,TARGETID,T21351,,
T21351,#N/A,TARGNAME,Nuclear receptor unspecific (NR),,
T21351,#N/A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T21395,CD46,TARGETID,T21395,,
T21395,CD46,TARGNAME,Membrane cofactor protein (CD46),,
T21395,CD46,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T21434,CHRNA10,TARGETID,T21434,,
T21434,CHRNA10,TARGNAME,Neuronal acetylcholine receptor alpha-10 (CHRNA10),,
T21434,CHRNA10,INDICATI,Phase 1,General pain disorder,[ICD-11: 8E43]
,#N/A,,,,
T21447,#N/A,TARGETID,T21447,,
T21447,#N/A,TARGNAME,Glutamine receptor (GluR),,
T21447,#N/A,INDICATI,Approved,Nasopharyngitis,[ICD-11: CA00]
,#N/A,,,,
T21617,#N/A,TARGETID,T21617,,
T21617,#N/A,TARGNAME,Signal transduction unspecific (ST),,
T21617,#N/A,INDICATI,Phase 3,Lupus erythematosus,[ICD-11: 4A40]
T21617,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T21669,GSTP1,TARGETID,T21669,,
T21669,GSTP1,TARGNAME,Glutathione S-transferase P (GSTP1),,
T21669,GSTP1,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T21669,GSTP1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T21678,GLA,TARGETID,T21678,,
T21678,GLA,TARGNAME,Alpha-galactosidase A (GLA),,
T21678,GLA,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T21679,HTT,TARGETID,T21679,,
T21679,HTT,TARGNAME,Huntingtin messenger RNA (HTT mRNA),,
T21679,HTT,INDICATI,Preclinical,Choreiform disorder,[ICD-11: 8A01]
,#N/A,,,,
T21689,APOE,TARGETID,T21689,,
T21689,APOE,TARGNAME,Apolipoprotein E (APOE),,
T21689,APOE,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T21689,APOE,INDICATI,Terminated,Glaucoma,[ICD-11: 9C61]
T21689,APOE,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T21689,APOE,INDICATI,Phase 2,Intracerebral haemorrhage,[ICD-11: 8B00]
,#N/A,,,,
T21701,#N/A,TARGETID,T21701,,
T21701,#N/A,TARGNAME,Transforming protein Rho (RHO),,
T21701,#N/A,INDICATI,Phase 2/3,Spine/trunk injury,[ICD-11: ND51]
,#N/A,,,,
T21782,PCNA,TARGETID,T21782,,
T21782,PCNA,TARGNAME,Proliferating cell nuclear antigen (PCNA),,
T21782,PCNA,INDICATI,Phase 3,Obesity,[ICD-11: 5B80-5B81]
T21782,PCNA,INDICATI,Discontinued in Phase 1,Retina disorder,[ICD-11: 9B70-9B7Z]
,#N/A,,,,
T21865,SELPLG,TARGETID,T21865,,
T21865,SELPLG,TARGNAME,P-selectin glycoprotein ligand 1 (SELPLG),,
T21865,SELPLG,INDICATI,Phase 2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T21865,SELPLG,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T21865,SELPLG,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T21865,SELPLG,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T21865,SELPLG,INDICATI,Phase 2,Psoriatic arthritis,[ICD-11: FA21]
,#N/A,,,,
T21890,CEACAM3,TARGETID,T21890,,
T21890,CEACAM3,TARGNAME,Carcinoembryonic antigen CGM1 (CD66d),,
T21890,CEACAM3,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T21945,SLC6A2,TARGETID,T21945,,
T21945,SLC6A2,TARGNAME,Norepinephrine transporter (NET),,
T21945,SLC6A2,INDICATI,Approved,Acute pain,[ICD-11: MG31]
T21945,SLC6A2,INDICATI,Phase 2,Adrenal cancer,[ICD-11: 2D11]
T21945,SLC6A2,INDICATI,Application submitted,Adrenomedullary hyperfunction,[ICD-11: 5A75]
T21945,SLC6A2,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T21945,SLC6A2,INDICATI,Phase 3,Binge eating disorder,[ICD-11: 6B82]
T21945,SLC6A2,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T21945,SLC6A2,INDICATI,Phase 2,Cocaine use disorder,[ICD-11: 6C45]
T21945,SLC6A2,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T21945,SLC6A2,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T21945,SLC6A2,INDICATI,Discontinued in Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T21945,SLC6A2,INDICATI,Phase 2,Fatigue,[ICD-11: MG22]
T21945,SLC6A2,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T21945,SLC6A2,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T21945,SLC6A2,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T21945,SLC6A2,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T21945,SLC6A2,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T21945,SLC6A2,INDICATI,Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T21945,SLC6A2,INDICATI,Approved,Nicotine use disorder,[ICD-11: 6C4A]
T21945,SLC6A2,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T21945,SLC6A2,INDICATI,Phase 1,Orthostatic hypotension,[ICD-11: BA21]
T21945,SLC6A2,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T21945,SLC6A2,INDICATI,Approved,Stomach cancer,[ICD-11: 2B72]
T21945,SLC6A2,INDICATI,Phase 2,Stomach disease,[ICD-11: DA43-DA4Y]
T21945,SLC6A2,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T21960,ANGPT2,TARGETID,T21960,,
T21960,ANGPT2,TARGNAME,Angiopoietin-2 (ANGPT2),,
T21960,ANGPT2,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T21960,ANGPT2,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T21960,ANGPT2,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T21960,ANGPT2,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T21960,ANGPT2,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T21960,ANGPT2,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T21960,ANGPT2,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T21960,ANGPT2,INDICATI,Approved,Retinopathy,[ICD-11: 9B71]
T21960,ANGPT2,INDICATI,Investigative,Sepsis,[ICD-11: 1G40-1G41]
T21960,ANGPT2,INDICATI,Preclinical,Sexual dysfunction,[ICD-11: HA00-HA01]
T21960,ANGPT2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T22032,PTH2R,TARGETID,T22032,,
T22032,PTH2R,TARGNAME,Parathyroid hormone receptor (PTH2R),,
T22032,PTH2R,INDICATI,Phase 1,Alopecia,[ICD-11: ED70]
T22032,PTH2R,INDICATI,Investigative,Endocrine disease,[ICD-11: 5B3Z]
T22032,PTH2R,INDICATI,Phase 3,Low bone mass disorder,[ICD-11: FB83]
,#N/A,,,,
T22095,IL17A,TARGETID,T22095,,
T22095,IL17A,TARGNAME,Interleukin-17 (IL17),,
T22095,IL17A,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
T22095,IL17A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T22095,IL17A,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T22095,IL17A,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T22095,IL17A,INDICATI,Phase 3,Psoriatic arthritis,[ICD-11: FA21]
T22095,IL17A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T22095,IL17A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T22118,DRD1,TARGETID,T22118,,
T22118,DRD1,TARGNAME,Dopamine D1 receptor (D1R),,
T22118,DRD1,INDICATI,Approved,Abortion,[ICD-11: JA00]
T22118,DRD1,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T22118,DRD1,INDICATI,Phase 3,Cocaine use disorder,[ICD-11: 6C45]
T22118,DRD1,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T22118,DRD1,INDICATI,Discontinued in Phase 1,Glaucoma,[ICD-11: 9C61]
T22118,DRD1,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T22118,DRD1,INDICATI,Terminated,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T22118,DRD1,INDICATI,Discontinued in Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T22118,DRD1,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T22118,DRD1,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T22118,DRD1,INDICATI,Phase 1/2,Psychotic disorder,[ICD-11: 6A20-6A25]
T22118,DRD1,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
T22118,DRD1,INDICATI,Phase 2,Tic disorder,[ICD-11: 8A05]
T22118,DRD1,INDICATI,Terminated,Type 2 diabetes mellitus,[ICD-11: 5A11]
T22118,DRD1,INDICATI,Terminated,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T22128,GAD2,TARGETID,T22128,,
T22128,GAD2,TARGNAME,Glutamate decarboxylase 2 (GAD2),,
T22128,GAD2,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T22212,FCGR2A,TARGETID,T22212,,
T22212,FCGR2A,TARGNAME,Immunoglobulin gamma Fc receptor IIA (FCGR2A),,
T22212,FCGR2A,INDICATI,Preclinical,Chronic kidney disease,[ICD-11: GB61]
T22212,FCGR2A,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T22212,FCGR2A,INDICATI,Approved (orphan drug),Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T22274,HDAC6,TARGETID,T22274,,
T22274,HDAC6,TARGNAME,Histone deacetylase 6 (HDAC6),,
T22274,HDAC6,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T22274,HDAC6,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T22285,GRIN2A,TARGETID,T22285,,
T22285,GRIN2A,TARGNAME,Glutamate receptor ionotropic NMDA 2A (NMDAR2A),,
T22285,GRIN2A,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T22285,GRIN2A,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T22285,GRIN2A,INDICATI,Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T22285,GRIN2A,INDICATI,Discontinued in Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T22285,GRIN2A,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T22285,GRIN2A,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
,#N/A,,,,
T22295,#N/A,TARGETID,T22295,,
T22295,#N/A,TARGNAME,Staphylococcus Capsular polysaccharide CP5 (Stap-coc CP5),,
T22295,#N/A,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T22295,#N/A,INDICATI,Phase 2,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T22302,SLC12A5,TARGETID,T22302,,
T22302,SLC12A5,TARGNAME,Solute carrier family 12 member 5 (SLC12A5),,
T22302,SLC12A5,INDICATI,Investigative,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
,#N/A,,,,
T22348,Bact gyrA; Bact gyrB,TARGETID,T22348,,
T22348,Bact gyrA; Bact gyrB,TARGNAME,Bacterial DNA gyrase (Bact gyrase),,
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
T22348,Bact gyrA; Bact gyrB,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T22348,Bact gyrA; Bact gyrB,INDICATI,Approved,Bronchitis,[ICD-11: CA20]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 3,Conjunctiva disorder,[ICD-11: 9A60]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 3,Diabetic foot ulcer,[ICD-11: BD54]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 1,Digestive organ benign neoplasm,[ICD-11: 2E92]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 2,Escherichia coli intestinal infection,[ICD-11: 1A03]
T22348,Bact gyrA; Bact gyrB,INDICATI,Terminated,Fungal infection,[ICD-11: 1F29-1F2F]
T22348,Bact gyrA; Bact gyrB,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 3,Gonococcal infection,[ICD-11: 1A70-1A7Z]
T22348,Bact gyrA; Bact gyrB,INDICATI,Approved,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T22348,Bact gyrA; Bact gyrB,INDICATI,Approved,Impetigo,[ICD-11: 1B72]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 1,Joint direct infection,[ICD-11: FA10]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 3,Otitis media,[ICD-11: AA80-AB0Z]
T22348,Bact gyrA; Bact gyrB,INDICATI,Approved,Pneumonia,[ICD-11: CA40]
T22348,Bact gyrA; Bact gyrB,INDICATI,Discontinued in Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
T22348,Bact gyrA; Bact gyrB,INDICATI,Approved,Respiratory infection,[ICD-11: CA07-CA4Z]
T22348,Bact gyrA; Bact gyrB,INDICATI,Phase 2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T22348,Bact gyrA; Bact gyrB,INDICATI,Terminated,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
T22348,Bact gyrA; Bact gyrB,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T22350,ENG,TARGETID,T22350,,
T22350,ENG,TARGNAME,Endoglin CD105 (ENG),,
T22350,ENG,INDICATI,Phase 3,Angiosarcoma,[ICD-11: 2B56]
T22350,ENG,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T22350,ENG,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T22350,ENG,INDICATI,Phase 2,Fallopian tube cancer,[ICD-11: 2C74]
T22350,ENG,INDICATI,Phase 2,Gynecologic cancer,[ICD-11: 2F33-2F76]
T22350,ENG,INDICATI,Phase 2,Kaposi sarcoma,[ICD-11: 2B57]
T22350,ENG,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T22350,ENG,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T22350,ENG,INDICATI,Phase 1,Non-small-cell lung cancer,[ICD-11: 2C25]
T22350,ENG,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T22350,ENG,INDICATI,Phase 2,Peritoneal cancer,[ICD-11: 2C51]
T22350,ENG,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T22350,ENG,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T22415,Pseudo pcrV,TARGETID,T22415,,
T22415,Pseudo pcrV,TARGNAME,Pseudomonas PcrV protein type III (Pseudo pcrV),,
T22415,Pseudo pcrV,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T22415,Pseudo pcrV,INDICATI,Phase 1,Glanders,[ICD-11: 1B92]
T22415,Pseudo pcrV,INDICATI,Phase 2,Medical/surgical procedure injury,[ICD-11: PK80-PK81]
T22415,Pseudo pcrV,INDICATI,Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T22496,HTT,TARGETID,T22496,,
T22496,HTT,TARGNAME,Huntingtin (HTT),,
T22496,HTT,INDICATI,Phase 3,Choreiform disorder,[ICD-11: 8A01]
,#N/A,,,,
T22583,SLC5A4,TARGETID,T22583,,
T22583,SLC5A4,TARGNAME,Sodium/glucose cotransporter 2 (SLC5A4),,
T22583,SLC5A4,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T22583,SLC5A4,INDICATI,Discontinued in Phase 3,Gout,[ICD-11: FA25]
T22583,SLC5A4,INDICATI,Phase 3,Type 2 diabetes mellitus,[ICD-11: 5A11]
T22583,SLC5A4,INDICATI,Phase 2,Type-1/2 diabete,[ICD-11: 5A10-5A11]
,#N/A,,,,
T22608,#N/A,TARGETID,T22608,,
T22608,#N/A,TARGNAME,TNF alpha production (TNFA produ),,
T22608,#N/A,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
,#N/A,,,,
T22655,MADCAM1,TARGETID,T22655,,
T22655,MADCAM1,TARGNAME,Mucosal addressin cell adhesion molecule 1 (MADCAM1),,
T22655,MADCAM1,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T22655,MADCAM1,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T22655,MADCAM1,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T22655,MADCAM1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T22655,MADCAM1,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T22658,CXCL8,TARGETID,T22658,,
T22658,CXCL8,TARGNAME,Interleukin-8 (IL8),,
T22658,CXCL8,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T22658,CXCL8,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T22658,CXCL8,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T22658,CXCL8,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T22658,CXCL8,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T22778,#N/A,TARGETID,T22778,,
T22778,#N/A,TARGNAME,Intracellular nitroreductase (INR),,
T22778,#N/A,INDICATI,Phase 1,Diagnostic imaging,[ICD-11: N.A.]
,#N/A,,,,
T22839,CELA1,TARGETID,T22839,,
T22839,CELA1,TARGNAME,Pancreatic elastase 1 (CELA1),,
T22839,CELA1,INDICATI,Approved,Alpha-1-antitrypsin deficiency,[ICD-11: 5C5A]
T22839,CELA1,INDICATI,Application submitted,Anterior uveitis,[ICD-11: 9A96]
T22839,CELA1,INDICATI,Approved,Bronchitis,[ICD-11: CA20]
T22839,CELA1,INDICATI,Terminated,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T22839,CELA1,INDICATI,Withdrawn from market,Chronic pain,[ICD-11: MG30]
T22839,CELA1,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T22839,CELA1,INDICATI,Terminated,Cystic fibrosis,[ICD-11: CA25]
T22839,CELA1,INDICATI,Terminated,Emphysema,[ICD-11: CA21]
T22839,CELA1,INDICATI,Application submitted,Inflammatory spondyloarthritis,[ICD-11: FA92]
T22839,CELA1,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T22839,CELA1,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T22839,CELA1,INDICATI,Phase 3,Psoriatic arthritis,[ICD-11: FA21]
T22839,CELA1,INDICATI,Phase 3,Pyoderma gangrenosum,[ICD-11: EB21]
T22839,CELA1,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T22839,CELA1,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T22939,PGR,TARGETID,T22939,,
T22939,PGR,TARGNAME,Progesterone receptor (PGR),,
T22939,PGR,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T22939,PGR,INDICATI,Approved,Contraceptive management,[ICD-11: QA21]
T22939,PGR,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T22939,PGR,INDICATI,Phase 3,Endometriosis,[ICD-11: GA10]
T22939,PGR,INDICATI,Investigative,Female genital system disease,[ICD-11: GA6Z]
T22939,PGR,INDICATI,Phase 3,Female pelvic pain,[ICD-11: GA34]
T22939,PGR,INDICATI,Terminated,Low bone mass disorder,[ICD-11: FB83]
T22939,PGR,INDICATI,Approved,Menstrual cycle bleeding disorder,[ICD-11: GA20]
T22939,PGR,INDICATI,Approved,Preterm labour/delivery,[ICD-11: JB00]
T22939,PGR,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T22939,PGR,INDICATI,Phase 2,Uterine fibroid,[ICD-11: 2E86]
,#N/A,,,,
T22956,CDK3,TARGETID,T22956,,
T22956,CDK3,TARGNAME,Cyclin-dependent kinase 3 (CDK3),,
T22956,CDK3,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T22976,dnk,TARGETID,T22976,,
T22976,dnk,TARGNAME,Thymidine kinase 2 (Mt-TK2),,
T22976,dnk,INDICATI,Phase 3,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
,#N/A,,,,
T22977,SOD1,TARGETID,T22977,,
T22977,SOD1,TARGNAME,Superoxide dismutase Cu-Zn (SOD Cu-Zn),,
T22977,SOD1,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T22977,SOD1,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T22977,SOD1,INDICATI,Phase 3,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T22977,SOD1,INDICATI,Phase 1/2,Eczema,[ICD-11: EA80-EA89]
T22977,SOD1,INDICATI,Terminated,Head injury,[ICD-11: NA00-NA0Z]
T22977,SOD1,INDICATI,Investigative,Motor neuron disease,[ICD-11: 8B60]
T22977,SOD1,INDICATI,Preclinical,Multiple sclerosis,[ICD-11: 8A40]
T22977,SOD1,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T22977,SOD1,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T22977,SOD1,INDICATI,Phase 2,Respiratory system disease,[ICD-11: CB40-CB7Z]
T22977,SOD1,INDICATI,Phase 1,Skin sensation disturbance,[ICD-11: ME65]
T22977,SOD1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T22977,SOD1,INDICATI,Phase 2,Spine/trunk injury,[ICD-11: ND51]
,#N/A,,,,
T22978,TGFB3,TARGETID,T22978,,
T22978,TGFB3,TARGNAME,Transforming growth factor beta 3 (TGFB3),,
T22978,TGFB3,INDICATI,Phase 3,Sarcoidosis,[ICD-11: 4B20]
,#N/A,,,,
T22995,HAMP,TARGETID,T22995,,
T22995,HAMP,TARGNAME,Hepcidin (HAMP),,
T22995,HAMP,INDICATI,Preclinical,Acute disease anaemia,[ICD-11: 3A90]
T22995,HAMP,INDICATI,Phase 2,Anemia,[ICD-11: 3A00-3A9Z]
T22995,HAMP,INDICATI,Phase 2,Mineral absorption/transport disorder,[ICD-11: 5C64]
T22995,HAMP,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T22995,HAMP,INDICATI,Phase 2,Thalassaemia,[ICD-11: 3A50]
,#N/A,,,,
T23003,#N/A,TARGETID,T23003,,
T23003,#N/A,TARGNAME,MAPK/ERK kinase kinase (MAP3K),,
T23003,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T23003,#N/A,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T23003,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T23003,#N/A,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T23003,#N/A,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
T23003,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T23003,#N/A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T23003,#N/A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T23003,#N/A,INDICATI,Phase 3,Thyroid cancer,[ICD-11: 2D10]
,#N/A,,,,
T23036,Stap-coc fabI,TARGETID,T23036,,
T23036,Stap-coc fabI,TARGNAME,Staphylococcus Enoyl ACP reductase (Stap-coc fabI),,
T23036,Stap-coc fabI,INDICATI,Preclinical,Anaerobic bacterial infection,[ICD-11: 1A00-1A09]
T23036,Stap-coc fabI,INDICATI,Phase 2,Bacterial infection,[ICD-11: 1A00-1C4Z]
T23036,Stap-coc fabI,INDICATI,Phase 2,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T23050,Pseudo lptD,TARGETID,T23050,,
T23050,Pseudo lptD,TARGNAME,Pseudomonas LPS-assembly protein LptD (Pseudo lptD),,
T23050,Pseudo lptD,INDICATI,Phase 3,Medical/surgical procedure injury,[ICD-11: PK80-PK81]
,#N/A,,,,
T23145,CYP11A1,TARGETID,T23145,,
T23145,CYP11A1,TARGNAME,Cholesterol desmolase (CYP11A1),,
T23145,CYP11A1,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T23145,CYP11A1,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T23172,JAK3,TARGETID,T23172,,
T23172,JAK3,TARGNAME,Janus kinase 3 (JAK-3),,
T23172,JAK3,INDICATI,Phase 1,Acquired hypomelanotic disorder,[ICD-11: ED63]
T23172,JAK3,INDICATI,Approved,Alopecia,ICD-11: ED70
T23172,JAK3,INDICATI,Phase 2/3,Alopecia,[ICD-11: ED70]
T23172,JAK3,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T23172,JAK3,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
T23172,JAK3,INDICATI,Phase 2,B-cell lymphoma,[ICD-11: 2A86]
T23172,JAK3,INDICATI,Phase 1,Crohn disease,[ICD-11: DD70]
T23172,JAK3,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T23172,JAK3,INDICATI,Investigative,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T23172,JAK3,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T23172,JAK3,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T23172,JAK3,INDICATI,Terminated,Multiple myeloma,[ICD-11: 2A83]
T23172,JAK3,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T23172,JAK3,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T23172,JAK3,INDICATI,Phase 1,Pruritus,[ICD-11: EC90]
T23172,JAK3,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T23172,JAK3,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T23172,JAK3,INDICATI,Terminated,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T23178,ITGB6,TARGETID,T23178,,
T23178,ITGB6,TARGNAME,Integrin beta-6 (ITGB6),,
T23178,ITGB6,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T23212,CD14,TARGETID,T23212,,
T23212,CD14,TARGNAME,Monocyte differentiation antigen CD14 (CD14),,
T23212,CD14,INDICATI,Phase 2,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T23276,MAPK3,TARGETID,T23276,,
T23276,MAPK3,TARGNAME,Extracellular signal-regulated kinase 1 (ERK1),,
T23276,MAPK3,INDICATI,Phase 1,Arteries/arterioles disorder,[ICD-11: BD52]
T23276,MAPK3,INDICATI,Preclinical,Mature T-cell lymphoma,[ICD-11: 2A90]
T23276,MAPK3,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T23276,MAPK3,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T23276,MAPK3,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T23292,GALNS,TARGETID,T23292,,
T23292,GALNS,TARGNAME,N-acetylgalactosamine 6 sulfatase (GALNS),,
T23292,GALNS,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T23343,HIV p24,TARGETID,T23343,,
T23343,HIV p24,TARGNAME,Human immunodeficiency virus Capsid p24 (HIV p24),,
T23343,HIV p24,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T23347,IL1R2,TARGETID,T23347,,
T23347,IL1R2,TARGNAME,Interleukin 1 receptor type 2 (IL1R2),,
T23347,IL1R2,INDICATI,Terminated,Immune system disease,[ICD-11: 4A01-4B41]
T23347,IL1R2,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T23348,VWF,TARGETID,T23348,,
T23348,VWF,TARGNAME,von Willebrand factor (VWF),,
T23348,VWF,INDICATI,Phase 1,Cerebral ischaemic stroke,[ICD-11: 8B11]
T23348,VWF,INDICATI,Phase 2,Intracranial embolism,[ICD-11: 8B22]
T23348,VWF,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T23348,VWF,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T23348,VWF,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
T23348,VWF,INDICATI,Approved,Von Willebrand disease,[ICD-11: 3B12]
,#N/A,,,,
T23355,ITGB3,TARGETID,T23355,,
T23355,ITGB3,TARGNAME,ITGB3 messenger RNA (ITGB3 mRNA),,
T23355,ITGB3,INDICATI,Discontinued in Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T23355,ITGB3,INDICATI,Discontinued in Phase 3,Chronic arterial occlusive disease,[ICD-11: BD4Z]
,#N/A,,,,
T23359,APP,TARGETID,T23359,,
T23359,APP,TARGNAME,APP messenger RNA (APP mRNA),,
T23359,APP,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T23389,TTR,TARGETID,T23389,,
T23389,TTR,TARGNAME,Transthyretin messenger RNA (TTR mRNA),,
T23389,TTR,INDICATI,Approved,Amyloidosis,[ICD-11: 5D00]
T23389,TTR,INDICATI,Approved,Amyloidosis,ICD-11: 5D00
,#N/A,,,,
T23459,EBV BLLF1,TARGETID,T23459,,
T23459,EBV BLLF1,TARGNAME,Epstein-Barr virus Envelope glycoprotein gp340 (EBV BLLF1),,
T23459,EBV BLLF1,INDICATI,Approved,Herpes simplex infection,[ICD-11: 1F00]
,#N/A,,,,
T23471,MPO,TARGETID,T23471,,
T23471,MPO,TARGNAME,Myeloperoxidase (MPO),,
T23471,MPO,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T23471,MPO,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
T23471,MPO,INDICATI,Phase 2/3,Left ventricular failure,ICD-11: BD11
T23471,MPO,INDICATI,Discontinued in Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T23471,MPO,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T23471,MPO,INDICATI,Phase 3,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T23499,EDNRA,TARGETID,T23499,,
T23499,EDNRA,TARGNAME,Endothelin A receptor (EDNRA),,
T23499,EDNRA,INDICATI,Discontinued in Phase 1,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T23499,EDNRA,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T23499,EDNRA,INDICATI,Approved,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T23499,EDNRA,INDICATI,Discontinued in Phase 2,Cerebrovascular disease,[ICD-11: 8B22-8B2Z]
T23499,EDNRA,INDICATI,Phase 3,Chronic kidney disease,[ICD-11: GB61]
T23499,EDNRA,INDICATI,Phase 3,Coronary vasospastic disease,[ICD-11: BA85]
T23499,EDNRA,INDICATI,Discontinued in Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T23499,EDNRA,INDICATI,Terminated,Heart disease,[ICD-11: BA41-BA42]
T23499,EDNRA,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T23499,EDNRA,INDICATI,Phase 3,Hypotension,[ICD-11: BA20-BA21]
T23499,EDNRA,INDICATI,Phase 1,Increased intracranial pressure,[ICD-11: 8D60]
T23499,EDNRA,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T23499,EDNRA,INDICATI,Investigative,Preterm labour/delivery,[ICD-11: JB00]
T23499,EDNRA,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T23499,EDNRA,INDICATI,Approved,Pulmonary hypertension,[ICD-11: BB01]
T23499,EDNRA,INDICATI,Discontinued in Phase 3,Retinal vascular occlusion,[ICD-11: 9B74]
T23499,EDNRA,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T23499,EDNRA,INDICATI,Discontinued in Phase 1,Unspecific body region injury,[ICD-11: ND56]
T23499,EDNRA,INDICATI,Approved,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T23519,GPRC5D,TARGETID,T23519,,
T23519,GPRC5D,TARGNAME,G-protein coupled receptor C 5D (GPRC5D),,
T23519,GPRC5D,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T23547,#N/A,TARGETID,T23547,,
T23547,#N/A,TARGNAME,Opioid receptor (OPR),,
T23547,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T23547,#N/A,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T23547,#N/A,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T23547,#N/A,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T23547,#N/A,INDICATI,Terminated,Cerebral ischaemic stroke,[ICD-11: 8B11]
T23547,#N/A,INDICATI,Phase 4,Chronic pain,[ICD-11: MG30]
T23547,#N/A,INDICATI,Approved,Cough,[ICD-11: MD12]
T23547,#N/A,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T23547,#N/A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T23547,#N/A,INDICATI,Phase 4,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T23547,#N/A,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T23547,#N/A,INDICATI,Preclinical,Irritable bowel syndrome,[ICD-11: DD91]
T23547,#N/A,INDICATI,Phase 3,Obesity,[ICD-11: 5B80-5B81]
T23547,#N/A,INDICATI,Approved,Opioid use disorder,[ICD-11: 6C43]
T23547,#N/A,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T23547,#N/A,INDICATI,Investigative,Parkinsonism,[ICD-11: 8A00]
T23547,#N/A,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T23547,#N/A,INDICATI,Terminated,Psychotic disorder,[ICD-11: 6A20-6A25]
T23547,#N/A,INDICATI,Approved,Sensation disturbance,[ICD-11: MB40]
T23547,#N/A,INDICATI,Preclinical,Sexual dysfunction,[ICD-11: HA00-HA01]
T23547,#N/A,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T23666,AHR,TARGETID,T23666,,
T23666,AHR,TARGNAME,Aryl hydrocarbon receptor (AHR),,
T23666,AHR,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T23666,AHR,INDICATI,Preclinical,Brain cancer,[ICD-11: 2A00]
T23666,AHR,INDICATI,Investigative,Eczema,[ICD-11: EA80-EA89]
T23666,AHR,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T23666,AHR,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T23666,AHR,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T23666,AHR,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T23666,AHR,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T23666,AHR,INDICATI,Clinical trial,Ulcerative colitis,[ICD-11: DD71]
T23666,AHR,INDICATI,Phase 1,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T23673,RAF1,TARGETID,T23673,,
T23673,RAF1,TARGNAME,Proto-oncogene c-RAF (c-RAF),,
T23673,RAF1,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T23673,RAF1,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T23673,RAF1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T23714,BDKRB2,TARGETID,T23714,,
T23714,BDKRB2,TARGNAME,B2 bradykinin receptor (BDKRB2),,
T23714,BDKRB2,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T23714,BDKRB2,INDICATI,Discontinued in Phase 2,Brain cancer,[ICD-11: 2A00]
T23714,BDKRB2,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T23714,BDKRB2,INDICATI,Phase 1/2,Chronic kidney disease,[ICD-11: GB61]
T23714,BDKRB2,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
T23714,BDKRB2,INDICATI,Approved,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T23714,BDKRB2,INDICATI,Phase 2,Intracranial injury,[ICD-11: NA07]
T23714,BDKRB2,INDICATI,Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T23714,BDKRB2,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T23714,BDKRB2,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T23714,BDKRB2,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T23714,BDKRB2,INDICATI,Phase 2,Sepsis,[ICD-11: 1G40-1G41]
T23714,BDKRB2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T23761,#N/A,TARGETID,T23761,,
T23761,#N/A,TARGNAME,Sarcoplasmic/endoplasmic reticulum calcium ATPase (ATP2A),,
T23761,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T23761,#N/A,INDICATI,Application submitted,Psoriasis,[ICD-11: EA90]
T23761,#N/A,INDICATI,Phase 3,Psoriatic arthritis,[ICD-11: FA21]
T23761,#N/A,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T23787,PFKFB3,TARGETID,T23787,,
T23787,PFKFB3,TARGNAME,Renal carcinoma antigen NY-REN-56 (PFKFB3),,
T23787,PFKFB3,INDICATI,Investigative,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T23787,PFKFB3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T23797,IL33,TARGETID,T23797,,
T23797,IL33,TARGNAME,Interleukin-33 (IL33),,
T23797,IL33,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T23797,IL33,INDICATI,Phase 1,Atopic eczema,[ICD-11: EA80]
T23797,IL33,INDICATI,Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T23797,IL33,INDICATI,Phase 3,Respiratory failure,ICD-11: CB41
,#N/A,,,,
T23953,PSCA,TARGETID,T23953,,
T23953,PSCA,TARGNAME,Prostate stem cell antigen (PSCA),,
T23953,PSCA,INDICATI,Phase 1,Non-small-cell lung cancer,[ICD-11: 2C25]
T23953,PSCA,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T23953,PSCA,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T23953,PSCA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T23953,PSCA,INDICATI,Phase 1/2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T23995,PRKCQ,TARGETID,T23995,,
T23995,PRKCQ,TARGNAME,Protein kinase C theta (PRKCQ),,
T23995,PRKCQ,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T23995,PRKCQ,INDICATI,Phase 2,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T24127,PYY,TARGETID,T24127,,
T24127,PYY,TARGNAME,Peptide tyrosine tyrosine PYY (PYY),,
T24127,PYY,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T24211,SERPING1,TARGETID,T24211,,
T24211,SERPING1,TARGNAME,C1 esterase inhibitor (SERPING1),,
T24211,SERPING1,INDICATI,Approved,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T24211,SERPING1,INDICATI,Approved,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T24373,LIPA,TARGETID,T24373,,
T24373,LIPA,TARGNAME,Lysosomal acid lipase (LIPA),,
T24373,LIPA,INDICATI,Approved,Enzyme deficiency,[ICD-11: 5C51-5C57]
,#N/A,,,,
T24555,ADRB2,TARGETID,T24555,,
T24555,ADRB2,TARGNAME,ADRB2 messenger RNA (ADRB2 mRNA),,
T24555,ADRB2,INDICATI,Phase 2,Glaucoma,[ICD-11: 9C61]
,#N/A,,,,
T24587,MGMT,TARGETID,T24587,,
T24587,MGMT,TARGNAME,O-6-methylguanine-DNA-alkyltransferase (MGMT),,
T24587,MGMT,INDICATI,Phase 3,Sarcoma,[ICD-11: 2A60-2C35]
,#N/A,,,,
T24626,Hae-influ lpxC,TARGETID,T24626,,
T24626,Hae-influ lpxC,TARGNAME,Haemophilus influenzae Acetylglucosamine deacetylase (Hae-influ lpxC),,
T24626,Hae-influ lpxC,INDICATI,Phase 1,Glanders,[ICD-11: 1B92]
,#N/A,,,,
T24634,Bact murA,TARGETID,T24634,,
T24634,Bact murA,TARGNAME,Bacterial UDP-N-acetylglucosamine carboxyvinyltransferase (Bact murA),,
T24634,Bact murA,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T24634,Bact murA,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
,#N/A,,,,
T24793,CACNA1D,TARGETID,T24793,,
T24793,CACNA1D,TARGNAME,Voltage-gated calcium channel alpha Cav1.3 (CACNA1D),,
T24793,CACNA1D,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T24793,CACNA1D,INDICATI,Discontinued in Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T24793,CACNA1D,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T24793,CACNA1D,INDICATI,Investigative,Heart failure,[ICD-11: BD10-BD1Z]
T24793,CACNA1D,INDICATI,Terminated,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T24835,#N/A,TARGETID,T24835,,
T24835,#N/A,TARGNAME,Mycobacterial lipoarabinomannan (MycB LAM),,
T24835,#N/A,INDICATI,Preclinical,Mycobacterium infection,[ICD-11: 1B10-1B21]
,#N/A,,,,
T24836,PROC,TARGETID,T24836,,
T24836,PROC,TARGNAME,Vitamin K-dependent protein C (PROC),,
T24836,PROC,INDICATI,Discontinued in Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T24836,PROC,INDICATI,Phase 2,Cerebral ischaemia,[ICD-11: 8B1Z]
T24836,PROC,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T24836,PROC,INDICATI,Approved,Chronic lower extremities peripheral venous insufficiency,[ICD-11: BD74]
T24836,PROC,INDICATI,Approved,Hemangioma,[ICD-11: 2E81-2F2Y]
T24836,PROC,INDICATI,Phase 3,Pregnancy/childbirth/puerperium maternal infection,[ICD-11: JB63]
,#N/A,,,,
T24982,SLC10A2,TARGETID,T24982,,
T24982,SLC10A2,TARGNAME,Ileal sodium/bile acid cotransporter (SLC10A2),,
T24982,SLC10A2,INDICATI,Phase 2,Autoimmune liver disease,[ICD-11: DB96]
T24982,SLC10A2,INDICATI,Phase 3,Gallbladder/bile ducts/liver structural developmental anomaly,[ICD-11: LB20]
T24982,SLC10A2,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T24982,SLC10A2,INDICATI,Phase 3,Inborn lipid metabolism error,[ICD-11: 5C52]
T24982,SLC10A2,INDICATI,Phase 3,Inborn porphyrin/heme metabolism error,[ICD-11: 5C58]
T24982,SLC10A2,INDICATI,Approved,Pruritus,[ICD-11: EC90]
T24982,SLC10A2,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T24983,DRD4,TARGETID,T24983,,
T24983,DRD4,TARGNAME,Dopamine D4 receptor (D4R),,
T24983,DRD4,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T24983,DRD4,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T24983,DRD4,INDICATI,Phase 1,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T24983,DRD4,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T24983,DRD4,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T24983,DRD4,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T24983,DRD4,INDICATI,Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T24983,DRD4,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T24983,DRD4,INDICATI,Discontinued in Phase 2,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T25005,BTK,TARGETID,T25005,,
T25005,BTK,TARGNAME,Tyrosine-protein kinase BTK (ATK),,
T25005,BTK,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T25005,BTK,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T25005,BTK,INDICATI,Phase 1,Autoimmune disease,[ICD-11: 4A40-4A45]
T25005,BTK,INDICATI,Phase 2,B-cell lymphoma,[ICD-11: 2A86]
T25005,BTK,INDICATI,Preclinical,Diabetes mellitus,[ICD-11: 5A10]
T25005,BTK,INDICATI,Phase 3,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T25005,BTK,INDICATI,Phase 3,Follicular lymphoma,[ICD-11: 2A80]
T25005,BTK,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T25005,BTK,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T25005,BTK,INDICATI,Phase 3,Mature B-cell leukaemia,[ICD-11: 2A82]
T25005,BTK,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T25005,BTK,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T25005,BTK,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T25005,BTK,INDICATI,Phase 2,Pemphigus,[ICD-11: EB40]
T25005,BTK,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T25005,BTK,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T25005,BTK,INDICATI,Phase 2,Spontaneous urticaria,[ICD-11: EB00]
,#N/A,,,,
T25064,#N/A,TARGETID,T25064,,
T25064,#N/A,TARGNAME,Neisseria gonorrhoeae Enoyl-[acyl-carrier-protein] reductase (Neisseria fabI),,
T25064,#N/A,INDICATI,Preclinical,Gonococcal infection,[ICD-11: 1A70-1A7Z]
,#N/A,,,,
T25076,EDN1,TARGETID,T25076,,
T25076,EDN1,TARGNAME,Endothelin-1 (EDN1),,
T25076,EDN1,INDICATI,Discontinued in Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
,#N/A,,,,
T25163,CPS1,TARGETID,T25163,,
T25163,CPS1,TARGNAME,Carbamoyl-phosphate synthetase I (CPS1),,
T25163,CPS1,INDICATI,Approved,Metabolism inborn error,[ICD-11: 5C50]
T25163,CPS1,INDICATI,Approved,Varicose veins,[ICD-11: BD74-BD75]
,#N/A,,,,
T25258,ABCB1,TARGETID,T25258,,
T25258,ABCB1,TARGNAME,Multidrug resistance protein 1 (ABCB1),,
T25258,ABCB1,INDICATI,Discontinued in Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T25258,ABCB1,INDICATI,Discontinued in Phase 2,Adrenal cancer,[ICD-11: 2D11]
T25258,ABCB1,INDICATI,Phase 1,Bacterial infection,[ICD-11: 1A00-1C4Z]
T25258,ABCB1,INDICATI,Discontinued in Phase 3,Lung cancer,[ICD-11: 2C25]
T25258,ABCB1,INDICATI,Discontinued in Phase 2,Ovarian cancer,[ICD-11: 2C73]
T25258,ABCB1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T25265,EZH2,TARGETID,T25265,,
T25265,EZH2,TARGNAME,Enhancer of zeste homolog 2 (EZH2),,
T25265,EZH2,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T25265,EZH2,INDICATI,Phase 1,B-cell lymphoma,[ICD-11: 2A86]
T25265,EZH2,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T25265,EZH2,INDICATI,Investigative,Breast cancer,[ICD-11: 2C60-2C6Y]
T25265,EZH2,INDICATI,Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T25265,EZH2,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
T25265,EZH2,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T25265,EZH2,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T25265,EZH2,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T25265,EZH2,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T25265,EZH2,INDICATI,Phase 2,Peritoneal cancer,[ICD-11: 2C51]
T25265,EZH2,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T25265,EZH2,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
T25265,EZH2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T25265,EZH2,INDICATI,Phase 1,Synovial sarcoma,[ICD-11: 2B5A]
T25265,EZH2,INDICATI,Phase 1,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T25307,RORC,TARGETID,T25307,,
T25307,RORC,TARGNAME,Nuclear receptor ROR-gamma (RORG),,
T25307,RORC,INDICATI,Preclinical,Arterial occlusive disease,[ICD-11: BD40]
T25307,RORC,INDICATI,Phase 1,Autoimmune disease,[ICD-11: 4A40-4A45]
T25307,RORC,INDICATI,Phase 1,Crohn disease,[ICD-11: DD70]
T25307,RORC,INDICATI,Preclinical,Liver cancer,[ICD-11: 2C12]
T25307,RORC,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T25307,RORC,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T25307,RORC,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T25307,RORC,INDICATI,Preclinical,Rheumatoid arthritis,[ICD-11: FA20]
T25307,RORC,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T25315,CXCR3,TARGETID,T25315,,
T25315,CXCR3,TARGNAME,C-X-C chemokine receptor type 3 (CXCR3),,
T25315,CXCR3,INDICATI,Preclinical,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T25315,CXCR3,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T25315,CXCR3,INDICATI,Discontinued in Phase 2,Psoriasis,[ICD-11: EA90]
T25315,CXCR3,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T25317,EBP,TARGETID,T25317,,
T25317,EBP,TARGNAME,Cholestenol delta-isomerase (EBP),,
T25317,EBP,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T25419,#N/A,TARGETID,T25419,,
T25419,#N/A,TARGNAME,Tropomyosin receptor kinase (Trk),,
T25419,#N/A,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T25464,PPP3CA,TARGETID,T25464,,
T25464,PPP3CA,TARGNAME,Calcineurin (PPP3CA),,
T25464,PPP3CA,INDICATI,Phase 3,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T25464,PPP3CA,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
T25464,PPP3CA,INDICATI,Phase 4,Intracranial injury,[ICD-11: NA07]
T25464,PPP3CA,INDICATI,Approved,Lupus erythematosus,[ICD-11: 4A40]
T25464,PPP3CA,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T25464,PPP3CA,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
T25464,PPP3CA,INDICATI,Phase 2,Urinary system disease,[ICD-11: GC2Z]
T25464,PPP3CA,INDICATI,Investigative,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T25537,#N/A,TARGETID,T25537,,
T25537,#N/A,TARGNAME,Mitogen-activated protein kinase (MAPK),,
T25537,#N/A,INDICATI,Phase 2,Keratosis pilaris,[ICD-11: ED56]
T25537,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T25608,FFAR1,TARGETID,T25608,,
T25608,FFAR1,TARGNAME,Free fatty acid receptor 1 (GPR40),,
T25608,FFAR1,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T25608,FFAR1,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T25608,FFAR1,INDICATI,Phase 3,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T25637,LOXL2,TARGETID,T25637,,
T25637,LOXL2,TARGNAME,Lysyl oxidase homolog 2 (LOXL2),,
T25637,LOXL2,INDICATI,Preclinical,Cardiac arrest,[ICD-11: MC82]
T25637,LOXL2,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
,#N/A,,,,
T25663,#N/A,TARGETID,T25663,,
T25663,#N/A,TARGNAME,Adenosine receptor (ADOR),,
T25663,#N/A,INDICATI,Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T25663,#N/A,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T25663,#N/A,INDICATI,Terminated,Hypertension,[ICD-11: BA00-BA04]
T25663,#N/A,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T25663,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T25698,#N/A,TARGETID,T25698,,
T25698,#N/A,TARGNAME,Pseudomonas Lipopolysaccharide (Pseudo LPS),,
T25698,#N/A,INDICATI,Phase 1/2,Glanders,[ICD-11: 1B92]
T25698,#N/A,INDICATI,Phase 2,Medical/surgical procedure injury,[ICD-11: PK80-PK81]
T25698,#N/A,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T25703,HMOX1,TARGETID,T25703,,
T25703,HMOX1,TARGNAME,Heme oxygenase 1 (HMOX1),,
T25703,HMOX1,INDICATI,Phase 2,Neonatal hyperbilirubinaemia,[ICD-11: KA87]
,#N/A,,,,
T25705,FPR3,TARGETID,T25705,,
T25705,FPR3,TARGNAME,N-formyl peptide receptor 3 (FPR3),,
T25705,FPR3,INDICATI,Preclinical,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T25726,GPC3,TARGETID,T25726,,
T25726,GPC3,TARGNAME,Glypican-3 (GPC3),,
T25726,GPC3,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T25726,GPC3,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T25726,GPC3,INDICATI,Phase 2,Metastatic liver/bile duct neoplasm,[ICD-11: 2D80]
T25726,GPC3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T25739,SLC39A6,TARGETID,T25739,,
T25739,SLC39A6,TARGNAME,Solute carrier family 39 member 6 (SLC39A6),,
T25739,SLC39A6,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T25739,SLC39A6,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T25739,SLC39A6,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T25847,PPIB,TARGETID,T25847,,
T25847,PPIB,TARGNAME,Rotamase B (PPIB),,
T25847,PPIB,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
,#N/A,,,,
T25889,#N/A,TARGETID,T25889,,
T25889,#N/A,TARGNAME,Adenylate cyclase (ADCY),,
T25889,#N/A,INDICATI,Terminated,Heart failure,[ICD-11: BD10-BD1Z]
T25889,#N/A,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T25950,#N/A,TARGETID,T25950,,
T25950,#N/A,TARGNAME,Bone metabolism (Bone metab),,
T25950,#N/A,INDICATI,Discontinued in Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T25956,EP300,TARGETID,T25956,,
T25956,EP300,TARGNAME,Histone acetyltransferase p300 (EP300),,
T25956,EP300,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T25956,EP300,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T26170,TNFRSF25,TARGETID,T26170,,
T26170,TNFRSF25,TARGNAME,Tumor necrosis factor receptor member 25 (TNFRSF25),,
T26170,TNFRSF25,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T26203,ICAM1,TARGETID,T26203,,
T26203,ICAM1,TARGNAME,Intercellular adhesion molecule ICAM-1 (ICAM1),,
T26203,ICAM1,INDICATI,Phase 3,Conjunctiva disorder,[ICD-11: 9A60]
T26203,ICAM1,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T26203,ICAM1,INDICATI,Terminated,Indeterminate colitis,[ICD-11: DD72]
T26203,ICAM1,INDICATI,Phase 3,Infectious gastroenteritis/colitis,[ICD-11: 1A40]
T26203,ICAM1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T26203,ICAM1,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T26203,ICAM1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T26203,ICAM1,INDICATI,Terminated,Psoriasis,[ICD-11: EA90]
T26203,ICAM1,INDICATI,Phase 1,Thyroid cancer,[ICD-11: 2D10]
T26203,ICAM1,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
T26203,ICAM1,INDICATI,Approved,Visual system disease,[ICD-11: 9E1Z]
,#N/A,,,,
T26220,#N/A,TARGETID,T26220,,
T26220,#N/A,TARGNAME,Somatostatin receptor (SSTR),,
T26220,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T26220,#N/A,INDICATI,Investigative,Duodenal ulcer,[ICD-11: DA63]
T26220,#N/A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T26220,#N/A,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T26220,#N/A,INDICATI,Discontinued in Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T26220,#N/A,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T26220,#N/A,INDICATI,Phase 2,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T26220,#N/A,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T26226,PRLR,TARGETID,T26226,,
T26226,PRLR,TARGNAME,Prolactin receptor (PRLR),,
T26226,PRLR,INDICATI,Phase 1,Fallopian tube cancer,[ICD-11: 2C74]
T26226,PRLR,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T26226,PRLR,INDICATI,Phase 1,Peritoneal cancer,[ICD-11: 2C51]
T26226,PRLR,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T26240,#N/A,TARGETID,T26240,,
T26240,#N/A,TARGNAME,Estramustine binding protein (EMBP),,
T26240,#N/A,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T26327,#N/A,TARGETID,T26327,,
T26327,#N/A,TARGNAME,Superoxide anion (SPA),,
T26327,#N/A,INDICATI,Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
,#N/A,,,,
T26368,GABRA5,TARGETID,T26368,,
T26368,GABRA5,TARGNAME,GABA(A) receptor alpha-5 (GABRA5),,
T26368,GABRA5,INDICATI,Phase 2,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T26368,GABRA5,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T26368,GABRA5,INDICATI,Phase 1,Autism spectrum disorder,[ICD-11: 6A02]
T26368,GABRA5,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T26368,GABRA5,INDICATI,Approved,Intentional self-harm,[ICD-11: PC91]
T26368,GABRA5,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T26368,GABRA5,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T26368,GABRA5,INDICATI,Phase 2,Sex development malformative disorder,[ICD-11: LD2A]
,#N/A,,,,
T26428,#N/A,TARGETID,T26428,,
T26428,#N/A,TARGNAME,Melanin-concentrating hormone receptor (MCHR),,
T26428,#N/A,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T26463,POLA1,TARGETID,T26463,,
T26463,POLA1,TARGNAME,DNA polymerase alpha catalytic p180 (POLA1),,
T26463,POLA1,INDICATI,Discontinued in Phase 1,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T26470,BCL11A,TARGETID,T26470,,
T26470,BCL11A,TARGNAME,B-cell lymphoma/leukemia 11A (BCL11A),,
T26470,BCL11A,INDICATI,Phase 1/2,Sickle-cell disorder,[ICD-11: 3A51]
T26470,BCL11A,INDICATI,Phase 1/2,Thalassaemia,[ICD-11: 3A50]
,#N/A,,,,
T26500,HRH4,TARGETID,T26500,,
T26500,HRH4,TARGNAME,Histamine H4 receptor (H4R),,
T26500,HRH4,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T26500,HRH4,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T26500,HRH4,INDICATI,Terminated,Mild neurocognitive disorder,[ICD-11: 6D71]
T26500,HRH4,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T26500,HRH4,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T26500,HRH4,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T26500,HRH4,INDICATI,Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T26623,AKR1B1,TARGETID,T26623,,
T26623,AKR1B1,TARGNAME,Aldose reductase (AKR1B1),,
T26623,AKR1B1,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T26623,AKR1B1,INDICATI,Withdrawn from market,Cataract,[ICD-11: 9B10]
T26623,AKR1B1,INDICATI,Phase 1,Glaucoma,[ICD-11: 9C61]
T26623,AKR1B1,INDICATI,Discontinued in Phase 3,Gout,[ICD-11: FA25]
T26623,AKR1B1,INDICATI,Discontinued in Phase 2,Head and neck cancer,[ICD-11: 2D42]
T26623,AKR1B1,INDICATI,Approved,Neuropathy,[ICD-11: 8C0Z]
T26623,AKR1B1,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T26623,AKR1B1,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T26623,AKR1B1,INDICATI,Phase 1,Schizophrenia,[ICD-11: 6A20]
T26623,AKR1B1,INDICATI,Phase 2/3,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T26851,C3,TARGETID,T26851,,
T26851,C3,TARGNAME,Complement C3 (CO3),,
T26851,C3,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T26851,C3,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T26851,C3,INDICATI,Phase 2,Gingival disease,[ICD-11: DA0B]
T26851,C3,INDICATI,Approved,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
T26851,C3,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T26851,C3,INDICATI,Phase 2,Macular degeneration,ICD-11: 9B75
T26851,C3,INDICATI,Phase 2/3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T26851,C3,INDICATI,Phase 1/2,Melanoma,[ICD-11: 2C30]
T26851,C3,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T26900,GAD1,TARGETID,T26900,,
T26900,GAD1,TARGNAME,Glutamic acid decarboxylase 1 (GAD1),,
T26900,GAD1,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T27021,#N/A,TARGETID,T27021,,
T27021,#N/A,TARGNAME,Transferase unspecific (TF),,
T27021,#N/A,INDICATI,Phase 4,Cerebral ischaemia,[ICD-11: 8B1Z]
T27021,#N/A,INDICATI,Approved,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T27021,#N/A,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
T27021,#N/A,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T27106,#N/A,TARGETID,T27106,,
T27106,#N/A,TARGNAME,FK506-binding protein (FKBP),,
T27106,#N/A,INDICATI,Phase 2,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
T27106,#N/A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T27106,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T27137,GRM1,TARGETID,T27137,,
T27137,GRM1,TARGNAME,Metabotropic glutamate receptor 1 (mGluR1),,
T27137,GRM1,INDICATI,Discontinued in Phase 3,Alzheimer disease,[ICD-11: 8A20]
T27137,GRM1,INDICATI,Preclinical,Cerebral ischaemia,[ICD-11: 8B1Z]
T27137,GRM1,INDICATI,Terminated,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T27137,GRM1,INDICATI,Discontinued in Phase 1,General pain disorder,[ICD-11: 8E43]
T27137,GRM1,INDICATI,Preclinical,Pain,[ICD-11: MG30-MG3Z]
T27137,GRM1,INDICATI,Discontinued in Phase 2,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T27198,Stre-coc metG,TARGETID,T27198,,
T27198,Stre-coc metG,TARGNAME,Streptococcus Methionyl-tRNA synthetase (Stre-coc metG),,
T27198,Stre-coc metG,INDICATI,Phase 1,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T27265,SRD5A1; SRD5A2; SRD5A3,TARGETID,T27265,,
T27265,SRD5A1; SRD5A2; SRD5A3,TARGNAME,Oxo-5-alpha-steroid 4-dehydrogenase (SRD5A),,
T27265,SRD5A1; SRD5A2; SRD5A3,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T27265,SRD5A1; SRD5A2; SRD5A3,INDICATI,Discontinued in Phase 2,Alopecia,[ICD-11: ED70]
T27265,SRD5A1; SRD5A2; SRD5A3,INDICATI,Phase 3,Hirsutism,[ICD-11: ED72]
T27265,SRD5A1; SRD5A2; SRD5A3,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
T27265,SRD5A1; SRD5A2; SRD5A3,INDICATI,Phase 2,Prostate disease,[ICD-11: GA91]
T27265,SRD5A1; SRD5A2; SRD5A3,INDICATI,Approved,Prostate hyperplasia,[ICD-11: GA90]
,#N/A,,,,
T27288,#N/A,TARGETID,T27288,,
T27288,#N/A,TARGNAME,Food intake (FI),,
T27288,#N/A,INDICATI,Discontinued in Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T27376,GABRD,TARGETID,T27376,,
T27376,GABRD,TARGNAME,GABA(A) receptor delta (GABRD),,
T27376,GABRD,INDICATI,Terminated,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T27376,GABRD,INDICATI,Terminated,Corneal disease,[ICD-11: 9A76-9A78]
T27376,GABRD,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T27376,GABRD,INDICATI,Discontinued in Phase 2,General pain disorder,[ICD-11: 8E43]
T27376,GABRD,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T27376,GABRD,INDICATI,Approved,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T27376,GABRD,INDICATI,Phase 3,Status epilepticus,[ICD-11: 8A66]
T27376,GABRD,INDICATI,Phase 2,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T27445,Bact ileS,TARGETID,T27445,,
T27445,Bact ileS,TARGNAME,Bacterial Isoleucyl-tRNA synthetase (Bact ileS),,
T27445,Bact ileS,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T27495,VARV p37,TARGETID,T27495,,
T27495,VARV p37,TARGNAME,Variola virus Envelope phospholipase F13 (VARV p37),,
T27495,VARV p37,INDICATI,Approved,Smallpox,[ICD-11: 1E70]
T27495,VARV p37,INDICATI,Phase 3,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T27602,PRSS1,TARGETID,T27602,,
T27602,PRSS1,TARGNAME,Cationic trypsinogen (PRSS1),,
T27602,PRSS1,INDICATI,Discontinued in Phase 1,Asthma,[ICD-11: CA23]
T27602,PRSS1,INDICATI,Discontinued in Phase 2,Atopic eczema,[ICD-11: EA80]
T27602,PRSS1,INDICATI,Phase 2,Coagulation defect,[ICD-11: 3B10]
T27602,PRSS1,INDICATI,Terminated,Hypotension,[ICD-11: BA20-BA21]
T27602,PRSS1,INDICATI,Phase 3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T27602,PRSS1,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T27602,PRSS1,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T27602,PRSS1,INDICATI,Phase 3,Preterm labour/delivery,[ICD-11: JB00]
T27602,PRSS1,INDICATI,Phase 1/2,Sepsis,[ICD-11: 1G40-1G41]
T27602,PRSS1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T27611,GDF2,TARGETID,T27611,,
T27611,GDF2,TARGNAME,Growth/differentiation factor 2 (GDF2),,
T27611,GDF2,INDICATI,Phase 1,Macular degeneration,[ICD-11: 9B75]
,#N/A,,,,
T27736,PDCD2,TARGETID,T27736,,
T27736,PDCD2,TARGNAME,Programmed cell death protein 2 (PD-2),,
T27736,PDCD2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T27770,#N/A,TARGETID,T27770,,
T27770,#N/A,TARGNAME,Late inward sodium current (LISC),,
T27770,#N/A,INDICATI,Phase 3,Genetic cardiac arrhythmia,[ICD-11: BC65]
T27770,#N/A,INDICATI,Phase 3,Ischemic heart disease,[ICD-11: BA40-BA6Z]
,#N/A,,,,
T27812,SLC6A4,TARGETID,T27812,,
T27812,SLC6A4,TARGNAME,Serotonin transporter (SERT),,
T27812,SLC6A4,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T27812,SLC6A4,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T27812,SLC6A4,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T27812,SLC6A4,INDICATI,Phase 3,Binge eating disorder,[ICD-11: 6B82]
T27812,SLC6A4,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T27812,SLC6A4,INDICATI,Phase 2,Cocaine use disorder,[ICD-11: 6C45]
T27812,SLC6A4,INDICATI,Approved,concerning food/fluid intake symptom,[ICD-11: MG43]
T27812,SLC6A4,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T27812,SLC6A4,INDICATI,Approved,Cough,[ICD-11: MD12]
T27812,SLC6A4,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T27812,SLC6A4,INDICATI,Discontinued in Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T27812,SLC6A4,INDICATI,Phase 2,Ejaculatory dysfunction,[ICD-11: HA03]
T27812,SLC6A4,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T27812,SLC6A4,INDICATI,Phase 3,Insomnia,[ICD-11: 7A00-7A0Z]
T27812,SLC6A4,INDICATI,Phase 3,Menopausal disorder,[ICD-11: GA30]
T27812,SLC6A4,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T27812,SLC6A4,INDICATI,Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T27812,SLC6A4,INDICATI,Phase 1,Nausea/vomiting,[ICD-11: MD90]
T27812,SLC6A4,INDICATI,Phase 2,Neurobehavioral disorder,[ICD-11: 8A00-8A0Z]
T27812,SLC6A4,INDICATI,Approved,Nicotine use disorder,[ICD-11: 6C4A]
T27812,SLC6A4,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T27812,SLC6A4,INDICATI,Phase 1,Orthostatic hypotension,[ICD-11: BA21]
T27812,SLC6A4,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T27812,SLC6A4,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T27812,SLC6A4,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T27812,SLC6A4,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
T27812,SLC6A4,INDICATI,Phase 1,Soft tissue disorder,[ICD-11: FB56]
T27812,SLC6A4,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T27812,SLC6A4,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T27816,SNCA,TARGETID,T27816,,
T27816,SNCA,TARGNAME,SNCA messenger RNA (SNCA mRNA),,
T27816,SNCA,INDICATI,Phase 1,Autonomic nervous system disorder,[ICD-11: 8D87]
T27816,SNCA,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T27826,SPTBN1,TARGETID,T27826,,
T27826,SPTBN1,TARGNAME,Spectrin non-erythroid beta chain 1 (SPTBN1),,
T27826,SPTBN1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T27861,CRBN,TARGETID,T27861,,
T27861,CRBN,TARGNAME,Protein cereblon (CRBN),,
T27861,CRBN,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T27861,CRBN,INDICATI,Phase 1,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T27861,CRBN,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T27861,CRBN,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T27861,CRBN,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T27861,CRBN,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T27861,CRBN,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T27861,CRBN,INDICATI,Phase 2,Sarcoidosis,[ICD-11: 4B20]
T27861,CRBN,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T27889,ACE2,TARGETID,T27889,,
T27889,ACE2,TARGNAME,Angiotensin-converting enzyme 2 (ACE2),,
T27889,ACE2,INDICATI,Phase 1/2,Acute diabete complication,[ICD-11: 5A2Y]
T27889,ACE2,INDICATI,Phase 2,Intrathoracic organs injury,[ICD-11: NB32]
T27889,ACE2,INDICATI,Phase 1,Pulmonary hypertension,[ICD-11: BB01]
T27889,ACE2,INDICATI,Discontinued in Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T27918,DDX5,TARGETID,T27918,,
T27918,DDX5,TARGNAME,ATP-dependent RNA helicase DDX5 (DDX5),,
T27918,DDX5,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T27918,DDX5,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T27944,NPY4R,TARGETID,T27944,,
T27944,NPY4R,TARGNAME,Neuropeptide Y receptor type 4 (NPY4R),,
T27944,NPY4R,INDICATI,Investigative,Acute diabete complication,[ICD-11: 5A2Y]
T27944,NPY4R,INDICATI,Discontinued in Phase 2,Obesity,[ICD-11: 5B80-5B81]
T27944,NPY4R,INDICATI,Discontinued in Phase 2,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T27999,Bact pagA,TARGETID,T27999,,
T27999,Bact pagA,TARGNAME,Bacterial Protective antigen (Bact pagA),,
T27999,Bact pagA,INDICATI,Approved,Anthrax,[ICD-11: 1B97]
T27999,Bact pagA,INDICATI,Phase 1,Bacterial infection,[ICD-11: 1A00-1C4Z]
T27999,Bact pagA,INDICATI,Phase 1,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T28043,RPS6KA2,TARGETID,T28043,,
T28043,RPS6KA2,TARGNAME,Ribosomal protein S6 kinase alpha-2 (RSK2),,
T28043,RPS6KA2,INDICATI,Preclinical,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T28076,FGF4,TARGETID,T28076,,
T28076,FGF4,TARGNAME,Fibroblast growth factor-4 (FGF4),,
T28076,FGF4,INDICATI,Phase 3,Angina pectoris,[ICD-11: BA40]
T28076,FGF4,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T28076,FGF4,INDICATI,Approved,Cystitis,[ICD-11: GC00]
T28076,FGF4,INDICATI,Phase 3,Heart disease,[ICD-11: BA41-BA42]
,#N/A,,,,
T28093,FAF1,TARGETID,T28093,,
T28093,FAF1,TARGNAME,FAS-associated factor 1 (FAF1),,
T28093,FAF1,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T28213,FFAR2,TARGETID,T28213,,
T28213,FFAR2,TARGNAME,Free fatty acid receptor 2 (FFAR2),,
T28213,FFAR2,INDICATI,Phase 2,Abortion,[ICD-11: JA00]
T28213,FFAR2,INDICATI,Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
,#N/A,,,,
T28217,KIR3DL2,TARGETID,T28217,,
T28217,KIR3DL2,TARGNAME,MHC class I NK cell receptor 3DL2 (CD158k),,
T28217,KIR3DL2,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
,#N/A,,,,
T28226,GCH1,TARGETID,T28226,,
T28226,GCH1,TARGNAME,GTP cyclohydrolase-I (GCH1),,
T28226,GCH1,INDICATI,Phase 1/2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T28265,SERPINA1,TARGETID,T28265,,
T28265,SERPINA1,TARGNAME,Alpha-1-antitrypsin (SERPINA1),,
T28265,SERPINA1,INDICATI,Phase 2,Alpha-1-antitrypsin deficiency,[ICD-11: 5C5A]
T28265,SERPINA1,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T28265,SERPINA1,INDICATI,Phase 1,Cystic fibrosis,[ICD-11: CA25]
T28265,SERPINA1,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T28265,SERPINA1,INDICATI,Approved,Emphysema,[ICD-11: CA21]
,#N/A,,,,
T28330,CCKAR,TARGETID,T28330,,
T28330,CCKAR,TARGNAME,Cholecystokinin receptor type A (CCKAR),,
T28330,CCKAR,INDICATI,Preclinical,Binge eating disorder,[ICD-11: 6B82]
T28330,CCKAR,INDICATI,Terminated,Bladder disorder,[ICD-11: GC01]
T28330,CCKAR,INDICATI,Discontinued in Phase 2,Digestive system disease,[ICD-11: DE2Z]
T28330,CCKAR,INDICATI,Terminated,Dyspepsia,[ICD-11: MD92]
T28330,CCKAR,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T28330,CCKAR,INDICATI,Discontinued in Phase 2,Obesity,[ICD-11: 5B80-5B81]
T28330,CCKAR,INDICATI,Discontinued in Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T28330,CCKAR,INDICATI,Phase 2,Pancreatic malfunction,[ICD-11: DC30-DC3Z]
,#N/A,,,,
T28385,CDH11,TARGETID,T28385,,
T28385,CDH11,TARGNAME,Osteoblast cadherin (CDH11),,
T28385,CDH11,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T28413,EPHA3,TARGETID,T28413,,
T28413,EPHA3,TARGNAME,Ephrin type-A receptor 3 (EPHA3),,
T28413,EPHA3,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T28413,EPHA3,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T28413,EPHA3,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T28413,EPHA3,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
,#N/A,,,,
T28481,#N/A,TARGETID,T28481,,
T28481,#N/A,TARGNAME,Lysosphingolipid receptor (LSPR),,
T28481,#N/A,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
,#N/A,,,,
T28484,KIF11,TARGETID,T28484,,
T28484,KIF11,TARGNAME,Kinesin-like protein KIF11 (KIF11),,
T28484,KIF11,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T28484,KIF11,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T28484,KIF11,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T28484,KIF11,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T28484,KIF11,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T28484,KIF11,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T28484,KIF11,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T28484,KIF11,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T28532,RPP14; RPP21,TARGETID,T28532,,
T28532,RPP14; RPP21,TARGNAME,Ribonuclease P protein (RPP),,
T28532,RPP14; RPP21,INDICATI,Discontinued in Phase 3,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T28658,#N/A,TARGETID,T28658,,
T28658,#N/A,TARGNAME,Plasmodium 80S ribosome (Malaria 80S),,
T28658,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T28661,TUBB2A,TARGETID,T28661,,
T28661,TUBB2A,TARGNAME,Tubulin beta-2 chain (TUBB2),,
T28661,TUBB2A,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T28692,LPL,TARGETID,T28692,,
T28692,LPL,TARGNAME,Lipoprotein lipase (LPL),,
T28692,LPL,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T28692,LPL,INDICATI,Phase 3,Pregnancy/childbirth/puerperium maternal infection,[ICD-11: JB63]
,#N/A,,,,
T28713,CHEK2,TARGETID,T28713,,
T28713,CHEK2,TARGNAME,Serine/threonine-protein kinase Chk2 (RAD53),,
T28713,CHEK2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T28717,TNFRSF12A,TARGETID,T28717,,
T28717,TNFRSF12A,TARGNAME,TNF superfamily receptor 12A (TNFRSF12A),,
T28717,TNFRSF12A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T28722,GABRG3,TARGETID,T28722,,
T28722,GABRG3,TARGNAME,GABA(A) receptor gamma-3 (GABRG3),,
T28722,GABRG3,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T28722,GABRG3,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T28722,GABRG3,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T28722,GABRG3,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T28722,GABRG3,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T28722,GABRG3,INDICATI,Investigative,Female pelvic pain,[ICD-11: GA34]
T28722,GABRG3,INDICATI,Phase 3,Fragile X chromosome,[ICD-11: LD55]
T28722,GABRG3,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
T28722,GABRG3,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T28722,GABRG3,INDICATI,Approved,Intentional self-harm,[ICD-11: PC91]
T28722,GABRG3,INDICATI,Phase 3,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T28722,GABRG3,INDICATI,Approved,Labour/delivery anaesthesia complication,[ICD-11: JB0C]
T28722,GABRG3,INDICATI,Approved,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T28722,GABRG3,INDICATI,Approved,Mood/affect symptom,[ICD-11: MB24]
T28722,GABRG3,INDICATI,Phase 2,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T28722,GABRG3,INDICATI,Discontinued in Phase 1,Pain,[ICD-11: MG30-MG3Z]
T28722,GABRG3,INDICATI,Investigative,Panic disorder,[ICD-11: 6B01]
T28722,GABRG3,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T28722,GABRG3,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T28722,GABRG3,INDICATI,Phase 3,Status epilepticus,[ICD-11: 8A66]
T28722,GABRG3,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T28722,GABRG3,INDICATI,Phase 2,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T28746,#N/A,TARGETID,T28746,,
T28746,#N/A,TARGNAME,Protein kinase unspecific (PK),,
T28746,#N/A,INDICATI,Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T28746,#N/A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T28848,#N/A,TARGETID,T28848,,
T28848,#N/A,TARGNAME,Virus Deoxyribonucleic acid (Viru DNA),,
T28848,#N/A,INDICATI,Approved,Herpes simplex infection,[ICD-11: 1F00]
,#N/A,,,,
T28869,Bact ureC,TARGETID,T28869,,
T28869,Bact ureC,TARGNAME,Bacterial Urease (Bact ureC),,
T28869,Bact ureC,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T28887,HDAC8,TARGETID,T28887,,
T28887,HDAC8,TARGNAME,Histone deacetylase 8 (HDAC8),,
T28887,HDAC8,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T28893,CHRM1,TARGETID,T28893,,
T28893,CHRM1,TARGNAME,Muscarinic acetylcholine receptor M1 (CHRM1),,
T28893,CHRM1,INDICATI,Approved,Abdominal pelvic pain,[ICD-11: MD81]
T28893,CHRM1,INDICATI,Phase 2,Abnormal micturition,[ICD-11: MF50]
T28893,CHRM1,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T28893,CHRM1,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T28893,CHRM1,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T28893,CHRM1,INDICATI,Phase 1,Dementia,[ICD-11: 6D80-6D8Z]
T28893,CHRM1,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T28893,CHRM1,INDICATI,Phase 1,Dyslipidemia,[ICD-11: 5C80-5C81]
T28893,CHRM1,INDICATI,Approved,Dystonic disorder,[ICD-11: 8A02]
T28893,CHRM1,INDICATI,Phase 1,Epileptic encephalopathy,[ICD-11: 8A62]
T28893,CHRM1,INDICATI,Phase 1,Frontotemporal dementia,ICD-11: 6D83
T28893,CHRM1,INDICATI,Approved,Functional bladder disorder,[ICD-11: GC50]
T28893,CHRM1,INDICATI,Approved,Gastric ulcer,[ICD-11: DA60]
T28893,CHRM1,INDICATI,Phase 1,General pain disorder,[ICD-11: 8E43]
T28893,CHRM1,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T28893,CHRM1,INDICATI,Approved,Hyperhidrosis,[ICD-11: EE00]
T28893,CHRM1,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
T28893,CHRM1,INDICATI,Phase 1,Intellectual development disorder,[ICD-11: LD90]
T28893,CHRM1,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T28893,CHRM1,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T28893,CHRM1,INDICATI,Phase 1,Neuropathy,[ICD-11: 8C0Z]
T28893,CHRM1,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T28893,CHRM1,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T28893,CHRM1,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T28893,CHRM1,INDICATI,Phase 2,Schizoaffective disorder,[ICD-11: 6A21]
T28893,CHRM1,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T28893,CHRM1,INDICATI,Approved,Sebaceous gland disorder,[ICD-11: ED91]
T28893,CHRM1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T28925,#N/A,TARGETID,T28925,,
T28925,#N/A,TARGNAME,Inosine-5'-monophosphate dehydrogenase (IMPDH),,
T28925,#N/A,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T28925,#N/A,INDICATI,Discontinued in Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T28925,#N/A,INDICATI,Discontinued in Phase 1,Indeterminate colitis,[ICD-11: DD72]
T28925,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T28925,#N/A,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T28993,IDS,TARGETID,T28993,,
T28993,IDS,TARGNAME,Iduronate 2-sulfatase (IDS),,
T28993,IDS,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
T28993,IDS,INDICATI,Phase 2/3,Lysosomal disease,ICD-11: 5C56
T28993,IDS,INDICATI,Approved,Male infertility,[ICD-11: GB04]
,#N/A,,,,
T29024,SOD1,TARGETID,T29024,,
T29024,SOD1,TARGNAME,SOD1 messenger RNA (SOD1 mRNA),,
T29024,SOD1,INDICATI,Approved,Motor neuron disease,[ICD-11: 8B60]
,#N/A,,,,
T29036,CCN2,TARGETID,T29036,,
T29036,CCN2,TARGNAME,CCN2 messenger RNA (CCN2 mRNA),,
T29036,CCN2,INDICATI,Phase 2,Fibrosis,[ICD-11: GA14-GC01]
T29036,CCN2,INDICATI,Phase 2,Keloid/hypertrophic scar,[ICD-11: EE60]
,#N/A,,,,
T29064,#N/A,TARGETID,T29064,,
T29064,#N/A,TARGNAME,Angiogenesis/myeloma cell growth (AMCG),,
T29064,#N/A,INDICATI,Approved,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T29075,#N/A,TARGETID,T29075,,
T29075,#N/A,TARGNAME,TNF-alpha signaling pathway (TNFA pathway),,
T29075,#N/A,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T29130,STAT3,TARGETID,T29130,,
T29130,STAT3,TARGNAME,Signal transducer and activator of transcription 3 (STAT3),,
T29130,STAT3,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T29130,STAT3,INDICATI,Phase 3,Colorectal cancer,[ICD-11: 2B91]
T29130,STAT3,INDICATI,Phase 2,Immune system disease,[ICD-11: 4A01-4B41]
T29130,STAT3,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T29130,STAT3,INDICATI,Phase 1/2,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T29130,STAT3,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T29130,STAT3,INDICATI,Phase 1/2,Mature B-cell leukaemia,[ICD-11: 2A82]
T29130,STAT3,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T29130,STAT3,INDICATI,Phase 1,Mycosis fungoides,[ICD-11: 2B01]
T29130,STAT3,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T29130,STAT3,INDICATI,Discontinued in Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
T29130,STAT3,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T29130,STAT3,INDICATI,Phase 1/2,Respiratory infection,[ICD-11: CA07-CA4Z]
T29130,STAT3,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T29130,STAT3,INDICATI,Phase 1,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T29143,IL13,TARGETID,T29143,,
T29143,IL13,TARGNAME,Interleukin-13 (IL13),,
T29143,IL13,INDICATI,Investigative,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T29143,IL13,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T29143,IL13,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
T29143,IL13,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T29143,IL13,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T29143,IL13,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T29143,IL13,INDICATI,Phase 3,Oesophagitis,[ICD-11: DA24]
T29143,IL13,INDICATI,Phase 3,Pulmonary eosinophilia,[ICD-11: CB02]
T29143,IL13,INDICATI,Phase 2,Systemic sclerosis,[ICD-11: 4A42]
T29143,IL13,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
T29143,IL13,INDICATI,Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T29144,ARG1; ARG2,TARGETID,T29144,,
T29144,ARG1; ARG2,TARGNAME,Arginase (ARG),,
T29144,ARG1; ARG2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T29303,#N/A,TARGETID,T29303,,
T29303,#N/A,TARGNAME,Sodium channel unspecific (NaC),,
T29303,#N/A,INDICATI,Discontinued in Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T29303,#N/A,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T29303,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T29303,#N/A,INDICATI,Discontinued in Phase 3,Bipolar disorder,[ICD-11: 6A60]
T29303,#N/A,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T29303,#N/A,INDICATI,Terminated,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T29303,#N/A,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T29303,#N/A,INDICATI,Terminated,Cerebral ischaemic stroke,[ICD-11: 8B11]
T29303,#N/A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T29303,#N/A,INDICATI,Phase 2,Cough,[ICD-11: MD12]
T29303,#N/A,INDICATI,Phase 1/2,Cystic fibrosis,[ICD-11: CA25]
T29303,#N/A,INDICATI,NDA filed,Diabetes mellitus,[ICD-11: 5A10]
T29303,#N/A,INDICATI,Discontinued in Preregistration,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T29303,#N/A,INDICATI,Phase 3,Dystonic disorder,[ICD-11: 8A02]
T29303,#N/A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T29303,#N/A,INDICATI,Approved,Epileptic encephalopathy,[ICD-11: 8A62]
T29303,#N/A,INDICATI,Phase 2,Functional bladder disorder,[ICD-11: GC50]
T29303,#N/A,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T29303,#N/A,INDICATI,Approved,Genetic cardiac arrhythmia,[ICD-11: BC65]
T29303,#N/A,INDICATI,Terminated,Heart failure,[ICD-11: BD10-BD1Z]
T29303,#N/A,INDICATI,Terminated,Ischemia,[ICD-11: 8B10-8B11]
T29303,#N/A,INDICATI,Phase 2,Metabolism inborn error,[ICD-11: 5C50]
T29303,#N/A,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T29303,#N/A,INDICATI,Phase 1,Neuropathy,[ICD-11: 8C0Z]
T29303,#N/A,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T29303,#N/A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T29303,#N/A,INDICATI,Approved,Postpartum haemorrhage,[ICD-11: JA43]
T29303,#N/A,INDICATI,Approved,Scabies,[ICD-11: 1G04]
T29303,#N/A,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T29303,#N/A,INDICATI,Approved,Sensation disturbance,[ICD-11: MB40]
T29303,#N/A,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T29303,#N/A,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T29303,#N/A,INDICATI,Discontinued in Phase 2,Tonus and reflex abnormality,[ICD-11: MB47]
T29303,#N/A,INDICATI,Phase 2,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T29339,DDX58,TARGETID,T29339,,
T29339,DDX58,TARGNAME,Retinoic acid-inducible gene-1 (RIG-1),,
T29339,DDX58,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T29339,DDX58,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T29339,DDX58,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T29339,DDX58,INDICATI,Phase 1,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
,#N/A,,,,
T29345,MUC17,TARGETID,T29345,,
T29345,MUC17,TARGNAME,Mucin-17 (MUC17),,
T29345,MUC17,INDICATI,Phase 1,Oesophagogastric junction cancer,[ICD-11: 2B71]
T29345,MUC17,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T29500,ADRA1B,TARGETID,T29500,,
T29500,ADRA1B,TARGNAME,Adrenergic receptor alpha-1B (ADRA1B),,
T29500,ADRA1B,INDICATI,Discontinued in Phase 2,Abnormal micturition,[ICD-11: MF50]
T29500,ADRA1B,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T29500,ADRA1B,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T29500,ADRA1B,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T29500,ADRA1B,INDICATI,Approved,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T29500,ADRA1B,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T29500,ADRA1B,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T29525,#N/A,TARGETID,T29525,,
T29525,#N/A,TARGNAME,Human immunodeficiency virus Deoxyribonucleic acid (HIV DNA),,
T29525,#N/A,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T29649,#N/A,TARGETID,T29649,,
T29649,#N/A,TARGNAME,Leukotriene receptor (LTR),,
T29649,#N/A,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T29649,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T29649,#N/A,INDICATI,Phase 1,Bacterial infection,[ICD-11: 1A00-1C4Z]
T29649,#N/A,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T29649,#N/A,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T29683,TACR3,TARGETID,T29683,,
T29683,TACR3,TARGNAME,Neuromedin-K receptor (TACR3),,
T29683,TACR3,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T29683,TACR3,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T29683,TACR3,INDICATI,Discontinued in Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T29683,TACR3,INDICATI,Terminated,Depression,[ICD-11: 6A70-6A7Z]
T29683,TACR3,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T29683,TACR3,INDICATI,Discontinued in Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T29683,TACR3,INDICATI,Approved,Menopausal disorder,[ICD-11: GA30]
T29683,TACR3,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T29683,TACR3,INDICATI,Discontinued in Phase 1,Psychotic disorder,[ICD-11: 6A20-6A25]
T29683,TACR3,INDICATI,Discontinued in Phase 2b,Schizoaffective disorder,[ICD-11: 6A21]
T29683,TACR3,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T29683,TACR3,INDICATI,Phase 1,Substance abuse,[ICD-11: 6C40]
T29683,TACR3,INDICATI,Phase 2,#N/A,#N/A
,#N/A,,,,
T29736,LAMB3,TARGETID,T29736,,
T29736,LAMB3,TARGNAME,Laminin beta-3 chain (LAMB3),,
T29736,LAMB3,INDICATI,Phase 1,Epidermolysis bullosa,[ICD-11: EC3Z]
,#N/A,,,,
T29741,NOX4,TARGETID,T29741,,
T29741,NOX4,TARGNAME,NADPH oxidase 4 (NOX4),,
T29741,NOX4,INDICATI,Phase 2,Fibrosis,[ICD-11: GA14-GC01]
,#N/A,,,,
T29754,MAPKAPK5,TARGETID,T29754,,
T29754,MAPKAPK5,TARGNAME,MAPK-activated protein kinase 5 (MAPKAPK5),,
T29754,MAPKAPK5,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T29774,LIF,TARGETID,T29774,,
T29774,LIF,TARGNAME,Leukemia inhibitory factor (LIF),,
T29774,LIF,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T29815,#N/A,TARGETID,T29815,,
T29815,#N/A,TARGNAME,Neoplasm antigen (NA),,
T29815,#N/A,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T29815,#N/A,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T29879,ITGA5,TARGETID,T29879,,
T29879,ITGA5,TARGNAME,Integrin alpha-5 (ITGA5),,
T29879,ITGA5,INDICATI,Discontinued in Phase 1,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T29879,ITGA5,INDICATI,Discontinued in Phase 1,Asthma,[ICD-11: CA23]
T29879,ITGA5,INDICATI,Discontinued in Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T29879,ITGA5,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T29879,ITGA5,INDICATI,Discontinued in Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T29960,WT1,TARGETID,T29960,,
T29960,WT1,TARGNAME,Wilms tumor protein (WT1),,
T29960,WT1,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T29960,WT1,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
T29960,WT1,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T29960,WT1,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T29999,#N/A,TARGETID,T29999,,
T29999,#N/A,TARGNAME,Vasopressin V1 receptor (V1R),,
T29999,#N/A,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T29999,#N/A,INDICATI,Approved,Cognition symptoms/signs/clinical sympton,[ICD-11: MB21]
T29999,#N/A,INDICATI,Approved,Hypo-osmolality/hyponatraemia,[ICD-11: 5C72]
T29999,#N/A,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T29999,#N/A,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T30014,#N/A,TARGETID,T30014,,
T30014,#N/A,TARGNAME,Immunoglobulin unspecific (Ig),,
T30014,#N/A,INDICATI,Approved,Vaccination,[ICD-11: N.A.]
,#N/A,,,,
T30028,VAMP1; VAMP2,TARGETID,T30028,,
T30028,VAMP1; VAMP2,TARGNAME,Vesicle-associated membrane protein (VAMP),,
T30028,VAMP1; VAMP2,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T30040,VEGFB,TARGETID,T30040,,
T30040,VEGFB,TARGNAME,Vascular endothelial growth factor B (VEGFB),,
T30040,VEGFB,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T30040,VEGFB,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
,#N/A,,,,
T30081,TK1,TARGETID,T30081,,
T30081,TK1,TARGNAME,Thymidine kinase 1 (TK1),,
T30081,TK1,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T30081,TK1,INDICATI,Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T30081,TK1,INDICATI,Discontinued in Phase 3,Brain cancer,[ICD-11: 2A00]
T30081,TK1,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T30081,TK1,INDICATI,Preregistration,Graft-versus-host disease,[ICD-11: 4B24]
T30081,TK1,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T30081,TK1,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T30081,TK1,INDICATI,Phase 2/3,Postoperative inflammation,[ICD-11: 1A00-CA43]
T30081,TK1,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T30081,TK1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T30081,TK1,INDICATI,Phase 3,Zoster,[ICD-11: 1E91]
,#N/A,,,,
T30082,ACHE,TARGETID,T30082,,
T30082,ACHE,TARGNAME,Acetylcholinesterase (AChE),,
T30082,ACHE,INDICATI,Approved,Alzheimer disease,[ICD-11: 8A20]
T30082,ACHE,INDICATI,Phase 1/2,Dementia,[ICD-11: 6D80-6D8Z]
T30082,ACHE,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T30082,ACHE,INDICATI,Discontinued in Phase 2,Lips/oral mucosa miscellaneous disorder,[ICD-11: DA02]
T30082,ACHE,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T30082,ACHE,INDICATI,Approved,Myasthenia gravis,[ICD-11: 8C6Y]
T30082,ACHE,INDICATI,Investigative,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T30082,ACHE,INDICATI,Approved,Oesophageal/gastroduodenal disorder,[ICD-11: DD90]
T30082,ACHE,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T30082,ACHE,INDICATI,Phase 3,Parasitic worm infestation,[ICD-11: 1F90]
T30082,ACHE,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T30082,ACHE,INDICATI,Approved,Pediculosis,[ICD-11: 1G00]
T30082,ACHE,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T30082,ACHE,INDICATI,Phase 1,Substance abuse,[ICD-11: 6C40]
T30082,ACHE,INDICATI,Approved,Unspecific substance harmful effect,[ICD-11: NE6Z]
T30082,ACHE,INDICATI,Discontinued in Phase 2,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T30085,SLC5A2,TARGETID,T30085,,
T30085,SLC5A2,TARGNAME,Sodium/glucose cotransporter 2 (SGLT2),,
T30085,SLC5A2,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T30085,SLC5A2,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T30085,SLC5A2,INDICATI,Phase 3,Chronic kidney disease,[ICD-11: GB61]
T30085,SLC5A2,INDICATI,Approved,Diabetes mellitus,[ICD-11: 5A10]
T30085,SLC5A2,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T30085,SLC5A2,INDICATI,Phase 3,Liver disease,[ICD-11: DB90-DB9Z]
T30085,SLC5A2,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
T30085,SLC5A2,INDICATI,Phase 2,Type-1/2 diabete,[ICD-11: 5A10-5A11]
,#N/A,,,,
T30208,#N/A,TARGETID,T30208,,
T30208,#N/A,TARGNAME,Growth hormone secretion (GH secr),,
T30208,#N/A,INDICATI,Phase 1,Cerebral ischaemia,[ICD-11: 8B1Z]
,#N/A,,,,
T30284,IFNGR2,TARGETID,T30284,,
T30284,IFNGR2,TARGNAME,Interferon gamma receptor (IFNGR2),,
T30284,IFNGR2,INDICATI,Approved,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T30284,IFNGR2,INDICATI,Approved,Lupus erythematosus,[ICD-11: 4A40]
,#N/A,,,,
T30356,RHD,TARGETID,T30356,,
T30356,RHD,TARGNAME,Blood group Rh(D) polypeptide (RHD),,
T30356,RHD,INDICATI,Phase 2/3,Anemia,[ICD-11: 3A00-3A9Z]
,#N/A,,,,
T30372,Trypano CYSP,TARGETID,T30372,,
T30372,Trypano CYSP,TARGNAME,Trypanosoma Cruzipain (Trypano CYSP),,
T30372,Trypano CYSP,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T30372,Trypano CYSP,INDICATI,Approved,Parasitic worm infestation,[ICD-11: 1F90]
,#N/A,,,,
T30374,#N/A,TARGETID,T30374,,
T30374,#N/A,TARGNAME,Gamma-aminobutyric acid uptake (GABAU),,
T30374,#N/A,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T30374,#N/A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
,#N/A,,,,
T30383,#N/A,TARGETID,T30383,,
T30383,#N/A,TARGNAME,Endogenous gut peptide (EGP),,
T30383,#N/A,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T30418,#N/A,TARGETID,T30418,,
T30418,#N/A,TARGNAME,DNA synthesis (DNA synth),,
T30418,#N/A,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T30418,#N/A,INDICATI,Phase 3,Biliary tract cancer,[ICD-11: 2C17]
T30418,#N/A,INDICATI,Phase 1,Bladder cancer,[ICD-11: 2C94]
T30418,#N/A,INDICATI,Approved,Leukaemia,[ICD-11: 2A60-2B33]
T30418,#N/A,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T30418,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T30418,#N/A,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T30418,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T30420,KMT5A,TARGETID,T30420,,
T30420,KMT5A,TARGNAME,SET domain containing 8 (KMT5A),,
T30420,KMT5A,INDICATI,Preclinical,Liver cancer,[ICD-11: 2C12]
T30420,KMT5A,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T30495,SIK2,TARGETID,T30495,,
T30495,SIK2,TARGNAME,Salt-inducible kinase 2 (SIK2),,
T30495,SIK2,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T30520,#N/A,TARGETID,T30520,,
T30520,#N/A,TARGNAME,Bacterial RNA polymerase switch region (Bact RNAP-SR),,
T30520,#N/A,INDICATI,Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
T30520,#N/A,INDICATI,Approved,Clostridium difficile enterocolitis,[ICD-11: 1A04]
T30520,#N/A,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
,#N/A,,,,
T30563,LTB4R2,TARGETID,T30563,,
T30563,LTB4R2,TARGNAME,Leukotriene B4 receptor 2 (LTB4R2),,
T30563,LTB4R2,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T30563,LTB4R2,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T30563,LTB4R2,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
T30563,LTB4R2,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
,#N/A,,,,
T30578,MycB embC,TARGETID,T30578,,
T30578,MycB embC,TARGNAME,Mycobacterium Arabinosyltransferase C (MycB embC),,
T30578,MycB embC,INDICATI,Approved,Tuberculosis,[ICD-11: 1B10-1B12]
,#N/A,,,,
T30635,CXCL10,TARGETID,T30635,,
T30635,CXCL10,TARGNAME,C-X-C motif chemokine 10 (CXCL10),,
T30635,CXCL10,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T30635,CXCL10,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T30635,CXCL10,INDICATI,Phase 2,Immune system disease,[ICD-11: 4A01-4B41]
T30635,CXCL10,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T30635,CXCL10,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T30635,CXCL10,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T30653,LPCAT1; LPCAT2,TARGETID,T30653,,
T30653,LPCAT1; LPCAT2,TARGNAME,Acetyl-CoA:lyso-PAF acetyltransferase (PCAT),,
T30653,LPCAT1; LPCAT2,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T30653,LPCAT1; LPCAT2,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T30687,NR3C1,TARGETID,T30687,,
T30687,NR3C1,TARGNAME,Glucocorticoid receptor messenger RNA (GCR mRNA),,
T30687,NR3C1,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T30687,NR3C1,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T30687,NR3C1,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T30687,NR3C1,INDICATI,Approved,Muscular dystrophy,ICD-11: 8C70
T30687,NR3C1,INDICATI,Phase 2,Muscular dystrophy,[ICD-11: 8C70]
T30687,NR3C1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T30687,NR3C1,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T30687,NR3C1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T30687,NR3C1,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T30731,KNG1,TARGETID,T30731,,
T30731,KNG1,TARGNAME,Kininogen (KNG1),,
T30731,KNG1,INDICATI,Phase 2/3,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
,#N/A,,,,
T30784,THBS1,TARGETID,T30784,,
T30784,THBS1,TARGNAME,Thrombospondin-1 (THBS1),,
T30784,THBS1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T30790,ORAI1,TARGETID,T30790,,
T30790,ORAI1,TARGNAME,Calcium-release activated calcium channel (CRACM),,
T30790,ORAI1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T30802,CALY,TARGETID,T30802,,
T30802,CALY,TARGNAME,Neuron-specific vesicular protein calcyon (CALY),,
T30802,CALY,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T30803,GSR,TARGETID,T30803,,
T30803,GSR,TARGNAME,Glutathione reductase (GR),,
T30803,GSR,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T30803,GSR,INDICATI,Investigative,Bacterial infection,[ICD-11: 1A00-1C4Z]
T30803,GSR,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T30803,GSR,INDICATI,Investigative,Circulatory system disease,[ICD-11: BE2Z]
T30803,GSR,INDICATI,Investigative,Indeterminate colitis,[ICD-11: DD72]
,#N/A,,,,
T30817,SPTLC1; SPTLC2; SPTLC3,TARGETID,T30817,,
T30817,SPTLC1; SPTLC2; SPTLC3,TARGNAME,Serine palmitoyltransferase (SPTC),,
T30817,SPTLC1; SPTLC2; SPTLC3,INDICATI,Preclinical,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T30823,CDC25A,TARGETID,T30823,,
T30823,CDC25A,TARGNAME,M-phase inducer phosphatase 1 (MPIP1),,
T30823,CDC25A,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T30823,CDC25A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T30827,PF4,TARGETID,T30827,,
T30827,PF4,TARGNAME,Platelet factor 4 (PF4),,
T30827,PF4,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T30834,CALCR-RAMP1/RAMP2/RAMP3,TARGETID,T30834,,
T30834,CALCR-RAMP1/RAMP2/RAMP3,TARGNAME,Amylin receptor (IAPPR),,
T30834,CALCR-RAMP1/RAMP2/RAMP3,INDICATI,Discontinued in Phase 1,Hypertension,[ICD-11: BA00-BA04]
T30834,CALCR-RAMP1/RAMP2/RAMP3,INDICATI,Discontinued in Phase 2,Obesity,[ICD-11: 5B80-5B81]
T30834,CALCR-RAMP1/RAMP2/RAMP3,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T30846,LILRB4,TARGETID,T30846,,
T30846,LILRB4,TARGNAME,Leukocyte immunoglobulin-like receptor B4 (LILRB4),,
T30846,LILRB4,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T30846,LILRB4,INDICATI,Phase 1,Chronic myelomonocytic leukaemia,[ICD-11: 2A40]
,#N/A,,,,
T30926,GRB2,TARGETID,T30926,,
T30926,GRB2,TARGNAME,GRB2 messenger RNA (GRB2 mRNA),,
T30926,GRB2,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T30926,GRB2,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T30926,GRB2,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
T30926,GRB2,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T30926,GRB2,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T30938,MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ,TARGETID,T30938,,
T30938,MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ,TARGNAME,Mycobacterium RNA polymerase (MycB RNAP),,
T30938,MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
T30938,MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T30938,MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ,INDICATI,Discontinued in Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T30938,MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ,INDICATI,Registered,Influenza,[ICD-11: 1E30-1E32]
T30938,MycB rpoA; MycB rpoB; MycB rpoC; MycB rpoZ,INDICATI,Phase 3,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T30940,HSPE1,TARGETID,T30940,,
T30940,HSPE1,TARGNAME,Mitochondrial 10kDa heat shock protein (HSPE1),,
T30940,HSPE1,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T30956,Anthrax PA,TARGETID,T30956,,
T30956,Anthrax PA,TARGNAME,Bacillus anthracis Protective antigen (Anthrax PA),,
T30956,Anthrax PA,INDICATI,Approved,Anthrax,[ICD-11: 1B97]
T30956,Anthrax PA,INDICATI,Phase 1/2,Neuropathy,[ICD-11: 8C0Z]
,#N/A,,,,
T30985,HRH2,TARGETID,T30985,,
T30985,HRH2,TARGNAME,Histamine H2 receptor (H2R),,
T30985,HRH2,INDICATI,Withdrawn from market,Duodenal ulcer,[ICD-11: DA63]
T30985,HRH2,INDICATI,Discontinued in Phase 1,Gastric ulcer,[ICD-11: DA60]
T30985,HRH2,INDICATI,Approved,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T30985,HRH2,INDICATI,Approved,Oesophageal/gastroduodenal disorder,[ICD-11: DD90]
T30985,HRH2,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T30985,HRH2,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T30985,HRH2,INDICATI,Discontinued in Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T31072,#N/A,TARGETID,T31072,,
T31072,#N/A,TARGNAME,Interleukine 12 (IL-12),,
T31072,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T31072,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T31072,#N/A,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T31072,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T31072,#N/A,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T31072,#N/A,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T31072,#N/A,INDICATI,Phase 3,Psoriatic arthritis,[ICD-11: FA21]
T31072,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T31133,#N/A,TARGETID,T31133,,
T31133,#N/A,TARGNAME,Potassium (K),,
T31133,#N/A,INDICATI,Approved,Hyperkalaemia,[ICD-11: 5C76]
,#N/A,,,,
T31204,HTR2B,TARGETID,T31204,,
T31204,HTR2B,TARGNAME,5-HT 2B receptor (HTR2B),,
T31204,HTR2B,INDICATI,Discontinued in Phase 3,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T31204,HTR2B,INDICATI,Phase 4,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T31204,HTR2B,INDICATI,Withdrawn from market,Coronary atherosclerosis,[ICD-11: BA80]
T31204,HTR2B,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T31204,HTR2B,INDICATI,Investigative,Irritable bowel syndrome,[ICD-11: DD91]
T31204,HTR2B,INDICATI,Discontinued in Phase 1,Migraine,[ICD-11: 8A80]
T31204,HTR2B,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T31204,HTR2B,INDICATI,Approved,Psychotic disorder,[ICD-11: 6A20-6A25]
T31204,HTR2B,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
,#N/A,,,,
T31230,Bact frdA,TARGETID,T31230,,
T31230,Bact frdA,TARGNAME,Bacterial Fumarate reductase flavoprotein (Bact frdA),,
T31230,Bact frdA,INDICATI,Approved,Hydrocephalus,[ICD-11: 8D64]
T31230,Bact frdA,INDICATI,Approved,Nematode disease,[ICD-11: 1F6Y]
T31230,Bact frdA,INDICATI,Approved,Parasitic worm infestation,[ICD-11: 1F90]
T31230,Bact frdA,INDICATI,Approved,Trichuriasis,[ICD-11: 1F6G]
,#N/A,,,,
T31299,#N/A,TARGETID,T31299,,
T31299,#N/A,TARGNAME,HLA-A02/AFP complex (HLA-A02/AFP),,
T31299,#N/A,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
,#N/A,,,,
T31309,BCL2,TARGETID,T31309,,
T31309,BCL2,TARGNAME,Apoptosis regulator Bcl-2 (BCL-2),,
T31309,BCL2,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T31309,BCL2,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T31309,BCL2,INDICATI,Phase 1,Chronic myelomonocytic leukaemia,[ICD-11: 2A40]
T31309,BCL2,INDICATI,Phase 1,Follicular lymphoma,[ICD-11: 2A80]
T31309,BCL2,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T31309,BCL2,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T31309,BCL2,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T31309,BCL2,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T31309,BCL2,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T31309,BCL2,INDICATI,Approved,Motor neuron disease,[ICD-11: 8B60]
T31309,BCL2,INDICATI,Phase 3,Multiple myeloma,[ICD-11: 2A83]
T31309,BCL2,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T31309,BCL2,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T31309,BCL2,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T31309,BCL2,INDICATI,Phase 2/3,Ovarian dysfunction,[ICD-11: 5A80]
T31309,BCL2,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T31309,BCL2,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T31309,BCL2,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T31309,BCL2,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T31309,BCL2,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T31329,Leishm TOP1,TARGETID,T31329,,
T31329,Leishm TOP1,TARGNAME,Leishmania DNA topoisomerase I (Leishm TOP1),,
T31329,Leishm TOP1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T31391,DPP4,TARGETID,T31391,,
T31391,DPP4,TARGNAME,Dipeptidyl peptidase 4 (DPP-4),,
T31391,DPP4,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T31391,DPP4,INDICATI,Phase 2,Autism spectrum disorder,[ICD-11: 6A02]
T31391,DPP4,INDICATI,Phase 1/2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T31391,DPP4,INDICATI,Preclinical,Colon cancer,[ICD-11: 2B90]
T31391,DPP4,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
T31391,DPP4,INDICATI,Investigative,Hypo-glycaemia,[ICD-11: 5A41]
T31391,DPP4,INDICATI,Preclinical,Lung cancer,[ICD-11: 2C25]
T31391,DPP4,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T31391,DPP4,INDICATI,Phase 3,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T31391,DPP4,INDICATI,Phase 1,Myocardial infarction,[ICD-11: BA41-BA43]
T31391,DPP4,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T31391,DPP4,INDICATI,Investigative,Transplanted organ/tissue,[ICD-11: QB63]
T31391,DPP4,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T31406,HCK,TARGETID,T31406,,
T31406,HCK,TARGNAME,Hematopoietic cell kinase (HCK),,
T31406,HCK,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
,#N/A,,,,
T31424,#N/A,TARGETID,T31424,,
T31424,#N/A,TARGNAME,Adrenergic receptor Alpha-2 (ADRA2),,
T31424,#N/A,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T31424,#N/A,INDICATI,Discontinued in Phase 3,Angina pectoris,[ICD-11: BA40]
T31424,#N/A,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T31424,#N/A,INDICATI,Approved,Breathing abnormality,[ICD-11: MD11]
T31424,#N/A,INDICATI,Approved,Cerebral ischaemia,[ICD-11: 8B1Z]
T31424,#N/A,INDICATI,Approved,Dementia,[ICD-11: 6D80-6D8Z]
T31424,#N/A,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T31424,#N/A,INDICATI,Approved,Eyelid inflammatory disorder,[ICD-11: 9A02]
T31424,#N/A,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T31424,#N/A,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T31424,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T31424,#N/A,INDICATI,Approved,Mood/affect symptom,[ICD-11: MB24]
T31424,#N/A,INDICATI,Approved,Muscle disorder,[ICD-11: FB32-FB3Z]
T31424,#N/A,INDICATI,Phase 3,Neuropathy,[ICD-11: 8C0Z]
T31424,#N/A,INDICATI,Approved,Opioid use disorder,[ICD-11: 6C43]
T31424,#N/A,INDICATI,Approved,Optic nerve disorder,[ICD-11: 9C40]
T31424,#N/A,INDICATI,Discontinued in Phase 2,Orgasmic dysfunction,[ICD-11: HA02]
T31424,#N/A,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T31424,#N/A,INDICATI,Approved,Sexual dysfunction,[ICD-11: HA00-HA01]
T31424,#N/A,INDICATI,Approved,Skin sensation disturbance,[ICD-11: ME65]
T31424,#N/A,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T31458,#N/A,TARGETID,T31458,,
T31458,#N/A,TARGNAME,Pyruvate kinase (PK),,
T31458,#N/A,INDICATI,Phase 1,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T31458,#N/A,INDICATI,Phase 2/3,Sickle-cell disorder,[ICD-11: 3A51]
,#N/A,,,,
T31479,PLA2G1B,TARGETID,T31479,,
T31479,PLA2G1B,TARGNAME,Phospholipase A2 (PLA2G1B),,
T31479,PLA2G1B,INDICATI,Phase 2b,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T31479,PLA2G1B,INDICATI,Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T31479,PLA2G1B,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T31479,PLA2G1B,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T31479,PLA2G1B,INDICATI,Phase 2,Contact dermatitis,[ICD-11: EK00-EK0Z]
T31479,PLA2G1B,INDICATI,Approved,Leishmaniasis,[ICD-11: 1F54]
T31479,PLA2G1B,INDICATI,Phase 2,Lichen planus,[ICD-11: EA91]
T31479,PLA2G1B,INDICATI,Phase 2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T31479,PLA2G1B,INDICATI,Approved,Peroxisomal disease,[ICD-11: 5C57]
T31479,PLA2G1B,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T31479,PLA2G1B,INDICATI,Discontinued in Phase 2,Pruritus,[ICD-11: EC90]
T31479,PLA2G1B,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T31479,PLA2G1B,INDICATI,Approved,Rosacea,[ICD-11: ED90]
T31479,PLA2G1B,INDICATI,Phase 2,Snakebite,ICD-11: N.A.
T31479,PLA2G1B,INDICATI,Approved,Synthesis disorder,[ICD-11: 5C52-5C59]
T31479,PLA2G1B,INDICATI,Discontinued in Phase 2,Unspecific body region injury,[ICD-11: ND56]
T31479,PLA2G1B,INDICATI,Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T31514,GAA,TARGETID,T31514,,
T31514,GAA,TARGNAME,Lysosomal alpha-glucosidase (GAA),,
T31514,GAA,INDICATI,Approved,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
T31514,GAA,INDICATI,Phase 1/2,Inborn carbohydrate metabolism error,ICD-11: 5C51
,#N/A,,,,
T31595,Influ NA,TARGETID,T31595,,
T31595,Influ NA,TARGNAME,Influenza Neuraminidase (Influ NA),,
T31595,Influ NA,INDICATI,Phase 3,Idiopathic inflammatory myopathy,[ICD-11: 4A41]
T31595,Influ NA,INDICATI,Approved,Influenza,[ICD-11: 1E30-1E32]
T31595,Influ NA,INDICATI,Phase 2,Muscle disorder,[ICD-11: FB32-FB3Z]
,#N/A,,,,
T31600,PKN3,TARGETID,T31600,,
T31600,PKN3,TARGNAME,Protein kinase N3 (PKN3),,
T31600,PKN3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T31621,FGF2,TARGETID,T31621,,
T31621,FGF2,TARGNAME,Fibroblast growth factor-2 (FGF2),,
T31621,FGF2,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T31621,FGF2,INDICATI,Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T31621,FGF2,INDICATI,Phase 1,Bladder cancer,[ICD-11: 2C94]
T31621,FGF2,INDICATI,Investigative,Multiple myeloma,[ICD-11: 2A83]
T31621,FGF2,INDICATI,Discontinued in Phase 2,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T31621,FGF2,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T31621,FGF2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T31621,FGF2,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T31751,Malaria DXR,TARGETID,T31751,,
T31751,Malaria DXR,TARGNAME,Plasmodium DOXP reductoisomerase (Malaria DXR),,
T31751,Malaria DXR,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T31818,ITGA1,TARGETID,T31818,,
T31818,ITGA1,TARGNAME,Integrin alpha-1 (VLA-1),,
T31818,ITGA1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T31825,HBB,TARGETID,T31825,,
T31825,HBB,TARGNAME,Hemoglobin subunit beta (HBB),,
T31825,HBB,INDICATI,Phase 1,Sickle-cell disorder,[ICD-11: 3A51]
T31825,HBB,INDICATI,Phase 3,Thalassaemia,[ICD-11: 3A50]
,#N/A,,,,
T31902,ADAM10,TARGETID,T31902,,
T31902,ADAM10,TARGNAME,Mammalian disintegrin-metalloprotease (ADAM10),,
T31902,ADAM10,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T31902,ADAM10,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T31946,#N/A,TARGETID,T31946,,
T31946,#N/A,TARGNAME,Vascular endothelial growth factor receptor (VEGFR),,
T31946,#N/A,INDICATI,Terminated,Angina pectoris,[ICD-11: BA40]
T31946,#N/A,INDICATI,Phase 1/2,Basal cell carcinoma,[ICD-11: 2C32]
T31946,#N/A,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T31946,#N/A,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T31946,#N/A,INDICATI,Approved,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T31946,#N/A,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T31946,#N/A,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T31946,#N/A,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
T31946,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T31946,#N/A,INDICATI,Phase 3,Peritoneal cancer,[ICD-11: 2C51]
T31946,#N/A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T31946,#N/A,INDICATI,Phase 3,Retinopathy,[ICD-11: 9B71]
T31946,#N/A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T31946,#N/A,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T31956,ENPEP,TARGETID,T31956,,
T31956,ENPEP,TARGNAME,Glutamyl aminopeptidase (ENPEP),,
T31956,ENPEP,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T31989,SPHK2,TARGETID,T31989,,
T31989,SPHK2,TARGNAME,Sphingosine kinase 2 (SPHK2),,
T31989,SPHK2,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T31989,SPHK2,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T31989,SPHK2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T31992,CA14,TARGETID,T31992,,
T31992,CA14,TARGNAME,Carbonic anhydrase XIV (CA-XIV),,
T31992,CA14,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T31992,CA14,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T31992,CA14,INDICATI,Approved,Inborn metabolism deficiency,[ICD-11: 5C50-5C59]
T31992,CA14,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T32060,HTR2A,TARGETID,T32060,,
T32060,HTR2A,TARGNAME,5-HT 2A receptor (HTR2A),,
T32060,HTR2A,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T32060,HTR2A,INDICATI,Withdrawn from market,Addictive disorder,[ICD-11: 6C50-6C5Z]
T32060,HTR2A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T32060,HTR2A,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T32060,HTR2A,INDICATI,Phase 1,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T32060,HTR2A,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T32060,HTR2A,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T32060,HTR2A,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T32060,HTR2A,INDICATI,Approved,Cerebral ischaemia,[ICD-11: 8B1Z]
T32060,HTR2A,INDICATI,Phase 3,Chronic insomnia,[ICD-11: 7A00]
T32060,HTR2A,INDICATI,Phase 1b,Chronic kidney disease,[ICD-11: GB61]
T32060,HTR2A,INDICATI,Phase 3,Chronic pain,[ICD-11: MG30]
T32060,HTR2A,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T32060,HTR2A,INDICATI,Phase 3,Depression,[ICD-11: 6A70-6A7Z]
T32060,HTR2A,INDICATI,Phase 2,Glaucoma,[ICD-11: 9C61]
T32060,HTR2A,INDICATI,Discontinued in Phase 3,Haemorrhoids,[ICD-11: DB60]
T32060,HTR2A,INDICATI,Discontinued in Phase 2,Hypertension,[ICD-11: BA00-BA04]
T32060,HTR2A,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T32060,HTR2A,INDICATI,Phase 3,Insomnia,[ICD-11: 7A00-7A0Z]
T32060,HTR2A,INDICATI,Investigative,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T32060,HTR2A,INDICATI,Discontinued in Phase 2,Migraine,[ICD-11: 8A80]
T32060,HTR2A,INDICATI,Approved,Mood disorder,[ICD-11: 6A60-6E23]
T32060,HTR2A,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T32060,HTR2A,INDICATI,Terminated,Pancreatitis,[ICD-11: DC31-DC34]
T32060,HTR2A,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T32060,HTR2A,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T32060,HTR2A,INDICATI,Phase 3,Post-traumatic stress disorder,[ICD-11: 6B40]
T32060,HTR2A,INDICATI,Patented,Prostate hyperplasia,[ICD-11: GA90]
T32060,HTR2A,INDICATI,Phase 1,Psychotic disorder,[ICD-11: 6A20-6A25]
T32060,HTR2A,INDICATI,Phase 2,Schizoaffective disorder,[ICD-11: 6A21]
T32060,HTR2A,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T32060,HTR2A,INDICATI,Phase 3,Sexual dysfunction,[ICD-11: HA00-HA01]
T32060,HTR2A,INDICATI,Phase 3,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
T32060,HTR2A,INDICATI,Phase 2,Social anxiety disorder,[ICD-11: 6B04]
T32060,HTR2A,INDICATI,Terminated,Substance abuse,[ICD-11: 6C40]
T32060,HTR2A,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T32137,#N/A,TARGETID,T32137,,
T32137,#N/A,TARGNAME,NADPH oxidase (NOX),,
T32137,#N/A,INDICATI,Phase 2,Fibrosis,[ICD-11: GA14-GC01]
T32137,#N/A,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T32227,CNGB3,TARGETID,T32227,,
T32227,CNGB3,TARGNAME,Cyclic nucleotide-gated channel beta-3 (CNGB3),,
T32227,CNGB3,INDICATI,Phase 1/2,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T32240,IL15,TARGETID,T32240,,
T32240,IL15,TARGNAME,Interleukin-15 (IL15),,
T32240,IL15,INDICATI,Phase 2,Coeliac disease,[ICD-11: DA95]
T32240,IL15,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T32240,IL15,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T32240,IL15,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T32240,IL15,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T32240,IL15,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T32247,CALCR,TARGETID,T32247,,
T32247,CALCR,TARGNAME,Calcitonin receptor (CALCR),,
T32247,CALCR,INDICATI,Approved,Bone paget disease,[ICD-11: FB85]
T32247,CALCR,INDICATI,Terminated,Hypertension,[ICD-11: BA00-BA04]
T32247,CALCR,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
T32247,CALCR,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T32247,CALCR,INDICATI,Phase 3,Pain,[ICD-11: MG30-MG3Z]
T32247,CALCR,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T32262,CALCRL,TARGETID,T32262,,
T32262,CALCRL,TARGNAME,Calcitonin gene-related peptide receptor (CGRPR),,
T32262,CALCRL,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T32262,CALCRL,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T32262,CALCRL,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T32262,CALCRL,INDICATI,Phase 2,Tension-type headache,[ICD-11: 8A81]
,#N/A,,,,
T32282,PRL,TARGETID,T32282,,
T32282,PRL,TARGNAME,Prolactin (PRL),,
T32282,PRL,INDICATI,Discontinued in Phase 2,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T32335,#N/A,TARGETID,T32335,,
T32335,#N/A,TARGNAME,Inhibitor of nuclear factor kappa-B kinase (IKK),,
T32335,#N/A,INDICATI,Investigative,Multiple myeloma,[ICD-11: 2A83]
T32335,#N/A,INDICATI,Investigative,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T32348,EGR1,TARGETID,T32348,,
T32348,EGR1,TARGNAME,Early growth response protein 1 (EGR-1),,
T32348,EGR1,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T32369,Influ PA,TARGETID,T32369,,
T32369,Influ PA,TARGNAME,Influenza Polymerase acidic endonuclease (Influ PA),,
T32369,Influ PA,INDICATI,Approved,Influenza,[ICD-11: 1E30-1E32]
,#N/A,,,,
T32387,#N/A,TARGETID,T32387,,
T32387,#N/A,TARGNAME,Endothelium of blood vessels (Endothelium),,
T32387,#N/A,INDICATI,Approved,Acquired cutaneous blood vessel malformation,[ICD-11: EF20]
,#N/A,,,,
T32456,#N/A,TARGETID,T32456,,
T32456,#N/A,TARGNAME,Second phase insulin secretion (SPI secr),,
T32456,#N/A,INDICATI,Phase 3,Arteries/arterioles disorder,[ICD-11: BD52]
,#N/A,,,,
T32468,Bact fabB,TARGETID,T32468,,
T32468,Bact fabB,TARGNAME,Bacterial Beta-ketoacyl-ACP synthase I (Bact fabB),,
T32468,Bact fabB,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T32468,Bact fabB,INDICATI,Investigative,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T32578,IL6,TARGETID,T32578,,
T32578,IL6,TARGNAME,Interleukin-6 (IL6),,
T32578,IL6,INDICATI,Approved,Anemia,[ICD-11: 3A00-3A9Z]
T32578,IL6,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T32578,IL6,INDICATI,Phase 3,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T32578,IL6,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T32578,IL6,INDICATI,Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
T32578,IL6,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T32578,IL6,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T32578,IL6,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T32578,IL6,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T32578,IL6,INDICATI,Phase 2,Psoriatic arthritis,[ICD-11: FA21]
T32578,IL6,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T32578,IL6,INDICATI,Phase 3,Vasculitis,[ICD-11: 4A44]
T32578,IL6,INDICATI,Phase 3,Vitreoretinopathy,ICD-11: 9B78
,#N/A,,,,
T32720,KIR2DS1,TARGETID,T32720,,
T32720,KIR2DS1,TARGNAME,MHC class I NK cell receptor 2DS1 (CD158h),,
T32720,KIR2DS1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T32764,AAK1,TARGETID,T32764,,
T32764,AAK1,TARGNAME,Adaptor-associated kinase 1 (AAK1),,
T32764,AAK1,INDICATI,Phase 1,General pain disorder,[ICD-11: 8E43]
,#N/A,,,,
T32780,ASGR1,TARGETID,T32780,,
T32780,ASGR1,TARGNAME,Asialoglycoprotein receptor 1 (ASGR1),,
T32780,ASGR1,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
,#N/A,,,,
T32790,LDHA,TARGETID,T32790,,
T32790,LDHA,TARGNAME,LDHA messenger RNA (LDHA mRNA),,
T32790,LDHA,INDICATI,Approved,Inborn carbohydrate metabolism error,ICD-11: 5C51
T32790,LDHA,INDICATI,Phase 2,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
,#N/A,,,,
T32855,NTF3,TARGETID,T32855,,
T32855,NTF3,TARGNAME,Neurotrophin-3 (NTF3),,
T32855,NTF3,INDICATI,Terminated,Central nervous system disease,[ICD-11: 8A04-8D87]
T32855,NTF3,INDICATI,Discontinued in Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
,#N/A,,,,
T32862,#N/A,TARGETID,T32862,,
T32862,#N/A,TARGNAME,Fungal Cell membrane ergosterol (Fung CME),,
T32862,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T32862,#N/A,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
T32862,#N/A,INDICATI,Investigative,Mycose,[ICD-11: 1F2Z]
,#N/A,,,,
T32880,EGLN1,TARGETID,T32880,,
T32880,EGLN1,TARGNAME,HIF-prolyl hydroxylase 2 (HPH-2),,
T32880,EGLN1,INDICATI,Phase 3,Acute disease anaemia,[ICD-11: 3A90]
T32880,EGLN1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T32880,EGLN1,INDICATI,Phase 3,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T32938,SLC36A2,TARGETID,T32938,,
T32938,SLC36A2,TARGNAME,Solute carrier family 36 member 2 (SLC36A2),,
T32938,SLC36A2,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T32972,CYP51A1,TARGETID,T32972,,
T32972,CYP51A1,TARGNAME,Lanosterol 14-alpha demethylase (CYP51A1),,
T32972,CYP51A1,INDICATI,Phase 1,Infectious meningitis,[ICD-11: 1D01]
T32972,CYP51A1,INDICATI,Phase 2,Nail/perionychium infection,[ICD-11: EE12]
T32972,CYP51A1,INDICATI,Phase 2,Onchocerciasis,[ICD-11: 1F6A]
,#N/A,,,,
T32973,LGMN,TARGETID,T32973,,
T32973,LGMN,TARGNAME,Legumain (LGMN),,
T32973,LGMN,INDICATI,Phase 2/3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T32984,#N/A,TARGETID,T32984,,
T32984,#N/A,TARGNAME,Microtubule (MicroTu),,
T32984,#N/A,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T32984,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T32984,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T32984,#N/A,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T33124,DAO,TARGETID,T33124,,
T33124,DAO,TARGNAME,D-amino acid oxidase (DAO),,
T33124,DAO,INDICATI,Phase 2,Ataxic disorder,[ICD-11: 8A03]
T33124,DAO,INDICATI,Terminated,Mild neurocognitive disorder,[ICD-11: 6D71]
T33124,DAO,INDICATI,Phase 1,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T33193,Bact mrcA,TARGETID,T33193,,
T33193,Bact mrcA,TARGNAME,Bacterial Penicillin binding protein 3 (Bact mrcA),,
T33193,Bact mrcA,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T33193,Bact mrcA,INDICATI,Approved,Respiratory infection,[ICD-11: CA07-CA4Z]
T33193,Bact mrcA,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T33245,GDF15,TARGETID,T33245,,
T33245,GDF15,TARGNAME,Growth/differentiation factor 15 (GDF15),,
T33245,GDF15,INDICATI,Phase 2,Cachexia,ICD-11: MG20
T33245,GDF15,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T33245,GDF15,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T33275,#N/A,TARGETID,T33275,,
T33275,#N/A,TARGNAME,Tuftsin receptor (TR),,
T33275,#N/A,INDICATI,Phase 2,Diagnostic imaging,[ICD-11: N.A.]
,#N/A,,,,
T33425,EGF,TARGETID,T33425,,
T33425,EGF,TARGNAME,Epidermal growth factor (EGF),,
T33425,EGF,INDICATI,Investigative,Oral mucositis,[ICD-11: DA01]
T33425,EGF,INDICATI,Phase 2,Skin postprocedural disorder,[ICD-11: EL8Y]
T33425,EGF,INDICATI,Approved,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T33455,IGFBP3,TARGETID,T33455,,
T33455,IGFBP3,TARGNAME,Insulin-like growth factor-binding protein 3 (IGFBP3),,
T33455,IGFBP3,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
,#N/A,,,,
T33489,STS,TARGETID,T33489,,
T33489,STS,TARGNAME,Steryl-sulfatase (STS),,
T33489,STS,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T33489,STS,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T33489,STS,INDICATI,Phase 2,Endometriosis,[ICD-11: GA10]
T33489,STS,INDICATI,Phase 2,Low bone mass disorder,[ICD-11: FB83]
T33489,STS,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T33491,Bact kinA,TARGETID,T33491,,
T33491,Bact kinA,TARGNAME,Bacterial Sporulation kinase A (Bact kinA),,
T33491,Bact kinA,INDICATI,Investigative,Binge eating disorder,[ICD-11: 6B82]
T33491,Bact kinA,INDICATI,Terminated,Fungal infection,[ICD-11: 1F29-1F2F]
T33491,Bact kinA,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T33584,GRIA1,TARGETID,T33584,,
T33584,GRIA1,TARGNAME,Glutamate receptor AMPA 1 (GRIA1),,
T33584,GRIA1,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T33584,GRIA1,INDICATI,Discontinued in Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T33584,GRIA1,INDICATI,Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T33584,GRIA1,INDICATI,Discontinued in Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T33584,GRIA1,INDICATI,Approved,Neuropathy,[ICD-11: 8C0Z]
T33584,GRIA1,INDICATI,Discontinued in Phase 3,Parkinsonism,[ICD-11: 8A00]
T33584,GRIA1,INDICATI,Discontinued in Phase 1,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T33629,#N/A,TARGETID,T33629,,
T33629,#N/A,TARGNAME,Prostate cance cell (PCC),,
T33629,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T33636,EBV LMP2,TARGETID,T33636,,
T33636,EBV LMP2,TARGNAME,Epstein-Barr virus Latent membrane protein 2 (EBV LMP2),,
T33636,EBV LMP2,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T33636,EBV LMP2,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
,#N/A,,,,
T33641,CYP46A1,TARGETID,T33641,,
T33641,CYP46A1,TARGNAME,Cholesterol 24-hydroxylase (CYP46A1),,
T33641,CYP46A1,INDICATI,Phase 1,Acidosis,[ICD-11: 5C73]
T33641,CYP46A1,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T33641,CYP46A1,INDICATI,Phase 2,Epileptic encephalopathy,[ICD-11: 8A62]
T33641,CYP46A1,INDICATI,Phase 2,Phakomatoses/hamartoneoplastic syndrome,[ICD-11: LD2D]
,#N/A,,,,
T33754,#N/A,TARGETID,T33754,,
T33754,#N/A,TARGNAME,Phosphodiesterase 3 (PDE3),,
T33754,#N/A,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T33754,#N/A,INDICATI,Approved,Arterial occlusive disease,[ICD-11: BD40]
T33754,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T33754,#N/A,INDICATI,Approved,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T33754,#N/A,INDICATI,Approved,Castlemans disease,[ICD-11: 4B2Y]
T33754,#N/A,INDICATI,Discontinued in Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T33754,#N/A,INDICATI,Approved,Cough,[ICD-11: MD12]
T33754,#N/A,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T33754,#N/A,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T33754,#N/A,INDICATI,Phase 2,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
T33754,#N/A,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T33754,#N/A,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T33754,#N/A,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T33754,#N/A,INDICATI,Phase 2,Opioid use disorder,[ICD-11: 6C43]
T33754,#N/A,INDICATI,Terminated,Sepsis,[ICD-11: 1G40-1G41]
T33754,#N/A,INDICATI,Phase 2,Stimulants use disorder,[ICD-11: 6C46]
T33754,#N/A,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T33754,#N/A,INDICATI,Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T33765,MCL1,TARGETID,T33765,,
T33765,MCL1,TARGNAME,Mcl-1 messenger RNA (MCL-1 mRNA),,
T33765,MCL1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T33765,MCL1,INDICATI,Phase 3,Malignant intestine neoplasm,[ICD-11: 2C0Z]
T33765,MCL1,INDICATI,Investigative,Mastocytosis,[ICD-11: 2A21]
T33765,MCL1,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T33765,MCL1,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T33846,IL17RA; IL17RB; IL17RC; IL17RD; IL17RE,TARGETID,T33846,,
T33846,IL17RA; IL17RB; IL17RC; IL17RD; IL17RE,TARGNAME,Interleukin 17 receptor (IL17R),,
T33846,IL17RA; IL17RB; IL17RC; IL17RD; IL17RE,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T33846,IL17RA; IL17RB; IL17RC; IL17RD; IL17RE,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T33846,IL17RA; IL17RB; IL17RC; IL17RD; IL17RE,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T33846,IL17RA; IL17RB; IL17RC; IL17RD; IL17RE,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T33901,NPC1L1,TARGETID,T33901,,
T33901,NPC1L1,TARGNAME,Niemann-Pick C1-like protein 1 (NPC1L1),,
T33901,NPC1L1,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T33917,#N/A,TARGETID,T33917,,
T33917,#N/A,TARGNAME,Hydroxy radical elimination (HYRE),,
T33917,#N/A,INDICATI,Phase 2,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T33976,TFRC,TARGETID,T33976,,
T33976,TFRC,TARGNAME,Transferrin receptor protein 1 (TFRC),,
T33976,TFRC,INDICATI,Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T33976,TFRC,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T33976,TFRC,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T33990,CSF1,TARGETID,T33990,,
T33990,CSF1,TARGNAME,Macrophage colony-stimulating factor 1 (CSF1),,
T33990,CSF1,INDICATI,Phase 1,Inflammatory arthropathy,[ICD-11: FA2Z]
T33990,CSF1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T34123,SCN11A,TARGETID,T34123,,
T34123,SCN11A,TARGNAME,Voltage-gated sodium channel alpha Nav1.9 (SCN11A),,
T34123,SCN11A,INDICATI,Approved,Bipolar disorder,[ICD-11: 6A60]
T34123,SCN11A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T34123,SCN11A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T34123,SCN11A,INDICATI,Phase 2,Female pelvic pain,[ICD-11: GA34]
T34123,SCN11A,INDICATI,Phase 1,Follicular lymphoma,[ICD-11: 2A80]
T34123,SCN11A,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T34123,SCN11A,INDICATI,Approved,Motor neuron disease,[ICD-11: 8B60]
T34123,SCN11A,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T34123,SCN11A,INDICATI,Phase 3,Neuropathy,[ICD-11: 8C0Z]
T34123,SCN11A,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T34123,SCN11A,INDICATI,Investigative,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T34123,SCN11A,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T34204,CNGA2,TARGETID,T34204,,
T34204,CNGA2,TARGNAME,Cyclic nucleotide-gated channel alpha-2 (CNGA2),,
T34204,CNGA2,INDICATI,Clinical trial,Myelopathy,[ICD-11: 8B42]
,#N/A,,,,
T34234,VDR,TARGETID,T34234,,
T34234,VDR,TARGNAME,Vitamin D3 receptor (VDR),,
T34234,VDR,INDICATI,Discontinued in Phase 2,Abnormal micturition,[ICD-11: MF50]
T34234,VDR,INDICATI,Terminated,Acne vulgaris,[ICD-11: ED80]
T34234,VDR,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T34234,VDR,INDICATI,Approved,Chronic kidney disease,[ICD-11: GB61]
T34234,VDR,INDICATI,Approved,Hair/hair growth developmental defect,[ICD-11: LC30]
T34234,VDR,INDICATI,Approved,Hyper-parathyroidism,[ICD-11: 5A51]
T34234,VDR,INDICATI,Approved,Hypo-parathyroidism,[ICD-11: 5A50]
T34234,VDR,INDICATI,Phase 3,Low bone mass disorder,[ICD-11: FB83]
T34234,VDR,INDICATI,Approved,Mineral deficiency,[ICD-11: 5B5K]
T34234,VDR,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T34234,VDR,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T34234,VDR,INDICATI,Phase 1,Prostate disease,[ICD-11: GA91]
T34234,VDR,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T34234,VDR,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T34234,VDR,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T34239,PPOX,TARGETID,T34239,,
T34239,PPOX,TARGNAME,Protoporphyrinogen oxidase (PPOX),,
T34239,PPOX,INDICATI,Approved,Epidermal dysplasias,[ICD-11: EK90]
,#N/A,,,,
T34287,Candi PMI1,TARGETID,T34287,,
T34287,Candi PMI1,TARGNAME,Candida Mannose-6-phosphate isomerase (Candi PMI1),,
T34287,Candi PMI1,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T34287,Candi PMI1,INDICATI,Approved,Dermatitis herpetiformis,[ICD-11: EB44]
,#N/A,,,,
T34296,MMP13,TARGETID,T34296,,
T34296,MMP13,TARGNAME,Matrix metalloproteinase-13 (MMP-13),,
T34296,MMP13,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T34296,MMP13,INDICATI,Discontinued in Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T34296,MMP13,INDICATI,Clinical trial,Pain,[ICD-11: MG30-MG3Z]
T34296,MMP13,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T34296,MMP13,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T34296,MMP13,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T34318,CAMP,TARGETID,T34318,,
T34318,CAMP,TARGNAME,Cathelicidin antimicrobial peptide (CAMP),,
T34318,CAMP,INDICATI,Approved,Asthma,[ICD-11: CA23]
,#N/A,,,,
T34429,CHRNA7,TARGETID,T34429,,
T34429,CHRNA7,TARGNAME,Neuronal acetylcholine receptor alpha-7 (CHRNA7),,
T34429,CHRNA7,INDICATI,Phase 1,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T34429,CHRNA7,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T34429,CHRNA7,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T34429,CHRNA7,INDICATI,Discontinued in Phase 1,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T34429,CHRNA7,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T34429,CHRNA7,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T34429,CHRNA7,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T34429,CHRNA7,INDICATI,Phase 2,Cough,ICD-11: MD12
T34429,CHRNA7,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T34429,CHRNA7,INDICATI,Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T34429,CHRNA7,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T34429,CHRNA7,INDICATI,Phase 1,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T34429,CHRNA7,INDICATI,Phase 1,Mild neurocognitive disorder,[ICD-11: 6D71]
T34429,CHRNA7,INDICATI,Phase 3,Nicotine use disorder,[ICD-11: 6C4A]
T34429,CHRNA7,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T34429,CHRNA7,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T34429,CHRNA7,INDICATI,Phase 1,Sex development malformative disorder,[ICD-11: LD2A]
T34429,CHRNA7,INDICATI,Preclinical,Sexual dysfunction,[ICD-11: HA00-HA01]
T34429,CHRNA7,INDICATI,Discontinued in Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T34596,Hae-influ gyrA,TARGETID,T34596,,
T34596,Hae-influ gyrA,TARGNAME,Haemophilus influenzae DNA gyrase A (Hae-influ gyrA),,
T34596,Hae-influ gyrA,INDICATI,Investigative,Bacterial infection,[ICD-11: 1A00-1C4Z]
T34596,Hae-influ gyrA,INDICATI,Phase 3,Otitis externa,[ICD-11: AA00-AA13]
,#N/A,,,,
T34601,DYSF,TARGETID,T34601,,
T34601,DYSF,TARGNAME,Dysferlin (DYSF),,
T34601,DYSF,INDICATI,Phase 1,Muscular dystrophy,ICD-11: 8C70
,#N/A,,,,
T34624,#N/A,TARGETID,T34624,,
T34624,#N/A,TARGNAME,Stress-activated protein kinase (p38),,
T34624,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T34624,#N/A,INDICATI,Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T34624,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T34624,#N/A,INDICATI,Phase 3,Cardiomyopathy,[ICD-11: BC43]
T34624,#N/A,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T34624,#N/A,INDICATI,Discontinued in Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T34624,#N/A,INDICATI,Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T34624,#N/A,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T34624,#N/A,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T34624,#N/A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T34624,#N/A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T34624,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T34743,#N/A,TARGETID,T34743,,
T34743,#N/A,TARGNAME,Bacterial Penicillin binding protein (Bact PBP),,
T34743,#N/A,INDICATI,Approved,Acute bronchitis,[ICD-11: CA42]
T34743,#N/A,INDICATI,Approved,Anaerobic bacterial infection,[ICD-11: 1A00-1A09]
T34743,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T34743,#N/A,INDICATI,Approved,Bronchitis,[ICD-11: CA20]
T34743,#N/A,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T34743,#N/A,INDICATI,Phase 1,Digestive organ benign neoplasm,[ICD-11: 2E92]
T34743,#N/A,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T34743,#N/A,INDICATI,Approved,Glanders,[ICD-11: 1B92]
T34743,#N/A,INDICATI,Approved,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T34743,#N/A,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T34743,#N/A,INDICATI,Approved,Myelodysplastic syndrome,[ICD-11: 2A37]
T34743,#N/A,INDICATI,Phase 3,Pneumonia,[ICD-11: CA40]
T34743,#N/A,INDICATI,Approved,Respiratory infection,[ICD-11: CA07-CA4Z]
T34743,#N/A,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T34743,#N/A,INDICATI,Approved,Sepsis,[ICD-11: 1G40-1G41]
T34743,#N/A,INDICATI,Phase 3,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T34743,#N/A,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T34772,#N/A,TARGETID,T34772,,
T34772,#N/A,TARGNAME,Endopeptidase (ENP),,
T34772,#N/A,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
,#N/A,,,,
T34843,GLP2R,TARGETID,T34843,,
T34843,GLP2R,TARGNAME,Glucagon-like peptide 2 receptor (GLP2R),,
T34843,GLP2R,INDICATI,Phase 2,Bowel habit change,[ICD-11: ME05]
T34843,GLP2R,INDICATI,Investigative,Digestive system disease,[ICD-11: DE2Z]
T34843,GLP2R,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T34843,GLP2R,INDICATI,Phase 1,Low bone mass disorder,[ICD-11: FB83]
T34843,GLP2R,INDICATI,Approved,Neonatal malabsorption syndrome,[ICD-11: KB89]
,#N/A,,,,
T34867,#N/A,TARGETID,T34867,,
T34867,#N/A,TARGNAME,Poly [ADP-ribose] polymerase (PARP),,
T34867,#N/A,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
T34867,#N/A,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T34867,#N/A,INDICATI,Phase 1/2,Cerebral ischaemia,[ICD-11: 8B1Z]
T34867,#N/A,INDICATI,Phase 1,Cerebral ischaemic stroke,[ICD-11: 8B11]
T34867,#N/A,INDICATI,Phase 1,Ewing sarcoma,[ICD-11: 2B52]
T34867,#N/A,INDICATI,Phase 1,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T34867,#N/A,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T34867,#N/A,INDICATI,Phase 3,Malignant mesenchymal neoplasm,[ICD-11: 2B5D-2B5Y]
T34867,#N/A,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T34867,#N/A,INDICATI,Approved,Ovarian cancer,[ICD-11: 2C73]
T34867,#N/A,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T34867,#N/A,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T34867,#N/A,INDICATI,Phase 3,Psoriatic arthritis,[ICD-11: FA21]
T34867,#N/A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T34867,#N/A,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T34949,CACNA1A,TARGETID,T34949,,
T34949,CACNA1A,TARGNAME,Voltage-gated calcium channel alpha Cav2.1 (CACNA1A),,
T34949,CACNA1A,INDICATI,Investigative,Heart failure,[ICD-11: BD10-BD1Z]
T34949,CACNA1A,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T34949,CACNA1A,INDICATI,Terminated,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T34997,HCV NS4A,TARGETID,T34997,,
T34997,HCV NS4A,TARGNAME,Hepatitis C virus Serine protease NS4A (HCV NS4A),,
T34997,HCV NS4A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T35040,BSG,TARGETID,T35040,,
T35040,BSG,TARGNAME,Basigin (BSG),,
T35040,BSG,INDICATI,Phase 2/3,Graft-versus-host disease,[ICD-11: 4B24]
T35040,BSG,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
,#N/A,,,,
T35063,GEM,TARGETID,T35063,,
T35063,GEM,TARGNAME,RAS-like protein KIR (GEM),,
T35063,GEM,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T35063,GEM,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T35063,GEM,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T35063,GEM,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T35173,BIRC3,TARGETID,T35173,,
T35173,BIRC3,TARGNAME,Cellular inhibitor of apoptosis 2 (BIRC3),,
T35173,BIRC3,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T35173,BIRC3,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T35173,BIRC3,INDICATI,Phase 3,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T35173,BIRC3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T35194,DUSP1,TARGETID,T35194,,
T35194,DUSP1,TARGNAME,Dual specificity protein phosphatase 1 (DUSP1),,
T35194,DUSP1,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T35194,DUSP1,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
,#N/A,,,,
T35212,TNFSF15,TARGETID,T35212,,
T35212,TNFSF15,TARGNAME,Vascular endothelial cell growth inhibitor (TNFSF15),,
T35212,TNFSF15,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T35212,TNFSF15,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T35212,TNFSF15,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T35232,IL7,TARGETID,T35232,,
T35232,IL7,TARGNAME,Interleukin-7 (IL7),,
T35232,IL7,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T35232,IL7,INDICATI,Phase 1,Sjogren syndrome,[ICD-11: 4A43]
T35232,IL7,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T35265,S100A4,TARGETID,T35265,,
T35265,S100A4,TARGNAME,S100 calcium-binding protein A4 (S100A4),,
T35265,S100A4,INDICATI,Preclinical,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T35289,KLRK1,TARGETID,T35289,,
T35289,KLRK1,TARGNAME,NKG2 D activating NK receptor (KLRK1),,
T35289,KLRK1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T35289,KLRK1,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T35289,KLRK1,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T35289,KLRK1,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T35289,KLRK1,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T35289,KLRK1,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T35303,PPY,TARGETID,T35303,,
T35303,PPY,TARGNAME,Pancreatic hormone (PH),,
T35303,PPY,INDICATI,Phase 1/2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T35423,VTCN1,TARGETID,T35423,,
T35423,VTCN1,TARGNAME,Immune costimulatory protein B7H4 (VTCN1),,
T35423,VTCN1,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T35423,VTCN1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T35445,SMAD3,TARGETID,T35445,,
T35445,SMAD3,TARGNAME,Mothers against decapentaplegic homolog 3 (SMAD3),,
T35445,SMAD3,INDICATI,Preclinical,Kidney fibrosis,[ICD-11: GC01]
,#N/A,,,,
T35465,SLC19A1,TARGETID,T35465,,
T35465,SLC19A1,TARGNAME,Solute carrier family 19 member 1 (SLC19A1),,
T35465,SLC19A1,INDICATI,Approved,Folate deficiency anaemia,[ICD-11: 3A02]
T35465,SLC19A1,INDICATI,Approved,Leukaemia,[ICD-11: 2A60-2B33]
T35465,SLC19A1,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T35465,SLC19A1,INDICATI,Investigative,Prostate cancer,[ICD-11: 2C82]
T35465,SLC19A1,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T35465,SLC19A1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T35465,SLC19A1,INDICATI,Phase 3,Vitreoretinopathy,[ICD-11: 9B78]
,#N/A,,,,
T35474,KRAS,TARGETID,T35474,,
T35474,KRAS,TARGNAME,KRAS messenger RNA (KRAS mRNA),,
T35474,KRAS,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T35486,NRAS,TARGETID,T35486,,
T35486,NRAS,TARGNAME,GTPase NRas (NRAS),,
T35486,NRAS,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T35486,NRAS,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T35486,NRAS,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T35486,NRAS,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T35486,NRAS,INDICATI,Investigative,Prostate cancer,[ICD-11: 2C82]
T35486,NRAS,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T35591,NECTIN4,TARGETID,T35591,,
T35591,NECTIN4,TARGNAME,Nectin cell adhesion molecule 4 (NECTIN4),,
T35591,NECTIN4,INDICATI,Phase 3,Bladder cancer,[ICD-11: 2C94]
T35591,NECTIN4,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T35591,NECTIN4,INDICATI,Approved,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T35640,ITGAL,TARGETID,T35640,,
T35640,ITGAL,TARGNAME,Integrin alpha-L (ITGAL),,
T35640,ITGAL,INDICATI,Phase 3,Conjunctiva disorder,[ICD-11: 9A60]
T35640,ITGAL,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T35640,ITGAL,INDICATI,Preclinical,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T35640,ITGAL,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T35640,ITGAL,INDICATI,Phase 2,Transplant rejection,[ICD-11: NE84]
T35640,ITGAL,INDICATI,Approved,Visual system disease,[ICD-11: 9E1Z]
,#N/A,,,,
T35734,EPHX2,TARGETID,T35734,,
T35734,EPHX2,TARGNAME,Soluble epoxide hydrolase (EPHX2),,
T35734,EPHX2,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T35734,EPHX2,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T35792,SMYD3,TARGETID,T35792,,
T35792,SMYD3,TARGNAME,Histone-lysine N-methyltransferase SMYD3 (SMYD3),,
T35792,SMYD3,INDICATI,Preclinical,Colon cancer,[ICD-11: 2B90]
T35792,SMYD3,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T35842,MC1R,TARGETID,T35842,,
T35842,MC1R,TARGNAME,Melanocortin receptor 1 (MC1R),,
T35842,MC1R,INDICATI,Phase 2,Acquired hypomelanotic disorder,[ICD-11: ED63]
T35842,MC1R,INDICATI,Investigative,Atopic eczema,[ICD-11: EA80]
T35842,MC1R,INDICATI,Approved,Hypoactive sexual desire dysfunction,[ICD-11: HA00]
T35842,MC1R,INDICATI,Approved,Inborn porphyrin/heme metabolism error,[ICD-11: 5C58]
T35842,MC1R,INDICATI,Phase 3,Inborn porphyrin/heme metabolism error,ICD-11: 5C58
T35842,MC1R,INDICATI,Phase 1/2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T35842,MC1R,INDICATI,Phase 3,Sexual dysfunction,[ICD-11: HA00-HA01]
T35842,MC1R,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T35940,MAP2K1,TARGETID,T35940,,
T35940,MAP2K1,TARGNAME,ERK activator kinase 1 (MEK1),,
T35940,MAP2K1,INDICATI,Investigative,Cardiac arrest,[ICD-11: MC82]
T35940,MAP2K1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T35940,MAP2K1,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T35940,MAP2K1,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T35940,MAP2K1,INDICATI,Phase 3,Thyroid cancer,[ICD-11: 2D10]
,#N/A,,,,
T36053,SLCO4C1,TARGETID,T36053,,
T36053,SLCO4C1,TARGNAME,Organic anion transporter M1 (SLCO4C1),,
T36053,SLCO4C1,INDICATI,Approved,Cardiac arrhythmia,[ICD-11: BC9Z]
T36053,SLCO4C1,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T36059,ADORA3,TARGETID,T36059,,
T36059,ADORA3,TARGNAME,Adenosine A3 receptor (ADORA3),,
T36059,ADORA3,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T36059,ADORA3,INDICATI,Investigative,Glaucoma,[ICD-11: 9C61]
T36059,ADORA3,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T36059,ADORA3,INDICATI,Phase 1/2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T36059,ADORA3,INDICATI,Preclinical,Ischaemic heart disease,[ICD-11: BA6Z]
T36059,ADORA3,INDICATI,Phase 1,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T36059,ADORA3,INDICATI,Investigative,Ischemia,[ICD-11: 8B10-8B11]
T36059,ADORA3,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T36059,ADORA3,INDICATI,Phase 2,Malaria,[ICD-11: 1F40-1F45]
T36059,ADORA3,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
T36059,ADORA3,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
T36059,ADORA3,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T36059,ADORA3,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T36059,ADORA3,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T36075,GLP1R,TARGETID,T36075,,
T36075,GLP1R,TARGNAME,Glucagon-like peptide 1 receptor (GLP1R),,
T36075,GLP1R,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T36075,GLP1R,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T36075,GLP1R,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T36075,GLP1R,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
T36075,GLP1R,INDICATI,Phase 2,Dyspepsia,[ICD-11: MD92]
T36075,GLP1R,INDICATI,Phase 2,Hypo-glycaemia,[ICD-11: 5A41]
T36075,GLP1R,INDICATI,Discontinued in Phase 1/2,Intracranial injury,[ICD-11: NA07]
T36075,GLP1R,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T36075,GLP1R,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T36075,GLP1R,INDICATI,Phase 3,Obesity,[ICD-11: 5B80-5B81]
T36075,GLP1R,INDICATI,Phase 2,Pancreatic internal secretion disorder,[ICD-11: 5A4Y]
T36075,GLP1R,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T36075,GLP1R,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
T36075,GLP1R,INDICATI,Approved,Type-1/2 diabete,[ICD-11: 5A10-5A11]
,#N/A,,,,
T36467,AICDA,TARGETID,T36467,,
T36467,AICDA,TARGNAME,Cytosine deaminase (AICDA),,
T36467,AICDA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T36479,CD96,TARGETID,T36479,,
T36479,CD96,TARGNAME,T-cell surface protein tactile (CD96),,
T36479,CD96,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T36483,F2R,TARGETID,T36483,,
T36483,F2R,TARGNAME,Proteinase activated receptor 1 (F2R),,
T36483,F2R,INDICATI,Investigative,Arterial occlusive disease,[ICD-11: BD40]
T36483,F2R,INDICATI,Terminated,Arteries/arterioles disorder,[ICD-11: BD52]
T36483,F2R,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T36483,F2R,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T36483,F2R,INDICATI,Terminated,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T36557,PPARD,TARGETID,T36557,,
T36557,PPARD,TARGNAME,Peroxisome proliferator-activated receptor delta (PPARD),,
T36557,PPARD,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T36557,PPARD,INDICATI,Phase 2,Autoimmune liver disease,[ICD-11: DB96]
T36557,PPARD,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T36557,PPARD,INDICATI,Discontinued in Phase 4,Diabetes mellitus,[ICD-11: 5A10]
T36557,PPARD,INDICATI,Phase 1,Dyslipidemia,[ICD-11: 5C80-5C81]
T36557,PPARD,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T36557,PPARD,INDICATI,Phase 1,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T36557,PPARD,INDICATI,Phase 3,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T36557,PPARD,INDICATI,Phase 2/3,Obesity,[ICD-11: 5B80-5B81]
T36557,PPARD,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T36658,#N/A,TARGETID,T36658,,
T36658,#N/A,TARGNAME,Oxidative stress (OS),,
T36658,#N/A,INDICATI,Discontinued in Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T36658,#N/A,INDICATI,Phase 1,Cerebral ischaemic stroke,[ICD-11: 8B11]
,#N/A,,,,
T36741,MDM4,TARGETID,T36741,,
T36741,MDM4,TARGNAME,p53-binding protein Mdm4 (MDM4),,
T36741,MDM4,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T36741,MDM4,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T36741,MDM4,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T36741,MDM4,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T36846,#N/A,TARGETID,T36846,,
T36846,#N/A,TARGNAME,Mitochondrial function (MF),,
T36846,#N/A,INDICATI,Phase 3,Motor neuron disease,[ICD-11: 8B60]
,#N/A,,,,
T36935,KLK3,TARGETID,T36935,,
T36935,KLK3,TARGNAME,Prostate specific antigen (KLK3),,
T36935,KLK3,INDICATI,Phase 3,Arteries/arterioles disorder,[ICD-11: BD52]
T36935,KLK3,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T36935,KLK3,INDICATI,Phase 3,Prostate hyperplasia,[ICD-11: GA90]
,#N/A,,,,
T36958,FOXP3,TARGETID,T36958,,
T36958,FOXP3,TARGNAME,FOXP3 messenger RNA (FOXP3 mRNA),,
T36958,FOXP3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T36959,ACVRL1,TARGETID,T36959,,
T36959,ACVRL1,TARGNAME,Activin receptor-like kinase-1 (ACVRL1),,
T36959,ACVRL1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T37012,GFRAL,TARGETID,T37012,,
T37012,GFRAL,TARGNAME,GDNF family receptor alpha-like (GFRAL),,
T37012,GFRAL,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T37046,BLVRA,TARGETID,T37046,,
T37046,BLVRA,TARGNAME,Biliverdin reductase A (BLVRA),,
T37046,BLVRA,INDICATI,Approved,Autoimmune liver disease,[ICD-11: DB96]
,#N/A,,,,
T37048,Stap-coc SpA,TARGETID,T37048,,
T37048,Stap-coc SpA,TARGNAME,Staphylococcus IgG binding protein A  (Stap-coc SpA),,
T37048,Stap-coc SpA,INDICATI,Phase 1/2,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T37154,CTSA,TARGETID,T37154,,
T37154,CTSA,TARGNAME,Cathepsin A (CTSA),,
T37154,CTSA,INDICATI,Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
,#N/A,,,,
T37245,DDIT4,TARGETID,T37245,,
T37245,DDIT4,TARGNAME,RTP801 messenger RNA (RTP801 mRNA),,
T37245,DDIT4,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T37245,DDIT4,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T37298,MYCBP,TARGETID,T37298,,
T37298,MYCBP,TARGNAME,MYCBP messenger RNA (MYCBP mRNA),,
T37298,MYCBP,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
,#N/A,,,,
T37308,#N/A,TARGETID,T37308,,
T37308,#N/A,TARGNAME,Immunoglobulin E (IgE),,
T37308,#N/A,INDICATI,Discontinued in Phase 2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T37308,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T37308,#N/A,INDICATI,Investigative,Myasthenia gravis,[ICD-11: 8C6Y]
T37308,#N/A,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T37308,#N/A,INDICATI,Phase 3,Spontaneous urticaria,[ICD-11: EB00]
T37308,#N/A,INDICATI,Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T37382,SLC23A1,TARGETID,T37382,,
T37382,SLC23A1,TARGNAME,Solute carrier family 23 member 1 (SLC23A1),,
T37382,SLC23A1,INDICATI,Phase 2,Urinary tract infection,[ICD-11: GC08]
T37382,SLC23A1,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T37434,PROM1,TARGETID,T37434,,
T37434,PROM1,TARGNAME,Prominin-1 (PROM1),,
T37434,PROM1,INDICATI,Preclinical,Acute myeloid leukaemia,[ICD-11: 2A60]
T37434,PROM1,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T37434,PROM1,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T37434,PROM1,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T37434,PROM1,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T37434,PROM1,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T37434,PROM1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T37510,F5,TARGETID,T37510,,
T37510,F5,TARGNAME,Coagulation factor Va (F5),,
T37510,F5,INDICATI,Approved,Cerebral ischaemia,[ICD-11: 8B1Z]
T37510,F5,INDICATI,Approved,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T37539,CD22,TARGETID,T37539,,
T37539,CD22,TARGNAME,B-cell receptor CD22 (CD22),,
T37539,CD22,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T37539,CD22,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T37539,CD22,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T37539,CD22,INDICATI,Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T37539,CD22,INDICATI,Phase 1/2,Follicular lymphoma,[ICD-11: 2A80]
T37539,CD22,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T37539,CD22,INDICATI,Phase 3,Lupus erythematosus,[ICD-11: 4A40]
T37539,CD22,INDICATI,Approved,Lyme borreliosis,[ICD-11: 1C1G]
T37539,CD22,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T37539,CD22,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T37539,CD22,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T37539,CD22,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T37539,CD22,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T37539,CD22,INDICATI,Phase 3,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T37693,CNR2,TARGETID,T37693,,
T37693,CNR2,TARGNAME,Cannabinoid receptor 2 (CB2),,
T37693,CNR2,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T37693,CNR2,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T37693,CNR2,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T37693,CNR2,INDICATI,Discontinued in Phase 1,Cerebral ischaemia,[ICD-11: 8B1Z]
T37693,CNR2,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T37693,CNR2,INDICATI,Patented,Endometriosis,[ICD-11: GA10]
T37693,CNR2,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T37693,CNR2,INDICATI,Investigative,Immune system disease,[ICD-11: 4A01-4B41]
T37693,CNR2,INDICATI,Phase 2,Inborn lipid metabolism error,[ICD-11: 5C52]
T37693,CNR2,INDICATI,Investigative,Indeterminate colitis,[ICD-11: DD72]
T37693,CNR2,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T37693,CNR2,INDICATI,Discontinued in Phase 2,Ischemia,[ICD-11: 8B10-8B11]
T37693,CNR2,INDICATI,Patented,Low bone mass disorder,[ICD-11: FB83]
T37693,CNR2,INDICATI,Investigative,Ovarian cancer,[ICD-11: 2C73]
T37693,CNR2,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T37693,CNR2,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T37693,CNR2,INDICATI,Patented,Prostate cancer,[ICD-11: 2C82]
T37693,CNR2,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T37693,CNR2,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
T37693,CNR2,INDICATI,Patented,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T37735,GLUL,TARGETID,T37735,,
T37735,GLUL,TARGNAME,Glutamate decarboxylase (GLUL),,
T37735,GLUL,INDICATI,Discontinued in Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T37742,APCS,TARGETID,T37742,,
T37742,APCS,TARGNAME,Serum amyloid P-component (APCS),,
T37742,APCS,INDICATI,Phase 1,Amyloidosis,[ICD-11: 5D00]
T37742,APCS,INDICATI,Phase 3,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T37742,APCS,INDICATI,Phase 1/2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T37847,HSV UL30,TARGETID,T37847,,
T37847,HSV UL30,TARGNAME,Herpes simplex virus DNA polymerase UL30 (HSV UL30),,
T37847,HSV UL30,INDICATI,Approved,Cytomegaloviral disease,[ICD-11: 1D82]
T37847,HSV UL30,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T37847,HSV UL30,INDICATI,Approved,Herpes simplex infection,[ICD-11: 1F00]
T37847,HSV UL30,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T37847,HSV UL30,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T37847,HSV UL30,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T37847,HSV UL30,INDICATI,Phase 2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T37847,HSV UL30,INDICATI,Approved,Retinal inflammation,[ICD-11: 9B72]
T37847,HSV UL30,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T37847,HSV UL30,INDICATI,Approved,Virus infection,[ICD-11: 1A24-1D9Z]
T37847,HSV UL30,INDICATI,Phase 2,Zoster,[ICD-11: 1E91]
,#N/A,,,,
T37848,CYP3A4,TARGETID,T37848,,
T37848,CYP3A4,TARGNAME,Albendazole monooxygenase (CYP3A4),,
T37848,CYP3A4,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T37848,CYP3A4,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T37876,HRV VP,TARGETID,T37876,,
T37876,HRV VP,TARGNAME,Rhinovirus Capsid protein (HRV VP),,
T37876,HRV VP,INDICATI,Phase 2,Acute upper respiratory infection,[ICD-11: CA07]
T37876,HRV VP,INDICATI,Discontinued in Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T37952,SYK,TARGETID,T37952,,
T37952,SYK,TARGNAME,SYK messenger RNA (SYK mRNA),,
T37952,SYK,INDICATI,Phase 2,Eczema,[ICD-11: EA80-EA89]
T37952,SYK,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T37952,SYK,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T38052,Crypto CpPNO,TARGETID,T38052,,
T38052,Crypto CpPNO,TARGNAME,Cryptosporidium Pyruvate:ferredoxin oxidoreductase (Crypto CpPNO),,
T38052,Crypto CpPNO,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
,#N/A,,,,
T38087,TNKS2,TARGETID,T38087,,
T38087,TNKS2,TARGNAME,Tankyrase-2 (TNKS-2),,
T38087,TNKS2,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T38143,#N/A,TARGETID,T38143,,
T38143,#N/A,TARGNAME,Phosphodiesterase 5 (PDE5),,
T38143,#N/A,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T38159,TFF1,TARGETID,T38159,,
T38159,TFF1,TARGNAME,Trefoil factor-1 (TFF1),,
T38159,TFF1,INDICATI,Phase 2/3,Oral mucositis,[ICD-11: DA01]
,#N/A,,,,
T38161,ANXA1,TARGETID,T38161,,
T38161,ANXA1,TARGNAME,Phospholipase A2 inhibitory protein (PA2IP),,
T38161,ANXA1,INDICATI,Approved,Ocular pain,[ICD-11: MC18]
,#N/A,,,,
T38179,Stap-coc blaZ,TARGETID,T38179,,
T38179,Stap-coc blaZ,TARGNAME,Staphylococcus Beta-lactamase (Stap-coc blaZ),,
T38179,Stap-coc blaZ,INDICATI,Phase 2,Anaerobic bacterial infection,[ICD-11: 1A00-1A09]
T38179,Stap-coc blaZ,INDICATI,Terminated,Antimicrobial drug resistance,[ICD-11: MG50-MG52]
T38179,Stap-coc blaZ,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T38179,Stap-coc blaZ,INDICATI,Phase 1,Gram-negative bacterial infection,[ICD-11: 1F41-1G40]
T38179,Stap-coc blaZ,INDICATI,Discontinued in Phase 3,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T38179,Stap-coc blaZ,INDICATI,Approved,Infectious gastroenteritis/colitis,[ICD-11: 1A40]
T38179,Stap-coc blaZ,INDICATI,Phase 1,Infectious meningitis,[ICD-11: 1D01]
T38179,Stap-coc blaZ,INDICATI,Discontinued in Phase 3,Otitis media,[ICD-11: AA80-AB0Z]
T38179,Stap-coc blaZ,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T38179,Stap-coc blaZ,INDICATI,Discontinued in Phase 2,Toxicity,[ICD-11: N.A.]
T38179,Stap-coc blaZ,INDICATI,Phase 3,Unspecific infection,[ICD-11: 1H0Z]
T38179,Stap-coc blaZ,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T38200,SLC6A11,TARGETID,T38200,,
T38200,SLC6A11,TARGNAME,GABA transporter-3 (SLC6A11),,
T38200,SLC6A11,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
,#N/A,,,,
T38201,TIPARP,TARGETID,T38201,,
T38201,TIPARP,TARGNAME,Protein mono-ADP-ribosyltransferase TIPARP (TIPARP),,
T38201,TIPARP,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T38284,BCR-ABL1,TARGETID,T38284,,
T38284,BCR-ABL1,TARGNAME,Fusion protein Bcr-Abl (Bcr-Abl),,
T38284,BCR-ABL1,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T38284,BCR-ABL1,INDICATI,Phase 3,Leukaemia,[ICD-11: 2A60-2B33]
T38284,BCR-ABL1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T38284,BCR-ABL1,INDICATI,Phase 3,Malignant intestine neoplasm,[ICD-11: 2C0Z]
T38284,BCR-ABL1,INDICATI,Investigative,Mastocytosis,[ICD-11: 2A21]
T38284,BCR-ABL1,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T38284,BCR-ABL1,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T38284,BCR-ABL1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T38284,BCR-ABL1,INDICATI,Phase 2,Musculoskeletal system/connective tissue disease,[ICD-11: FC0Z]
T38284,BCR-ABL1,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T38301,RRM2,TARGETID,T38301,,
T38301,RRM2,TARGNAME,Ribonucleoside-diphosphate reductase M2 (RRM2),,
T38301,RRM2,INDICATI,Discontinued in Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T38301,RRM2,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T38301,RRM2,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T38301,RRM2,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T38301,RRM2,INDICATI,Discontinued in Phase 2,Stomach cancer,[ICD-11: 2B72]
T38301,RRM2,INDICATI,Phase 2,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T38338,CACNA1B,TARGETID,T38338,,
T38338,CACNA1B,TARGNAME,Voltage-gated calcium channel alpha Cav2.2 (CACNA1B),,
T38338,CACNA1B,INDICATI,Discontinued in Phase 3,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T38338,CACNA1B,INDICATI,Phase 3,Essential hypertension,[ICD-11: BA00]
T38338,CACNA1B,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T38338,CACNA1B,INDICATI,Investigative,Heart failure,[ICD-11: BD10-BD1Z]
T38338,CACNA1B,INDICATI,Phase 1/2,Intracranial injury,[ICD-11: NA07]
T38338,CACNA1B,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T38338,CACNA1B,INDICATI,Approved,Non-thrombocytopenic purpura,[ICD-11: 3B60]
T38338,CACNA1B,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T38338,CACNA1B,INDICATI,Terminated,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T38431,S100A9,TARGETID,T38431,,
T38431,S100A9,TARGNAME,Calgranulin B (S100A9),,
T38431,S100A9,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T38431,S100A9,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T38509,F12,TARGETID,T38509,,
T38509,F12,TARGNAME,Coagulation factor XII (F12),,
T38509,F12,INDICATI,Phase 3,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T38509,F12,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T38528,#N/A,TARGETID,T38528,,
T38528,#N/A,TARGNAME,AdoHcy hydrolase (SAHase),,
T38528,#N/A,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T38529,PTGER2,TARGETID,T38529,,
T38529,PTGER2,TARGNAME,Prostaglandin E2 receptor EP2 (PTGER2),,
T38529,PTGER2,INDICATI,Approved,Abortion,[ICD-11: JA00]
T38529,PTGER2,INDICATI,Discontinued in Phase 3,Arterial occlusive disease,[ICD-11: BD40]
T38529,PTGER2,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T38529,PTGER2,INDICATI,Approved,Diabetic foot ulcer,[ICD-11: BD54]
T38529,PTGER2,INDICATI,Phase 1,Endometriosis,[ICD-11: GA10]
T38529,PTGER2,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T38529,PTGER2,INDICATI,Investigative,Immune system disease,[ICD-11: 4A01-4B41]
T38529,PTGER2,INDICATI,Phase 2,Low bone mass disorder,[ICD-11: FB83]
T38529,PTGER2,INDICATI,Phase 3,Pemphigus,[ICD-11: EB40]
T38529,PTGER2,INDICATI,Approved,Pulmonary hypertension,[ICD-11: BB01]
T38529,PTGER2,INDICATI,Approved,Sexual dysfunction,[ICD-11: HA00-HA01]
T38529,PTGER2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T38529,PTGER2,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
T38529,PTGER2,INDICATI,Phase 2,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T38763,#N/A,TARGETID,T38763,,
T38763,#N/A,TARGNAME,Hepatitis C virus Non-structural 5 (HCV NS5),,
T38763,#N/A,INDICATI,Phase 1/2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T38810,LPA,TARGETID,T38810,,
T38810,LPA,TARGNAME,Apolipoprotein A messenger RNA (LPA mRNA),,
T38810,LPA,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T38810,LPA,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
T38810,LPA,INDICATI,Phase 2,Hyperlipidemia,[ICD-11: 5C80]
T38810,LPA,INDICATI,Phase 3,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T38810,LPA,INDICATI,Phase 2,Hyper-lipoproteinaemia,ICD-11: 5C80
T38810,LPA,INDICATI,Phase 2,Liver vascular disorder,[ICD-11: DB98]
,#N/A,,,,
T38875,PRKAA1; PRKAB1; PRKAG1,TARGETID,T38875,,
T38875,PRKAA1; PRKAB1; PRKAG1,TARGNAME,AMP-activated protein kinase (AMPK),,
T38875,PRKAA1; PRKAB1; PRKAG1,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T38875,PRKAA1; PRKAB1; PRKAG1,INDICATI,Phase 2,Alopecia,[ICD-11: ED70]
T38875,PRKAA1; PRKAB1; PRKAG1,INDICATI,Investigative,Breast cancer,[ICD-11: 2C60-2C6Y]
T38875,PRKAA1; PRKAB1; PRKAG1,INDICATI,Investigative,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T38875,PRKAA1; PRKAB1; PRKAG1,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T38875,PRKAA1; PRKAB1; PRKAG1,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T38875,PRKAA1; PRKAB1; PRKAG1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T38875,PRKAA1; PRKAB1; PRKAG1,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T38950,CD33,TARGETID,T38950,,
T38950,CD33,TARGNAME,Myeloid cell surface antigen CD33 (CD33),,
T38950,CD33,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T38950,CD33,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T38950,CD33,INDICATI,Phase 1/2,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T38950,CD33,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T38950,CD33,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T38950,CD33,INDICATI,Phase 1/2,Mastocytosis,[ICD-11: 2A21]
T38950,CD33,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T38950,CD33,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
,#N/A,,,,
T39031,#N/A,TARGETID,T39031,,
T39031,#N/A,TARGNAME,Tumor antigen NGcGM3 (NGcGM3),,
T39031,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T39047,LAIR1,TARGETID,T39047,,
T39047,LAIR1,TARGNAME,Leukocyte-associated Ig-like receptor 1 (LAIR1),,
T39047,LAIR1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T39054,DUT,TARGETID,T39054,,
T39054,DUT,TARGNAME,dUTP pyrophosphatase (DUT),,
T39054,DUT,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T39054,DUT,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T39078,#N/A,TARGETID,T39078,,
T39078,#N/A,TARGNAME,Calcium-activated potassium channel (KCN),,
T39078,#N/A,INDICATI,Approved,Acute pain,[ICD-11: MG31]
T39078,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T39078,#N/A,INDICATI,Investigative,Conjunctiva disorder,[ICD-11: 9A60]
T39078,#N/A,INDICATI,Approved,Neurological toxicity disorder,[ICD-11: 8D43]
T39078,#N/A,INDICATI,Discontinued in Phase 2,Neutropenia,[ICD-11: 4B00]
,#N/A,,,,
T39087,HIV IN,TARGETID,T39087,,
T39087,HIV IN,TARGNAME,Human immunodeficiency virus Integrase (HIV IN),,
T39087,HIV IN,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T39123,KISS1R,TARGETID,T39123,,
T39123,KISS1R,TARGNAME,G-protein coupled receptor 54 (KISS1R),,
T39123,KISS1R,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T39123,KISS1R,INDICATI,Discontinued in Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T39147,#N/A,TARGETID,T39147,,
T39147,#N/A,TARGNAME,Cytomegalovirus Terminase (CMV TRM),,
T39147,#N/A,INDICATI,Approved,Cytomegaloviral disease,[ICD-11: 1D82]
T39147,#N/A,INDICATI,Terminated,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T39231,TNKS,TARGETID,T39231,,
T39231,TNKS,TARGNAME,Tankyrase-1 (TNKS-1),,
T39231,TNKS,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T39321,GAPDH,TARGETID,T39321,,
T39321,GAPDH,TARGNAME,Glyceraldehyde-3-phosphate dehydrogenase (GAPDH),,
T39321,GAPDH,INDICATI,Phase 2,Muscular atrophy,[ICD-11: 8B61]
T39321,GAPDH,INDICATI,Phase 1,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T39523,PDE7A,TARGETID,T39523,,
T39523,PDE7A,TARGNAME,Phosphodiesterase 7A (PDE7A),,
T39523,PDE7A,INDICATI,Discontinued in Phase 1,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T39554,#N/A,TARGETID,T39554,,
T39554,#N/A,TARGNAME,MAPK/ERK signaling pathway (MAPK pathway),,
T39554,#N/A,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
,#N/A,,,,
T39610,CALM,TARGETID,T39610,,
T39610,CALM,TARGNAME,Calmodulin (CALM),,
T39610,CALM,INDICATI,Approved,Cardiac arrhythmia,[ICD-11: BC9Z]
T39610,CALM,INDICATI,Investigative,Choreiform disorder,[ICD-11: 8A01]
T39610,CALM,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T39610,CALM,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T39664,#N/A,TARGETID,T39664,,
T39664,#N/A,TARGNAME,Estradiol 17 beta-dehydrogenase (17-beta-HSD),,
T39664,#N/A,INDICATI,Terminated,Low bone mass disorder,[ICD-11: FB83]
,#N/A,,,,
T39676,SLC47A1,TARGETID,T39676,,
T39676,SLC47A1,TARGNAME,Solute carrier family 47 member 1 (SLC47A1),,
T39676,SLC47A1,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T39677,CEL,TARGETID,T39677,,
T39677,CEL,TARGNAME,Bile-salt-activated lipase (CEL),,
T39677,CEL,INDICATI,Terminated,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T39677,CEL,INDICATI,Phase 3,Pancreas disease,[ICD-11: DC35-DC3Z]
T39677,CEL,INDICATI,Investigative,Pancreatic malfunction,[ICD-11: DC30-DC3Z]
T39677,CEL,INDICATI,Phase 1/2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T39716,SCN5A,TARGETID,T39716,,
T39716,SCN5A,TARGNAME,Voltage-gated sodium channel alpha Nav1.5 (SCN5A),,
T39716,SCN5A,INDICATI,Withdrawn from market,Abnormal micturition,[ICD-11: MF50]
T39716,SCN5A,INDICATI,Phase 1,Angina pectoris,[ICD-11: BA40]
T39716,SCN5A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T39716,SCN5A,INDICATI,Approved,Cardiac arrhythmia,[ICD-11: BC9Z]
T39716,SCN5A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T39716,SCN5A,INDICATI,Approved,Cough,[ICD-11: MD12]
T39716,SCN5A,INDICATI,Discontinued in Preregistration,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T39716,SCN5A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T39716,SCN5A,INDICATI,Withdrawn from market,Genetic cardiac arrhythmia,[ICD-11: BC65]
T39716,SCN5A,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T39716,SCN5A,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T39716,SCN5A,INDICATI,Discontinued in Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T39716,SCN5A,INDICATI,Approved,Ventricular tachyarrhythmia,[ICD-11: BC71]
,#N/A,,,,
T39797,FZD7,TARGETID,T39797,,
T39797,FZD7,TARGNAME,Frizzled-7 receptor (FZD7),,
T39797,FZD7,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T39921,HSPB1,TARGETID,T39921,,
T39921,HSPB1,TARGNAME,Heat shock protein 20 (HSP20),,
T39921,HSPB1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T39977,MIF,TARGETID,T39977,,
T39977,MIF,TARGNAME,Macrophage migration inhibitory factor (MIF),,
T39977,MIF,INDICATI,Investigative,Autoimmune disease,[ICD-11: 4A40-4A45]
T39977,MIF,INDICATI,Phase 4,Diabetes mellitus,[ICD-11: 5A10]
T39977,MIF,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
T39977,MIF,INDICATI,Phase 4,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T39996,EHMT1,TARGETID,T39996,,
T39996,EHMT1,TARGNAME,Euchromatic histone-lysine N-methyltransferase 1 (EHMT1),,
T39996,EHMT1,INDICATI,Preclinical,Breast cancer,[ICD-11: 2C60-2C6Y]
T39996,EHMT1,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T40000,KLK1,TARGETID,T40000,,
T40000,KLK1,TARGNAME,Tissue kallikrein (KLK1),,
T40000,KLK1,INDICATI,Investigative,Respiratory system disease,[ICD-11: CB40-CB7Z]
,#N/A,,,,
T40010,EGFL7,TARGETID,T40010,,
T40010,EGFL7,TARGNAME,Epidermal growth factor-like protein 7 (EGFL7),,
T40010,EGFL7,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T40010,EGFL7,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T40016,NR3C1,TARGETID,T40016,,
T40016,NR3C1,TARGNAME,Glucocorticoid receptor (NR3C1),,
T40016,NR3C1,INDICATI,Approved,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T40016,NR3C1,INDICATI,Phase 2,Adrenogenital disorder,[ICD-11: 5A71]
T40016,NR3C1,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T40016,NR3C1,INDICATI,Terminated,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T40016,NR3C1,INDICATI,Approved,Asthma,[ICD-11: CA23]
T40016,NR3C1,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T40016,NR3C1,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T40016,NR3C1,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T40016,NR3C1,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T40016,NR3C1,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T40016,NR3C1,INDICATI,Phase 2,Eczema,[ICD-11: EA80-EA89]
T40016,NR3C1,INDICATI,Phase 3,Herpes simplex infection,[ICD-11: 1F00]
T40016,NR3C1,INDICATI,Phase 3,Knee osteoarthritis,[ICD-11: FA01]
T40016,NR3C1,INDICATI,Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T40016,NR3C1,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T40016,NR3C1,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T40016,NR3C1,INDICATI,Approved,Muscular dystrophy,[ICD-11: 8C70]
T40016,NR3C1,INDICATI,Approved,Oesophagitis,[ICD-11: DA24]
T40016,NR3C1,INDICATI,Phase 3,Otitis externa,[ICD-11: AA00-AA13]
T40016,NR3C1,INDICATI,Approved,Postoperative inflammation,[ICD-11: 1A00-CA43]
T40016,NR3C1,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T40016,NR3C1,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T40016,NR3C1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T40016,NR3C1,INDICATI,Investigative,Spine/trunk injury,[ICD-11: ND51]
T40016,NR3C1,INDICATI,Phase 1,Substance abuse,ICD-11: 6C40
T40016,NR3C1,INDICATI,Clinical trial,Substance abuse,[ICD-11: 6C40]
T40016,NR3C1,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
T40016,NR3C1,INDICATI,Approved,Vasomotor/allergic rhinitis,[ICD-11: CA08]
T40016,NR3C1,INDICATI,Phase 2,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T40045,RRM1,TARGETID,T40045,,
T40045,RRM1,TARGNAME,RRM1 messenger RNA (RRM1 mRNA),,
T40045,RRM1,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T40097,MAPK8,TARGETID,T40097,,
T40097,MAPK8,TARGNAME,Stress-activated protein kinase JNK1 (JNK1),,
T40097,MAPK8,INDICATI,Investigative,Intracranial injury,[ICD-11: NA07]
T40097,MAPK8,INDICATI,Preclinical,Mature T-cell lymphoma,[ICD-11: 2A90]
T40097,MAPK8,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T40111,IMPDH1,TARGETID,T40111,,
T40111,IMPDH1,TARGNAME,Inosine-5'-monophosphate dehydrogenase 1 (IMPDH1),,
T40111,IMPDH1,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T40111,IMPDH1,INDICATI,Phase 4,Crohn disease,[ICD-11: DD70]
T40111,IMPDH1,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T40111,IMPDH1,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T40111,IMPDH1,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T40111,IMPDH1,INDICATI,Patented,Psoriasis,[ICD-11: EA90]
T40111,IMPDH1,INDICATI,Withdrawn from market,Sensation disturbance,[ICD-11: MB40]
T40111,IMPDH1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T40111,IMPDH1,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T40111,IMPDH1,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T40126,Pseudo kynU,TARGETID,T40126,,
T40126,Pseudo kynU,TARGNAME,Pseudomonas Kynureninase (Pseudo kynU),,
T40126,Pseudo kynU,INDICATI,Preclinical,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T40149,PRKCH,TARGETID,T40149,,
T40149,PRKCH,TARGNAME,PKC-eta messenger RNA (PRKCH mRNA),,
T40149,PRKCH,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T40160,#N/A,TARGETID,T40160,,
T40160,#N/A,TARGNAME,Aryl hydrocarbon receptor signaling pathway (AhR pathway),,
T40160,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T40192,NFKB1,TARGETID,T40192,,
T40192,NFKB1,TARGNAME,DNA-binding factor KBF1 (p105),,
T40192,NFKB1,INDICATI,Phase 2,Muscular dystrophy,[ICD-11: 8C70]
T40192,NFKB1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T40192,NFKB1,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T40276,PRKCB,TARGETID,T40276,,
T40276,PRKCB,TARGNAME,Protein kinase C beta (PRKCB),,
T40276,PRKCB,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T40276,PRKCB,INDICATI,Phase 1,Central nervous system disease,[ICD-11: 8A04-8D87]
T40276,PRKCB,INDICATI,Phase 3,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T40276,PRKCB,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T40276,PRKCB,INDICATI,Phase 3,Lymphoma,[ICD-11: 2A80-2A86]
T40276,PRKCB,INDICATI,Phase 3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T40276,PRKCB,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T40276,PRKCB,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T40276,PRKCB,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T40276,PRKCB,INDICATI,Phase 2,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T40332,ELANE,TARGETID,T40332,,
T40332,ELANE,TARGNAME,Neutrophil elastase (NE),,
T40332,ELANE,INDICATI,Investigative,Acute respiratory distress syndrome,[ICD-11: CB00]
T40332,ELANE,INDICATI,Application submitted,Anterior uveitis,[ICD-11: 9A96]
T40332,ELANE,INDICATI,Discontinued in Phase 2,Atopic eczema,[ICD-11: EA80]
T40332,ELANE,INDICATI,Phase 2,Bronchiectasis,[ICD-11: CA24]
T40332,ELANE,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T40332,ELANE,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T40332,ELANE,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T40332,ELANE,INDICATI,Discontinued in Phase 2,Emphysema,[ICD-11: CA21]
T40332,ELANE,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T40332,ELANE,INDICATI,Application submitted,Inflammatory spondyloarthritis,[ICD-11: FA92]
T40332,ELANE,INDICATI,Investigative,Injury,[ICD-11: NA00-ND5Z]
T40332,ELANE,INDICATI,Phase 4,Intrathoracic organs injury,[ICD-11: NB32]
T40332,ELANE,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T40332,ELANE,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T40332,ELANE,INDICATI,Discontinued in Phase 3,Phlegmy cough,[ICD-11: SA80-SA8Z]
T40332,ELANE,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
T40332,ELANE,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T40332,ELANE,INDICATI,Phase 3,Psoriatic arthritis,[ICD-11: FA21]
T40332,ELANE,INDICATI,Investigative,Pulmonary disease,[ICD-11: 1B10-1F85]
T40332,ELANE,INDICATI,Phase 3,Pyoderma gangrenosum,[ICD-11: EB21]
T40332,ELANE,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T40332,ELANE,INDICATI,Investigative,Sepsis,[ICD-11: 1G40-1G41]
T40332,ELANE,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T40459,IL13RA2,TARGETID,T40459,,
T40459,IL13RA2,TARGNAME,Interleukin 13 receptor alpha-2 (IL13RA2),,
T40459,IL13RA2,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T40459,IL13RA2,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
T40459,IL13RA2,INDICATI,Phase 2,Oesophagitis,[ICD-11: DA24]
,#N/A,,,,
T40474,MET,TARGETID,T40474,,
T40474,MET,TARGNAME,Proto-oncogene c-Met (MET),,
T40474,MET,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T40474,MET,INDICATI,Phase 2,Biliary tract cancer,[ICD-11: 2C17]
T40474,MET,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T40474,MET,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T40474,MET,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T40474,MET,INDICATI,Phase 3,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T40474,MET,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T40474,MET,INDICATI,Phase 1/2,Fibrosis,[ICD-11: GA14-GC01]
T40474,MET,INDICATI,Discontinued in Phase 2,Glaucoma,[ICD-11: 9C61]
T40474,MET,INDICATI,Phase 1,Head and neck cancer,[ICD-11: 2D42]
T40474,MET,INDICATI,Phase 3,Heart disease,[ICD-11: BA41-BA42]
T40474,MET,INDICATI,Phase 2,Injury,[ICD-11: NA00-ND5Z]
T40474,MET,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T40474,MET,INDICATI,Phase 1,Liver disease,[ICD-11: DB90-DB9Z]
T40474,MET,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T40474,MET,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T40474,MET,INDICATI,Phase 2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T40474,MET,INDICATI,Preclinical,Nasopharyngitis,[ICD-11: CA00]
T40474,MET,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T40474,MET,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T40474,MET,INDICATI,Phase 3,Renal cell carcinoma,[ICD-11: 2C90]
T40474,MET,INDICATI,Phase 2,Sarcoma,[ICD-11: 2A60-2C35]
T40474,MET,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T40474,MET,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T40474,MET,INDICATI,Approved,Thyroid cancer,[ICD-11: 2D10]
,#N/A,,,,
T40490,NCR1,TARGETID,T40490,,
T40490,NCR1,TARGNAME,Natural cytotoxic triggering receptor 1 (NCR1),,
T40490,NCR1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T40491,PPP2CA,TARGETID,T40491,,
T40491,PPP2CA,TARGNAME,Serine/threonine PP2A-alpha (PPP2CA),,
T40491,PPP2CA,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T40491,PPP2CA,INDICATI,Phase 2,Common warts,[ICD-11: 1E80]
T40491,PPP2CA,INDICATI,Phase 3,Molluscum contagiosum,[ICD-11: 1E76]
T40491,PPP2CA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T40492,HCV NS3,TARGETID,T40492,,
T40492,HCV NS3,TARGNAME,Hepatitis C virus NS3 helicase (HCV NS3),,
T40492,HCV NS3,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T40492,HCV NS3,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T40555,HCV NS5A,TARGETID,T40555,,
T40555,HCV NS5A,TARGNAME,Hepatitis C virus Non-structural 5A (HCV NS5A),,
T40555,HCV NS5A,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T40556,BRD4,TARGETID,T40556,,
T40556,BRD4,TARGNAME,Bromodomain-containing protein 4 (BRD4),,
T40556,BRD4,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T40556,BRD4,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T40556,BRD4,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T40556,BRD4,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T40556,BRD4,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T40556,BRD4,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T40556,BRD4,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T40556,BRD4,INDICATI,Phase 1,Testicular cancer,[ICD-11: 2C80]
,#N/A,,,,
T40628,HSD3B1; HSD3B2,TARGETID,T40628,,
T40628,HSD3B1; HSD3B2,TARGNAME,Hydroxysteroid dehydrogenase 3-beta (HSD3B),,
T40628,HSD3B1; HSD3B2,INDICATI,Investigative,Abortion,[ICD-11: JA00]
,#N/A,,,,
T40663,#N/A,TARGETID,T40663,,
T40663,#N/A,TARGNAME,Regulatory protein unspecific (RGP),,
T40663,#N/A,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
T40663,#N/A,INDICATI,Phase 3,Graft-versus-host disease,[ICD-11: 4B24]
T40663,#N/A,INDICATI,Terminated,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T40694,PLK1,TARGETID,T40694,,
T40694,PLK1,TARGNAME,Polo-like kinase 1 (PLK1),,
T40694,PLK1,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T40694,PLK1,INDICATI,Investigative,Lymphoma,[ICD-11: 2A80-2A86]
T40694,PLK1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T40694,PLK1,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T40694,PLK1,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T40694,PLK1,INDICATI,Discontinued in Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T40694,PLK1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T40694,PLK1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T40696,Stap-coc parC,TARGETID,T40696,,
T40696,Stap-coc parC,TARGNAME,Staphylococcus Topoisomerase IV (Stap-coc parC),,
T40696,Stap-coc parC,INDICATI,Phase 1,Acute upper respiratory infection,[ICD-11: CA07]
T40696,Stap-coc parC,INDICATI,Phase 3,Anaerobic bacterial infection,[ICD-11: 1A00-1A09]
T40696,Stap-coc parC,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T40696,Stap-coc parC,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T40696,Stap-coc parC,INDICATI,Phase 1,Digestive organ benign neoplasm,[ICD-11: 2E92]
T40696,Stap-coc parC,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T40696,Stap-coc parC,INDICATI,Approved,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T40696,Stap-coc parC,INDICATI,Approved,Impetigo,[ICD-11: 1B72]
T40696,Stap-coc parC,INDICATI,Phase 2,Infectious meningitis,[ICD-11: 1D01]
T40696,Stap-coc parC,INDICATI,Phase 3,Pneumonia,[ICD-11: CA40]
T40696,Stap-coc parC,INDICATI,Approved,Respiratory infection,[ICD-11: CA07-CA4Z]
T40696,Stap-coc parC,INDICATI,Approved,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T40696,Stap-coc parC,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T40730,Bact folB,TARGETID,T40730,,
T40730,Bact folB,TARGNAME,Bacterial Dihydroneopterinaldolase (Bact folB),,
T40730,Bact folB,INDICATI,Discontinued in Phase 3,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T40785,Fung FKS1,TARGETID,T40785,,
T40785,Fung FKS1,TARGNAME,Fungal Papulacandin B resistance protein 1 (Fung FKS1),,
T40785,Fung FKS1,INDICATI,Terminated,Candidosis,[ICD-11: 1F23]
T40785,Fung FKS1,INDICATI,Phase 3,Fungal infection,[ICD-11: 1F29-1F2F]
,#N/A,,,,
T40787,MTAP,TARGETID,T40787,,
T40787,MTAP,TARGNAME,S-methyl-5'-thioadenosine phosphorylase (MTAP),,
T40787,MTAP,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T40800,ATP1A1,TARGETID,T40800,,
T40800,ATP1A1,TARGNAME,Sodium pump subunit alpha-1 (ATP1A1),,
T40800,ATP1A1,INDICATI,Approved,Cardiac arrhythmia,[ICD-11: BC9Z]
T40800,ATP1A1,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T40800,ATP1A1,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T40800,ATP1A1,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T40800,ATP1A1,INDICATI,Approved,Hyperhidrosis,[ICD-11: EE00]
T40800,ATP1A1,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T40800,ATP1A1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T40800,ATP1A1,INDICATI,Approved,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T40812,PARP2,TARGETID,T40812,,
T40812,PARP2,TARGNAME,Poly [ADP-ribose] polymerase 2 (PARP2),,
T40812,PARP2,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T40812,PARP2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T40874,TIGIT,TARGETID,T40874,,
T40874,TIGIT,TARGNAME,V-set and immunoglobulin domain-containing protein 9 (TIGIT),,
T40874,TIGIT,INDICATI,Phase 2,Cervical cancer,[ICD-11: 2C77]
T40874,TIGIT,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T40874,TIGIT,INDICATI,Phase 3,Non-small-cell lung cancer,[ICD-11: 2C25]
T40874,TIGIT,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T40909,HRV P3C,TARGETID,T40909,,
T40909,HRV P3C,TARGNAME,Rhinovirus Protease 3C (HRV P3C),,
T40909,HRV P3C,INDICATI,Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T40954,XDH,TARGETID,T40954,,
T40954,XDH,TARGNAME,Xanthine dehydrogenase/oxidase (XDH),,
T40954,XDH,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T40954,XDH,INDICATI,Phase 2,Encephalopathy,[ICD-11: 8E47]
T40954,XDH,INDICATI,Phase 2,Gout,[ICD-11: FA25]
T40954,XDH,INDICATI,Phase 2/3,Heart failure,[ICD-11: BD10-BD1Z]
T40954,XDH,INDICATI,Approved,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
T40954,XDH,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T40954,XDH,INDICATI,Approved,Mineral deficiency,[ICD-11: 5B5K]
T40954,XDH,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T41003,EPAS1,TARGETID,T41003,,
T41003,EPAS1,TARGNAME,HIF2-alpha messenger RNA (EPAS1 mRNA),,
T41003,EPAS1,INDICATI,Phase 2,Adrenomedullary hyperfunction,[ICD-11: 5A75]
T41003,EPAS1,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T41003,EPAS1,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
,#N/A,,,,
T41141,CTSL,TARGETID,T41141,,
T41141,CTSL,TARGNAME,Cathepsin L (CTSL),,
T41141,CTSL,INDICATI,Patented,Alopecia,[ICD-11: ED70]
T41141,CTSL,INDICATI,Preclinical,Alzheimer disease,[ICD-11: 8A20]
T41141,CTSL,INDICATI,Patented,Aneurysm/dissection,[ICD-11: BD50]
T41141,CTSL,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T41141,CTSL,INDICATI,Patented,Bone cancer,[ICD-11: 2B5Z]
T41141,CTSL,INDICATI,Patented,Brain cancer,[ICD-11: 2A00]
T41141,CTSL,INDICATI,Patented,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T41141,CTSL,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
T41141,CTSL,INDICATI,Clinical trial,Coagulation defect,[ICD-11: 3B10]
T41141,CTSL,INDICATI,Patented,Coronavirus infection,[ICD-11: 1D92]
T41141,CTSL,INDICATI,Patented,Digestive system disease,[ICD-11: DE2Z]
T41141,CTSL,INDICATI,Patented,Henipavirus encephalitis,[ICD-11: 1D63]
T41141,CTSL,INDICATI,Patented,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T41141,CTSL,INDICATI,Patented,Multiple sclerosis,[ICD-11: 8A40]
T41141,CTSL,INDICATI,Preclinical,Osteoarthritis,[ICD-11: FA00-FA05]
T41141,CTSL,INDICATI,Patented,Psoriasis,[ICD-11: EA90]
T41141,CTSL,INDICATI,Patented,Rheumatoid arthritis,[ICD-11: FA20]
T41141,CTSL,INDICATI,Patented,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T41171,IL17D,TARGETID,T41171,,
T41171,IL17D,TARGNAME,Interleukin-27 (IL27),,
T41171,IL17D,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T41171,IL17D,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T41201,DPEP1,TARGETID,T41201,,
T41201,DPEP1,TARGNAME,Dehydropeptidase I (DPEP1),,
T41201,DPEP1,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T41202,#N/A,TARGETID,T41202,,
T41202,#N/A,TARGNAME,microRNA hsa-miR-29b (MIR29b),,
T41202,#N/A,INDICATI,Phase 2,Keloid/hypertrophic scar,[ICD-11: EE60]
,#N/A,,,,
T41239,#N/A,TARGETID,T41239,,
T41239,#N/A,TARGNAME,Hydroxyapatite (HA),,
T41239,#N/A,INDICATI,Phase 3,Calcific uremic arteriolopathy,[ICD-11: EB90]
,#N/A,,,,
T41263,TAS1R1; TAS1R2; TAS1R3,TARGETID,T41263,,
T41263,TAS1R1; TAS1R2; TAS1R3,TARGNAME,Taste receptor (TASR),,
T41263,TAS1R1; TAS1R2; TAS1R3,INDICATI,Approved,Cholera,[ICD-11: 1A00]
,#N/A,,,,
T41380,LRRC32,TARGETID,T41380,,
T41380,LRRC32,TARGNAME,Transforming growth factor beta activator LRRC32 (LRRC32),,
T41380,LRRC32,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T41515,FGFR4,TARGETID,T41515,,
T41515,FGFR4,TARGNAME,FGFR4 messenger RNA (FGFR4 mRNA),,
T41515,FGFR4,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T41515,FGFR4,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
T41515,FGFR4,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
T41515,FGFR4,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T41560,EGFR,TARGETID,T41560,,
T41560,EGFR,TARGNAME,EGFR messenger RNA (EGFR mRNA),,
T41560,EGFR,INDICATI,Phase 1/2,Head and neck cancer,[ICD-11: 2D42]
T41560,EGFR,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T41560,EGFR,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T41580,ADRA2B,TARGETID,T41580,,
T41580,ADRA2B,TARGNAME,Adrenergic receptor alpha-2B (ADRA2B),,
T41580,ADRA2B,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T41580,ADRA2B,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T41580,ADRA2B,INDICATI,Withdrawn from market,Hypertension,[ICD-11: BA00-BA04]
T41580,ADRA2B,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T41580,ADRA2B,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T41597,DGAT2,TARGETID,T41597,,
T41597,DGAT2,TARGNAME,DGAT2 messenger RNA (DGAT2 mRNA),,
T41597,DGAT2,INDICATI,Phase 1,Non-alcoholic fatty liver disease,[ICD-11: DB92]
,#N/A,,,,
T41750,GIPR,TARGETID,T41750,,
T41750,GIPR,TARGNAME,Gastric inhibitory polypeptide receptor (GIPR),,
T41750,GIPR,INDICATI,Phase 3,Obesity,[ICD-11: 5B80-5B81]
T41750,GIPR,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T41756,BKV VP1,TARGETID,T41756,,
T41756,BKV VP1,TARGNAME,BV virus Major capsid protein VP1 (BKV VP1),,
T41756,BKV VP1,INDICATI,Phase 1,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T41820,Fung ILS1,TARGETID,T41820,,
T41820,Fung ILS1,TARGNAME,Fungal Isoleucyl t-RNA synthetase (Fung ILS1),,
T41820,Fung ILS1,INDICATI,Terminated,Bacterial infection,[ICD-11: 1A00-1C4Z]
T41820,Fung ILS1,INDICATI,Phase 2,Fungal infection,[ICD-11: 1F29-1F2F]
,#N/A,,,,
T41955,TRPM8,TARGETID,T41955,,
T41955,TRPM8,TARGNAME,Long transient receptor potential channel 8 (TRPM8),,
T41955,TRPM8,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
T41955,TRPM8,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T41955,TRPM8,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T41955,TRPM8,INDICATI,Approved,Upper respiratory tract disorder,[ICD-11: CA0Z]
,#N/A,,,,
T41963,#N/A,TARGETID,T41963,,
T41963,#N/A,TARGNAME,Toll-like receptor (TLR),,
T41963,#N/A,INDICATI,Phase 1,Autoimmune disease,[ICD-11: 4A40-4A45]
T41963,#N/A,INDICATI,Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T41963,#N/A,INDICATI,Discontinued in Phase 2,Immune system disease,[ICD-11: 4A01-4B41]
T41963,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T41963,#N/A,INDICATI,Patented,Malaria,[ICD-11: 1F40-1F45]
T41963,#N/A,INDICATI,Phase 1/2,Mature B-cell lymphoma,[ICD-11: 2A85]
T41963,#N/A,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T41963,#N/A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T41963,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T42000,IL1B,TARGETID,T42000,,
T42000,IL1B,TARGNAME,Interleukin-1 beta (IL1B),,
T42000,IL1B,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T42000,IL1B,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T42000,IL1B,INDICATI,Phase 3,Gout,[ICD-11: FA25]
T42000,IL1B,INDICATI,Discontinued in Phase 1/2,Immune system disease,[ICD-11: 4A01-4B41]
T42000,IL1B,INDICATI,Approved,Mineral excesses,[ICD-11: 5B91]
T42000,IL1B,INDICATI,Approved,Monogenic autoinflammatory syndrome,[ICD-11: 4A60]
T42000,IL1B,INDICATI,Preclinical,Motor neuron disease,[ICD-11: 8B60]
T42000,IL1B,INDICATI,Approved,Osteoarthritis,[ICD-11: FA00-FA05]
T42000,IL1B,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T42000,IL1B,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T42000,IL1B,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T42000,IL1B,INDICATI,Phase 3,Type 2 diabetes mellitus,[ICD-11: 5A11]
T42000,IL1B,INDICATI,Phase 2,Urticaria,[ICD-11: EB00-EB05]
T42000,IL1B,INDICATI,Phase 2,Vasculitis,[ICD-11: 4A44]
,#N/A,,,,
T42048,BRD3,TARGETID,T42048,,
T42048,BRD3,TARGNAME,Bromodomain-containing protein 3 (BRD3),,
T42048,BRD3,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T42048,BRD3,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T42065,GNE,TARGETID,T42065,,
T42065,GNE,TARGNAME,N-acetylmannosamine kinase (GNE),,
T42065,GNE,INDICATI,Phase 1,Muscle disorder,[ICD-11: FB32-FB3Z]
,#N/A,,,,
T42157,MAP3K19,TARGETID,T42157,,
T42157,MAP3K19,TARGNAME,SPS1/STE20-related protein kinase YSK4 (YSK4),,
T42157,MAP3K19,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T42354,Bact sigA,TARGETID,T42354,,
T42354,Bact sigA,TARGNAME,Bacterial RNA polymerase sigma factor SigA (Bact sigA),,
T42354,Bact sigA,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
T42354,Bact sigA,INDICATI,Phase 3,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T42392,GRIA2,TARGETID,T42392,,
T42392,GRIA2,TARGNAME,Glutamate receptor AMPA 2 (GRIA2),,
T42392,GRIA2,INDICATI,Approved,Neuropathy,[ICD-11: 8C0Z]
T42392,GRIA2,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T42446,GABBR1; GABBR2,TARGETID,T42446,,
T42446,GABBR1; GABBR2,TARGNAME,Gamma-aminobutyric acid B receptor (GABBR),,
T42446,GABBR1; GABBR2,INDICATI,Investigative,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T42446,GABBR1; GABBR2,INDICATI,Phase 2,Autism spectrum disorder,[ICD-11: 6A02]
T42446,GABBR1; GABBR2,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T42446,GABBR1; GABBR2,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T42446,GABBR1; GABBR2,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T42446,GABBR1; GABBR2,INDICATI,Phase 3,Fragile X chromosome,[ICD-11: LD55]
T42446,GABBR1; GABBR2,INDICATI,Discontinued in Phase 2,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T42446,GABBR1; GABBR2,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T42446,GABBR1; GABBR2,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T42446,GABBR1; GABBR2,INDICATI,Approved,Narcolepsy,[ICD-11: 7A20]
T42446,GABBR1; GABBR2,INDICATI,Discontinued in Phase 3,Newborn muscle tone disorder,[ICD-11: KB08]
T42446,GABBR1; GABBR2,INDICATI,Investigative,Nicotine use disorder,[ICD-11: 6C4A]
T42446,GABBR1; GABBR2,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T42446,GABBR1; GABBR2,INDICATI,Investigative,Psychoactive substances use disorder,[ICD-11: 6C4G]
T42446,GABBR1; GABBR2,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T42446,GABBR1; GABBR2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T42446,GABBR1; GABBR2,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T42521,Bact stxII,TARGETID,T42521,,
T42521,Bact stxII,TARGNAME,Bacterial Shiga toxin 2 subunit B (Bact stxII),,
T42521,Bact stxII,INDICATI,Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
T42521,Bact stxII,INDICATI,Phase 2,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
,#N/A,,,,
T42658,USP7,TARGETID,T42658,,
T42658,USP7,TARGNAME,Herpesvirus ubiquitin-specific protease (HAUSP),,
T42658,USP7,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
T42658,USP7,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T42724,KCNN4,TARGETID,T42724,,
T42724,KCNN4,TARGNAME,Calcium-activated potassium channel KCa3.1 (KCNN4),,
T42724,KCNN4,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T42724,KCNN4,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T42724,KCNN4,INDICATI,Investigative,Conjunctiva disorder,[ICD-11: 9A60]
T42724,KCNN4,INDICATI,Discontinued in Phase 2,Neutropenia,[ICD-11: 4B00]
,#N/A,,,,
T42748,#N/A,TARGETID,T42748,,
T42748,#N/A,TARGNAME,Serotoninnorepinephrinedopamine reuptake (SNDR),,
T42748,#N/A,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T42748,#N/A,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T42748,#N/A,INDICATI,Phase 3,Binge eating disorder,[ICD-11: 6B82]
T42748,#N/A,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T42748,#N/A,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T42748,#N/A,INDICATI,Phase 1,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T42748,#N/A,INDICATI,Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T42748,#N/A,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T42748,#N/A,INDICATI,Phase 1,Pulmonary hypertension,[ICD-11: BB01]
T42748,#N/A,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T42760,RPS6KB2,TARGETID,T42760,,
T42760,RPS6KB2,TARGNAME,Ribosomal protein S6 kinase beta-2 (RPS6KB2),,
T42760,RPS6KB2,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T42822,FECH,TARGETID,T42822,,
T42822,FECH,TARGNAME,Ferrochelatase (FECH),,
T42822,FECH,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T42822,FECH,INDICATI,Approved,Peroxisomal disease,[ICD-11: 5C57]
T42822,FECH,INDICATI,Approved,Synthesis disorder,[ICD-11: 5C52-5C59]
,#N/A,,,,
T42854,MAGEA1,TARGETID,T42854,,
T42854,MAGEA1,TARGNAME,Melanoma-associated antigen 1 (MAGEA1),,
T42854,MAGEA1,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T42854,MAGEA1,INDICATI,Discontinued in Phase 2,Melanoma,[ICD-11: 2C30]
,#N/A,,,,
T42882,Pseudo pslG,TARGETID,T42882,,
T42882,Pseudo pslG,TARGNAME,Pseudomonas Psl exopolysaccharide (Pseudo pslG),,
T42882,Pseudo pslG,INDICATI,Phase 1,Glanders,[ICD-11: 1B92]
T42882,Pseudo pslG,INDICATI,Phase 2,Medical/surgical procedure injury,[ICD-11: PK80-PK81]
,#N/A,,,,
T42928,FGF21,TARGETID,T42928,,
T42928,FGF21,TARGNAME,Fibroblast growth factor-21 (FGF21),,
T42928,FGF21,INDICATI,Phase 3,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T42928,FGF21,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T42974,GAS6,TARGETID,T42974,,
T42974,GAS6,TARGNAME,AXL receptor tyrosine kinase ligand (GAS6),,
T42974,GAS6,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T42974,GAS6,INDICATI,Phase 2,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T43025,#N/A,TARGETID,T43025,,
T43025,#N/A,TARGNAME,Alpha-crystallin (CRYA),,
T43025,#N/A,INDICATI,Preclinical,Mycobacterium infection,[ICD-11: 1B10-1B21]
,#N/A,,,,
T43115,PTPRC,TARGETID,T43115,,
T43115,PTPRC,TARGNAME,Leukocyte common antigen (PTPRC),,
T43115,PTPRC,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T43115,PTPRC,INDICATI,Phase 1,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T43115,PTPRC,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
T43115,PTPRC,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T43115,PTPRC,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T43115,PTPRC,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T43115,PTPRC,INDICATI,Phase 1,Transplant rejection,[ICD-11: NE84]
T43115,PTPRC,INDICATI,Phase 3,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T43189,#N/A,TARGETID,T43189,,
T43189,#N/A,TARGNAME,Tubulin (TUB),,
T43189,#N/A,INDICATI,Discontinued in Phase 3,Bladder cancer,[ICD-11: 2C94]
T43189,#N/A,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T43189,#N/A,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T43189,#N/A,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T43189,#N/A,INDICATI,Phase 1,Epidermal dysplasias,[ICD-11: EK90]
T43189,#N/A,INDICATI,Approved,Gout,[ICD-11: FA25]
T43189,#N/A,INDICATI,Discontinued in Phase 1,Immune system disease,[ICD-11: 4A01-4B41]
T43189,#N/A,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T43189,#N/A,INDICATI,Discontinued in Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T43189,#N/A,INDICATI,Phase 2,Sarcoma,[ICD-11: 2A60-2C35]
T43189,#N/A,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T43206,RORA,TARGETID,T43206,,
T43206,RORA,TARGNAME,Nuclear receptor ROR-alpha (RORA),,
T43206,RORA,INDICATI,Preclinical,Liver cancer,[ICD-11: 2C12]
T43206,RORA,INDICATI,Preclinical,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T43332,F7,TARGETID,T43332,,
T43332,F7,TARGNAME,Coagulation factor VII (F7),,
T43332,F7,INDICATI,Phase 3,Bleeding disorder,[ICD-11: GA20-GA21]
T43332,F7,INDICATI,Investigative,Christmas disease,[ICD-11: 3B11]
T43332,F7,INDICATI,Approved,Coagulation defect,[ICD-11: 3B10]
T43332,F7,INDICATI,Discontinued in Phase 2,Colorectal cancer,[ICD-11: 2B91]
T43332,F7,INDICATI,Phase 1/2,Inherited coagulation factor deficiency,[ICD-11: 3B14]
,#N/A,,,,
T43415,#N/A,TARGETID,T43415,,
T43415,#N/A,TARGNAME,Tyrosine-protein kinase (PTK),,
T43415,#N/A,INDICATI,Phase 2,Acquired hypomelanotic disorder,[ICD-11: ED63]
T43415,#N/A,INDICATI,Terminated,Acute diabete complication,[ICD-11: 5A2Y]
T43415,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T43415,#N/A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T43415,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T43415,#N/A,INDICATI,Phase 2,Cystic/dysplastic kidney disease,[ICD-11: GB8Y]
T43415,#N/A,INDICATI,Phase 2,Eczema,[ICD-11: EA80-EA89]
T43415,#N/A,INDICATI,Phase 3,Gastrointestinal stromal tumour,[ICD-11: 2B5B]
T43415,#N/A,INDICATI,Discontinued in Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T43415,#N/A,INDICATI,Terminated,Low bone mass disorder,[ICD-11: FB83]
T43415,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T43415,#N/A,INDICATI,Phase 3,Metastatic digestive system neoplasm,[ICD-11: 2D8Y]
T43415,#N/A,INDICATI,Phase 2,Metastatic meninges neoplasm,[ICD-11: 2D51]
T43415,#N/A,INDICATI,Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T43415,#N/A,INDICATI,Phase 3,Motor neuron disease,[ICD-11: 8B60]
T43415,#N/A,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T43415,#N/A,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T43415,#N/A,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T43415,#N/A,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T43415,#N/A,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T43415,#N/A,INDICATI,Phase 1,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T43658,HAO1,TARGETID,T43658,,
T43658,HAO1,TARGNAME,HAO1 messenger RNA (HAO1 mRNA),,
T43658,HAO1,INDICATI,Approved,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
,#N/A,,,,
T43718,TLR5,TARGETID,T43718,,
T43718,TLR5,TARGNAME,Toll-like receptor 5 (TLR5),,
T43718,TLR5,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T43718,TLR5,INDICATI,Phase 2,Radiation effect,[ICD-11: NF00]
T43718,TLR5,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T43721,HSD11B2,TARGETID,T43721,,
T43721,HSD11B2,TARGNAME,Corticosteroid 11-beta-dehydrogenase 2 (HSD11B2),,
T43721,HSD11B2,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T43739,SCN10A,TARGETID,T43739,,
T43739,SCN10A,TARGNAME,Voltage-gated sodium channel alpha Nav1.8 (SCN10A),,
T43739,SCN10A,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T43739,SCN10A,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T43739,SCN10A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T43739,SCN10A,INDICATI,Discontinued in Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T43739,SCN10A,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T43739,SCN10A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T43739,SCN10A,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T43739,SCN10A,INDICATI,Approved,Sensation disturbance,[ICD-11: MB40]
T43739,SCN10A,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T43760,#N/A,TARGETID,T43760,,
T43760,#N/A,TARGNAME,Thyroid hormone receptor (THR),,
T43760,#N/A,INDICATI,Phase 1,Dementia,[ICD-11: 6D80-6D8Z]
T43760,#N/A,INDICATI,Phase 1,Dyslipidemia,[ICD-11: 5C80-5C81]
T43760,#N/A,INDICATI,Terminated,Inborn lipid metabolism error,[ICD-11: 5C52]
T43760,#N/A,INDICATI,Phase 1,Schizophrenia,[ICD-11: 6A20]
T43760,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T43902,#N/A,TARGETID,T43902,,
T43902,#N/A,TARGNAME,Histamine release (His rele),,
T43902,#N/A,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
,#N/A,,,,
T43920,#N/A,TARGETID,T43920,,
T43920,#N/A,TARGNAME,Carbonic anhydrase (CA),,
T43920,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T43920,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T43920,#N/A,INDICATI,Patented,Cas mediated disorder,[ICD-11: N.A.]
T43920,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T43920,#N/A,INDICATI,Phase 3,Obesity,[ICD-11: 5B80-5B81]
T43920,#N/A,INDICATI,Approved,Seborrhoeic dermatitis,[ICD-11: EA81]
T43920,#N/A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T43980,ILDR2,TARGETID,T43980,,
T43980,ILDR2,TARGNAME,Ig-like domain-containing receptor 2 (ILDR2),,
T43980,ILDR2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T44008,#N/A,TARGETID,T44008,,
T44008,#N/A,TARGNAME,cAMP formation (cAMP form),,
T44008,#N/A,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
,#N/A,,,,
T44057,AQP1,TARGETID,T44057,,
T44057,AQP1,TARGNAME,Aquaporin-1 (AQP1),,
T44057,AQP1,INDICATI,Phase 1/2,Lips/oral mucosa miscellaneous disorder,[ICD-11: DA02]
,#N/A,,,,
T44068,ADRB1,TARGETID,T44068,,
T44068,ADRB1,TARGNAME,Adrenergic receptor beta-1 (ADRB1),,
T44068,ADRB1,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T44068,ADRB1,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T44068,ADRB1,INDICATI,Terminated,Angina pectoris,[ICD-11: BA40]
T44068,ADRB1,INDICATI,Approved,Asthma,[ICD-11: CA23]
T44068,ADRB1,INDICATI,Approved,Cardiac arrhythmia,[ICD-11: BC9Z]
T44068,ADRB1,INDICATI,Approved,Central and peripheral nervous disease,[ICD-11: 8A04-8E7Z]
T44068,ADRB1,INDICATI,Approved,Circulatory system disease,[ICD-11: BE2Z]
T44068,ADRB1,INDICATI,Approved,Conduction disorder,[ICD-11: BC63]
T44068,ADRB1,INDICATI,Approved,Coronary atherosclerosis,[ICD-11: BA80]
T44068,ADRB1,INDICATI,Phase 1/2,Diabetic foot ulcer,[ICD-11: BD54]
T44068,ADRB1,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T44068,ADRB1,INDICATI,Withdrawn from market,Genetic cardiac arrhythmia,[ICD-11: BC65]
T44068,ADRB1,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T44068,ADRB1,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T44068,ADRB1,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T44068,ADRB1,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T44068,ADRB1,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T44068,ADRB1,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T44068,ADRB1,INDICATI,Approved,Sepsis,[ICD-11: 1G40-1G41]
T44068,ADRB1,INDICATI,Approved,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T44068,ADRB1,INDICATI,Approved,Ventricular tachyarrhythmia,[ICD-11: BC71]
,#N/A,,,,
T44141,ANGPT1,TARGETID,T44141,,
T44141,ANGPT1,TARGNAME,Angiopoietin-1 (ANGPT1),,
T44141,ANGPT1,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T44141,ANGPT1,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T44141,ANGPT1,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T44141,ANGPT1,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T44141,ANGPT1,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T44141,ANGPT1,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T44141,ANGPT1,INDICATI,Preclinical,Sexual dysfunction,[ICD-11: HA00-HA01]
T44141,ANGPT1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T44282,ALDH2,TARGETID,T44282,,
T44282,ALDH2,TARGNAME,Mitochondrial aldehyde dehydrogenase (ALDH2),,
T44282,ALDH2,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T44282,ALDH2,INDICATI,Phase 2,Cerebral ischaemia,[ICD-11: 8B1Z]
T44282,ALDH2,INDICATI,Investigative,Substance abuse,[ICD-11: 6C40]
T44282,ALDH2,INDICATI,Phase 1,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T44351,#N/A,TARGETID,T44351,,
T44351,#N/A,TARGNAME,Cannabinoid receptor (CB),,
T44351,#N/A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T44351,#N/A,INDICATI,Approved,Epileptic encephalopathy,[ICD-11: 8A62]
T44351,#N/A,INDICATI,Phase 3,Tic disorder,[ICD-11: 8A05]
,#N/A,,,,
T44458,CDK9,TARGETID,T44458,,
T44458,CDK9,TARGNAME,Cyclin-dependent kinase 9 (CDK9),,
T44458,CDK9,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T44458,CDK9,INDICATI,Discontinued in Phase 2,Lung cancer,[ICD-11: 2C25]
T44458,CDK9,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T44458,CDK9,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T44458,CDK9,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T44458,CDK9,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
T44458,CDK9,INDICATI,Phase 1,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T44458,CDK9,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T44479,GJA1,TARGETID,T44479,,
T44479,GJA1,TARGNAME,Gap junction alpha-1 protein (GJA1),,
T44479,GJA1,INDICATI,Phase 3,Diabetic foot ulcer,[ICD-11: BD54]
T44479,GJA1,INDICATI,Phase 1/2,Osteosarcoma,[ICD-11: 2B51]
T44479,GJA1,INDICATI,Phase 3,Radiation effect,[ICD-11: NF00]
T44479,GJA1,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T44479,GJA1,INDICATI,Phase 3,Skin postprocedural disorder,[ICD-11: EL8Y]
T44479,GJA1,INDICATI,Phase 2,Skin surgical scar,[ICD-11: EL50]
T44479,GJA1,INDICATI,Phase 1,Spine/trunk injury,[ICD-11: ND51]
,#N/A,,,,
T44513,CEACAM6,TARGETID,T44513,,
T44513,CEACAM6,TARGNAME,Normal cross-reacting antigen (CD66c),,
T44513,CEACAM6,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T44589,CSF2RB,TARGETID,T44589,,
T44589,CSF2RB,TARGNAME,Interleukin 3 receptor (CSF2RB),,
T44589,CSF2RB,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T44589,CSF2RB,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T44589,CSF2RB,INDICATI,Phase 2,Immune system disease,[ICD-11: 4A01-4B41]
T44589,CSF2RB,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T44589,CSF2RB,INDICATI,Phase 1/2,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T44614,Malaria CPF2,TARGETID,T44614,,
T44614,Malaria CPF2,TARGNAME,Plasmodium Cysteine protease falcipain-2 (Malaria CPF2),,
T44614,Malaria CPF2,INDICATI,Terminated,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T44682,IL22,TARGETID,T44682,,
T44682,IL22,TARGNAME,Interleukin-22 (IL22),,
T44682,IL22,INDICATI,Phase 2,Diabetic foot ulcer,[ICD-11: BD54]
T44682,IL22,INDICATI,Phase 2,Graft-versus-host disease,[ICD-11: 4B24]
T44682,IL22,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T44682,IL22,INDICATI,Phase 1,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T44684,NOTCH3,TARGETID,T44684,,
T44684,NOTCH3,TARGNAME,Notch-3 receptor (NOTCH3),,
T44684,NOTCH3,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T44684,NOTCH3,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T44771,TGFB2,TARGETID,T44771,,
T44771,TGFB2,TARGNAME,TGF beta-2 messenger RNA (TGFB2 mRNA),,
T44771,TGFB2,INDICATI,Phase 2/3,Brain cancer,[ICD-11: 2A00]
T44771,TGFB2,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T44771,TGFB2,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T44771,TGFB2,INDICATI,Phase 2/3,Melanoma,[ICD-11: 2C30]
T44771,TGFB2,INDICATI,Phase 2/3,Neuroendocrine carcinoma,[ICD-11: 2C34]
T44771,TGFB2,INDICATI,Phase 2/3,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T44818,TDO2,TARGETID,T44818,,
T44818,TDO2,TARGNAME,"Tryptophan 2,3-dioxygenase (TDO)",,
T44818,TDO2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T44861,PRKCD,TARGETID,T44861,,
T44861,PRKCD,TARGNAME,Protein kinase C delta (PRKCD),,
T44861,PRKCD,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T44861,PRKCD,INDICATI,Phase 1/2,Myocardial infarction,[ICD-11: BA41-BA43]
,#N/A,,,,
T44862,HCV UL83,TARGETID,T44862,,
T44862,HCV UL83,TARGNAME,Cytomegalovirus 65kDa phosphoprotein (HCV UL83),,
T44862,HCV UL83,INDICATI,Phase 2,Cytomegaloviral disease,[ICD-11: 1D82]
,#N/A,,,,
T44916,EED,TARGETID,T44916,,
T44916,EED,TARGNAME,Embryonic ectoderm development protein (EED),,
T44916,EED,INDICATI,Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T44916,EED,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T44919,GCG,TARGETID,T44919,,
T44919,GCG,TARGNAME,Glucagon (GCG),,
T44919,GCG,INDICATI,Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
T44919,GCG,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T44919,GCG,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
T44919,GCG,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T44919,GCG,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T45074,CRAT,TARGETID,T45074,,
T45074,CRAT,TARGNAME,Carnitine acyltransferase (CRAT),,
T45074,CRAT,INDICATI,Discontinued in Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T45074,CRAT,INDICATI,Terminated,Ischemia,[ICD-11: 8B10-8B11]
,#N/A,,,,
T45083,#N/A,TARGETID,T45083,,
T45083,#N/A,TARGNAME,Tryptophan 5-hydroxylase (TPH),,
T45083,#N/A,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
,#N/A,,,,
T45086,TREM2,TARGETID,T45086,,
T45086,TREM2,TARGNAME,Triggering receptor expressed on monocytes 2 (TREM2),,
T45086,TREM2,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T45151,SERPINE1; SERPINB2; SERPINA5,TARGETID,T45151,,
T45151,SERPINE1; SERPINB2; SERPINA5,TARGNAME,Plasminogen activator inhibitor (PAI),,
T45151,SERPINE1; SERPINB2; SERPINA5,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T45151,SERPINE1; SERPINB2; SERPINA5,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
T45151,SERPINE1; SERPINB2; SERPINA5,INDICATI,Terminated,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T45182,GRN,TARGETID,T45182,,
T45182,GRN,TARGNAME,Progranulin (PGRN),,
T45182,GRN,INDICATI,Phase 1/2,Frontotemporal dementia,ICD-11: 6D83
,#N/A,,,,
T45196,#N/A,TARGETID,T45196,,
T45196,#N/A,TARGNAME,Angiogenesis (AGG),,
T45196,#N/A,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T45196,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T45228,MBOAT4,TARGETID,T45228,,
T45228,MBOAT4,TARGNAME,Ghrelin O acyltransferase (GOAT),,
T45228,MBOAT4,INDICATI,Patented,Obesity,[ICD-11: 5B80-5B81]
T45228,MBOAT4,INDICATI,Patented,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T45262,CRHR1,TARGETID,T45262,,
T45262,CRHR1,TARGNAME,Corticotropin-releasing factor receptor 1 (CRHR1),,
T45262,CRHR1,INDICATI,Phase 2,Adrenogenital disorder,[ICD-11: 5A71]
T45262,CRHR1,INDICATI,Phase 2/3,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T45262,CRHR1,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T45262,CRHR1,INDICATI,Discontinued in Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T45262,CRHR1,INDICATI,Discontinued in Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T45262,CRHR1,INDICATI,Approved,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
T45262,CRHR1,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T45287,DNPEP,TARGETID,T45287,,
T45287,DNPEP,TARGNAME,Aspartyl aminopeptidase (DNPEP),,
T45287,DNPEP,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T45299,PLAT,TARGETID,T45299,,
T45299,PLAT,TARGNAME,Tissue-type plasminogen activator (PLAT),,
T45299,PLAT,INDICATI,Approved,Bleeding disorder,[ICD-11: GA20-GA21]
T45299,PLAT,INDICATI,Approved,Procedure injury,[ICD-11: NE81]
,#N/A,,,,
T45457,#N/A,TARGETID,T45457,,
T45457,#N/A,TARGNAME,Melanocortin receptor (MCR),,
T45457,#N/A,INDICATI,Investigative,Sexual dysfunction,[ICD-11: HA00-HA01]
T45457,#N/A,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T45516,#N/A,TARGETID,T45516,,
T45516,#N/A,TARGNAME,Cyclin D1 synthesis (CCND1 synthesis),,
T45516,#N/A,INDICATI,Phase 2,Neutropenia,[ICD-11: 4B00]
,#N/A,,,,
T45591,NPM1,TARGETID,T45591,,
T45591,NPM1,TARGNAME,Nucleophosmin (NPM1),,
T45591,NPM1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T45593,MAPT,TARGETID,T45593,,
T45593,MAPT,TARGNAME,Microtubule-associated protein tau (MAPT),,
T45593,MAPT,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T45593,MAPT,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T45593,MAPT,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T45593,MAPT,INDICATI,Phase 2,Choreiform disorder,[ICD-11: 8A01]
T45593,MAPT,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T45593,MAPT,INDICATI,Investigative,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T45593,MAPT,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T45596,#N/A,TARGETID,T45596,,
T45596,#N/A,TARGNAME,JNK signaling pathway (JNK pathway),,
T45596,#N/A,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
,#N/A,,,,
T45597,#N/A,TARGETID,T45597,,
T45597,#N/A,TARGNAME,Ribosomal protein S6 kinase (S6K),,
T45597,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T45598,#N/A,TARGETID,T45598,,
T45598,#N/A,TARGNAME,Interferon alpha (IFNA),,
T45598,#N/A,INDICATI,Phase 2,Behcet disease,[ICD-11: 4A62]
T45598,#N/A,INDICATI,Phase 1,Bladder cancer,[ICD-11: 2C94]
T45598,#N/A,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T45598,#N/A,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T45598,#N/A,INDICATI,Terminated,Head and neck cancer,[ICD-11: 2D42]
T45598,#N/A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T45598,#N/A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T45598,#N/A,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T45598,#N/A,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T45598,#N/A,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T45598,#N/A,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T45598,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T45612,CD276,TARGETID,T45612,,
T45612,CD276,TARGNAME,B7 homolog 3 (CD276),,
T45612,CD276,INDICATI,Phase 2/3,Adrenal cancer,[ICD-11: 2D11]
T45612,CD276,INDICATI,Phase 2/3,Brain cancer,[ICD-11: 2A00]
T45612,CD276,INDICATI,Phase 1,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T45612,CD276,INDICATI,Phase 1/2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T45612,CD276,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T45612,CD276,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T45674,TMEM97,TARGETID,T45674,,
T45674,TMEM97,TARGNAME,Sigma intracellular receptor 2 (TMEM97),,
T45674,TMEM97,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T45674,TMEM97,INDICATI,Preclinical,Melanoma,[ICD-11: 2C30]
T45674,TMEM97,INDICATI,Preclinical,Pancreatic cancer,[ICD-11: 2C10]
T45674,TMEM97,INDICATI,Preclinical,Prostate cancer,[ICD-11: 2C82]
T45674,TMEM97,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T45737,FCAR,TARGETID,T45737,,
T45737,FCAR,TARGNAME,Immunoglobulin alpha Fc receptor (FCAR),,
T45737,FCAR,INDICATI,Discontinued in Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T45758,CD40,TARGETID,T45758,,
T45758,CD40,TARGNAME,CD40L receptor (CD40),,
T45758,CD40,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T45758,CD40,INDICATI,Phase 1,Crohn disease,[ICD-11: DD70]
T45758,CD40,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T45758,CD40,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T45758,CD40,INDICATI,Investigative,Mature B-cell leukaemia,[ICD-11: 2A82]
T45758,CD40,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T45758,CD40,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T45758,CD40,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T45758,CD40,INDICATI,Phase 2,Myasthenia gravis,[ICD-11: 8C6Y]
T45758,CD40,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T45758,CD40,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T45758,CD40,INDICATI,Phase 2,Sjogren syndrome,[ICD-11: 4A43]
T45758,CD40,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T45758,CD40,INDICATI,Phase 1,Thrombocytopenia,[ICD-11: 3B64]
T45758,CD40,INDICATI,Phase 2,Thyrotoxicosis,[ICD-11: 5A02]
T45758,CD40,INDICATI,Phase 2,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T45760,HRSV L,TARGETID,T45760,,
T45760,HRSV L,TARGNAME,HRSV RNA-directed RNA polymerase L (HRSV L),,
T45760,HRSV L,INDICATI,Phase 1,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T45968,RNF43,TARGETID,T45968,,
T45968,RNF43,TARGNAME,RING finger protein 43 (RNF43),,
T45968,RNF43,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
,#N/A,,,,
T45993,#N/A,TARGETID,T45993,,
T45993,#N/A,TARGNAME,Calcium channel unspecific (CaC),,
T45993,#N/A,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T45993,#N/A,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T45993,#N/A,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T45993,#N/A,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T45993,#N/A,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T45993,#N/A,INDICATI,Terminated,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T45993,#N/A,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T45993,#N/A,INDICATI,Discontinued in Phase 3,Colorectal cancer,[ICD-11: 2B91]
T45993,#N/A,INDICATI,Approved,Coronary vasospastic disease,[ICD-11: BA85]
T45993,#N/A,INDICATI,Phase 1,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T45993,#N/A,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T45993,#N/A,INDICATI,Phase 2,Genetic cardiac arrhythmia,[ICD-11: BC65]
T45993,#N/A,INDICATI,Discontinued in Phase 1,Glaucoma,[ICD-11: 9C61]
T45993,#N/A,INDICATI,Preclinical,Heart failure,[ICD-11: BD10-BD1Z]
T45993,#N/A,INDICATI,Phase 3,Herpes simplex infection,[ICD-11: 1F00]
T45993,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T45993,#N/A,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T45993,#N/A,INDICATI,Discontinued in Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T45993,#N/A,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T45993,#N/A,INDICATI,Terminated,Pancreatic internal secretion disorder,[ICD-11: 5A4Y]
T45993,#N/A,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T45993,#N/A,INDICATI,Phase 1,Sarcoma,[ICD-11: 2A60-2C35]
T45993,#N/A,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T45993,#N/A,INDICATI,Discontinued in Phase 2,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T46040,F11,TARGETID,T46040,,
T46040,F11,TARGNAME,Coagulation factor XI (F11),,
T46040,F11,INDICATI,Phase 3,Cerebral ischaemic stroke,[ICD-11: 8B11]
T46040,F11,INDICATI,Phase 1,Chronic kidney disease,[ICD-11: GB61]
T46040,F11,INDICATI,IND submitted,Clotting disorder,ICD-11: 3B4Z
T46040,F11,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T46040,F11,INDICATI,Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T46052,LAMP2,TARGETID,T46052,,
T46052,LAMP2,TARGNAME,Lysosome-associated membrane glycoprotein 2 (LAMP2),,
T46052,LAMP2,INDICATI,Phase 1,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
,#N/A,,,,
T46084,TNFSF10,TARGETID,T46084,,
T46084,TNFSF10,TARGNAME,TNF related apoptosis inducing ligand (TNFSF10),,
T46084,TNFSF10,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T46084,TNFSF10,INDICATI,Terminated,Colorectal cancer,[ICD-11: 2B91]
T46084,TNFSF10,INDICATI,Terminated,Lung cancer,[ICD-11: 2C25]
T46084,TNFSF10,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T46084,TNFSF10,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T46084,TNFSF10,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T46128,PMEL,TARGETID,T46128,,
T46128,PMEL,TARGNAME,Melanocytes lineage-specific antigen GP100 (PMEL),,
T46128,PMEL,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T46128,PMEL,INDICATI,Approved,Stomach cancer,ICD-11: 2B72
,#N/A,,,,
T46185,CHRM2,TARGETID,T46185,,
T46185,CHRM2,TARGNAME,Muscarinic acetylcholine receptor M2 (CHRM2),,
T46185,CHRM2,INDICATI,Phase 2,Abnormal micturition,[ICD-11: MF50]
T46185,CHRM2,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T46185,CHRM2,INDICATI,Approved,Asthma,[ICD-11: CA23]
T46185,CHRM2,INDICATI,Terminated,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T46185,CHRM2,INDICATI,Discontinued in Phase 2,Functional bladder disorder,[ICD-11: GC50]
T46185,CHRM2,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T46185,CHRM2,INDICATI,Discontinued in Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T46185,CHRM2,INDICATI,Approved,Muscle disorder,[ICD-11: FB32-FB3Z]
T46185,CHRM2,INDICATI,Discontinued in Phase 1,Parkinsonism,[ICD-11: 8A00]
T46185,CHRM2,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T46185,CHRM2,INDICATI,Approved,Respiratory system disease,[ICD-11: CB40-CB7Z]
T46185,CHRM2,INDICATI,Approved,Sebaceous gland disorder,[ICD-11: ED91]
,#N/A,,,,
T46208,PMEL,TARGETID,T46208,,
T46208,PMEL,TARGNAME,Gp100[209-217] peptide (PMEL),,
T46208,PMEL,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
,#N/A,,,,
T46216,BRD9,TARGETID,T46216,,
T46216,BRD9,TARGNAME,Bromodomain-containing protein 9 (BRD9),,
T46216,BRD9,INDICATI,Investigative,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T46245,QPCT,TARGETID,T46245,,
T46245,QPCT,TARGNAME,Glutaminyl cyclase (QPCT),,
T46245,QPCT,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
,#N/A,,,,
T46263,SLC3A2,TARGETID,T46263,,
T46263,SLC3A2,TARGNAME,Lymphocyte activation antigen 4F2 (SLC3A2),,
T46263,SLC3A2,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T46360,SIGMAR1,TARGETID,T46360,,
T46360,SIGMAR1,TARGNAME,Opioid receptor sigma 1 (OPRS1),,
T46360,SIGMAR1,INDICATI,Terminated,Abnormal micturition,[ICD-11: MF50]
T46360,SIGMAR1,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T46360,SIGMAR1,INDICATI,Terminated,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T46360,SIGMAR1,INDICATI,Phase 2,Bulimia nervosa,[ICD-11: 6B81]
T46360,SIGMAR1,INDICATI,Withdrawn from market,Cataract,[ICD-11: 9B10]
T46360,SIGMAR1,INDICATI,Phase 1,Central nervous system disease,[ICD-11: 8A04-8D87]
T46360,SIGMAR1,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T46360,SIGMAR1,INDICATI,Approved,Cough,[ICD-11: MD12]
T46360,SIGMAR1,INDICATI,Phase 1,Cystic fibrosis,[ICD-11: CA25]
T46360,SIGMAR1,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T46360,SIGMAR1,INDICATI,Terminated,Dermal/subcutaneous connective tissue atrophy/degeneration,[ICD-11: EE40]
T46360,SIGMAR1,INDICATI,Phase 1,Epileptic encephalopathy,[ICD-11: 8A62]
T46360,SIGMAR1,INDICATI,Phase 1,Frontotemporal dementia,ICD-11: 6D83
T46360,SIGMAR1,INDICATI,Phase 1,Immune system disease,[ICD-11: 4A01-4B41]
T46360,SIGMAR1,INDICATI,Phase 1,Intellectual development disorder,[ICD-11: LD90]
T46360,SIGMAR1,INDICATI,Investigative,Intracranial injury,[ICD-11: NA07]
T46360,SIGMAR1,INDICATI,Preclinical,Melanoma,[ICD-11: 2C30]
T46360,SIGMAR1,INDICATI,Phase 1,Mild neurocognitive disorder,[ICD-11: 6D71]
T46360,SIGMAR1,INDICATI,Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T46360,SIGMAR1,INDICATI,Phase 2,Neurobehavioral disorder,[ICD-11: 8A00-8A0Z]
T46360,SIGMAR1,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T46360,SIGMAR1,INDICATI,Preclinical,Pancreatic cancer,[ICD-11: 2C10]
T46360,SIGMAR1,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T46360,SIGMAR1,INDICATI,Discontinued in Phase 2,Peptic ulcer,[ICD-11: DA61]
T46360,SIGMAR1,INDICATI,Preclinical,Prostate cancer,[ICD-11: 2C82]
T46360,SIGMAR1,INDICATI,Investigative,Psychoactive substances use disorder,[ICD-11: 6C4G]
T46360,SIGMAR1,INDICATI,Discontinued in Phase 3,Psychotic disorder,[ICD-11: 6A20-6A25]
T46360,SIGMAR1,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
T46360,SIGMAR1,INDICATI,Phase 1,Sexual dysfunction,[ICD-11: HA00-HA01]
T46360,SIGMAR1,INDICATI,Phase 2,Somnolence,[ICD-11: MG42]
,#N/A,,,,
T46365,CDC25B,TARGETID,T46365,,
T46365,CDC25B,TARGNAME,M-phase inducer phosphatase 2 (MPIP2),,
T46365,CDC25B,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T46365,CDC25B,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T46365,CDC25B,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T46456,RXRG,TARGETID,T46456,,
T46456,RXRG,TARGNAME,Retinoic acid receptor RXR-gamma (RXRG),,
T46456,RXRG,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T46456,RXRG,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T46456,RXRG,INDICATI,Approved,Kaposi sarcoma,[ICD-11: 2B57]
T46456,RXRG,INDICATI,Investigative,Kinetoplastids,[ICD-11: 1F61-1G2Z]
T46456,RXRG,INDICATI,Approved,Light sensitivity impairment,[ICD-11: 9D45]
T46456,RXRG,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T46456,RXRG,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T46456,RXRG,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T46456,RXRG,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T46465,Malaria PLA2,TARGETID,T46465,,
T46465,Malaria PLA2,TARGNAME,Plasmodium Plasmepsin 2 (Malaria PLA2),,
T46465,Malaria PLA2,INDICATI,Terminated,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T46482,TLR7,TARGETID,T46482,,
T46482,TLR7,TARGNAME,Toll-like receptor 7 (TLR7),,
T46482,TLR7,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T46482,TLR7,INDICATI,Phase 1,Autoimmune disease,[ICD-11: 4A40-4A45]
T46482,TLR7,INDICATI,Investigative,Bladder cancer,[ICD-11: 2C94]
T46482,TLR7,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T46482,TLR7,INDICATI,Discontinued in Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T46482,TLR7,INDICATI,Phase 2,Epidermal dysplasias,[ICD-11: EK90]
T46482,TLR7,INDICATI,Phase 2a,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T46482,TLR7,INDICATI,Phase 1/2,Herpes simplex infection,[ICD-11: 1F00]
T46482,TLR7,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T46482,TLR7,INDICATI,Phase 2,Immune system disease,[ICD-11: 4A01-4B41]
T46482,TLR7,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T46482,TLR7,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T46482,TLR7,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T46482,TLR7,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T46482,TLR7,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T46482,TLR7,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T46482,TLR7,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T46482,TLR7,INDICATI,Approved,Skin cancer,[ICD-11: 2C30-2C37]
T46482,TLR7,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T46482,TLR7,INDICATI,Phase 1,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
T46482,TLR7,INDICATI,Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T46521,AR,TARGETID,T46521,,
T46521,AR,TARGNAME,Androgen receptor messenger RNA (AR mRNA),,
T46521,AR,INDICATI,Discontinued in Phase 1,Acne vulgaris,[ICD-11: ED80]
T46521,AR,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T46521,AR,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T46521,AR,INDICATI,Phase 4,Prostate hyperplasia,[ICD-11: GA90]
T46521,AR,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T46524,TNFSF12,TARGETID,T46524,,
T46524,TNFSF12,TARGNAME,TNF-related weak inducer of apoptosis (TWEAK),,
T46524,TNFSF12,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T46524,TNFSF12,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T46526,Bact FimH,TARGETID,T46526,,
T46526,Bact FimH,TARGNAME,Bacterial Fimbrin D-mannose adhesin (Bact FimH),,
T46526,Bact FimH,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T46526,Bact FimH,INDICATI,Patented,Ulcerative colitis,[ICD-11: DD71]
T46526,Bact FimH,INDICATI,Phase 1,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T46616,Bact botA,TARGETID,T46616,,
T46616,Bact botA,TARGNAME,Bacterial Botulinum toxin A (Bact botA),,
T46616,Bact botA,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
T46616,Bact botA,INDICATI,Phase 1/2,Ataxic disorder,[ICD-11: 8A03]
T46616,Bact botA,INDICATI,Phase 1,Clostridium difficile enterocolitis,[ICD-11: 1A04]
,#N/A,,,,
T46628,MTTP,TARGETID,T46628,,
T46628,MTTP,TARGNAME,Microsomal triglyceride transfer protein (MTTP),,
T46628,MTTP,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T46628,MTTP,INDICATI,Discontinued in Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T46628,MTTP,INDICATI,Phase 2,Dyslipidemia,[ICD-11: 5C80-5C81]
T46628,MTTP,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T46628,MTTP,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
T46628,MTTP,INDICATI,Phase 1/2,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T46642,ALOX5AP,TARGETID,T46642,,
T46642,ALOX5AP,TARGNAME,Arachidonate 5-lipoxygenase activating protein (FLAP),,
T46642,ALOX5AP,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T46642,ALOX5AP,INDICATI,Discontinued in Phase 3,Asthma,[ICD-11: CA23]
T46642,ALOX5AP,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T46642,ALOX5AP,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T46658,#N/A,TARGETID,T46658,,
T46658,#N/A,TARGNAME,Eosinophil/lymphocyte-rich accumulation (ELR accum),,
T46658,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T46781,AURKB,TARGETID,T46781,,
T46781,AURKB,TARGNAME,Aurora kinase B (AURKB),,
T46781,AURKB,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T46781,AURKB,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T46781,AURKB,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T46781,AURKB,INDICATI,Investigative,Oral cavity/oesophagus/stomach in situ carcinoma,[ICD-11: 2E60]
T46781,AURKB,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T46781,AURKB,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T46789,SIRPA,TARGETID,T46789,,
T46789,SIRPA,TARGNAME,Inhibitory receptor SHPS-1 (SIRPA),,
T46789,SIRPA,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T46789,SIRPA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T46828,DRD5,TARGETID,T46828,,
T46828,DRD5,TARGNAME,Dopamine D5 receptor (D5R),,
T46828,DRD5,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T46828,DRD5,INDICATI,Preclinical,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T46871,INPP5D,TARGETID,T46871,,
T46871,INPP5D,TARGNAME,SH2 domain inositol 5'-phosphatase 1 (INPP5D),,
T46871,INPP5D,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
,#N/A,,,,
T46904,SCT,TARGETID,T46904,,
T46904,SCT,TARGNAME,Secretin receptor (SCT),,
T46904,SCT,INDICATI,Approved,Pancreas disease,[ICD-11: DC35-DC3Z]
T46904,SCT,INDICATI,Approved,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T46937,P2RY12,TARGETID,T46937,,
T46937,P2RY12,TARGNAME,P2Y purinoceptor 12 (P2RY12),,
T46937,P2RY12,INDICATI,Phase 3,Arterial thrombosis,[ICD-11: DB61-DD30]
T46937,P2RY12,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T46937,P2RY12,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T46937,P2RY12,INDICATI,Approved,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T47077,#N/A,TARGETID,T47077,,
T47077,#N/A,TARGNAME,Prostaglandin receptor (PTGR),,
T47077,#N/A,INDICATI,Discontinued in Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T47077,#N/A,INDICATI,Approved,Alopecia,[ICD-11: ED70]
T47077,#N/A,INDICATI,Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
T47077,#N/A,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T47077,#N/A,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T47077,#N/A,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
T47077,#N/A,INDICATI,Terminated,Psoriasis,[ICD-11: EA90]
T47077,#N/A,INDICATI,Discontinued in Phase 2,Sarcoidosis,[ICD-11: 4B20]
T47077,#N/A,INDICATI,Investigative,Sexual dysfunction,[ICD-11: HA00-HA01]
T47077,#N/A,INDICATI,Phase 2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T47077,#N/A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T47077,#N/A,INDICATI,Discontinued in Phase 3,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T47081,PPIA,TARGETID,T47081,,
T47081,PPIA,TARGNAME,Rotamase A (PPIA),,
T47081,PPIA,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
,#N/A,,,,
T47087,HPV E1 mRNA,TARGETID,T47087,,
T47087,HPV E1 mRNA,TARGNAME,Human papillomavirus E1 region messenger RNA (HPV E1 mRNA),,
T47087,HPV E1 mRNA,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T47094,TACR1,TARGETID,T47094,,
T47094,TACR1,TARGNAME,Substance-P receptor (TACR1),,
T47094,TACR1,INDICATI,Phase 2,Abnormal micturition,[ICD-11: MF50]
T47094,TACR1,INDICATI,Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
T47094,TACR1,INDICATI,Terminated,Acute upper respiratory infection,[ICD-11: CA07]
T47094,TACR1,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T47094,TACR1,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T47094,TACR1,INDICATI,Phase 3,Atopic eczema,[ICD-11: EA80]
T47094,TACR1,INDICATI,Discontinued in Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T47094,TACR1,INDICATI,Investigative,Chronic pain,[ICD-11: MG30]
T47094,TACR1,INDICATI,Phase 2,Cough,[ICD-11: MD12]
T47094,TACR1,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T47094,TACR1,INDICATI,Phase 1,Eczema,[ICD-11: EA80-EA89]
T47094,TACR1,INDICATI,Discontinued in Phase 2,Functional bladder disorder,[ICD-11: GC50]
T47094,TACR1,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T47094,TACR1,INDICATI,Investigative,Influenza,[ICD-11: 1E30-1E32]
T47094,TACR1,INDICATI,Investigative,Intracranial injury,[ICD-11: NA07]
T47094,TACR1,INDICATI,Discontinued in Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T47094,TACR1,INDICATI,Phase 3,Menopausal disorder,[ICD-11: GA30]
T47094,TACR1,INDICATI,Phase 2,Migraine,[ICD-11: 8A80]
T47094,TACR1,INDICATI,Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T47094,TACR1,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T47094,TACR1,INDICATI,Discontinued in Phase 1,Oesophagus motility disorder,[ICD-11: DA21]
T47094,TACR1,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T47094,TACR1,INDICATI,Phase 3,Prurigo,[ICD-11: EC91]
T47094,TACR1,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T47094,TACR1,INDICATI,Phase 1,Schizophrenia,[ICD-11: 6A20]
T47094,TACR1,INDICATI,Patented,Skin tag/polyp,[ICD-11: EK71]
T47094,TACR1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T47094,TACR1,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T47101,FGFR1,TARGETID,T47101,,
T47101,FGFR1,TARGNAME,Fibroblast growth factor receptor 1 (FGFR1),,
T47101,FGFR1,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T47101,FGFR1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T47101,FGFR1,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T47101,FGFR1,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T47101,FGFR1,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T47101,FGFR1,INDICATI,Investigative,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T47101,FGFR1,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T47101,FGFR1,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
T47101,FGFR1,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T47101,FGFR1,INDICATI,Phase 2,Epidermal dysplasias,[ICD-11: EK90]
T47101,FGFR1,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T47101,FGFR1,INDICATI,Approved,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T47101,FGFR1,INDICATI,Approved,Liver cancer,[ICD-11: 2C12]
T47101,FGFR1,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T47101,FGFR1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T47101,FGFR1,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T47101,FGFR1,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T47101,FGFR1,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T47101,FGFR1,INDICATI,Phase 2,Oesophagitis,[ICD-11: DA24]
T47101,FGFR1,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T47101,FGFR1,INDICATI,Phase 3,Peritoneal cancer,[ICD-11: 2C51]
T47101,FGFR1,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
T47101,FGFR1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T47101,FGFR1,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T47101,FGFR1,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T47101,FGFR1,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T47107,PRKCG,TARGETID,T47107,,
T47107,PRKCG,TARGNAME,Protein kinase C gamma (PRKCG),,
T47107,PRKCG,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T47107,PRKCG,INDICATI,Phase 2,Chronic myelomonocytic leukaemia,[ICD-11: 2A40]
T47107,PRKCG,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T47107,PRKCG,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T47107,PRKCG,INDICATI,Approved,Mastocytosis,[ICD-11: 2A21]
,#N/A,,,,
T47164,STK4,TARGETID,T47164,,
T47164,STK4,TARGNAME,MST-1 protein kinase (STK4),,
T47164,STK4,INDICATI,Investigative,Ischemic heart disease,[ICD-11: BA40-BA6Z]
,#N/A,,,,
T47165,#N/A,TARGETID,T47165,,
T47165,#N/A,TARGNAME,Neural cell adhesion molecule (NCAM),,
T47165,#N/A,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T47165,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T47215,#N/A,TARGETID,T47215,,
T47215,#N/A,TARGNAME,Cholecystokinin receptor (CCKR),,
T47215,#N/A,INDICATI,Terminated,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T47366,ACVR2A,TARGETID,T47366,,
T47366,ACVR2A,TARGNAME,Activin receptor type IIA (ACVR2A),,
T47366,ACVR2A,INDICATI,Phase 2/3,Acute myeloid leukaemia,[ICD-11: 2A60]
T47366,ACVR2A,INDICATI,Phase 3,Idiopathic inflammatory myopathy,[ICD-11: 4A41]
T47366,ACVR2A,INDICATI,Phase 2,Muscle disorder,[ICD-11: FB32-FB3Z]
,#N/A,,,,
T47381,GSTP1,TARGETID,T47381,,
T47381,GSTP1,TARGNAME,GSTP1 messenger RNA (GSTP1 mRNA),,
T47381,GSTP1,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T47381,GSTP1,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T47381,GSTP1,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T47387,BCL2,TARGETID,T47387,,
T47387,BCL2,TARGNAME,BCL-2 messenger RNA (BCL2 mRNA),,
T47387,BCL2,INDICATI,Investigative,Acute myeloid leukaemia,[ICD-11: 2A60]
T47387,BCL2,INDICATI,Investigative,Colorectal cancer,[ICD-11: 2B91]
T47387,BCL2,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T47387,BCL2,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T47387,BCL2,INDICATI,Investigative,Lung cancer,[ICD-11: 2C25]
T47387,BCL2,INDICATI,Investigative,Lymphoma,[ICD-11: 2A80-2A86]
T47387,BCL2,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T47387,BCL2,INDICATI,Investigative,Melanoma,[ICD-11: 2C30]
T47387,BCL2,INDICATI,Investigative,Multiple myeloma,[ICD-11: 2A83]
T47387,BCL2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T47415,HLA-B,TARGETID,T47415,,
T47415,HLA-B,TARGNAME,HLA class I antigen B-7 (HLA-B),,
T47415,HLA-B,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
,#N/A,,,,
T47466,HMBS,TARGETID,T47466,,
T47466,HMBS,TARGNAME,Porphobilinogen deaminase (HMBS),,
T47466,HMBS,INDICATI,Phase 2,Inborn porphyrin/heme metabolism error,[ICD-11: 5C58]
,#N/A,,,,
T47583,WRN,TARGETID,T47583,,
T47583,WRN,TARGNAME,Werner syndrome ATP-dependent helicase (WRN),,
T47583,WRN,INDICATI,Investigative,Mature T-cell lymphoma,[ICD-11: 2A90]
,#N/A,,,,
T47610,IL11RA,TARGETID,T47610,,
T47610,IL11RA,TARGNAME,Interleukin 11 receptor alpha (IL11RA),,
T47610,IL11RA,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T47610,IL11RA,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T47623,HPSE,TARGETID,T47623,,
T47623,HPSE,TARGNAME,Heparanase (HPSE),,
T47623,HPSE,INDICATI,Phase 1,African trypanosomiasis,[ICD-11: 1F51]
T47623,HPSE,INDICATI,Discontinued in Phase 3,Circulatory system disease,[ICD-11: BE2Z]
T47623,HPSE,INDICATI,Phase 1,Herpes simplex infection,[ICD-11: 1F00]
,#N/A,,,,
T47768,OPRM1,TARGETID,T47768,,
T47768,OPRM1,TARGNAME,Opioid receptor mu (MOP),,
T47768,OPRM1,INDICATI,Discontinued in Phase 1,Abnormal micturition,[ICD-11: MF50]
T47768,OPRM1,INDICATI,Approved,Acute pain,[ICD-11: MG31]
T47768,OPRM1,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T47768,OPRM1,INDICATI,Phase 2,Binge eating disorder,[ICD-11: 6B82]
T47768,OPRM1,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
T47768,OPRM1,INDICATI,Phase 3,Breathing abnormality,[ICD-11: MD11]
T47768,OPRM1,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T47768,OPRM1,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T47768,OPRM1,INDICATI,Phase 1,Coronary vasospastic disease,[ICD-11: BA85]
T47768,OPRM1,INDICATI,Approved,Cough,[ICD-11: MD12]
T47768,OPRM1,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T47768,OPRM1,INDICATI,Approved,Digestive system disease,[ICD-11: DE2Z]
T47768,OPRM1,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T47768,OPRM1,INDICATI,Phase 1,Headache,[ICD-11: 8A80-8A84]
T47768,OPRM1,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T47768,OPRM1,INDICATI,Approved,Large intestine motility disorder,[ICD-11: DB32]
T47768,OPRM1,INDICATI,Investigative,Lung cancer,[ICD-11: 2C25]
T47768,OPRM1,INDICATI,Phase 3,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T47768,OPRM1,INDICATI,Phase 2,Migraine,[ICD-11: 8A80]
T47768,OPRM1,INDICATI,Investigative,Movement disorder,[ICD-11: 8A07-8A0Z]
T47768,OPRM1,INDICATI,Phase 3,Neuropathy,[ICD-11: 8C0Z]
T47768,OPRM1,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T47768,OPRM1,INDICATI,Approved,Opioid use disorder,[ICD-11: 6C43]
T47768,OPRM1,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T47768,OPRM1,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T47768,OPRM1,INDICATI,Approved,Pruritus,[ICD-11: EC90]
T47768,OPRM1,INDICATI,Approved,Sensation disturbance,[ICD-11: MB40]
T47768,OPRM1,INDICATI,Phase 3,Spinal pain,[ICD-11: ME84]
T47768,OPRM1,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T47768,OPRM1,INDICATI,Discontinued in Phase 1,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T47818,SLC6A14,TARGETID,T47818,,
T47818,SLC6A14,TARGNAME,Amino acid transporter ATB0+ (SLC6A14),,
T47818,SLC6A14,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T47863,EPCAM,TARGETID,T47863,,
T47863,EPCAM,TARGNAME,Tumor-associated calcium signal transducer 1 (EPCAM),,
T47863,EPCAM,INDICATI,Phase 3,Bladder cancer,[ICD-11: 2C94]
T47863,EPCAM,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T47863,EPCAM,INDICATI,Phase 1/2,Colon cancer,[ICD-11: 2B90]
T47863,EPCAM,INDICATI,Discontinued in Phase 2,Colorectal cancer,[ICD-11: 2B91]
T47863,EPCAM,INDICATI,Phase 1/2,Esophageal cancer,[ICD-11: 2B70]
T47863,EPCAM,INDICATI,Phase 2/3,Head and neck cancer,[ICD-11: 2D42]
T47863,EPCAM,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T47863,EPCAM,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T47863,EPCAM,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T47863,EPCAM,INDICATI,Phase 1,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T47863,EPCAM,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
T47863,EPCAM,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T47863,EPCAM,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T47863,EPCAM,INDICATI,Phase 1/2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T47864,TDGF1,TARGETID,T47864,,
T47864,TDGF1,TARGNAME,Teratocarcinoma-derived growth factor 1 (TDGF1),,
T47864,TDGF1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T47885,PRKD1,TARGETID,T47885,,
T47885,PRKD1,TARGNAME,Protein kinase D (PRKD1),,
T47885,PRKD1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T47885,PRKD1,INDICATI,Investigative,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T47888,S1PR2,TARGETID,T47888,,
T47888,S1PR2,TARGNAME,Sphingosine-1-phosphate receptor 2 (S1PR2),,
T47888,S1PR2,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T47891,#N/A,TARGETID,T47891,,
T47891,#N/A,TARGNAME,Natural killer cell receptor (NKCR),,
T47891,#N/A,INDICATI,Phase 3,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T47941,#N/A,TARGETID,T47941,,
T47941,#N/A,TARGNAME,Phosphodiesterase 4 (PDE4),,
T47941,#N/A,INDICATI,Approved,Asthma,[ICD-11: CA23]
T47941,#N/A,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
T47941,#N/A,INDICATI,Discontinued in Phase 3,Bronchitis,[ICD-11: CA20]
T47941,#N/A,INDICATI,Approved,Castlemans disease,[ICD-11: 4B2Y]
T47941,#N/A,INDICATI,Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T47941,#N/A,INDICATI,Approved,Cough,[ICD-11: MD12]
T47941,#N/A,INDICATI,Discontinued in Phase 3,Emphysema,[ICD-11: CA21]
T47941,#N/A,INDICATI,Phase 2,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T47941,#N/A,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T47941,#N/A,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T47941,#N/A,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T47941,#N/A,INDICATI,Phase 2,Opioid use disorder,[ICD-11: 6C43]
T47941,#N/A,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T47941,#N/A,INDICATI,Phase 2,Psoriasis,ICD-11: EA90
T47941,#N/A,INDICATI,Phase 2,Stimulants use disorder,[ICD-11: 6C46]
T47941,#N/A,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T47941,#N/A,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T48069,IGF1R,TARGETID,T48069,,
T48069,IGF1R,TARGNAME,Insulin-like growth factor I receptor (IGF1R),,
T48069,IGF1R,INDICATI,Discontinued in Phase 1,Adrenal cancer,[ICD-11: 2D11]
T48069,IGF1R,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T48069,IGF1R,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T48069,IGF1R,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T48069,IGF1R,INDICATI,Phase 2,Extraocular muscle disorder,[ICD-11: 9C82]
T48069,IGF1R,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T48069,IGF1R,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T48069,IGF1R,INDICATI,Phase 1,Motor neuron disease,[ICD-11: 8B60]
T48069,IGF1R,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T48069,IGF1R,INDICATI,Approved,Multiple structural anomalies syndrome,[ICD-11: LD2F]
T48069,IGF1R,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T48069,IGF1R,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T48069,IGF1R,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T48069,IGF1R,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T48069,IGF1R,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T48069,IGF1R,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T48069,IGF1R,INDICATI,Approved,Thyrotoxicosis,[ICD-11: 5A02]
,#N/A,,,,
T48268,MTNR1B,TARGETID,T48268,,
T48268,MTNR1B,TARGNAME,Melatonin receptor type 1B (MTNR1B),,
T48268,MTNR1B,INDICATI,Terminated,Circadian rhythm sleep disorder,[ICD-11: 7A60-7A65]
T48268,MTNR1B,INDICATI,Phase 3,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T48268,MTNR1B,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
,#N/A,,,,
T48429,IL15RA,TARGETID,T48429,,
T48429,IL15RA,TARGNAME,Interleukin 15 receptor alpha (IL15RA),,
T48429,IL15RA,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T48429,IL15RA,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T48429,IL15RA,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T48429,IL15RA,INDICATI,Phase 1/2,Head and neck cancer,[ICD-11: 2D42]
T48429,IL15RA,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T48429,IL15RA,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T48429,IL15RA,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T48429,IL15RA,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T48429,IL15RA,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T48429,IL15RA,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T48457,CR1,TARGETID,T48457,,
T48457,CR1,TARGNAME,Complement receptor type 1 (CR1),,
T48457,CR1,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T48470,#N/A,TARGETID,T48470,,
T48470,#N/A,TARGNAME,Hormone unspecific (HOM),,
T48470,#N/A,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T48470,#N/A,INDICATI,Investigative,Indeterminate colitis,[ICD-11: DD72]
,#N/A,,,,
T48472,#N/A,TARGETID,T48472,,
T48472,#N/A,TARGNAME,Bacterial 70S ribosomal RNA (Bact 70S rRNA),,
T48472,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T48472,#N/A,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T48472,#N/A,INDICATI,Phase 2,Mycobacterium infection,[ICD-11: 1B10-1B21]
,#N/A,,,,
T48598,KRAS,TARGETID,T48598,,
T48598,KRAS,TARGNAME,GTPase KRas (KRAS),,
T48598,KRAS,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T48703,TLR8,TARGETID,T48703,,
T48703,TLR8,TARGNAME,Toll-like receptor 8 (TLR8),,
T48703,TLR8,INDICATI,Discontinued in Phase 2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T48703,TLR8,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T48703,TLR8,INDICATI,Discontinued in Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T48703,TLR8,INDICATI,Phase 2,Epidermal dysplasias,[ICD-11: EK90]
T48703,TLR8,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T48703,TLR8,INDICATI,Phase 1/2,Herpes simplex infection,[ICD-11: 1F00]
T48703,TLR8,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T48703,TLR8,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T48703,TLR8,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T48703,TLR8,INDICATI,Investigative,Rheumatoid arthritis,[ICD-11: FA20]
T48703,TLR8,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T48703,TLR8,INDICATI,Phase 1,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
T48703,TLR8,INDICATI,Phase 1,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T48873,SLC18A2,TARGETID,T48873,,
T48873,SLC18A2,TARGNAME,Synaptic vesicle amine transporter (SLC18A2),,
T48873,SLC18A2,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T48873,SLC18A2,INDICATI,Approved,Choreiform disorder,[ICD-11: 8A01]
T48873,SLC18A2,INDICATI,Approved,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T48873,SLC18A2,INDICATI,Approved,Dystonic disorder,[ICD-11: 8A02]
T48873,SLC18A2,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T48873,SLC18A2,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T48873,SLC18A2,INDICATI,Phase 3,Movement disorder,[ICD-11: 8A07-8A0Z]
T48873,SLC18A2,INDICATI,Phase 2,Tic disorder,[ICD-11: 8A05]
T48873,SLC18A2,INDICATI,Phase 2,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T48881,TNFSF14,TARGETID,T48881,,
T48881,TNFSF14,TARGNAME,Herpes virus entry mediator ligand (CD258),,
T48881,TNFSF14,INDICATI,Phase 2,Asthma,ICD-11: CA23
,#N/A,,,,
T48940,#N/A,TARGETID,T48940,,
T48940,#N/A,TARGNAME,HIF-prolyl hydroxylase (HPH),,
T48940,#N/A,INDICATI,Phase 3,Acute disease anaemia,[ICD-11: 3A90]
T48940,#N/A,INDICATI,Phase 1,Anemia,[ICD-11: 3A00-3A9Z]
T48940,#N/A,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
T48940,#N/A,INDICATI,Preclinical,Mineral deficiency,[ICD-11: 5B5K]
T48940,#N/A,INDICATI,Phase 2,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T48945,TERT,TARGETID,T48945,,
T48945,TERT,TARGNAME,TERT messenger RNA (TERT mRNA),,
T48945,TERT,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T48945,TERT,INDICATI,Investigative,Colorectal cancer,[ICD-11: 2B91]
T48945,TERT,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T48945,TERT,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T49040,#N/A,TARGETID,T49040,,
T49040,#N/A,TARGNAME,Glucose metabolism (Glucose metab),,
T49040,#N/A,INDICATI,Phase 2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
,#N/A,,,,
T49049,#N/A,TARGETID,T49049,,
T49049,#N/A,TARGNAME,Immunoglobulin Fc receptor (FCR),,
T49049,#N/A,INDICATI,Investigative,Ischemic heart disease,[ICD-11: BA40-BA6Z]
T49049,#N/A,INDICATI,Approved,Myasthenia gravis,ICD-11: 8C60
T49049,#N/A,INDICATI,Phase 3,Myasthenia gravis,[ICD-11: 8C6Y]
T49049,#N/A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T49064,LIPF,TARGETID,T49064,,
T49064,LIPF,TARGNAME,Gastric triacylglycerol lipase (LIPF),,
T49064,LIPF,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T49064,LIPF,INDICATI,Phase 3,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T49072,UTS2R,TARGETID,T49072,,
T49072,UTS2R,TARGNAME,Urotensin II receptor (UTS2R),,
T49072,UTS2R,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T49072,UTS2R,INDICATI,Discontinued in Phase 1,Chronic kidney disease,[ICD-11: GB61]
T49072,UTS2R,INDICATI,Discontinued in Phase 2,Kidney failure,[ICD-11: GB60-GB6Z]
,#N/A,,,,
T49105,PVRIG,TARGETID,T49105,,
T49105,PVRIG,TARGNAME,Transmembrane protein PVRIG (PVRIG),,
T49105,PVRIG,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T49146,HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5,TARGETID,T49146,,
T49146,HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5,TARGNAME,MHC class II antigen DR (HLA-DR),,
T49146,HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5,INDICATI,Phase 1,Influenza,[ICD-11: 1E30-1E32]
T49146,HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T49146,HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T49146,HLA-DRA; HLA-DRB1; HLA-DRB3; HLA-DRB4; HLA-DRB5,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T49156,PTPN2,TARGETID,T49156,,
T49156,PTPN2,TARGNAME,Tyrosine-protein phosphatase non-receptor type 2 (PTPN2),,
T49156,PTPN2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T49327,ABCA4,TARGETID,T49327,,
T49327,ABCA4,TARGNAME,ATP-binding cassette transporter A4 (ABCA4),,
T49327,ABCA4,INDICATI,Phase 1/2,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T49368,PRKCD,TARGETID,T49368,,
T49368,PRKCD,TARGNAME,PKC-delta messenger RNA (PRKCD mRNA),,
T49368,PRKCD,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T49453,NOTCH4,TARGETID,T49453,,
T49453,NOTCH4,TARGNAME,Notch-4 receptor (NOTCH4),,
T49453,NOTCH4,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T49453,NOTCH4,INDICATI,Phase 1/2,Mature T-cell lymphoma,[ICD-11: 2A90]
T49453,NOTCH4,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T49493,HBA2,TARGETID,T49493,,
T49493,HBA2,TARGNAME,Hemoglobin (HB),,
T49493,HBA2,INDICATI,Terminated,Alopecia,[ICD-11: ED70]
T49493,HBA2,INDICATI,Phase 2/3,Anemia,[ICD-11: 3A00-3A9Z]
T49493,HBA2,INDICATI,Phase 1/2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T49493,HBA2,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T49493,HBA2,INDICATI,Discontinued in Phase 3,Hypotension,[ICD-11: BA20-BA21]
T49493,HBA2,INDICATI,Approved,Iron deficiency anaemia,[ICD-11: 3A00]
T49493,HBA2,INDICATI,Terminated,Liver cancer,[ICD-11: 2C12]
T49493,HBA2,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T49493,HBA2,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T49493,HBA2,INDICATI,Phase 2,Mineral absorption/transport disorder,[ICD-11: 5C64]
T49493,HBA2,INDICATI,Discontinued in Phase 1,Myeloproliferative neoplasm,[ICD-11: 2A20]
T49493,HBA2,INDICATI,Discontinued in Phase 2,Neutropenia,[ICD-11: 4B00]
T49493,HBA2,INDICATI,Phase 3,Pregnancy/childbirth/puerperium maternal infection,[ICD-11: JB63]
T49493,HBA2,INDICATI,Approved,Sickle-cell disorder,[ICD-11: 3A51]
T49493,HBA2,INDICATI,Phase 2,Thalassaemia,[ICD-11: 3A50]
T49493,HBA2,INDICATI,Terminated,Undiagnosed blood transfusion,[ICD-11: QB98]
T49493,HBA2,INDICATI,Terminated,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T49507,EPHB4,TARGETID,T49507,,
T49507,EPHB4,TARGNAME,Ephrin type-B receptor 4 (EPHB4),,
T49507,EPHB4,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T49507,EPHB4,INDICATI,Phase 2,Cystic/dysplastic kidney disease,[ICD-11: GB8Y]
T49507,EPHB4,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T49507,EPHB4,INDICATI,Phase 2,Metastatic meninges neoplasm,[ICD-11: 2D51]
T49507,EPHB4,INDICATI,Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T49507,EPHB4,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T49526,KCNQ1,TARGETID,T49526,,
T49526,KCNQ1,TARGNAME,Voltage-gated potassium channel Kv7.1 (KCNQ1),,
T49526,KCNQ1,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T49571,#N/A,TARGETID,T49571,,
T49571,#N/A,TARGNAME,Aminotransferase (AT),,
T49571,#N/A,INDICATI,Phase 2,Liver disease,[ICD-11: DB90-DB9Z]
,#N/A,,,,
T49578,#N/A,TARGETID,T49578,,
T49578,#N/A,TARGNAME,Transient receptor potential channel (TRP channel),,
T49578,#N/A,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T49578,#N/A,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T49578,#N/A,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T49578,#N/A,INDICATI,Phase 2,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T49630,OLR1,TARGETID,T49630,,
T49630,OLR1,TARGNAME,Lectin-like oxidized LDL receptor (OLR1),,
T49630,OLR1,INDICATI,Discontinued in Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T49630,OLR1,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T49630,OLR1,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
,#N/A,,,,
T49639,HSPA1A; HSPA1B,TARGETID,T49639,,
T49639,HSPA1A; HSPA1B,TARGNAME,Heat shock protein 70 (HSP70),,
T49639,HSPA1A; HSPA1B,INDICATI,Discontinued in Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T49639,HSPA1A; HSPA1B,INDICATI,Phase 1,Diabetic foot ulcer,[ICD-11: BD54]
T49639,HSPA1A; HSPA1B,INDICATI,Investigative,Heart failure,[ICD-11: BD10-BD1Z]
T49639,HSPA1A; HSPA1B,INDICATI,Phase 1,Herpes simplex infection,[ICD-11: 1F00]
T49639,HSPA1A; HSPA1B,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
T49639,HSPA1A; HSPA1B,INDICATI,Phase 1,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T49639,HSPA1A; HSPA1B,INDICATI,Phase 1,Metastatic malignant neoplasm,[ICD-11: 2D50-2E09]
T49639,HSPA1A; HSPA1B,INDICATI,Discontinued in Phase 2,Motor neuron disease,[ICD-11: 8B60]
T49639,HSPA1A; HSPA1B,INDICATI,Phase 2,Neuropathy,[ICD-11: 8C0Z]
T49639,HSPA1A; HSPA1B,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T49639,HSPA1A; HSPA1B,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
T49639,HSPA1A; HSPA1B,INDICATI,Discontinued in Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T49689,#N/A,TARGETID,T49689,,
T49689,#N/A,TARGNAME,Immunoglobulin G1k (IgG1k),,
T49689,#N/A,INDICATI,Phase 1,Sickle-cell disorder,[ICD-11: 3A51]
,#N/A,,,,
T49736,CD6,TARGETID,T49736,,
T49736,CD6,TARGNAME,T-cell differentiation antigen CD6 (TP120),,
T49736,CD6,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T49755,LRP6,TARGETID,T49755,,
T49755,LRP6,TARGNAME,LDL receptor related protein-6 (LRP-6),,
T49755,LRP6,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T49814,#N/A,TARGETID,T49814,,
T49814,#N/A,TARGNAME,Bacterial Deoxyribonucleic acid (Bact DNA),,
T49814,#N/A,INDICATI,Approved,Amoebiasis,[ICD-11: 1A36]
T49814,#N/A,INDICATI,Approved,Blastomycosis,[ICD-11: 1F22]
T49814,#N/A,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
T49814,#N/A,INDICATI,Phase 2,Clostridium difficile enterocolitis,[ICD-11: 1A04]
T49814,#N/A,INDICATI,Approved,Crohn disease,[ICD-11: DD70]
T49814,#N/A,INDICATI,Investigative,Mycobacterium infection,[ICD-11: 1B10-1B21]
T49814,#N/A,INDICATI,Approved,Sepsis,[ICD-11: 1G40-1G41]
T49814,#N/A,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T49833,#N/A,TARGETID,T49833,,
T49833,#N/A,TARGNAME,TNF/IL-10 release (TNF/IL10 rele),,
T49833,#N/A,INDICATI,Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T49898,CDK1,TARGETID,T49898,,
T49898,CDK1,TARGNAME,Cyclin-dependent kinase 1 (CDK1),,
T49898,CDK1,INDICATI,Patented,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T49898,CDK1,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T49898,CDK1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T49898,CDK1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T49898,CDK1,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
T49898,CDK1,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T49898,CDK1,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
T49898,CDK1,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T49898,CDK1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T49898,CDK1,INDICATI,Patented,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T49989,TGFBR2,TARGETID,T49989,,
T49989,TGFBR2,TARGNAME,TGF-beta receptor type II (TGFBR2),,
T49989,TGFBR2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T50066,CLCN2,TARGETID,T50066,,
T50066,CLCN2,TARGNAME,Chloride channel protein 2 (CLC-2),,
T50066,CLCN2,INDICATI,Phase 2,Alopecia,[ICD-11: ED70]
T50066,CLCN2,INDICATI,Approved,Chronic pancreatitis,[ICD-11: DC32]
,#N/A,,,,
T50089,S1PR5,TARGETID,T50089,,
T50089,S1PR5,TARGNAME,Sphingosine-1-phosphate receptor 5 (S1PR5),,
T50089,S1PR5,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T50261,#N/A,TARGETID,T50261,,
T50261,#N/A,TARGNAME,PI3-kinase (PIK3C),,
T50261,#N/A,INDICATI,Investigative,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T50269,GLRA1,TARGETID,T50269,,
T50269,GLRA1,TARGNAME,Strychnine-binding glycine receptor (GLRA1),,
T50269,GLRA1,INDICATI,Terminated,Sepsis,[ICD-11: 1G40-1G41]
T50269,GLRA1,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T50289,BMP7,TARGETID,T50289,,
T50289,BMP7,TARGNAME,Bone morphogenetic protein 7 (BMP7),,
T50289,BMP7,INDICATI,Phase 2,Kidney fibrosis,[ICD-11: GC01]
,#N/A,,,,
T50444,CTGF,TARGETID,T50444,,
T50444,CTGF,TARGNAME,Connective tissue growth factor (CTGF),,
T50444,CTGF,INDICATI,Phase 1b,Chronic kidney disease,[ICD-11: GB61]
T50444,CTGF,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T50444,CTGF,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T50444,CTGF,INDICATI,Phase 2,Schizoaffective disorder,[ICD-11: 6A21]
T50444,CTGF,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T50444,CTGF,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T50445,CD40,TARGETID,T50445,,
T50445,CD40,TARGNAME,CD40 messenger RNA (CD40 mRNA),,
T50445,CD40,INDICATI,Phase 1,Graft-versus-host disease,[ICD-11: 4B24]
,#N/A,,,,
T50461,#N/A,TARGETID,T50461,,
T50461,#N/A,TARGNAME,Ribonuclease (RNase),,
T50461,#N/A,INDICATI,Phase 2,Cervical cancer,[ICD-11: 2C77]
T50461,#N/A,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T50461,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T50461,#N/A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T50547,Malaria PLA1,TARGETID,T50547,,
T50547,Malaria PLA1,TARGNAME,Plasmodium Plasmepsin 1 (Malaria PLA1),,
T50547,Malaria PLA1,INDICATI,Terminated,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T50584,BPI,TARGETID,T50584,,
T50584,BPI,TARGNAME,Protein bactericidal permeability-increasing (BPI),,
T50584,BPI,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
,#N/A,,,,
T50594,PIM1,TARGETID,T50594,,
T50594,PIM1,TARGNAME,Serine/threonine-protein kinase pim-1 (PIM1),,
T50594,PIM1,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T50594,PIM1,INDICATI,Investigative,Non-small-cell lung cancer,[ICD-11: 2C25]
T50594,PIM1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T50688,ITGA2B; ITGB3,TARGETID,T50688,,
T50688,ITGA2B; ITGB3,TARGNAME,Glycoprotein IIb/IIIa receptor (GPIIb/IIIa),,
T50688,ITGA2B; ITGB3,INDICATI,Approved,Acquired hypermelanosis,[ICD-11: ED60]
T50688,ITGA2B; ITGB3,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T50688,ITGA2B; ITGB3,INDICATI,Discontinued in Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T50688,ITGA2B; ITGB3,INDICATI,Terminated,Arterial thrombosis,[ICD-11: DB61-DD30]
T50688,ITGA2B; ITGB3,INDICATI,Discontinued in Phase 2,Arteries/arterioles disorder,[ICD-11: BD52]
T50688,ITGA2B; ITGB3,INDICATI,Discontinued in Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T50688,ITGA2B; ITGB3,INDICATI,Discontinued in Phase 3,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T50688,ITGA2B; ITGB3,INDICATI,Discontinued in Phase 2,Circulatory system disease,[ICD-11: BE2Z]
T50688,ITGA2B; ITGB3,INDICATI,Phase 3,Coronary atherosclerosis,[ICD-11: BA80]
T50688,ITGA2B; ITGB3,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T50688,ITGA2B; ITGB3,INDICATI,Phase 1/2,Obstetric embolism,[ICD-11: JB42]
T50688,ITGA2B; ITGB3,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T50699,LTBR,TARGETID,T50699,,
T50699,LTBR,TARGNAME,Lymphotoxin beta receptor (LTBR),,
T50699,LTBR,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T50699,LTBR,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T50823,SEMA4D,TARGETID,T50823,,
T50823,SEMA4D,TARGNAME,Semaphorin-4D (SEMA4D),,
T50823,SEMA4D,INDICATI,Phase 2,Choreiform disorder,[ICD-11: 8A01]
T50823,SEMA4D,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T50823,SEMA4D,INDICATI,Phase 1/2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T50823,SEMA4D,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T50912,CD86,TARGETID,T50912,,
T50912,CD86,TARGNAME,T-lymphocyte activation antigen CD86 (FUN1),,
T50912,CD86,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T50912,CD86,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T50912,CD86,INDICATI,Terminated,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T50942,NGFR,TARGETID,T50942,,
T50942,NGFR,TARGNAME,Low-affinity nerve growth factor receptor (NGFR),,
T50942,NGFR,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T50942,NGFR,INDICATI,Investigative,Cerebral ischaemia,[ICD-11: 8B1Z]
T50942,NGFR,INDICATI,Phase 3,Chronic pain,[ICD-11: MG30]
T50942,NGFR,INDICATI,Terminated,Cystitis,[ICD-11: GC00]
T50942,NGFR,INDICATI,Phase 3,Joint pain,[ICD-11: ME82]
T50942,NGFR,INDICATI,Discontinued in Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T50942,NGFR,INDICATI,Investigative,Motor neuron disease,[ICD-11: 8B60]
T50942,NGFR,INDICATI,Investigative,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T50942,NGFR,INDICATI,Approved,Neurotrophic keratitis,[ICD-11: 9A74]
T50942,NGFR,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T50942,NGFR,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T50942,NGFR,INDICATI,Phase 3,Spinal pain,[ICD-11: ME84]
,#N/A,,,,
T50973,KMO,TARGETID,T50973,,
T50973,KMO,TARGNAME,Kynurenine 3-hydroxylase (KMO),,
T50973,KMO,INDICATI,Preclinical,Choreiform disorder,[ICD-11: 8A01]
T50973,KMO,INDICATI,Preclinical,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T50973,KMO,INDICATI,Phase 1,Pancreatitis,[ICD-11: DC31-DC34]
,#N/A,,,,
T51038,#N/A,TARGETID,T51038,,
T51038,#N/A,TARGNAME,Hyaluronic acid (HA),,
T51038,#N/A,INDICATI,Approved,Resorption of radiopaque agents,[ICD-11: N.A.]
T51038,#N/A,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T51076,NTRK3,TARGETID,T51076,,
T51076,NTRK3,TARGNAME,NT-3 growth factor receptor (TrkC),,
T51076,NTRK3,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T51076,NTRK3,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T51076,NTRK3,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T51076,NTRK3,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
T51076,NTRK3,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T51076,NTRK3,INDICATI,Patented,General pain disorder,[ICD-11: 8E43]
T51076,NTRK3,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T51076,NTRK3,INDICATI,Patented,Pruritus,[ICD-11: EC90]
T51076,NTRK3,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T51076,NTRK3,INDICATI,Patented,Thymoma,[ICD-11: 2C27]
,#N/A,,,,
T51115,CACNA1C,TARGETID,T51115,,
T51115,CACNA1C,TARGNAME,Voltage-gated calcium channel alpha Cav1.2 (CACNA1C),,
T51115,CACNA1C,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T51115,CACNA1C,INDICATI,Terminated,Angina pectoris,[ICD-11: BA40]
T51115,CACNA1C,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T51115,CACNA1C,INDICATI,Investigative,Heart failure,[ICD-11: BD10-BD1Z]
T51115,CACNA1C,INDICATI,Terminated,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T51120,TPO,TARGETID,T51120,,
T51120,TPO,TARGNAME,Thyroid peroxidase (TPO),,
T51120,TPO,INDICATI,Investigative,Thrombocytopenia,[ICD-11: 3B64]
T51120,TPO,INDICATI,Approved,Thyrotoxicosis,[ICD-11: 5A02]
,#N/A,,,,
T51146,FUT4,TARGETID,T51146,,
T51146,FUT4,TARGNAME,Fucosyltransferase IV (CD15),,
T51146,FUT4,INDICATI,Approved,Appendicitis,[ICD-11: DB10]
,#N/A,,,,
T51191,HDAC2,TARGETID,T51191,,
T51191,HDAC2,TARGNAME,Histone deacetylase 2 (HDAC2),,
T51191,HDAC2,INDICATI,Investigative,Eczema,[ICD-11: EA80-EA89]
T51191,HDAC2,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T51191,HDAC2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T51223,IL21,TARGETID,T51223,,
T51223,IL21,TARGNAME,Interleukin-21 (IL21),,
T51223,IL21,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T51223,IL21,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
,#N/A,,,,
T51282,ROCK1,TARGETID,T51282,,
T51282,ROCK1,TARGNAME,Rho-associated protein kinase 1 (ROCK1),,
T51282,ROCK1,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T51282,ROCK1,INDICATI,Investigative,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T51282,ROCK1,INDICATI,Phase 2,Coronary microvascular disease,[ICD-11: BA86]
T51282,ROCK1,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T51282,ROCK1,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T51282,ROCK1,INDICATI,Clinical trial,Postoperative inflammation,[ICD-11: 1A00-CA43]
T51282,ROCK1,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
T51282,ROCK1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T51407,XPO1,TARGETID,T51407,,
T51407,XPO1,TARGNAME,Exportin-1 (XPO1),,
T51407,XPO1,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T51407,XPO1,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T51407,XPO1,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T51407,XPO1,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T51407,XPO1,INDICATI,Phase 3,Liposarcoma,[ICD-11: 2B59]
T51407,XPO1,INDICATI,Phase 3,Multiple myeloma,[ICD-11: 2A83]
T51407,XPO1,INDICATI,Phase 1/2,Myelodysplastic syndrome,[ICD-11: 2A37]
T51407,XPO1,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T51407,XPO1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T51407,XPO1,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T51408,ADRB3,TARGETID,T51408,,
T51408,ADRB3,TARGNAME,Adrenergic receptor beta-3 (ADRB3),,
T51408,ADRB3,INDICATI,Phase 2,Abnormal micturition,[ICD-11: MF50]
T51408,ADRB3,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T51408,ADRB3,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T51408,ADRB3,INDICATI,Approved,Asthma,[ICD-11: CA23]
T51408,ADRB3,INDICATI,Phase 1,Bladder disorder,[ICD-11: GC01]
T51408,ADRB3,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T51408,ADRB3,INDICATI,Discontinued in Phase 3,Depression,[ICD-11: 6A70-6A7Z]
T51408,ADRB3,INDICATI,Terminated,Digestive system disease,[ICD-11: DE2Z]
T51408,ADRB3,INDICATI,Approved,Dystonic disorder,[ICD-11: 8A02]
T51408,ADRB3,INDICATI,Approved,Functional bladder disorder,[ICD-11: GC50]
T51408,ADRB3,INDICATI,Phase 1/2,Glaucoma,[ICD-11: 9C61]
T51408,ADRB3,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T51408,ADRB3,INDICATI,Terminated,Irritable bowel syndrome,[ICD-11: DD91]
T51408,ADRB3,INDICATI,Phase 2/3,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T51408,ADRB3,INDICATI,Phase 2,Left ventricular failure,ICD-11: BD11
T51408,ADRB3,INDICATI,Discontinued in Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T51408,ADRB3,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
T51408,ADRB3,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T51408,ADRB3,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T51425,VEGFC,TARGETID,T51425,,
T51425,VEGFC,TARGNAME,Vascular endothelial growth factor C (VEGFC),,
T51425,VEGFC,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T51425,VEGFC,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T51426,NR1H4,TARGETID,T51426,,
T51426,NR1H4,TARGNAME,Farnesoid X-activated receptor (FXR),,
T51426,NR1H4,INDICATI,Approved,Autoimmune liver disease,[ICD-11: DB96]
T51426,NR1H4,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T51426,NR1H4,INDICATI,Approved,Cholelithiasis,[ICD-11: DC11]
T51426,NR1H4,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T51426,NR1H4,INDICATI,Phase 1,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T51426,NR1H4,INDICATI,Phase 1,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T51426,NR1H4,INDICATI,Clinical trial,Insomnia,[ICD-11: 7A00-7A0Z]
T51426,NR1H4,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T51426,NR1H4,INDICATI,Approved,Osteoarthritis,[ICD-11: FA00-FA05]
T51426,NR1H4,INDICATI,Phase 2,Skeletal anomaly,[ICD-11: LD24]
T51426,NR1H4,INDICATI,Discontinued in Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T51452,GABRA2,TARGETID,T51452,,
T51452,GABRA2,TARGNAME,GABA(A) receptor alpha-2 (GABRA2),,
T51452,GABRA2,INDICATI,Discontinued in Phase 2,General pain disorder,[ICD-11: 8E43]
T51452,GABRA2,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T51452,GABRA2,INDICATI,Approved,Intentional self-harm,[ICD-11: PC91]
T51452,GABRA2,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T51452,GABRA2,INDICATI,Terminated,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T51468,#N/A,TARGETID,T51468,,
T51468,#N/A,TARGNAME,Cdc-like kinase (CLK),,
T51468,#N/A,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T51487,GABRA1,TARGETID,T51487,,
T51487,GABRA1,TARGNAME,GABA(A) receptor alpha-1 (GABRA1),,
T51487,GABRA1,INDICATI,Approved,Acute respiratory distress syndrome,[ICD-11: CB00]
T51487,GABRA1,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T51487,GABRA1,INDICATI,Approved,Chronic insomnia,[ICD-11: 7A00]
T51487,GABRA1,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T51487,GABRA1,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T51487,GABRA1,INDICATI,Approved,Cystitis,[ICD-11: GC00]
T51487,GABRA1,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T51487,GABRA1,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T51487,GABRA1,INDICATI,Discontinued in Phase 3,Female pelvic pain,[ICD-11: GA34]
T51487,GABRA1,INDICATI,Approved,Headache,[ICD-11: 8A80-8A84]
T51487,GABRA1,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T51487,GABRA1,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T51487,GABRA1,INDICATI,Discontinued in Phase 1,Liver vascular disorder,[ICD-11: DB98]
T51487,GABRA1,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T51487,GABRA1,INDICATI,Approved,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T51487,GABRA1,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T51487,GABRA1,INDICATI,Phase 3,Status epilepticus,[ICD-11: 8A66]
T51487,GABRA1,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
T51487,GABRA1,INDICATI,Phase 2,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T51499,GM2A,TARGETID,T51499,,
T51499,GM2A,TARGNAME,Ganglioside GM2 activator (GM2A),,
T51499,GM2A,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T51565,CSNK2A1,TARGETID,T51565,,
T51565,CSNK2A1,TARGNAME,Casein kinase II alpha (CSNK2A1),,
T51565,CSNK2A1,INDICATI,Phase 2,Coronavirus infection,[ICD-11: 1D92]
T51565,CSNK2A1,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T51565,CSNK2A1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T51593,TPH1; TPH2,TARGETID,T51593,,
T51593,TPH1; TPH2,TARGNAME,Tryptophan hydroxylase (TPH),,
T51593,TPH1; TPH2,INDICATI,Approved,Carcinoid syndrome,[ICD-11: 5B10]
T51593,TPH1; TPH2,INDICATI,Approved,Small intestine developmental anomaly,[ICD-11: DA90]
,#N/A,,,,
T51666,ATP4A,TARGETID,T51666,,
T51666,ATP4A,TARGNAME,Gastric H(+)/K(+) ATPase alpha (ATP4A),,
T51666,ATP4A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T51666,ATP4A,INDICATI,Investigative,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T51666,ATP4A,INDICATI,Investigative,Colorectal cancer,[ICD-11: 2B91]
T51666,ATP4A,INDICATI,Phase 3,Gastric ulcer,[ICD-11: DA60]
T51666,ATP4A,INDICATI,Approved,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T51666,ATP4A,INDICATI,Investigative,Helicobacter infection,[ICD-11: DA42-DA63]
T51666,ATP4A,INDICATI,Approved,Oesophageal ulcer,[ICD-11: DA25]
T51666,ATP4A,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T51666,ATP4A,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T51666,ATP4A,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T51672,NFKBIA,TARGETID,T51672,,
T51672,NFKBIA,TARGNAME,NF-kappa-B inhibitor alpha (NFKBIA),,
T51672,NFKBIA,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T51672,NFKBIA,INDICATI,Phase 2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
,#N/A,,,,
T51693,MAGEA3,TARGETID,T51693,,
T51693,MAGEA3,TARGNAME,Melanoma-associated antigen 3 (MAGEA3),,
T51693,MAGEA3,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T51693,MAGEA3,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T51693,MAGEA3,INDICATI,Phase 2,Lip/oral cavity/pharynx neoplasm,[ICD-11: 2B6E]
T51693,MAGEA3,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T51693,MAGEA3,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T51693,MAGEA3,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T51693,MAGEA3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T51693,MAGEA3,INDICATI,Phase 2,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
,#N/A,,,,
T51694,#N/A,TARGETID,T51694,,
T51694,#N/A,TARGNAME,Histone synthesis (Histone synth),,
T51694,#N/A,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T51748,HIF1A,TARGETID,T51748,,
T51748,HIF1A,TARGNAME,HIF1-alpha messenger RNA (HIF1A mRNA),,
T51748,HIF1A,INDICATI,Phase 2,Adrenomedullary hyperfunction,[ICD-11: 5A75]
T51748,HIF1A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
,#N/A,,,,
T51803,#N/A,TARGETID,T51803,,
T51803,#N/A,TARGNAME,microRNA hsa-miR-34 (MIR34),,
T51803,#N/A,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
,#N/A,,,,
T51843,Viru RdRP,TARGETID,T51843,,
T51843,Viru RdRP,TARGNAME,Virus RNA-dependent RNA polymerase (Viru RdRP),,
T51843,Viru RdRP,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T51843,Viru RdRP,INDICATI,Investigative,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T51883,ARAF; BRAF; RAF1,TARGETID,T51883,,
T51883,ARAF; BRAF; RAF1,TARGNAME,Serine/threonine-protein kinase Raf (RAF),,
T51883,ARAF; BRAF; RAF1,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T51883,ARAF; BRAF; RAF1,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
T51883,ARAF; BRAF; RAF1,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T51883,ARAF; BRAF; RAF1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T51908,CRY2,TARGETID,T51908,,
T51908,CRY2,TARGNAME,Cryptochrome-2 (CRY2),,
T51908,CRY2,INDICATI,Preclinical,Brain cancer,[ICD-11: 2A00]
T51908,CRY2,INDICATI,Preclinical,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T52007,#N/A,TARGETID,T52007,,
T52007,#N/A,TARGNAME,Peripheral carotid chemoreceptor (PCC),,
T52007,#N/A,INDICATI,Approved,Respiratory system disease,[ICD-11: CB40-CB7Z]
,#N/A,,,,
T52034,SERPINH1,TARGETID,T52034,,
T52034,SERPINH1,TARGNAME,SERPINH1 messenger RNA (SERPINH1 mRNA),,
T52034,SERPINH1,INDICATI,Phase 2,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
,#N/A,,,,
T52036,USP20,TARGETID,T52036,,
T52036,USP20,TARGNAME,Ubiquitin carboxyl-terminal hydrolase 20 (USP20),,
T52036,USP20,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T52037,TLR6,TARGETID,T52037,,
T52037,TLR6,TARGNAME,Toll-like receptor 6 (TLR6),,
T52037,TLR6,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T52098,OTC,TARGETID,T52098,,
T52098,OTC,TARGNAME,Ornithine transcarbamylase (OTC),,
T52098,OTC,INDICATI,Phase 3,Metabolism inborn error,[ICD-11: 5C50]
,#N/A,,,,
T52110,LBP,TARGETID,T52110,,
T52110,LBP,TARGNAME,Lipopolysaccharide-binding protein (LBP),,
T52110,LBP,INDICATI,Discontinued in Phase 2,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T52138,HBV S mRNA,TARGETID,T52138,,
T52138,HBV S mRNA,TARGNAME,Hepatitis B virus Large envelope protein messenger RNA (HBV S mRNA),,
T52138,HBV S mRNA,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T52173,SCNN1A; SCNN1B; SCNN1G; SCNN1D,TARGETID,T52173,,
T52173,SCNN1A; SCNN1B; SCNN1G; SCNN1D,TARGNAME,Amiloride-sensitive sodium channel (ENaC),,
T52173,SCNN1A; SCNN1B; SCNN1G; SCNN1D,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T52173,SCNN1A; SCNN1B; SCNN1G; SCNN1D,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T52173,SCNN1A; SCNN1B; SCNN1G; SCNN1D,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T52173,SCNN1A; SCNN1B; SCNN1G; SCNN1D,INDICATI,Phase 2,Lung structural developmental anomaly,[ICD-11: LA75]
T52173,SCNN1A; SCNN1B; SCNN1G; SCNN1D,INDICATI,Approved,Oedema,[ICD-11: MG29]
,#N/A,,,,
T52188,Malaria ACC1,TARGETID,T52188,,
T52188,Malaria ACC1,TARGNAME,Plasmodium Acetyl-CoA carboxylase 1 (Malaria ACC1),,
T52188,Malaria ACC1,INDICATI,Investigative,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T52189,ACLY,TARGETID,T52189,,
T52189,ACLY,TARGNAME,ATP-citrate synthase (ACLY),,
T52189,ACLY,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T52189,ACLY,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T52227,Candi TMP1,TARGETID,T52227,,
T52227,Candi TMP1,TARGNAME,Candida Thymidylate synthase (Candi TMP1),,
T52227,Candi TMP1,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T52227,Candi TMP1,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T52227,Candi TMP1,INDICATI,Approved,Colon cancer,[ICD-11: 2B90]
T52227,Candi TMP1,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T52227,Candi TMP1,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T52227,Candi TMP1,INDICATI,Phase 1,Digestive organ benign neoplasm,[ICD-11: 2E92]
T52227,Candi TMP1,INDICATI,Approved,Endocarditis,[ICD-11: BB40-BA42]
T52227,Candi TMP1,INDICATI,Approved,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T52227,Candi TMP1,INDICATI,Terminated,Keratosis pilaris,[ICD-11: ED56]
T52227,Candi TMP1,INDICATI,Approved,Pleural mesothelioma,[ICD-11: 2C26]
T52227,Candi TMP1,INDICATI,Approved,Rectum cancer,[ICD-11: 2B92]
T52227,Candi TMP1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T52227,Candi TMP1,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
T52227,Candi TMP1,INDICATI,Approved,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T52258,#N/A,TARGETID,T52258,,
T52258,#N/A,TARGNAME,Hepatitis B virus messenger RNA (HBV mRNA),,
T52258,#N/A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T52297,NR1H3,TARGETID,T52297,,
T52297,NR1H3,TARGNAME,Oxysterols receptor LXR-alpha (NR1H3),,
T52297,NR1H3,INDICATI,Investigative,Depression,[ICD-11: 6A70-6A7Z]
,#N/A,,,,
T52316,RAF1,TARGETID,T52316,,
T52316,RAF1,TARGNAME,Raf messenger RNA (Raf mRNA),,
T52316,RAF1,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T52316,RAF1,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T52316,RAF1,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T52316,RAF1,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T52316,RAF1,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T52316,RAF1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T52349,Ente-cocc fsrC,TARGETID,T52349,,
T52349,Ente-cocc fsrC,TARGNAME,Enterococcus fsrC (Ente-cocc fsrC),,
T52349,Ente-cocc fsrC,INDICATI,Preclinical,Infectious meningitis,[ICD-11: 1D01]
,#N/A,,,,
T52389,NQO1,TARGETID,T52389,,
T52389,NQO1,TARGNAME,Quinone reductase 1 (NQO1),,
T52389,NQO1,INDICATI,Phase 2,Choreiform disorder,[ICD-11: 8A01]
T52389,NQO1,INDICATI,Phase 2,CNS anomalies syndrome,[ICD-11: LD20]
T52389,NQO1,INDICATI,Phase 2,Inborn energy metabolism error,[ICD-11: 5C53]
T52389,NQO1,INDICATI,Phase 2,Intellectual development disorder,[ICD-11: LD90]
T52389,NQO1,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T52389,NQO1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T52450,MMP1,TARGETID,T52450,,
T52450,MMP1,TARGNAME,Matrix metalloproteinase-1 (MMP-1),,
T52450,MMP1,INDICATI,Discontinued in Phase 3,Brain cancer,[ICD-11: 2A00]
T52450,MMP1,INDICATI,Discontinued in Phase 2,Chronic kidney disease,[ICD-11: GB61]
T52450,MMP1,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T52450,MMP1,INDICATI,Discontinued in Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T52450,MMP1,INDICATI,Discontinued in Phase 3,Kaposi sarcoma,[ICD-11: 2B57]
T52450,MMP1,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T52450,MMP1,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
T52450,MMP1,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T52450,MMP1,INDICATI,Discontinued in Phase 3,Prostate cancer,[ICD-11: 2C82]
T52450,MMP1,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T52450,MMP1,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T52489,RAPGEF3,TARGETID,T52489,,
T52489,RAPGEF3,TARGNAME,Rap guanine nucleotide exchange factor 3 (RAPGEF3),,
T52489,RAPGEF3,INDICATI,Phase 2,Epidermal dysplasias,[ICD-11: EK90]
,#N/A,,,,
T52522,ADRB2,TARGETID,T52522,,
T52522,ADRB2,TARGNAME,Adrenergic receptor beta-2 (ADRB2),,
T52522,ADRB2,INDICATI,Approved,Asthma,[ICD-11: CA23]
T52522,ADRB2,INDICATI,Phase 1,Bladder disorder,[ICD-11: GC01]
T52522,ADRB2,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T52522,ADRB2,INDICATI,Phase 2,Cachexia,[ICD-11: MG20]
T52522,ADRB2,INDICATI,Terminated,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T52522,ADRB2,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T52522,ADRB2,INDICATI,Approved,Conduction disorder,[ICD-11: BC63]
T52522,ADRB2,INDICATI,Phase 2,Dermal/subcutaneous connective tissue atrophy/degeneration,[ICD-11: EE40]
T52522,ADRB2,INDICATI,Discontinued in Preregistration,Ejaculatory dysfunction,[ICD-11: HA03]
T52522,ADRB2,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T52522,ADRB2,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T52522,ADRB2,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T52522,ADRB2,INDICATI,Approved,Preterm labour/delivery,[ICD-11: JB00]
T52522,ADRB2,INDICATI,Phase 2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T52522,ADRB2,INDICATI,Approved,Sleep-related breathing disorder,[ICD-11: 7A4Z]
T52522,ADRB2,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T52522,ADRB2,INDICATI,Phase 2/3,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T52534,#N/A,TARGETID,T52534,,
T52534,#N/A,TARGNAME,Bacterial Protein synthesis (Bact PROS),,
T52534,#N/A,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
T52534,#N/A,INDICATI,Phase 2,Bacterial infection,[ICD-11: 1A00-1C4Z]
T52534,#N/A,INDICATI,Phase 2,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T52534,#N/A,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T52624,#N/A,TARGETID,T52624,,
T52624,#N/A,TARGNAME,Platelet-derived growth factor receptor (PDGFR),,
T52624,#N/A,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T52624,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T52624,#N/A,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T52624,#N/A,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T52624,#N/A,INDICATI,Approved,Diabetic foot ulcer,[ICD-11: BD54]
T52624,#N/A,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T52624,#N/A,INDICATI,Approved,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T52624,#N/A,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T52624,#N/A,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T52624,#N/A,INDICATI,Phase 3,Malignant intestine neoplasm,[ICD-11: 2C0Z]
T52624,#N/A,INDICATI,Investigative,Mastocytosis,[ICD-11: 2A21]
T52624,#N/A,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T52624,#N/A,INDICATI,Investigative,Multiple myeloma,[ICD-11: 2A83]
T52624,#N/A,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T52624,#N/A,INDICATI,Phase 4,Myocardial infarction,[ICD-11: BA41-BA43]
T52624,#N/A,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
T52624,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T52624,#N/A,INDICATI,Phase 3,Peritoneal cancer,[ICD-11: 2C51]
T52624,#N/A,INDICATI,Patented,Pulmonary hypertension,[ICD-11: BB01]
T52624,#N/A,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T52624,#N/A,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T52624,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T52624,#N/A,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T52671,LPA,TARGETID,T52671,,
T52671,LPA,TARGNAME,Apolipoprotein(a) (LPA),,
T52671,LPA,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T52671,LPA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T52771,MycB Prop,TARGETID,T52771,,
T52771,MycB Prop,TARGNAME,Mycobacterium Proton pump (MycB Prop),,
T52771,MycB Prop,INDICATI,Approved,Antimicrobial drug resistance,[ICD-11: MG50-MG52]
,#N/A,,,,
T52790,TACR2,TARGETID,T52790,,
T52790,TACR2,TARGNAME,Substance-K receptor (TACR2),,
T52790,TACR2,INDICATI,Discontinued in Phase 1,Abnormal micturition,[ICD-11: MF50]
T52790,TACR2,INDICATI,Discontinued in Phase 1,Acute/chronic pain,[ICD-11: MG30-MG31]
T52790,TACR2,INDICATI,Discontinued in Phase 3,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T52790,TACR2,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T52790,TACR2,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T52790,TACR2,INDICATI,Discontinued in Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T52790,TACR2,INDICATI,Discontinued in Phase 3,Depression,[ICD-11: 6A70-6A7Z]
T52790,TACR2,INDICATI,Phase 1/2,Infants/toddlers/children functional digestive disorder,[ICD-11: DD93]
T52790,TACR2,INDICATI,Phase 3,Irritable bowel syndrome,[ICD-11: DD91]
T52790,TACR2,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T52790,TACR2,INDICATI,Phase 1/2,Postoperative ileus,[ICD-11: DA91-DB30]
T52790,TACR2,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T52873,#N/A,TARGETID,T52873,,
T52873,#N/A,TARGNAME,3-oxo-dodecanoyl-homoserine lactone (C12),,
T52873,#N/A,INDICATI,Preclinical,Glanders,[ICD-11: 1B92]
,#N/A,,,,
T52910,USP30,TARGETID,T52910,,
T52910,USP30,TARGNAME,Ubiquitin carboxyl-terminal hydrolase 30 (USP30),,
T52910,USP30,INDICATI,Preclinical,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
,#N/A,,,,
T52921,OPRL1,TARGETID,T52921,,
T52921,OPRL1,TARGNAME,Nociceptin receptor (OPRL1),,
T52921,OPRL1,INDICATI,Investigative,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T52921,OPRL1,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T52921,OPRL1,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T52921,OPRL1,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T52921,OPRL1,INDICATI,Phase 1,Headache,[ICD-11: 8A80-8A84]
T52921,OPRL1,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T52921,OPRL1,INDICATI,Preclinical,Irritable bowel syndrome,[ICD-11: DD91]
T52921,OPRL1,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T52921,OPRL1,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T52921,OPRL1,INDICATI,Investigative,Stress,[ICD-11: 6B40-6B45]
,#N/A,,,,
T52937,AGRP,TARGETID,T52937,,
T52937,AGRP,TARGNAME,Agouti-related protein (AGRP),,
T52937,AGRP,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T52953,CRP,TARGETID,T52953,,
T52953,CRP,TARGNAME,CRP messenger RNA (CRP mRNA),,
T52953,CRP,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T52953,CRP,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
T52953,CRP,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T52969,#N/A,TARGETID,T52969,,
T52969,#N/A,TARGNAME,CAP-dependent endonuclease (CDE),,
T52969,#N/A,INDICATI,Discontinued in Phase 2,Colon cancer,[ICD-11: 2B90]
T52969,#N/A,INDICATI,Discontinued in Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T52969,#N/A,INDICATI,Discontinued in Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T53024,SSTR2,TARGETID,T53024,,
T53024,SSTR2,TARGNAME,Somatostatin receptor type 2 (SSTR2),,
T53024,SSTR2,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T53024,SSTR2,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T53024,SSTR2,INDICATI,Approved,Diagnostic imaging,[ICD-11: N.A.]
T53024,SSTR2,INDICATI,Phase 2,Endocrine gland neoplasm,[ICD-11: 2F37]
T53024,SSTR2,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T53024,SSTR2,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T53024,SSTR2,INDICATI,Phase 1/2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T53103,NAGLU,TARGETID,T53103,,
T53103,NAGLU,TARGNAME,Alpha-N-acetylglucosaminidase (NAGLU),,
T53103,NAGLU,INDICATI,Approved,Diabetes mellitus,[ICD-11: 5A10]
T53103,NAGLU,INDICATI,Phase 1/2,Lysosomal disease,[ICD-11: 5C56]
T53103,NAGLU,INDICATI,Phase 1/2,Lysosomal disease,ICD-11: 5C56
,#N/A,,,,
T53139,ANGPTL3,TARGETID,T53139,,
T53139,ANGPTL3,TARGNAME,Angiopoietin-related protein 3 (ANGPTL3),,
T53139,ANGPTL3,INDICATI,Phase 2,Blood/blood-forming organ sympton,[ICD-11: MA14]
T53139,ANGPTL3,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T53139,ANGPTL3,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T53139,ANGPTL3,INDICATI,Phase 2,Knee osteoarthritis,[ICD-11: FA01]
,#N/A,,,,
T53242,MycB cmaA1; MycB cmaA2; MycB pcaA,TARGETID,T53242,,
T53242,MycB cmaA1; MycB cmaA2; MycB pcaA,TARGNAME,Mycobacterium Mycolic acid synthase (MycB cma),,
T53242,MycB cmaA1; MycB cmaA2; MycB pcaA,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T53242,MycB cmaA1; MycB cmaA2; MycB pcaA,INDICATI,Phase 3,Mycobacterium infection,[ICD-11: 1B10-1B21]
,#N/A,,,,
T53251,EHMT2,TARGETID,T53251,,
T53251,EHMT2,TARGNAME,Histone-lysine N-methyltransferase EHMT2 (EHMT2),,
T53251,EHMT2,INDICATI,Preclinical,Breast cancer,[ICD-11: 2C60-2C6Y]
T53251,EHMT2,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
T53251,EHMT2,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T53378,CA4,TARGETID,T53378,,
T53378,CA4,TARGNAME,Carbonic anhydrase IV (CA-IV),,
T53378,CA4,INDICATI,Phase 1/2,Asthma,[ICD-11: CA23]
T53378,CA4,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T53378,CA4,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T53378,CA4,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T53378,CA4,INDICATI,Approved,Seborrhoeic dermatitis,[ICD-11: EA81]
T53378,CA4,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T53381,ADRA1D,TARGETID,T53381,,
T53381,ADRA1D,TARGNAME,Adrenergic receptor alpha-1D (ADRA1D),,
T53381,ADRA1D,INDICATI,Discontinued in Phase 2,Abnormal micturition,[ICD-11: MF50]
T53381,ADRA1D,INDICATI,Discontinued in Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T53381,ADRA1D,INDICATI,Discontinued in Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T53381,ADRA1D,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T53381,ADRA1D,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T53381,ADRA1D,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T53381,ADRA1D,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T53381,ADRA1D,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T53381,ADRA1D,INDICATI,Discontinued in Phase 2,Prostate disease,[ICD-11: GA91]
T53381,ADRA1D,INDICATI,Approved,Prostate hyperplasia,[ICD-11: GA90]
T53381,ADRA1D,INDICATI,Approved,Sexual dysfunction,[ICD-11: HA00-HA01]
T53381,ADRA1D,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T53389,TGFBR1,TARGETID,T53389,,
T53389,TGFBR1,TARGNAME,TGF-beta receptor type I (TGFBR1),,
T53389,TGFBR1,INDICATI,Phase 2/3,Arterial occlusive disease,[ICD-11: BD40]
T53389,TGFBR1,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T53389,TGFBR1,INDICATI,Investigative,Cachexia,[ICD-11: MG20]
T53389,TGFBR1,INDICATI,Terminated,Fibrosis,[ICD-11: GA14-GC01]
T53389,TGFBR1,INDICATI,Preclinical,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T53389,TGFBR1,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T53389,TGFBR1,INDICATI,Phase 2/3,Lung cancer,[ICD-11: 2C25]
T53389,TGFBR1,INDICATI,Phase 1/2,Myelodysplastic syndrome,[ICD-11: 2A37]
T53389,TGFBR1,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T53389,TGFBR1,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T53389,TGFBR1,INDICATI,Investigative,Pulmonary disease,[ICD-11: 1B10-1F85]
T53389,TGFBR1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T53389,TGFBR1,INDICATI,Phase 1/2,Systemic sclerosis,[ICD-11: 4A42]
T53389,TGFBR1,INDICATI,Phase 2,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T53472,KIR2DL3,TARGETID,T53472,,
T53472,KIR2DL3,TARGNAME,MHC class I NK cell receptor 2DL3 (CD158b2),,
T53472,KIR2DL3,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T53472,KIR2DL3,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T53524,PDGFRA,TARGETID,T53524,,
T53524,PDGFRA,TARGNAME,Platelet-derived growth factor receptor alpha (PDGFRA),,
T53524,PDGFRA,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T53524,PDGFRA,INDICATI,Phase 2,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T53524,PDGFRA,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T53524,PDGFRA,INDICATI,Patented,Breast cancer,[ICD-11: 2C60-2C6Y]
T53524,PDGFRA,INDICATI,Patented,Colon cancer,[ICD-11: 2B90]
T53524,PDGFRA,INDICATI,Patented,Colorectal cancer,[ICD-11: 2B91]
T53524,PDGFRA,INDICATI,Approved,Gastrointestinal stromal tumour,[ICD-11: 2B5B]
T53524,PDGFRA,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T53524,PDGFRA,INDICATI,Approved,Kaposi sarcoma,[ICD-11: 2B57]
T53524,PDGFRA,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T53524,PDGFRA,INDICATI,Phase 3,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T53524,PDGFRA,INDICATI,Phase 1,Mastocytosis,[ICD-11: 2A21]
T53524,PDGFRA,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T53524,PDGFRA,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T53524,PDGFRA,INDICATI,Patented,Pancreatic cancer,[ICD-11: 2C10]
T53524,PDGFRA,INDICATI,Patented,Prostate cancer,[ICD-11: 2C82]
T53524,PDGFRA,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T53524,PDGFRA,INDICATI,Patented,Stomach cancer,[ICD-11: 2B72]
T53524,PDGFRA,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T53549,#N/A,TARGETID,T53549,,
T53549,#N/A,TARGNAME,Protein thiol group (PTG),,
T53549,#N/A,INDICATI,Discontinued in Phase 1,Indeterminate colitis,[ICD-11: DD72]
,#N/A,,,,
T53585,HMGCR,TARGETID,T53585,,
T53585,HMGCR,TARGNAME,HMG-CoA reductase (HMGCR),,
T53585,HMGCR,INDICATI,Discontinued in Phase 3,Arterial occlusive disease,[ICD-11: BD40]
T53585,HMGCR,INDICATI,Phase 3,Blood/blood-forming organ sympton,[ICD-11: MA14]
T53585,HMGCR,INDICATI,Approved,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T53585,HMGCR,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T53585,HMGCR,INDICATI,Approved,Dyslipidemia,[ICD-11: 5C80-5C81]
T53585,HMGCR,INDICATI,Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T53585,HMGCR,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T53585,HMGCR,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T53585,HMGCR,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T53585,HMGCR,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T53585,HMGCR,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T53585,HMGCR,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T53585,HMGCR,INDICATI,Discontinued in Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T53588,Bact fabI,TARGETID,T53588,,
T53588,Bact fabI,TARGNAME,Bacterial NADH-dependent enoyl-ACP reductase (Bact fabI),,
T53588,Bact fabI,INDICATI,Preclinical,Anaerobic bacterial infection,[ICD-11: 1A00-1A09]
,#N/A,,,,
T53601,#N/A,TARGETID,T53601,,
T53601,#N/A,TARGNAME,Bacterial 50S ribosomal RNA (Bact 50S rRNA),,
T53601,#N/A,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T53601,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T53601,#N/A,INDICATI,Approved,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T53601,#N/A,INDICATI,Approved,Impetigo,[ICD-11: 1B72]
T53601,#N/A,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T53601,#N/A,INDICATI,Phase 1,Respiratory infection,[ICD-11: CA07-CA4Z]
T53601,#N/A,INDICATI,Phase 3,Sepsis,[ICD-11: 1G40-1G41]
T53601,#N/A,INDICATI,Approved,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T53601,#N/A,INDICATI,Approved,Syphilis,[ICD-11: 1A61-1A6Z]
T53601,#N/A,INDICATI,Phase 3,Vaginal discharge,[ICD-11: MF3A]
,#N/A,,,,
T53640,HBV S,TARGETID,T53640,,
T53640,HBV S,TARGNAME,Hepatitis B virus Large envelope protein (HBV S),,
T53640,HBV S,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T53669,CRLF2,TARGETID,T53669,,
T53669,CRLF2,TARGNAME,Thymic stromal lymphoprotein receptor (CRLF2),,
T53669,CRLF2,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
,#N/A,,,,
T53684,#N/A,TARGETID,T53684,,
T53684,#N/A,TARGNAME,Inflammation pathogenesis (IP),,
T53684,#N/A,INDICATI,Phase 3,Indeterminate colitis,[ICD-11: DD72]
,#N/A,,,,
T53748,Malaria fabI,TARGETID,T53748,,
T53748,Malaria fabI,TARGNAME,Plasmodium Enoyl-ACP reductase (Malaria fabI),,
T53748,Malaria fabI,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T53748,Malaria fabI,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T53748,Malaria fabI,INDICATI,Investigative,Trypanosomiasis,[ICD-11: 1D51-1F53]
T53748,Malaria fabI,INDICATI,Investigative,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T53764,FAP,TARGETID,T53764,,
T53764,FAP,TARGNAME,Prolyl endopeptidase FAP (FAP),,
T53764,FAP,INDICATI,Preclinical,Colon cancer,[ICD-11: 2B90]
T53764,FAP,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T53764,FAP,INDICATI,Investigative,Indeterminate colitis,[ICD-11: DD72]
T53764,FAP,INDICATI,Preclinical,Lung cancer,[ICD-11: 2C25]
T53764,FAP,INDICATI,Phase 3,Neutropenia,[ICD-11: 4B00]
T53764,FAP,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T53811,HPV E6,TARGETID,T53811,,
T53811,HPV E6,TARGNAME,Human papillomavirus protein E6 (HPV E6),,
T53811,HPV E6,INDICATI,Phase 3,Cervical intraepithelial neoplasia,[ICD-11: 2E66]
T53811,HPV E6,INDICATI,Phase 3,Dysplasia,[ICD-11: LB30-LD2F]
T53811,HPV E6,INDICATI,Phase 2,Genital organ in situ carcinoma,[ICD-11: 2E67]
T53811,HPV E6,INDICATI,Phase 2,Sexually transmitted infection,[ICD-11: 1A9Y-1A9Z]
,#N/A,,,,
T53903,HCV NS3 mRNA,TARGETID,T53903,,
T53903,HCV NS3 mRNA,TARGNAME,Hepatitis C virus NS3 helicase messenger RNA (HCV NS3 mRNA),,
T53903,HCV NS3 mRNA,INDICATI,Discontinued in Phase 1/2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T53904,EGLN2,TARGETID,T53904,,
T53904,EGLN2,TARGNAME,HIF-prolyl hydroxylase 1 (HPH-1),,
T53904,EGLN2,INDICATI,Approved,Acute disease anaemia,[ICD-11: 3A90]
T53904,EGLN2,INDICATI,Phase 2,Anemia,[ICD-11: 3A00-3A9Z]
T53904,EGLN2,INDICATI,Phase 2,Autism spectrum disorder,[ICD-11: 6A02]
T53904,EGLN2,INDICATI,Phase 1,Diabetic foot ulcer,[ICD-11: BD54]
T53904,EGLN2,INDICATI,Phase 3,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T54031,RS1,TARGETID,T54031,,
T54031,RS1,TARGNAME,Retinoschisin (RS1),,
T54031,RS1,INDICATI,Phase 1/2,Retinal detachment,[ICD-11: 9B73]
,#N/A,,,,
T54055,LYVE1,TARGETID,T54055,,
T54055,LYVE1,TARGNAME,Hyaluronic acid receptor (LYVE1),,
T54055,LYVE1,INDICATI,Investigative,Aplastic anaemia,[ICD-11: 3A70]
T54055,LYVE1,INDICATI,Phase 3,Enthesopathy,[ICD-11: FB53-FB55]
T54055,LYVE1,INDICATI,Approved,Joint lubricant,[ICD-11: FA30-FA38]
T54055,LYVE1,INDICATI,Discontinued in Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T54065,Bact aroA,TARGETID,T54065,,
T54065,Bact aroA,TARGNAME,Bacterial Phosphoshikimate1-carboxyvinyltransferase (Bact aroA),,
T54065,Bact aroA,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T54093,T,TARGETID,T54093,,
T54093,T,TARGNAME,T-box transcription factor T (TBXT),,
T54093,T,INDICATI,Phase 2,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T54093,T,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T54128,#N/A,TARGETID,T54128,,
T54128,#N/A,TARGNAME,Glutamate receptor AMPA (GRIA),,
T54128,#N/A,INDICATI,Approved,Alzheimer disease,[ICD-11: 8A20]
T54128,#N/A,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T54128,#N/A,INDICATI,Approved,Appearance/behaviour symptom,[ICD-11: MB23]
T54128,#N/A,INDICATI,Phase 2,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T54128,#N/A,INDICATI,Discontinued in Phase 1,Cerebral ischaemia,[ICD-11: 8B1Z]
T54128,#N/A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T54128,#N/A,INDICATI,Phase 1,Coronary atherosclerosis,[ICD-11: BA80]
T54128,#N/A,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T54128,#N/A,INDICATI,Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T54128,#N/A,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T54128,#N/A,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T54128,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T54128,#N/A,INDICATI,Phase 1,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T54128,#N/A,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T54128,#N/A,INDICATI,Approved,Monitored anaesthesia care,[ICD-11: N.A.]
T54128,#N/A,INDICATI,Approved,Neuropathy,[ICD-11: 8C0Z]
T54128,#N/A,INDICATI,Phase 2,Obstructive sleep apnoea,[ICD-11: 7A41]
T54128,#N/A,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T54128,#N/A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T54128,#N/A,INDICATI,Approved,Pediculosis,[ICD-11: 1G00]
T54128,#N/A,INDICATI,Phase 2/3,Pervasive developmental disorder,[ICD-11: 6A00-6A0Z]
T54128,#N/A,INDICATI,Phase 2/3,Schizophrenia,[ICD-11: 6A20]
T54128,#N/A,INDICATI,Phase 2,Spine/trunk injury,[ICD-11: ND51]
T54128,#N/A,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T54132,KCNQ3,TARGETID,T54132,,
T54132,KCNQ3,TARGNAME,Voltage-gated potassium channel Kv7.3 (KCNQ3),,
T54132,KCNQ3,INDICATI,Approved,Behcet disease,[ICD-11: 4A62]
T54132,KCNQ3,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T54132,KCNQ3,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T54132,KCNQ3,INDICATI,Preclinical,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T54156,MMP9,TARGETID,T54156,,
T54156,MMP9,TARGNAME,Matrix metalloproteinase-9 (MMP-9),,
T54156,MMP9,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T54156,MMP9,INDICATI,Terminated,Colorectal cancer,[ICD-11: 2B91]
T54156,MMP9,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T54156,MMP9,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T54156,MMP9,INDICATI,Discontinued in Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T54156,MMP9,INDICATI,Phase 3,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T54156,MMP9,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T54156,MMP9,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
T54156,MMP9,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T54156,MMP9,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T54156,MMP9,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T54156,MMP9,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T54347,Candi CHS3,TARGETID,T54347,,
T54347,Candi CHS3,TARGNAME,Candida Chitin synthase 3 (Candi CHS3),,
T54347,Candi CHS3,INDICATI,Phase 1/2,Candidosis,[ICD-11: 1F23]
,#N/A,,,,
T54379,#N/A,TARGETID,T54379,,
T54379,#N/A,TARGNAME,Wnt signaling pathway (Wnt pathway),,
T54379,#N/A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T54379,#N/A,INDICATI,Phase 2/3,Alopecia,[ICD-11: ED70]
T54379,#N/A,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T54379,#N/A,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T54379,#N/A,INDICATI,Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T54379,#N/A,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T54379,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T54447,SERPINF1,TARGETID,T54447,,
T54447,SERPINF1,TARGNAME,Pigment epithelium-derived factor (SERPINF1),,
T54447,SERPINF1,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T54519,sch PNP,TARGETID,T54519,,
T54519,sch PNP,TARGNAME,Schistosoma Purine nucleoside phosphorylase (sch PNP),,
T54519,sch PNP,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T54582,NAMPT,TARGETID,T54582,,
T54582,NAMPT,TARGNAME,Nicotinamide phosphoribosyltransferase (NAMPT),,
T54582,NAMPT,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
T54582,NAMPT,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T54582,NAMPT,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T54606,Stap-coc lukF,TARGETID,T54606,,
T54606,Stap-coc lukF,TARGNAME,Staphylococcus Five leukocidin toxins (Stap-coc lukF),,
T54606,Stap-coc lukF,INDICATI,Phase 2,Medical/surgical procedure injury,[ICD-11: PK80-PK81]
T54606,Stap-coc lukF,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T54644,CACNA1H,TARGETID,T54644,,
T54644,CACNA1H,TARGNAME,Voltage-gated calcium channel alpha Cav3.2 (CACNA1H),,
T54644,CACNA1H,INDICATI,Approved,Acidosis,[ICD-11: 5C73]
T54644,CACNA1H,INDICATI,Investigative,Angina pectoris,[ICD-11: BA40]
T54644,CACNA1H,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T54644,CACNA1H,INDICATI,Preclinical,Insomnia,[ICD-11: 7A00-7A0Z]
T54644,CACNA1H,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T54644,CACNA1H,INDICATI,Withdrawn from market,Ovarian cancer,[ICD-11: 2C73]
T54644,CACNA1H,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T54644,CACNA1H,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T54761,MBP,TARGETID,T54761,,
T54761,MBP,TARGNAME,Myelin basic protein (MBP),,
T54761,MBP,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T54771,SLC5A1,TARGETID,T54771,,
T54771,SLC5A1,TARGNAME,Sodium/glucose cotransporter 1 (SGLT1),,
T54771,SLC5A1,INDICATI,Discontinued in Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T54771,SLC5A1,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T54771,SLC5A1,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T54771,SLC5A1,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T54789,RPGR,TARGETID,T54789,,
T54789,RPGR,TARGNAME,X-linked retinitis pigmentosa GTPase regulator (RPGR),,
T54789,RPGR,INDICATI,Phase 3,Inherited retinal dystrophy,ICD-11: 9B70
T54789,RPGR,INDICATI,Phase 2/3,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T54902,KIR2DL2,TARGETID,T54902,,
T54902,KIR2DL2,TARGNAME,MHC class I NK cell receptor 2DL2 (CD158b1),,
T54902,KIR2DL2,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T54902,KIR2DL2,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T54931,CHRNA2-CHRNA3,TARGETID,T54931,,
T54931,CHRNA2-CHRNA3,TARGNAME,Neuronal acetylcholine receptor alpha-2/alpha-3 (CHRNA2/A3),,
T54931,CHRNA2-CHRNA3,INDICATI,Investigative,Psychoactive substances use disorder,[ICD-11: 6C4G]
T54931,CHRNA2-CHRNA3,INDICATI,Discontinued in Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T54940,#N/A,TARGETID,T54940,,
T54940,#N/A,TARGNAME,Plasmodium Cysteine protease falcipain (Malaria CPF),,
T54940,#N/A,INDICATI,Terminated,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T55012,#N/A,TARGETID,T55012,,
T55012,#N/A,TARGNAME,Ion channel unspecific (IC),,
T55012,#N/A,INDICATI,Phase 2,Bipolar disorder,[ICD-11: 6A60]
T55012,#N/A,INDICATI,Terminated,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T55012,#N/A,INDICATI,Discontinued in Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T55012,#N/A,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
T55012,#N/A,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T55094,ASIC1,TARGETID,T55094,,
T55094,ASIC1,TARGNAME,Acid-sensing ion channel 1 (ASIC1),,
T55094,ASIC1,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T55094,ASIC1,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T55260,PPM1A,TARGETID,T55260,,
T55260,PPM1A,TARGNAME,Protein phosphatase 1A (PPM1A),,
T55260,PPM1A,INDICATI,Phase 2,Common warts,[ICD-11: 1E80]
T55260,PPM1A,INDICATI,Phase 3,Molluscum contagiosum,[ICD-11: 1E76]
,#N/A,,,,
T55269,#N/A,TARGETID,T55269,,
T55269,#N/A,TARGNAME,Nucleoside transporter (SLC),,
T55269,#N/A,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
,#N/A,,,,
T55273,DLL4,TARGETID,T55273,,
T55273,DLL4,TARGNAME,Delta-like protein 4 (DLL4),,
T55273,DLL4,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T55273,DLL4,INDICATI,Phase 1,Fallopian tube cancer,[ICD-11: 2C74]
T55273,DLL4,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T55273,DLL4,INDICATI,Phase 1,Peritoneal cancer,[ICD-11: 2C51]
T55273,DLL4,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,TARGETID,T55285,,
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,TARGNAME,Glycine receptor (GlyR),,
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,INDICATI,Phase 1,Cerebral ischaemia,[ICD-11: 8B1Z]
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,INDICATI,Phase 1,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,INDICATI,Discontinued in Phase 2,Migraine,[ICD-11: 8A80]
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,INDICATI,Discontinued in Phase 2,Nicotine use disorder,[ICD-11: 6C4A]
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,INDICATI,Terminated,Sepsis,[ICD-11: 1G40-1G41]
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
T55285,GLRA1; GLRA2; GLRA3; GLRA4; GLRB,INDICATI,Phase 1,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T55293,ITGA2,TARGETID,T55293,,
T55293,ITGA2,TARGNAME,Integrin alpha-2 (ITGA2),,
T55293,ITGA2,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T55293,ITGA2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T55302,NPPB,TARGETID,T55302,,
T55302,NPPB,TARGNAME,B-type natriuretic peptide (BNP),,
T55302,NPPB,INDICATI,Investigative,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T55352,#N/A,TARGETID,T55352,,
T55352,#N/A,TARGNAME,Amyloid precursor protein (APP),,
T55352,#N/A,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T55398,IRAK4,TARGETID,T55398,,
T55398,IRAK4,TARGNAME,Renal carcinoma antigen NY-REN-64 (IRAK-4),,
T55398,IRAK4,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T55398,IRAK4,INDICATI,Phase 1,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T55398,IRAK4,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T55398,IRAK4,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T55398,IRAK4,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T55398,IRAK4,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T55610,HIF1A,TARGETID,T55610,,
T55610,HIF1A,TARGNAME,Hypoxia-inducible factor 1 alpha (HIF-1A),,
T55610,HIF1A,INDICATI,Phase 4,Lymphoma,[ICD-11: 2A80-2A86]
T55610,HIF1A,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
T55610,HIF1A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T55643,#N/A,TARGETID,T55643,,
T55643,#N/A,TARGNAME,Heat shock protein (HSP),,
T55643,#N/A,INDICATI,Phase 2/3,Cerebral ischaemia,[ICD-11: 8B1Z]
T55643,#N/A,INDICATI,Phase 2/3,Idiopathic inflammatory myopathy,[ICD-11: 4A41]
T55643,#N/A,INDICATI,Phase 2,Meningococcal disease,[ICD-11: 1C1C]
,#N/A,,,,
T55654,CFTR,TARGETID,T55654,,
T55654,CFTR,TARGNAME,cAMP-dependent chloride channel (CFTR),,
T55654,CFTR,INDICATI,Phase 2,Bowel habit change,[ICD-11: ME05]
T55654,CFTR,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T55654,CFTR,INDICATI,Approved,Cystic fibrosis,[ICD-11: CA25]
T55654,CFTR,INDICATI,Approved,Intrathoracic organs injury,[ICD-11: NB32]
T55654,CFTR,INDICATI,Approved,Viral intestinal infection,[ICD-11: 1A2Z]
,#N/A,,,,
T55689,LIPE,TARGETID,T55689,,
T55689,LIPE,TARGNAME,Hormone sensitive lipase (LIPE),,
T55689,LIPE,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T55689,LIPE,INDICATI,Clinical trial,Pancreatitis,[ICD-11: DC31-DC34]
T55689,LIPE,INDICATI,Approved,Pediculosis,[ICD-11: 1G00]
,#N/A,,,,
T55703,RBP4,TARGETID,T55703,,
T55703,RBP4,TARGNAME,Plasma retinol-binding protein (RBP4),,
T55703,RBP4,INDICATI,Phase 3,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T55709,CHKA,TARGETID,T55709,,
T55709,CHKA,TARGNAME,Choline kinase (CHKA),,
T55709,CHKA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T55729,MAPK11,TARGETID,T55729,,
T55729,MAPK11,TARGNAME,Stress-activated protein kinase 2b (p38 beta),,
T55729,MAPK11,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T55729,MAPK11,INDICATI,Discontinued in Phase 1,Psoriasis,[ICD-11: EA90]
T55729,MAPK11,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T55781,MERTK,TARGETID,T55781,,
T55781,MERTK,TARGNAME,Tyrosine-protein kinase Mer (MERTK),,
T55781,MERTK,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T55781,MERTK,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T55781,MERTK,INDICATI,Investigative,Brain cancer,[ICD-11: 2A00]
T55781,MERTK,INDICATI,Investigative,Mature B-cell lymphoma,[ICD-11: 2A85]
T55781,MERTK,INDICATI,Phase 1/2,Myelodysplastic syndrome,[ICD-11: 2A37]
T55781,MERTK,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T55815,CHRNA2,TARGETID,T55815,,
T55815,CHRNA2,TARGNAME,Neuronal acetylcholine receptor alpha-2 (CHRNA2),,
T55815,CHRNA2,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T55815,CHRNA2,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T55815,CHRNA2,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T55815,CHRNA2,INDICATI,Approved,Nicotine use disorder,[ICD-11: 6C4A]
T55815,CHRNA2,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T55860,TNFSF4,TARGETID,T55860,,
T55860,TNFSF4,TARGNAME,TAX transcriptionally-activated glycoprotein 1 (OX40),,
T55860,TNFSF4,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T55860,TNFSF4,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T55860,TNFSF4,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T55860,TNFSF4,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T55860,TNFSF4,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T55860,TNFSF4,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T55860,TNFSF4,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T55860,TNFSF4,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T55860,TNFSF4,INDICATI,Preclinical,Sexual dysfunction,[ICD-11: HA00-HA01]
T55860,TNFSF4,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T55860,TNFSF4,INDICATI,Phase 2,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T55922,AMD1,TARGETID,T55922,,
T55922,AMD1,TARGNAME,S-adenosylmethionine decarboxylase proenzyme (AMD1),,
T55922,AMD1,INDICATI,Approved,Acidosis,[ICD-11: 5C73]
T55922,AMD1,INDICATI,Discontinued in Phase 2,Burn and burn infection,[ICD-11: ND90-NE2Z]
T55922,AMD1,INDICATI,Terminated,Head and neck cancer,[ICD-11: 2D42]
T55922,AMD1,INDICATI,Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T55922,AMD1,INDICATI,Terminated,Pneumonia,[ICD-11: CA40]
T55922,AMD1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T55936,MycB pssA,TARGETID,T55936,,
T55936,MycB pssA,TARGNAME,Mycobacterium CDP-diacylglycerol-inositol phosphatidyltransferase (MycB pssA),,
T55936,MycB pssA,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T55959,SLC6A3,TARGETID,T55959,,
T55959,SLC6A3,TARGNAME,Dopamine transporter (DAT),,
T55959,SLC6A3,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T55959,SLC6A3,INDICATI,Phase 3,Binge eating disorder,[ICD-11: 6B82]
T55959,SLC6A3,INDICATI,Phase 4,Bipolar disorder,[ICD-11: 6A60]
T55959,SLC6A3,INDICATI,Phase 2,Cocaine use disorder,[ICD-11: 6C45]
T55959,SLC6A3,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T55959,SLC6A3,INDICATI,Phase 3,Dementia,[ICD-11: 6D80-6D8Z]
T55959,SLC6A3,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T55959,SLC6A3,INDICATI,Discontinued in Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T55959,SLC6A3,INDICATI,Discontinued in Phase 1,General pain disorder,[ICD-11: 8E43]
T55959,SLC6A3,INDICATI,Phase 4,Intracranial injury,[ICD-11: NA07]
T55959,SLC6A3,INDICATI,Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T55959,SLC6A3,INDICATI,Approved,Narcolepsy,[ICD-11: 7A20]
T55959,SLC6A3,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T55959,SLC6A3,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T55959,SLC6A3,INDICATI,Phase 2,Stomach disease,[ICD-11: DA43-DA4Y]
T55959,SLC6A3,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T56051,UCHL1,TARGETID,T56051,,
T56051,UCHL1,TARGNAME,Ubiquitin thioesterase L1 (UCHL1),,
T56051,UCHL1,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T56175,LSS,TARGETID,T56175,,
T56175,LSS,TARGNAME,Lanosterol synthase (LSS),,
T56175,LSS,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
,#N/A,,,,
T56262,TPP1,TARGETID,T56262,,
T56262,TPP1,TARGNAME,Tripeptidyl-peptidase I (TPP1),,
T56262,TPP1,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
T56262,TPP1,INDICATI,Phase 1/2,Lysosomal disease,ICD-11: 5C56
T56262,TPP1,INDICATI,Approved,Metabolism inborn error,[ICD-11: 5C50]
,#N/A,,,,
T56269,IAPP,TARGETID,T56269,,
T56269,IAPP,TARGNAME,Islet amyloid polypeptide (IAPP),,
T56269,IAPP,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T56308,IL11,TARGETID,T56308,,
T56308,IL11,TARGNAME,Interleukin-11 (IL11),,
T56308,IL11,INDICATI,Phase 3,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T56349,CXCL9,TARGETID,T56349,,
T56349,CXCL9,TARGNAME,C-X-C motif chemokine 9 (CXCL9),,
T56349,CXCL9,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T56362,SLC44A4,TARGETID,T56362,,
T56362,SLC44A4,TARGNAME,Choline transporter-like protein 4 (SLC44A4),,
T56362,SLC44A4,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T56362,SLC44A4,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T56365,CD19,TARGETID,T56365,,
T56365,CD19,TARGNAME,B-lymphocyte surface antigen B4 (CD19),,
T56365,CD19,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T56365,CD19,INDICATI,Phase 2/3,B-cell lymphoma,[ICD-11: 2A86]
T56365,CD19,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T56365,CD19,INDICATI,Approved,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T56365,CD19,INDICATI,Phase 1/2,Diffuse large B-cell lymphoma,ICD-11: 2A81
T56365,CD19,INDICATI,Phase 2,Encephalopathy,[ICD-11: 8E47]
T56365,CD19,INDICATI,Phase 2/3,Follicular lymphoma,[ICD-11: 2A80]
T56365,CD19,INDICATI,Phase 0,Hodgkin lymphoma,[ICD-11: 2B30]
T56365,CD19,INDICATI,Phase 1,Immune system disease,[ICD-11: 4A01-4B41]
T56365,CD19,INDICATI,Phase 1,Immunoproliferative disorder,[ICD-11: 2B32]
T56365,CD19,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
T56365,CD19,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T56365,CD19,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T56365,CD19,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T56365,CD19,INDICATI,Phase 3,Mature B-cell leukaemia,[ICD-11: 2A82]
T56365,CD19,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T56365,CD19,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T56365,CD19,INDICATI,Approved,Nervous system paraneoplastic/autoimmune disorder,[ICD-11: 8E4A]
T56365,CD19,INDICATI,Phase 2,Neuromyelitis optica,[ICD-11: 8A43]
T56365,CD19,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T56365,CD19,INDICATI,Phase 2,Precursor B-lymphoblastic neoplasm,[ICD-11: 2A70]
T56365,CD19,INDICATI,Phase 1/2,Rheumatoid arthritis,[ICD-11: FA20]
T56365,CD19,INDICATI,Phase 3,Sjogren syndrome,[ICD-11: 4A43]
T56365,CD19,INDICATI,Phase 1,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T56367,#N/A,TARGETID,T56367,,
T56367,#N/A,TARGNAME,Phosphodiesterase 1 (PDE1),,
T56367,#N/A,INDICATI,Phase 1,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T56367,#N/A,INDICATI,Approved,Cerebral ischaemic stroke,[ICD-11: 8B11]
T56367,#N/A,INDICATI,Phase 1/2,Parkinsonism,[ICD-11: 8A00]
T56367,#N/A,INDICATI,Phase 1,Schizophrenia,[ICD-11: 6A20]
T56367,#N/A,INDICATI,Phase 1,Sex development malformative disorder,[ICD-11: LD2A]
T56367,#N/A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T56418,ALK,TARGETID,T56418,,
T56418,ALK,TARGNAME,ALK tyrosine kinase receptor (ALK),,
T56418,ALK,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T56418,ALK,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T56418,ALK,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T56418,ALK,INDICATI,Phase 1,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T56418,ALK,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T56418,ALK,INDICATI,Investigative,Lymphoma,[ICD-11: 2A80-2A86]
T56418,ALK,INDICATI,Approved,Mature T-cell lymphoma,[ICD-11: 2A90]
T56418,ALK,INDICATI,Patented,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T56418,ALK,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T56418,ALK,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T56510,BCL2L1,TARGETID,T56510,,
T56510,BCL2L1,TARGNAME,Apoptosis regulator Bcl-xL (BCL-xL),,
T56510,BCL2L1,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T56510,BCL2L1,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T56510,BCL2L1,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T56510,BCL2L1,INDICATI,Investigative,Mature T-cell lymphoma,[ICD-11: 2A90]
T56510,BCL2L1,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T56510,BCL2L1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T56518,HBV RT,TARGETID,T56518,,
T56518,HBV RT,TARGNAME,Hepatitis B virus Reverse transcriptase (HBV RT),,
T56518,HBV RT,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T56545,APOA1,TARGETID,T56545,,
T56545,APOA1,TARGNAME,Apolipoprotein A-I (APOA1),,
T56545,APOA1,INDICATI,Phase 1,Aortic valve stenosis,[ICD-11: BB70]
T56545,APOA1,INDICATI,Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T56545,APOA1,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T56545,APOA1,INDICATI,Discontinued in Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T56545,APOA1,INDICATI,Terminated,Lipidaemia,[ICD-11: 5C8Z]
T56545,APOA1,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
,#N/A,,,,
T56556,ABCG2,TARGETID,T56556,,
T56556,ABCG2,TARGNAME,ATP-binding cassette transporter G2 (ABCG2),,
T56556,ABCG2,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T56556,ABCG2,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T56588,GRIN2D,TARGETID,T56588,,
T56588,GRIN2D,TARGNAME,Glutamate receptor ionotropic NMDA 2D (GluN2D),,
T56588,GRIN2D,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
,#N/A,,,,
T56625,TPP2,TARGETID,T56625,,
T56625,TPP2,TARGNAME,Tripeptidyl-peptidase II (TPP2),,
T56625,TPP2,INDICATI,Discontinued in Phase 1,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T56697,DKK1,TARGETID,T56697,,
T56697,DKK1,TARGNAME,Dickkopf-related protein 1 (DKK1),,
T56697,DKK1,INDICATI,Phase 2,Biliary tract cancer,[ICD-11: 2C17]
T56697,DKK1,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T56697,DKK1,INDICATI,Phase 2,Esophageal cancer,[ICD-11: 2B70]
T56697,DKK1,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T56697,DKK1,INDICATI,Phase 1,Low bone mass disorder,[ICD-11: FB83]
T56697,DKK1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T56697,DKK1,INDICATI,Phase 1/2,Oesophagogastric junction cancer,[ICD-11: 2B71]
T56697,DKK1,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T56697,DKK1,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T56824,Vibrio tcpN,TARGETID,T56824,,
T56824,Vibrio tcpN,TARGNAME,Vibrio TCP pilus virulence regulatory protein (Vibrio tcpN),,
T56824,Vibrio tcpN,INDICATI,Preclinical,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T56915,HIV PR,TARGETID,T56915,,
T56915,HIV PR,TARGNAME,Human immunodeficiency virus Protease (HIV PR),,
T56915,HIV PR,INDICATI,Phase 3,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T56915,HIV PR,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T56915,HIV PR,INDICATI,Discontinued in Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T56923,CXCR2,TARGETID,T56923,,
T56923,CXCR2,TARGNAME,C-X-C chemokine receptor type 2 (CXCR2),,
T56923,CXCR2,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T56923,CXCR2,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T56923,CXCR2,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T56923,CXCR2,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
T56923,CXCR2,INDICATI,Withdrawn from market,Gout,[ICD-11: FA25]
T56923,CXCR2,INDICATI,Phase 2,Hidradenitis suppurativa,[ICD-11: ED92]
T56923,CXCR2,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T56923,CXCR2,INDICATI,Phase 2,Liver vascular disorder,[ICD-11: DB98]
T56923,CXCR2,INDICATI,Phase 2,Medical/surgical procedure injury,[ICD-11: PK80-PK81]
T56923,CXCR2,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T56923,CXCR2,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T56923,CXCR2,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T56923,CXCR2,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T56923,CXCR2,INDICATI,Preclinical,Schizophrenia,[ICD-11: 6A20]
T56923,CXCR2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T56923,CXCR2,INDICATI,Phase 3,Transplant rejection,[ICD-11: NE84]
T56923,CXCR2,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T57001,GPA33,TARGETID,T57001,,
T57001,GPA33,TARGNAME,Cell surface A33 antigen (GPA33),,
T57001,GPA33,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
,#N/A,,,,
T57011,ICAM1,TARGETID,T57011,,
T57011,ICAM1,TARGNAME,ICAM1 messenger RNA (ICAM1 mRNA),,
T57011,ICAM1,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T57011,ICAM1,INDICATI,Approved,Infectious gastroenteritis/colitis,[ICD-11: 1A40]
T57011,ICAM1,INDICATI,Terminated,Transplant rejection,[ICD-11: NE84]
T57011,ICAM1,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T57034,PTPRB,TARGETID,T57034,,
T57034,PTPRB,TARGNAME,Protein tyrosine phosphatase beta (PTPRB),,
T57034,PTPRB,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T57034,PTPRB,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T57059,E2F1,TARGETID,T57059,,
T57059,E2F1,TARGNAME,E2F transcription factor 1 (E2F1),,
T57059,E2F1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T57211,CMV DNA polymerase mRNA,TARGETID,T57211,,
T57211,CMV DNA polymerase mRNA,TARGNAME,Cytomegalovirus DNA polymerase messenger RNA (CMV DNA polymerase mRNA),,
T57211,CMV DNA polymerase mRNA,INDICATI,Withdrawn from market,Cytomegaloviral disease,[ICD-11: 1D82]
,#N/A,,,,
T57278,EPHA2,TARGETID,T57278,,
T57278,EPHA2,TARGNAME,Ephrin type-A receptor 2 (EPHA2),,
T57278,EPHA2,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T57278,EPHA2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T57361,#N/A,TARGETID,T57361,,
T57361,#N/A,TARGNAME,Kallikrein-related peptidase (KLK),,
T57361,#N/A,INDICATI,Phase 2,Congenital ichthyosis,[ICD-11: EC20]
T57361,#N/A,INDICATI,Phase 3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T57361,#N/A,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T57361,#N/A,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T57361,#N/A,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T57361,#N/A,INDICATI,Approved,Retinal vascular occlusion,[ICD-11: 9B74]
,#N/A,,,,
T57364,HIV rev mRNA,TARGETID,T57364,,
T57364,HIV rev mRNA,TARGNAME,Human immunodeficiency virus Rev messenger RNA (HIV rev mRNA),,
T57364,HIV rev mRNA,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T57392,CYP2D6,TARGETID,T57392,,
T57392,CYP2D6,TARGNAME,Debrisoquine 4-hydroxylase (CYP2D6),,
T57392,CYP2D6,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T57392,CYP2D6,INDICATI,Phase 1,Malaria,[ICD-11: 1F40-1F45]
T57392,CYP2D6,INDICATI,Investigative,Migraine,[ICD-11: 8A80]
,#N/A,,,,
T57585,#N/A,TARGETID,T57585,,
T57585,#N/A,TARGNAME,Chloride channel unspecific (ClC),,
T57585,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T57585,#N/A,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T57585,#N/A,INDICATI,Discontinued in Phase 2,Cystic fibrosis,[ICD-11: CA25]
T57585,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T57654,Influ PB2,TARGETID,T57654,,
T57654,Influ PB2,TARGNAME,Influenza Polymerase basic protein 2 (Influ PB2),,
T57654,Influ PB2,INDICATI,Phase 3,Influenza,[ICD-11: 1E30-1E32]
,#N/A,,,,
T57680,GUCY1A1; GUCY1B1,TARGETID,T57680,,
T57680,GUCY1A1; GUCY1B1,TARGNAME,Soluble guanylate cyclase (GCS),,
T57680,GUCY1A1; GUCY1B1,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T57680,GUCY1A1; GUCY1B1,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T57680,GUCY1A1; GUCY1B1,INDICATI,Phase 2,Ataxic disorder,[ICD-11: 8A03]
T57680,GUCY1A1; GUCY1B1,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T57680,GUCY1A1; GUCY1B1,INDICATI,Discontinued in Phase 2,Dermatophytosis,[ICD-11: 1F28]
T57680,GUCY1A1; GUCY1B1,INDICATI,Approved,Diabetic foot ulcer,[ICD-11: BD54]
T57680,GUCY1A1; GUCY1B1,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T57680,GUCY1A1; GUCY1B1,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T57680,GUCY1A1; GUCY1B1,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
T57680,GUCY1A1; GUCY1B1,INDICATI,Approved,Respiratory failure,[ICD-11: CB41]
T57680,GUCY1A1; GUCY1B1,INDICATI,Phase 2,Retinopathy,ICD-11: 9B71
T57680,GUCY1A1; GUCY1B1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T57700,KIT,TARGETID,T57700,,
T57700,KIT,TARGNAME,Tyrosine-protein kinase Kit (KIT),,
T57700,KIT,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T57700,KIT,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T57700,KIT,INDICATI,Approved,Bone/articular cartilage neoplasm,[ICD-11: 2F7B]
T57700,KIT,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T57700,KIT,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T57700,KIT,INDICATI,Approved,Gastrointestinal stromal tumour,[ICD-11: 2B5B]
T57700,KIT,INDICATI,Phase 3,Inflammatory arthropathy,[ICD-11: FA2Z]
T57700,KIT,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T57700,KIT,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T57700,KIT,INDICATI,Phase 3,Malignant intestine neoplasm,[ICD-11: 2C0Z]
T57700,KIT,INDICATI,Phase 1,Mastocytosis,[ICD-11: 2A21]
T57700,KIT,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T57700,KIT,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T57700,KIT,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T57700,KIT,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T57700,KIT,INDICATI,Phase 1/2,Phakomatoses/hamartoneoplastic syndrome,[ICD-11: LD2D]
T57700,KIT,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T57700,KIT,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T57700,KIT,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T57700,KIT,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T57700,KIT,INDICATI,Phase 1/2,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T57718,MAGEC2,TARGETID,T57718,,
T57718,MAGEC2,TARGNAME,Melanoma-associated antigen C2 (MAGEC2),,
T57718,MAGEC2,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T57941,MAGEA6,TARGETID,T57941,,
T57941,MAGEA6,TARGNAME,Melanoma-associated antigen 6 (MAGEA6),,
T57941,MAGEA6,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T57943,CASP3,TARGETID,T57943,,
T57943,CASP3,TARGNAME,Caspase-3 (CASP3),,
T57943,CASP3,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T57943,CASP3,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T58093,Stap-coc def,TARGETID,T58093,,
T58093,Stap-coc def,TARGNAME,Staphylococcus Peptide deformylase (Stap-coc def),,
T58093,Stap-coc def,INDICATI,Phase 2,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T58184,#N/A,TARGETID,T58184,,
T58184,#N/A,TARGNAME,Ribosome (hRBS),,
T58184,#N/A,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T58184,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T58238,CD80,TARGETID,T58238,,
T58238,CD80,TARGNAME,Activation B7-1 antigen (CD80),,
T58238,CD80,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T58238,CD80,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T58238,CD80,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T58238,CD80,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T58238,CD80,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T58238,CD80,INDICATI,Terminated,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T58298,ENTPD1,TARGETID,T58298,,
T58298,ENTPD1,TARGNAME,Ectonucleoside triphosphate diphosphohydrolase 1 (CD39),,
T58298,ENTPD1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T58298,ENTPD1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T58449,CDK7,TARGETID,T58449,,
T58449,CDK7,TARGNAME,Cyclin-dependent kinase 7 (CDK7),,
T58449,CDK7,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T58449,CDK7,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T58449,CDK7,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T58449,CDK7,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T58449,CDK7,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T58454,FGFR2,TARGETID,T58454,,
T58454,FGFR2,TARGNAME,Fibroblast growth factor receptor 2 (FGFR2),,
T58454,FGFR2,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T58454,FGFR2,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T58454,FGFR2,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T58454,FGFR2,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T58454,FGFR2,INDICATI,Approved,Liver cancer,[ICD-11: 2C12]
T58454,FGFR2,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T58454,FGFR2,INDICATI,Approved,Oral mucositis,[ICD-11: DA01]
T58454,FGFR2,INDICATI,Phase 3,Periodontal disease,[ICD-11: DA0C]
T58454,FGFR2,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
T58454,FGFR2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T58454,FGFR2,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T58470,CCNA2,TARGETID,T58470,,
T58470,CCNA2,TARGNAME,Cyclin A2 (CCNA2),,
T58470,CCNA2,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
,#N/A,,,,
T58479,VEGFA,TARGETID,T58479,,
T58479,VEGFA,TARGNAME,VEGF messenger RNA (VEGF mRNA),,
T58479,VEGFA,INDICATI,Terminated,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T58496,TRPV3,TARGETID,T58496,,
T58496,TRPV3,TARGNAME,Transient receptor potential cation channel V3 (TRPV3),,
T58496,TRPV3,INDICATI,Investigative,Depression,[ICD-11: 6A70-6A7Z]
T58496,TRPV3,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T58496,TRPV3,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T58589,BDKRB1,TARGETID,T58589,,
T58589,BDKRB1,TARGNAME,B1 bradykinin receptor (BDKRB1),,
T58589,BDKRB1,INDICATI,Investigative,Depression,[ICD-11: 6A70-6A7Z]
T58589,BDKRB1,INDICATI,Phase 1,Osteoarthritis,[ICD-11: FA00-FA05]
T58589,BDKRB1,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T58589,BDKRB1,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T58589,BDKRB1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T58679,PABPC1,TARGETID,T58679,,
T58679,PABPC1,TARGNAME,Polyadenylate-binding protein 1 (PABPC1),,
T58679,PABPC1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T58716,SMPD4,TARGETID,T58716,,
T58716,SMPD4,TARGNAME,Sphingomyelin phosphodiesterase 4 (SMPD4),,
T58716,SMPD4,INDICATI,Discontinued in Phase 1,Depression,[ICD-11: 6A70-6A7Z]
,#N/A,,,,
T58741,SCN8A,TARGETID,T58741,,
T58741,SCN8A,TARGNAME,Voltage-gated sodium channel alpha Nav1.6 (SCN8A),,
T58741,SCN8A,INDICATI,Phase 1,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T58741,SCN8A,INDICATI,Phase 2,Epileptic encephalopathy,ICD-11: 8A62
,#N/A,,,,
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,TARGETID,T58772,,
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,TARGNAME,Mammalian target of rapamycin complex 1 (mTORC1),,
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,INDICATI,Investigative,Influenza,[ICD-11: 1E30-1E32]
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,INDICATI,Phase 1,Pleural mesothelioma,[ICD-11: 2C26]
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,INDICATI,Phase 3,Respiratory infection,[ICD-11: CA07-CA4Z]
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T58772,MTOR-RPTORA-MLST8-KT1S1-DEPTOR,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T58902,#N/A,TARGETID,T58902,,
T58902,#N/A,TARGNAME,Tau protein aggregation (TauA),,
T58902,#N/A,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T58902,#N/A,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T58920,TRH,TARGETID,T58920,,
T58920,TRH,TARGNAME,Thyrotropin-releasing hormone (TRH),,
T58920,TRH,INDICATI,Discontinued in Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T58920,TRH,INDICATI,Phase 3,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T58921,PPARG,TARGETID,T58921,,
T58921,PPARG,TARGNAME,Peroxisome proliferator-activated receptor gamma (PPAR-gamma),,
T58921,PPARG,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T58921,PPARG,INDICATI,Approved,Alzheimer disease,[ICD-11: 8A20]
T58921,PPARG,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
T58921,PPARG,INDICATI,Phase 3,Glaucoma,[ICD-11: 9C61]
T58921,PPARG,INDICATI,Phase 2/3,Gout,[ICD-11: FA25]
T58921,PPARG,INDICATI,Phase 1,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T58921,PPARG,INDICATI,Preclinical,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T58921,PPARG,INDICATI,Phase 3,Inborn lipid metabolism error,[ICD-11: 5C52]
T58921,PPARG,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T58921,PPARG,INDICATI,Preclinical,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T58921,PPARG,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T58921,PPARG,INDICATI,Phase 2,Nicotine use disorder,[ICD-11: 6C4A]
T58921,PPARG,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T58921,PPARG,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T58921,PPARG,INDICATI,Phase 2,Opioid use disorder,[ICD-11: 6C43]
T58921,PPARG,INDICATI,Phase 3,Peroxisomal disease,ICD-11: 5C57
T58921,PPARG,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T58921,PPARG,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T58970,MAPK1,TARGETID,T58970,,
T58970,MAPK1,TARGNAME,Extracellular signal-regulated kinase 2 (ERK2),,
T58970,MAPK1,INDICATI,Patented,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T58970,MAPK1,INDICATI,Phase 1,Arteries/arterioles disorder,[ICD-11: BD52]
T58970,MAPK1,INDICATI,Preclinical,Mature T-cell lymphoma,[ICD-11: 2A90]
T58970,MAPK1,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T58970,MAPK1,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T58970,MAPK1,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
T58970,MAPK1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T58970,MAPK1,INDICATI,Patented,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T58992,OPRD1,TARGETID,T58992,,
T58992,OPRD1,TARGNAME,Opioid receptor delta (OPRD1),,
T58992,OPRD1,INDICATI,Investigative,Abnormal micturition,[ICD-11: MF50]
T58992,OPRD1,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T58992,OPRD1,INDICATI,Investigative,Bladder disorder,[ICD-11: GC01]
T58992,OPRD1,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
T58992,OPRD1,INDICATI,Phase 3,Chronic pain,[ICD-11: MG30]
T58992,OPRD1,INDICATI,Phase 1,Coronary vasospastic disease,[ICD-11: BA85]
T58992,OPRD1,INDICATI,Phase 1,Cough,[ICD-11: MD12]
T58992,OPRD1,INDICATI,Investigative,Depression,[ICD-11: 6A70-6A7Z]
T58992,OPRD1,INDICATI,Investigative,Ejaculatory dysfunction,[ICD-11: HA03]
T58992,OPRD1,INDICATI,Phase 1,Functional bladder disorder,[ICD-11: GC50]
T58992,OPRD1,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T58992,OPRD1,INDICATI,Investigative,Ischemic heart disease,[ICD-11: BA40-BA6Z]
T58992,OPRD1,INDICATI,Phase 1,Migraine,[ICD-11: 8A80]
T58992,OPRD1,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
T58992,OPRD1,INDICATI,Phase 1,Opioid use disorder,[ICD-11: 6C43]
T58992,OPRD1,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T58992,OPRD1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T58992,OPRD1,INDICATI,Phase 3,Spinal pain,[ICD-11: ME84]
T58992,OPRD1,INDICATI,Preclinical,Substance abuse,[ICD-11: 6C40]
T58992,OPRD1,INDICATI,Discontinued in Phase 1,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T58998,#N/A,TARGETID,T58998,,
T58998,#N/A,TARGNAME,Bromodomain and extraterminal domain protein (BET),,
T58998,#N/A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T58998,#N/A,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T58998,#N/A,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T58998,#N/A,INDICATI,Phase 1/2,Mature B-cell lymphoma,[ICD-11: 2A85]
T58998,#N/A,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T58998,#N/A,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T58998,#N/A,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T58998,#N/A,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T58998,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T58998,#N/A,INDICATI,Phase 1,Testicular cancer,[ICD-11: 2C80]
,#N/A,,,,
T59001,FCGR3A,TARGETID,T59001,,
T59001,FCGR3A,TARGNAME,Immunoglobulin gamma Fc receptor IIIA (FCGR3A),,
T59001,FCGR3A,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
T59001,FCGR3A,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T59001,FCGR3A,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T59001,FCGR3A,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T59001,FCGR3A,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T59001,FCGR3A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T59045,ABAT,TARGETID,T59045,,
T59045,ABAT,TARGNAME,GABA transaminase (ABAT),,
T59045,ABAT,INDICATI,Approved,Brain cancer,[ICD-11: 2A00]
T59045,ABAT,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T59045,ABAT,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T59045,ABAT,INDICATI,Approved,Epileptic encephalopathy,[ICD-11: 8A62]
T59045,ABAT,INDICATI,Approved,Mineral deficiency,[ICD-11: 5B5K]
T59045,ABAT,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T59045,ABAT,INDICATI,Phase 2,Tic disorder,[ICD-11: 8A05]
T59045,ABAT,INDICATI,Phase 1,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T59056,CYP11B2,TARGETID,T59056,,
T59056,CYP11B2,TARGNAME,Aldosterone synthase (CYP11B2),,
T59056,CYP11B2,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T59102,PDGFRB,TARGETID,T59102,,
T59102,PDGFRB,TARGNAME,Platelet-derived growth factor receptor beta (PDGFRB),,
T59102,PDGFRB,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T59102,PDGFRB,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T59102,PDGFRB,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T59102,PDGFRB,INDICATI,Phase 1/2,Intracranial injury,[ICD-11: NA07]
T59102,PDGFRB,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T59102,PDGFRB,INDICATI,Investigative,Lung cancer,[ICD-11: 2C25]
T59102,PDGFRB,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T59102,PDGFRB,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T59102,PDGFRB,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T59102,PDGFRB,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T59102,PDGFRB,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T59122,CD58,TARGETID,T59122,,
T59122,CD58,TARGNAME,Surface glycoprotein LFA-3 (CD58),,
T59122,CD58,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T59174,#N/A,TARGETID,T59174,,
T59174,#N/A,TARGNAME,Sodium/hydrogen exchanger (SLC),,
T59174,#N/A,INDICATI,Terminated,Hypertension,[ICD-11: BA00-BA04]
T59174,#N/A,INDICATI,Investigative,Myocardial infarction,[ICD-11: BA41-BA43]
,#N/A,,,,
T59190,PRKCZ,TARGETID,T59190,,
T59190,PRKCZ,TARGNAME,Protein kinase C zeta (PRKCZ),,
T59190,PRKCZ,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T59273,PLK1,TARGETID,T59273,,
T59273,PLK1,TARGNAME,PLK1 messenger RNA (PLK1 mRNA),,
T59273,PLK1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T59328,EGFR,TARGETID,T59328,,
T59328,EGFR,TARGNAME,Epidermal growth factor receptor (EGFR),,
T59328,EGFR,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T59328,EGFR,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
T59328,EGFR,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T59328,EGFR,INDICATI,Investigative,Cerebral ischaemia,[ICD-11: 8B1Z]
T59328,EGFR,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T59328,EGFR,INDICATI,Phase 2,Colon cancer,[ICD-11: 2B90]
T59328,EGFR,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T59328,EGFR,INDICATI,Investigative,Cryptosporidiosis,[ICD-11: 1A32]
T59328,EGFR,INDICATI,Approved,Diabetic foot ulcer,[ICD-11: BD54]
T59328,EGFR,INDICATI,Investigative,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T59328,EGFR,INDICATI,Terminated,Digestive system disease,[ICD-11: DE2Z]
T59328,EGFR,INDICATI,Discontinued in Phase 2,Esophageal cancer,[ICD-11: 2B70]
T59328,EGFR,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T59328,EGFR,INDICATI,Phase 3,Head and neck cancer,[ICD-11: 2D42]
T59328,EGFR,INDICATI,Patented,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T59328,EGFR,INDICATI,Phase 1/2,Hypopharyngeal cancer,[ICD-11: 2B6D]
T59328,EGFR,INDICATI,Phase 1,Intracerebral haemorrhage,[ICD-11: 8B00]
T59328,EGFR,INDICATI,Approved,Ischemia,[ICD-11: 8B10-8B11]
T59328,EGFR,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T59328,EGFR,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T59328,EGFR,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T59328,EGFR,INDICATI,Phase 1/2,Malignant mesenchymal neoplasm,[ICD-11: 2B5D-2B5Y]
T59328,EGFR,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T59328,EGFR,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T59328,EGFR,INDICATI,Phase 2/3,Metastatic biliary tract neoplasms,[ICD-11: 2C14-2C17]
T59328,EGFR,INDICATI,Phase 1,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T59328,EGFR,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T59328,EGFR,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T59328,EGFR,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T59328,EGFR,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T59328,EGFR,INDICATI,Discontinued in Phase 1,Psoriasis,[ICD-11: EA90]
T59328,EGFR,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T59328,EGFR,INDICATI,Phase 2,Skin postprocedural disorder,[ICD-11: EL8Y]
T59328,EGFR,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T59328,EGFR,INDICATI,Phase 1,Spinal cord/cranial nerve neoplasm,[ICD-11: 2A02]
T59328,EGFR,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T59328,EGFR,INDICATI,Phase 1,Testicular cancer,[ICD-11: 2C80]
T59328,EGFR,INDICATI,Approved,Unspecific body region injury,[ICD-11: ND56]
T59328,EGFR,INDICATI,Phase 2,Urethral cancer,[ICD-11: 2C93]
,#N/A,,,,
T59382,SGCB,TARGETID,T59382,,
T59382,SGCB,TARGNAME,Beta-sarcoglycan (SGCB),,
T59382,SGCB,INDICATI,Phase 1/2,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T59463,KRAS,TARGETID,T59463,,
T59463,KRAS,TARGNAME,KRAS G12D mutant messenger RNA (KRAS mRNA),,
T59463,KRAS,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T59480,KRAS,TARGETID,T59480,,
T59480,KRAS,TARGNAME,KRAS G12C mutant (KRAS G12C),,
T59480,KRAS,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T59480,KRAS,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T59480,KRAS,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T59550,IGF2R,TARGETID,T59550,,
T59550,IGF2R,TARGNAME,CI Man-6-P receptor (IGF2R),,
T59550,IGF2R,INDICATI,Phase 1,Fibrosis,[ICD-11: GA14-GC01]
T59550,IGF2R,INDICATI,Phase 2,Sarcoidosis,[ICD-11: 4B20]
T59550,IGF2R,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T59554,McyB dprE1,TARGETID,T59554,,
T59554,McyB dprE1,TARGNAME,Mycobacterium Decaprenylphosphoryl-beta-D-ribose oxidase (McyB dprE1),,
T59554,McyB dprE1,INDICATI,Phase 2,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T59554,McyB dprE1,INDICATI,Phase 1,Mycobacterium infection,[ICD-11: 1B10-1B21]
,#N/A,,,,
T59604,GHSR,TARGETID,T59604,,
T59604,GHSR,TARGNAME,Growth hormone secretagogue receptor 1 (GHSR),,
T59604,GHSR,INDICATI,Terminated,Anorexia nervosa,[ICD-11: 6B80]
T59604,GHSR,INDICATI,Investigative,Cachexia,[ICD-11: MG20]
T59604,GHSR,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T59604,GHSR,INDICATI,Phase 2b,Digestive system disease,[ICD-11: DE2Z]
T59604,GHSR,INDICATI,Phase 2b,Gastroduodenal motor/secretory disorder,[ICD-11: DA41]
T59604,GHSR,INDICATI,Phase 3,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
T59604,GHSR,INDICATI,Phase 1,Irritable bowel syndrome,[ICD-11: DD91]
T59604,GHSR,INDICATI,Preclinical,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T59604,GHSR,INDICATI,Discontinued in Phase 1/2,Obesity,[ICD-11: 5B80-5B81]
T59604,GHSR,INDICATI,Investigative,Oesophagus motility disorder,[ICD-11: DA21]
T59604,GHSR,INDICATI,Phase 2,Old age,[ICD-11: MG2A]
T59604,GHSR,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T59604,GHSR,INDICATI,Phase 1/2,Postoperative ileus,[ICD-11: DA91-DB30]
T59604,GHSR,INDICATI,Phase 2b,Small intestine motility disorder,[ICD-11: DA93]
T59604,GHSR,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T59604,GHSR,INDICATI,Preclinical,Substance abuse,[ICD-11: 6C40]
T59604,GHSR,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T59626,LTB4R,TARGETID,T59626,,
T59626,LTB4R,TARGNAME,Leukotriene B4 receptor 1 (LTB4R),,
T59626,LTB4R,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T59626,LTB4R,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T59626,LTB4R,INDICATI,Discontinued in Phase 2,Cystic fibrosis,[ICD-11: CA25]
T59626,LTB4R,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T59626,LTB4R,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
T59626,LTB4R,INDICATI,Terminated,Low bone mass disorder,[ICD-11: FB83]
T59626,LTB4R,INDICATI,Discontinued in Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T59626,LTB4R,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T59626,LTB4R,INDICATI,Discontinued in Phase 1,Prostate cancer,[ICD-11: 2C82]
T59626,LTB4R,INDICATI,Discontinued in Phase 2,Psoriasis,[ICD-11: EA90]
T59626,LTB4R,INDICATI,Phase 2,Pulmonary disease,[ICD-11: 1B10-1F85]
T59626,LTB4R,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
T59626,LTB4R,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T59631,PDCD1,TARGETID,T59631,,
T59631,PDCD1,TARGNAME,Programmed cell death protein 1 (PD-1),,
T59631,PDCD1,INDICATI,Phase 3,Bladder cancer,[ICD-11: 2C94]
T59631,PDCD1,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
T59631,PDCD1,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T59631,PDCD1,INDICATI,Phase 3,Cervical cancer,[ICD-11: 2C77]
T59631,PDCD1,INDICATI,Phase 3,Colorectal cancer,[ICD-11: 2B91]
T59631,PDCD1,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T59631,PDCD1,INDICATI,Approved,Endometrial cancer,[ICD-11: 2C76]
T59631,PDCD1,INDICATI,Phase 3,Epidermal dysplasias,[ICD-11: EK90]
T59631,PDCD1,INDICATI,Phase 3,Esophageal cancer,[ICD-11: 2B70]
T59631,PDCD1,INDICATI,Phase 2,Follicular lymphoma,[ICD-11: 2A80]
T59631,PDCD1,INDICATI,Approved,Hodgkin lymphoma,[ICD-11: 2B30]
T59631,PDCD1,INDICATI,Patented,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T59631,PDCD1,INDICATI,Patented,Inflammatory liver disease,[ICD-11: DB97]
T59631,PDCD1,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T59631,PDCD1,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T59631,PDCD1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T59631,PDCD1,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T59631,PDCD1,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T59631,PDCD1,INDICATI,Phase 1,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T59631,PDCD1,INDICATI,Phase 3,Multiple myeloma,[ICD-11: 2A83]
T59631,PDCD1,INDICATI,Phase 1,Myeloproliferative neoplasm,[ICD-11: 2A20]
T59631,PDCD1,INDICATI,Approved in China,Nasopharyngeal cancer,ICD-11: 2B6B
T59631,PDCD1,INDICATI,Phase 2,Neuroendocrine carcinoma,[ICD-11: 2C34]
T59631,PDCD1,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
T59631,PDCD1,INDICATI,Phase 3,Oral cavity/oesophagus/stomach in situ carcinoma,[ICD-11: 2E60]
T59631,PDCD1,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T59631,PDCD1,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
T59631,PDCD1,INDICATI,Phase 1,Penile cancer,[ICD-11: 2C81]
T59631,PDCD1,INDICATI,Phase 3,Pleural mesothelioma,[ICD-11: 2C26]
T59631,PDCD1,INDICATI,Patented,Postoperative inflammation,[ICD-11: 1A00-CA43]
T59631,PDCD1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T59631,PDCD1,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T59631,PDCD1,INDICATI,Phase 3,Renal cell carcinoma,[ICD-11: 2C90]
T59631,PDCD1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T59631,PDCD1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T59631,PDCD1,INDICATI,Phase 3,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
T59631,PDCD1,INDICATI,Approved,Stomach cancer,[ICD-11: 2B72]
T59631,PDCD1,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
T59631,PDCD1,INDICATI,Approved in China,Ureteral cancer,[ICD-11: 2C92]
T59631,PDCD1,INDICATI,Phase 1,Uterine ligament/parametrium/uterine adnexa neoplasm,[ICD-11: 2C72]
,#N/A,,,,
T59654,PLK2,TARGETID,T59654,,
T59654,PLK2,TARGNAME,Polo-like kinase 2 (PLK2),,
T59654,PLK2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T59679,HTR4,TARGETID,T59679,,
T59679,HTR4,TARGNAME,5-HT 4 receptor (HTR4),,
T59679,HTR4,INDICATI,Investigative,Abnormal micturition,[ICD-11: MF50]
T59679,HTR4,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T59679,HTR4,INDICATI,Phase 2,Digestive system disease,[ICD-11: DE2Z]
T59679,HTR4,INDICATI,Withdrawn from market,Dyspepsia,[ICD-11: MD92]
T59679,HTR4,INDICATI,Phase 2,Gastroduodenal motor/secretory disorder,[ICD-11: DA41]
T59679,HTR4,INDICATI,Approved,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T59679,HTR4,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
T59679,HTR4,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
T59679,HTR4,INDICATI,Terminated,Indeterminate colitis,[ICD-11: DD72]
T59679,HTR4,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T59679,HTR4,INDICATI,Phase 1,Mild neurocognitive disorder,[ICD-11: 6D71]
T59679,HTR4,INDICATI,Phase 2,Nausea/vomiting,[ICD-11: MD90]
T59679,HTR4,INDICATI,Investigative,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T59679,HTR4,INDICATI,Discontinued in Phase 2,Oesophagus motility disorder,[ICD-11: DA21]
T59679,HTR4,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T59679,HTR4,INDICATI,Discontinued in Phase 2,Parkinsonism,[ICD-11: 8A00]
T59679,HTR4,INDICATI,Phase 2,Post-traumatic stress disorder,[ICD-11: 6B40]
T59679,HTR4,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T59686,MECP2,TARGETID,T59686,,
T59686,MECP2,TARGNAME,Methyl cpg binding protein 2 (MECP2),,
T59686,MECP2,INDICATI,Phase 1,Intellectual development disorder,[ICD-11: LD90]
,#N/A,,,,
T59702,FZD10,TARGETID,T59702,,
T59702,FZD10,TARGNAME,Frizzled-10 (FZD10),,
T59702,FZD10,INDICATI,Phase 1,Synovial sarcoma,[ICD-11: 2B5A]
,#N/A,,,,
T59720,FHIT,TARGETID,T59720,,
T59720,FHIT,TARGNAME,Fragile histidine triad protein (FHIT),,
T59720,FHIT,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
,#N/A,,,,
T59735,#N/A,TARGETID,T59735,,
T59735,#N/A,TARGNAME,Interferon receptor (IFNR),,
T59735,#N/A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T59735,#N/A,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T59735,#N/A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T59735,#N/A,INDICATI,Discontinued in Phase 3,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T59845,PPP1CA,TARGETID,T59845,,
T59845,PPP1CA,TARGNAME,Serine/threonine PP1-alpha (PPP1CA),,
T59845,PPP1CA,INDICATI,Approved,Molluscum contagiosum,[ICD-11: 1E76]
,#N/A,,,,
T59870,#N/A,TARGETID,T59870,,
T59870,#N/A,TARGNAME,Cholesterol absorption (Chole absorp),,
T59870,#N/A,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T59881,AVPR1B,TARGETID,T59881,,
T59881,AVPR1B,TARGNAME,Vasopressin V1b receptor (V1BR),,
T59881,AVPR1B,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T59881,AVPR1B,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T59881,AVPR1B,INDICATI,Approved,Autism spectrum disorder,[ICD-11: 6A02]
T59881,AVPR1B,INDICATI,Phase 3,Childbirth associated breast/lactation disorder,[ICD-11: JB46]
T59881,AVPR1B,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T59881,AVPR1B,INDICATI,Approved,Hypo-osmolality/hyponatraemia,[ICD-11: 5C72]
,#N/A,,,,
T59909,#N/A,TARGETID,T59909,,
T59909,#N/A,TARGNAME,Protein prenyl transferase (PPTF),,
T59909,#N/A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T59929,TYMP,TARGETID,T59929,,
T59929,TYMP,TARGNAME,Thymidine phosphorylase (TYMP),,
T59929,TYMP,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
,#N/A,,,,
T59955,#N/A,TARGETID,T59955,,
T59955,#N/A,TARGNAME,Progesterone (PG),,
T59955,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T59955,#N/A,INDICATI,Discontinued in Phase 2,Contraceptive management,[ICD-11: QA21]
,#N/A,,,,
T60077,RXRB,TARGETID,T60077,,
T60077,RXRB,TARGNAME,Retinoic acid receptor RXR-beta (RXRB),,
T60077,RXRB,INDICATI,Approved,Kaposi sarcoma,[ICD-11: 2B57]
,#N/A,,,,
T60136,#N/A,TARGETID,T60136,,
T60136,#N/A,TARGNAME,Trigeminal ganglion stimulation-induced response (TGSR),,
T60136,#N/A,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
,#N/A,,,,
T60182,GCGR,TARGETID,T60182,,
T60182,GCGR,TARGNAME,Glucagon receptor (GCGR),,
T60182,GCGR,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T60182,GCGR,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T60182,GCGR,INDICATI,Approved,Hypo-glycaemia,[ICD-11: 5A41]
T60182,GCGR,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T60182,GCGR,INDICATI,Phase 3,Obesity,[ICD-11: 5B80-5B81]
T60182,GCGR,INDICATI,Phase 2,Pancreatic internal secretion disorder,[ICD-11: 5A4Y]
T60182,GCGR,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T60213,BMPR2,TARGETID,T60213,,
T60213,BMPR2,TARGNAME,Bone morphogenetic protein receptor (BMPR2),,
T60213,BMPR2,INDICATI,Investigative,Joint derangement,[ICD-11: FA34]
T60213,BMPR2,INDICATI,Investigative,Prostate cancer,[ICD-11: 2C82]
T60213,BMPR2,INDICATI,Investigative,Urinary system disease,[ICD-11: GC2Z]
T60213,BMPR2,INDICATI,Investigative,Urinary/pelvic organs injury,[ICD-11: NB92]
,#N/A,,,,
T60345,#N/A,TARGETID,T60345,,
T60345,#N/A,TARGNAME,T-cell surface glycoprotein CD3 (CD3),,
T60345,#N/A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T60345,#N/A,INDICATI,Phase 1,B-cell lymphoma,[ICD-11: 2A86]
T60345,#N/A,INDICATI,Phase 1,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T60345,#N/A,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T60345,#N/A,INDICATI,Phase 1,Brain cancer,ICD-11: 2A00
T60345,#N/A,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T60345,#N/A,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T60345,#N/A,INDICATI,Approved,Diabetes mellitus,[ICD-11: 5A10]
T60345,#N/A,INDICATI,Approved,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T60345,#N/A,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
T60345,#N/A,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T60345,#N/A,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T60345,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T60345,#N/A,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T60345,#N/A,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T60345,#N/A,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T60345,#N/A,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T60345,#N/A,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T60345,#N/A,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T60345,#N/A,INDICATI,Phase 1,Non-small-cell lung cancer,[ICD-11: 2C25]
T60345,#N/A,INDICATI,Phase 1,Oesophagogastric junction cancer,[ICD-11: 2B71]
T60345,#N/A,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T60345,#N/A,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T60345,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T60345,#N/A,INDICATI,Phase 1,Stomach cancer,ICD-11: 2B72
T60345,#N/A,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T60348,#N/A,TARGETID,T60348,,
T60348,#N/A,TARGNAME,Voltage-dependent anion channel (VDAC),,
T60348,#N/A,INDICATI,Phase 2,Epidermal dysplasias,[ICD-11: EK90]
,#N/A,,,,
T60366,ODC1,TARGETID,T60366,,
T60366,ODC1,TARGNAME,Ornithine decarboxylase (ODC1),,
T60366,ODC1,INDICATI,Approved,African trypanosomiasis,[ICD-11: 1F51]
T60366,ODC1,INDICATI,Discontinued in Phase 2,Burn and burn infection,[ICD-11: ND90-NE2Z]
T60366,ODC1,INDICATI,Investigative,Head and neck cancer,[ICD-11: 2D42]
T60366,ODC1,INDICATI,Phase 2,Trypanosomiasis,[ICD-11: 1D51-1F53]
,#N/A,,,,
T60433,CD1A,TARGETID,T60433,,
T60433,CD1A,TARGNAME,T-cell surface glycoprotein CD1a (CD1A),,
T60433,CD1A,INDICATI,Approved,Aplastic anaemia,[ICD-11: 3A70]
T60433,CD1A,INDICATI,Phase 1,Atopic eczema,[ICD-11: EA80]
,#N/A,,,,
T60514,GP6,TARGETID,T60514,,
T60514,GP6,TARGNAME,Platelet glycoprotein VI (GP6),,
T60514,GP6,INDICATI,Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T60514,GP6,INDICATI,Phase 1/2,Cerebral ischaemic stroke,[ICD-11: 8B11]
,#N/A,,,,
T60526,SELL,TARGETID,T60526,,
T60526,SELL,TARGNAME,L-selectin (SELL),,
T60526,SELL,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T60526,SELL,INDICATI,Phase 3,Circulatory system disease,[ICD-11: BE2Z]
T60526,SELL,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T60526,SELL,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T60526,SELL,INDICATI,Terminated,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T60529,PTGS1,TARGETID,T60529,,
T60529,PTGS1,TARGNAME,Prostaglandin G/H synthase 1 (COX-1),,
T60529,PTGS1,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T60529,PTGS1,INDICATI,Phase 1/2,Ataxic disorder,[ICD-11: 8A03]
T60529,PTGS1,INDICATI,Discontinued in Phase 2,Colorectal cancer,[ICD-11: 2B91]
T60529,PTGS1,INDICATI,Investigative,Endometriosis,[ICD-11: GA10]
T60529,PTGS1,INDICATI,Approved,Eye anterior segment structural developmental anomaly,[ICD-11: LA11]
T60529,PTGS1,INDICATI,Approved,Female pelvic pain,[ICD-11: GA34]
T60529,PTGS1,INDICATI,Withdrawn from market,Fever,[ICD-11: MG26]
T60529,PTGS1,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
T60529,PTGS1,INDICATI,Withdrawn from market,Gout,[ICD-11: FA25]
T60529,PTGS1,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T60529,PTGS1,INDICATI,Approved,Indeterminate colitis,[ICD-11: DD72]
T60529,PTGS1,INDICATI,Phase 1/2,Muscular dystrophy,[ICD-11: 8C70]
T60529,PTGS1,INDICATI,Phase 1/2,Neuropathy,[ICD-11: 8C0Z]
T60529,PTGS1,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T60529,PTGS1,INDICATI,Approved,Osteoarthritis,[ICD-11: FA00-FA05]
T60529,PTGS1,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T60529,PTGS1,INDICATI,Approved,Postoperative inflammation,[ICD-11: 1A00-CA43]
T60529,PTGS1,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T60529,PTGS1,INDICATI,Approved,Seborrhoeic dermatitis,[ICD-11: EA81]
T60529,PTGS1,INDICATI,Withdrawn from market,Sensation disturbance,[ICD-11: MB40]
T60529,PTGS1,INDICATI,Preregistration,Shoulder lesion,[ICD-11: FB53]
T60529,PTGS1,INDICATI,Preregistration,Soft tissue disorder,[ICD-11: FB56]
T60529,PTGS1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T60529,PTGS1,INDICATI,Phase 3,Systemic sclerosis,[ICD-11: 4A42]
T60529,PTGS1,INDICATI,Approved,Tuberculosis,[ICD-11: 1B10-1B12]
T60529,PTGS1,INDICATI,Discontinued in Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
T60529,PTGS1,INDICATI,Approved,Ulcerative colitis,[ICD-11: DD71]
T60529,PTGS1,INDICATI,Phase 3,Vasculitis,[ICD-11: 4A44]
,#N/A,,,,
T60568,HIV tat mRNA,TARGETID,T60568,,
T60568,HIV tat mRNA,TARGNAME,Human immunodeficiency virus Tat messenger RNA (HIV tat mRNA),,
T60568,HIV tat mRNA,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T60606,TSHR,TARGETID,T60606,,
T60606,TSHR,TARGNAME,Thyrotropin receptor (TSHR),,
T60606,TSHR,INDICATI,Approved,Hypo-thyroidism,[ICD-11: 5A00]
T60606,TSHR,INDICATI,Approved,Thyroid cancer,[ICD-11: 2D10]
,#N/A,,,,
T60628,#N/A,TARGETID,T60628,,
T60628,#N/A,TARGNAME,Kappa myeloma antigen (KMA),,
T60628,#N/A,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T60631,RET,TARGETID,T60631,,
T60631,RET,TARGNAME,Proto-oncogene c-Ret (RET),,
T60631,RET,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T60631,RET,INDICATI,Phase 1/2,Colon cancer,[ICD-11: 2B90]
T60631,RET,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T60631,RET,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T60631,RET,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T60631,RET,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T60631,RET,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T60631,RET,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T60631,RET,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T60631,RET,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T60631,RET,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T60631,RET,INDICATI,Approved,Thyroid cancer,[ICD-11: 2D10]
,#N/A,,,,
T60636,OGDH,TARGETID,T60636,,
T60636,OGDH,TARGNAME,Alpha-ketoglutarate dehydrogenase (OGDH),,
T60636,OGDH,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T60636,OGDH,INDICATI,Phase 2,B-cell lymphoma,[ICD-11: 2A86]
T60636,OGDH,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T60636,OGDH,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
T60636,OGDH,INDICATI,Phase 1,Mature T-cell lymphoma,[ICD-11: 2A90]
T60636,OGDH,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T60636,OGDH,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T60693,OPRK1,TARGETID,T60693,,
T60693,OPRK1,TARGNAME,Opioid receptor kappa (OPRK1),,
T60693,OPRK1,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T60693,OPRK1,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T60693,OPRK1,INDICATI,Phase 1,Coronary vasospastic disease,[ICD-11: BA85]
T60693,OPRK1,INDICATI,Phase 3,Depression,[ICD-11: 6A70-6A7Z]
T60693,OPRK1,INDICATI,Terminated,Indeterminate colitis,[ICD-11: DD72]
T60693,OPRK1,INDICATI,Phase 3,Irritable bowel syndrome,[ICD-11: DD91]
T60693,OPRK1,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T60693,OPRK1,INDICATI,Approved,Non-specific cutaneous vascular sympton,[ICD-11: ME64]
T60693,OPRK1,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
T60693,OPRK1,INDICATI,Phase 1,Opioid use disorder,[ICD-11: 6C43]
T60693,OPRK1,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T60693,OPRK1,INDICATI,Phase 2/3,Prurigo,[ICD-11: EC91]
T60693,OPRK1,INDICATI,Approved,Pruritus,[ICD-11: EC90]
T60693,OPRK1,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T60693,OPRK1,INDICATI,Discontinued in Phase 1,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T60708,C5,TARGETID,T60708,,
T60708,C5,TARGNAME,Complement C5 (CO5),,
T60708,C5,INDICATI,Preclinical,Amyloidosis,[ICD-11: 5D00]
T60708,C5,INDICATI,Discontinued in Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T60708,C5,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T60708,C5,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T60708,C5,INDICATI,Approved,Diffuse large B-cell lymphoma,ICD-11: 2A81
T60708,C5,INDICATI,Approved,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
T60708,C5,INDICATI,Phase 2,Hidradenitis suppurativa,[ICD-11: ED92]
T60708,C5,INDICATI,Approved,Macular degeneration,ICD-11: 9B75
T60708,C5,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T60708,C5,INDICATI,Approved,Myasthenia gravis,ICD-11: 8C60
T60708,C5,INDICATI,Phase 3,Myasthenia gravis,[ICD-11: 8C6Y]
T60708,C5,INDICATI,Phase 3,Pemphigoid,[ICD-11: EB41]
T60708,C5,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T60708,C5,INDICATI,Phase 3,Retinopathy,[ICD-11: 9B71]
T60708,C5,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T60708,C5,INDICATI,Phase 3,Thrombotic microangiopathy,[ICD-11: 3B65]
,#N/A,,,,
T60724,SOST,TARGETID,T60724,,
T60724,SOST,TARGNAME,Sclerostin (SOST),,
T60724,SOST,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
T60724,SOST,INDICATI,Phase 2,Osteopathy/chondropathy,[ICD-11: FB8Y]
T60724,SOST,INDICATI,Phase 3,Skeletal anomaly,[ICD-11: LD24]
,#N/A,,,,
T60810,#N/A,TARGETID,T60810,,
T60810,#N/A,TARGNAME,Cell mediated immunity response (CMIR),,
T60810,#N/A,INDICATI,Approved,Acute viral hepatitis,[ICD-11: 1E50]
T60810,#N/A,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T60810,#N/A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T60810,#N/A,INDICATI,Approved,Influenza,[ICD-11: 1E30-1E32]
T60810,#N/A,INDICATI,Phase 2,Leishmaniasis,[ICD-11: 1F54]
T60810,#N/A,INDICATI,Phase 1,Malaria,[ICD-11: 1F40-1F45]
T60810,#N/A,INDICATI,Approved,Postoperative inflammation,[ICD-11: 1A00-CA43]
T60810,#N/A,INDICATI,Phase 1,Vaccination,[ICD-11: N.A.]
T60810,#N/A,INDICATI,Approved,Whooping cough,[ICD-11: 1C12]
,#N/A,,,,
T60857,AKR1C3,TARGETID,T60857,,
T60857,AKR1C3,TARGNAME,Dihydrodiol dehydrogenase type I (AKR1C3),,
T60857,AKR1C3,INDICATI,Approved,Female pelvic pain,[ICD-11: GA34]
T60857,AKR1C3,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T60930,IGF1,TARGETID,T60930,,
T60930,IGF1,TARGNAME,Insulin-like growth factor-I (IGF1),,
T60930,IGF1,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T60930,IGF1,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T60930,IGF1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T61033,CNTFR,TARGETID,T61033,,
T61033,CNTFR,TARGNAME,Ciliary neurotrophic factor receptor alpha (CNTFR),,
T61033,CNTFR,INDICATI,Phase 2/3,Glaucoma,[ICD-11: 9C61]
T61033,CNTFR,INDICATI,Phase 2/3,Inherited retinal dystrophy,[ICD-11: 9B70]
T61033,CNTFR,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T61033,CNTFR,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T61052,#N/A,TARGETID,T61052,,
T61052,#N/A,TARGNAME,Neuroepithelial receptor (NR),,
T61052,#N/A,INDICATI,Phase 3,Female pelvic pain,[ICD-11: GA34]
,#N/A,,,,
T61317,Malaria fabG,TARGETID,T61317,,
T61317,Malaria fabG,TARGNAME,Plasmodium Oxoacyl-[acyl-carrier protein] reductase (Malaria fabG),,
T61317,Malaria fabG,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
,#N/A,,,,
T61339,GAA; GANAB; GANC,TARGETID,T61339,,
T61339,GAA; GANAB; GANC,TARGNAME,Alpha-glucosidase (GLA),,
T61339,GAA; GANAB; GANC,INDICATI,Approved in EU,Inborn carbohydrate metabolism error,ICD-11: 5C51
T61339,GAA; GANAB; GANC,INDICATI,Approved,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
T61339,GAA; GANAB; GANC,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T61400,DHODH,TARGETID,T61400,,
T61400,DHODH,TARGNAME,Dihydroorotate dehydrogenase (DHODH),,
T61400,DHODH,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T61400,DHODH,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T61400,DHODH,INDICATI,Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T61400,DHODH,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T61400,DHODH,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T61400,DHODH,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T61400,DHODH,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T61400,DHODH,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T61400,DHODH,INDICATI,Discontinued in Phase 2,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T61484,#N/A,TARGETID,T61484,,
T61484,#N/A,TARGNAME,Chymotrypsin (CTR),,
T61484,#N/A,INDICATI,Phase 3,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T61484,#N/A,INDICATI,Phase 3,Autism spectrum disorder,[ICD-11: 6A02]
T61484,#N/A,INDICATI,Phase 3,Cystic fibrosis,[ICD-11: CA25]
T61484,#N/A,INDICATI,NDA filed,Pancreatic malfunction,[ICD-11: DC30-DC3Z]
T61484,#N/A,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T61518,MELK,TARGETID,T61518,,
T61518,MELK,TARGNAME,Tyrosine-protein kinase MELK (MELK),,
T61518,MELK,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T61518,MELK,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T61518,MELK,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T61518,MELK,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T61518,MELK,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T61518,MELK,INDICATI,Phase 1,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T61544,SP1,TARGETID,T61544,,
T61544,SP1,TARGNAME,Transcription factor Sp1 (SP1),,
T61544,SP1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T61547,Stap-coc MntC,TARGETID,T61547,,
T61547,Stap-coc MntC,TARGNAME,Staphylococcus Manganese transporter C (Stap-coc MntC),,
T61547,Stap-coc MntC,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T61547,Stap-coc MntC,INDICATI,Phase 2,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T61581,GUCY1B1,TARGETID,T61581,,
T61581,GUCY1B1,TARGNAME,Guanylate cyclase soluble beta-1 (GUCY1B1),,
T61581,GUCY1B1,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T61581,GUCY1B1,INDICATI,Discontinued in Phase 1,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T61622,REN,TARGETID,T61622,,
T61622,REN,TARGNAME,Angiotensinogenase renin (REN),,
T61622,REN,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T61622,REN,INDICATI,Phase 2,Glaucoma,[ICD-11: 9C61]
T61622,REN,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T61622,REN,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
T61622,REN,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T61657,RARB,TARGETID,T61657,,
T61657,RARB,TARGNAME,Retinoic acid receptor beta (RARB),,
T61657,RARB,INDICATI,Phase 2/3,Alzheimer disease,[ICD-11: 8A20]
T61657,RARB,INDICATI,Approved,Kaposi sarcoma,[ICD-11: 2B57]
T61657,RARB,INDICATI,Phase 3,Mature T-cell lymphoma,[ICD-11: 2A90]
,#N/A,,,,
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,TARGETID,T61683,,
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,TARGNAME,Inhibitor of apoptosis protein (hIAP),,
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Phase 3,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T61683,XIAP; BIRC2; BIRC3; NAIP; BIRC5; BIRC7,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T61698,IL2,TARGETID,T61698,,
T61698,IL2,TARGNAME,Interleukin-2 (IL2),,
T61698,IL2,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T61698,IL2,INDICATI,Phase 2,Adrenal cancer,[ICD-11: 2D11]
T61698,IL2,INDICATI,Phase 2/3,Bipolar disorder,[ICD-11: 6A60]
T61698,IL2,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T61698,IL2,INDICATI,Phase 2,Immune system disease,[ICD-11: 4A01-4B41]
T61698,IL2,INDICATI,Phase 2/3,Lung cancer,[ICD-11: 2C25]
T61698,IL2,INDICATI,Discontinued in Phase 3,Lupus erythematosus,[ICD-11: 4A40]
T61698,IL2,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T61698,IL2,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T61698,IL2,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T61698,IL2,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T61698,IL2,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T61698,IL2,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T61698,IL2,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T61698,IL2,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T61698,IL2,INDICATI,Preclinical,Prostate cancer,[ICD-11: 2C82]
T61698,IL2,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T61698,IL2,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T61698,IL2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T61722,PTGDR2,TARGETID,T61722,,
T61722,PTGDR2,TARGNAME,Prostaglandin D2 receptor 2 (PTGDR2),,
T61722,PTGDR2,INDICATI,Phase 2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T61722,PTGDR2,INDICATI,Phase 2,Alopecia,[ICD-11: ED70]
T61722,PTGDR2,INDICATI,Discontinued in Phase 3,Arterial occlusive disease,[ICD-11: BD40]
T61722,PTGDR2,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T61722,PTGDR2,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T61722,PTGDR2,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T61722,PTGDR2,INDICATI,Phase 1,Respiratory system disease,[ICD-11: CB40-CB7Z]
T61722,PTGDR2,INDICATI,Clinical trial,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T61722,PTGDR2,INDICATI,Phase 2/3,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T61729,P4HA1,TARGETID,T61729,,
T61729,P4HA1,TARGNAME,Prolyl 4-hydroxylasesubunit alpha-1 (P4HA1),,
T61729,P4HA1,INDICATI,Phase 2,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T61729,P4HA1,INDICATI,Phase 1,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T61744,PDE4A,TARGETID,T61744,,
T61744,PDE4A,TARGNAME,Phosphodiesterase 4A (PDE4A),,
T61744,PDE4A,INDICATI,Investigative,Acute upper respiratory infection,[ICD-11: CA07]
T61744,PDE4A,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T61744,PDE4A,INDICATI,Terminated,Amyloidosis,[ICD-11: 5D00]
T61744,PDE4A,INDICATI,Approved,Asthma,[ICD-11: CA23]
T61744,PDE4A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T61744,PDE4A,INDICATI,Discontinued in Phase 3,Bronchitis,[ICD-11: CA20]
T61744,PDE4A,INDICATI,Phase 1,Choreiform disorder,[ICD-11: 8A01]
T61744,PDE4A,INDICATI,Terminated,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T61744,PDE4A,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T61744,PDE4A,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T61744,PDE4A,INDICATI,Discontinued in Phase 3,Emphysema,[ICD-11: CA21]
T61744,PDE4A,INDICATI,Phase 2,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
T61744,PDE4A,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T61744,PDE4A,INDICATI,Investigative,Mature B-cell leukaemia,[ICD-11: 2A82]
T61744,PDE4A,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T61744,PDE4A,INDICATI,Phase 1,Mood disorder,[ICD-11: 6A60-6E23]
T61744,PDE4A,INDICATI,Discontinued in Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T61744,PDE4A,INDICATI,Discontinued in Phase 1,Mycosis fungoides,[ICD-11: 2B01]
T61744,PDE4A,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T61744,PDE4A,INDICATI,Investigative,Pneumonia,[ICD-11: CA40]
T61744,PDE4A,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T61744,PDE4A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T61744,PDE4A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T61744,PDE4A,INDICATI,Investigative,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T61746,CTSB,TARGETID,T61746,,
T61746,CTSB,TARGNAME,Cathepsin B (CTSB),,
T61746,CTSB,INDICATI,Patented,Alopecia,[ICD-11: ED70]
T61746,CTSB,INDICATI,Patented,Alzheimer disease,[ICD-11: 8A20]
T61746,CTSB,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T61746,CTSB,INDICATI,Patented,Bone cancer,[ICD-11: 2B5Z]
T61746,CTSB,INDICATI,Patented,Brain cancer,[ICD-11: 2A00]
T61746,CTSB,INDICATI,Preclinical,Cardiac arrest,[ICD-11: MC82]
T61746,CTSB,INDICATI,Patented,Cerebral ischaemic stroke,[ICD-11: 8B11]
T61746,CTSB,INDICATI,Patented,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T61746,CTSB,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
T61746,CTSB,INDICATI,Preclinical,Cystic fibrosis,[ICD-11: CA25]
T61746,CTSB,INDICATI,Patented,Digestive system disease,[ICD-11: DE2Z]
T61746,CTSB,INDICATI,Patented,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T61746,CTSB,INDICATI,Preclinical,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T61746,CTSB,INDICATI,Patented,Meningioma,[ICD-11: 2A01]
T61746,CTSB,INDICATI,Patented,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T61746,CTSB,INDICATI,Patented,Multiple sclerosis,[ICD-11: 8A40]
T61746,CTSB,INDICATI,Patented,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T61746,CTSB,INDICATI,Patented,Osteoarthritis,[ICD-11: FA00-FA05]
T61746,CTSB,INDICATI,Patented,Pancreatitis,[ICD-11: DC31-DC34]
T61746,CTSB,INDICATI,Patented,Psoriasis,[ICD-11: EA90]
T61746,CTSB,INDICATI,Patented,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T62047,HBV S,TARGETID,T62047,,
T62047,HBV S,TARGNAME,Hepatitis B virus Large envelope protein (HBV S),,
T62047,HBV S,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T62094,#N/A,TARGETID,T62094,,
T62094,#N/A,TARGNAME,Bacterial 30S ribosomal RNA (Bact 30S rRNA),,
T62094,#N/A,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T62094,#N/A,INDICATI,Phase 1,Antimicrobial drug resistance,[ICD-11: MG50-MG52]
T62094,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T62094,#N/A,INDICATI,Phase 2,Diabetic foot ulcer,[ICD-11: BD54]
T62094,#N/A,INDICATI,Approved,Gingival/edentulous alveolar ridge disorder,[ICD-11: DA0D]
T62094,#N/A,INDICATI,Approved,Infectious gastroenteritis/colitis,[ICD-11: 1A40]
T62094,#N/A,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T62094,#N/A,INDICATI,Approved,Periodontal disease,[ICD-11: DA0C]
T62094,#N/A,INDICATI,Approved,Pneumonia,[ICD-11: CA40]
T62094,#N/A,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T62094,#N/A,INDICATI,Phase 1,Respiratory infection,[ICD-11: CA07-CA4Z]
T62094,#N/A,INDICATI,Approved,Skin sensation disturbance,[ICD-11: ME65]
,#N/A,,,,
T62151,#N/A,TARGETID,T62151,,
T62151,#N/A,TARGNAME,Monoamine oxidase (MAO),,
T62151,#N/A,INDICATI,Approved,Acquired methaemoglobinaemia,[ICD-11: 3A93]
T62151,#N/A,INDICATI,Patented,Alopecia,[ICD-11: ED70]
T62151,#N/A,INDICATI,Approved,Alzheimer disease,[ICD-11: 8A20]
T62151,#N/A,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T62151,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T62151,#N/A,INDICATI,Discontinued in Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T62151,#N/A,INDICATI,Patented,Muscular dystrophy,[ICD-11: 8C70]
T62151,#N/A,INDICATI,Discontinued in Phase 3,Nausea/vomiting,[ICD-11: MD90]
T62151,#N/A,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T62151,#N/A,INDICATI,Patented,Prostate cancer,[ICD-11: 2C82]
T62151,#N/A,INDICATI,Patented,Skin tag/polyp,[ICD-11: EK71]
,#N/A,,,,
T62166,#N/A,TARGETID,T62166,,
T62166,#N/A,TARGNAME,Adenine synthesis (Adeni synth),,
T62166,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
,#N/A,,,,
T62184,SLC6A1,TARGETID,T62184,,
T62184,SLC6A1,TARGNAME,GABA transporter GAT-1 (SLC6A1),,
T62184,SLC6A1,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T62184,SLC6A1,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T62184,SLC6A1,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T62184,SLC6A1,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T62187,HSV UL8,TARGETID,T62187,,
T62187,HSV UL8,TARGNAME,Herpes simplex virus Helicase-primase (HSV UL8),,
T62187,HSV UL8,INDICATI,Phase 3,Herpes simplex infection,[ICD-11: 1F00]
,#N/A,,,,
T62193,DDC,TARGETID,T62193,,
T62193,DDC,TARGNAME,Aromatic-L-amino-acid decarboxylase (DDC),,
T62193,DDC,INDICATI,Phase 2,Neurotransmitter metabolic error,[ICD-11: 5C59]
T62193,DDC,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T62193,DDC,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T62206,PCSK9,TARGETID,T62206,,
T62206,PCSK9,TARGNAME,Proprotein convertase subtilisin/kexin type 9 (PCSK9),,
T62206,PCSK9,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T62206,PCSK9,INDICATI,Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T62206,PCSK9,INDICATI,Investigative,Coronary atherosclerosis,[ICD-11: BA80]
T62206,PCSK9,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T62206,PCSK9,INDICATI,Approved,Hyper-lipoproteinaemia,ICD-11: 5C80
,#N/A,,,,
T62241,IL25,TARGETID,T62241,,
T62241,IL25,TARGNAME,Interleukin-25 (IL25),,
T62241,IL25,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T62276,GRIN1,TARGETID,T62276,,
T62276,GRIN1,TARGNAME,Glutamate receptor ionotropic NMDA 1 (NMDAR1),,
T62276,GRIN1,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T62276,GRIN1,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T62276,GRIN1,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T62276,GRIN1,INDICATI,Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T62276,GRIN1,INDICATI,Discontinued in Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T62276,GRIN1,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T62276,GRIN1,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T62276,GRIN1,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T62276,GRIN1,INDICATI,Phase 2,Obsessive-compulsive disorder,[ICD-11: 6B20]
,#N/A,,,,
T62292,GABRA3,TARGETID,T62292,,
T62292,GABRA3,TARGNAME,GABA(A) receptor alpha-3 (GABRA3),,
T62292,GABRA3,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T62292,GABRA3,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T62292,GABRA3,INDICATI,Approved,Intentional self-harm,[ICD-11: PC91]
T62292,GABRA3,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T62292,GABRA3,INDICATI,Discontinued in Phase 1,Schizophrenia,[ICD-11: 6A20]
T62292,GABRA3,INDICATI,Phase 2,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
,#N/A,,,,
T62306,MLNR,TARGETID,T62306,,
T62306,MLNR,TARGNAME,Motilin receptor (MLNR),,
T62306,MLNR,INDICATI,Investigative,Bowel habit change,[ICD-11: ME05]
T62306,MLNR,INDICATI,Phase 1,Digestive system disease,[ICD-11: DE2Z]
T62306,MLNR,INDICATI,Preclinical,Dyspepsia,[ICD-11: MD92]
T62306,MLNR,INDICATI,Phase 2,Gastroduodenal motor/secretory disorder,[ICD-11: DA41]
T62306,MLNR,INDICATI,Phase 1,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T62306,MLNR,INDICATI,Phase 1,Irritable bowel syndrome,[ICD-11: DD91]
T62306,MLNR,INDICATI,Discontinued in Phase 2,Oesophagus motility disorder,[ICD-11: DA21]
T62306,MLNR,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T62390,TH,TARGETID,T62390,,
T62390,TH,TARGNAME,Tyrosine 3-monooxygenase (TH),,
T62390,TH,INDICATI,Approved,Adrenomedullary hyperfunction,[ICD-11: 5A75]
T62390,TH,INDICATI,Phase 2,Autism spectrum disorder,[ICD-11: 6A02]
T62390,TH,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T62390,TH,INDICATI,Phase 1/2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T62391,GRIA3,TARGETID,T62391,,
T62391,GRIA3,TARGNAME,Glutamate receptor AMPA 3 (GRIA3),,
T62391,GRIA3,INDICATI,Approved,Neuropathy,[ICD-11: 8C0Z]
T62391,GRIA3,INDICATI,Discontinued in Phase 3,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T62431,SYK,TARGETID,T62431,,
T62431,SYK,TARGNAME,Tyrosine-protein kinase SYK (SYK),,
T62431,SYK,INDICATI,Phase 1,Acquired hypomelanotic disorder,[ICD-11: ED63]
T62431,SYK,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T62431,SYK,INDICATI,Investigative,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T62431,SYK,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T62431,SYK,INDICATI,Phase 1,Atopic eczema,[ICD-11: EA80]
T62431,SYK,INDICATI,Phase 2,B-cell lymphoma,[ICD-11: 2A86]
T62431,SYK,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T62431,SYK,INDICATI,Phase 2,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T62431,SYK,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T62431,SYK,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T62431,SYK,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T62431,SYK,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T62431,SYK,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T62431,SYK,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T62431,SYK,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T62431,SYK,INDICATI,Investigative,Thrombosis,[ICD-11: DB61-GB90]
T62431,SYK,INDICATI,Phase 1,Urticaria,[ICD-11: EB00-EB05]
,#N/A,,,,
T62449,CHEK1,TARGETID,T62449,,
T62449,CHEK1,TARGNAME,Checkpoint kinase-1 (CHK1),,
T62449,CHEK1,INDICATI,Phase 1,Anal cancer,[ICD-11: 2C00]
T62449,CHEK1,INDICATI,Investigative,Breast cancer,[ICD-11: 2C60-2C6Y]
T62449,CHEK1,INDICATI,Phase 1,Head and neck cancer,[ICD-11: 2D42]
T62449,CHEK1,INDICATI,Phase 1,Hodgkin lymphoma,[ICD-11: 2B30]
T62449,CHEK1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T62449,CHEK1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T62449,CHEK1,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T62449,CHEK1,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T62449,CHEK1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T62460,JAK1,TARGETID,T62460,,
T62460,JAK1,TARGNAME,Janus kinase 1 (JAK-1),,
T62460,JAK1,INDICATI,Phase 1/2,Acquired hypomelanotic disorder,[ICD-11: ED63]
T62460,JAK1,INDICATI,Phase 2,Alopecia,[ICD-11: ED70]
T62460,JAK1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T62460,JAK1,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
T62460,JAK1,INDICATI,Phase 2,B-cell lymphoma,[ICD-11: 2A86]
T62460,JAK1,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T62460,JAK1,INDICATI,Phase 2,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T62460,JAK1,INDICATI,Investigative,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T62460,JAK1,INDICATI,Phase 2,Hidradenitis suppurativa,[ICD-11: ED92]
T62460,JAK1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T62460,JAK1,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T62460,JAK1,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T62460,JAK1,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T62460,JAK1,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T62460,JAK1,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T62460,JAK1,INDICATI,Phase 3,Psoriatic arthritis,[ICD-11: FA21]
T62460,JAK1,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T62460,JAK1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T62460,JAK1,INDICATI,Approved,Thrombocytosis,[ICD-11: 3B63]
T62460,JAK1,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T62501,#N/A,TARGETID,T62501,,
T62501,#N/A,TARGNAME,Toxic methotrexate (TM),,
T62501,#N/A,INDICATI,Approved,Delayed methotrexate clearance,[ICD-11: N.A.]
,#N/A,,,,
T62553,HSV RIR1,TARGETID,T62553,,
T62553,HSV RIR1,TARGNAME,Herpes simplex virus Ribonucleoside-diphosphate reductase (HSV RIR1),,
T62553,HSV RIR1,INDICATI,Terminated,Herpes simplex infection,[ICD-11: 1F00]
,#N/A,,,,
T62705,ICOS,TARGETID,T62705,,
T62705,ICOS,TARGNAME,Inducible T-cell costimulator (ICOS),,
T62705,ICOS,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T62705,ICOS,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T62739,STMN1,TARGETID,T62739,,
T62739,STMN1,TARGNAME,STMN1 messenger RNA (STMN1 mRNA),,
T62739,STMN1,INDICATI,Investigative,Breast cancer,[ICD-11: 2C60-2C6Y]
T62739,STMN1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T62753,AKT1; AKT2; AKT3,TARGETID,T62753,,
T62753,AKT1; AKT2; AKT3,TARGNAME,Phosphorylated protein kinase B (pAKT),,
T62753,AKT1; AKT2; AKT3,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T62753,AKT1; AKT2; AKT3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T62763,FGF10,TARGETID,T62763,,
T62763,FGF10,TARGNAME,Fibroblast growth factor-10 (FGF10),,
T62763,FGF10,INDICATI,Discontinued in Phase 2,Oral mucositis,[ICD-11: DA01]
,#N/A,,,,
T62820,GRM2,TARGETID,T62820,,
T62820,GRM2,TARGNAME,Metabotropic glutamate receptor 2 (mGluR2),,
T62820,GRM2,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T62820,GRM2,INDICATI,Discontinued in Phase 3,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T62820,GRM2,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T62820,GRM2,INDICATI,Phase 2,Dengue fever,[ICD-11: 1D2Z]
T62820,GRM2,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T62820,GRM2,INDICATI,Phase 1,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T62820,GRM2,INDICATI,Phase 1,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T62820,GRM2,INDICATI,Discontinued in Phase 2,Migraine,[ICD-11: 8A80]
T62820,GRM2,INDICATI,Discontinued in Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T62820,GRM2,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
T62820,GRM2,INDICATI,Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T62820,GRM2,INDICATI,Phase 1,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T62841,F2RL1,TARGETID,T62841,,
T62841,F2RL1,TARGNAME,Proteinase activated receptor 2 (PAR2),,
T62841,F2RL1,INDICATI,Patented,Acquired cutaneous blood vessel malformation,[ICD-11: EF20]
T62841,F2RL1,INDICATI,Patented,Arterial occlusive disease,[ICD-11: BD40]
T62841,F2RL1,INDICATI,Patented,Atopic eczema,[ICD-11: EA80]
T62841,F2RL1,INDICATI,Patented,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T62841,F2RL1,INDICATI,Phase 1,Chronic pain,[ICD-11: MG30]
T62841,F2RL1,INDICATI,Patented,Digestive system disease,[ICD-11: DE2Z]
T62841,F2RL1,INDICATI,Patented,Gastric ulcer,[ICD-11: DA60]
T62841,F2RL1,INDICATI,Patented,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T62841,F2RL1,INDICATI,Patented,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T62841,F2RL1,INDICATI,Patented,Multiple sclerosis,[ICD-11: 8A40]
T62841,F2RL1,INDICATI,Patented,Pain,[ICD-11: MG30-MG3Z]
T62841,F2RL1,INDICATI,Patented,Postoperative inflammation,[ICD-11: 1A00-CA43]
T62841,F2RL1,INDICATI,Patented,Psoriasis,[ICD-11: EA90]
T62841,F2RL1,INDICATI,Patented,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T62841,F2RL1,INDICATI,Patented,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T62905,SLC5A6,TARGETID,T62905,,
T62905,SLC5A6,TARGNAME,Sodium-dependent multivitamin transporter (SLC5A6),,
T62905,SLC5A6,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T62945,#N/A,TARGETID,T62945,,
T62945,#N/A,TARGNAME,Voltage-gated calcium channel (Cav),,
T62945,#N/A,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T62945,#N/A,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T62974,SSTR4,TARGETID,T62974,,
T62974,SSTR4,TARGNAME,Somatostatin receptor type 4 (SSTR4),,
T62974,SSTR4,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T62974,SSTR4,INDICATI,Phase 2,Chronic pain,ICD-11: MG30
T62974,SSTR4,INDICATI,Phase 1,Chronic pain,[ICD-11: MG30]
T62974,SSTR4,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T62974,SSTR4,INDICATI,Investigative,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T63068,ALB,TARGETID,T63068,,
T63068,ALB,TARGNAME,Serum albumin (ALB),,
T63068,ALB,INDICATI,Approved,Aneurysm/dissection,[ICD-11: BD50]
T63068,ALB,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
T63068,ALB,INDICATI,Approved,Cholelithiasis,[ICD-11: DC11]
T63068,ALB,INDICATI,Phase 2/3,Coagulation defect,[ICD-11: 3B10]
T63068,ALB,INDICATI,Approved,Inborn energy metabolism error,[ICD-11: 5C53]
T63068,ALB,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T63068,ALB,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T63068,ALB,INDICATI,Approved,Preprocedural examination,[ICD-11: QA0B]
T63068,ALB,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T63068,ALB,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T63068,ALB,INDICATI,Approved,Unspecific body region injury,[ICD-11: ND56]
T63068,ALB,INDICATI,Phase 1/2,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T63083,RAD51,TARGETID,T63083,,
T63083,RAD51,TARGNAME,DNA repair protein RAD51 homolog 1 (RAD51),,
T63083,RAD51,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T63083,RAD51,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63140,Bact lmrP,TARGETID,T63140,,
T63140,Bact lmrP,TARGNAME,Bacterial Integral membrane LmrP (Bact lmrP),,
T63140,Bact lmrP,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T63155,PKLR,TARGETID,T63155,,
T63155,PKLR,TARGNAME,Pyruvate kinase PKLR (PKLR),,
T63155,PKLR,INDICATI,Approved,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
T63155,PKLR,INDICATI,Phase 2,Inborn energy metabolism error,[ICD-11: 5C53]
T63155,PKLR,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T63156,MAN2B1,TARGETID,T63156,,
T63156,MAN2B1,TARGNAME,Lysosomal alpha-mannosidase (MAN2B1),,
T63156,MAN2B1,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T63158,SMPD1,TARGETID,T63158,,
T63158,SMPD1,TARGNAME,Sphingomyelin phosphodiesterase (SMPD1),,
T63158,SMPD1,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T63160,APOL1,TARGETID,T63160,,
T63160,APOL1,TARGNAME,Apolipoprotein L1 messenger RNA (APOL1 mRNA),,
T63160,APOL1,INDICATI,Phase 1,Chronic kidney disease,[ICD-11: GB61]
T63160,APOL1,INDICATI,Phase 1,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T63161,ATXN3,TARGETID,T63161,,
T63161,ATXN3,TARGNAME,Ataxin-3 messenger RNA (ATXN3 mRNA),,
T63161,ATXN3,INDICATI,Phase 1,Ataxic disorder,ICD-11: 8A03
,#N/A,,,,
T63163,BCKDK,TARGETID,T63163,,
T63163,BCKDK,TARGNAME,[3-methyl-2-oxobutanoate dehydrogenase] kinase (BCKDK),,
T63163,BCKDK,INDICATI,Phase 1,Left ventricular failure,ICD-11: BD11
,#N/A,,,,
T63164,CDH6,TARGETID,T63164,,
T63164,CDH6,TARGNAME,Cadherin-6 (CDH6),,
T63164,CDH6,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T63165,CCR6,TARGETID,T63165,,
T63165,CCR6,TARGNAME,C-C chemokine receptor type 6 (CCR6),,
T63165,CCR6,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
,#N/A,,,,
T63166,CLDN6,TARGETID,T63166,,
T63166,CLDN6,TARGNAME,Claudin-6 (CLDN6),,
T63166,CLDN6,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63168,ENTPD3,TARGETID,T63168,,
T63168,ENTPD3,TARGNAME,Ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3),,
T63168,ENTPD3,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
,#N/A,,,,
T63169,G6PC1,TARGETID,T63169,,
T63169,G6PC1,TARGNAME,Glucose-6-phosphatase catalytic subunit 1 messenger RNA (G6PC1 mRNA),,
T63169,G6PC1,INDICATI,Phase 1,Inborn carbohydrate metabolism error,ICD-11: 5C51
,#N/A,,,,
T63170,HAO1,TARGETID,T63170,,
T63170,HAO1,TARGNAME,2-Hydroxyacid oxidase 1 (HAO1),,
T63170,HAO1,INDICATI,Phase 1,Inborn carbohydrate metabolism error,ICD-11: 5C51
,#N/A,,,,
T63173,IKZF3,TARGETID,T63173,,
T63173,IKZF3,TARGNAME,Zinc finger protein Aiolos (IKZF3),,
T63173,IKZF3,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T63173,IKZF3,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T63174,IL1RN,TARGETID,T63174,,
T63174,IL1RN,TARGNAME,Interleukin-1 receptor antagonist protein (IL1RN),,
T63174,IL1RN,INDICATI,Phase 1,Osteoarthritis,[ICD-11: FA00-FA05]
,#N/A,,,,
T63175,KAT6A,TARGETID,T63175,,
T63175,KAT6A,TARGNAME,Histone acetyltransferase KAT6A (KAT6A),,
T63175,KAT6A,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T63176,#N/A,TARGETID,T63176,,
T63176,#N/A,TARGNAME,CD85k-Fibronectin interaction (LILRB4-FN1 PPI),,
T63176,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63177,LRRK2,TARGETID,T63177,,
T63177,LRRK2,TARGNAME,Leucine-rich repeat serine/threonine-protein kinase 2 messenger RNA (LRRK2 mRNA),,
T63177,LRRK2,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T63178,MAGEA10,TARGETID,T63178,,
T63178,MAGEA10,TARGNAME,Melanoma-associated antigen 10 (MAGEA10),,
T63178,MAGEA10,INDICATI,Phase 1,Bladder cancer,[ICD-11: 2C94]
T63178,MAGEA10,INDICATI,Phase 1,Head and neck cancer,[ICD-11: 2D42]
T63178,MAGEA10,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T63178,MAGEA10,INDICATI,Phase 1,Non-small-cell lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T63180,MUC5AC,TARGETID,T63180,,
T63180,MUC5AC,TARGNAME,Mucin-5AC messenger RNA (MUC5AC mRNA),,
T63180,MUC5AC,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
,#N/A,,,,
T63182,N,TARGETID,T63182,,
T63182,N,TARGNAME,Nucleoprotein (N),,
T63182,N,INDICATI,Phase 1,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T63183,PANK3,TARGETID,T63183,,
T63183,PANK3,TARGNAME,Pantothenate kinase 3 (PANK3),,
T63183,PANK3,INDICATI,Phase 1,Metabolism inborn error,[ICD-11: 5C50]
T63183,PANK3,INDICATI,Phase 1,Metabolism inborn error,ICD-11: 5C50
,#N/A,,,,
T63184,AGER,TARGETID,T63184,,
T63184,AGER,TARGNAME,Advanced glycosylation end product-specific receptor messenger RNA (AGER mRNA),,
T63184,AGER,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
,#N/A,,,,
T63185,KRAS,TARGETID,T63185,,
T63185,KRAS,TARGNAME,KRas D816V mutant (KRAS D816V),,
T63185,KRAS,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63187,TBL1X,TARGETID,T63187,,
T63187,TBL1X,TARGNAME,F-box-like/WD repeat-containing protein TBL1X (TBL1X),,
T63187,TBL1X,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T63187,TBL1X,INDICATI,Phase 1,Desmoid tumour,[ICD-11: 2F7C]
,#N/A,,,,
T63188,ASPA,TARGETID,T63188,,
T63188,ASPA,TARGNAME,Aspartoacylase (ASPA),,
T63188,ASPA,INDICATI,Phase 1/2,Metabolism inborn error,ICD-11: 5C50
,#N/A,,,,
T63189,CDC123,TARGETID,T63189,,
T63189,CDC123,TARGNAME,Cell division cycle protein 123 (CDC123),,
T63189,CDC123,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T63190,CLN3,TARGETID,T63190,,
T63190,CLN3,TARGNAME,Battenin (CLN3),,
T63190,CLN3,INDICATI,Phase 1/2,Lysosomal disease,ICD-11: 5C56
,#N/A,,,,
T63191,CLN6,TARGETID,T63191,,
T63191,CLN6,TARGNAME,Ceroid-lipofuscinosis neuronal protein 6 (CLN6),,
T63191,CLN6,INDICATI,Phase 1/2,Lysosomal disease,ICD-11: 5C56
,#N/A,,,,
T63192,CYP21A2,TARGETID,T63192,,
T63192,CYP21A2,TARGNAME,Steroid 21-hydroxylase (CYP21A2),,
T63192,CYP21A2,INDICATI,Phase 1/2,Adrenogenital disorder,[ICD-11: 5A71]
,#N/A,,,,
T63193,DGKZ,TARGETID,T63193,,
T63193,DGKZ,TARGNAME,Diacylglycerol kinase zeta (DGKZ),,
T63193,DGKZ,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63194,ENPP1,TARGETID,T63194,,
T63194,ENPP1,TARGNAME,Ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1),,
T63194,ENPP1,INDICATI,Phase 1/2,Pseudoxanthoma elasticum,ICD-11: EC40
T63194,ENPP1,INDICATI,Phase 1/2,Vitamin/non-protein cofactor absorption/transport disorder,ICD-11: 5C63
,#N/A,,,,
T63195,GAN,TARGETID,T63195,,
T63195,GAN,TARGNAME,Gigaxonin (GAN),,
T63195,GAN,INDICATI,Phase 1/2,Giant axonal neuropathy,ICD-11: 8C2Y
,#N/A,,,,
T63196,HEXA,TARGETID,T63196,,
T63196,HEXA,TARGNAME,Beta-hexosaminidase subunit alpha (HEXA),,
T63196,HEXA,INDICATI,Phase 1/2,Lysosomal disease,ICD-11: 5C56
,#N/A,,,,
T63197,HEXB,TARGETID,T63197,,
T63197,HEXB,TARGNAME,Beta-hexosaminidase subunit beta (HEXB),,
T63197,HEXB,INDICATI,Phase 1/2,Lysosomal disease,ICD-11: 5C56
,#N/A,,,,
T63198,RHO,TARGETID,T63198,,
T63198,RHO,TARGNAME,Rhodopsin P23H mutant messenger RNA (RHO P23H mRNA),,
T63198,RHO,INDICATI,Phase 1/2,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T63200,XDH,TARGETID,T63200,,
T63200,XDH,TARGNAME,Xanthine dehydrogenase/oxidase messenger RNA (XDH mRNA),,
T63200,XDH,INDICATI,Phase 1/2,Gout,[ICD-11: FA25]
,#N/A,,,,
T63201,AGT,TARGETID,T63201,,
T63201,AGT,TARGNAME,Angiotensinogen messenger RNA (AGT mRNA),,
T63201,AGT,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T63202,ATP7B,TARGETID,T63202,,
T63202,ATP7B,TARGNAME,Copper-transporting ATPase 2 (ATP7B),,
T63202,ATP7B,INDICATI,Phase 2,Mineral absorption/transport disorder,[ICD-11: 5C64]
,#N/A,,,,
T63203,ATXN2,TARGETID,T63203,,
T63203,ATXN2,TARGNAME,Ataxin-2 messenger RNA (ATXN2 mRNA),,
T63203,ATXN2,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
,#N/A,,,,
T63204,#N/A,TARGETID,T63204,,
T63204,#N/A,TARGNAME,CD47-SHPS1 interaction (CD47-SHPS1 PPI),,
T63204,#N/A,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T63204,#N/A,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T63206,#N/A,TARGETID,T63206,,
T63206,#N/A,TARGNAME,Integrin alpha-5/beta-1 (ITGA5/B1),,
T63206,#N/A,INDICATI,Phase 2,Autoimmune liver disease,[ICD-11: DB96]
T63206,#N/A,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
,#N/A,,,,
T63207,LANCL2,TARGETID,T63207,,
T63207,LANCL2,TARGNAME,LanC-like protein 2 (LANCL2),,
T63207,LANCL2,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T63207,LANCL2,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T63208,LILRA4,TARGETID,T63208,,
T63208,LILRA4,TARGNAME,Leukocyte immunoglobulin-like receptor subfamily A member 4 (LILRA4),,
T63208,LILRA4,INDICATI,Phase 2,Alopecia,ICD-11: ED70
T63208,LILRA4,INDICATI,Phase 2,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T63208,LILRA4,INDICATI,Phase 2,Idiopathic inflammatory myopathy,ICD-11: 4A41
T63208,LILRA4,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
,#N/A,,,,
T63209,LILRB1,TARGETID,T63209,,
T63209,LILRB1,TARGNAME,Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1),,
T63209,LILRB1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63210,ALOX12B,TARGETID,T63210,,
T63210,ALOX12B,TARGNAME,"Arachidonate 12-lipoxygenase, 12R-type (ALOX12B)",,
T63210,ALOX12B,INDICATI,Phase 2,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T63211,NLRX1,TARGETID,T63211,,
T63211,NLRX1,TARGNAME,NLR family member X1 (NLRX1),,
T63211,NLRX1,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T63212,PCCA,TARGETID,T63212,,
T63212,PCCA,TARGNAME,"Propionyl-CoA carboxylase alpha chain, mitochondrial messenger RNA (PCCA mRNA)",,
T63212,PCCA,INDICATI,Phase 2,Metabolism inborn error,ICD-11: 5C50
,#N/A,,,,
T63213,PCCB,TARGETID,T63213,,
T63213,PCCB,TARGNAME,"Propionyl-CoA carboxylase beta chain, mitochondrial messenger RNA (PCCB mRNA)",,
T63213,PCCB,INDICATI,Phase 2,Metabolism inborn error,ICD-11: 5C50
,#N/A,,,,
T63214,PNPLA3,TARGETID,T63214,,
T63214,PNPLA3,TARGNAME,1-acylglycerol-3-phosphate O-acyltransferase PNPLA3 messenger RNA (PNPLA3 mRNA),,
T63214,PNPLA3,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
,#N/A,,,,
T63215,SEMA3A,TARGETID,T63215,,
T63215,SEMA3A,TARGNAME,Semaphorin-3A (SEMA3A),,
T63215,SEMA3A,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T63216,SLIT2,TARGETID,T63216,,
T63216,SLIT2,TARGNAME,Slit homolog 2 protein (SLIT2),,
T63216,SLIT2,INDICATI,Phase 2,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T63217,TGM1,TARGETID,T63217,,
T63217,TGM1,TARGNAME,Protein-glutamine gamma-glutamyltransferase K (TGM1),,
T63217,TGM1,INDICATI,Phase 2,Autosomal Recessive Ichthyosis,ICD-11: ED20
,#N/A,,,,
T63218,ACAA2,TARGETID,T63218,,
T63218,ACAA2,TARGNAME,"3-ketoacyl-CoA thiolase, mitochondrial (ACAA2)",,
T63218,ACAA2,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
,#N/A,,,,
T63221,KLRG1,TARGETID,T63221,,
T63221,KLRG1,TARGNAME,Killer cell lectin-like receptor subfamily G member 1 (KLRG1),,
T63221,KLRG1,INDICATI,Phase 2/3,Idiopathic inflammatory myopathy,[ICD-11: 4A41]
,#N/A,,,,
T63222,USH2A,TARGETID,T63222,,
T63222,USH2A,TARGNAME,Usherin messenger RNA (USH2A mRNA),,
T63222,USH2A,INDICATI,Phase 2/3,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T63224,ARG1,TARGETID,T63224,,
T63224,ARG1,TARGNAME,Arginase-1 (ARG1),,
T63224,ARG1,INDICATI,Phase 3,Metabolism inborn error,[ICD-11: 5C50]
,#N/A,,,,
T63225,ADAMTS13,TARGETID,T63225,,
T63225,ADAMTS13,TARGNAME,A disintegrin and metalloproteinase with thrombospondin motifs 13 (ADAMTS13),,
T63225,ADAMTS13,INDICATI,Phase 3,Thrombocytopenia,[ICD-11: 3B64]
T63225,ADAMTS13,INDICATI,Phase 3,Thrombocytopenia,ICD-11: 3B64
,#N/A,,,,
T63226,CLEC4C,TARGETID,T63226,,
T63226,CLEC4C,TARGNAME,C-type lectin domain family 4 member C (CLEC4C),,
T63226,CLEC4C,INDICATI,Phase 3,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T63226,CLEC4C,INDICATI,Phase 3,Lupus erythematosus,[ICD-11: 4A40]
,#N/A,,,,
T63227,FUS,TARGETID,T63227,,
T63227,FUS,TARGNAME,RNA-binding protein FUS messenger RNA (FUS mRNA),,
T63227,FUS,INDICATI,Phase 3,Motor neuron disease,[ICD-11: 8B60]
,#N/A,,,,
T63228,GFAP,TARGETID,T63228,,
T63228,GFAP,TARGNAME,Glial fibrillary acidic protein messenger RNA (GFAP mRNA),,
T63228,GFAP,INDICATI,Phase 3,Leukodystrophy,ICD-11: 8A44
,#N/A,,,,
T63229,IL1RL1,TARGETID,T63229,,
T63229,IL1RL1,TARGNAME,Interleukin-1 receptor-like 1 (IL1RL1),,
T63229,IL1RL1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T63229,IL1RL1,INDICATI,Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
,#N/A,,,,
T63230,INHBA,TARGETID,T63230,,
T63230,INHBA,TARGNAME,Inhibin beta A chain (INHBA),,
T63230,INHBA,INDICATI,Phase 3,Muscle calcification/ossification,[ICD-11: FB31]
,#N/A,,,,
T63231,KIT,TARGETID,T63231,,
T63231,KIT,TARGNAME,KIT D816V mutant (KIT D816V),,
T63231,KIT,INDICATI,Phase 3,Gastrointestinal stromal tumour,[ICD-11: 2B5B]
,#N/A,,,,
T63233,SORT1,TARGETID,T63233,,
T63233,SORT1,TARGNAME,Sortilin (SORT1),,
T63233,SORT1,INDICATI,Phase 3,Frontotemporal dementia,ICD-11: 6D83
T63233,SORT1,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T63233,SORT1,INDICATI,Phase 1,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
,#N/A,,,,
T63234,qcrB,TARGETID,T63234,,
T63234,qcrB,TARGNAME,Cytochrome bc1 complex cytochrome b subunit (qcrB),,
T63234,qcrB,INDICATI,Preclinical,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
,#N/A,,,,
T63235,BRAF,TARGETID,T63235,,
T63235,BRAF,TARGNAME,BRAF V600E mutant (BRAF V600E),,
T63235,BRAF,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63236,CCL17,TARGETID,T63236,,
T63236,CCL17,TARGNAME,C-C motif chemokine 17 (CCL17),,
T63236,CCL17,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
,#N/A,,,,
T63237,HSD17B13,TARGETID,T63237,,
T63237,HSD17B13,TARGNAME,17-beta-hydroxysteroid dehydrogenase 13 (HSD17B13),,
T63237,HSD17B13,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
,#N/A,,,,
T63238,GPR6,TARGETID,T63238,,
T63238,GPR6,TARGNAME,G-protein coupled receptor 6 (GPR6),,
T63238,GPR6,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T63239,HLA-A,TARGETID,T63239,,
T63239,HLA-A,TARGNAME,"HLA class I histocompatibility antigen, A alpha chain (HLA-A)",,
T63239,HLA-A,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T63240,lepB,TARGETID,T63240,,
T63240,lepB,TARGNAME,Signal peptidase I (lepB),,
T63240,lepB,INDICATI,Phase 1,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T63241,TENT4B,TARGETID,T63241,,
T63241,TENT4B,TARGNAME,Terminal nucleotidyltransferase 4B (TENT4B),,
T63241,TENT4B,INDICATI,Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T63242,TENT4A,TARGETID,T63242,,
T63242,TENT4A,TARGNAME,Terminal nucleotidyltransferase 4A (TENT4A),,
T63242,TENT4A,INDICATI,Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T63243,GBA1,TARGETID,T63243,,
T63243,GBA1,TARGNAME,Lysosomal acid glucosylceramidase (GBA1),,
T63243,GBA1,INDICATI,Phase 2/3,Lysosomal disease,[ICD-11: 5C56]
T63243,GBA1,INDICATI,Phase 1/2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T63244,FGF19,TARGETID,T63244,,
T63244,FGF19,TARGNAME,Fibroblast growth factor 19 (FGF19),,
T63244,FGF19,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
,#N/A,,,,
T63245,MOGAT2,TARGETID,T63245,,
T63245,MOGAT2,TARGNAME,2-acylglycerol O-acyltransferase 2 (MOGAT2),,
T63245,MOGAT2,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T63246,CTNS,TARGETID,T63246,,
T63246,CTNS,TARGNAME,Cystinosin (CTNS),,
T63246,CTNS,INDICATI,Clinical trial,Amino acid absorption/transport disorder,ICD-11: 5C60
,#N/A,,,,
T63414,P2RX7,TARGETID,T63414,,
T63414,P2RX7,TARGNAME,P2X purinoceptor 7 (P2RX7),,
T63414,P2RX7,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T63414,P2RX7,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T63414,P2RX7,INDICATI,Phase 1,CNS non-viral infection,[ICD-11: 1D0Y]
T63414,P2RX7,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T63414,P2RX7,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T63414,P2RX7,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T63414,P2RX7,INDICATI,Phase 2/3,Joint pain,[ICD-11: ME82]
T63414,P2RX7,INDICATI,Phase 1,Mood disorder,[ICD-11: 6A60-6E23]
T63414,P2RX7,INDICATI,Phase 1,Mood/affect symptom,[ICD-11: MB24]
T63414,P2RX7,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T63414,P2RX7,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T63414,P2RX7,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T63414,P2RX7,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63484,G6PD,TARGETID,T63484,,
T63484,G6PD,TARGNAME,Glucose-6-phosphate dehydrogenase (G6PD),,
T63484,G6PD,INDICATI,Phase 4,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T63484,G6PD,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T63484,G6PD,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T63505,ABL1,TARGETID,T63505,,
T63505,ABL1,TARGNAME,Tyrosine-protein kinase ABL1 (ABL),,
T63505,ABL1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T63505,ABL1,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T63505,ABL1,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T63505,ABL1,INDICATI,Discontinued in Phase 2,Heart beat abnormality,[ICD-11: MC81]
T63505,ABL1,INDICATI,Phase 2,Heart disease,[ICD-11: BA41-BA42]
T63505,ABL1,INDICATI,Approved,Ischemia,[ICD-11: 8B10-8B11]
T63505,ABL1,INDICATI,Preclinical,Leukaemia,[ICD-11: 2A60-2B33]
T63505,ABL1,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T63505,ABL1,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T63505,ABL1,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T63505,ABL1,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T63505,ABL1,INDICATI,Phase 2,Osteosarcoma,[ICD-11: 2B51]
T63505,ABL1,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T63505,ABL1,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T63505,ABL1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63512,ENPP2,TARGETID,T63512,,
T63512,ENPP2,TARGNAME,Extracellular lysophospholipase D (E-NPP2),,
T63512,ENPP2,INDICATI,Patented,Fibrosis,[ICD-11: GA14-GC01]
T63512,ENPP2,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T63512,ENPP2,INDICATI,Patented,Pain,[ICD-11: MG30-MG3Z]
T63512,ENPP2,INDICATI,Patented,Postoperative inflammation,[ICD-11: 1A00-CA43]
T63512,ENPP2,INDICATI,Patented,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63551,#N/A,TARGETID,T63551,,
T63551,#N/A,TARGNAME,Integrin (ITG),,
T63551,#N/A,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T63598,Pedhc nAChR,TARGETID,T63598,,
T63598,Pedhc nAChR,TARGNAME,Pediculus humanus Nicotinic acetylcholine receptor (Pedhc nAChR),,
T63598,Pedhc nAChR,INDICATI,Approved,Pediculosis,[ICD-11: 1G00]
,#N/A,,,,
T63609,ADCY1,TARGETID,T63609,,
T63609,ADCY1,TARGNAME,Adenylate cyclase type 1 (ADCY1),,
T63609,ADCY1,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
,#N/A,,,,
T63803,VEGFD,TARGETID,T63803,,
T63803,VEGFD,TARGNAME,Vascular endothelial growth factor D (VEGFD),,
T63803,VEGFD,INDICATI,Discontinued in Phase 1/2,Angina pectoris,[ICD-11: BA40]
T63803,VEGFD,INDICATI,Discontinued in Phase 1/2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T63803,VEGFD,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T63816,HDAC4,TARGETID,T63816,,
T63816,HDAC4,TARGNAME,Histone deacetylase 4 (HDAC4),,
T63816,HDAC4,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T63934,IFNA2,TARGETID,T63934,,
T63934,IFNA2,TARGNAME,Interferon-alpha 2 (IFNA2),,
T63934,IFNA2,INDICATI,Phase 1,Basal cell carcinoma,[ICD-11: 2C32]
T63934,IFNA2,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T63934,IFNA2,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T63934,IFNA2,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T63934,IFNA2,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T63934,IFNA2,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T63934,IFNA2,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T63934,IFNA2,INDICATI,Phase 1,Peritoneal cancer,[ICD-11: 2C51]
T63934,IFNA2,INDICATI,Phase 3,Thrombocytosis,[ICD-11: 3B63]
T63934,IFNA2,INDICATI,Phase 3,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T63966,FLT1,TARGETID,T63966,,
T63966,FLT1,TARGNAME,Vascular endothelial growth factor receptor 1 (FLT-1),,
T63966,FLT1,INDICATI,Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T63966,FLT1,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T63966,FLT1,INDICATI,Phase 1,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T63966,FLT1,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T63966,FLT1,INDICATI,Discontinued in Phase 2,Diabetic foot ulcer,[ICD-11: BD54]
T63966,FLT1,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T63966,FLT1,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T63966,FLT1,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T63966,FLT1,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T63966,FLT1,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T63966,FLT1,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T63967,CHRNA4-CHRNB2,TARGETID,T63967,,
T63967,CHRNA4-CHRNB2,TARGNAME,Neuronal acetylcholine receptor alpha-4/beta-2 (CHRNA4/B2),,
T63967,CHRNA4-CHRNB2,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T63967,CHRNA4-CHRNB2,INDICATI,Discontinued in Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T63967,CHRNA4-CHRNB2,INDICATI,Phase 2,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T63967,CHRNA4-CHRNB2,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T63967,CHRNA4-CHRNB2,INDICATI,Discontinued in Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T63967,CHRNA4-CHRNB2,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T63967,CHRNA4-CHRNB2,INDICATI,Phase 2,Digestive system disease,[ICD-11: DE2Z]
T63967,CHRNA4-CHRNB2,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T63967,CHRNA4-CHRNB2,INDICATI,Phase 1,Mood disorder,[ICD-11: 6A60-6E23]
T63967,CHRNA4-CHRNB2,INDICATI,Approved,Nicotine use disorder,[ICD-11: 6C4A]
T63967,CHRNA4-CHRNB2,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T63967,CHRNA4-CHRNB2,INDICATI,Terminated,Parkinsonism,[ICD-11: 8A00]
T63967,CHRNA4-CHRNB2,INDICATI,Discontinued in Phase 2,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T63986,KIF11,TARGETID,T63986,,
T63986,KIF11,TARGNAME,Kinesin spindle messenger RNA (KIF11 mRNA),,
T63986,KIF11,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T63986,KIF11,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T64074,DCPS,TARGETID,T64074,,
T64074,DCPS,TARGNAME,Scavenger decapping enzyme DcpS (DCPS),,
T64074,DCPS,INDICATI,Phase 1,Muscular atrophy,[ICD-11: 8B61]
,#N/A,,,,
T64205,STAT1,TARGETID,T64205,,
T64205,STAT1,TARGNAME,Signal transducer and activator of transcription 1 (STAT1),,
T64205,STAT1,INDICATI,Discontinued in Phase 2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
,#N/A,,,,
T64213,TRPV4,TARGETID,T64213,,
T64213,TRPV4,TARGNAME,Transient receptor potential cation channel V4 (TRPV4),,
T64213,TRPV4,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T64213,TRPV4,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T64213,TRPV4,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
,#N/A,,,,
T64242,CYP46A1,TARGETID,T64242,,
T64242,CYP46A1,TARGNAME,Cholesterol 24-monooxygenase (CYP46A1),,
T64242,CYP46A1,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T64258,MAP1A; MAP1B,TARGETID,T64258,,
T64258,MAP1A; MAP1B,TARGNAME,Microtubule-associated protein (MAP),,
T64258,MAP1A; MAP1B,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T64376,#N/A,TARGETID,T64376,,
T64376,#N/A,TARGNAME,Fibroblast growth factor (FGF),,
T64376,#N/A,INDICATI,Phase 3,Skin sensation disturbance,[ICD-11: ME65]
T64376,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T64382,#N/A,TARGETID,T64382,,
T64382,#N/A,TARGNAME,Gamma-aminobutyric acid receptor (GAR),,
T64382,#N/A,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T64382,#N/A,INDICATI,Approved,Ascariasis,[ICD-11: 1F62]
T64382,#N/A,INDICATI,Approved,Bipolar disorder,[ICD-11: 6A60]
T64382,#N/A,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T64382,#N/A,INDICATI,Approved,Enterobiasis,[ICD-11: 1F65]
T64382,#N/A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T64382,#N/A,INDICATI,Discontinued in Phase 3,Female pelvic pain,[ICD-11: GA34]
T64382,#N/A,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T64382,#N/A,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T64382,#N/A,INDICATI,Approved,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T64382,#N/A,INDICATI,Phase 2,Metabolism inborn error,[ICD-11: 5C50]
T64382,#N/A,INDICATI,Phase 3,Obesity,[ICD-11: 5B80-5B81]
T64382,#N/A,INDICATI,Approved,Onchocerciasis,[ICD-11: 1F6A]
T64382,#N/A,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T64382,#N/A,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T64382,#N/A,INDICATI,Phase 3,Status epilepticus,[ICD-11: 8A66]
T64382,#N/A,INDICATI,Terminated,Substance abuse,[ICD-11: 6C40]
T64382,#N/A,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
T64382,#N/A,INDICATI,Phase 2,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T64410,Bact vanYB,TARGETID,T64410,,
T64410,Bact vanYB,TARGNAME,Bacterial DD-carboxypeptidase (Bact vanYB),,
T64410,Bact vanYB,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T64410,Bact vanYB,INDICATI,Phase 2,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T64410,Bact vanYB,INDICATI,Phase 3,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
,#N/A,,,,
T64526,Stap-coc ClfA,TARGETID,T64526,,
T64526,Stap-coc ClfA,TARGNAME,Staphylococcus Clumping factor A (Stap-coc ClfA),,
T64526,Stap-coc ClfA,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T64526,Stap-coc ClfA,INDICATI,Phase 2,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T64567,CA9,TARGETID,T64567,,
T64567,CA9,TARGNAME,Carbonic anhydrase IX (CA-IX),,
T64567,CA9,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T64567,CA9,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T64567,CA9,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T64567,CA9,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T64591,HTR3A,TARGETID,T64591,,
T64591,HTR3A,TARGNAME,5-HT 3A receptor (HTR3A),,
T64591,HTR3A,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T64591,HTR3A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T64591,HTR3A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T64591,HTR3A,INDICATI,Discontinued in Phase 2,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T64591,HTR3A,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T64591,HTR3A,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T64591,HTR3A,INDICATI,Terminated,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T64597,ITGB8,TARGETID,T64597,,
T64597,ITGB8,TARGNAME,Integrin beta-8 (ITGB8),,
T64597,ITGB8,INDICATI,Phase 1,Chronic kidney disease,[ICD-11: GB61]
,#N/A,,,,
T64645,SGSH,TARGETID,T64645,,
T64645,SGSH,TARGNAME,N-sulphoglucosamine sulphohydrolase (SGSH),,
T64645,SGSH,INDICATI,Phase 2/3,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T64682,SGK1,TARGETID,T64682,,
T64682,SGK1,TARGNAME,Serine/threonine-protein kinase Sgk1 (SGK1),,
T64682,SGK1,INDICATI,Investigative,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T64721,#N/A,TARGETID,T64721,,
T64721,#N/A,TARGNAME,Cancer stemness kinase (CSK),,
T64721,#N/A,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T64721,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T64721,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T64765,HRH3,TARGETID,T64765,,
T64765,HRH3,TARGNAME,Histamine H3 receptor (H3R),,
T64765,HRH3,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T64765,HRH3,INDICATI,Terminated,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T64765,HRH3,INDICATI,Phase 2,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T64765,HRH3,INDICATI,Terminated,Binge eating disorder,[ICD-11: 6B82]
T64765,HRH3,INDICATI,Patented,Central nervous system disease,[ICD-11: 8A04-8D87]
T64765,HRH3,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T64765,HRH3,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T64765,HRH3,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T64765,HRH3,INDICATI,Patented,Eexposure to noxious substances harmful effect,[ICD-11: NE61]
T64765,HRH3,INDICATI,Terminated,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T64765,HRH3,INDICATI,Patented,General pain disorder,[ICD-11: 8E43]
T64765,HRH3,INDICATI,Clinical trial,Insulin-resistance syndrome,[ICD-11: 5A44]
T64765,HRH3,INDICATI,Investigative,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T64765,HRH3,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T64765,HRH3,INDICATI,Phase 2,Narcolepsy,[ICD-11: 7A20]
T64765,HRH3,INDICATI,Phase 2,Neuropathy,[ICD-11: 8C0Z]
T64765,HRH3,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T64765,HRH3,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T64765,HRH3,INDICATI,Patented,Parkinsonism,[ICD-11: 8A00]
T64765,HRH3,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
T64765,HRH3,INDICATI,Phase 1,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
T64765,HRH3,INDICATI,Approved,Somnolence,[ICD-11: MG42]
T64765,HRH3,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T64765,HRH3,INDICATI,Phase 1,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T64774,VDAC3,TARGETID,T64774,,
T64774,VDAC3,TARGNAME,Voltage-dependent anion-selective channel 3 (VDAC3),,
T64774,VDAC3,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T64795,CACNA1G,TARGETID,T64795,,
T64795,CACNA1G,TARGNAME,Voltage-gated calcium channel alpha Cav3.1 (CACNA1G),,
T64795,CACNA1G,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T64795,CACNA1G,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T64795,CACNA1G,INDICATI,Phase 2,Insomnia,[ICD-11: 7A00-7A0Z]
T64795,CACNA1G,INDICATI,Approved,Multiple structural anomalies syndrome,[ICD-11: LD2F]
T64795,CACNA1G,INDICATI,Approved,Pancreatic cancer,[ICD-11: 2C10]
T64795,CACNA1G,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T64795,CACNA1G,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T64830,SSTR5,TARGETID,T64830,,
T64830,SSTR5,TARGNAME,Somatostatin receptor type 5 (SSTR5),,
T64830,SSTR5,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T64830,SSTR5,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T64830,SSTR5,INDICATI,Investigative,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T64969,EGFR,TARGETID,T64969,,
T64969,EGFR,TARGNAME,Epidermal growth factor receptor variant III (EGFR vIII),,
T64969,EGFR,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T64969,EGFR,INDICATI,Phase 1,Brain cancer,ICD-11: 2A00
T64969,EGFR,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T64969,EGFR,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T64969,EGFR,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T64977,IGF1R,TARGETID,T64977,,
T64977,IGF1R,TARGNAME,IGF1R messenger RNA (IGF1R mRNA),,
T64977,IGF1R,INDICATI,Preclinical,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T64987,EBV LMP1,TARGETID,T64987,,
T64987,EBV LMP1,TARGNAME,Epstein-Barr virus Latent membrane protein 1 (EBV LMP1),,
T64987,EBV LMP1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T64987,EBV LMP1,INDICATI,Phase 1/2,Nasopharyngeal cancer,[ICD-11: 2B6B]
,#N/A,,,,
T65019,MMP14,TARGETID,T65019,,
T65019,MMP14,TARGNAME,Matrix metalloproteinase-14 (MMP-14),,
T65019,MMP14,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T65019,MMP14,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T65019,MMP14,INDICATI,Phase 1/2a,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T65054,#N/A,TARGETID,T65054,,
T65054,#N/A,TARGNAME,Actin (ACT),,
T65054,#N/A,INDICATI,Phase 2,Vaginitis,[ICD-11: GA02]
,#N/A,,,,
T65074,#N/A,TARGETID,T65074,,
T65074,#N/A,TARGNAME,microRNA hsa-miR-92 (MIR92),,
T65074,#N/A,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T65116,NT5E,TARGETID,T65116,,
T65116,NT5E,TARGNAME,Ecto-5'-nucleotidase (CD73),,
T65116,NT5E,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T65116,NT5E,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T65116,NT5E,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T65197,EPOR,TARGETID,T65197,,
T65197,EPOR,TARGNAME,Erythropoietin Receptor (EPOR),,
T65197,EPOR,INDICATI,Approved,Anemia,[ICD-11: 3A00-3A9Z]
T65197,EPOR,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T65197,EPOR,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T65197,EPOR,INDICATI,Phase 1,Neuropathy,[ICD-11: 8C0Z]
T65197,EPOR,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T65197,EPOR,INDICATI,Phase 2,Sarcoidosis,[ICD-11: 4B20]
T65197,EPOR,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T65197,EPOR,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T65198,NRG1,TARGETID,T65198,,
T65198,NRG1,TARGNAME,Pro-neuregulin-1 (Pro-NRG1),,
T65198,NRG1,INDICATI,Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T65200,HSD11B1,TARGETID,T65200,,
T65200,HSD11B1,TARGNAME,Corticosteroid 11-beta-dehydrogenase 1 (HSD11B1),,
T65200,HSD11B1,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T65200,HSD11B1,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T65200,HSD11B1,INDICATI,Phase 2,Glaucoma,[ICD-11: 9C61]
T65200,HSD11B1,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T65200,HSD11B1,INDICATI,Phase 1,Inborn lipid metabolism error,[ICD-11: 5C52]
T65200,HSD11B1,INDICATI,Phase 3,Influenza,[ICD-11: 1E30-1E32]
T65200,HSD11B1,INDICATI,Phase 3,Lupus erythematosus,[ICD-11: 4A40]
T65200,HSD11B1,INDICATI,Phase 2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T65200,HSD11B1,INDICATI,Phase 2,Myasthenia gravis,[ICD-11: 8C6Y]
T65200,HSD11B1,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T65200,HSD11B1,INDICATI,Phase 2a,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T65236,GPER1,TARGETID,T65236,,
T65236,GPER1,TARGNAME,G-protein coupled estrogen receptor 1 (GPER1),,
T65236,GPER1,INDICATI,Approved,Contraceptive management,[ICD-11: QA21]
T65236,GPER1,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T65236,GPER1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T65291,ALDH3A2,TARGETID,T65291,,
T65291,ALDH3A2,TARGNAME,Fatty aldehyde dehydrogenase (ALDH3A2),,
T65291,ALDH3A2,INDICATI,Discontinued in Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T65291,ALDH3A2,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T65414,HIV env mRNA,TARGETID,T65414,,
T65414,HIV env mRNA,TARGNAME,Human immunodeficiency virus Envelope messenger RNA (HIV env mRNA),,
T65414,HIV env mRNA,INDICATI,Approved,Coronavirus infection,[ICD-11: 1D92]
T65414,HIV env mRNA,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T65429,GPR20,TARGETID,T65429,,
T65429,GPR20,TARGNAME,G-protein coupled receptor 20 (GPR20),,
T65429,GPR20,INDICATI,Phase 1,Gastrointestinal stromal tumour,[ICD-11: 2B5B]
,#N/A,,,,
T65501,DNMT3B,TARGETID,T65501,,
T65501,DNMT3B,TARGNAME,DNA [cytosine-5]-methyltransferase 3B (DNMT3B),,
T65501,DNMT3B,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T65570,ADH1A,TARGETID,T65570,,
T65570,ADH1A,TARGNAME,Alcohol dehydrogenase 1A (ADH1A),,
T65570,ADH1A,INDICATI,Approved,Eexposure to noxious substances harmful effect,[ICD-11: NE61]
,#N/A,,,,
T65667,#N/A,TARGETID,T65667,,
T65667,#N/A,TARGNAME,PMN apoptosis and chemotaxis (PMNAC),,
T65667,#N/A,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T65731,#N/A,TARGETID,T65731,,
T65731,#N/A,TARGNAME,Nitric oxide elimination (NOE),,
T65731,#N/A,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T65755,#N/A,TARGETID,T65755,,
T65755,#N/A,TARGNAME,Histone deacetylase (HDAC),,
T65755,#N/A,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T65755,#N/A,INDICATI,Phase 1,Acute upper respiratory infection,[ICD-11: CA07]
T65755,#N/A,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T65755,#N/A,INDICATI,Phase 2,Basal cell carcinoma,[ICD-11: 2C32]
T65755,#N/A,INDICATI,Phase 1/2,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T65755,#N/A,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T65755,#N/A,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T65755,#N/A,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
T65755,#N/A,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T65755,#N/A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T65755,#N/A,INDICATI,Phase 3,Follicular lymphoma,[ICD-11: 2A80]
T65755,#N/A,INDICATI,Phase 2,Gynecologic cancer,[ICD-11: 2F33-2F76]
T65755,#N/A,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T65755,#N/A,INDICATI,Phase 2,Keratosis pilaris,[ICD-11: ED56]
T65755,#N/A,INDICATI,Discontinued in Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T65755,#N/A,INDICATI,Registered,Lung cancer,[ICD-11: 2C25]
T65755,#N/A,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T65755,#N/A,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T65755,#N/A,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T65755,#N/A,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T65755,#N/A,INDICATI,Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T65755,#N/A,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T65755,#N/A,INDICATI,Approved,Muscular atrophy,[ICD-11: 8B61]
T65755,#N/A,INDICATI,Phase 3,Muscular dystrophy,[ICD-11: 8C70]
T65755,#N/A,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T65755,#N/A,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T65755,#N/A,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T65755,#N/A,INDICATI,Phase 1/2,Neuroendocrine carcinoma,[ICD-11: 2C34]
T65755,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T65755,#N/A,INDICATI,Phase 3,Renal cell carcinoma,[ICD-11: 2C90]
T65755,#N/A,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T65755,#N/A,INDICATI,Registered,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T65755,#N/A,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T65755,#N/A,INDICATI,Phase 2,Thrombocytosis,[ICD-11: 3B63]
,#N/A,,,,
T65783,APLNR,TARGETID,T65783,,
T65783,APLNR,TARGNAME,Apelin receptor (APLNR),,
T65783,APLNR,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T65864,MAPK14,TARGETID,T65864,,
T65864,MAPK14,TARGNAME,Stress-activated protein kinase 2a (p38 alpha),,
T65864,MAPK14,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T65864,MAPK14,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T65864,MAPK14,INDICATI,Phase 2a,Coronary atherosclerosis,[ICD-11: BA80]
T65864,MAPK14,INDICATI,Phase 2,Intrathoracic organs injury,[ICD-11: NB32]
T65864,MAPK14,INDICATI,Phase 3,Myocardial infarction,[ICD-11: BA41-BA43]
T65864,MAPK14,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T65864,MAPK14,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T65864,MAPK14,INDICATI,Discontinued in Phase 1,Psoriasis,[ICD-11: EA90]
T65864,MAPK14,INDICATI,Investigative,Retinopathy,[ICD-11: 9B71]
T65864,MAPK14,INDICATI,Phase 2a,Rheumatoid arthritis,[ICD-11: FA20]
T65864,MAPK14,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T65864,MAPK14,INDICATI,Phase 4,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T65868,#N/A,TARGETID,T65868,,
T65868,#N/A,TARGNAME,RNA synthesis (hRNA synth),,
T65868,#N/A,INDICATI,Investigative,Lung cancer,[ICD-11: 2C25]
T65868,#N/A,INDICATI,Approved,Mineral excesses,[ICD-11: 5B91]
T65868,#N/A,INDICATI,Investigative,Ovarian cancer,[ICD-11: 2C73]
T65868,#N/A,INDICATI,Withdrawn from market,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T65868,#N/A,INDICATI,Approved,Testicular cancer,[ICD-11: 2C80]
,#N/A,,,,
T65879,CHUK,TARGETID,T65879,,
T65879,CHUK,TARGNAME,Inhibitor of nuclear factor kappa-B kinase alpha (IKKA),,
T65879,CHUK,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T65883,CLDN18,TARGETID,T65883,,
T65883,CLDN18,TARGNAME,Claudin-18 (CLDN18),,
T65883,CLDN18,INDICATI,Clinical trial,Adenocarcinoma,[ICD-11: 2D40]
T65883,CLDN18,INDICATI,Phase 2,Esophageal cancer,[ICD-11: 2B70]
T65883,CLDN18,INDICATI,Phase 3,Oesophagogastric junction cancer,[ICD-11: 2B71]
T65883,CLDN18,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T65883,CLDN18,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T65883,CLDN18,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T65883,CLDN18,INDICATI,Phase 1/2,Stomach cancer,ICD-11: 2B72
,#N/A,,,,
T65889,PKM,TARGETID,T65889,,
T65889,PKM,TARGNAME,Pyruvate kinase M2 (PKM),,
T65889,PKM,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T65889,PKM,INDICATI,Phase 2a,Renal cell carcinoma,[ICD-11: 2C90]
T65889,PKM,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T65941,SERPINA1,TARGETID,T65941,,
T65941,SERPINA1,TARGNAME,SERPINA1 messenger RNA (SERPINA1 mRNA),,
T65941,SERPINA1,INDICATI,Phase 2,Alopecia,[ICD-11: ED70]
T65941,SERPINA1,INDICATI,Phase 3,Alpha-1-antitrypsin deficiency,[ICD-11: 5C5A]
,#N/A,,,,
T65978,Pseudo MvfR,TARGETID,T65978,,
T65978,Pseudo MvfR,TARGNAME,Pseudomonas Multiple virulence factor regulator MvfR (Pseudo MvfR),,
T65978,Pseudo MvfR,INDICATI,Preclinical,Glanders,[ICD-11: 1B92]
,#N/A,,,,
T66011,CFB,TARGETID,T66011,,
T66011,CFB,TARGNAME,Complement factor B (CFB),,
T66011,CFB,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T66011,CFB,INDICATI,Discontinued in Phase 1,Coronary atherosclerosis,[ICD-11: BA80]
T66011,CFB,INDICATI,Approved,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
T66011,CFB,INDICATI,Phase 2,Macular degeneration,ICD-11: 9B75
T66011,CFB,INDICATI,Investigative,Macular degeneration,[ICD-11: 9B75]
T66011,CFB,INDICATI,Phase 3,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T66023,#N/A,TARGETID,T66023,,
T66023,#N/A,TARGNAME,Schistosoma Deoxyribonucleic acid (Schist DNA),,
T66023,#N/A,INDICATI,Approved,Schistosomiasis,[ICD-11: 1F86]
,#N/A,,,,
T66030,#N/A,TARGETID,T66030,,
T66030,#N/A,TARGNAME,Natural killer cell activation (NKA),,
T66030,#N/A,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T66040,Bact mrdA,TARGETID,T66040,,
T66040,Bact mrdA,TARGNAME,Bacterial Penicillin binding protein 2 (Bact mrdA),,
T66040,Bact mrdA,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T66093,#N/A,TARGETID,T66093,,
T66093,#N/A,TARGNAME,Hepatitis C virus microRNA miR-122 (HCV MIR122),,
T66093,#N/A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T66120,Bact kdsB,TARGETID,T66120,,
T66120,Bact kdsB,TARGNAME,Bacterial Deoxy-manno-octulosonate cytidylyltransferase (Bact kdsB),,
T66120,Bact kdsB,INDICATI,Phase 3,Idiopathic inflammatory myopathy,[ICD-11: 4A41]
T66120,Bact kdsB,INDICATI,Phase 2,Muscle disorder,[ICD-11: FB32-FB3Z]
,#N/A,,,,
T66161,FLNA,TARGETID,T66161,,
T66161,FLNA,TARGNAME,Filamin A (FLNA),,
T66161,FLNA,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T66237,AVPR2,TARGETID,T66237,,
T66237,AVPR2,TARGNAME,Vasopressin V2 receptor (V2R),,
T66237,AVPR2,INDICATI,Discontinued in Phase 1,Abnormal micturition,[ICD-11: MF50]
T66237,AVPR2,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T66237,AVPR2,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T66237,AVPR2,INDICATI,Approved,Autism spectrum disorder,[ICD-11: 6A02]
T66237,AVPR2,INDICATI,Phase 3,Childbirth associated breast/lactation disorder,[ICD-11: JB46]
T66237,AVPR2,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T66237,AVPR2,INDICATI,Approved,Enuresis,[ICD-11: 6C00]
T66237,AVPR2,INDICATI,Terminated,Female pelvic pain,[ICD-11: GA34]
T66237,AVPR2,INDICATI,Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
T66237,AVPR2,INDICATI,Approved,Hypo-osmolality/hyponatraemia,[ICD-11: 5C72]
T66237,AVPR2,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T66237,AVPR2,INDICATI,Approved,Polyuria,[ICD-11: MF55]
T66237,AVPR2,INDICATI,Phase 2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
,#N/A,,,,
T66252,DPP9,TARGETID,T66252,,
T66252,DPP9,TARGNAME,Dipeptidyl peptidase 9 (DPP-9),,
T66252,DPP9,INDICATI,Phase 3,Neutropenia,[ICD-11: 4B00]
T66252,DPP9,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T66252,DPP9,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T66266,CD7,TARGETID,T66266,,
T66266,CD7,TARGNAME,T-cell antigen CD7 (CD7),,
T66266,CD7,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T66266,CD7,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T66266,CD7,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T66266,CD7,INDICATI,Phase 1,Mycosis fungoides,[ICD-11: 2B01]
,#N/A,,,,
T66350,RAB9A,TARGETID,T66350,,
T66350,RAB9A,TARGNAME,Ras-related protein Rab-9A (RAB9A),,
T66350,RAB9A,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
,#N/A,,,,
T66383,CFD,TARGETID,T66383,,
T66383,CFD,TARGNAME,Complement factor D (CFD),,
T66383,CFD,INDICATI,Phase 2,Acute disease anaemia,[ICD-11: 3A90]
T66383,CFD,INDICATI,Phase 1,Amyloidosis,[ICD-11: 5D00]
T66383,CFD,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T66383,CFD,INDICATI,Phase 3,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
T66383,CFD,INDICATI,Phase 2,Lupus erythematosus,ICD-11: 4A40
T66383,CFD,INDICATI,Phase 1/2,Macular degeneration,[ICD-11: 9B75]
T66383,CFD,INDICATI,Phase 2,Myasthenia gravis,ICD-11: 8C60
T66383,CFD,INDICATI,Phase 3,Retinopathy,[ICD-11: 9B71]
T66383,CFD,INDICATI,Phase 2,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T66426,CD34,TARGETID,T66426,,
T66426,CD34,TARGNAME,Hematopoietic progenitor cell antigen CD34 (CD34),,
T66426,CD34,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T66426,CD34,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T66426,CD34,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
,#N/A,,,,
T66505,SMO,TARGETID,T66505,,
T66505,SMO,TARGNAME,Smoothened homolog (SMO),,
T66505,SMO,INDICATI,Approved,Basal cell carcinoma,[ICD-11: 2C32]
T66505,SMO,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T66505,SMO,INDICATI,Approved,Chronic myelomonocytic leukaemia,[ICD-11: 2A40]
T66505,SMO,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T66505,SMO,INDICATI,Phase 2,Skin cancer,[ICD-11: 2C30-2C37]
T66505,SMO,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T66514,#N/A,TARGETID,T66514,,
T66514,#N/A,TARGNAME,Carbohydrate antigen Lewis-Y (Lewis-Y),,
T66514,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T66538,KCNMA1,TARGETID,T66538,,
T66538,KCNMA1,TARGNAME,Calcium-activated potassium channel KCa1.1 (KCNMA1),,
T66538,KCNMA1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T66538,KCNMA1,INDICATI,Phase 2,Functional bladder disorder,[ICD-11: GC50]
,#N/A,,,,
T66540,TRPV1,TARGETID,T66540,,
T66540,TRPV1,TARGNAME,TRPV1 messenger RNA (TRPV1 mRNA),,
T66540,TRPV1,INDICATI,Phase 3,Visual system disease,[ICD-11: 9E1Z]
,#N/A,,,,
T66665,PTGS2,TARGETID,T66665,,
T66665,PTGS2,TARGNAME,Prostaglandin G/H synthase 2 (COX-2),,
T66665,PTGS2,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T66665,PTGS2,INDICATI,Phase 2/3,Asthma,[ICD-11: CA23]
T66665,PTGS2,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T66665,PTGS2,INDICATI,Terminated,Colorectal cancer,[ICD-11: 2B91]
T66665,PTGS2,INDICATI,Terminated,Endometriosis,[ICD-11: GA10]
T66665,PTGS2,INDICATI,Approved,Female pelvic pain,[ICD-11: GA34]
T66665,PTGS2,INDICATI,Terminated,Fever,[ICD-11: MG26]
T66665,PTGS2,INDICATI,Discontinued in Phase 3,General pain disorder,[ICD-11: 8E43]
T66665,PTGS2,INDICATI,Withdrawn from market,Gout,[ICD-11: FA25]
T66665,PTGS2,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T66665,PTGS2,INDICATI,Approved,Indeterminate colitis,[ICD-11: DD72]
T66665,PTGS2,INDICATI,Approved,Knee osteoarthritis,[ICD-11: FA01]
T66665,PTGS2,INDICATI,Discontinued in Phase 2,Large intestine polyp,[ICD-11: DB35]
T66665,PTGS2,INDICATI,Discontinued in Phase 2,Lung cancer,[ICD-11: 2C25]
T66665,PTGS2,INDICATI,Discontinued in Phase 3,Lupus erythematosus,[ICD-11: 4A40]
T66665,PTGS2,INDICATI,Terminated,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T66665,PTGS2,INDICATI,Phase 2,Migraine,[ICD-11: 8A80]
T66665,PTGS2,INDICATI,Approved,Osteoarthritis,[ICD-11: FA00-FA05]
T66665,PTGS2,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T66665,PTGS2,INDICATI,Discontinued in Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T66665,PTGS2,INDICATI,Discontinued in Phase 3,Postoperative inflammation,[ICD-11: 1A00-CA43]
T66665,PTGS2,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T66665,PTGS2,INDICATI,Preregistration,Shoulder lesion,[ICD-11: FB53]
T66665,PTGS2,INDICATI,Preregistration,Soft tissue disorder,[ICD-11: FB56]
T66665,PTGS2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T66665,PTGS2,INDICATI,Approved,Tuberculosis,[ICD-11: 1B10-1B12]
T66665,PTGS2,INDICATI,Discontinued in Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T66693,TNFRSF17,TARGETID,T66693,,
T66693,TNFRSF17,TARGNAME,B-cell maturation protein (TNFRSF17),,
T66693,TNFRSF17,INDICATI,Clinical trial,Follicular lymphoma,[ICD-11: 2A80]
T66693,TNFRSF17,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T66693,TNFRSF17,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T66693,TNFRSF17,INDICATI,Clinical trial,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T66693,TNFRSF17,INDICATI,Clinical trial,Mature B-cell leukaemia,[ICD-11: 2A82]
T66693,TNFRSF17,INDICATI,Clinical trial,Mature B-cell lymphoma,[ICD-11: 2A85]
T66693,TNFRSF17,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T66693,TNFRSF17,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T66903,FSCN1,TARGETID,T66903,,
T66903,FSCN1,TARGNAME,Fascin (FSCN1),,
T66903,FSCN1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T67022,#N/A,TARGETID,T67022,,
T67022,#N/A,TARGNAME,Caspase (CASP),,
T67022,#N/A,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T67022,#N/A,INDICATI,Preclinical,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T67022,#N/A,INDICATI,Preclinical,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T67022,#N/A,INDICATI,Investigative,Mature T-cell lymphoma,[ICD-11: 2A90]
T67022,#N/A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T67046,#N/A,TARGETID,T67046,,
T67046,#N/A,TARGNAME,Platelet activating factor (PAF),,
T67046,#N/A,INDICATI,Preclinical,Fungal infection,[ICD-11: 1F29-1F2F]
,#N/A,,,,
T67054,#N/A,TARGETID,T67054,,
T67054,#N/A,TARGNAME,5-HT 1 receptor (5HT1R),,
T67054,#N/A,INDICATI,Terminated,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T67054,#N/A,INDICATI,Terminated,Depression,[ICD-11: 6A70-6A7Z]
T67054,#N/A,INDICATI,Terminated,Migraine,[ICD-11: 8A80]
,#N/A,,,,
T67058,#N/A,TARGETID,T67058,,
T67058,#N/A,TARGNAME,Staphylococcus Capsular polysaccharide CP8 (Stap-coc CP8),,
T67058,#N/A,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T67058,#N/A,INDICATI,Phase 2,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T67063,KCNMB4,TARGETID,T67063,,
T67063,KCNMB4,TARGNAME,Charybdotoxin receptor beta-4 (BKbeta4),,
T67063,KCNMB4,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T67063,KCNMB4,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T67063,KCNMB4,INDICATI,Phase 2,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T67079,IL9,TARGETID,T67079,,
T67079,IL9,TARGNAME,Interleukin-9 (IL9),,
T67079,IL9,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T67079,IL9,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T67079,IL9,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
,#N/A,,,,
T67084,#N/A,TARGETID,T67084,,
T67084,#N/A,TARGNAME,Glucosidase unspecific (GAN),,
T67084,#N/A,INDICATI,Discontinued in Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
,#N/A,,,,
T67089,SERPINC1,TARGETID,T67089,,
T67089,SERPINC1,TARGNAME,SERPINC1 messenger RNA (SERPINC1 mRNA),,
T67089,SERPINC1,INDICATI,Phase 3,Coagulation defect,[ICD-11: 3B10]
,#N/A,,,,
T67102,CTSD,TARGETID,T67102,,
T67102,CTSD,TARGNAME,Cathepsin D (CTSD),,
T67102,CTSD,INDICATI,Terminated,Hypertension,[ICD-11: BA00-BA04]
T67102,CTSD,INDICATI,Clinical trial,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T67103,ITGAV,TARGETID,T67103,,
T67103,ITGAV,TARGNAME,Integrin alpha-V (ITGAV),,
T67103,ITGAV,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T67103,ITGAV,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T67162,DRD2,TARGETID,T67162,,
T67162,DRD2,TARGNAME,Dopamine D2 receptor (D2R),,
T67162,DRD2,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T67162,DRD2,INDICATI,Approved,Alzheimer disease,[ICD-11: 8A20]
T67162,DRD2,INDICATI,Phase 1,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T67162,DRD2,INDICATI,Approved,Asthma,[ICD-11: CA23]
T67162,DRD2,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T67162,DRD2,INDICATI,Discontinued in Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
T67162,DRD2,INDICATI,Approved,Bipolar disorder,[ICD-11: 6A60]
T67162,DRD2,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T67162,DRD2,INDICATI,Withdrawn from market,Breast cancer,[ICD-11: 2C60-2C6Y]
T67162,DRD2,INDICATI,Approved,Breathing abnormality,[ICD-11: MD11]
T67162,DRD2,INDICATI,Phase 2,Carcinoid syndrome,[ICD-11: 5B10]
T67162,DRD2,INDICATI,Approved,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T67162,DRD2,INDICATI,Approved,Cerebral ischaemia,[ICD-11: 8B1Z]
T67162,DRD2,INDICATI,Phase 3,Choreiform disorder,[ICD-11: 8A01]
T67162,DRD2,INDICATI,Phase 1b,Chronic kidney disease,[ICD-11: GB61]
T67162,DRD2,INDICATI,Discontinued in Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T67162,DRD2,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T67162,DRD2,INDICATI,Approved,Digestive system disease,[ICD-11: DE2Z]
T67162,DRD2,INDICATI,Phase 2,Endocrine gland neoplasm,[ICD-11: 2F37]
T67162,DRD2,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T67162,DRD2,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T67162,DRD2,INDICATI,Approved,Faecal incontinence,[ICD-11: ME07]
T67162,DRD2,INDICATI,Withdrawn from market,Fatigue,[ICD-11: MG22]
T67162,DRD2,INDICATI,Phase 3,Fibrosis,[ICD-11: GA14-GC01]
T67162,DRD2,INDICATI,Approved,Gangrene,[ICD-11: MC85]
T67162,DRD2,INDICATI,Phase 2,Gastroduodenal motor/secretory disorder,[ICD-11: DA41]
T67162,DRD2,INDICATI,Phase 1,General pain disorder,[ICD-11: 8E43]
T67162,DRD2,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T67162,DRD2,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T67162,DRD2,INDICATI,Approved,Hyperaemia,[ICD-11: 9A61-9B7Y]
T67162,DRD2,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T67162,DRD2,INDICATI,Approved,Hypotension,[ICD-11: BA20-BA21]
T67162,DRD2,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T67162,DRD2,INDICATI,Approved,Inborn porphyrin/heme metabolism error,[ICD-11: 5C58]
T67162,DRD2,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
T67162,DRD2,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T67162,DRD2,INDICATI,Phase 2/3,Intellectual development disorder,[ICD-11: LD90]
T67162,DRD2,INDICATI,Approved,Itching,[ICD-11: 1F28-1G07]
T67162,DRD2,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T67162,DRD2,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T67162,DRD2,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T67162,DRD2,INDICATI,Investigative,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T67162,DRD2,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T67162,DRD2,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T67162,DRD2,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T67162,DRD2,INDICATI,Terminated,Nicotine use disorder,[ICD-11: 6C4A]
T67162,DRD2,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T67162,DRD2,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T67162,DRD2,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T67162,DRD2,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T67162,DRD2,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T67162,DRD2,INDICATI,Approved,Postpartum haemorrhage,[ICD-11: JA43]
T67162,DRD2,INDICATI,Discontinued in Phase 3,Psoriasis,[ICD-11: EA90]
T67162,DRD2,INDICATI,Approved,Psychotic disorder,[ICD-11: 6A20-6A25]
T67162,DRD2,INDICATI,Approved,Pulmonary hypertension,[ICD-11: BB01]
T67162,DRD2,INDICATI,Phase 2,Respiratory infection,[ICD-11: CA07-CA4Z]
T67162,DRD2,INDICATI,Phase 3,Restless legs syndrome,[ICD-11: 7A80]
T67162,DRD2,INDICATI,Phase 2,Schizoaffective disorder,[ICD-11: 6A21]
T67162,DRD2,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T67162,DRD2,INDICATI,Phase 2,Sexual dysfunction,[ICD-11: HA00-HA01]
T67162,DRD2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T67162,DRD2,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
T67162,DRD2,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
T67162,DRD2,INDICATI,Investigative,Thrombocytopenia,[ICD-11: 3B64]
T67162,DRD2,INDICATI,Approved,Thyrotoxicosis,[ICD-11: 5A02]
T67162,DRD2,INDICATI,Patented,Tonus and reflex abnormality,[ICD-11: MB47]
T67162,DRD2,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
T67162,DRD2,INDICATI,Terminated,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T67207,FCER2,TARGETID,T67207,,
T67207,FCER2,TARGNAME,Lymphocyte IgE receptor (CD23),,
T67207,FCER2,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
,#N/A,,,,
T67233,#N/A,TARGETID,T67233,,
T67233,#N/A,TARGNAME,Cholesterol uptake (Chole uptake),,
T67233,#N/A,INDICATI,Phase 3,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T67272,ANPEP,TARGETID,T67272,,
T67272,ANPEP,TARGNAME,Aminopeptidase N (ANPEP),,
T67272,ANPEP,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T67282,Stap-coc leuS,TARGETID,T67282,,
T67282,Stap-coc leuS,TARGNAME,Staphylococcus Leucyl-tRNA synthetase (Stap-coc leuS),,
T67282,Stap-coc leuS,INDICATI,Phase 1,Fungal infection,[ICD-11: 1F29-1F2F]
T67282,Stap-coc leuS,INDICATI,Approved,Nail/perionychium infection,[ICD-11: EE12]
T67282,Stap-coc leuS,INDICATI,Phase 2,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T67310,#N/A,TARGETID,T67310,,
T67310,#N/A,TARGNAME,Glutamate receptor ionotropic (GRI),,
T67310,#N/A,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T67310,#N/A,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
,#N/A,,,,
T67363,ITGAV-ITGB3,TARGETID,T67363,,
T67363,ITGAV-ITGB3,TARGNAME,Integrin alpha-V/beta-3 (ITGAV/B3),,
T67363,ITGAV-ITGB3,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T67363,ITGAV-ITGB3,INDICATI,Terminated,Herpes simplex infection,[ICD-11: 1F00]
T67363,ITGAV-ITGB3,INDICATI,Discontinued in Phase 1,Low bone mass disorder,[ICD-11: FB83]
T67363,ITGAV-ITGB3,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T67363,ITGAV-ITGB3,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T67363,ITGAV-ITGB3,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T67363,ITGAV-ITGB3,INDICATI,Phase 1/2,Retinopathy,[ICD-11: 9B71]
T67363,ITGAV-ITGB3,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T67363,ITGAV-ITGB3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T67364,Stre-coc skc,TARGETID,T67364,,
T67364,Stre-coc skc,TARGNAME,Streptococcus Streptokinase (Stre-coc skc),,
T67364,Stre-coc skc,INDICATI,Phase 3,Haemorrhoids,[ICD-11: DB60]
,#N/A,,,,
T67416,EPRS,TARGETID,T67416,,
T67416,EPRS,TARGNAME,Bifunctional aminoacyl-tRNA synthetase (EPRS),,
T67416,EPRS,INDICATI,Phase 2,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T67619,AKT1,TARGETID,T67619,,
T67619,AKT1,TARGNAME,RAC-alpha serine/threonine-protein kinase (AKT1),,
T67619,AKT1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T67619,AKT1,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
T67619,AKT1,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T67619,AKT1,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T67619,AKT1,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T67619,AKT1,INDICATI,Phase 1,Central nervous system disease,[ICD-11: 8A04-8D87]
T67619,AKT1,INDICATI,Phase 3,Colorectal cancer,[ICD-11: 2B91]
T67619,AKT1,INDICATI,Phase 3,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T67619,AKT1,INDICATI,Phase 2,Injury,[ICD-11: NA00-ND5Z]
T67619,AKT1,INDICATI,Phase 2,Leukaemia,[ICD-11: 2A60-2B33]
T67619,AKT1,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T67619,AKT1,INDICATI,Phase 3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T67619,AKT1,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T67619,AKT1,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T67619,AKT1,INDICATI,Phase 2,Overgrowth syndrome,[ICD-11: LD2C]
T67619,AKT1,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T67619,AKT1,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T67619,AKT1,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T67619,AKT1,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T67619,AKT1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T67619,AKT1,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T67658,SLC2A4,TARGETID,T67658,,
T67658,SLC2A4,TARGNAME,Glucose transporter type 4 (SLC2A4),,
T67658,SLC2A4,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T67684,CHRM3,TARGETID,T67684,,
T67684,CHRM3,TARGNAME,Muscarinic acetylcholine receptor M3 (CHRM3),,
T67684,CHRM3,INDICATI,Discontinued in Phase 3,Abnormal micturition,[ICD-11: MF50]
T67684,CHRM3,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T67684,CHRM3,INDICATI,Approved,Asthma,[ICD-11: CA23]
T67684,CHRM3,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T67684,CHRM3,INDICATI,Approved,Functional bladder disorder,[ICD-11: GC50]
T67684,CHRM3,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T67684,CHRM3,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T67684,CHRM3,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T67684,CHRM3,INDICATI,Approved,Respiratory system disease,[ICD-11: CB40-CB7Z]
T67684,CHRM3,INDICATI,Approved,Sebaceous gland disorder,[ICD-11: ED91]
T67684,CHRM3,INDICATI,Approved,Sjogren syndrome,[ICD-11: 4A43]
T67684,CHRM3,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T67710,PTH1R,TARGETID,T67710,,
T67710,PTH1R,TARGNAME,Parathyroid hormone 1 receptor (PTH1R),,
T67710,PTH1R,INDICATI,Phase 1,Hypo-parathyroidism,[ICD-11: 5A50]
T67710,PTH1R,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
,#N/A,,,,
T67801,LTF,TARGETID,T67801,,
T67801,LTF,TARGNAME,Lactotransferrin (LTF),,
T67801,LTF,INDICATI,Phase 1/2,Bacterial infection,[ICD-11: 1A00-1C4Z]
T67801,LTF,INDICATI,Phase 1/2,Candidosis,[ICD-11: 1F23]
T67801,LTF,INDICATI,Terminated,Colorectal cancer,[ICD-11: 2B91]
T67801,LTF,INDICATI,Phase 3,Diabetic foot ulcer,[ICD-11: BD54]
T67801,LTF,INDICATI,Phase 1/2,Gonococcal infection,[ICD-11: 1A70-1A7Z]
T67801,LTF,INDICATI,Terminated,Lung cancer,[ICD-11: 2C25]
T67801,LTF,INDICATI,Terminated,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T67805,CD70,TARGETID,T67805,,
T67805,CD70,TARGNAME,CD70 antigen (CD27-L),,
T67805,CD70,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T67805,CD70,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T67805,CD70,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T67805,CD70,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T67805,CD70,INDICATI,Phase 1,Mature T-cell lymphoma,[ICD-11: 2A90]
T67805,CD70,INDICATI,Investigative,Melanoma,[ICD-11: 2C30]
T67805,CD70,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T67805,CD70,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T67805,CD70,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T67805,CD70,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
T67805,CD70,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T67849,PIK3CD,TARGETID,T67849,,
T67849,PIK3CD,TARGNAME,PI3-kinase delta (PIK3CD),,
T67849,PIK3CD,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T67849,PIK3CD,INDICATI,Phase 1,B-cell lymphoma,[ICD-11: 2A86]
T67849,PIK3CD,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T67849,PIK3CD,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T67849,PIK3CD,INDICATI,Phase 2/3,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T67849,PIK3CD,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
T67849,PIK3CD,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T67849,PIK3CD,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T67849,PIK3CD,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T67849,PIK3CD,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T67849,PIK3CD,INDICATI,Phase 1,Mycosis fungoides,[ICD-11: 2B01]
T67849,PIK3CD,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T67849,PIK3CD,INDICATI,Phase 2,Sjogren syndrome,[ICD-11: 4A43]
T67849,PIK3CD,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T67849,PIK3CD,INDICATI,Approved,Stomach cancer,ICD-11: 2B72
,#N/A,,,,
T67894,TLR3,TARGETID,T67894,,
T67894,TLR3,TARGNAME,Toll-like receptor 3 (TLR3),,
T67894,TLR3,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T67894,TLR3,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T67894,TLR3,INDICATI,Discontinued in Phase 3,Digestive organ benign neoplasm,[ICD-11: 2E92]
T67894,TLR3,INDICATI,Phase 3,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T67894,TLR3,INDICATI,Investigative,Keratosis pilaris,[ICD-11: ED56]
T67894,TLR3,INDICATI,Discontinued in Phase 3,Sexually transmitted infection,[ICD-11: 1A9Y-1A9Z]
T67894,TLR3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T67908,#N/A,TARGETID,T67908,,
T67908,#N/A,TARGNAME,Globohexaosylceramide (Globo H),,
T67908,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T67942,Bact metB,TARGETID,T67942,,
T67942,Bact metB,TARGNAME,Bacterial Cystathionine gamma-synthase (Bact metB),,
T67942,Bact metB,INDICATI,Preclinical,Chronic obstructive pulmonary disease,[ICD-11: CA22]
,#N/A,,,,
T67952,#N/A,TARGETID,T67952,,
T67952,#N/A,TARGNAME,Potassium channel unspecific (KC),,
T67952,#N/A,INDICATI,Phase 1,Abnormal micturition,[ICD-11: MF50]
T67952,#N/A,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T67952,#N/A,INDICATI,Terminated,Alopecia,[ICD-11: ED70]
T67952,#N/A,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T67952,#N/A,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
T67952,#N/A,INDICATI,Discontinued in Phase 1,Asthma,[ICD-11: CA23]
T67952,#N/A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T67952,#N/A,INDICATI,Approved,Cardiac arrhythmia,[ICD-11: BC9Z]
T67952,#N/A,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T67952,#N/A,INDICATI,Discontinued in Preregistration,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T67952,#N/A,INDICATI,Terminated,Depression,[ICD-11: 6A70-6A7Z]
T67952,#N/A,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T67952,#N/A,INDICATI,Discontinued in Phase 2,Functional bladder disorder,[ICD-11: GC50]
T67952,#N/A,INDICATI,Phase 2,Genetic cardiac arrhythmia,[ICD-11: BC65]
T67952,#N/A,INDICATI,Phase 2,Glaucoma,[ICD-11: 9C61]
T67952,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T67952,#N/A,INDICATI,Approved,Lambert-Eaton syndrome,[ICD-11: 8C62]
T67952,#N/A,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T67952,#N/A,INDICATI,Phase 1,Obstructive sleep apnoea,[ICD-11: 7A41]
T67952,#N/A,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T67952,#N/A,INDICATI,Discontinued in Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T67952,#N/A,INDICATI,Approved,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T67952,#N/A,INDICATI,Discontinued in Phase 3,Unspecific body region injury,[ICD-11: ND56]
T67952,#N/A,INDICATI,Approved,Ventricular tachyarrhythmia,[ICD-11: BC71]
,#N/A,,,,
T67977,#N/A,TARGETID,T67977,,
T67977,#N/A,TARGNAME,Cytochrome P450 3A (CYP3A),,
T67977,#N/A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T68001,BTLA,TARGETID,T68001,,
T68001,BTLA,TARGNAME,B- and T-lymphocyte attenuator (BTLA),,
T68001,BTLA,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T68001,BTLA,INDICATI,Phase 2,Sjogren syndrome,[ICD-11: 4A43]
T68001,BTLA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T68039,#N/A,TARGETID,T68039,,
T68039,#N/A,TARGNAME,Cell adhesion molecule (CADM),,
T68039,#N/A,INDICATI,Terminated,Cerebrovascular disease,[ICD-11: 8B22-8B2Z]
T68039,#N/A,INDICATI,Terminated,Deep vein thrombosis,[ICD-11: BD71]
T68039,#N/A,INDICATI,Terminated,Graft-versus-host disease,[ICD-11: 4B24]
T68039,#N/A,INDICATI,Discontinued in Phase 1,Melanoma,[ICD-11: 2C30]
T68039,#N/A,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T68039,#N/A,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T68039,#N/A,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T68039,#N/A,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T68066,ESRRA; ESRRB; ESRRG,TARGETID,T68066,,
T68066,ESRRA; ESRRB; ESRRG,TARGNAME,Steroid hormone receptor ERR (ESRR),,
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Asthma,[ICD-11: CA23]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Contact dermatitis,[ICD-11: EK00-EK0Z]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Eyelid inflammatory disorder,[ICD-11: 9A02]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Inflammatory arthropathy,[ICD-11: FA2Z]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Postoperative inflammation,[ICD-11: 1A00-CA43]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Skin disease,[ICD-11: EA00-EM0Z]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T68066,ESRRA; ESRRB; ESRRG,INDICATI,Approved,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T68163,LYN,TARGETID,T68163,,
T68163,LYN,TARGNAME,Tyrosine-protein kinase Lyn (JTK8),,
T68163,LYN,INDICATI,Phase 2,Musculoskeletal system/connective tissue disease,[ICD-11: FC0Z]
T68163,LYN,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T68230,CD toxA,TARGETID,T68230,,
T68230,CD toxA,TARGNAME,Clostridium difficile Toxin A (CD toxA),,
T68230,CD toxA,INDICATI,Phase 3,Clostridium difficile enterocolitis,[ICD-11: 1A04]
T68230,CD toxA,INDICATI,Phase 3,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T68251,MMP2,TARGETID,T68251,,
T68251,MMP2,TARGNAME,Matrix metalloproteinase-2 (MMP-2),,
T68251,MMP2,INDICATI,Phase 1,Acne vulgaris,[ICD-11: ED80]
T68251,MMP2,INDICATI,Discontinued in Phase 3,Brain cancer,[ICD-11: 2A00]
T68251,MMP2,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T68251,MMP2,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T68251,MMP2,INDICATI,Discontinued in Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T68251,MMP2,INDICATI,Discontinued in Phase 3,Kaposi sarcoma,[ICD-11: 2B57]
T68251,MMP2,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T68251,MMP2,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
T68251,MMP2,INDICATI,Discontinued in Phase 3,Osteoarthritis,[ICD-11: FA00-FA05]
T68251,MMP2,INDICATI,Discontinued in Phase 3,Ovarian cancer,[ICD-11: 2C73]
T68251,MMP2,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T68251,MMP2,INDICATI,Discontinued in Phase 3,Prostate cancer,[ICD-11: 2C82]
T68251,MMP2,INDICATI,Phase 1,Renal cell carcinoma,[ICD-11: 2C90]
T68251,MMP2,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T68290,CTSS,TARGETID,T68290,,
T68290,CTSS,TARGNAME,Cathepsin S (CTSS),,
T68290,CTSS,INDICATI,Patented,Alopecia,[ICD-11: ED70]
T68290,CTSS,INDICATI,Patented,Aneurysm/dissection,[ICD-11: BD50]
T68290,CTSS,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T68290,CTSS,INDICATI,Phase 2,Autoimmune disease,[ICD-11: 4A40-4A45]
T68290,CTSS,INDICATI,Patented,Bone cancer,[ICD-11: 2B5Z]
T68290,CTSS,INDICATI,Patented,Brain cancer,[ICD-11: 2A00]
T68290,CTSS,INDICATI,Discontinued in Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T68290,CTSS,INDICATI,Patented,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T68290,CTSS,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
T68290,CTSS,INDICATI,Phase 1,Coeliac disease,[ICD-11: DA95]
T68290,CTSS,INDICATI,Phase 1,Crohn disease,[ICD-11: DD70]
T68290,CTSS,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T68290,CTSS,INDICATI,Patented,Digestive system disease,[ICD-11: DE2Z]
T68290,CTSS,INDICATI,Phase 1,General pain disorder,[ICD-11: 8E43]
T68290,CTSS,INDICATI,Patented,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T68290,CTSS,INDICATI,Preclinical,Lupus erythematosus,[ICD-11: 4A40]
T68290,CTSS,INDICATI,Patented,Multiple sclerosis,[ICD-11: 8A40]
T68290,CTSS,INDICATI,Preclinical,Osteoarthritis,[ICD-11: FA00-FA05]
T68290,CTSS,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T68290,CTSS,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T68290,CTSS,INDICATI,Patented,Psoriasis,[ICD-11: EA90]
T68290,CTSS,INDICATI,Patented,Rheumatoid arthritis,[ICD-11: FA20]
T68290,CTSS,INDICATI,Phase 2,Sjogren syndrome,[ICD-11: 4A43]
T68290,CTSS,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T68315,#N/A,TARGETID,T68315,,
T68315,#N/A,TARGNAME,Endothelin receptor (EDNR),,
T68315,#N/A,INDICATI,Phase 3,Coronary vasospastic disease,[ICD-11: BA85]
T68315,#N/A,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T68315,#N/A,INDICATI,Discontinued in Phase 2,Kidney failure,[ICD-11: GB60-GB6Z]
T68315,#N/A,INDICATI,Discontinued in Phase 3,Retinal vascular occlusion,[ICD-11: 9B74]
,#N/A,,,,
T68334,FSHR,TARGETID,T68334,,
T68334,FSHR,TARGNAME,Follicle-stimulating hormone receptor (FSHR),,
T68334,FSHR,INDICATI,Phase 1,African trypanosomiasis,[ICD-11: 1F51]
T68334,FSHR,INDICATI,Investigative,Contraceptive management,[ICD-11: QA21]
T68334,FSHR,INDICATI,Approved,Female infertility,[ICD-11: GA31]
,#N/A,,,,
T68383,BMP2,TARGETID,T68383,,
T68383,BMP2,TARGNAME,Bone morphogenetic protein 2 (BMP2),,
T68383,BMP2,INDICATI,Phase 3,Bone growth disorder,[ICD-11: FB86]
,#N/A,,,,
T68443,MMP21,TARGETID,T68443,,
T68443,MMP21,TARGNAME,Matrix metalloproteinase-21 (MMP-21),,
T68443,MMP21,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
,#N/A,,,,
T68461,SLC25A4,TARGETID,T68461,,
T68461,SLC25A4,TARGNAME,Adenine nucleotide translocator 1 (SLC25A4),,
T68461,SLC25A4,INDICATI,Approved,Mineral excesses,[ICD-11: 5B91]
,#N/A,,,,
T68470,USP1,TARGETID,T68470,,
T68470,USP1,TARGNAME,Deubiquitinating enzyme 1 (USP1),,
T68470,USP1,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T68517,HSPB3,TARGETID,T68517,,
T68517,HSPB3,TARGNAME,Heat shock protein 27 (HSP27),,
T68517,HSPB3,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T68517,HSPB3,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T68517,HSPB3,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T68517,HSPB3,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T68517,HSPB3,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T68517,HSPB3,INDICATI,Discontinued in Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T68525,PTK7,TARGETID,T68525,,
T68525,PTK7,TARGNAME,Inactive tyrosine-protein kinase 7 (PTK7),,
T68525,PTK7,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T68536,#N/A,TARGETID,T68536,,
T68536,#N/A,TARGNAME,Tubulin beta (TUBB),,
T68536,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T68536,#N/A,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T68536,#N/A,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T68536,#N/A,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T68536,#N/A,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T68536,#N/A,INDICATI,Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T68536,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T68536,#N/A,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T68536,#N/A,INDICATI,Approved,Parasitic worm infestation,[ICD-11: 1F90]
T68536,#N/A,INDICATI,Phase 2,Peritoneal cancer,[ICD-11: 2C51]
T68536,#N/A,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T68536,#N/A,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T68547,HDAC1,TARGETID,T68547,,
T68547,HDAC1,TARGNAME,Histone deacetylase 1 (HDAC1),,
T68547,HDAC1,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T68547,HDAC1,INDICATI,Phase 1,Ataxic disorder,[ICD-11: 8A03]
T68547,HDAC1,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T68547,HDAC1,INDICATI,Phase 2,Cerebral ischaemia,[ICD-11: 8B1Z]
T68547,HDAC1,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T68547,HDAC1,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T68547,HDAC1,INDICATI,Phase 1/2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T68547,HDAC1,INDICATI,Phase 2,Intracranial injury,[ICD-11: NA07]
T68547,HDAC1,INDICATI,Phase 2,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T68547,HDAC1,INDICATI,Discontinued in Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T68547,HDAC1,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T68547,HDAC1,INDICATI,Registered,Lung cancer,[ICD-11: 2C25]
T68547,HDAC1,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T68547,HDAC1,INDICATI,Phase 3,Mature T-cell lymphoma,[ICD-11: 2A90]
T68547,HDAC1,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T68547,HDAC1,INDICATI,Phase 2,Metabolism inborn error,[ICD-11: 5C50]
T68547,HDAC1,INDICATI,Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T68547,HDAC1,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T68547,HDAC1,INDICATI,Phase 3,Muscular dystrophy,[ICD-11: 8C70]
T68547,HDAC1,INDICATI,Approved,Mycosis fungoides,[ICD-11: 2B01]
T68547,HDAC1,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T68547,HDAC1,INDICATI,Phase 1/2,Neuroendocrine carcinoma,[ICD-11: 2C34]
T68547,HDAC1,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T68547,HDAC1,INDICATI,Phase 3,Renal cell carcinoma,[ICD-11: 2C90]
T68547,HDAC1,INDICATI,Phase 2,Sickle-cell disorder,[ICD-11: 3A51]
T68547,HDAC1,INDICATI,Registered,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T68547,HDAC1,INDICATI,Phase 2,Thrombocytosis,[ICD-11: 3B63]
T68547,HDAC1,INDICATI,Phase 3,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T68668,MAN2A1,TARGETID,T68668,,
T68668,MAN2A1,TARGNAME,Golgi alpha-mannosidase II (MAN2A1),,
T68668,MAN2A1,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T68706,FURIN,TARGETID,T68706,,
T68706,FURIN,TARGNAME,Dibasic-processing enzyme (Furin),,
T68706,FURIN,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
,#N/A,,,,
T68766,DMPK,TARGETID,T68766,,
T68766,DMPK,TARGNAME,DMPK messenger RNA (DMPK mRNA),,
T68766,DMPK,INDICATI,Phase 1/2,Myotonic disorder,[ICD-11: 8C71]
,#N/A,,,,
T68782,PTGDR,TARGETID,T68782,,
T68782,PTGDR,TARGNAME,Prostaglandin D2 receptor (PTGDR),,
T68782,PTGDR,INDICATI,Phase 2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T68782,PTGDR,INDICATI,Discontinued in Phase 3,Arterial occlusive disease,[ICD-11: BD40]
T68782,PTGDR,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T68782,PTGDR,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T68782,PTGDR,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T68782,PTGDR,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T68782,PTGDR,INDICATI,Discontinued in Phase 3,Dyslipidemia,[ICD-11: 5C80-5C81]
T68782,PTGDR,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T68782,PTGDR,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T68782,PTGDR,INDICATI,Clinical trial,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T68782,PTGDR,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
T68782,PTGDR,INDICATI,Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T68887,NMBR; GRPR; BRS3,TARGETID,T68887,,
T68887,NMBR; GRPR; BRS3,TARGNAME,Bombesin receptor (BS),,
T68887,NMBR; GRPR; BRS3,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T68887,NMBR; GRPR; BRS3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T68934,#N/A,TARGETID,T68934,,
T68934,#N/A,TARGNAME,Collagen (CO),,
T68934,#N/A,INDICATI,Approved,Amoebiasis,[ICD-11: 1A36]
T68934,#N/A,INDICATI,Phase 2,Keloid/hypertrophic scar,[ICD-11: EE60]
T68934,#N/A,INDICATI,Approved,Skin sensation disturbance,[ICD-11: ME65]
T68934,#N/A,INDICATI,Phase 1,Systemic sclerosis,[ICD-11: 4A42]
T68934,#N/A,INDICATI,Phase 2,Urinary tract infection,[ICD-11: GC08]
T68934,#N/A,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T68967,SGMS1; SGMS2,TARGETID,T68967,,
T68967,SGMS1; SGMS2,TARGNAME,Sphingomyelin synthase (SMS),,
T68967,SGMS1; SGMS2,INDICATI,Phase 1/2,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T69085,JUN,TARGETID,T69085,,
T69085,JUN,TARGNAME,Transcription factor AP-1 (JUN),,
T69085,JUN,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T69128,ROS1,TARGETID,T69128,,
T69128,ROS1,TARGNAME,Proto-oncogene c-Ros (ROS1),,
T69128,ROS1,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T69128,ROS1,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T69128,ROS1,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T69128,ROS1,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T69128,ROS1,INDICATI,Patented,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T69128,ROS1,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T69128,ROS1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T69146,UCP3,TARGETID,T69146,,
T69146,UCP3,TARGNAME,Mitochondrial uncoupling protein 3 (UCP3),,
T69146,UCP3,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T69189,#N/A,TARGETID,T69189,,
T69189,#N/A,TARGNAME,Hedgehog signaling pathway (HS pathway),,
T69189,#N/A,INDICATI,Phase 2,Basal cell carcinoma,[ICD-11: 2C32]
T69189,#N/A,INDICATI,Discontinued in Phase 2,Chondrosarcoma,[ICD-11: 2B50]
T69189,#N/A,INDICATI,Approved,Chronic myelomonocytic leukaemia,[ICD-11: 2A40]
T69189,#N/A,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
T69189,#N/A,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T69189,#N/A,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T69375,MAPK9,TARGETID,T69375,,
T69375,MAPK9,TARGNAME,Stress-activated protein kinase JNK2 (JNK2),,
T69375,MAPK9,INDICATI,Preclinical,Mature T-cell lymphoma,[ICD-11: 2A90]
,#N/A,,,,
T69485,HCRTR2,TARGETID,T69485,,
T69485,HCRTR2,TARGNAME,Orexin receptor type 2 (HCRTR2),,
T69485,HCRTR2,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T69485,HCRTR2,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T69485,HCRTR2,INDICATI,Phase 2,Narcolepsy,ICD-11: 7A20
T69485,HCRTR2,INDICATI,Phase 1,Narcolepsy,[ICD-11: 7A20]
,#N/A,,,,
T69494,#N/A,TARGETID,T69494,,
T69494,#N/A,TARGNAME,N-methyl-D-aspartate receptor (NMDAR),,
T69494,#N/A,INDICATI,Approved,Acute pain,[ICD-11: MG31]
T69494,#N/A,INDICATI,Approved,Alzheimer disease,[ICD-11: 8A20]
T69494,#N/A,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T69494,#N/A,INDICATI,Phase 2,Autism spectrum disorder,[ICD-11: 6A02]
T69494,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T69494,#N/A,INDICATI,Discontinued in Phase 3,Cerebral ischaemia,[ICD-11: 8B1Z]
T69494,#N/A,INDICATI,Approved,Cerebral ischaemic stroke,[ICD-11: 8B11]
T69494,#N/A,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T69494,#N/A,INDICATI,Phase 2,Clostridium difficile enterocolitis,[ICD-11: 1A04]
T69494,#N/A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T69494,#N/A,INDICATI,Terminated,Dementia,[ICD-11: 6D80-6D8Z]
T69494,#N/A,INDICATI,Phase 3,Depression,[ICD-11: 6A70-6A7Z]
T69494,#N/A,INDICATI,Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T69494,#N/A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T69494,#N/A,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T69494,#N/A,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T69494,#N/A,INDICATI,Phase 1,Intellectual development disorder,[ICD-11: LD90]
T69494,#N/A,INDICATI,Phase 3,Intracranial injury,[ICD-11: NA07]
T69494,#N/A,INDICATI,Discontinued in Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T69494,#N/A,INDICATI,Terminated,Nervous system disease,[ICD-11: 8A00-8E7Z]
T69494,#N/A,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T69494,#N/A,INDICATI,Phase 2,Neuropathy,[ICD-11: 8C0Z]
T69494,#N/A,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T69494,#N/A,INDICATI,Phase 2,Obsessive-compulsive disorder,[ICD-11: 6B20]
T69494,#N/A,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T69494,#N/A,INDICATI,Phase 1,Panic disorder,[ICD-11: 6B01]
T69494,#N/A,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T69494,#N/A,INDICATI,Phase 2/3,Post-traumatic stress disorder,[ICD-11: 6B40]
T69494,#N/A,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T69494,#N/A,INDICATI,Phase 1,Thought content symptom,[ICD-11: MB26]
T69494,#N/A,INDICATI,Phase 2,Zoster,[ICD-11: 1E91]
,#N/A,,,,
T69506,NR1I3,TARGETID,T69506,,
T69506,NR1I3,TARGNAME,Orphan nuclear receptor NR1I3 (NR1I3),,
T69506,NR1I3,INDICATI,Approved,Dizziness and giddiness,[ICD-11: MB48]
,#N/A,,,,
T69563,IDH1,TARGETID,T69563,,
T69563,IDH1,TARGNAME,Oxalosuccinate decarboxylase (IDH1),,
T69563,IDH1,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T69563,IDH1,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T69563,IDH1,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T69563,IDH1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T69563,IDH1,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T69563,IDH1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T69619,AOC3,TARGETID,T69619,,
T69619,AOC3,TARGNAME,Membrane copper amine oxidase (AOC3),,
T69619,AOC3,INDICATI,Investigative,Acute diabete complication,[ICD-11: 5A2Y]
T69619,AOC3,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T69619,AOC3,INDICATI,Investigative,Atopic eczema,[ICD-11: EA80]
T69619,AOC3,INDICATI,Investigative,Cerebral ischaemia,[ICD-11: 8B1Z]
T69619,AOC3,INDICATI,Phase 1,Chronic kidney disease,[ICD-11: GB61]
T69619,AOC3,INDICATI,Investigative,Circulatory system disease,[ICD-11: BE2Z]
T69619,AOC3,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T69619,AOC3,INDICATI,Phase 3,Neuropathy,[ICD-11: 8C0Z]
T69619,AOC3,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T69619,AOC3,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T69619,AOC3,INDICATI,Investigative,Pulmonary disease,[ICD-11: 1B10-1F85]
T69619,AOC3,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T69685,SLC6A9,TARGETID,T69685,,
T69685,SLC6A9,TARGNAME,Glycine transporter GlyT-1 (SLC6A9),,
T69685,SLC6A9,INDICATI,Investigative,Dementia,[ICD-11: 6D80-6D8Z]
T69685,SLC6A9,INDICATI,Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T69685,SLC6A9,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T69707,#N/A,TARGETID,T69707,,
T69707,#N/A,TARGNAME,Proteasome (PS),,
T69707,#N/A,INDICATI,Approved,Amyloidosis,[ICD-11: 5D00]
T69707,#N/A,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
T69707,#N/A,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
T69707,#N/A,INDICATI,Phase 1,Leishmaniasis,[ICD-11: 1F54]
T69707,#N/A,INDICATI,Terminated,Liver vascular disorder,[ICD-11: DB98]
T69707,#N/A,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T69707,#N/A,INDICATI,Phase 3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T69707,#N/A,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T69707,#N/A,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T69707,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T69823,TP53,TARGETID,T69823,,
T69823,TP53,TARGNAME,P53 Y220C mutant (TP53 Y220C),,
T69823,TP53,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T69912,PLA2G7,TARGETID,T69912,,
T69912,PLA2G7,TARGNAME,Platelet-activating factor acetylhydrolase (PLA2G7),,
T69912,PLA2G7,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T69912,PLA2G7,INDICATI,Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T69912,PLA2G7,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T69912,PLA2G7,INDICATI,Discontinued in Phase 3,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T69991,WEE1,TARGETID,T69991,,
T69991,WEE1,TARGNAME,Wee1-like protein kinase (WEE1),,
T69991,WEE1,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T69991,WEE1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T69991,WEE1,INDICATI,Phase 2,Uterine ligament/parametrium/uterine adnexa neoplasm,[ICD-11: 2C72]
,#N/A,,,,
T70062,RTN4,TARGETID,T70062,,
T70062,RTN4,TARGNAME,Reticulon-4 (RTN4),,
T70062,RTN4,INDICATI,Phase 1,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T70067,TNFRSF10B,TARGETID,T70067,,
T70067,TNFRSF10B,TARGNAME,TRAIL receptor 2 (TRAIL-R2),,
T70067,TNFRSF10B,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T70067,TNFRSF10B,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T70067,TNFRSF10B,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T70067,TNFRSF10B,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T70067,TNFRSF10B,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T70071,#N/A,TARGETID,T70071,,
T70071,#N/A,TARGNAME,Endothelin-converting enzyme (ECE),,
T70071,#N/A,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T70071,#N/A,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T70071,#N/A,INDICATI,Terminated,Hypertension,[ICD-11: BA00-BA04]
T70071,#N/A,INDICATI,Phase 2,Intracranial injury,[ICD-11: NA07]
,#N/A,,,,
T70101,CTPS1,TARGETID,T70101,,
T70101,CTPS1,TARGNAME,CTP synthase (CTPS1),,
T70101,CTPS1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T70134,C9orf72,TARGETID,T70134,,
T70134,C9orf72,TARGNAME,C9orf72 messenger RNA (C9orf72 mRNA),,
T70134,C9orf72,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
,#N/A,,,,
T70176,CDK2,TARGETID,T70176,,
T70176,CDK2,TARGNAME,Cyclin-dependent kinase 2 (CDK2),,
T70176,CDK2,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T70176,CDK2,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T70176,CDK2,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T70176,CDK2,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T70176,CDK2,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T70176,CDK2,INDICATI,Discontinued in Phase 3,Mature B-cell lymphoma,[ICD-11: 2A85]
T70176,CDK2,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T70176,CDK2,INDICATI,Phase 1,Non-small-cell lung cancer,[ICD-11: 2C25]
T70176,CDK2,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
T70176,CDK2,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
T70176,CDK2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T70176,CDK2,INDICATI,Phase 2,Thymoma,[ICD-11: 2C27]
,#N/A,,,,
T70201,GLIPR1,TARGETID,T70201,,
T70201,GLIPR1,TARGNAME,Glioma pathogenesis-related protein 1 (GLIPR1),,
T70201,GLIPR1,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T70227,#N/A,TARGETID,T70227,,
T70227,#N/A,TARGNAME,Transcription factor unspecific (TF),,
T70227,#N/A,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T70234,EPHA4,TARGETID,T70234,,
T70234,EPHA4,TARGNAME,Ephrin type-A receptor 4 (EPHA4),,
T70234,EPHA4,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T70309,SRD5A1,TARGETID,T70309,,
T70309,SRD5A1,TARGNAME,Steroid 5-alpha-reductase 1 (SRD5A1),,
T70309,SRD5A1,INDICATI,Discontinued in Phase 2,Acne vulgaris,[ICD-11: ED80]
T70309,SRD5A1,INDICATI,Phase 2,Prostate disease,[ICD-11: GA91]
,#N/A,,,,
T70449,GHRHR,TARGETID,T70449,,
T70449,GHRHR,TARGNAME,Growth hormone-releasing hormone receptor (GHRHR),,
T70449,GHRHR,INDICATI,Approved,Bone growth disorder,[ICD-11: FB86]
T70449,GHRHR,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T70449,GHRHR,INDICATI,Discontinued in Phase 2,Lipoatrophy/lipodystrophy,[ICD-11: EF01]
T70449,GHRHR,INDICATI,Discontinued in Phase 2,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T70490,CTSC,TARGETID,T70490,,
T70490,CTSC,TARGNAME,Dipeptidyl peptidase I (CTSC),,
T70490,CTSC,INDICATI,Phase 2,Bronchiectasis,[ICD-11: CA24]
,#N/A,,,,
T70508,#N/A,TARGETID,T70508,,
T70508,#N/A,TARGNAME,Cyclin-dependent kinase (CDK),,
T70508,#N/A,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T70508,#N/A,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T70508,#N/A,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T70508,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T70508,#N/A,INDICATI,Discontinued in Phase 3,Mature B-cell leukaemia,[ICD-11: 2A82]
T70508,#N/A,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T70508,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T70518,CBR1,TARGETID,T70518,,
T70518,CBR1,TARGNAME,S-nitrosoglutathione reductase (CBR1),,
T70518,CBR1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T70532,NCK1,TARGETID,T70532,,
T70532,NCK1,TARGNAME,NCK adaptor protein 1 (NCK1),,
T70532,NCK1,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T70680,SLC22A8,TARGETID,T70680,,
T70680,SLC22A8,TARGNAME,Solute carrier family 22 member 8 (SLC22A8),,
T70680,SLC22A8,INDICATI,Approved,Gout,[ICD-11: FA25]
T70680,SLC22A8,INDICATI,Approved,Herpes simplex infection,[ICD-11: 1F00]
T70680,SLC22A8,INDICATI,Approved,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
T70680,SLC22A8,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T70792,PGF,TARGETID,T70792,,
T70792,PGF,TARGNAME,Placenta growth factor (PlGF),,
T70792,PGF,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T70792,PGF,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T70792,PGF,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T70792,PGF,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T70888,#N/A,TARGETID,T70888,,
T70888,#N/A,TARGNAME,TNF receptor (TNFR),,
T70888,#N/A,INDICATI,Discontinued in Phase 3,Asthma,[ICD-11: CA23]
T70888,#N/A,INDICATI,Phase 1,Crohn disease,[ICD-11: DD70]
T70888,#N/A,INDICATI,Terminated,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T70967,CHRNA4,TARGETID,T70967,,
T70967,CHRNA4,TARGNAME,Neuronal acetylcholine receptor alpha-4 (CHRNA4),,
T70967,CHRNA4,INDICATI,Discontinued in Phase 2,Alzheimer disease,[ICD-11: 8A20]
T70967,CHRNA4,INDICATI,Approved,Aneurysm/dissection,[ICD-11: BD50]
T70967,CHRNA4,INDICATI,Approved,Hypertensive crisis,[ICD-11: BA03]
T70967,CHRNA4,INDICATI,Approved,Hypotension,[ICD-11: BA20-BA21]
T70967,CHRNA4,INDICATI,Phase 3,Nicotine use disorder,[ICD-11: 6C4A]
,#N/A,,,,
T70977,GSK3B,TARGETID,T70977,,
T70977,GSK3B,TARGNAME,Glycogen synthase kinase-3 beta (GSK-3B),,
T70977,GSK3B,INDICATI,Investigative,Acute diabete complication,[ICD-11: 5A2Y]
T70977,GSK3B,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T70977,GSK3B,INDICATI,Patented,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T70977,GSK3B,INDICATI,Discontinued in Phase 1,Alzheimer disease,[ICD-11: 8A20]
T70977,GSK3B,INDICATI,Patented,Brain cancer,[ICD-11: 2A00]
T70977,GSK3B,INDICATI,Phase 2,Fragile X chromosome,[ICD-11: LD55]
T70977,GSK3B,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T70977,GSK3B,INDICATI,Phase 2/3,Myotonic disorder,[ICD-11: 8C71]
T70977,GSK3B,INDICATI,Phase 2,Osteosarcoma,[ICD-11: 2B51]
T70977,GSK3B,INDICATI,Patented,Ovarian cancer,[ICD-11: 2C73]
T70977,GSK3B,INDICATI,Phase 1/2,Parkinsonism,[ICD-11: 8A00]
T70977,GSK3B,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T70977,GSK3B,INDICATI,Patented,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T71011,EntBac stxB2,TARGETID,T71011,,
T71011,EntBac stxB2,TARGNAME,Enterobacteria Shiga-like toxin 2B (EntBac stxB2),,
T71011,EntBac stxB2,INDICATI,Discontinued in Phase 2,Escherichia coli intestinal infection,[ICD-11: 1A03]
,#N/A,,,,
T71023,SNAP25,TARGETID,T71023,,
T71023,SNAP25,TARGNAME,Synaptosomal-associated protein 25 (SNAP25),,
T71023,SNAP25,INDICATI,Approved,Eyelid inflammatory/movement disorder,[ICD-11: 9A05]
,#N/A,,,,
T71039,#N/A,TARGETID,T71039,,
T71039,#N/A,TARGNAME,Carbohydrate antigen 19-9 (CA 19-9),,
T71039,#N/A,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T71054,#N/A,TARGETID,T71054,,
T71054,#N/A,TARGNAME,C-C chemokine receptor (CCR),,
T71054,#N/A,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T71086,CFH,TARGETID,T71086,,
T71086,CFH,TARGNAME,Complement factor H (CFH),,
T71086,CFH,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T71086,CFH,INDICATI,Approved,Infectious meningitis,[ICD-11: 1D01]
T71086,CFH,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T71141,ITGAV-ITGB6,TARGETID,T71141,,
T71141,ITGAV-ITGB6,TARGNAME,Integrin alpha-V/beta-6 (ITGAV/B6),,
T71141,ITGAV-ITGB6,INDICATI,Phase 2,Autoimmune liver disease,[ICD-11: DB96]
T71141,ITGAV-ITGB6,INDICATI,Preclinical,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T71141,ITGAV-ITGB6,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
,#N/A,,,,
T71164,#N/A,TARGETID,T71164,,
T71164,#N/A,TARGNAME,Ganglioside GD2 (GD2),,
T71164,#N/A,INDICATI,Phase 2,Adrenal cancer,[ICD-11: 2D11]
T71164,#N/A,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T71164,#N/A,INDICATI,Phase 1/2,Cervical cancer,[ICD-11: 2C77]
T71164,#N/A,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T71164,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T71164,#N/A,INDICATI,Phase 2,Osteosarcoma,[ICD-11: 2B51]
T71164,#N/A,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T71164,#N/A,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T71164,#N/A,INDICATI,Phase 1,Sarcoma,[ICD-11: 2A60-2C35]
T71164,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T71167,#N/A,TARGETID,T71167,,
T71167,#N/A,TARGNAME,Oxysterols receptor LXR (NR1H),,
T71167,#N/A,INDICATI,Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T71167,#N/A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T71167,#N/A,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T71167,#N/A,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T71167,#N/A,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T71167,#N/A,INDICATI,Phase 1,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T71167,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T71192,CYSLTR1,TARGETID,T71192,,
T71192,CYSLTR1,TARGNAME,Leukotriene CysLT1 receptor (CYSLTR1),,
T71192,CYSLTR1,INDICATI,Phase 1,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T71192,CYSLTR1,INDICATI,Approved,Asthma,[ICD-11: CA23]
T71192,CYSLTR1,INDICATI,Discontinued in Phase 2,Migraine,[ICD-11: 8A80]
T71192,CYSLTR1,INDICATI,Phase 3,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T71205,CLEC12A,TARGETID,T71205,,
T71205,CLEC12A,TARGNAME,Myeloid inhibitory C-type lectin-like receptor (CD371),,
T71205,CLEC12A,INDICATI,Phase 2/3,Acute myeloid leukaemia,[ICD-11: 2A60]
T71205,CLEC12A,INDICATI,Phase 1,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T71205,CLEC12A,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T71205,CLEC12A,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T71205,CLEC12A,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T71230,NPR1,TARGETID,T71230,,
T71230,NPR1,TARGNAME,Atrial natriuretic peptide receptor A (NPR1),,
T71230,NPR1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T71230,NPR1,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T71230,NPR1,INDICATI,Phase 2,Heart disease,[ICD-11: BA41-BA42]
T71230,NPR1,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T71230,NPR1,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T71266,AKT3,TARGETID,T71266,,
T71266,AKT3,TARGNAME,RAC-gamma serine/threonine-protein kinase (AKT3),,
T71266,AKT3,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T71266,AKT3,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T71266,AKT3,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T71266,AKT3,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T71266,AKT3,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T71266,AKT3,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T71266,AKT3,INDICATI,Phase 2,Overgrowth syndrome,[ICD-11: LD2C]
T71266,AKT3,INDICATI,Phase 2,Rectum cancer,[ICD-11: 2B92]
T71266,AKT3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T71369,BCL11A,TARGETID,T71369,,
T71369,BCL11A,TARGNAME,BCL11A messenger RNA (BCL11A mRNA),,
T71369,BCL11A,INDICATI,Phase 1,Sickle-cell disorder,[ICD-11: 3A51]
,#N/A,,,,
T71374,PLK4,TARGETID,T71374,,
T71374,PLK4,TARGNAME,Polo-like kinase 4 (PLK4),,
T71374,PLK4,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T71377,IL3RA,TARGETID,T71377,,
T71377,IL3RA,TARGNAME,Interleukin 3 receptor alpha (IL3RA),,
T71377,IL3RA,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T71377,IL3RA,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T71377,IL3RA,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T71377,IL3RA,INDICATI,Phase 1,Follicular lymphoma,[ICD-11: 2A80]
T71377,IL3RA,INDICATI,Phase 2,Kidney failure,[ICD-11: GB60-GB6Z]
T71377,IL3RA,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T71377,IL3RA,INDICATI,Terminated,Low bone mass disorder,[ICD-11: FB83]
T71377,IL3RA,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T71377,IL3RA,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T71377,IL3RA,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T71377,IL3RA,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
,#N/A,,,,
T71390,SRD5A2,TARGETID,T71390,,
T71390,SRD5A2,TARGNAME,Steroid 5-alpha-reductase 2 (SRD5A2),,
T71390,SRD5A2,INDICATI,Approved,Prostate hyperplasia,[ICD-11: GA90]
,#N/A,,,,
T71398,#N/A,TARGETID,T71398,,
T71398,#N/A,TARGNAME,Guanylate cyclase (GC),,
T71398,#N/A,INDICATI,Approved,Acquired methaemoglobinaemia,[ICD-11: 3A93]
T71398,#N/A,INDICATI,Approved,Anal fissure/fistula,[ICD-11: DB50]
T71398,#N/A,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T71398,#N/A,INDICATI,Discontinued in Phase 2,Dermatophytosis,[ICD-11: 1F28]
T71398,#N/A,INDICATI,Approved,Hydrocephalus,[ICD-11: 8D64]
T71398,#N/A,INDICATI,Approved,Respiratory failure,[ICD-11: CB41]
T71398,#N/A,INDICATI,Phase 2,Sickle-cell disorder,[ICD-11: 3A51]
T71398,#N/A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T71446,#N/A,TARGETID,T71446,,
T71446,#N/A,TARGNAME,Transporter unspecfic (TP),,
T71446,#N/A,INDICATI,Investigative,Toxicity,[ICD-11: N.A.]
,#N/A,,,,
T71479,#N/A,TARGETID,T71479,,
T71479,#N/A,TARGNAME,JAK-STAT signaling pathway (JAK-STAT pathway),,
T71479,#N/A,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T71479,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T71484,#N/A,TARGETID,T71484,,
T71484,#N/A,TARGNAME,Fungal Microtubule (Fung MicroTU),,
T71484,#N/A,INDICATI,Approved,Dermatophytosis,[ICD-11: 1F28]
,#N/A,,,,
T71501,HBV P,TARGETID,T71501,,
T71501,HBV P,TARGNAME,Hepatitis B virus Polymerase (HBV P),,
T71501,HBV P,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T71536,#N/A,TARGETID,T71536,,
T71536,#N/A,TARGNAME,Human Deoxyribonucleic acid minor groove (hDNA min),,
T71536,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T71536,#N/A,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T71536,#N/A,INDICATI,Phase 3,Leukaemia,[ICD-11: 2A60-2B33]
T71536,#N/A,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T71536,#N/A,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T71536,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T71556,#N/A,TARGETID,T71556,,
T71556,#N/A,TARGNAME,Lymphoid cell adhesion molecule expression (LCDME),,
T71556,#N/A,INDICATI,Approved,Atopic eczema,[ICD-11: EA80]
,#N/A,,,,
T71690,Bact aceE,TARGETID,T71690,,
T71690,Bact aceE,TARGNAME,Bacterial Pyruvate decarboxylase (Bact aceE),,
T71690,Bact aceE,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T71905,#N/A,TARGETID,T71905,,
T71905,#N/A,TARGNAME,Bacterial 16S ribosomal RNA (Bact 16S rRNA),,
T71905,#N/A,INDICATI,Approved,Acute/subacute hepatic failure,[ICD-11: DB91]
T71905,#N/A,INDICATI,Approved,Alcoholic liver disease,[ICD-11: DB94]
T71905,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T71905,#N/A,INDICATI,Phase 1,Gram-negative bacterial infection,[ICD-11: 1F41-1G40]
T71905,#N/A,INDICATI,Phase 2,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
,#N/A,,,,
T71907,SMN1,TARGETID,T71907,,
T71907,SMN1,TARGNAME,Survival motor neuron protein (SMN1),,
T71907,SMN1,INDICATI,Approved,Muscular atrophy,[ICD-11: 8B61]
,#N/A,,,,
T71928,KIR2DL1,TARGETID,T71928,,
T71928,KIR2DL1,TARGNAME,MHC class I NK cell receptor 2DL1 (CD158A),,
T71928,KIR2DL1,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T71928,KIR2DL1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T72024,GALC,TARGETID,T72024,,
T72024,GALC,TARGNAME,Galactocerebrosidase (GALC),,
T72024,GALC,INDICATI,Phase 1/2,Leukodystrophy,ICD-11: 8A44
,#N/A,,,,
T72032,GPRC6A,TARGETID,T72032,,
T72032,GPRC6A,TARGNAME,G-protein coupled receptor GPCR33 (GPRC6A),,
T72032,GPRC6A,INDICATI,Phase 3,Intrathoracic organs injury,[ICD-11: NB32]
,#N/A,,,,
T72038,LGALS3,TARGETID,T72038,,
T72038,LGALS3,TARGNAME,Galectin-3 (LGALS3),,
T72038,LGALS3,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T72038,LGALS3,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T72038,LGALS3,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T72038,LGALS3,INDICATI,Phase 1,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T72038,LGALS3,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T72042,GART,TARGETID,T72042,,
T72042,GART,TARGNAME,GAR transformylase (GART),,
T72042,GART,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T72065,#N/A,TARGETID,T72065,,
T72065,#N/A,TARGNAME,Voltage-gated sodium channel (Nav),,
T72065,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T72065,#N/A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T72065,#N/A,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T72065,#N/A,INDICATI,Phase 3,Neuropathy,[ICD-11: 8C0Z]
T72065,#N/A,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T72065,#N/A,INDICATI,Phase 1,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T72065,#N/A,INDICATI,Approved,Ventricular tachyarrhythmia,[ICD-11: BC71]
,#N/A,,,,
T72120,UTRN,TARGETID,T72120,,
T72120,UTRN,TARGNAME,Utrophin (UTRN),,
T72120,UTRN,INDICATI,Phase 2,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T72168,NR3C2,TARGETID,T72168,,
T72168,NR3C2,TARGNAME,Mineralocorticoid receptor  (MR),,
T72168,NR3C2,INDICATI,Approved,Adrenocortical insufficiency,[ICD-11: 5A74]
T72168,NR3C2,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T72168,NR3C2,INDICATI,Approved,Chronic kidney disease,[ICD-11: GB61]
T72168,NR3C2,INDICATI,Approved,Contraceptive management,[ICD-11: QA21]
T72168,NR3C2,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T72168,NR3C2,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T72168,NR3C2,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T72168,NR3C2,INDICATI,Approved,Hypo-osmolality/hyponatraemia,[ICD-11: 5C72]
T72168,NR3C2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T72168,NR3C2,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T72171,CCR5,TARGETID,T72171,,
T72171,CCR5,TARGNAME,CCR5 messenger RNA (CCR5 mRNA),,
T72171,CCR5,INDICATI,Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T72171,CCR5,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T72182,#N/A,TARGETID,T72182,,
T72182,#N/A,TARGNAME,TNF-alpha/IL-1 beta production (TNFA/IL1B produ),,
T72182,#N/A,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T72195,ANXA5,TARGETID,T72195,,
T72195,ANXA5,TARGNAME,Annexin A5 (ANXA5),,
T72195,ANXA5,INDICATI,Phase 2,Injury,[ICD-11: NA00-ND5Z]
,#N/A,,,,
T72252,CASP7,TARGETID,T72252,,
T72252,CASP7,TARGNAME,Caspase-7 (CASP7),,
T72252,CASP7,INDICATI,Clinical trial,Cystic fibrosis,[ICD-11: CA25]
,#N/A,,,,
T72269,EEF1A1; EEF1A2,TARGETID,T72269,,
T72269,EEF1A1; EEF1A2,TARGNAME,Elongation factor 1A (EF1A),,
T72269,EEF1A1; EEF1A2,INDICATI,Investigative,Melanoma,[ICD-11: 2C30]
,#N/A,,,,
T72295,PRKCQ,TARGETID,T72295,,
T72295,PRKCQ,TARGNAME,PKC-theta messenger RNA (PRKCQ mRNA),,
T72295,PRKCQ,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T72335,Bact lef,TARGETID,T72335,,
T72335,Bact lef,TARGNAME,Bacterial Lethal factor (Bact lef),,
T72335,Bact lef,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T72335,Bact lef,INDICATI,Phase 1,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T72437,#N/A,TARGETID,T72437,,
T72437,#N/A,TARGNAME,VWF-dependent platelet-collagen conversion (VDDPCC),,
T72437,#N/A,INDICATI,Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T72444,Bact fabH,TARGETID,T72444,,
T72444,Bact fabH,TARGNAME,Bacterial Beta-ketoacyl-ACP synthase III (Bact fabH),,
T72444,Bact fabH,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T72444,Bact fabH,INDICATI,Investigative,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T72458,MC4R,TARGETID,T72458,,
T72458,MC4R,TARGNAME,Melanocortin receptor 4 (MC4R),,
T72458,MC4R,INDICATI,Preclinical,Acute diabete complication,[ICD-11: 5A2Y]
T72458,MC4R,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T72458,MC4R,INDICATI,Investigative,Anorexia nervosa,[ICD-11: 6B80]
T72458,MC4R,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T72458,MC4R,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T72458,MC4R,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T72458,MC4R,INDICATI,Investigative,Cachexia,[ICD-11: MG20]
T72458,MC4R,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T72458,MC4R,INDICATI,Approved,Hypoactive sexual desire dysfunction,[ICD-11: HA00]
T72458,MC4R,INDICATI,Phase 2,Intellectual development disorder,[ICD-11: LD90]
T72458,MC4R,INDICATI,Approved,Large intestine motility disorder,[ICD-11: DB32]
T72458,MC4R,INDICATI,Phase 1/2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T72458,MC4R,INDICATI,Phase 1,Nutritional deficiency,[ICD-11: 5B50-5B71]
T72458,MC4R,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T72458,MC4R,INDICATI,Phase 3,Pituitary hypofunction,[ICD-11: 5A61]
T72458,MC4R,INDICATI,Phase 3,Sexual dysfunction,[ICD-11: HA00-HA01]
T72458,MC4R,INDICATI,Preclinical,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T72478,#N/A,TARGETID,T72478,,
T72478,#N/A,TARGNAME,Sodium/calcium exchanger (SLC),,
T72478,#N/A,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T72478,#N/A,INDICATI,Investigative,Cerebral ischaemia,[ICD-11: 8B1Z]
,#N/A,,,,
T72514,IL36G,TARGETID,T72514,,
T72514,IL36G,TARGNAME,Interleukin-36 gamma (IL36G),,
T72514,IL36G,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T72515,IL1R1,TARGETID,T72515,,
T72515,IL1R1,TARGNAME,Interleukin 1 receptor type 1 (IL1R1),,
T72515,IL1R1,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T72545,Bact parC,TARGETID,T72545,,
T72545,Bact parC,TARGNAME,Bacterial DNA topoisomerase 4A (Bact parC),,
T72545,Bact parC,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
T72545,Bact parC,INDICATI,Phase 3,Conjunctiva disorder,[ICD-11: 9A60]
T72545,Bact parC,INDICATI,Phase 2,Escherichia coli intestinal infection,[ICD-11: 1A03]
T72545,Bact parC,INDICATI,Phase 1,Joint direct infection,[ICD-11: FA10]
T72545,Bact parC,INDICATI,Phase 2,Pneumonia,[ICD-11: CA40]
T72545,Bact parC,INDICATI,Phase 2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T72545,Bact parC,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T72595,GRIN2C,TARGETID,T72595,,
T72595,GRIN2C,TARGNAME,Glutamate receptor ionotropic NMDA 2C (GluN2C),,
T72595,GRIN2C,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
,#N/A,,,,
T72657,Stap-coc pbp2,TARGETID,T72657,,
T72657,Stap-coc pbp2,TARGNAME,Staphylococcus 30S ribosomal subunit (Stap-coc pbp2),,
T72657,Stap-coc pbp2,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T72657,Stap-coc pbp2,INDICATI,Approved,Acute/subacute hepatic failure,[ICD-11: DB91]
T72657,Stap-coc pbp2,INDICATI,Approved,Alcoholic liver disease,[ICD-11: DB94]
T72657,Stap-coc pbp2,INDICATI,Approved,Amoebiasis,[ICD-11: 1A36]
T72657,Stap-coc pbp2,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T72657,Stap-coc pbp2,INDICATI,Approved,Bronchitis,[ICD-11: CA20]
T72657,Stap-coc pbp2,INDICATI,Investigative,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T72657,Stap-coc pbp2,INDICATI,Approved,Lyme borreliosis,[ICD-11: 1C1G]
T72657,Stap-coc pbp2,INDICATI,Phase 2,Rosacea,[ICD-11: ED90]
T72657,Stap-coc pbp2,INDICATI,Approved,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
,#N/A,,,,
T72702,F3,TARGETID,T72702,,
T72702,F3,TARGNAME,Tissue factor (F3),,
T72702,F3,INDICATI,Phase 2,Acute respiratory distress syndrome,[ICD-11: CB00]
T72702,F3,INDICATI,Phase 2,Bleeding disorder,[ICD-11: GA20-GA21]
T72702,F3,INDICATI,Approved,Cervical cancer,[ICD-11: 2C77]
T72702,F3,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T72702,F3,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T72702,F3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T72737,#N/A,TARGETID,T72737,,
T72737,#N/A,TARGNAME,Cytomegalovirus Deoxyribonucleic acid (CMV DNA),,
T72737,#N/A,INDICATI,Phase 3,Cytomegaloviral disease,[ICD-11: 1D82]
,#N/A,,,,
T72835,SELE,TARGETID,T72835,,
T72835,SELE,TARGNAME,E-selectin (SELE),,
T72835,SELE,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T72835,SELE,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T72835,SELE,INDICATI,Phase 2a,Atopic eczema,[ICD-11: EA80]
T72835,SELE,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T72835,SELE,INDICATI,Phase 2a,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T72835,SELE,INDICATI,Phase 3,Circulatory system disease,[ICD-11: BE2Z]
T72835,SELE,INDICATI,Phase 2/3,Hypertension,[ICD-11: BA00-BA04]
T72835,SELE,INDICATI,Terminated,Indeterminate colitis,[ICD-11: DD72]
T72835,SELE,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T72835,SELE,INDICATI,Phase 2a,Psoriasis,[ICD-11: EA90]
T72835,SELE,INDICATI,Phase 1,Sickle-cell disorder,[ICD-11: 3A51]
T72835,SELE,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T72841,ESRRA,TARGETID,T72841,,
T72841,ESRRA,TARGNAME,Estrogen-related receptor-alpha (ESRRA),,
T72841,ESRRA,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T72841,ESRRA,INDICATI,Terminated,Cachexia,[ICD-11: MG20]
T72841,ESRRA,INDICATI,Phase 1/2,Degenerative high myopia,[ICD-11: 9B76]
T72841,ESRRA,INDICATI,Investigative,Eczema,[ICD-11: EA80-EA89]
T72841,ESRRA,INDICATI,Investigative,Oesophagitis,[ICD-11: DA24]
T72841,ESRRA,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T72841,ESRRA,INDICATI,Phase 4,Schizophrenia,[ICD-11: 6A20]
T72841,ESRRA,INDICATI,Discontinued in Phase 2,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T72850,FOXO1,TARGETID,T72850,,
T72850,FOXO1,TARGNAME,Forkhead box protein O1A (FOXO1),,
T72850,FOXO1,INDICATI,Investigative,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T72915,#N/A,TARGETID,T72915,,
T72915,#N/A,TARGNAME,Casein kinase 1 (CK1),,
T72915,#N/A,INDICATI,Preclinical,Mood disorder,[ICD-11: 6A60-6E23]
,#N/A,,,,
T72957,#N/A,TARGETID,T72957,,
T72957,#N/A,TARGNAME,Chemokine receptor (CHR),,
T72957,#N/A,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T72957,#N/A,INDICATI,Discontinued in Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T72957,#N/A,INDICATI,Discontinued in Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T72957,#N/A,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T73019,#N/A,TARGETID,T73019,,
T73019,#N/A,TARGNAME,Phosphodiesterase 7 (PDE7),,
T73019,#N/A,INDICATI,Phase 1,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T73075,HSPG2,TARGETID,T73075,,
T73075,HSPG2,TARGNAME,Perlecan (HSPG),,
T73075,HSPG2,INDICATI,Discontinued in Phase 1,Arterial occlusive disease,[ICD-11: BD40]
,#N/A,,,,
T73097,CSF2RA,TARGETID,T73097,,
T73097,CSF2RA,TARGNAME,GMCSFR-alpha (CSF2RA),,
T73097,CSF2RA,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T73097,CSF2RA,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T73097,CSF2RA,INDICATI,Preregistration,Follicular lymphoma,[ICD-11: 2A80]
T73097,CSF2RA,INDICATI,Phase 3,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T73097,CSF2RA,INDICATI,Phase 3,Infancy/childhood primary interstitial lung disease,[ICD-11: CB04]
T73097,CSF2RA,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T73097,CSF2RA,INDICATI,Phase 1/2,Multiple sclerosis,[ICD-11: 8A40]
T73097,CSF2RA,INDICATI,Investigative,Neutropenia,[ICD-11: 4B00]
T73097,CSF2RA,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T73097,CSF2RA,INDICATI,Phase 1,Skin postprocedural disorder,[ICD-11: EL8Y]
T73097,CSF2RA,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T73097,CSF2RA,INDICATI,Approved,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T73134,GLB1,TARGETID,T73134,,
T73134,GLB1,TARGNAME,Beta-galactosidase (GLB1),,
T73134,GLB1,INDICATI,Phase 1/2,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T73184,SETD7,TARGETID,T73184,,
T73184,SETD7,TARGNAME,Histone-lysine N-methyltransferase SETD7 (SETD7),,
T73184,SETD7,INDICATI,Preclinical,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T73189,Fung GSC2,TARGETID,T73189,,
T73189,Fung GSC2,TARGNAME,"Fungal 1,3-beta-glucan synthase (Fung GSC2)",,
T73189,Fung GSC2,INDICATI,Terminated,Aspergillosis,[ICD-11: 1F20]
T73189,Fung GSC2,INDICATI,Approved,Candidosis,[ICD-11: 1F23]
T73189,Fung GSC2,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T73189,Fung GSC2,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
,#N/A,,,,
T73215,MS4A1,TARGETID,T73215,,
T73215,MS4A1,TARGNAME,Leukocyte surface antigen Leu-16 (CD20),,
T73215,MS4A1,INDICATI,Application submitted,Acute myeloid leukaemia,[ICD-11: 2A60]
T73215,MS4A1,INDICATI,Phase 2,Bacterial infection,[ICD-11: 1A00-1C4Z]
T73215,MS4A1,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T73215,MS4A1,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T73215,MS4A1,INDICATI,Approved,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T73215,MS4A1,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
T73215,MS4A1,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T73215,MS4A1,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T73215,MS4A1,INDICATI,Phase 3,Lymphoma,[ICD-11: 2A80-2A86]
T73215,MS4A1,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T73215,MS4A1,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T73215,MS4A1,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T73215,MS4A1,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T73215,MS4A1,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T73215,MS4A1,INDICATI,Phase 3,Pemphigus,[ICD-11: EB40]
T73215,MS4A1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T73215,MS4A1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T73215,MS4A1,INDICATI,Investigative,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T73215,MS4A1,INDICATI,Phase 3,Tension-type headache,[ICD-11: 8A81]
T73215,MS4A1,INDICATI,Phase 1/2,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T73342,RIR,TARGETID,T73342,,
T73342,RIR,TARGNAME,Ribonucleotide reductase (RIR),,
T73342,RIR,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T73342,RIR,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T73342,RIR,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T73342,RIR,INDICATI,Approved,Myelodysplastic syndrome,[ICD-11: 2A37]
T73342,RIR,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T73404,ALCAM,TARGETID,T73404,,
T73404,ALCAM,TARGNAME,Activated leukocyte cell adhesionmolecule (ALCAM),,
T73404,ALCAM,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T73475,MMP7,TARGETID,T73475,,
T73475,MMP7,TARGNAME,Matrix metalloproteinase-7 (MMP-7),,
T73475,MMP7,INDICATI,Discontinued in Phase 3,Brain cancer,[ICD-11: 2A00]
T73475,MMP7,INDICATI,Discontinued in Phase 3,Kaposi sarcoma,[ICD-11: 2B57]
T73475,MMP7,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T73475,MMP7,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T73475,MMP7,INDICATI,Discontinued in Phase 3,Prostate cancer,[ICD-11: 2C82]
T73475,MMP7,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T73476,SERPINC1,TARGETID,T73476,,
T73476,SERPINC1,TARGNAME,Antithrombin-III (ATIII),,
T73476,SERPINC1,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T73476,SERPINC1,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T73476,SERPINC1,INDICATI,Approved,Coagulation defect,[ICD-11: 3B10]
T73476,SERPINC1,INDICATI,Approved,Coronary thrombosis,[ICD-11: BA43]
T73476,SERPINC1,INDICATI,Approved,Deep vein thrombosis,[ICD-11: BD71]
T73476,SERPINC1,INDICATI,Phase 1,kidney/ureter disorder,[ICD-11: GB90]
T73476,SERPINC1,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T73476,SERPINC1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T73476,SERPINC1,INDICATI,Phase 3,Thrombosis,[ICD-11: DB61-GB90]
T73476,SERPINC1,INDICATI,Approved,Tinnitus,[ICD-11: MC41]
T73476,SERPINC1,INDICATI,Discontinued in Phase 3,Ulcerative colitis,[ICD-11: DD71]
T73476,SERPINC1,INDICATI,Phase 3,Venous thromboembolism,[ICD-11: BD72]
,#N/A,,,,
T73482,HCRTR1,TARGETID,T73482,,
T73482,HCRTR1,TARGNAME,Orexin receptor type 1 (HCRTR1),,
T73482,HCRTR1,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T73482,HCRTR1,INDICATI,Phase 2,Insomnia,[ICD-11: 7A00-7A0Z]
T73482,HCRTR1,INDICATI,Phase 1,Opioid use disorder,ICD-11: 6C43
T73482,HCRTR1,INDICATI,Terminated,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
,#N/A,,,,
T73495,GRIK1,TARGETID,T73495,,
T73495,GRIK1,TARGNAME,Glutamate receptor ionotropic kainate 1 (GRIK1),,
T73495,GRIK1,INDICATI,Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T73495,GRIK1,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T73495,GRIK1,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T73495,GRIK1,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T73495,GRIK1,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T73582,USP10,TARGETID,T73582,,
T73582,USP10,TARGNAME,Ubiquitin carboxyl-terminal hydrolase 10 (USP10),,
T73582,USP10,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T73671,#N/A,TARGETID,T73671,,
T73671,#N/A,TARGNAME,Interferon (IFN),,
T73671,#N/A,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T73671,#N/A,INDICATI,Investigative,Sexually transmitted infection,[ICD-11: 1A9Y-1A9Z]
,#N/A,,,,
T73676,SV2A,TARGETID,T73676,,
T73676,SV2A,TARGNAME,Synaptic vesicle glycoprotein 2A (SV2A),,
T73676,SV2A,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
T73676,SV2A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T73676,SV2A,INDICATI,Phase 3,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T73694,PTK6,TARGETID,T73694,,
T73694,PTK6,TARGNAME,Tyrosine-protein kinase BRK (PTK6),,
T73694,PTK6,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T73694,PTK6,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T73696,RXFP1,TARGETID,T73696,,
T73696,RXFP1,TARGNAME,Relaxin receptor 1 (RXFP1),,
T73696,RXFP1,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T73696,RXFP1,INDICATI,Approval submitted,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T73708,NRP2,TARGETID,T73708,,
T73708,NRP2,TARGNAME,Neuropilin-2 (NRP2),,
T73708,NRP2,INDICATI,Phase 3,Sarcoidosis,[ICD-11: 4B20]
,#N/A,,,,
T73712,FABP1,TARGETID,T73712,,
T73712,FABP1,TARGNAME,Fatty acid-binding protein 1 (FABP1),,
T73712,FABP1,INDICATI,Approved,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T73712,FABP1,INDICATI,Withdrawn from market,Gout,[ICD-11: FA25]
,#N/A,,,,
T73724,CHRNB4,TARGETID,T73724,,
T73724,CHRNB4,TARGNAME,Neuronal acetylcholine receptor beta-4 (CHRNB4),,
T73724,CHRNB4,INDICATI,Discontinued in Phase 2,Alzheimer disease,[ICD-11: 8A20]
T73724,CHRNB4,INDICATI,Phase 3,Nicotine use disorder,[ICD-11: 6C4A]
,#N/A,,,,
T73726,Candi ERG11,TARGETID,T73726,,
T73726,Candi ERG11,TARGNAME,Candida Cytochrome P450 51 (Candi ERG11),,
T73726,Candi ERG11,INDICATI,Approved,Aspergillosis,[ICD-11: 1F20]
T73726,Candi ERG11,INDICATI,Approved,Candidosis,[ICD-11: 1F23]
T73726,Candi ERG11,INDICATI,Phase 1,Coccidioidomycosis,ICD-11: 1F25
T73726,Candi ERG11,INDICATI,Approved,Dermatophytosis,[ICD-11: 1F28]
T73726,Candi ERG11,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
T73726,Candi ERG11,INDICATI,Discontinued in Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T73726,Candi ERG11,INDICATI,Approved,Nail/perionychium infection,[ICD-11: EE12]
T73726,Candi ERG11,INDICATI,Approved,Non-dermatophyte superficial dermatomycose,[ICD-11: 1F2D]
T73726,Candi ERG11,INDICATI,Phase 2,Oesophagitis,[ICD-11: DA24]
T73726,Candi ERG11,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T73726,Candi ERG11,INDICATI,Phase 2/3,Visual system disease,[ICD-11: 9E1Z]
,#N/A,,,,
T73756,EPHB2,TARGETID,T73756,,
T73756,EPHB2,TARGNAME,Ephrin type-B receptor 2 (EPHB2),,
T73756,EPHB2,INDICATI,Phase 2,Kaposi sarcoma,[ICD-11: 2B57]
T73756,EPHB2,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T73756,EPHB2,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T73756,EPHB2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T73760,#N/A,TARGETID,T73760,,
T73760,#N/A,TARGNAME,T(H2) cytokine production (TH2 produ),,
T73760,#N/A,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
,#N/A,,,,
T73977,CACNA1E,TARGETID,T73977,,
T73977,CACNA1E,TARGNAME,Voltage-gated calcium channel alpha Cav2.3 (CACNA1E),,
T73977,CACNA1E,INDICATI,Investigative,Heart failure,[ICD-11: BD10-BD1Z]
T73977,CACNA1E,INDICATI,Terminated,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T73992,#N/A,TARGETID,T73992,,
T73992,#N/A,TARGNAME,Beta-secretase (BACE),,
T73992,#N/A,INDICATI,Clinical trial,Acute diabete complication,[ICD-11: 5A2Y]
T73992,#N/A,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T73992,#N/A,INDICATI,Clinical trial,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T73992,#N/A,INDICATI,Clinical trial,Chronic kidney disease,[ICD-11: GB61]
T73992,#N/A,INDICATI,Preregistration,Osteoarthritis,[ICD-11: FA00-FA05]
T73992,#N/A,INDICATI,Clinical trial,Rheumatoid arthritis,[ICD-11: FA20]
T73992,#N/A,INDICATI,Preregistration,Shoulder lesion,[ICD-11: FB53]
T73992,#N/A,INDICATI,Preregistration,Soft tissue disorder,[ICD-11: FB56]
T73992,#N/A,INDICATI,Clinical trial,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T74002,CSF2,TARGETID,T74002,,
T74002,CSF2,TARGNAME,Granulocyte-macrophage colony-stimulating factor (CSF2),,
T74002,CSF2,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T74002,CSF2,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T74002,CSF2,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T74002,CSF2,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T74002,CSF2,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T74002,CSF2,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T74002,CSF2,INDICATI,Phase 1,Myeloproliferative neoplasm,[ICD-11: 2A20]
T74002,CSF2,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T74002,CSF2,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T74002,CSF2,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T74002,CSF2,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T74002,CSF2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T74034,#N/A,TARGETID,T74034,,
T74034,#N/A,TARGNAME,Hepatitis C virus Deoxyribonucleic acid (HCV DNA),,
T74034,#N/A,INDICATI,Phase 1/2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T74066,BMI1,TARGETID,T74066,,
T74066,BMI1,TARGNAME,Polycomb complex protein BMI-1 (BMI1),,
T74066,BMI1,INDICATI,Phase 2/3,Leiomyosarcoma,[ICD-11: 2B58]
,#N/A,,,,
T74073,#N/A,TARGETID,T74073,,
T74073,#N/A,TARGNAME,Serine/threonine-protein kinase pim (PIM),,
T74073,#N/A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T74073,#N/A,INDICATI,Phase 1,Myeloproliferative neoplasm,[ICD-11: 2A20]
T74073,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T74166,CHRNA3-CHRNB4,TARGETID,T74166,,
T74166,CHRNA3-CHRNB4,TARGNAME,Neuronal acetylcholine receptor alpha-3/beta-4 (CHRNA3/B4),,
T74166,CHRNA3-CHRNB4,INDICATI,Approved,Cough,[ICD-11: MD12]
T74166,CHRNA3-CHRNB4,INDICATI,Phase 2,Hyperhidrosis,[ICD-11: EE00]
T74166,CHRNA3-CHRNB4,INDICATI,Phase 1,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T74203,MycB fbpA,TARGETID,T74203,,
T74203,MycB fbpA,TARGNAME,Mycobacterium Antigen complex 85A (MycB fbpA),,
T74203,MycB fbpA,INDICATI,Phase 2,Mycobacterium infection,[ICD-11: 1B10-1B21]
,#N/A,,,,
T74225,#N/A,TARGETID,T74225,,
T74225,#N/A,TARGNAME,GPCR secretin protein unspecific (GPCRB),,
T74225,#N/A,INDICATI,Discontinued in Phase 2,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T74238,CYSLTR2,TARGETID,T74238,,
T74238,CYSLTR2,TARGNAME,Leukotriene CysLT2 receptor (CYSLTR2),,
T74238,CYSLTR2,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T74312,FLT3,TARGETID,T74312,,
T74312,FLT3,TARGNAME,Fms-like tyrosine kinase 3 (FLT-3),,
T74312,FLT3,INDICATI,Terminated,Acute laryngitis/tracheitis,[ICD-11: CA05]
T74312,FLT3,INDICATI,Approved (orphan drug),Acute myeloid leukaemia,[ICD-11: 2A60]
T74312,FLT3,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T74312,FLT3,INDICATI,Approved,Bone/articular cartilage neoplasm,[ICD-11: 2F7B]
T74312,FLT3,INDICATI,Discontinued in Phase 2,Brain cancer,[ICD-11: 2A00]
T74312,FLT3,INDICATI,Phase 2,Chronic myelomonocytic leukaemia,[ICD-11: 2A40]
T74312,FLT3,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T74312,FLT3,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T74312,FLT3,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T74312,FLT3,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T74312,FLT3,INDICATI,Approved,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T74312,FLT3,INDICATI,Phase 3,Inflammatory arthropathy,[ICD-11: FA2Z]
T74312,FLT3,INDICATI,Phase 3,Leukaemia,[ICD-11: 2A60-2B33]
T74312,FLT3,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T74312,FLT3,INDICATI,Phase 3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T74312,FLT3,INDICATI,Approved,Mastocytosis,[ICD-11: 2A21]
T74312,FLT3,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T74312,FLT3,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T74312,FLT3,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T74312,FLT3,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T74312,FLT3,INDICATI,Phase 3,Peritoneal cancer,[ICD-11: 2C51]
T74312,FLT3,INDICATI,Phase 1/2,Phakomatoses/hamartoneoplastic syndrome,[ICD-11: LD2D]
T74312,FLT3,INDICATI,Phase 2/3,Psoriasis,[ICD-11: EA90]
T74312,FLT3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T74312,FLT3,INDICATI,Phase 2,Transplanted organ/tissue,[ICD-11: QB63]
T74312,FLT3,INDICATI,Investigative,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T74363,PLAUR,TARGETID,T74363,,
T74363,PLAUR,TARGNAME,Urokinase plasminogen activator surface receptor (PLAUR),,
T74363,PLAUR,INDICATI,Phase 1/2,Acquired hypomelanotic disorder,[ICD-11: ED63]
T74363,PLAUR,INDICATI,Phase 1/2,Atopic eczema,[ICD-11: EA80]
T74363,PLAUR,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T74363,PLAUR,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T74363,PLAUR,INDICATI,Approved,Thrombocytosis,[ICD-11: 3B63]
,#N/A,,,,
T74381,MAGEC1,TARGETID,T74381,,
T74381,MAGEC1,TARGNAME,Cancer/testis antigen MAGE-C1/CT7 (MAGEC1),,
T74381,MAGEC1,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T74402,#N/A,TARGETID,T74402,,
T74402,#N/A,TARGNAME,NF-kappa-B-p38 signaling pathway (NFKB-p38 pathway),,
T74402,#N/A,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T74429,#N/A,TARGETID,T74429,,
T74429,#N/A,TARGNAME,Calcium (Ca),,
T74429,#N/A,INDICATI,Approved,Abnormal urine serum electrolytes level,[ICD-11: MF98]
T74429,#N/A,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
,#N/A,,,,
T74437,#N/A,TARGETID,T74437,,
T74437,#N/A,TARGNAME,Actin polymerization (Actin poly),,
T74437,#N/A,INDICATI,Phase 2,Arteries/arterioles disorder,[ICD-11: BD52]
,#N/A,,,,
T74456,AGTR1,TARGETID,T74456,,
T74456,AGTR1,TARGNAME,Angiotensin II receptor type-1 (AGTR1),,
T74456,AGTR1,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T74456,AGTR1,INDICATI,Investigative,Arteries/arterioles disorder,[ICD-11: BD52]
T74456,AGTR1,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T74456,AGTR1,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T74456,AGTR1,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T74456,AGTR1,INDICATI,Discontinued in Phase 2,Hypotension,[ICD-11: BA20-BA21]
T74456,AGTR1,INDICATI,Phase 3,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T74456,AGTR1,INDICATI,Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T74456,AGTR1,INDICATI,Approved,Secondary hypertension,[ICD-11: BA04]
T74456,AGTR1,INDICATI,Approved,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T74483,KCNQ2,TARGETID,T74483,,
T74483,KCNQ2,TARGNAME,Voltage-gated potassium channel Kv7.2 (KCNQ2),,
T74483,KCNQ2,INDICATI,Preclinical,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T74500,KCND3,TARGETID,T74500,,
T74500,KCND3,TARGNAME,Voltage-gated potassium channel Kv4.3 (KCND3),,
T74500,KCND3,INDICATI,Approved,Acidosis,[ICD-11: 5C73]
T74500,KCND3,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
,#N/A,,,,
T74654,#N/A,TARGETID,T74654,,
T74654,#N/A,TARGNAME,Adrenergic neuron (AD neuro),,
T74654,#N/A,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T74654,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T74839,CDK13,TARGETID,T74839,,
T74839,CDK13,TARGNAME,Cyclin-dependent kinase 13 (CDK13),,
T74839,CDK13,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T74891,Eh CP4,TARGETID,T74891,,
T74891,Eh CP4,TARGNAME,Entamoeba Cysteine proteinase CP4  (Eh CP4),,
T74891,Eh CP4,INDICATI,Investigative,Amoebiasis,[ICD-11: 1A36]
,#N/A,,,,
T74937,DBH,TARGETID,T74937,,
T74937,DBH,TARGNAME,Dopamine beta hydroxylase (DBH),,
T74937,DBH,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T74937,DBH,INDICATI,Phase 2,Post-traumatic stress disorder,[ICD-11: 6B40]
,#N/A,,,,
T74977,TTK,TARGETID,T74977,,
T74977,TTK,TARGNAME,Dual specificity protein kinase TTK (MPS1),,
T74977,TTK,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T75041,#N/A,TARGETID,T75041,,
T75041,#N/A,TARGNAME,Tumor-associated glycoprotein 72 (TAG-72),,
T75041,#N/A,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T75243,MTOR,TARGETID,T75243,,
T75243,MTOR,TARGNAME,Serine/threonine-protein kinase mTOR (mTOR),,
T75243,MTOR,INDICATI,Approved,Arteries/arterioles disorder,[ICD-11: BD52]
T75243,MTOR,INDICATI,Phase 1/2,Bladder cancer,[ICD-11: 2C94]
T75243,MTOR,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T75243,MTOR,INDICATI,Approved,Chronic myelomonocytic leukaemia,[ICD-11: 2A40]
T75243,MTOR,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T75243,MTOR,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T75243,MTOR,INDICATI,Phase 1/2,Hydrocephalus,[ICD-11: 8D64]
T75243,MTOR,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T75243,MTOR,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T75243,MTOR,INDICATI,Phase 1,Lymphangioleiomyomatosis,[ICD-11: CB07]
T75243,MTOR,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T75243,MTOR,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T75243,MTOR,INDICATI,Phase 2,Malignant mesenchymal neoplasm,[ICD-11: 2B5D-2B5Y]
T75243,MTOR,INDICATI,Investigative,Mature T-cell lymphoma,[ICD-11: 2A90]
T75243,MTOR,INDICATI,Phase 2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T75243,MTOR,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T75243,MTOR,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T75243,MTOR,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T75243,MTOR,INDICATI,Phase 1,Pleural mesothelioma,[ICD-11: 2C26]
T75243,MTOR,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T75243,MTOR,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T75243,MTOR,INDICATI,Phase 1,Pulmonary hypertension,[ICD-11: BB01]
T75243,MTOR,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T75243,MTOR,INDICATI,Phase 3,Sarcoma,[ICD-11: 2A60-2C35]
T75243,MTOR,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T75243,MTOR,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
T75243,MTOR,INDICATI,Investigative,Ulcerative colitis,[ICD-11: DD71]
T75243,MTOR,INDICATI,Phase 1,Vascular system developmental anomaly,ICD-11: LA90
,#N/A,,,,
T75251,#N/A,TARGETID,T75251,,
T75251,#N/A,TARGNAME,Tubulin receptor (TUBR),,
T75251,#N/A,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T75256,MLANA,TARGETID,T75256,,
T75256,MLANA,TARGNAME,MART-1 melanoma antigen (MLANA),,
T75256,MLANA,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
,#N/A,,,,
T75273,Stap-coc gyrA,TARGETID,T75273,,
T75273,Stap-coc gyrA,TARGNAME,Staphylococcus DNA gyrase A (Stap-coc gyrA),,
T75273,Stap-coc gyrA,INDICATI,Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
T75273,Stap-coc gyrA,INDICATI,Approved,Impetigo,[ICD-11: 1B72]
,#N/A,,,,
T75440,TSPO,TARGETID,T75440,,
T75440,TSPO,TARGNAME,Translocator protein (TSPO),,
T75440,TSPO,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T75440,TSPO,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T75440,TSPO,INDICATI,Phase 2,Brain disease,[ICD-11: 8C70-8E61]
T75440,TSPO,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T75440,TSPO,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T75440,TSPO,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T75440,TSPO,INDICATI,Approved,Intentional self-harm,[ICD-11: PC91]
T75440,TSPO,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T75440,TSPO,INDICATI,Discontinued in Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T75440,TSPO,INDICATI,Approved,Mood/affect symptom,[ICD-11: MB24]
T75440,TSPO,INDICATI,Discontinued in Phase 2,Muscular atrophy,[ICD-11: 8B61]
T75440,TSPO,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T75440,TSPO,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T75440,TSPO,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T75440,TSPO,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T75498,NQO2,TARGETID,T75498,,
T75498,NQO2,TARGNAME,Quinone reductase 2 (NQO2),,
T75498,NQO2,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T75498,NQO2,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T75498,NQO2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T75499,#N/A,TARGETID,T75499,,
T75499,#N/A,TARGNAME,Human Deoxyribonucleic acid major groove (hDNA maj),,
T75499,#N/A,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T75570,YES1,TARGETID,T75570,,
T75570,YES1,TARGNAME,Yes tyrosine kinase (YES),,
T75570,YES1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T75596,METAP2,TARGETID,T75596,,
T75596,METAP2,TARGNAME,Methionine aminopeptidase 2 (METAP2),,
T75596,METAP2,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T75596,METAP2,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T75596,METAP2,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T75596,METAP2,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T75613,LAMC2,TARGETID,T75613,,
T75613,LAMC2,TARGNAME,Laminin gamma-2 subunit (LAMC2),,
T75613,LAMC2,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T75643,NOD2,TARGETID,T75643,,
T75643,NOD2,TARGNAME,Pattern recognition receptor NOD2 (NOD2),,
T75643,NOD2,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T75643,NOD2,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T75643,NOD2,INDICATI,Investigative,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T75716,DLL3,TARGETID,T75716,,
T75716,DLL3,TARGNAME,Delta-like protein 3 (DLL3),,
T75716,DLL3,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T75716,DLL3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T75716,DLL3,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T75788,COL18A1,TARGETID,T75788,,
T75788,COL18A1,TARGNAME,Endostatin (COL18A1),,
T75788,COL18A1,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T75797,PTGFR,TARGETID,T75797,,
T75797,PTGFR,TARGNAME,Prostaglandin F2-alpha receptor (PTGFR),,
T75797,PTGFR,INDICATI,Approved,Abortion,[ICD-11: JA00]
T75797,PTGFR,INDICATI,Clinical trial,Alzheimer disease,[ICD-11: 8A20]
T75797,PTGFR,INDICATI,Discontinued in Phase 3,Arterial occlusive disease,[ICD-11: BD40]
T75797,PTGFR,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T75797,PTGFR,INDICATI,Phase 1,Female pelvic pain,[ICD-11: GA34]
T75797,PTGFR,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T75797,PTGFR,INDICATI,Investigative,Herpes simplex infection,[ICD-11: 1F00]
T75797,PTGFR,INDICATI,Phase 3,Renal cell carcinoma,[ICD-11: 2C90]
T75797,PTGFR,INDICATI,Clinical trial,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T75819,FBXO3,TARGETID,T75819,,
T75819,FBXO3,TARGNAME,F-box only protein 3 (FBXO3),,
T75819,FBXO3,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T75888,CPT1B,TARGETID,T75888,,
T75888,CPT1B,TARGNAME,Carnitine O-palmitoyltransferase I (CPT1B),,
T75888,CPT1B,INDICATI,Discontinued in Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
T75888,CPT1B,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T75888,CPT1B,INDICATI,Terminated,Heart failure,[ICD-11: BD10-BD1Z]
T75888,CPT1B,INDICATI,Approved,Mild neurocognitive disorder,[ICD-11: 6D71]
T75888,CPT1B,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T75888,CPT1B,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T75888,CPT1B,INDICATI,Terminated,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T75890,DPYD,TARGETID,T75890,,
T75890,DPYD,TARGNAME,Dihydrothymine dehydrogenase (DPYD),,
T75890,DPYD,INDICATI,Investigative,Colorectal cancer,[ICD-11: 2B91]
T75890,DPYD,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T75890,DPYD,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T75907,#N/A,TARGETID,T75907,,
T75907,#N/A,TARGNAME,ATP synthase (ATPS),,
T75907,#N/A,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T75984,#N/A,TARGETID,T75984,,
T75984,#N/A,TARGNAME,5-HT 2 receptor (5HT2R),,
T75984,#N/A,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T75984,#N/A,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T75984,#N/A,INDICATI,Discontinued in Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T75984,#N/A,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T75984,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T75984,#N/A,INDICATI,Terminated,Migraine,[ICD-11: 8A80]
T75984,#N/A,INDICATI,Approved,Psychotic disorder,[ICD-11: 6A20-6A25]
T75984,#N/A,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T75984,#N/A,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T75984,#N/A,INDICATI,Phase 2,Social anxiety disorder,[ICD-11: 6B04]
T75984,#N/A,INDICATI,Terminated,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T76024,C1S,TARGETID,T76024,,
T76024,C1S,TARGNAME,Complement C1s component (C1S),,
T76024,C1S,INDICATI,Phase 1,Acquired haemolytic anaemia,ICD-11: 3A20
T76024,C1S,INDICATI,Approved,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
T76024,C1S,INDICATI,Phase 2,Inflammatory polyneuropathy,[ICD-11: 8C01]
T76024,C1S,INDICATI,Approved,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T76024,C1S,INDICATI,Phase 1,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T76024,C1S,INDICATI,Phase 1,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T76024,C1S,INDICATI,Phase 1,Neuromyelitis optica,[ICD-11: 8A43]
T76024,C1S,INDICATI,Phase 1,Pemphigoid,[ICD-11: EB41]
T76024,C1S,INDICATI,Phase 2,Thrombocytopenia,ICD-11: 3B64
,#N/A,,,,
T76059,FKBP1A,TARGETID,T76059,,
T76059,FKBP1A,TARGNAME,FK506-binding protein 1A (FKBP1A),,
T76059,FKBP1A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T76059,FKBP1A,INDICATI,Phase 2,Pruritus,[ICD-11: EC90]
T76059,FKBP1A,INDICATI,Phase 1/2,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T76093,HBEGF,TARGETID,T76093,,
T76093,HBEGF,TARGNAME,Proheparin-binding EGF-like growth factor (HBEGF),,
T76093,HBEGF,INDICATI,Phase 1,Chronic tympanic membrane perforation,ICD-11: AB13
T76093,HBEGF,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T76093,HBEGF,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T76198,TBXA2R,TARGETID,T76198,,
T76198,TBXA2R,TARGNAME,Thromboxane A2 receptor (TBXA2R),,
T76198,TBXA2R,INDICATI,Phase 2,Angina pectoris,[ICD-11: BA40]
T76198,TBXA2R,INDICATI,Discontinued in Phase 3,Arterial occlusive disease,[ICD-11: BD40]
T76198,TBXA2R,INDICATI,Phase 2,Asthma,ICD-11: CA23
T76198,TBXA2R,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T76198,TBXA2R,INDICATI,Terminated,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T76198,TBXA2R,INDICATI,Phase 1,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T76198,TBXA2R,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T76198,TBXA2R,INDICATI,Approved,Diabetic foot ulcer,[ICD-11: BD54]
T76198,TBXA2R,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T76198,TBXA2R,INDICATI,Phase 2,Neuropathy,[ICD-11: 8C0Z]
T76198,TBXA2R,INDICATI,Approved,Sexual dysfunction,[ICD-11: HA00-HA01]
T76198,TBXA2R,INDICATI,Clinical trial,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T76198,TBXA2R,INDICATI,Phase 2,Thrombosis,[ICD-11: DB61-GB90]
T76198,TBXA2R,INDICATI,Phase 2/3,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T76213,PAH,TARGETID,T76213,,
T76213,PAH,TARGNAME,Phenylalanine hydroxylase (PAH),,
T76213,PAH,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T76213,PAH,INDICATI,Investigative,Genetic prion disease,[ICD-11: 8E02]
T76213,PAH,INDICATI,Phase 2,Liver disease,[ICD-11: DB90-DB9Z]
T76213,PAH,INDICATI,Approved,Metabolism inborn error,[ICD-11: 5C50]
,#N/A,,,,
T76233,Hepatitis A virus HAVCR2,TARGETID,T76233,,
T76233,Hepatitis A virus HAVCR2,TARGNAME,Hepatitis A virus cellular receptor 2 (TIM3),,
T76233,Hepatitis A virus HAVCR2,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T76233,Hepatitis A virus HAVCR2,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
T76233,Hepatitis A virus HAVCR2,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T76233,Hepatitis A virus HAVCR2,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T76233,Hepatitis A virus HAVCR2,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
T76233,Hepatitis A virus HAVCR2,INDICATI,Phase 2,Oral cavity/oesophagus/stomach in situ carcinoma,[ICD-11: 2E60]
T76233,Hepatitis A virus HAVCR2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T76285,ENPP3,TARGETID,T76285,,
T76285,ENPP3,TARGNAME,Phosphodiesterase I beta (ENPP3),,
T76285,ENPP3,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
,#N/A,,,,
T76310,#N/A,TARGETID,T76310,,
T76310,#N/A,TARGNAME,Calcium release (Ca rele),,
T76310,#N/A,INDICATI,Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T76369,CES1,TARGETID,T76369,,
T76369,CES1,TARGNAME,Liver carboxylesterase (CES1),,
T76369,CES1,INDICATI,Phase 2/3,Arterial occlusive disease,[ICD-11: BD40]
T76369,CES1,INDICATI,Discontinued in Phase 3,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T76369,CES1,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T76369,CES1,INDICATI,Clinical trial,Mature B-cell lymphoma,[ICD-11: 2A85]
T76369,CES1,INDICATI,Approved,Peroxisomal disease,[ICD-11: 5C57]
T76369,CES1,INDICATI,Approved,Synthesis disorder,[ICD-11: 5C52-5C59]
,#N/A,,,,
T76396,PGGT1B,TARGETID,T76396,,
T76396,PGGT1B,TARGNAME,Geranylgeranyl transferase I (GGTase-I),,
T76396,PGGT1B,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T76396,PGGT1B,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T76414,GRIN2B,TARGETID,T76414,,
T76414,GRIN2B,TARGNAME,Glutamate receptor ionotropic NMDA 2B (NMDAR2B),,
T76414,GRIN2B,INDICATI,Approved,Alpha-1-antitrypsin deficiency,[ICD-11: 5C5A]
T76414,GRIN2B,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T76414,GRIN2B,INDICATI,Phase 1,Cardiac arrest,[ICD-11: MC82]
T76414,GRIN2B,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T76414,GRIN2B,INDICATI,Investigative,Cerebral ischaemic stroke,[ICD-11: 8B11]
T76414,GRIN2B,INDICATI,Withdrawn from market,Chronic pain,[ICD-11: MG30]
T76414,GRIN2B,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T76414,GRIN2B,INDICATI,Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T76414,GRIN2B,INDICATI,Phase 1,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T76414,GRIN2B,INDICATI,Discontinued in Phase 2,General pain disorder,[ICD-11: 8E43]
T76414,GRIN2B,INDICATI,Investigative,Intracranial injury,[ICD-11: NA07]
T76414,GRIN2B,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T76414,GRIN2B,INDICATI,Terminated,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T76414,GRIN2B,INDICATI,Phase 2,Neuropathy,[ICD-11: 8C0Z]
T76414,GRIN2B,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T76497,PGD,TARGETID,T76497,,
T76497,PGD,TARGNAME,Phosphogluconate dehydrogenase (PGD),,
T76497,PGD,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T76630,CD52,TARGETID,T76630,,
T76630,CD52,TARGNAME,Cambridge pathology 1 antigen (CD52),,
T76630,CD52,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T76630,CD52,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T76685,CNR1,TARGETID,T76685,,
T76685,CNR1,TARGNAME,Cannabinoid receptor 1 (CB1),,
T76685,CNR1,INDICATI,Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
T76685,CNR1,INDICATI,Approved,Anorexia nervosa,[ICD-11: 6B80]
T76685,CNR1,INDICATI,Phase 2,Cannabis use disorder,[ICD-11: 6C41]
T76685,CNR1,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T76685,CNR1,INDICATI,Discontinued in Phase 1,Cerebral ischaemia,[ICD-11: 8B1Z]
T76685,CNR1,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T76685,CNR1,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T76685,CNR1,INDICATI,Patented,General pain disorder,[ICD-11: 8E43]
T76685,CNR1,INDICATI,Discontinued in Phase 1,Hypertension,[ICD-11: BA00-BA04]
T76685,CNR1,INDICATI,Phase 2,Inborn lipid metabolism error,[ICD-11: 5C52]
T76685,CNR1,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T76685,CNR1,INDICATI,Discontinued in Phase 2,Ischemia,[ICD-11: 8B10-8B11]
T76685,CNR1,INDICATI,Patented,Low bone mass disorder,[ICD-11: FB83]
T76685,CNR1,INDICATI,Phase 1,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T76685,CNR1,INDICATI,Phase 2/3,Nausea/vomiting,[ICD-11: MD90]
T76685,CNR1,INDICATI,Phase 2,Nicotine use disorder,[ICD-11: 6C4A]
T76685,CNR1,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T76685,CNR1,INDICATI,Investigative,Ovarian cancer,[ICD-11: 2C73]
T76685,CNR1,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T76685,CNR1,INDICATI,Patented,Prostate cancer,[ICD-11: 2C82]
T76685,CNR1,INDICATI,Investigative,Psychoactive substances use disorder,[ICD-11: 6C4G]
T76685,CNR1,INDICATI,Discontinued in Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T76685,CNR1,INDICATI,Discontinued in Phase 1,Schizophrenia,[ICD-11: 6A20]
T76685,CNR1,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
T76685,CNR1,INDICATI,Phase 3,Urinary tract infection,[ICD-11: GC08]
T76685,CNR1,INDICATI,Discontinued in Phase 2,Zoster,[ICD-11: 1E91]
,#N/A,,,,
T76701,#N/A,TARGETID,T76701,,
T76701,#N/A,TARGNAME,Cyclin D1/E2F pathway (CCND1/E2F pathway),,
T76701,#N/A,INDICATI,Discontinued in Phase 2,Qualitative platelet defect,[ICD-11: 3B62]
,#N/A,,,,
T76846,MC3R,TARGETID,T76846,,
T76846,MC3R,TARGNAME,Melanocortin receptor 3 (MC3R),,
T76846,MC3R,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
T76846,MC3R,INDICATI,Preclinical,Sexual dysfunction,[ICD-11: HA00-HA01]
T76846,MC3R,INDICATI,Preclinical,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T76855,Stap-coc tuf,TARGETID,T76855,,
T76855,Stap-coc tuf,TARGNAME,Staphylococcus Elongation factor Tu (Stap-coc tuf),,
T76855,Stap-coc tuf,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
T76855,Stap-coc tuf,INDICATI,Phase 1,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T76904,COMT,TARGETID,T76904,,
T76904,COMT,TARGNAME,Catechol-O-methyl-transferase (COMT),,
T76904,COMT,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T76904,COMT,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T76904,COMT,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T76904,COMT,INDICATI,Phase 3,Restless legs syndrome,[ICD-11: 7A80]
T76904,COMT,INDICATI,Preclinical,Schizophrenia,[ICD-11: 6A20]
T76904,COMT,INDICATI,Investigative,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T76910,GSK3A,TARGETID,T76910,,
T76910,GSK3A,TARGNAME,Glycogen synthase kinase-3 alpha (GSK-3A),,
T76910,GSK3A,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T76910,GSK3A,INDICATI,Patented,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T76910,GSK3A,INDICATI,Patented,Brain cancer,[ICD-11: 2A00]
T76910,GSK3A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T76910,GSK3A,INDICATI,Phase 2,Fragile X chromosome,[ICD-11: LD55]
T76910,GSK3A,INDICATI,Patented,Ovarian cancer,[ICD-11: 2C73]
T76910,GSK3A,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T76910,GSK3A,INDICATI,Patented,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T76914,KCNA3,TARGETID,T76914,,
T76914,KCNA3,TARGNAME,Voltage-gated potassium channel Kv1.3 (KCNA3),,
T76914,KCNA3,INDICATI,Phase 1b/2a,Idiopathic inflammatory myopathy,[ICD-11: 4A41]
T76914,KCNA3,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T76914,KCNA3,INDICATI,Phase 1b/2a,Psoriasis,[ICD-11: EA90]
T76914,KCNA3,INDICATI,Phase 1,Psoriatic arthritis,[ICD-11: FA21]
,#N/A,,,,
T76937,SCN3A,TARGETID,T76937,,
T76937,SCN3A,TARGNAME,Voltage-gated sodium channel alpha Nav1.3 (SCN3A),,
T76937,SCN3A,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T76937,SCN3A,INDICATI,Discontinued in Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T76937,SCN3A,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T77009,PRDX5,TARGETID,T77009,,
T77009,PRDX5,TARGNAME,Thioredoxin reductase (PRDX5),,
T77009,PRDX5,INDICATI,Approved,Brain cancer,[ICD-11: 2A00]
T77009,PRDX5,INDICATI,Phase 3,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T77009,PRDX5,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T77009,PRDX5,INDICATI,Phase 1/2,Mature B-cell leukaemia,[ICD-11: 2A82]
T77009,PRDX5,INDICATI,Phase 1/2,Mature B-cell lymphoma,[ICD-11: 2A85]
,#N/A,,,,
T77158,#N/A,TARGETID,T77158,,
T77158,#N/A,TARGNAME,Protein synthesis (hPRO synth),,
T77158,#N/A,INDICATI,Phase 2,Bacterial infection,[ICD-11: 1A00-1C4Z]
T77158,#N/A,INDICATI,Phase 2,Infectious meningitis,[ICD-11: 1D01]
T77158,#N/A,INDICATI,Phase 2,Melioidosis,[ICD-11: 1C42]
T77158,#N/A,INDICATI,Phase 2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T77158,#N/A,INDICATI,Discontinued in Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T77190,SLITRK6,TARGETID,T77190,,
T77190,SLITRK6,TARGNAME,SLIT and NTRK-like family member 6 (SLITRK6),,
T77190,SLITRK6,INDICATI,Phase 1,Bladder cancer,[ICD-11: 2C94]
T77190,SLITRK6,INDICATI,Phase 1,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T77195,MT-ND3,TARGETID,T77195,,
T77195,MT-ND3,TARGNAME,NADH dehydrogenase (MT-ND3),,
T77195,MT-ND3,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T77236,CTSF,TARGETID,T77236,,
T77236,CTSF,TARGNAME,Cathepsin F (CTSF),,
T77236,CTSF,INDICATI,Patented,Bone cancer,[ICD-11: 2B5Z]
T77236,CTSF,INDICATI,Patented,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T77236,CTSF,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
T77236,CTSF,INDICATI,Patented,Digestive system disease,[ICD-11: DE2Z]
T77236,CTSF,INDICATI,Patented,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T77236,CTSF,INDICATI,Patented,Multiple sclerosis,[ICD-11: 8A40]
T77236,CTSF,INDICATI,Patented,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T77350,PSMB8,TARGETID,T77350,,
T77350,PSMB8,TARGNAME,Proteasome beta-8 (PS beta-8),,
T77350,PSMB8,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T77365,ADORA2A,TARGETID,T77365,,
T77365,ADORA2A,TARGNAME,Adenosine A2a receptor (ADORA2A),,
T77365,ADORA2A,INDICATI,Discontinued in Phase 3,Alzheimer disease,[ICD-11: 8A20]
T77365,ADORA2A,INDICATI,Phase 1/2,Arterial occlusive disease,[ICD-11: BD40]
T77365,ADORA2A,INDICATI,Phase 1,Choreiform disorder,[ICD-11: 8A01]
T77365,ADORA2A,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T77365,ADORA2A,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T77365,ADORA2A,INDICATI,Phase 3,Coronary atherosclerosis,[ICD-11: BA80]
T77365,ADORA2A,INDICATI,Phase 2,Diabetic foot ulcer,[ICD-11: BD54]
T77365,ADORA2A,INDICATI,Discontinued in Phase 1,General pain disorder,[ICD-11: 8E43]
T77365,ADORA2A,INDICATI,Phase 1/2,Glaucoma,[ICD-11: 9C61]
T77365,ADORA2A,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T77365,ADORA2A,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T77365,ADORA2A,INDICATI,Phase 3,Hypertension,[ICD-11: BA00-BA04]
T77365,ADORA2A,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T77365,ADORA2A,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
T77365,ADORA2A,INDICATI,Approved,Orthostatic hypotension,[ICD-11: BA21]
T77365,ADORA2A,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T77365,ADORA2A,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T77365,ADORA2A,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T77365,ADORA2A,INDICATI,Approved,Radionuclide imaging,[ICD-11: N.A.]
T77365,ADORA2A,INDICATI,Discontinued in Phase 2,Schizophrenia,[ICD-11: 6A20]
T77365,ADORA2A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T77365,ADORA2A,INDICATI,Phase 1,Unspecific substance use disorder,[ICD-11: 6C4Z]
T77365,ADORA2A,INDICATI,Phase 1,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T77400,PDE2A,TARGETID,T77400,,
T77400,PDE2A,TARGNAME,Phosphodiesterase 2A (PDE2A),,
T77400,PDE2A,INDICATI,Phase 2,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
T77400,PDE2A,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T77400,PDE2A,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T77400,PDE2A,INDICATI,Phase 1,Mood disorder,[ICD-11: 6A60-6E23]
,#N/A,,,,
T77473,TPT1,TARGETID,T77473,,
T77473,TPT1,TARGNAME,Translationally-controlled tumor protein (TPT1),,
T77473,TPT1,INDICATI,Discontinued in Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T77515,KIR2DS2,TARGETID,T77515,,
T77515,KIR2DS2,TARGNAME,MHC class I NK cell receptor 2DS2 (CD158j),,
T77515,KIR2DS2,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T77534,#N/A,TARGETID,T77534,,
T77534,#N/A,TARGNAME,Phospholipase C (PLC),,
T77534,#N/A,INDICATI,Terminated,Leukaemia,[ICD-11: 2A60-2B33]
T77534,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T77594,HSPA5,TARGETID,T77594,,
T77594,HSPA5,TARGNAME,Endoplasmic reticulum chaperone BiP (HSPA5),,
T77594,HSPA5,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T77594,HSPA5,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T77613,PDE1B,TARGETID,T77613,,
T77613,PDE1B,TARGNAME,Phosphodiesterase 1B (PDE1B),,
T77613,PDE1B,INDICATI,Investigative,Mild neurocognitive disorder,[ICD-11: 6D71]
,#N/A,,,,
T77645,TNFRSF10A,TARGETID,T77645,,
T77645,TNFRSF10A,TARGNAME,TRAIL receptor 1 (TRAIL-R1),,
T77645,TNFRSF10A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T77645,TNFRSF10A,INDICATI,Discontinued in Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T77664,IFNG,TARGETID,T77664,,
T77664,IFNG,TARGNAME,Interferon-gamma (IFNG),,
T77664,IFNG,INDICATI,Approved,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T77664,IFNG,INDICATI,Phase 1,Basal cell carcinoma,[ICD-11: 2C32]
T77664,IFNG,INDICATI,Discontinued in Phase 2,B-cell lymphoma,[ICD-11: 2A86]
T77664,IFNG,INDICATI,Phase 1,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T77664,IFNG,INDICATI,Phase 1/2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T77664,IFNG,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
T77664,IFNG,INDICATI,Phase 1,Lupus erythematosus,[ICD-11: 4A40]
T77664,IFNG,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T77664,IFNG,INDICATI,Preclinical,Prostate cancer,[ICD-11: 2C82]
T77664,IFNG,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T77664,IFNG,INDICATI,Discontinued in Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T77764,AURKB,TARGETID,T77764,,
T77764,AURKB,TARGNAME,Aurora B messenger RNA (AURKB mRNA),,
T77764,AURKB,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T77796,TRHR,TARGETID,T77796,,
T77796,TRHR,TARGNAME,Thyrotropin-releasing hormone receptor (TRHR),,
T77796,TRHR,INDICATI,Approved,Central nervous system disease,[ICD-11: 8A04-8D87]
T77796,TRHR,INDICATI,Investigative,Endocrine disease,[ICD-11: 5B3Z]
T77796,TRHR,INDICATI,Discontinued in Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T77796,TRHR,INDICATI,Discontinued in Phase 3,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T77796,TRHR,INDICATI,Phase 3,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T77913,HRH1,TARGETID,T77913,,
T77913,HRH1,TARGNAME,Histamine H1 receptor (H1R),,
T77913,HRH1,INDICATI,Approved,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T77913,HRH1,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T77913,HRH1,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T77913,HRH1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T77913,HRH1,INDICATI,Phase 1,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T77913,HRH1,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T77913,HRH1,INDICATI,Approved,Breathing abnormality,[ICD-11: MD11]
T77913,HRH1,INDICATI,Approved,Conjunctiva disorder,[ICD-11: 9A60]
T77913,HRH1,INDICATI,Withdrawn from market,Corneal disease,[ICD-11: 9A76-9A78]
T77913,HRH1,INDICATI,Approved,Cough,[ICD-11: MD12]
T77913,HRH1,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T77913,HRH1,INDICATI,Approved,Episodic vestibular syndrome,[ICD-11: AB31]
T77913,HRH1,INDICATI,Approved,Headache,[ICD-11: 8A80-8A84]
T77913,HRH1,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T77913,HRH1,INDICATI,Approved,Morning sickness disorder,[ICD-11: SC00]
T77913,HRH1,INDICATI,Approved,Nasopharyngitis,[ICD-11: CA00]
T77913,HRH1,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T77913,HRH1,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
T77913,HRH1,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T77913,HRH1,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T77913,HRH1,INDICATI,Approved,Pruritus,[ICD-11: EC90]
T77913,HRH1,INDICATI,Phase 2,Respiratory system disease,[ICD-11: CB40-CB7Z]
T77913,HRH1,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T77913,HRH1,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T77913,HRH1,INDICATI,Approved,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
T77913,HRH1,INDICATI,Approved,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T77990,Stap-coc isdB,TARGETID,T77990,,
T77990,Stap-coc isdB,TARGNAME,Staphylococcus Iron-regulated surface determinant B (Stap-coc isdB),,
T77990,Stap-coc isdB,INDICATI,Phase 2/3,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T78111,#N/A,TARGETID,T78111,,
T78111,#N/A,TARGNAME,Nicotinic acetylcholine receptor (nAChR),,
T78111,#N/A,INDICATI,Discontinued in Preregistration,Abnormal micturition,[ICD-11: MF50]
T78111,#N/A,INDICATI,Discontinued in Phase 2,Alzheimer disease,[ICD-11: 8A20]
T78111,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T78111,#N/A,INDICATI,Phase 1/2,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T78111,#N/A,INDICATI,Approved,Corneal disease,[ICD-11: 9A76-9A78]
T78111,#N/A,INDICATI,Phase 1/2,Diabetic foot ulcer,[ICD-11: BD54]
T78111,#N/A,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T78111,#N/A,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T78111,#N/A,INDICATI,Approved,Insecticide,[ICD-11: N.A.]
T78111,#N/A,INDICATI,Discontinued in Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T78111,#N/A,INDICATI,Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T78111,#N/A,INDICATI,Phase 1,Motor neuron disease,[ICD-11: 8B60]
T78111,#N/A,INDICATI,Phase 1,Multiple sclerosis,[ICD-11: 8A40]
T78111,#N/A,INDICATI,Phase 2,Neuropathy,[ICD-11: 8C0Z]
T78111,#N/A,INDICATI,Approved,Nicotine use disorder,[ICD-11: 6C4A]
T78111,#N/A,INDICATI,Discontinued in Phase 1,Pain,[ICD-11: MG30-MG3Z]
T78111,#N/A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T78111,#N/A,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T78111,#N/A,INDICATI,Discontinued in Phase 2,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T78114,CD55,TARGETID,T78114,,
T78114,CD55,TARGNAME,Complement decay-accelerating factor (CD55),,
T78114,CD55,INDICATI,Phase 1/2,Bladder cancer,[ICD-11: 2C94]
T78114,CD55,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T78114,CD55,INDICATI,Discontinued in Phase 1,Colorectal cancer,[ICD-11: 2B91]
T78114,CD55,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T78114,CD55,INDICATI,Phase 1/2,Melanoma,[ICD-11: 2C30]
T78114,CD55,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T78114,CD55,INDICATI,Phase 1/2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T78173,Candi ERG1,TARGETID,T78173,,
T78173,Candi ERG1,TARGNAME,Candida Squalene epoxidase (Candi ERG1),,
T78173,Candi ERG1,INDICATI,Approved,Dermatophytosis,[ICD-11: 1F28]
T78173,Candi ERG1,INDICATI,Approved,Fungal infection,[ICD-11: 1F29-1F2F]
T78173,Candi ERG1,INDICATI,Phase 2,Nail/perionychium infection,[ICD-11: EE12]
,#N/A,,,,
T78198,PNP,TARGETID,T78198,,
T78198,PNP,TARGNAME,Purine nucleoside phosphorylase (PNP),,
T78198,PNP,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T78198,PNP,INDICATI,Phase 2,Gout,[ICD-11: FA25]
T78198,PNP,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T78198,PNP,INDICATI,Phase 1/2,Mycosis fungoides,[ICD-11: 2B01]
T78198,PNP,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T78198,PNP,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T78244,#N/A,TARGETID,T78244,,
T78244,#N/A,TARGNAME,Vasoactive intestinal polypeptide receptor (VIPR),,
T78244,#N/A,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T78277,ASRGL1,TARGETID,T78277,,
T78277,ASRGL1,TARGNAME,Asparaginase (ASRGL1),,
T78277,ASRGL1,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T78277,ASRGL1,INDICATI,Phase 3,Mature B-cell lymphoma,[ICD-11: 2A85]
T78277,ASRGL1,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T78318,KCNT2,TARGETID,T78318,,
T78318,KCNT2,TARGNAME,Calcium-activated potassium channel KCa4.2 (KCNT2),,
T78318,KCNT2,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T78318,KCNT2,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
,#N/A,,,,
T78319,CD44,TARGETID,T78319,,
T78319,CD44,TARGNAME,Extracellular matrix receptor III (CD44),,
T78319,CD44,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T78319,CD44,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T78319,CD44,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T78356,TBXAS1,TARGETID,T78356,,
T78356,TBXAS1,TARGNAME,Thromboxane-A synthase (TBXAS1),,
T78356,TBXAS1,INDICATI,Phase 3,Angina pectoris,[ICD-11: BA40]
T78356,TBXAS1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T78356,TBXAS1,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T78356,TBXAS1,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T78356,TBXAS1,INDICATI,Discontinued in Phase 2,Nephritic syndrome,[ICD-11: GB40]
T78356,TBXAS1,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
T78356,TBXAS1,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T78381,IFNL1,TARGETID,T78381,,
T78381,IFNL1,TARGNAME,Interleukin-29 (IL29),,
T78381,IFNL1,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T78381,IFNL1,INDICATI,Phase 1,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T78383,#N/A,TARGETID,T78383,,
T78383,#N/A,TARGNAME,Chemosensory receptor (CheR),,
T78383,#N/A,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
,#N/A,,,,
T78393,MIF,TARGETID,T78393,,
T78393,MIF,TARGNAME,MIF messenger RNA (MIF mRNA),,
T78393,MIF,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T78429,IKBKB,TARGETID,T78429,,
T78429,IKBKB,TARGNAME,Inhibitor of nuclear factor kappa-B kinase beta (IKKB),,
T78429,IKBKB,INDICATI,Phase 1,Acne vulgaris,[ICD-11: ED80]
T78429,IKBKB,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T78429,IKBKB,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T78429,IKBKB,INDICATI,Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T78429,IKBKB,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T78510,CNGA3,TARGETID,T78510,,
T78510,CNGA3,TARGNAME,Cyclic nucleotide-gated channel alpha-3 (CNGA3),,
T78510,CNGA3,INDICATI,Phase 1/2,Inherited retinal dystrophy,[ICD-11: 9B70]
,#N/A,,,,
T78552,CD59,TARGETID,T78552,,
T78552,CD59,TARGNAME,Membrane inhibitor of reactive lysis (CD59),,
T78552,CD59,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T78552,CD59,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T78567,OSMR,TARGETID,T78567,,
T78567,OSMR,TARGNAME,Oncostatin-M-specific receptor beta (OSMR),,
T78567,OSMR,INDICATI,Phase 1,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T78567,OSMR,INDICATI,Phase 1,Pruritus,[ICD-11: EC90]
,#N/A,,,,
T78581,GALR1,TARGETID,T78581,,
T78581,GALR1,TARGNAME,Galanin receptor type 1 (GAL1-R),,
T78581,GALR1,INDICATI,Investigative,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
,#N/A,,,,
T78585,IL5,TARGETID,T78585,,
T78585,IL5,TARGNAME,Interleukin-5 (IL5),,
T78585,IL5,INDICATI,Approved,Asthma,[ICD-11: CA23]
T78585,IL5,INDICATI,Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T78585,IL5,INDICATI,Phase 3,Chronic rhinosinusitis,ICD-11: CA0A
T78585,IL5,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T78585,IL5,INDICATI,Phase 3,Pulmonary eosinophilia,[ICD-11: CB02]
T78585,IL5,INDICATI,Phase 3,Vasculitis,[ICD-11: 4A44]
,#N/A,,,,
T78590,#N/A,TARGETID,T78590,,
T78590,#N/A,TARGNAME,Polymorphonuclear neutrophil adhesion (PMNA),,
T78590,#N/A,INDICATI,Discontinued in Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T78656,HTR1F,TARGETID,T78656,,
T78656,HTR1F,TARGNAME,5-HT 1F receptor (HTR1F),,
T78656,HTR1F,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T78656,HTR1F,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T78692,KCNJ5,TARGETID,T78692,,
T78692,KCNJ5,TARGNAME,Inward rectifier potassium channel Kir3.4 (KCNJ5),,
T78692,KCNJ5,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T78692,KCNJ5,INDICATI,Phase 2,Hodgkin lymphoma,[ICD-11: 2B30]
,#N/A,,,,
T78709,HTR1A,TARGETID,T78709,,
T78709,HTR1A,TARGNAME,5-HT 1A receptor (HTR1A),,
T78709,HTR1A,INDICATI,Discontinued in Phase 2,Abnormal micturition,[ICD-11: MF50]
T78709,HTR1A,INDICATI,Withdrawn from market,Addictive disorder,[ICD-11: 6C50-6C5Z]
T78709,HTR1A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T78709,HTR1A,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T78709,HTR1A,INDICATI,Phase 3,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T78709,HTR1A,INDICATI,Terminated,Binge eating disorder,[ICD-11: 6B82]
T78709,HTR1A,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T78709,HTR1A,INDICATI,Phase 2,Bulimia nervosa,[ICD-11: 6B81]
T78709,HTR1A,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
T78709,HTR1A,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T78709,HTR1A,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T78709,HTR1A,INDICATI,Discontinued in Phase 1,Dystonic disorder,[ICD-11: 8A02]
T78709,HTR1A,INDICATI,Phase 1,Ejaculatory dysfunction,[ICD-11: HA03]
T78709,HTR1A,INDICATI,Discontinued in Phase 2,Episode,[ICD-11: N.A.]
T78709,HTR1A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T78709,HTR1A,INDICATI,Phase 2,Hypoactive sexual desire dysfunction,[ICD-11: HA00]
T78709,HTR1A,INDICATI,Phase 2,Insomnia,[ICD-11: 7A00-7A0Z]
T78709,HTR1A,INDICATI,Phase 2/3,Intellectual development disorder,[ICD-11: LD90]
T78709,HTR1A,INDICATI,Phase 3,Juvenile idiopathic arthritis,[ICD-11: FA24]
T78709,HTR1A,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T78709,HTR1A,INDICATI,Investigative,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T78709,HTR1A,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T78709,HTR1A,INDICATI,Phase 2/3,Mild neurocognitive disorder,[ICD-11: 6D71]
T78709,HTR1A,INDICATI,Approved,Mood disorder,[ICD-11: 6A60-6E23]
T78709,HTR1A,INDICATI,Discontinued in Phase 3,Muscular atrophy,[ICD-11: 8B61]
T78709,HTR1A,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
T78709,HTR1A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T78709,HTR1A,INDICATI,Phase 1/2,Postoperative inflammation,[ICD-11: 1A00-CA43]
T78709,HTR1A,INDICATI,Preclinical,Post-traumatic stress disorder,[ICD-11: 6B40]
T78709,HTR1A,INDICATI,Patented,Prostate hyperplasia,[ICD-11: GA90]
T78709,HTR1A,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T78709,HTR1A,INDICATI,Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T78709,HTR1A,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
T78709,HTR1A,INDICATI,Phase 3,Sexual dysfunction,[ICD-11: HA00-HA01]
T78709,HTR1A,INDICATI,Discontinued in Phase 3,Skin/mucosal anomaly,[ICD-11: LD27]
T78709,HTR1A,INDICATI,Phase 2,Social anxiety disorder,[ICD-11: 6B04]
T78709,HTR1A,INDICATI,Phase 2,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T78874,#N/A,TARGETID,T78874,,
T78874,#N/A,TARGNAME,Protein kinase (PK),,
T78874,#N/A,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T78874,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T78874,#N/A,INDICATI,Phase 2,Biliary tract cancer,[ICD-11: 2C17]
T78874,#N/A,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T78874,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T78874,#N/A,INDICATI,Phase 1/2,Glaucoma,[ICD-11: 9C61]
T78874,#N/A,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T78874,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T78874,#N/A,INDICATI,Phase 2/3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T78874,#N/A,INDICATI,Discontinued in Phase 1,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T78890,TFPI,TARGETID,T78890,,
T78890,TFPI,TARGNAME,Tissue factor pathway inhibitor (TFPI),,
T78890,TFPI,INDICATI,Phase 3,Christmas disease,[ICD-11: 3B11]
T78890,TFPI,INDICATI,Phase 3,Coagulation defect,[ICD-11: 3B10]
T78890,TFPI,INDICATI,Phase 3,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T78892,ITGA4,TARGETID,T78892,,
T78892,ITGA4,TARGNAME,ITGA4 messenger RNA (ITGA4 mRNA),,
T78892,ITGA4,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T78915,TPH1,TARGETID,T78915,,
T78915,TPH1,TARGNAME,Tryptophan 5-hydroxylase 1 (TPH1),,
T78915,TPH1,INDICATI,Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T78915,TPH1,INDICATI,Phase 1,Pulmonary hypertension,[ICD-11: BB01]
,#N/A,,,,
T78932,TYK2,TARGETID,T78932,,
T78932,TYK2,TARGNAME,TYK2 tyrosine kinase (TYK2),,
T78932,TYK2,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T78932,TYK2,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T78932,TYK2,INDICATI,Phase 2,Psoriatic arthritis,[ICD-11: FA21]
,#N/A,,,,
T78937,#N/A,TARGETID,T78937,,
T78937,#N/A,TARGNAME,Ribosome A (hRA),,
T78937,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T78937,#N/A,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T79001,Bact aroC,TARGETID,T79001,,
T79001,Bact aroC,TARGNAME,Bacterial Chorismate synthase (Bact aroC),,
T79001,Bact aroC,INDICATI,Terminated,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T79027,CDA,TARGETID,T79027,,
T79027,CDA,TARGNAME,Cytidine deaminase (CDA),,
T79027,CDA,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T79031,BACE1,TARGETID,T79031,,
T79031,BACE1,TARGNAME,Beta-secretase 1 (BACE1),,
T79031,BACE1,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T79051,EWS-FLI1,TARGETID,T79051,,
T79051,EWS-FLI1,TARGNAME,EWS-FLI1 fusion gene mRNA (EWS-FLI1 mRNA),,
T79051,EWS-FLI1,INDICATI,Phase 1,Ewing sarcoma,[ICD-11: 2B52]
,#N/A,,,,
T79062,HTR7,TARGETID,T79062,,
T79062,HTR7,TARGNAME,5-HT 7 receptor (HTR7),,
T79062,HTR7,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T79062,HTR7,INDICATI,Phase 1,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T79062,HTR7,INDICATI,Phase 1,Bipolar disorder,[ICD-11: 6A60]
T79062,HTR7,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T79062,HTR7,INDICATI,Investigative,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T79062,HTR7,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T79062,HTR7,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T79062,HTR7,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T79062,HTR7,INDICATI,Terminated,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
,#N/A,,,,
T79068,Bact inhA,TARGETID,T79068,,
T79068,Bact inhA,TARGNAME,Bacterial Fatty acid synthetase I (Bact inhA),,
T79068,Bact inhA,INDICATI,Phase 2,Bacterial infection,[ICD-11: 1A00-1C4Z]
T79068,Bact inhA,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T79068,Bact inhA,INDICATI,Terminated,Malaria,[ICD-11: 1F40-1F45]
T79068,Bact inhA,INDICATI,Approved,Mycobacterium infection,[ICD-11: 1B10-1B21]
,#N/A,,,,
T79157,EREG,TARGETID,T79157,,
T79157,EREG,TARGNAME,Epiregulin (EREG),,
T79157,EREG,INDICATI,Phase 1/2,Chronic kidney disease,[ICD-11: GB61]
,#N/A,,,,
T79160,GDNF,TARGETID,T79160,,
T79160,GDNF,TARGNAME,Glial cell line-derived neurotrophic factor (GDNF),,
T79160,GDNF,INDICATI,Phase 1/2,Muscular atrophy,[ICD-11: 8B61]
,#N/A,,,,
T79162,RSPO3,TARGETID,T79162,,
T79162,RSPO3,TARGNAME,R-spondin-3 (RSPO3),,
T79162,RSPO3,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T79162,RSPO3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T79184,Stap-coc agrA,TARGETID,T79184,,
T79184,Stap-coc agrA,TARGNAME,Staphylococcus Accessory gene regulator protein A (Stap-coc agrA),,
T79184,Stap-coc agrA,INDICATI,Preclinical,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T79232,AVPR1A,TARGETID,T79232,,
T79232,AVPR1A,TARGNAME,Vasopressin V1a receptor (V1AR),,
T79232,AVPR1A,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T79232,AVPR1A,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T79232,AVPR1A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T79232,AVPR1A,INDICATI,Approved,Autism spectrum disorder,[ICD-11: 6A02]
T79232,AVPR1A,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T79232,AVPR1A,INDICATI,Phase 3,Childbirth associated breast/lactation disorder,[ICD-11: JB46]
T79232,AVPR1A,INDICATI,Phase 2,Choreiform disorder,[ICD-11: 8A01]
T79232,AVPR1A,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T79232,AVPR1A,INDICATI,Phase 2,Female pelvic pain,[ICD-11: GA34]
T79232,AVPR1A,INDICATI,Preclinical,Heart failure,[ICD-11: BD10-BD1Z]
T79232,AVPR1A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T79232,AVPR1A,INDICATI,Approved,Hypo-osmolality/hyponatraemia,[ICD-11: 5C72]
T79232,AVPR1A,INDICATI,Phase 1/2,Intermittent explosive disorder,[ICD-11: 6C73]
T79232,AVPR1A,INDICATI,Approved,Localisation,[ICD-11: N.A.]
T79232,AVPR1A,INDICATI,Investigative,Male infertility,[ICD-11: GB04]
T79232,AVPR1A,INDICATI,Phase 2,Post-traumatic stress disorder,[ICD-11: 6B40]
T79232,AVPR1A,INDICATI,Phase 2,Sepsis,[ICD-11: 1G40-1G41]
T79232,AVPR1A,INDICATI,Discontinued in Phase 1,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T79249,TYMS,TARGETID,T79249,,
T79249,TYMS,TARGNAME,Thymidylate synthase messenger RNA (TYMS mRNA),,
T79249,TYMS,INDICATI,Investigative,Colorectal cancer,[ICD-11: 2B91]
T79249,TYMS,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T79368,CEBPA,TARGETID,T79368,,
T79368,CEBPA,TARGNAME,CEBPA messenger RNA (CEBPA mRNA),,
T79368,CEBPA,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
,#N/A,,,,
T79401,DENV E,TARGETID,T79401,,
T79401,DENV E,TARGNAME,Dengue virus Envelope (DENV E),,
T79401,DENV E,INDICATI,Preclinical,Dengue fever,[ICD-11: 1D2Z]
,#N/A,,,,
T79422,#N/A,TARGETID,T79422,,
T79422,#N/A,TARGNAME,M1-prime segment of membrane-expressed IgE (M1 IgE),,
T79422,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T79473,LHCGR,TARGETID,T79473,,
T79473,LHCGR,TARGNAME,Luteinizing hormone receptor (LHCGR),,
T79473,LHCGR,INDICATI,Approved,Female infertility,[ICD-11: GA31]
T79473,LHCGR,INDICATI,Terminated,Heart disease,[ICD-11: BA41-BA42]
T79473,LHCGR,INDICATI,Discontinued in Phase 3,Leukaemia,[ICD-11: 2A60-2B33]
T79473,LHCGR,INDICATI,Phase 1,Male infertility,[ICD-11: GB04]
T79473,LHCGR,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T79473,LHCGR,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T79473,LHCGR,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T79534,#N/A,TARGETID,T79534,,
T79534,#N/A,TARGNAME,P450-dependent ergosterol synthesis (PDE synth),,
T79534,#N/A,INDICATI,Discontinued in Phase 2,Fungal infection,[ICD-11: 1F29-1F2F]
,#N/A,,,,
T79591,THRA,TARGETID,T79591,,
T79591,THRA,TARGNAME,Thyroid hormone receptor alpha (THRA),,
T79591,THRA,INDICATI,Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
T79591,THRA,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T79591,THRA,INDICATI,Approved,Hypo-thyroidism,[ICD-11: 5A00]
T79591,THRA,INDICATI,Clinical trial,Skin postprocedural disorder,[ICD-11: EL8Y]
,#N/A,,,,
T79724,Bact folK,TARGETID,T79724,,
T79724,Bact folK,TARGNAME,Bacterial Hydroxymethyl-dihydropterin pyrophosphokinase (Bact folK),,
T79724,Bact folK,INDICATI,Preclinical,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T79747,PORCN,TARGETID,T79747,,
T79747,PORCN,TARGNAME,Protein-serine O-palmitoleoyltransferase porcupine (PORCN),,
T79747,PORCN,INDICATI,Phase 1,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T79747,PORCN,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T79798,MAPK12,TARGETID,T79798,,
T79798,MAPK12,TARGNAME,MAP kinase p38 (MAPK12),,
T79798,MAPK12,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T79798,MAPK12,INDICATI,Phase 2,Cardiomyopathy,[ICD-11: BC43]
T79798,MAPK12,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T79798,MAPK12,INDICATI,Preclinical,Chronic kidney disease,[ICD-11: GB61]
T79798,MAPK12,INDICATI,Discontinued in Phase 2,Indeterminate colitis,[ICD-11: DD72]
T79798,MAPK12,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T79798,MAPK12,INDICATI,Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T79798,MAPK12,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T79798,MAPK12,INDICATI,Discontinued in Phase 2,Psoriasis,[ICD-11: EA90]
T79798,MAPK12,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T79798,MAPK12,INDICATI,Approved (orphan drug),Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T79961,CHRM5,TARGETID,T79961,,
T79961,CHRM5,TARGNAME,Muscarinic acetylcholine receptor M5 (CHRM5),,
T79961,CHRM5,INDICATI,Approved,Abnormal micturition,[ICD-11: MF50]
T79961,CHRM5,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T79961,CHRM5,INDICATI,Approved,Anterior uveitis,[ICD-11: 9A96]
T79961,CHRM5,INDICATI,Approved,Appearance/behaviour symptom,[ICD-11: MB23]
T79961,CHRM5,INDICATI,Approved,Asthma,[ICD-11: CA23]
T79961,CHRM5,INDICATI,Investigative,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T79961,CHRM5,INDICATI,Approved (orphan drug),Brain disease,[ICD-11: 8C70-8E61]
T79961,CHRM5,INDICATI,Approved,Central and peripheral nervous disease,[ICD-11: 8A04-8E7Z]
T79961,CHRM5,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T79961,CHRM5,INDICATI,Approved,Cognition symptoms/signs/clinical sympton,[ICD-11: MB21]
T79961,CHRM5,INDICATI,Approved,Cough,[ICD-11: MD12]
T79961,CHRM5,INDICATI,Withdrawn from market,Depression,[ICD-11: 6A70-6A7Z]
T79961,CHRM5,INDICATI,Approved,Digestive system disease,[ICD-11: DE2Z]
T79961,CHRM5,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T79961,CHRM5,INDICATI,Approved,Female pelvic pain,[ICD-11: GA34]
T79961,CHRM5,INDICATI,Approved,Functional bladder disorder,[ICD-11: GC50]
T79961,CHRM5,INDICATI,Terminated,Gastric ulcer,[ICD-11: DA60]
T79961,CHRM5,INDICATI,Approved,Gastritis,[ICD-11: DA42]
T79961,CHRM5,INDICATI,Approved,General examination,[ICD-11: QA00]
T79961,CHRM5,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T79961,CHRM5,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T79961,CHRM5,INDICATI,Approved,Infectious gastroenteritis/colitis,[ICD-11: 1A40]
T79961,CHRM5,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T79961,CHRM5,INDICATI,Discontinued in Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T79961,CHRM5,INDICATI,Investigative,Myasthenia gravis,[ICD-11: 8C6Y]
T79961,CHRM5,INDICATI,Approved,Nystagmus,[ICD-11: 9C84]
T79961,CHRM5,INDICATI,Approved,Oesophagus motility disorder,[ICD-11: DA21]
T79961,CHRM5,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T79961,CHRM5,INDICATI,Approved,Pancreatitis,[ICD-11: DC31-DC34]
T79961,CHRM5,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T79961,CHRM5,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T79961,CHRM5,INDICATI,Approved,Polyuria,[ICD-11: MF55]
T79961,CHRM5,INDICATI,Discontinued in Phase 1,Schizophrenia,[ICD-11: 6A20]
T79961,CHRM5,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T79961,CHRM5,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
T79961,CHRM5,INDICATI,Approved,Unspecific substance harmful effect,[ICD-11: NE6Z]
T79961,CHRM5,INDICATI,Approved,Urgency,[ICD-11: N.A.]
T79961,CHRM5,INDICATI,Investigative,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T80002,LY75,TARGETID,T80002,,
T80002,LY75,TARGNAME,Lymphocyte antigen 75 (LY75),,
T80002,LY75,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T80011,EIF4EBP2,TARGETID,T80011,,
T80011,EIF4EBP2,TARGNAME,eIF4E-BP2 messenger RNA (eIF4E-BP2 mRNA),,
T80011,EIF4EBP2,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T80011,EIF4EBP2,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T80011,EIF4EBP2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T80020,L1CAM,TARGETID,T80020,,
T80020,L1CAM,TARGNAME,Neural cell adhesion molecule L1 (L1CAM),,
T80020,L1CAM,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T80020,L1CAM,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
,#N/A,,,,
T80024,MSTN,TARGETID,T80024,,
T80024,MSTN,TARGNAME,Myostatin (MSTN),,
T80024,MSTN,INDICATI,Phase 1/2,Idiopathic inflammatory myopathy,[ICD-11: 4A41]
T80024,MSTN,INDICATI,Phase 2,Muscular atrophy,[ICD-11: 8B61]
T80024,MSTN,INDICATI,Phase 1/2,Muscular dystrophy,[ICD-11: 8C70]
T80024,MSTN,INDICATI,Phase 1/2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T80276,PIK3CA,TARGETID,T80276,,
T80276,PIK3CA,TARGNAME,PI3-kinase alpha (PIK3CA),,
T80276,PIK3CA,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T80276,PIK3CA,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T80276,PIK3CA,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
T80276,PIK3CA,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T80276,PIK3CA,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T80276,PIK3CA,INDICATI,Investigative,Rheumatoid arthritis,[ICD-11: FA20]
T80276,PIK3CA,INDICATI,Phase 2/3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T80338,ACVR2B,TARGETID,T80338,,
T80338,ACVR2B,TARGNAME,Activin receptor type IIB (ACVR2B),,
T80338,ACVR2B,INDICATI,Investigative,Nervous system paraneoplastic/autoimmune disorder,[ICD-11: 8E4A]
,#N/A,,,,
T80387,GABRB2,TARGETID,T80387,,
T80387,GABRB2,TARGNAME,GABA(A) receptor beta-2 (GABRB2),,
T80387,GABRB2,INDICATI,Discontinued in Phase 1,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T80387,GABRB2,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T80387,GABRB2,INDICATI,Phase 3,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T80387,GABRB2,INDICATI,Discontinued in Phase 3,Female pelvic pain,[ICD-11: GA34]
T80387,GABRB2,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T80387,GABRB2,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T80387,GABRB2,INDICATI,Approved,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T80387,GABRB2,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T80387,GABRB2,INDICATI,Phase 3,Status epilepticus,[ICD-11: 8A66]
T80387,GABRB2,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
T80387,GABRB2,INDICATI,Phase 2,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T80452,#N/A,TARGETID,T80452,,
T80452,#N/A,TARGNAME,Mucin (MUC),,
T80452,#N/A,INDICATI,Discontinued in Phase 3,Herpes simplex infection,[ICD-11: 1F00]
T80452,#N/A,INDICATI,Phase 2,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T80518,#N/A,TARGETID,T80518,,
T80518,#N/A,TARGNAME,Synaptic transmission (ST),,
T80518,#N/A,INDICATI,Phase 1,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
,#N/A,,,,
T80701,IGFBP1; IGFBP2; IGFBP3,TARGETID,T80701,,
T80701,IGFBP1; IGFBP2; IGFBP3,TARGNAME,Bone resorption factor (BRF),,
T80701,IGFBP1; IGFBP2; IGFBP3,INDICATI,Discontinued in Phase 2,Low bone mass disorder,[ICD-11: FB83]
,#N/A,,,,
T80782,FLT1,TARGETID,T80782,,
T80782,FLT1,TARGNAME,VEGFR1 messenger RNA (VEGFR1 mRNA),,
T80782,FLT1,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T80782,FLT1,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T80782,FLT1,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T80782,FLT1,INDICATI,Phase 1/2,Retinopathy,[ICD-11: 9B71]
T80782,FLT1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T80782,FLT1,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T80886,BACH1,TARGETID,T80886,,
T80886,BACH1,TARGNAME,Transcription regulator protein BACH1 (Bach1),,
T80886,BACH1,INDICATI,Phase 1,Sickle-cell disorder,[ICD-11: 3A51]
,#N/A,,,,
T80896,ESR2,TARGETID,T80896,,
T80896,ESR2,TARGNAME,Estrogen receptor beta (ESR2),,
T80896,ESR2,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T80896,ESR2,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T80896,ESR2,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T80896,ESR2,INDICATI,Phase 3,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T80896,ESR2,INDICATI,Investigative,Herpes simplex infection,[ICD-11: 1F00]
T80896,ESR2,INDICATI,Phase 3,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T80896,ESR2,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T80896,ESR2,INDICATI,Withdrawn from market,Irregularities,[ICD-11: N.A.]
T80896,ESR2,INDICATI,Discontinued in Phase 3,Low bone mass disorder,[ICD-11: FB83]
T80896,ESR2,INDICATI,Approved,Menopausal disorder,[ICD-11: GA30]
T80896,ESR2,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T80896,ESR2,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T80896,ESR2,INDICATI,Phase 2,Prostate hyperplasia,[ICD-11: GA90]
T80896,ESR2,INDICATI,Phase 1,Sepsis,[ICD-11: 1G40-1G41]
T80896,ESR2,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T80896,ESR2,INDICATI,Discontinued in Phase 1,Thrombocytopenia,[ICD-11: 3B64]
T80896,ESR2,INDICATI,Withdrawn from market,Trematode disease,[ICD-11: 1F8Y]
T80896,ESR2,INDICATI,Approved,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T80912,TCIRG1,TARGETID,T80912,,
T80912,TCIRG1,TARGNAME,T-cell immune regulator 1 (TCIRG1),,
T80912,TCIRG1,INDICATI,Phase 1,Skeletal anomaly,ICD-11: LD24
,#N/A,,,,
T80942,#N/A,TARGETID,T80942,,
T80942,#N/A,TARGNAME,Matrix metalloproteinase (MMP),,
T80942,#N/A,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T80942,#N/A,INDICATI,Discontinued in Phase 1,Indeterminate colitis,[ICD-11: DD72]
T80942,#N/A,INDICATI,Discontinued in Phase 1,Osteoarthritis,[ICD-11: FA00-FA05]
T80942,#N/A,INDICATI,Approved,Pediculosis,[ICD-11: 1G00]
T80942,#N/A,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T80942,#N/A,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
T80942,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T80975,KDR,TARGETID,T80975,,
T80975,KDR,TARGNAME,Vascular endothelial growth factor receptor 2 (KDR),,
T80975,KDR,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T80975,KDR,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T80975,KDR,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T80975,KDR,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T80975,KDR,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T80975,KDR,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T80975,KDR,INDICATI,Patented,Circulatory system disease,[ICD-11: BE2Z]
T80975,KDR,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T80975,KDR,INDICATI,Phase 1/2,Digestive organ benign neoplasm,[ICD-11: 2E92]
T80975,KDR,INDICATI,Approved,Gastrointestinal stromal tumour,[ICD-11: 2B5B]
T80975,KDR,INDICATI,Phase 1,Head and neck cancer,[ICD-11: 2D42]
T80975,KDR,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T80975,KDR,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T80975,KDR,INDICATI,Approved,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T80975,KDR,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T80975,KDR,INDICATI,Phase 2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T80975,KDR,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T80975,KDR,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T80975,KDR,INDICATI,Phase 1/2,Non-small-cell lung cancer,[ICD-11: 2C25]
T80975,KDR,INDICATI,Phase 1,Oesophagogastric junction cancer,ICD-11: 2B71
T80975,KDR,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T80975,KDR,INDICATI,Phase 3,Peritoneal cancer,[ICD-11: 2C51]
T80975,KDR,INDICATI,Approved,Renal cell carcinoma,[ICD-11: 2C90]
T80975,KDR,INDICATI,Phase 2,Sarcoma,[ICD-11: 2A60-2C35]
T80975,KDR,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T80975,KDR,INDICATI,Approved,Stomach cancer,[ICD-11: 2B72]
T80975,KDR,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T80975,KDR,INDICATI,Approved,Thyroid cancer,[ICD-11: 2D10]
,#N/A,,,,
T81100,SLC5A2,TARGETID,T81100,,
T81100,SLC5A2,TARGNAME,SLC5A2 messenger RNA (SLC5A2 mRNA),,
T81100,SLC5A2,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T81103,CASP2,TARGETID,T81103,,
T81103,CASP2,TARGNAME,Caspase 2 messenger RNA (CASP2 mRNA),,
T81103,CASP2,INDICATI,Phase 2/3,Glaucoma,[ICD-11: 9C61]
T81103,CASP2,INDICATI,Phase 3,Optic nerve disorder,[ICD-11: 9C40]
,#N/A,,,,
T81183,#N/A,TARGETID,T81183,,
T81183,#N/A,TARGNAME,Adrenergic receptor Alpha-1 (ADRA1),,
T81183,#N/A,INDICATI,Discontinued in Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T81183,#N/A,INDICATI,Approved,Headache,[ICD-11: 8A80-8A84]
T81183,#N/A,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T81183,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T81183,#N/A,INDICATI,Withdrawn from market,Obesity,[ICD-11: 5B80-5B81]
T81183,#N/A,INDICATI,Approved,Orthostatic hypotension,[ICD-11: BA21]
T81183,#N/A,INDICATI,Phase 1/2,Postoperative inflammation,[ICD-11: 1A00-CA43]
T81183,#N/A,INDICATI,Approved,Prostate hyperplasia,[ICD-11: GA90]
,#N/A,,,,
T81281,DSG3,TARGETID,T81281,,
T81281,DSG3,TARGNAME,Desmoglein-3 (DSG3),,
T81281,DSG3,INDICATI,Phase 1,Pemphigus,[ICD-11: EB40]
,#N/A,,,,
T81311,HSP90B1,TARGETID,T81311,,
T81311,HSP90B1,TARGNAME,Endoplasmin (HSP90B1),,
T81311,HSP90B1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T81358,CDC7,TARGETID,T81358,,
T81358,CDC7,TARGNAME,CDC7-related kinase (CDC7),,
T81358,CDC7,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T81358,CDC7,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T81386,CDK9-CCNT1,TARGETID,T81386,,
T81386,CDK9-CCNT1,TARGNAME,Positive transcription elongation factor b (P-TEFb),,
T81386,CDK9-CCNT1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T81386,CDK9-CCNT1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T81443,TLR4,TARGETID,T81443,,
T81443,TLR4,TARGNAME,Toll-like receptor 4 (TLR4),,
T81443,TLR4,INDICATI,Preregistration,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T81443,TLR4,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T81443,TLR4,INDICATI,Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T81443,TLR4,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T81443,TLR4,INDICATI,Investigative,Melanoma,[ICD-11: 2C30]
T81443,TLR4,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T81443,TLR4,INDICATI,Phase 3,Sepsis,[ICD-11: 1G40-1G41]
T81443,TLR4,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T81503,Bact gyrB,TARGETID,T81503,,
T81503,Bact gyrB,TARGNAME,Bacterial DNA gyrase B (Bact gyrB),,
T81503,Bact gyrB,INDICATI,Phase 1/2,Mycobacterium infection,[ICD-11: 1B10-1B21]
,#N/A,,,,
T81548,MycB groL2,TARGETID,T81548,,
T81548,MycB groL2,TARGNAME,Mycobacterium Heat shock protein 65 (MycB groL2),,
T81548,MycB groL2,INDICATI,Discontinued in Phase 3,Cervical intraepithelial neoplasia,[ICD-11: 2E66]
,#N/A,,,,
T81569,IKZF2,TARGETID,T81569,,
T81569,IKZF2,TARGNAME,Zinc finger protein Helios (IKZF2),,
T81569,IKZF2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T81694,HRV P1D,TARGETID,T81694,,
T81694,HRV P1D,TARGNAME,Rhinovirus Protein 1 (HRV P1D),,
T81694,HRV P1D,INDICATI,Discontinued in Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T81695,CD200,TARGETID,T81695,,
T81695,CD200,TARGNAME,Membrane glycoprotein OX2 (CD200),,
T81695,CD200,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T81695,CD200,INDICATI,Phase 1/2,Mature B-cell leukaemia,[ICD-11: 2A82]
T81695,CD200,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T81735,PRKDC,TARGETID,T81735,,
T81735,PRKDC,TARGNAME,DNA-dependent protein kinase catalytic (PRKDC),,
T81735,PRKDC,INDICATI,Investigative,Prostate cancer,[ICD-11: 2C82]
T81735,PRKDC,INDICATI,Phase 1/2,Rectum cancer,[ICD-11: 2B92]
T81735,PRKDC,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T81774,#N/A,TARGETID,T81774,,
T81774,#N/A,TARGNAME,Tubulin polymerization (TubP),,
T81774,#N/A,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T81774,#N/A,INDICATI,Approved,Epidermal dysplasias,[ICD-11: EK90]
T81774,#N/A,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T81780,UBA1,TARGETID,T81780,,
T81780,UBA1,TARGNAME,Ubiquitin-activating enzyme E1 (UBAE1),,
T81780,UBA1,INDICATI,Investigative,Leukaemia,[ICD-11: 2A60-2B33]
,#N/A,,,,
T81830,SIK3,TARGETID,T81830,,
T81830,SIK3,TARGNAME,SIK family kinase 3 (SIK3),,
T81830,SIK3,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T81850,FDFT1,TARGETID,T81850,,
T81850,FDFT1,TARGNAME,Squalene synthetase (FDFT1),,
T81850,FDFT1,INDICATI,Discontinued in Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T81850,FDFT1,INDICATI,Discontinued in Phase 3,Hyper-lipoproteinaemia,[ICD-11: 5C80]
,#N/A,,,,
T81892,XIAP,TARGETID,T81892,,
T81892,XIAP,TARGNAME,XIAP messenger RNA (XIAP mRNA),,
T81892,XIAP,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T81892,XIAP,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T81900,IDE,TARGETID,T81900,,
T81900,IDE,TARGNAME,Insulin-degrading enzyme (IDE),,
T81900,IDE,INDICATI,Phase 2,Inherited retinal dystrophy,[ICD-11: 9B70]
T81900,IDE,INDICATI,Approved,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
,#N/A,,,,
T81905,#N/A,TARGETID,T81905,,
T81905,#N/A,TARGNAME,Histamine receptor (HR),,
T81905,#N/A,INDICATI,Terminated,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T81905,#N/A,INDICATI,Approved,Asthma,[ICD-11: CA23]
T81905,#N/A,INDICATI,Discontinued in Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T81905,#N/A,INDICATI,Terminated,Carcinoid syndrome,[ICD-11: 5B10]
T81905,#N/A,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T81905,#N/A,INDICATI,Approved,Diagnostic imaging,[ICD-11: N.A.]
T81905,#N/A,INDICATI,Phase 3,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T81916,KLF4,TARGETID,T81916,,
T81916,KLF4,TARGNAME,Kruppel like factor 4 (KLF4),,
T81916,KLF4,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T82028,SLC9A1,TARGETID,T82028,,
T82028,SLC9A1,TARGNAME,Sodium/hydrogen exchanger 1 (SLC9A1),,
T82028,SLC9A1,INDICATI,Phase 3,Angina pectoris,[ICD-11: BA40]
T82028,SLC9A1,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T82028,SLC9A1,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T82028,SLC9A1,INDICATI,Investigative,Myocardial infarction,[ICD-11: BA41-BA43]
,#N/A,,,,
T82051,TP53,TARGETID,T82051,,
T82051,TP53,TARGNAME,P53 messenger RNA (TP53 mRNA),,
T82051,TP53,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T82051,TP53,INDICATI,Investigative,Hearing disorder,[ICD-11: AB50-AB57]
T82051,TP53,INDICATI,Phase 2,Kidney failure,[ICD-11: GB60-GB6Z]
,#N/A,,,,
T82075,Bact ftsZ,TARGETID,T82075,,
T82075,Bact ftsZ,TARGNAME,Bacterial Celldivision protein FtsZ (Bact ftsZ),,
T82075,Bact ftsZ,INDICATI,Phase 1,Infectious meningitis,[ICD-11: 1D01]
,#N/A,,,,
T82078,TLR2,TARGETID,T82078,,
T82078,TLR2,TARGNAME,Toll-like receptor 2 (TLR2),,
T82078,TLR2,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T82078,TLR2,INDICATI,Discontinued in Phase 1,Melanoma,[ICD-11: 2C30]
T82078,TLR2,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T82078,TLR2,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
T82078,TLR2,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T82078,TLR2,INDICATI,Investigative,Radiation effect,[ICD-11: NF00]
T82078,TLR2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T82083,P2RY4,TARGETID,T82083,,
T82083,P2RY4,TARGNAME,P2Y purinoceptor 4 (P2RY4),,
T82083,P2RY4,INDICATI,Discontinued in Phase 3,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T82105,CEACAM1,TARGETID,T82105,,
T82105,CEACAM1,TARGNAME,Biliary glycoprotein 1 (CEACAM1),,
T82105,CEACAM1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T82146,RARG,TARGETID,T82146,,
T82146,RARG,TARGNAME,Retinoic acid receptor gamma (RARG),,
T82146,RARG,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T82146,RARG,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T82146,RARG,INDICATI,Phase 2,Emphysema,[ICD-11: CA21]
T82146,RARG,INDICATI,Approved,Kaposi sarcoma,[ICD-11: 2B57]
T82146,RARG,INDICATI,Approved,Muscle calcification/ossification,[ICD-11: FB31]
T82146,RARG,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T82240,FCGR3A; FCGR3B,TARGETID,T82240,,
T82240,FCGR3A; FCGR3B,TARGNAME,Immunoglobulin gamma Fc receptor III (FCGR3),,
T82240,FCGR3A; FCGR3B,INDICATI,Phase 1/2,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T82240,FCGR3A; FCGR3B,INDICATI,Phase 1/2,Mastocytosis,[ICD-11: 2A21]
T82240,FCGR3A; FCGR3B,INDICATI,Phase 1/2,Myelodysplastic syndrome,[ICD-11: 2A37]
T82240,FCGR3A; FCGR3B,INDICATI,Approved (orphan drug),Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T82266,#N/A,TARGETID,T82266,,
T82266,#N/A,TARGNAME,Voltage-gated L-type calcium channel (L-CaC),,
T82266,#N/A,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T82266,#N/A,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T82266,#N/A,INDICATI,Phase 2a,Bipolar disorder,[ICD-11: 6A60]
T82266,#N/A,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T82266,#N/A,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T82266,#N/A,INDICATI,Phase 3,Essential hypertension,[ICD-11: BA00]
T82266,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T82266,#N/A,INDICATI,Phase 3,Irritable bowel syndrome,[ICD-11: DD91]
T82266,#N/A,INDICATI,Approved,Neuropathy,[ICD-11: 8C0Z]
T82266,#N/A,INDICATI,Approved,Oesophagus motility disorder,[ICD-11: DA21]
T82266,#N/A,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T82266,#N/A,INDICATI,Discontinued in Phase 3,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T82277,CTAG1A,TARGETID,T82277,,
T82277,CTAG1A,TARGNAME,Cancer/testis antigen 1 (NY-ESO-1),,
T82277,CTAG1A,INDICATI,Phase 1/2,Esophageal cancer,[ICD-11: 2B70]
T82277,CTAG1A,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T82277,CTAG1A,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T82277,CTAG1A,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T82277,CTAG1A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T82277,CTAG1A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T82277,CTAG1A,INDICATI,Phase 1/2,Synovial sarcoma,[ICD-11: 2B5A]
,#N/A,,,,
T82309,KCNK18,TARGETID,T82309,,
T82309,KCNK18,TARGNAME,TWIK-related spinal cord potassium channel (TRESK),,
T82309,KCNK18,INDICATI,Investigative,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
,#N/A,,,,
T82349,#N/A,TARGETID,T82349,,
T82349,#N/A,TARGNAME,Bacterial Cell membrane (Bact CM),,
T82349,#N/A,INDICATI,Approved,Antimicrobial drug resistance,[ICD-11: MG50-MG52]
T82349,#N/A,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T82349,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T82349,#N/A,INDICATI,Phase 3,Burn and burn infection,[ICD-11: ND90-NE2Z]
T82349,#N/A,INDICATI,Approved,Clostridium difficile enterocolitis,[ICD-11: 1A04]
T82349,#N/A,INDICATI,Terminated,Fungal infection,[ICD-11: 1F29-1F2F]
T82349,#N/A,INDICATI,Phase 3,Mycobacterium infection,[ICD-11: 1B10-1B21]
T82349,#N/A,INDICATI,Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T82383,AXL,TARGETID,T82383,,
T82383,AXL,TARGNAME,Tyrosine-protein kinase UFO (AXL),,
T82383,AXL,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T82383,AXL,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T82383,AXL,INDICATI,Phase 2,Kaposi sarcoma,[ICD-11: 2B57]
T82383,AXL,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T82383,AXL,INDICATI,Phase 1/2,Mature B-cell leukaemia,[ICD-11: 2A82]
T82383,AXL,INDICATI,Investigative,Metastatic malignant neoplasm,[ICD-11: 2D50-2E09]
T82383,AXL,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T82383,AXL,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T82383,AXL,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T82383,AXL,INDICATI,Preclinical,Peritoneal cancer,[ICD-11: 2C51]
T82383,AXL,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T82391,NDUFA13,TARGETID,T82391,,
T82391,NDUFA13,TARGNAME,Mitochondrial complex I (NDUFA13),,
T82391,NDUFA13,INDICATI,Phase 3,Cardiomyopathy,[ICD-11: BC43]
,#N/A,,,,
T82393,ADAM17,TARGETID,T82393,,
T82393,ADAM17,TARGNAME,TNF alpha converting enzyme (ADAM17),,
T82393,ADAM17,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T82393,ADAM17,INDICATI,Preclinical,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T82393,ADAM17,INDICATI,Terminated,Indeterminate colitis,[ICD-11: DD72]
T82393,ADAM17,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T82463,#N/A,TARGETID,T82463,,
T82463,#N/A,TARGNAME,Cocaine (Coca),,
T82463,#N/A,INDICATI,Phase 2,Cocaine use disorder,[ICD-11: 6C45]
,#N/A,,,,
T82494,#N/A,TARGETID,T82494,,
T82494,#N/A,TARGNAME,T-cell receptor (TCR),,
T82494,#N/A,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T82494,#N/A,INDICATI,Phase 1/2,Bladder cancer,[ICD-11: 2C94]
T82494,#N/A,INDICATI,Phase 2,Graft-versus-host disease,[ICD-11: 4B24]
T82494,#N/A,INDICATI,Phase 1/2,Head and neck cancer,[ICD-11: 2D42]
T82494,#N/A,INDICATI,Phase 1/2,Liposarcoma,[ICD-11: 2B59]
T82494,#N/A,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T82494,#N/A,INDICATI,Phase 1/2,Melanoma,[ICD-11: 2C30]
T82494,#N/A,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T82494,#N/A,INDICATI,Phase 1/2,Multiple sclerosis,[ICD-11: 8A40]
T82494,#N/A,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T82494,#N/A,INDICATI,Phase 1/2,Neuroendocrine carcinoma,[ICD-11: 2C34]
T82494,#N/A,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T82494,#N/A,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T82494,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T82494,#N/A,INDICATI,Phase 1/2,Synovial sarcoma,[ICD-11: 2B5A]
,#N/A,,,,
T82514,#N/A,TARGETID,T82514,,
T82514,#N/A,TARGNAME,Neurokinin receptor (NKR),,
T82514,#N/A,INDICATI,Terminated,General pain disorder,[ICD-11: 8E43]
,#N/A,,,,
T82543,CHRNB2,TARGETID,T82543,,
T82543,CHRNB2,TARGNAME,Neuronal acetylcholine receptor beta-2 (CHRNB2),,
T82543,CHRNB2,INDICATI,Discontinued in Phase 2,Alzheimer disease,[ICD-11: 8A20]
T82543,CHRNB2,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T82543,CHRNB2,INDICATI,Phase 2,Hyperhidrosis,[ICD-11: EE00]
T82543,CHRNB2,INDICATI,Phase 3,Nicotine use disorder,[ICD-11: 6C4A]
T82543,CHRNB2,INDICATI,Discontinued in Phase 2,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T82577,SLC33A1,TARGETID,T82577,,
T82577,SLC33A1,TARGNAME,Angiotensin-converting enzyme (ACE),,
T82577,SLC33A1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T82577,SLC33A1,INDICATI,Approved,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T82577,SLC33A1,INDICATI,Discontinued in Phase 2/3,Chronic kidney disease,[ICD-11: GB61]
T82577,SLC33A1,INDICATI,Discontinued in Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T82577,SLC33A1,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T82577,SLC33A1,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T82577,SLC33A1,INDICATI,Phase 1,Hypotension,[ICD-11: BA20-BA21]
T82577,SLC33A1,INDICATI,Discontinued in Phase 2/3,Kidney failure,[ICD-11: GB60-GB6Z]
T82577,SLC33A1,INDICATI,Phase 2/3,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T82624,ITPR1; ITPR2; ITPR3,TARGETID,T82624,,
T82624,ITPR1; ITPR2; ITPR3,TARGNAME,"Inositol 1,4,5-trisphosphate receptor (ITPR)",,
T82624,ITPR1; ITPR2; ITPR3,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T82665,PRMT5,TARGETID,T82665,,
T82665,PRMT5,TARGNAME,Protein arginine methyltransferase 5 (PRMT5),,
T82665,PRMT5,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T82665,PRMT5,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T82665,PRMT5,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T82665,PRMT5,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T82665,PRMT5,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T82668,AADAT,TARGETID,T82668,,
T82668,AADAT,TARGNAME,Kynurenine oxoglutarate transaminase II (AADAT),,
T82668,AADAT,INDICATI,Preclinical,Mild neurocognitive disorder,[ICD-11: 6D71]
T82668,AADAT,INDICATI,Preclinical,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T82723,Bact fabF,TARGETID,T82723,,
T82723,Bact fabF,TARGNAME,Bacterial Oxoacyl-[acyl-carrier-protein] synthase II (Bact fabF),,
T82723,Bact fabF,INDICATI,Investigative,Bacterial infection,[ICD-11: 1A00-1C4Z]
T82723,Bact fabF,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T82723,Bact fabF,INDICATI,Investigative,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T82739,KLKB1,TARGETID,T82739,,
T82739,KLKB1,TARGNAME,Plasma kallikrein (KLKB1),,
T82739,KLKB1,INDICATI,Approved,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T82739,KLKB1,INDICATI,Approved,Retinal vascular occlusion,[ICD-11: 9B74]
T82739,KLKB1,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T82795,CTNNB1,TARGETID,T82795,,
T82795,CTNNB1,TARGNAME,Beta-catenin (CTNNB1),,
T82795,CTNNB1,INDICATI,Phase 1/2,Colon cancer,[ICD-11: 2B90]
T82795,CTNNB1,INDICATI,Phase 1,Desmoid tumour,[ICD-11: 2F7C]
T82795,CTNNB1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T82795,CTNNB1,INDICATI,Phase 1/2,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T82841,INS,TARGETID,T82841,,
T82841,INS,TARGNAME,Insulin (INS),,
T82841,INS,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T82841,INS,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
T82841,INS,INDICATI,Approved,Kidney malfunction,[ICD-11: MG02]
T82841,INS,INDICATI,Phase 3,Malaria,[ICD-11: 1F40-1F45]
T82841,INS,INDICATI,Phase 1,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T82841,INS,INDICATI,Phase 3,Type 2 diabetes mellitus,[ICD-11: 5A11]
T82841,INS,INDICATI,Approved,Type-1/2 diabete,[ICD-11: 5A10-5A11]
,#N/A,,,,
T82913,Malaria MEF-1,TARGETID,T82913,,
T82913,Malaria MEF-1,TARGNAME,Plasmodium Elongation factor 1-alpha 1 (Malaria MEF-1),,
T82913,Malaria MEF-1,INDICATI,Phase 1,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T82943,#N/A,TARGETID,T82943,,
T82943,#N/A,TARGNAME,microRNA hsa-miR-17 (MIR17),,
T82943,#N/A,INDICATI,Phase 1,Autosomal dominant polycystic kidney disease,[ICD-11: GB81]
,#N/A,,,,
T82958,CMV gB,TARGETID,T82958,,
T82958,CMV gB,TARGNAME,Cytomegalovirus Glycoprotein B (CMV gB),,
T82958,CMV gB,INDICATI,Phase 1,Cytomegaloviral disease,[ICD-11: 1D82]
,#N/A,,,,
T83011,MAOB,TARGETID,T83011,,
T83011,MAOB,TARGNAME,Monoamine oxidase type B (MAO-B),,
T83011,MAOB,INDICATI,Phase 1/2,Acquired hypomelanotic disorder,[ICD-11: ED63]
T83011,MAOB,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T83011,MAOB,INDICATI,Preclinical,Bacterial infection,[ICD-11: 1A00-1C4Z]
T83011,MAOB,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T83011,MAOB,INDICATI,Approved,Dementia,[ICD-11: 6D80-6D8Z]
T83011,MAOB,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T83011,MAOB,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T83011,MAOB,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T83011,MAOB,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T83011,MAOB,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T83011,MAOB,INDICATI,Discontinued in Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T83011,MAOB,INDICATI,Discontinued in Phase 1,Multiple myeloma,[ICD-11: 2A83]
T83011,MAOB,INDICATI,Patented,Muscular dystrophy,[ICD-11: 8C70]
T83011,MAOB,INDICATI,Discontinued in Phase 3,Nausea/vomiting,[ICD-11: MD90]
T83011,MAOB,INDICATI,Investigative,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T83011,MAOB,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T83011,MAOB,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T83011,MAOB,INDICATI,Investigative,Primary psychotic disorder manifestation,[ICD-11: 6A25]
T83011,MAOB,INDICATI,Patented,Prostate cancer,[ICD-11: 2C82]
T83011,MAOB,INDICATI,Patented,Skin cancer,[ICD-11: 2C30-2C37]
T83011,MAOB,INDICATI,Patented,Skin tag/polyp,[ICD-11: EK71]
,#N/A,,,,
T83051,#N/A,TARGETID,T83051,,
T83051,#N/A,TARGNAME,Bacterial Ribosome (Bact RIBS),,
T83051,#N/A,INDICATI,Preclinical,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T83051,#N/A,INDICATI,Approved,Infectious gastroenteritis/colitis,[ICD-11: 1A40]
T83051,#N/A,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
,#N/A,,,,
T83059,#N/A,TARGETID,T83059,,
T83059,#N/A,TARGNAME,Tankyrase (TNKS),,
T83059,#N/A,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T83059,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T83059,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T83059,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T83103,#N/A,TARGETID,T83103,,
T83103,#N/A,TARGNAME,Interleukin (IL),,
T83103,#N/A,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T83103,#N/A,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
,#N/A,,,,
T83145,NFKB1; NFKB2; RELA; RELB; REL,TARGETID,T83145,,
T83145,NFKB1; NFKB2; RELA; RELB; REL,TARGNAME,Nuclear factor NF-kappa-B (NFKB),,
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 2,Acute/subacute hepatic failure,[ICD-11: DB91]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 2,Choreiform disorder,[ICD-11: 8A01]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Patented,Circulatory system disease,[ICD-11: BE2Z]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Terminated,Cystic fibrosis,[ICD-11: CA25]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Discontinued in Phase 1,Female genital system disease,[ICD-11: GA6Z]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 2,Fungal infection,[ICD-11: 1F29-1F2F]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Patented,Immune system disease,[ICD-11: 4A01-4B41]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 3,Lupus erythematosus,[ICD-11: 4A40]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Patented,Mineral absorption/transport disorder,[ICD-11: 5C64]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Discontinued in Phase 1,Multiple myeloma,[ICD-11: 2A83]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Patented,Muscle disorder,[ICD-11: FB32-FB3Z]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 3,Muscular dystrophy,[ICD-11: 8C70]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Patented,Nervous system disease,[ICD-11: 8A00-8E7Z]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Patented,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 1/2,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Patented,Skin disease,[ICD-11: EA00-EM0Z]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T83145,NFKB1; NFKB2; RELA; RELB; REL,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T83174,PRKCI,TARGETID,T83174,,
T83174,PRKCI,TARGNAME,Protein kinase C iota (PRKCI),,
T83174,PRKCI,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T83192,CNTF,TARGETID,T83192,,
T83192,CNTF,TARGNAME,Ciliary neurotrophic factor (CNTF),,
T83192,CNTF,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T83193,TRPV1,TARGETID,T83193,,
T83193,TRPV1,TARGNAME,Transient receptor potential cation channel V1 (TRPV1),,
T83193,TRPV1,INDICATI,Discontinued in Phase 2,Acute/chronic pain,[ICD-11: MG30-MG31]
T83193,TRPV1,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T83193,TRPV1,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T83193,TRPV1,INDICATI,Phase 1,Chronic pain,[ICD-11: MG30]
T83193,TRPV1,INDICATI,Investigative,Cough,[ICD-11: MD12]
T83193,TRPV1,INDICATI,Discontinued in Phase 2,Esophagus sensitivity,[ICD-11: DA2Y-DA2Z]
T83193,TRPV1,INDICATI,Phase 2,Functional bladder disorder,[ICD-11: GC50]
T83193,TRPV1,INDICATI,Discontinued in Phase 2,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T83193,TRPV1,INDICATI,Approved,General pain disorder,[ICD-11: 8E43]
T83193,TRPV1,INDICATI,Phase 1,Intellectual development disorder,[ICD-11: LD90]
T83193,TRPV1,INDICATI,Phase 3,Knee osteoarthritis,[ICD-11: FA01]
T83193,TRPV1,INDICATI,Phase 2,Lower limb mononeuropathy,[ICD-11: 8C11]
T83193,TRPV1,INDICATI,Discontinued in Phase 1,Migraine,[ICD-11: 8A80]
T83193,TRPV1,INDICATI,Discontinued in Phase 2,Neuropathy,[ICD-11: 8C0Z]
T83193,TRPV1,INDICATI,Phase 1,Osteoarthritis,[ICD-11: FA00-FA05]
T83193,TRPV1,INDICATI,Phase 3,Pain,[ICD-11: MG30-MG3Z]
T83193,TRPV1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T83193,TRPV1,INDICATI,Discontinued in Phase 2,Zoster,[ICD-11: 1E91]
,#N/A,,,,
T83198,KEAP1,TARGETID,T83198,,
T83198,KEAP1,TARGNAME,Cysteines of Keap1 (KEAP1 Cysteines),,
T83198,KEAP1,INDICATI,Preclinical,Multiple sclerosis,[ICD-11: 8A40]
T83198,KEAP1,INDICATI,Preclinical,Psoriasis,[ICD-11: EA90]
T83198,KEAP1,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
T83198,KEAP1,INDICATI,Phase 2,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T83202,RPS6KA1,TARGETID,T83202,,
T83202,RPS6KA1,TARGNAME,Ribosomal protein S6 kinase alpha-1 (RSK1),,
T83202,RPS6KA1,INDICATI,Preclinical,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T83335,#N/A,TARGETID,T83335,,
T83335,#N/A,TARGNAME,Human immunodeficiency virus Transmission (HIV Tran),,
T83335,#N/A,INDICATI,Phase 3,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T83369,F9,TARGETID,T83369,,
T83369,F9,TARGNAME,Coagulation factor IX (F9),,
T83369,F9,INDICATI,Approved,Bleeding disorder,[ICD-11: GA20-GA21]
T83369,F9,INDICATI,Phase 3,Christmas disease,[ICD-11: 3B11]
T83369,F9,INDICATI,Discontinued in Phase 3,Circulatory system disease,[ICD-11: BE2Z]
T83369,F9,INDICATI,Approved,Coagulation defect,[ICD-11: 3B10]
T83369,F9,INDICATI,Discontinued in Phase 3,Coronary atherosclerosis,[ICD-11: BA80]
T83369,F9,INDICATI,Phase 2,Pregnancy/childbirth/puerperium maternal infection,[ICD-11: JB63]
T83369,F9,INDICATI,Discontinued in Phase 1,Sepsis,[ICD-11: 1G40-1G41]
T83369,F9,INDICATI,Discontinued in Phase 3,Thrombosis,[ICD-11: DB61-GB90]
T83369,F9,INDICATI,Terminated,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T83376,TUSC2,TARGETID,T83376,,
T83376,TUSC2,TARGNAME,Tumor suppressor candidate 2 (TUSC2),,
T83376,TUSC2,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T83386,FOLR1,TARGETID,T83386,,
T83386,FOLR1,TARGNAME,Folate receptor alpha (FOLR1),,
T83386,FOLR1,INDICATI,Phase 1,Endometrial cancer,[ICD-11: 2C76]
T83386,FOLR1,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T83386,FOLR1,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T83386,FOLR1,INDICATI,Approved,Ovarian cancer,[ICD-11: 2C73]
T83386,FOLR1,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T83386,FOLR1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T83391,FBP1; FBP2,TARGETID,T83391,,
T83391,FBP1; FBP2,TARGNAME,"Fructose-1,6-bisphosphatase (FBP)",,
T83391,FBP1; FBP2,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T83561,DDIT4,TARGETID,T83561,,
T83561,DDIT4,TARGNAME,HIF-1 responsive protein RTP801 (DDIT4),,
T83561,DDIT4,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T83585,WAS,TARGETID,T83585,,
T83585,WAS,TARGNAME,Wiskott-Aldrich syndrome protein (WAS),,
T83585,WAS,INDICATI,Phase 3,Qualitative platelet defect,[ICD-11: 3B62]
,#N/A,,,,
T83611,HLA-DRB1,TARGETID,T83611,,
T83611,HLA-DRB1,TARGNAME,MHC class II antigen DRB1*1 (HLA-DRB1),,
T83611,HLA-DRB1,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T83687,TNFRSF13C,TARGETID,T83687,,
T83687,TNFRSF13C,TARGNAME,B-cell-activating factor receptor (TNFRSF13C),,
T83687,TNFRSF13C,INDICATI,Phase 2,Pemphigus,[ICD-11: EB40]
T83687,TNFRSF13C,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T83687,TNFRSF13C,INDICATI,Phase 2,Sjogren syndrome,[ICD-11: 4A43]
,#N/A,,,,
T83717,#N/A,TARGETID,T83717,,
T83717,#N/A,TARGNAME,Neuronal acetylcholine receptor alpha (NACHRA),,
T83717,#N/A,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T83793,HIV nef,TARGETID,T83793,,
T83793,HIV nef,TARGNAME,Human immunodeficiency virus Negative factor (HIV nef),,
T83793,HIV nef,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T83797,HGF,TARGETID,T83797,,
T83797,HGF,TARGNAME,Hepatocyte growth factor (HGF),,
T83797,HGF,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T83797,HGF,INDICATI,Phase 3,Angina pectoris,[ICD-11: BA40]
T83797,HGF,INDICATI,Discontinued in Phase 2,Brain cancer,[ICD-11: 2A00]
T83797,HGF,INDICATI,Phase 3,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T83797,HGF,INDICATI,Phase 3,Diabetic foot ulcer,[ICD-11: BD54]
T83797,HGF,INDICATI,Phase 3,Graft-versus-host disease,[ICD-11: 4B24]
T83797,HGF,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T83797,HGF,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T83797,HGF,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T83797,HGF,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T83797,HGF,INDICATI,Phase 3,Neuropathy,[ICD-11: 8C0Z]
T83797,HGF,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T83797,HGF,INDICATI,Phase 2,Peripheral Ischemic Ulcers,ICD-11: BD41
T83797,HGF,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T83797,HGF,INDICATI,Phase 2,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
,#N/A,,,,
T83813,HTR2C,TARGETID,T83813,,
T83813,HTR2C,TARGNAME,5-HT 2C receptor (HTR2C),,
T83813,HTR2C,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T83813,HTR2C,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T83813,HTR2C,INDICATI,Phase 1,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T83813,HTR2C,INDICATI,Phase 3,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T83813,HTR2C,INDICATI,Phase 3,Chronic insomnia,[ICD-11: 7A00]
T83813,HTR2C,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T83813,HTR2C,INDICATI,Terminated,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T83813,HTR2C,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T83813,HTR2C,INDICATI,Approved,Migraine,[ICD-11: 8A80]
T83813,HTR2C,INDICATI,Discontinued in Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T83813,HTR2C,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T83813,HTR2C,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T83813,HTR2C,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T83813,HTR2C,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T83813,HTR2C,INDICATI,Phase 1,Psychoactive substances use disorder,[ICD-11: 6C4G]
T83813,HTR2C,INDICATI,Phase 2,Psychotic disorder,[ICD-11: 6A20-6A25]
T83813,HTR2C,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
T83813,HTR2C,INDICATI,Phase 3,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
T83813,HTR2C,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T83813,HTR2C,INDICATI,Phase 2,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T83875,MAOA,TARGETID,T83875,,
T83875,MAOA,TARGNAME,Monoamine oxidase type A (MAO-A),,
T83875,MAOA,INDICATI,Phase 1/2,Acquired hypomelanotic disorder,[ICD-11: ED63]
T83875,MAOA,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T83875,MAOA,INDICATI,Discontinued in Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T83875,MAOA,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T83875,MAOA,INDICATI,Discontinued in Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T83875,MAOA,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T83875,MAOA,INDICATI,Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T83875,MAOA,INDICATI,Discontinued in Phase 1,Multiple myeloma,[ICD-11: 2A83]
T83875,MAOA,INDICATI,Approved,Parkinsonism,[ICD-11: 8A00]
T83875,MAOA,INDICATI,Patented,Prostate cancer,[ICD-11: 2C82]
T83875,MAOA,INDICATI,Patented,Skin tag/polyp,[ICD-11: EK71]
T83875,MAOA,INDICATI,Phase 1,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T83904,SIRT2,TARGETID,T83904,,
T83904,SIRT2,TARGNAME,NAD-dependent deacetylase sirtuin-2 (SIRT2),,
T83904,SIRT2,INDICATI,Investigative,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T83905,CDH3,TARGETID,T83905,,
T83905,CDH3,TARGNAME,Placental cadherin (CDH3),,
T83905,CDH3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T83982,USP8,TARGETID,T83982,,
T83982,USP8,TARGNAME,Ubiquitin isopeptidase Y (USP8),,
T83982,USP8,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T84040,TRPA1,TARGETID,T84040,,
T84040,TRPA1,TARGNAME,Transformation-sensitive protein p120 (TRPA1),,
T84040,TRPA1,INDICATI,Phase 2,Chronic pain,ICD-11: MG30
T84040,TRPA1,INDICATI,Phase 1,Neuropathy,[ICD-11: 8C0Z]
T84040,TRPA1,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T84040,TRPA1,INDICATI,Approved,Upper respiratory tract disorder,[ICD-11: CA0Z]
,#N/A,,,,
T84117,HTR1E,TARGETID,T84117,,
T84117,HTR1E,TARGNAME,5-HT 1E receptor (HTR1E),,
T84117,HTR1E,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T84133,PDE10A,TARGETID,T84133,,
T84133,PDE10A,TARGNAME,Phosphodiesterase 10A (PDE10),,
T84133,PDE10A,INDICATI,Phase 2,Choreiform disorder,[ICD-11: 8A01]
T84133,PDE10A,INDICATI,Phase 2,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
T84133,PDE10A,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T84133,PDE10A,INDICATI,Phase 2,Schizophrenia,[ICD-11: 6A20]
T84133,PDE10A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T84160,#N/A,TARGETID,T84160,,
T84160,#N/A,TARGNAME,5-HT 3 receptor (5HT3R),,
T84160,#N/A,INDICATI,Phase 3,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T84160,#N/A,INDICATI,Investigative,Dementia,[ICD-11: 6D80-6D8Z]
T84160,#N/A,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T84160,#N/A,INDICATI,Phase 1,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T84160,#N/A,INDICATI,Phase 4,Irritable bowel syndrome,[ICD-11: DD91]
T84160,#N/A,INDICATI,Phase 1,Mild neurocognitive disorder,[ICD-11: 6D71]
T84160,#N/A,INDICATI,Phase 3,Mood disorder,[ICD-11: 6A60-6E23]
T84160,#N/A,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T84160,#N/A,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
T84160,#N/A,INDICATI,Discontinued in Phase 1,Obstructive sleep apnoea,[ICD-11: 7A41]
T84160,#N/A,INDICATI,Discontinued in Phase 2,Oesophageal/gastroduodenal disorder,[ICD-11: DD90]
T84160,#N/A,INDICATI,Discontinued in Phase 2,Oesophagus motility disorder,[ICD-11: DA21]
T84160,#N/A,INDICATI,Phase 1,Opioid use disorder,[ICD-11: 6C43]
T84160,#N/A,INDICATI,Phase 1,Schizophrenia,[ICD-11: 6A20]
T84160,#N/A,INDICATI,Phase 1,Sex development malformative disorder,[ICD-11: LD2A]
T84160,#N/A,INDICATI,Phase 2,Substance abuse,[ICD-11: 6C40]
T84160,#N/A,INDICATI,Phase 3,Testicular cancer,[ICD-11: 2C80]
T84160,#N/A,INDICATI,Terminated,Unspecific substance use disorder,[ICD-11: 6C4Z]
,#N/A,,,,
T84173,GBA,TARGETID,T84173,,
T84173,GBA,TARGNAME,Glucosylceramidase (GBA),,
T84173,GBA,INDICATI,Discontinued in Phase 2,Lysosomal disease,[ICD-11: 5C56]
T84173,GBA,INDICATI,Approved,Metabolic disorder,[ICD-11: 5C50-5D2Z]
,#N/A,,,,
T84316,CACNA2D1,TARGETID,T84316,,
T84316,CACNA2D1,TARGNAME,Voltage-gated calcium channel alpha-2/delta-1 (CACNA2D1),,
T84316,CACNA2D1,INDICATI,Phase 3,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T84316,CACNA2D1,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T84316,CACNA2D1,INDICATI,Approved,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T84316,CACNA2D1,INDICATI,Phase 3,Chronic pain,[ICD-11: MG30]
T84316,CACNA2D1,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T84316,CACNA2D1,INDICATI,Registered,Neuropathy,[ICD-11: 8C0Z]
T84316,CACNA2D1,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T84397,TUBB1,TARGETID,T84397,,
T84397,TUBB1,TARGNAME,Tubulin beta-1 chain (TUBB1),,
T84397,TUBB1,INDICATI,Investigative,Lung cancer,[ICD-11: 2C25]
T84397,TUBB1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T84439,GPR139,TARGETID,T84439,,
T84439,GPR139,TARGNAME,G-protein-coupled receptor PGR3 (GPR139),,
T84439,GPR139,INDICATI,Phase 1,Sex development malformative disorder,[ICD-11: LD2A]
,#N/A,,,,
T84457,#N/A,TARGETID,T84457,,
T84457,#N/A,TARGNAME,GABA(A) receptor (GABAR),,
T84457,#N/A,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T84457,#N/A,INDICATI,Phase 2,Fragile X chromosome,[ICD-11: LD55]
T84457,#N/A,INDICATI,Phase 3,Intellectual development disorder,[ICD-11: LD90]
T84457,#N/A,INDICATI,Phase 2,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T84457,#N/A,INDICATI,Phase 2,Narcolepsy,[ICD-11: 7A20]
T84457,#N/A,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T84457,#N/A,INDICATI,Phase 2,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
T84457,#N/A,INDICATI,Phase 3,Social anxiety disorder,[ICD-11: 6B04]
T84457,#N/A,INDICATI,Phase 2,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T84472,#N/A,TARGETID,T84472,,
T84472,#N/A,TARGNAME,Geranylgeranyl transferase (GGTase),,
T84472,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T84486,OXTR,TARGETID,T84486,,
T84486,OXTR,TARGNAME,Oxytocin receptor (OTR),,
T84486,OXTR,INDICATI,Discontinued in Phase 1,Abortion,[ICD-11: JA00]
T84486,OXTR,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T84486,OXTR,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T84486,OXTR,INDICATI,Approved,Autism spectrum disorder,[ICD-11: 6A02]
T84486,OXTR,INDICATI,Phase 3,Childbirth associated breast/lactation disorder,[ICD-11: JB46]
T84486,OXTR,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T84486,OXTR,INDICATI,Phase 2,Ejaculatory dysfunction,[ICD-11: HA03]
T84486,OXTR,INDICATI,Approved,Postpartum haemorrhage,[ICD-11: JA43]
T84486,OXTR,INDICATI,Phase 3,Preterm labour/delivery,[ICD-11: JB00]
T84486,OXTR,INDICATI,Phase 2,Sexual dysfunction,[ICD-11: HA00-HA01]
T84486,OXTR,INDICATI,Phase 2,Testicular dysfunction,[ICD-11: 5A81]
,#N/A,,,,
T84560,UCP2,TARGETID,T84560,,
T84560,UCP2,TARGNAME,Mitochondrial uncoupling protein 2 (UCP2),,
T84560,UCP2,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T84575,#N/A,TARGETID,T84575,,
T84575,#N/A,TARGNAME,Samarium (SAM),,
T84575,#N/A,INDICATI,Approved,Chronic pain,[ICD-11: MG30]
,#N/A,,,,
T84581,TXNRD1,TARGETID,T84581,,
T84581,TXNRD1,TARGNAME,Cytoplasmic thioredoxin reductase (TXNRD1),,
T84581,TXNRD1,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
T84581,TXNRD1,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T84581,TXNRD1,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T84581,TXNRD1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T84584,SGCA,TARGETID,T84584,,
T84584,SGCA,TARGNAME,Sarcoglycan alpha (SGCA),,
T84584,SGCA,INDICATI,Phase 1/2,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T84591,EIF2B1; EIF2B2,TARGETID,T84591,,
T84591,EIF2B1; EIF2B2,TARGNAME,Guanine nucleotide exchange factor (GNEF),,
T84591,EIF2B1; EIF2B2,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T84614,IL31RA,TARGETID,T84614,,
T84614,IL31RA,TARGNAME,Interleukin 31 receptor (IL31R),,
T84614,IL31RA,INDICATI,Phase 3,Atopic eczema,[ICD-11: EA80]
,#N/A,,,,
T84621,CYP11B1,TARGETID,T84621,,
T84621,CYP11B1,TARGNAME,Steroid 11-beta-hydroxylase (CYP11B1),,
T84621,CYP11B1,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T84621,CYP11B1,INDICATI,Investigative,Cardiomyopathy,[ICD-11: BC43]
T84621,CYP11B1,INDICATI,Approved,Cushing syndrome,[ICD-11: 5A70]
T84621,CYP11B1,INDICATI,Investigative,Heart failure,[ICD-11: BD10-BD1Z]
T84621,CYP11B1,INDICATI,Investigative,Hyperaldosteronism,[ICD-11: 5A72]
,#N/A,,,,
T84631,F10,TARGETID,T84631,,
T84631,F10,TARGNAME,Coagulation factor Xa (F10),,
T84631,F10,INDICATI,Discontinued in Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T84631,F10,INDICATI,Discontinued in Phase 3,Angina pectoris,[ICD-11: BA40]
T84631,F10,INDICATI,Phase 2,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T84631,F10,INDICATI,Phase 3,Bleeding disorder,[ICD-11: GA20-GA21]
T84631,F10,INDICATI,Approved,Blood-forming organ disease,[ICD-11: 3C0Z]
T84631,F10,INDICATI,Phase 3,Cerebral ischaemia,[ICD-11: 8B1Z]
T84631,F10,INDICATI,Approved,Christmas disease,[ICD-11: 3B11]
T84631,F10,INDICATI,Approved,Coagulation defect,[ICD-11: 3B10]
T84631,F10,INDICATI,Approved,Coronary thrombosis,[ICD-11: BA43]
T84631,F10,INDICATI,Approved,Deep vein thrombosis,[ICD-11: BD71]
T84631,F10,INDICATI,Discontinued in Phase 3,Myocardial infarction,[ICD-11: BA41-BA43]
T84631,F10,INDICATI,Discontinued in Phase 2,Psoriasis,[ICD-11: EA90]
T84631,F10,INDICATI,BLA submitted,Renal cell carcinoma,[ICD-11: 2C90]
T84631,F10,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T84631,F10,INDICATI,Approved,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T84631,F10,INDICATI,Approved,Thrombosis,[ICD-11: DB61-GB90]
T84631,F10,INDICATI,Approved,Venous thromboembolism,[ICD-11: BD72]
,#N/A,,,,
T84634,CYP26A1,TARGETID,T84634,,
T84634,CYP26A1,TARGNAME,Cytochrome P450 26 (CYP26A1),,
T84634,CYP26A1,INDICATI,Investigative,Asthma,[ICD-11: CA23]
T84634,CYP26A1,INDICATI,Phase 2/3,Oesophagitis,[ICD-11: DA24]
T84634,CYP26A1,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T84665,#N/A,TARGETID,T84665,,
T84665,#N/A,TARGNAME,Tromboxane A2 synthesis (TA2 synth),,
T84665,#N/A,INDICATI,Approved,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T84703,NTRK2,TARGETID,T84703,,
T84703,NTRK2,TARGNAME,BDNF/NT-3 growth factors receptor (TrkB),,
T84703,NTRK2,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T84703,NTRK2,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T84703,NTRK2,INDICATI,Patented,Bone growth disorder,[ICD-11: FB86]
T84703,NTRK2,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T84703,NTRK2,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
T84703,NTRK2,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T84703,NTRK2,INDICATI,Patented,General pain disorder,[ICD-11: 8E43]
T84703,NTRK2,INDICATI,Investigative,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T84703,NTRK2,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T84703,NTRK2,INDICATI,Patented,Pruritus,[ICD-11: EC90]
T84703,NTRK2,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T84703,NTRK2,INDICATI,Patented,Thymoma,[ICD-11: 2C27]
,#N/A,,,,
T84726,#N/A,TARGETID,T84726,,
T84726,#N/A,TARGNAME,Rho-associated protein kinase (ROCK),,
T84726,#N/A,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T84726,#N/A,INDICATI,Approved,Glaucoma,[ICD-11: 9C61]
T84726,#N/A,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T84726,#N/A,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T84726,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T84726,#N/A,INDICATI,Phase 1/2,Spine/trunk injury,[ICD-11: ND51]
,#N/A,,,,
T84780,BIRC2,TARGETID,T84780,,
T84780,BIRC2,TARGNAME,Cellular inhibitor of apoptosis 1 (BIRC2),,
T84780,BIRC2,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T84780,BIRC2,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T84780,BIRC2,INDICATI,Investigative,Mature T-cell lymphoma,[ICD-11: 2A90]
T84780,BIRC2,INDICATI,Phase 3,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T84780,BIRC2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T84885,PicVir VP1,TARGETID,T84885,,
T84885,PicVir VP1,TARGNAME,Picornavirus Capsid protein VP1 (PicVir VP1),,
T84885,PicVir VP1,INDICATI,Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T84886,SLC12A3,TARGETID,T84886,,
T84886,SLC12A3,TARGNAME,Solute carrier family 12 member 3 (SLC12A3),,
T84886,SLC12A3,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T84886,SLC12A3,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T84886,SLC12A3,INDICATI,Approved,Oedema,[ICD-11: MG29]
,#N/A,,,,
T84894,#N/A,TARGETID,T84894,,
T84894,#N/A,TARGNAME,Casein kinase II (CSNK2),,
T84894,#N/A,INDICATI,Phase 3,Cervical cancer,[ICD-11: 2C77]
T84894,#N/A,INDICATI,Phase 2,Coronavirus infection,[ICD-11: 1D92]
T84894,#N/A,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T84894,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T84972,Stre-coc fusA,TARGETID,T84972,,
T84972,Stre-coc fusA,TARGNAME,Streptococcus Elongation factor G (Stre-coc fusA),,
T84972,Stre-coc fusA,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T84972,Stre-coc fusA,INDICATI,Phase 3,Infectious meningitis,[ICD-11: 1D01]
,#N/A,,,,
T84981,CCR7,TARGETID,T84981,,
T84981,CCR7,TARGNAME,C-C chemokine receptor type 7 (CCR7),,
T84981,CCR7,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T84981,CCR7,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T85025,IL7R,TARGETID,T85025,,
T85025,IL7R,TARGNAME,Interleukin 7 receptor alpha (IL7R),,
T85025,IL7R,INDICATI,Phase 2,Atopic eczema,[ICD-11: EA80]
T85025,IL7R,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T85025,IL7R,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T85025,IL7R,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T85042,#N/A,TARGETID,T85042,,
T85042,#N/A,TARGNAME,Peroxisome proliferator-activated receptor (PPAR),,
T85042,#N/A,INDICATI,IND submitted,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T85042,#N/A,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T85072,HPV E7,TARGETID,T85072,,
T85072,HPV E7,TARGNAME,Human papillomavirus protein E7 (HPV E7),,
T85072,HPV E7,INDICATI,Phase 2,Cervical cancer,[ICD-11: 2C77]
T85072,HPV E7,INDICATI,Phase 3,Cervical intraepithelial neoplasia,[ICD-11: 2E66]
T85072,HPV E7,INDICATI,Phase 3,Dysplasia,[ICD-11: LB30-LD2F]
T85072,HPV E7,INDICATI,Phase 2,Genital organ in situ carcinoma,[ICD-11: 2E67]
T85072,HPV E7,INDICATI,Phase 2,Sexually transmitted infection,[ICD-11: 1A9Y-1A9Z]
T85072,HPV E7,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85076,CBLB,TARGETID,T85076,,
T85076,CBLB,TARGNAME,CBLB messenger RNA (CBLB mRNA),,
T85076,CBLB,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85158,LTA,TARGETID,T85158,,
T85158,LTA,TARGNAME,Lymphotoxin-alpha (LTA),,
T85158,LTA,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T85221,G6PC,TARGETID,T85221,,
T85221,G6PC,TARGNAME,Glucose-6-phosphatase (G6PC),,
T85221,G6PC,INDICATI,Phase 1,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
,#N/A,,,,
T85228,CCR3,TARGETID,T85228,,
T85228,CCR3,TARGNAME,CCR3 messenger RNA (CCR3 mRNA),,
T85228,CCR3,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
,#N/A,,,,
T85241,CDC20,TARGETID,T85241,,
T85241,CDC20,TARGNAME,Cell division cycle protein 20 homolog (CDC20),,
T85241,CDC20,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85309,CBS,TARGETID,T85309,,
T85309,CBS,TARGNAME,Cystathionine beta-synthase (CBS),,
T85309,CBS,INDICATI,Phase 1/2,Metabolism inborn error,[ICD-11: 5C50]
,#N/A,,,,
T85419,Influenza NA mRNA,TARGETID,T85419,,
T85419,Influenza NA mRNA,TARGNAME,Influenza NA messenger RNA (Influenza NA mRNA),,
T85419,Influenza NA mRNA,INDICATI,Preclinical,Influenza,[ICD-11: 1E30-1E32]
,#N/A,,,,
T85421,MAPK8; MAPK9; MAPK10,TARGETID,T85421,,
T85421,MAPK8; MAPK9; MAPK10,TARGNAME,Jun N terminal kinase (JNK),,
T85421,MAPK8; MAPK9; MAPK10,INDICATI,Phase 2,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T85421,MAPK8; MAPK9; MAPK10,INDICATI,Phase 3,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T85421,MAPK8; MAPK9; MAPK10,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T85421,MAPK8; MAPK9; MAPK10,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T85421,MAPK8; MAPK9; MAPK10,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T85426,HBV C,TARGETID,T85426,,
T85426,HBV C,TARGNAME,Hepatitis B virus Capsid protein (HBV C),,
T85426,HBV C,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T85435,INSR,TARGETID,T85435,,
T85435,INSR,TARGNAME,Insulin receptor (INSR),,
T85435,INSR,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T85435,INSR,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T85435,INSR,INDICATI,Discontinued in Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T85435,INSR,INDICATI,Phase 2,Crohn disease,[ICD-11: DD70]
T85435,INSR,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T85435,INSR,INDICATI,Terminated,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T85435,INSR,INDICATI,Investigative,Hypo-glycaemia,[ICD-11: 5A41]
T85435,INSR,INDICATI,Investigative,Lymphoma,[ICD-11: 2A80-2A86]
T85435,INSR,INDICATI,Phase 1,Lysosomal disease,[ICD-11: 5C56]
T85435,INSR,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T85435,INSR,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T85435,INSR,INDICATI,Phase 2,Pancreatic internal secretion disorder,[ICD-11: 5A4Y]
T85435,INSR,INDICATI,Phase 4,Psychotic disorder,[ICD-11: 6A20-6A25]
T85435,INSR,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
T85435,INSR,INDICATI,Phase 1,Type-1/2 diabete,[ICD-11: 5A10-5A11]
,#N/A,,,,
T85467,PTGER3,TARGETID,T85467,,
T85467,PTGER3,TARGNAME,Prostaglandin E2 receptor EP3 (PTGER3),,
T85467,PTGER3,INDICATI,Discontinued in Phase 1,Asthma,[ICD-11: CA23]
T85467,PTGER3,INDICATI,Discontinued in Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T85467,PTGER3,INDICATI,Phase 2,Glaucoma,[ICD-11: 9C61]
T85467,PTGER3,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
T85467,PTGER3,INDICATI,Clinical trial,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T85467,PTGER3,INDICATI,Phase 2,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T85507,SIGLEC15,TARGETID,T85507,,
T85507,SIGLEC15,TARGNAME,Sialic acid-binding immunoglobulin-like lectin 15 (SIGLEC15),,
T85507,SIGLEC15,INDICATI,Phase 2,Non-small-cell lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T85523,MYBPC3,TARGETID,T85523,,
T85523,MYBPC3,TARGNAME,Cardiac myosin (MYBPC3),,
T85523,MYBPC3,INDICATI,Phase 3,Cardiomyopathy,ICD-11: BC43
T85523,MYBPC3,INDICATI,Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T85529,CD28,TARGETID,T85529,,
T85529,CD28,TARGNAME,T-cell-specific surface glycoprotein CD28 (CD28),,
T85529,CD28,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T85529,CD28,INDICATI,Discontinued in Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T85529,CD28,INDICATI,Investigative,Immune system disease,[ICD-11: 4A01-4B41]
T85529,CD28,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T85529,CD28,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T85529,CD28,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T85529,CD28,INDICATI,Phase 3,Necrotising fasciitis,[ICD-11: 1B71]
T85529,CD28,INDICATI,Phase 1/2,Osteosarcoma,[ICD-11: 2B51]
T85529,CD28,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T85529,CD28,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
T85529,CD28,INDICATI,Phase 1/2,Respiratory infection,[ICD-11: CA07-CA4Z]
T85529,CD28,INDICATI,Phase 1/2,Sarcoma,[ICD-11: 2A60-2C35]
T85529,CD28,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T85529,CD28,INDICATI,Phase 1,Stomach cancer,ICD-11: 2B72
T85529,CD28,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T85544,MAPKAP1,TARGETID,T85544,,
T85544,MAPKAP1,TARGNAME,Target of rapamycin complex 2 MAPKAP1 (MTORC2),,
T85544,MAPKAP1,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T85544,MAPKAP1,INDICATI,Phase 1,Pleural mesothelioma,[ICD-11: 2C26]
T85544,MAPKAP1,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T85544,MAPKAP1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85554,CD27,TARGETID,T85554,,
T85554,CD27,TARGNAME,T-cell activation antigen CD27 (CD27),,
T85554,CD27,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T85554,CD27,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T85554,CD27,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T85554,CD27,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T85554,CD27,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T85554,CD27,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T85554,CD27,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T85554,CD27,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85574,#N/A,TARGETID,T85574,,
T85574,#N/A,TARGNAME,Angiotensin II receptor (AGTR),,
T85574,#N/A,INDICATI,Discontinued in Phase 2,Anemia,[ICD-11: 3A00-3A9Z]
T85574,#N/A,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T85581,SLC12A1; SLC12A2,TARGETID,T85581,,
T85581,SLC12A1; SLC12A2,TARGNAME,Na-K-Cl cotransporter (NKCC),,
T85581,SLC12A1; SLC12A2,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T85605,#N/A,TARGETID,T85605,,
T85605,#N/A,TARGNAME,5-HT receptor (5HTR),,
T85605,#N/A,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T85605,#N/A,INDICATI,Phase 2,Bipolar disorder,[ICD-11: 6A60]
T85605,#N/A,INDICATI,Terminated,Carcinoid syndrome,[ICD-11: 5B10]
T85605,#N/A,INDICATI,Approved,Cerebral ischaemia,[ICD-11: 8B1Z]
T85605,#N/A,INDICATI,Phase 3,Depression,[ICD-11: 6A70-6A7Z]
T85605,#N/A,INDICATI,Phase 3,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T85605,#N/A,INDICATI,Phase 3,Epileptic encephalopathy,[ICD-11: 8A62]
T85605,#N/A,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
T85605,#N/A,INDICATI,Approved,Headache,[ICD-11: 8A80-8A84]
T85605,#N/A,INDICATI,Phase 3,Insomnia,[ICD-11: 7A00-7A0Z]
T85605,#N/A,INDICATI,Phase 4,Irritable bowel syndrome,[ICD-11: DD91]
T85605,#N/A,INDICATI,Phase 1,Migraine,[ICD-11: 8A80]
T85605,#N/A,INDICATI,Approved,Nausea/vomiting,[ICD-11: MD90]
T85605,#N/A,INDICATI,Withdrawn from market,Obesity,[ICD-11: 5B80-5B81]
T85605,#N/A,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T85605,#N/A,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T85605,#N/A,INDICATI,Terminated,Psychotic disorder,[ICD-11: 6A20-6A25]
T85605,#N/A,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T85605,#N/A,INDICATI,Phase 1,Tension-type headache,[ICD-11: 8A81]
,#N/A,,,,
T85616,TXN,TARGETID,T85616,,
T85616,TXN,TARGNAME,Thioredoxin (TXN),,
T85616,TXN,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85651,MYC,TARGETID,T85651,,
T85651,MYC,TARGNAME,Myc messenger RNA (MYC mRNA),,
T85651,MYC,INDICATI,Phase 2,Coronary atherosclerosis,[ICD-11: BA80]
T85651,MYC,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85670,NGF,TARGETID,T85670,,
T85670,NGF,TARGNAME,Nerve growth factor (NGF),,
T85670,NGF,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T85670,NGF,INDICATI,Phase 3,Chronic pain,[ICD-11: MG30]
T85670,NGF,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T85670,NGF,INDICATI,Phase 1/2,Neurodegenerative disorder,[ICD-11: 8A20-8A23]
T85670,NGF,INDICATI,Phase 3,Osteoarthritis,[ICD-11: FA00-FA05]
T85670,NGF,INDICATI,Phase 3,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T85733,TOP2B,TARGETID,T85733,,
T85733,TOP2B,TARGNAME,DNA topoisomerase II beta (TOP2B),,
T85733,TOP2B,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T85733,TOP2B,INDICATI,Approved,Chemoprotection,[ICD-11: N.A.]
T85733,TOP2B,INDICATI,Investigative,Respiratory system disease,[ICD-11: CB40-CB7Z]
T85733,TOP2B,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85799,CDK4,TARGETID,T85799,,
T85799,CDK4,TARGNAME,Cyclin-dependent kinase 4 (CDK4),,
T85799,CDK4,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T85799,CDK4,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T85799,CDK4,INDICATI,Phase 1,Liposarcoma,[ICD-11: 2B59]
T85799,CDK4,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T85799,CDK4,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T85799,CDK4,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
T85799,CDK4,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T85799,CDK4,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T85799,CDK4,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
T85799,CDK4,INDICATI,Terminated,Schizophrenia,[ICD-11: 6A20]
T85799,CDK4,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T85857,TSLP,TARGETID,T85857,,
T85857,TSLP,TARGNAME,Thymic stromal lymphopoietin (TSLP),,
T85857,TSLP,INDICATI,Approved,Asthma,[ICD-11: CA23]
T85857,TSLP,INDICATI,Phase 1,Atopic eczema,[ICD-11: EA80]
T85857,TSLP,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
,#N/A,,,,
T85889,#N/A,TARGETID,T85889,,
T85889,#N/A,TARGNAME,Phosphate (PHO),,
T85889,#N/A,INDICATI,Approved,Mineral absorption/transport disorder,[ICD-11: 5C64]
,#N/A,,,,
T85943,SRC,TARGETID,T85943,,
T85943,SRC,TARGNAME,Proto-oncogene c-Src (SRC),,
T85943,SRC,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T85943,SRC,INDICATI,Phase 2,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T85943,SRC,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T85943,SRC,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T85943,SRC,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T85943,SRC,INDICATI,Phase 1/2,Cervical cancer,[ICD-11: 2C77]
T85943,SRC,INDICATI,Phase 1,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T85943,SRC,INDICATI,Phase 1/2,Endometrial cancer,[ICD-11: 2C76]
T85943,SRC,INDICATI,Phase 3,Epidermal dysplasias,[ICD-11: EK90]
T85943,SRC,INDICATI,Phase 1/2,Fallopian tube cancer,[ICD-11: 2C74]
T85943,SRC,INDICATI,Phase 3,Gastrointestinal stromal tumour,[ICD-11: 2B5B]
T85943,SRC,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T85943,SRC,INDICATI,Approved,Ischemia,[ICD-11: 8B10-8B11]
T85943,SRC,INDICATI,Phase 3,Leiomyosarcoma,[ICD-11: 2B58]
T85943,SRC,INDICATI,Terminated,Low bone mass disorder,[ICD-11: FB83]
T85943,SRC,INDICATI,Phase 3,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T85943,SRC,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T85943,SRC,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T85943,SRC,INDICATI,Phase 3,Metastatic digestive system neoplasm,[ICD-11: 2D8Y]
T85943,SRC,INDICATI,Phase 3,Motor neuron disease,[ICD-11: 8B60]
T85943,SRC,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T85943,SRC,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T85943,SRC,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T85943,SRC,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T85943,SRC,INDICATI,Phase 2,Osteosarcoma,[ICD-11: 2B51]
T85943,SRC,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T85943,SRC,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T85943,SRC,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T85943,SRC,INDICATI,Phase 1/2,Peritoneal cancer,[ICD-11: 2C51]
T85943,SRC,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
T85943,SRC,INDICATI,Phase 3,Sarcoma,[ICD-11: 2A60-2C35]
T85943,SRC,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T85943,SRC,INDICATI,Phase 3,Synovial sarcoma,[ICD-11: 2B5A]
,#N/A,,,,
T85944,Pseudo lpxC,TARGETID,T85944,,
T85944,Pseudo lpxC,TARGNAME,Pseudomonas UDP-3-O-acyl-GlcNAc deacetylase (Pseudo lpxC),,
T85944,Pseudo lpxC,INDICATI,Terminated,Gram-negative bacterial infection,[ICD-11: 1F41-1G40]
T85944,Pseudo lpxC,INDICATI,Preclinical,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T86014,SPHK1,TARGETID,T86014,,
T86014,SPHK1,TARGNAME,Sphingosine kinase 1 (SPHK1),,
T86014,SPHK1,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
T86014,SPHK1,INDICATI,Investigative,Circulatory system disease,[ICD-11: BE2Z]
T86014,SPHK1,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T86014,SPHK1,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T86014,SPHK1,INDICATI,Phase 1,Psychoactive substances use disorder,[ICD-11: 6C4G]
,#N/A,,,,
T86041,ALAS1,TARGETID,T86041,,
T86041,ALAS1,TARGNAME,ALAS1 messenger RNA (ALAS1 mRNA),,
T86041,ALAS1,INDICATI,Approved,Inborn porphyrin/heme metabolism error,[ICD-11: 5C58]
,#N/A,,,,
T86052,TERT,TARGETID,T86052,,
T86052,TERT,TARGNAME,Telomerase reverse transcriptase (TERT),,
T86052,TERT,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T86052,TERT,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T86052,TERT,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T86052,TERT,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T86052,TERT,INDICATI,Phase 1,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T86052,TERT,INDICATI,Phase 1/2,Glaucoma,[ICD-11: 9C61]
T86052,TERT,INDICATI,Phase 1/2,Head and neck cancer,[ICD-11: 2D42]
T86052,TERT,INDICATI,Phase 2/3,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T86052,TERT,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T86052,TERT,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T86052,TERT,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T86052,TERT,INDICATI,Phase 2,Multiple myeloma,[ICD-11: 2A83]
T86052,TERT,INDICATI,Phase 2/3,Myelodysplastic syndrome,[ICD-11: 2A37]
T86052,TERT,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T86052,TERT,INDICATI,Phase 1,Old age,ICD-11: MG2A
T86052,TERT,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T86052,TERT,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T86052,TERT,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T86052,TERT,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T86052,TERT,INDICATI,Phase 2,Thrombocytosis,[ICD-11: 3B63]
,#N/A,,,,
T86057,SLC22A12,TARGETID,T86057,,
T86057,SLC22A12,TARGNAME,Urate anion exchanger 1 (URAT1),,
T86057,SLC22A12,INDICATI,Phase 3,Gout,[ICD-11: FA25]
T86057,SLC22A12,INDICATI,Approved,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
,#N/A,,,,
T86072,LRP5,TARGETID,T86072,,
T86072,LRP5,TARGNAME,Low-density lipoprotein receptor-related protein 5 (LRP5),,
T86072,LRP5,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T86115,APOC3,TARGETID,T86115,,
T86115,APOC3,TARGNAME,ApoC-III messenger RNA (APOC3 mRNA),,
T86115,APOC3,INDICATI,Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T86115,APOC3,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T86115,APOC3,INDICATI,Phase 1,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T86115,APOC3,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T86130,ITGA4-ITGB1,TARGETID,T86130,,
T86130,ITGA4-ITGB1,TARGNAME,Integrin alpha-4/beta-1 (ITGA4/B1),,
T86130,ITGA4-ITGB1,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T86130,ITGA4-ITGB1,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T86130,ITGA4-ITGB1,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T86130,ITGA4-ITGB1,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T86130,ITGA4-ITGB1,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T86130,ITGA4-ITGB1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T86130,ITGA4-ITGB1,INDICATI,Phase 3,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T86161,PREP,TARGETID,T86161,,
T86161,PREP,TARGNAME,Prolyl endopeptidase (PREP),,
T86161,PREP,INDICATI,Phase 2,Coeliac disease,[ICD-11: DA95]
T86161,PREP,INDICATI,Terminated,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T86161,PREP,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T86161,PREP,INDICATI,Clinical trial,Lung cancer,[ICD-11: 2C25]
T86161,PREP,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T86161,PREP,INDICATI,Discontinued in Phase 1,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T86192,#N/A,TARGETID,T86192,,
T86192,#N/A,TARGNAME,Voltage-gated potassium channel Kv7 (KCNQ),,
T86192,#N/A,INDICATI,Approved,Behcet disease,[ICD-11: 4A62]
T86192,#N/A,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T86192,#N/A,INDICATI,Withdrawn from market,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T86192,#N/A,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
T86192,#N/A,INDICATI,Discontinued in Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T86254,TNC,TARGETID,T86254,,
T86254,TNC,TARGNAME,Tenascin (TNC),,
T86254,TNC,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T86254,TNC,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T86254,TNC,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T86264,SLC40A1,TARGETID,T86264,,
T86264,SLC40A1,TARGNAME,Solute carrier family 40 member 1 (SLC40A1),,
T86264,SLC40A1,INDICATI,Phase 2,Acute disease anaemia,[ICD-11: 3A90]
T86264,SLC40A1,INDICATI,Phase 1,Anemia,[ICD-11: 3A00-3A9Z]
T86264,SLC40A1,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T86264,SLC40A1,INDICATI,Phase 1,Myeloproliferative neoplasm,[ICD-11: 2A20]
T86264,SLC40A1,INDICATI,Phase 1,Thalassaemia,[ICD-11: 3A50]
,#N/A,,,,
T86271,KCNN2,TARGETID,T86271,,
T86271,KCNN2,TARGNAME,Calcium-activated potassium channel KCa2.2 (KCNN2),,
T86271,KCNN2,INDICATI,Terminated,Multiple myeloma,[ICD-11: 2A83]
T86271,KCNN2,INDICATI,Clinical trial,Myelopathy,[ICD-11: 8B42]
,#N/A,,,,
T86273,GPBAR1,TARGETID,T86273,,
T86273,GPBAR1,TARGNAME,G-protein coupled bile acid receptor 1 (GPBAR1),,
T86273,GPBAR1,INDICATI,Preclinical,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T86273,GPBAR1,INDICATI,Investigative,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T86273,GPBAR1,INDICATI,Phase 1/2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T86321,SULF2,TARGETID,T86321,,
T86321,SULF2,TARGNAME,Extracellular sulfatase Sulf-2 (SULF2),,
T86321,SULF2,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
,#N/A,,,,
T86323,NCAM1,TARGETID,T86323,,
T86323,NCAM1,TARGNAME,Neural cell adhesion molecule 1 (NCAM1),,
T86323,NCAM1,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T86323,NCAM1,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T86323,NCAM1,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
,#N/A,,,,
T86350,ERBB3,TARGETID,T86350,,
T86350,ERBB3,TARGNAME,Erbb3 tyrosine kinase receptor (Erbb-3),,
T86350,ERBB3,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T86350,ERBB3,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T86350,ERBB3,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T86350,ERBB3,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T86350,ERBB3,INDICATI,Phase 1/2,Malignant mesenchymal neoplasm,[ICD-11: 2B5D-2B5Y]
T86350,ERBB3,INDICATI,Phase 1,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T86350,ERBB3,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T86350,ERBB3,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T86350,ERBB3,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T86350,ERBB3,INDICATI,Phase 2,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
,#N/A,,,,
T86364,VIPR1,TARGETID,T86364,,
T86364,VIPR1,TARGNAME,Vasoactive intestinal polypeptide receptor 1 (VIPR1),,
T86364,VIPR1,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T86364,VIPR1,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
,#N/A,,,,
T86385,CTSG,TARGETID,T86385,,
T86385,CTSG,TARGNAME,Cathepsin G (CTSG),,
T86385,CTSG,INDICATI,Discontinued in Phase 2,Atopic eczema,[ICD-11: EA80]
T86385,CTSG,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T86385,CTSG,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
T86385,CTSG,INDICATI,Discontinued in Phase 3,Dissociative neurological symptom disorder,[ICD-11: 6B60]
,#N/A,,,,
T86399,BRD2,TARGETID,T86399,,
T86399,BRD2,TARGNAME,Bromodomain-containing protein 2 (BRD2),,
T86399,BRD2,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T86399,BRD2,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T86399,BRD2,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T86399,BRD2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T86428,FNTB,TARGETID,T86428,,
T86428,FNTB,TARGNAME,CAAX farnesyltransferase beta (FNTB),,
T86428,FNTB,INDICATI,Terminated,Colorectal cancer,[ICD-11: 2B91]
T86428,FNTB,INDICATI,Terminated,Lung cancer,[ICD-11: 2C25]
T86428,FNTB,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T86437,#N/A,TARGETID,T86437,,
T86437,#N/A,TARGNAME,HUMAN janus kinase 1 (JAK-1),,
T86437,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T86437,#N/A,INDICATI,Approved,Myelofibrosis,[ICD-11: 2A22]
,#N/A,,,,
T86462,TTR,TARGETID,T86462,,
T86462,TTR,TARGNAME,Transthyretin (TTR),,
T86462,TTR,INDICATI,Approved,Amyloidosis,[ICD-11: 5D00]
T86462,TTR,INDICATI,Phase 1,Amyloidosis,ICD-11: 5D00
T86462,TTR,INDICATI,Phase 3,Cardiomyopathy,[ICD-11: BC43]
,#N/A,,,,
T86513,#N/A,TARGETID,T86513,,
T86513,#N/A,TARGNAME,HUMAN interleukin-6 receptor (IL6R),,
T86513,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T86513,#N/A,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T86513,#N/A,INDICATI,Approved,Vasculitis,[ICD-11: 4A44]
,#N/A,,,,
T86528,FDPS,TARGETID,T86528,,
T86528,FDPS,TARGNAME,Geranyltranstransferase (FDPS),,
T86528,FDPS,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T86528,FDPS,INDICATI,Approved,Bone paget disease,[ICD-11: FB85]
T86528,FDPS,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T86528,FDPS,INDICATI,Phase 3,Focal/segmental autonomic disorder,[ICD-11: 8D8A]
T86528,FDPS,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
T86528,FDPS,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T86528,FDPS,INDICATI,Approved,Mineral excesses,[ICD-11: 5B91]
T86528,FDPS,INDICATI,Approved,Musculoskeletal system/connective tissue disease,[ICD-11: FC0Z]
T86528,FDPS,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T86528,FDPS,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T86528,FDPS,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
T86528,FDPS,INDICATI,Phase 2,Sexually transmitted infection,[ICD-11: 1A9Y-1A9Z]
T86528,FDPS,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T86541,ASIC2,TARGETID,T86541,,
T86541,ASIC2,TARGNAME,Acid-sensing ion channel 2 (ASIC2),,
T86541,ASIC2,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
,#N/A,,,,
T86552,TNFRSF1A,TARGETID,T86552,,
T86552,TNFRSF1A,TARGNAME,Tumor necrosis factor receptor type I (TNF-R1),,
T86552,TNFRSF1A,INDICATI,Phase 1,Acute respiratory distress syndrome,[ICD-11: CB00]
T86552,TNFRSF1A,INDICATI,Investigative,Acute/subacute hepatic failure,[ICD-11: DB91]
T86552,TNFRSF1A,INDICATI,Terminated,Alopecia,[ICD-11: ED70]
T86552,TNFRSF1A,INDICATI,Phase 3,Brain cancer,[ICD-11: 2A00]
T86552,TNFRSF1A,INDICATI,Investigative,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T86552,TNFRSF1A,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T86552,TNFRSF1A,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T86552,TNFRSF1A,INDICATI,Phase 2,Intrathoracic organs injury,[ICD-11: NB32]
T86552,TNFRSF1A,INDICATI,Investigative,Multiple sclerosis,[ICD-11: 8A40]
T86552,TNFRSF1A,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T86552,TNFRSF1A,INDICATI,Investigative,Rheumatoid arthritis,[ICD-11: FA20]
T86552,TNFRSF1A,INDICATI,Phase 1,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T86573,#N/A,TARGETID,T86573,,
T86573,#N/A,TARGNAME,HUMAN inosine-5'-monophosphate dehydrogenase 2 (IMPDH2),,
T86573,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T86573,#N/A,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T86573,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T86573,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T86577,#N/A,TARGETID,T86577,,
T86577,#N/A,TARGNAME,HUMAN mannose receptor (MRC1),,
T86577,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T86577,#N/A,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T86591,PPARA,TARGETID,T86591,,
T86591,PPARA,TARGNAME,Peroxisome proliferator-activated receptor alpha (PPARA),,
T86591,PPARA,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T86591,PPARA,INDICATI,Discontinued in Phase 1,Arterial occlusive disease,[ICD-11: BD40]
T86591,PPARA,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T86591,PPARA,INDICATI,Phase 3,Diabetes mellitus,[ICD-11: 5A10]
T86591,PPARA,INDICATI,Phase 2,Dyslipidemia,[ICD-11: 5C80-5C81]
T86591,PPARA,INDICATI,Phase 1,Gout,[ICD-11: FA25]
T86591,PPARA,INDICATI,Discontinued in Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T86591,PPARA,INDICATI,Approved,Hyperlipidemia,[ICD-11: 5C80]
T86591,PPARA,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T86591,PPARA,INDICATI,Preclinical,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T86591,PPARA,INDICATI,Phase 3,Inborn lipid metabolism error,[ICD-11: 5C52]
T86591,PPARA,INDICATI,Preclinical,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T86591,PPARA,INDICATI,Phase 3,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T86591,PPARA,INDICATI,Preclinical,Rheumatoid arthritis,[ICD-11: FA20]
T86591,PPARA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T86591,PPARA,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T86597,#N/A,TARGETID,T86597,,
T86597,#N/A,TARGNAME,HUMAN bromodomain-containing protein 2 (BRD2),,
T86597,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T86609,#N/A,TARGETID,T86609,,
T86609,#N/A,TARGNAME,Glycoside hydrolase (GlyH),,
T86609,#N/A,INDICATI,Preclinical,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T86646,#N/A,TARGETID,T86646,,
T86646,#N/A,TARGNAME,HUMAN beta adrenergic receptor (BAR),,
T86646,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T86646,#N/A,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T86652,PCSK9,TARGETID,T86652,,
T86652,PCSK9,TARGNAME,PCSK9 messenger RNA (PCSK9 mRNA),,
T86652,PCSK9,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T86652,PCSK9,INDICATI,Preclinical,Coronary atherosclerosis,[ICD-11: BA80]
T86652,PCSK9,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T86652,PCSK9,INDICATI,Phase 1,Metabolic disorder,[ICD-11: 5C50-5D2Z]
,#N/A,,,,
T86671,#N/A,TARGETID,T86671,,
T86671,#N/A,TARGNAME,Orexin receptor (HCRTR),,
T86671,#N/A,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
,#N/A,,,,
T86674,Influ HA,TARGETID,T86674,,
T86674,Influ HA,TARGNAME,Influenza Hemagglutinin (Influ HA),,
T86674,Influ HA,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T86674,Influ HA,INDICATI,Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
T86674,Influ HA,INDICATI,Approved,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T86679,ADORA2B,TARGETID,T86679,,
T86679,ADORA2B,TARGNAME,Adenosine A2b receptor (ADORA2B),,
T86679,ADORA2B,INDICATI,Discontinued in Phase 3,Alzheimer disease,[ICD-11: 8A20]
T86679,ADORA2B,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T86679,ADORA2B,INDICATI,Phase 1,Breathing abnormality,[ICD-11: MD11]
T86679,ADORA2B,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T86679,ADORA2B,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
T86679,ADORA2B,INDICATI,Approved,Herpes simplex infection,[ICD-11: 1F00]
T86679,ADORA2B,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T86679,ADORA2B,INDICATI,Preclinical,Ischaemic heart disease,[ICD-11: BA6Z]
T86679,ADORA2B,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T86679,ADORA2B,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
T86679,ADORA2B,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T86679,ADORA2B,INDICATI,IND submitted,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T86679,ADORA2B,INDICATI,Approved,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T86679,ADORA2B,INDICATI,Investigative,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T86702,MMP3,TARGETID,T86702,,
T86702,MMP3,TARGNAME,Matrix metalloproteinase-3 (MMP-3),,
T86702,MMP3,INDICATI,Discontinued in Phase 2,Corneal disease,[ICD-11: 9A76-9A78]
T86702,MMP3,INDICATI,Discontinued in Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T86702,MMP3,INDICATI,Preclinical,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T86702,MMP3,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
T86702,MMP3,INDICATI,Discontinued in Phase 2,Myocardial infarction,[ICD-11: BA41-BA43]
T86702,MMP3,INDICATI,Discontinued in Phase 2,Osteoarthritis,[ICD-11: FA00-FA05]
T86702,MMP3,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T86734,GLS; GLS2,TARGETID,T86734,,
T86734,GLS; GLS2,TARGNAME,Glutaminase (GLS),,
T86734,GLS; GLS2,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T86734,GLS; GLS2,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T86734,GLS; GLS2,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T86734,GLS; GLS2,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T86748,CD248,TARGETID,T86748,,
T86748,CD248,TARGNAME,Endosialin (CD248),,
T86748,CD248,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T86748,CD248,INDICATI,Phase 2,Kaposi sarcoma,[ICD-11: 2B57]
T86748,CD248,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T86748,CD248,INDICATI,Phase 2,Neuroendocrine carcinoma,[ICD-11: 2C34]
T86748,CD248,INDICATI,Phase 2,Sarcoma,[ICD-11: 2A60-2C35]
,#N/A,,,,
T86803,STAT3,TARGETID,T86803,,
T86803,STAT3,TARGNAME,STAT3 messenger RNA (STAT3 mRNA),,
T86803,STAT3,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T86805,#N/A,TARGETID,T86805,,
T86805,#N/A,TARGNAME,HUMAN eukaryotic initiation factor-4A (eIF4A),,
T86805,#N/A,INDICATI,Investigative,Mature T-cell lymphoma,[ICD-11: 2A90]
T86805,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T86805,#N/A,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T86836,#N/A,TARGETID,T86836,,
T86836,#N/A,TARGNAME,Human Deoxyribonucleic acid (hDNA),,
T86836,#N/A,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T86836,#N/A,INDICATI,Phase 3,Bladder cancer,[ICD-11: 2C94]
T86836,#N/A,INDICATI,Approved,Brain cancer,[ICD-11: 2A00]
T86836,#N/A,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T86836,#N/A,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T86836,#N/A,INDICATI,Approved,Cystic fibrosis,[ICD-11: CA25]
T86836,#N/A,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T86836,#N/A,INDICATI,Preclinical,Fungal infection,[ICD-11: 1F29-1F2F]
T86836,#N/A,INDICATI,Discontinued in Phase 2,Head and neck cancer,[ICD-11: 2D42]
T86836,#N/A,INDICATI,Approved,Hodgkin lymphoma,[ICD-11: 2B30]
T86836,#N/A,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T86836,#N/A,INDICATI,Phase 1,Influenza,[ICD-11: 1E30-1E32]
T86836,#N/A,INDICATI,Approved,Kaposi sarcoma,[ICD-11: 2B57]
T86836,#N/A,INDICATI,Approved,Leukaemia,[ICD-11: 2A60-2B33]
T86836,#N/A,INDICATI,Approved,Liver cancer,[ICD-11: 2C12]
T86836,#N/A,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T86836,#N/A,INDICATI,Discontinued in Phase 3,Lupus erythematosus,[ICD-11: 4A40]
T86836,#N/A,INDICATI,Phase 3,Malaria,[ICD-11: 1F40-1F45]
T86836,#N/A,INDICATI,Approved,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T86836,#N/A,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
T86836,#N/A,INDICATI,Approved,Mature T-cell lymphoma,[ICD-11: 2A90]
T86836,#N/A,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T86836,#N/A,INDICATI,Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T86836,#N/A,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T86836,#N/A,INDICATI,Phase 1/2,Mycobacterium infection,[ICD-11: 1B10-1B21]
T86836,#N/A,INDICATI,Approved,Myelodysplastic syndrome,[ICD-11: 2A37]
T86836,#N/A,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T86836,#N/A,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T86836,#N/A,INDICATI,Phase 2,Osteosarcoma,[ICD-11: 2B51]
T86836,#N/A,INDICATI,Approved,Ovarian cancer,[ICD-11: 2C73]
T86836,#N/A,INDICATI,Approved,Pancreatic cancer,[ICD-11: 2C10]
T86836,#N/A,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
T86836,#N/A,INDICATI,Phase 3,Respiratory infection,[ICD-11: CA07-CA4Z]
T86836,#N/A,INDICATI,Phase 1,Skin disease,[ICD-11: EA00-EM0Z]
T86836,#N/A,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T86836,#N/A,INDICATI,Phase 1,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
T86836,#N/A,INDICATI,Discontinued in Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T86837,#N/A,TARGETID,T86837,,
T86837,#N/A,TARGNAME,HUMAN calpain-2/calpain small subunit 1 heterodimer (CAPN2/CAPNS1),,
T86837,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T86885,APOH,TARGETID,T86885,,
T86885,APOH,TARGNAME,Beta-2-glycoprotein 1 (APOH),,
T86885,APOH,INDICATI,Discontinued in Phase 1,Antiphospholipid syndrome,[ICD-11: 4A45]
,#N/A,,,,
T86918,AMY2A,TARGETID,T86918,,
T86918,AMY2A,TARGNAME,Pancreatic alpha-amylase (AMY2A),,
T86918,AMY2A,INDICATI,Phase 3,Cystic fibrosis,[ICD-11: CA25]
T86918,AMY2A,INDICATI,NDA filed,Pancreatic malfunction,[ICD-11: DC30-DC3Z]
,#N/A,,,,
T86928,#N/A,TARGETID,T86928,,
T86928,#N/A,TARGNAME,HUMAN casein kinase II (CSK2),,
T86928,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T86928,#N/A,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
,#N/A,,,,
T86992,MycB antigens,TARGETID,T86992,,
T86992,MycB antigens,TARGNAME,Mycobacterium Fusion protein Rv2608-Rv3619-Rv3620-Rv1813 (MycB antigens),,
T86992,MycB antigens,INDICATI,Phase 2,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
,#N/A,,,,
T87023,PTAFR,TARGETID,T87023,,
T87023,PTAFR,TARGNAME,Platelet-activating factor receptor (PTAFR),,
T87023,PTAFR,INDICATI,Discontinued in Phase 1,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T87023,PTAFR,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T87023,PTAFR,INDICATI,Terminated,Cardiac arrhythmia,[ICD-11: BC9Z]
T87023,PTAFR,INDICATI,Investigative,Cerebral ischaemia,[ICD-11: 8B1Z]
T87023,PTAFR,INDICATI,Terminated,Cerebral ischaemic stroke,[ICD-11: 8B11]
T87023,PTAFR,INDICATI,Discontinued in Phase 2,Conjunctiva disorder,[ICD-11: 9A60]
T87023,PTAFR,INDICATI,Phase 2,Dengue fever,[ICD-11: 1D2Z]
T87023,PTAFR,INDICATI,Investigative,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T87023,PTAFR,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T87023,PTAFR,INDICATI,Approved,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T87023,PTAFR,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T87023,PTAFR,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T87023,PTAFR,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T87023,PTAFR,INDICATI,Phase 2,Sepsis,[ICD-11: 1G40-1G41]
T87023,PTAFR,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T87023,PTAFR,INDICATI,Terminated,Thrombocytopenia,[ICD-11: 3B64]
T87023,PTAFR,INDICATI,Terminated,Thrombosis,[ICD-11: DB61-GB90]
T87023,PTAFR,INDICATI,Phase 2,Unspecific body region injury,[ICD-11: ND56]
,#N/A,,,,
T87024,APP,TARGETID,T87024,,
T87024,APP,TARGNAME,Amyloid beta A4 protein (APP),,
T87024,APP,INDICATI,Approved,Alzheimer disease,[ICD-11: 8A20]
T87024,APP,INDICATI,Phase 1,Amyloidosis,[ICD-11: 5D00]
T87024,APP,INDICATI,Investigative,Brain cancer,[ICD-11: 2A00]
T87024,APP,INDICATI,Approved,Diagnostic imaging,[ICD-11: N.A.]
T87024,APP,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T87024,APP,INDICATI,Phase 1/2,Dystrophic epidermolysis bullosa,[ICD-11: EC32]
T87024,APP,INDICATI,Preclinical,Intracranial injury,[ICD-11: NA07]
T87024,APP,INDICATI,Discontinued in Phase 2,Macular degeneration,[ICD-11: 9B75]
T87024,APP,INDICATI,Investigative,Mild neurocognitive disorder,[ICD-11: 6D71]
T87024,APP,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T87024,APP,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T87075,CD3E,TARGETID,T87075,,
T87075,CD3E,TARGNAME,T-cell surface glycoprotein CD3 epsilon (CD3E),,
T87075,CD3E,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T87075,CD3E,INDICATI,Phase 1/2,Melanoma,[ICD-11: 2C30]
T87075,CD3E,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T87075,CD3E,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T87075,CD3E,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T87075,CD3E,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T87108,MSLN,TARGETID,T87108,,
T87108,MSLN,TARGNAME,Mesothelin (MSLN),,
T87108,MSLN,INDICATI,Phase 1/2,Breast cancer,[ICD-11: 2C60-2C6Y]
T87108,MSLN,INDICATI,Phase 1/2,Cervical cancer,[ICD-11: 2C77]
T87108,MSLN,INDICATI,Phase 1,Endometrial cancer,[ICD-11: 2C76]
T87108,MSLN,INDICATI,Phase 1,Fallopian tube cancer,[ICD-11: 2C74]
T87108,MSLN,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T87108,MSLN,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T87108,MSLN,INDICATI,Phase 1,Lymphatic vessel/lymph nodes disorder,[ICD-11: BD9Z]
T87108,MSLN,INDICATI,Phase 1,Mesothelial tumour,[ICD-11: 2F10]
T87108,MSLN,INDICATI,Phase 1,Mesothelin positive tumour,[ICD-11: 2C51-2F10]
T87108,MSLN,INDICATI,Phase 1,Metastatic malignant neoplasm,[ICD-11: 2D50-2E09]
T87108,MSLN,INDICATI,Phase 1,Metastatic pleura neoplasm,[ICD-11: 2D72]
T87108,MSLN,INDICATI,Phase 1/2,Non-small-cell lung cancer,[ICD-11: 2C25]
T87108,MSLN,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T87108,MSLN,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T87108,MSLN,INDICATI,Phase 2,Peritoneal cancer,[ICD-11: 2C51]
T87108,MSLN,INDICATI,Phase 1,Pleural mesothelioma,[ICD-11: 2C26]
T87108,MSLN,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T87108,MSLN,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T87109,CSNK1D,TARGETID,T87109,,
T87109,CSNK1D,TARGNAME,Casein kinase I delta (CSNK1D),,
T87109,CSNK1D,INDICATI,Preclinical,Mature B-cell leukaemia,[ICD-11: 2A82]
T87109,CSNK1D,INDICATI,Preclinical,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T87119,#N/A,TARGETID,T87119,,
T87119,#N/A,TARGNAME,Fungal Cell membrane (Fung CM),,
T87119,#N/A,INDICATI,Approved,Candidosis,[ICD-11: 1F23]
T87119,#N/A,INDICATI,Approved,Conjunctiva disorder,[ICD-11: 9A60]
T87119,#N/A,INDICATI,Approved,Dermatophytosis,[ICD-11: 1F28]
,#N/A,,,,
T87166,GCK,TARGETID,T87166,,
T87166,GCK,TARGNAME,Glucokinase (GCK),,
T87166,GCK,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T87166,GCK,INDICATI,Phase 1/2,Diabetes mellitus,[ICD-11: 5A10]
T87166,GCK,INDICATI,Phase 1,Obesity,[ICD-11: 5B80-5B81]
T87166,GCK,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T87206,S100B,TARGETID,T87206,,
T87206,S100B,TARGNAME,S100 calcium-binding protein B (S100B),,
T87206,S100B,INDICATI,Phase 2/3,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T87206,S100B,INDICATI,Terminated,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T87237,#N/A,TARGETID,T87237,,
T87237,#N/A,TARGNAME,Cell differentiation (CD),,
T87237,#N/A,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T87237,#N/A,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T87237,#N/A,INDICATI,Phase 1/2,Myelodysplastic syndrome,[ICD-11: 2A37]
T87237,#N/A,INDICATI,Phase 1/2,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T87259,ITGAV,TARGETID,T87259,,
T87259,ITGAV,TARGNAME,ITGAV messenger RNA (ITGAV mRNA),,
T87259,ITGAV,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T87325,#N/A,TARGETID,T87325,,
T87325,#N/A,TARGNAME,COVID-19 papain-like proteinase (PL-PRO),,
T87325,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T87325,#N/A,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
T87325,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T87325,#N/A,INDICATI,Phase 2b,Episodic vestibular syndrome,[ICD-11: AB31]
T87325,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T87325,#N/A,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T87325,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
T87325,#N/A,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T87350,PDGFB,TARGETID,T87350,,
T87350,PDGFB,TARGNAME,Platelet-derived growth factor B (PDGFB),,
T87350,PDGFB,INDICATI,Phase 1,Cystic fibrosis,[ICD-11: CA25]
T87350,PDGFB,INDICATI,Phase 3,Diabetic foot ulcer,[ICD-11: BD54]
T87350,PDGFB,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T87374,#N/A,TARGETID,T87374,,
T87374,#N/A,TARGNAME,COVID-19 spike glycoprotein (S),,
T87374,#N/A,INDICATI,Phase 1,Coronavirus infection,[ICD-11: 1D92]
T87374,#N/A,INDICATI,Approved in EU,COVID-19,[ICD-11: 1D6Y]
T87374,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
,#N/A,,,,
T87467,#N/A,TARGETID,T87467,,
T87467,#N/A,TARGNAME,Folate receptor (FOLR),,
T87467,#N/A,INDICATI,Approved,Folate deficiency anaemia,[ICD-11: 3A02]
T87467,#N/A,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
,#N/A,,,,
T87554,#N/A,TARGETID,T87554,,
T87554,#N/A,TARGNAME,HUMAN janus kinase 2 (JAK-2),,
T87554,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T87554,#N/A,INDICATI,Approved,Myelofibrosis,[ICD-11: 2A22]
T87554,#N/A,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T87608,#N/A,TARGETID,T87608,,
T87608,#N/A,TARGNAME,Mitochondrial gene transcription (MGT),,
T87608,#N/A,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T87633,#N/A,TARGETID,T87633,,
T87633,#N/A,TARGNAME,HUMAN toll-like receptor 9 (TLR9),,
T87633,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T87670,GPR55,TARGETID,T87670,,
T87670,GPR55,TARGNAME,G-protein coupled receptor 55 (GPR55),,
T87670,GPR55,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T87670,GPR55,INDICATI,Phase 1,Intellectual development disorder,[ICD-11: LD90]
,#N/A,,,,
T87675,AURKA,TARGETID,T87675,,
T87675,AURKA,TARGNAME,Aurora kinase A (AURKA),,
T87675,AURKA,INDICATI,Phase 3,Acute diabete complication,[ICD-11: 5A2Y]
T87675,AURKA,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T87675,AURKA,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T87675,AURKA,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T87675,AURKA,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T87675,AURKA,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T87675,AURKA,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T87675,AURKA,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T87686,DOT1L,TARGETID,T87686,,
T87686,DOT1L,TARGNAME,Histone-lysine N-methyltransferase (HLNM),,
T87686,DOT1L,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T87686,DOT1L,INDICATI,Investigative,Leukaemia,[ICD-11: 2A60-2B33]
T87686,DOT1L,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T87686,DOT1L,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
,#N/A,,,,
T87742,#N/A,TARGETID,T87742,,
T87742,#N/A,TARGNAME,Gap junction protein (GJP),,
T87742,#N/A,INDICATI,Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T87742,#N/A,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T87749,MSTN,TARGETID,T87749,,
T87749,MSTN,TARGNAME,Growth/differentiation factor 8 (GDF-8),,
T87749,MSTN,INDICATI,Phase 2,Muscle disorder,[ICD-11: FB32-FB3Z]
T87749,MSTN,INDICATI,Phase 2,Muscular atrophy,[ICD-11: 8B61]
T87749,MSTN,INDICATI,Phase 2,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T87831,FPR1,TARGETID,T87831,,
T87831,FPR1,TARGNAME,N-formyl peptide receptor (FPR1),,
T87831,FPR1,INDICATI,Phase 3,Peptic ulcer,[ICD-11: DA61]
T87831,FPR1,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T87871,ROR1,TARGETID,T87871,,
T87871,ROR1,TARGNAME,Neurotrophic tyrosine kinase ROR1 (ROR1),,
T87871,ROR1,INDICATI,Phase 2/3,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T87871,ROR1,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T87871,ROR1,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T87871,ROR1,INDICATI,Phase 2,Mature B-cell lymphoma,[ICD-11: 2A85]
T87871,ROR1,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T87871,ROR1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T87875,GCGR,TARGETID,T87875,,
T87875,GCGR,TARGNAME,Glucagon receptor messenger RNA (GCGR mRNA),,
T87875,GCGR,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T87875,GCGR,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T87939,KLKB1,TARGETID,T87939,,
T87939,KLKB1,TARGNAME,Plasma kallikrein messenger RNA (KLKB1 mRNA),,
T87939,KLKB1,INDICATI,Phase 3,Amyloidosis,[ICD-11: 5D00]
T87939,KLKB1,INDICATI,Phase 3,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
,#N/A,,,,
T87946,#N/A,TARGETID,T87946,,
T87946,#N/A,TARGNAME,Cytokine receptor unspecific (CRF),,
T87946,#N/A,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T87946,#N/A,INDICATI,Discontinued in Phase 1,Alzheimer disease,[ICD-11: 8A20]
T87946,#N/A,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T87946,#N/A,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T87946,#N/A,INDICATI,Investigative,Leukaemia,[ICD-11: 2A60-2B33]
T87946,#N/A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T87946,#N/A,INDICATI,Discontinued in Phase 2,Sepsis,[ICD-11: 1G40-1G41]
T87946,#N/A,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T87946,#N/A,INDICATI,Phase 2,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
,#N/A,,,,
T87975,#N/A,TARGETID,T87975,,
T87975,#N/A,TARGNAME,Fungal Proton pump (FPPCM),,
T87975,#N/A,INDICATI,Approved,Seborrhoeic dermatitis,[ICD-11: EA81]
,#N/A,,,,
T88015,#N/A,TARGETID,T88015,,
T88015,#N/A,TARGNAME,COVID-19 3C-like protease (3CLpro),,
T88015,#N/A,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
T88015,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T88015,#N/A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T88015,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T88015,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T88023,TNFRSF8,TARGETID,T88023,,
T88023,TNFRSF8,TARGNAME,Lymphocyte activation antigen CD30 (TNFRSF8),,
T88023,TNFRSF8,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T88023,TNFRSF8,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T88023,TNFRSF8,INDICATI,Phase 1,Follicular lymphoma,[ICD-11: 2A80]
T88023,TNFRSF8,INDICATI,Approved,Hodgkin lymphoma,[ICD-11: 2B30]
T88023,TNFRSF8,INDICATI,Phase 1/2,Immune system disease,[ICD-11: 4A01-4B41]
T88023,TNFRSF8,INDICATI,Phase 1/2,Immunoproliferative disorder,[ICD-11: 2B32]
T88023,TNFRSF8,INDICATI,Phase 1/2,Leukaemia,[ICD-11: 2A60-2B33]
T88023,TNFRSF8,INDICATI,Phase 1/2,Lymphatic vessel/lymph nodes disorder,[ICD-11: BD9Z]
T88023,TNFRSF8,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T88023,TNFRSF8,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T88023,TNFRSF8,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T88023,TNFRSF8,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
T88023,TNFRSF8,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T88023,TNFRSF8,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T88182,GGCX,TARGETID,T88182,,
T88182,GGCX,TARGNAME,Vitamin K-dependent gamma-carboxylase (GGCX),,
T88182,GGCX,INDICATI,Approved,Bleeding disorder,[ICD-11: GA20-GA21]
T88182,GGCX,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T88185,HCAR2,TARGETID,T88185,,
T88185,HCAR2,TARGNAME,Nicotinic acid receptor (HCAR2),,
T88185,HCAR2,INDICATI,Phase 2,Arterial occlusive disease,[ICD-11: BD40]
T88185,HCAR2,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T88185,HCAR2,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T88185,HCAR2,INDICATI,Investigative,Depression,[ICD-11: 6A70-6A7Z]
T88185,HCAR2,INDICATI,Phase 2,Dyslipidemia,[ICD-11: 5C80-5C81]
T88185,HCAR2,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T88185,HCAR2,INDICATI,Approved,Inborn lipid metabolism error,[ICD-11: 5C52]
T88185,HCAR2,INDICATI,Clinical trial,Psoriasis,[ICD-11: EA90]
T88185,HCAR2,INDICATI,Discontinued in Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T88240,Bact folP,TARGETID,T88240,,
T88240,Bact folP,TARGNAME,Bacterial Dihydropteroate synthetase (Bact folP),,
T88240,Bact folP,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T88240,Bact folP,INDICATI,Approved,Cystitis,[ICD-11: GC00]
T88240,Bact folP,INDICATI,Approved,Dermatitis herpetiformis,[ICD-11: EB44]
T88240,Bact folP,INDICATI,Approved,Glanders,[ICD-11: 1B92]
T88240,Bact folP,INDICATI,Approved,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T88240,Bact folP,INDICATI,Investigative,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T88240,Bact folP,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T88240,Bact folP,INDICATI,Approved,Respiratory infection,[ICD-11: CA07-CA4Z]
T88240,Bact folP,INDICATI,Approved,Rheumatic fever,[ICD-11: 1B40]
T88240,Bact folP,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T88285,GLO1,TARGETID,T88285,,
T88285,GLO1,TARGNAME,Lactoylglutathione lyase (GLO1),,
T88285,GLO1,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
,#N/A,,,,
T88304,DNMT1,TARGETID,T88304,,
T88304,DNMT1,TARGNAME,DNA [cytosine-5]-methyltransferase 1 (DNMT1),,
T88304,DNMT1,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T88304,DNMT1,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T88304,DNMT1,INDICATI,Investigative,Brain cancer,[ICD-11: 2A00]
T88304,DNMT1,INDICATI,Phase 1,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T88304,DNMT1,INDICATI,Phase 2,Kaposi sarcoma,[ICD-11: 2B57]
T88304,DNMT1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T88304,DNMT1,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T88304,DNMT1,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T88304,DNMT1,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T88304,DNMT1,INDICATI,Phase 1,Sickle-cell disorder,[ICD-11: 3A51]
T88304,DNMT1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T88318,#N/A,TARGETID,T88318,,
T88318,#N/A,TARGNAME,Protein kinase C (PRKC),,
T88318,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T88318,#N/A,INDICATI,Discontinued in Phase 3,Cardiac arrhythmia,[ICD-11: BC9Z]
T88318,#N/A,INDICATI,Phase 2,Diabetic foot ulcer,[ICD-11: BD54]
T88318,#N/A,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T88318,#N/A,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T88318,#N/A,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T88318,#N/A,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T88318,#N/A,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T88318,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T88318,#N/A,INDICATI,Discontinued in Phase 3,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T88318,#N/A,INDICATI,Phase 2,Transplant rejection,[ICD-11: NE84]
T88318,#N/A,INDICATI,Phase 3,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T88322,SSRP1,TARGETID,T88322,,
T88322,SSRP1,TARGNAME,Facilitates chromatin transcription complex (FACT),,
T88322,SSRP1,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T88322,SSRP1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T88338,#N/A,TARGETID,T88338,,
T88338,#N/A,TARGNAME,Bacterial 23S ribosomal RNA (Bact 23S rRNA),,
T88338,#N/A,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T88338,#N/A,INDICATI,Phase 2,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T88338,#N/A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T88338,#N/A,INDICATI,Approved,Pneumonia,[ICD-11: CA40]
,#N/A,,,,
T88360,RSV N,TARGETID,T88360,,
T88360,RSV N,TARGNAME,Respiratory syncytial virus protein N (RSV N),,
T88360,RSV N,INDICATI,Phase 2,Viral encephalitis,[ICD-11: 1C80]
T88360,RSV N,INDICATI,Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T88430,ARAF,TARGETID,T88430,,
T88430,ARAF,TARGNAME,A-Raf messenger RNA (ARAF mRNA),,
T88430,ARAF,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T88452,SERPINA6,TARGETID,T88452,,
T88452,SERPINA6,TARGNAME,Corticosteroid-binding globulin (SERPINA6),,
T88452,SERPINA6,INDICATI,Approved,Asthma,[ICD-11: CA23]
T88452,SERPINA6,INDICATI,Approved,Postoperative inflammation,[ICD-11: 1A00-CA43]
T88452,SERPINA6,INDICATI,Approved,Respiratory system disease,[ICD-11: CB40-CB7Z]
T88452,SERPINA6,INDICATI,Phase 3,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T88479,#N/A,TARGETID,T88479,,
T88479,#N/A,TARGNAME,Malondialdehyde (MDA),,
T88479,#N/A,INDICATI,Phase 3,Inborn lipid metabolism error,[ICD-11: 5C52]
,#N/A,,,,
T88483,#N/A,TARGETID,T88483,,
T88483,#N/A,TARGNAME,microRNA hsa-miR-155 (MIR155),,
T88483,#N/A,INDICATI,Phase 1,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T88483,#N/A,INDICATI,Phase 2,Keloid/hypertrophic scar,[ICD-11: EE60]
T88483,#N/A,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T88483,#N/A,INDICATI,Phase 2,Mycosis fungoides,[ICD-11: 2B01]
T88483,#N/A,INDICATI,Phase 1,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T88505,NFE2L2,TARGETID,T88505,,
T88505,NFE2L2,TARGNAME,Nuclear factor erythroid 2-related factor 2 (Nrf2),,
T88505,NFE2L2,INDICATI,Preclinical,Alpha-1-antitrypsin deficiency,[ICD-11: 5C5A]
T88505,NFE2L2,INDICATI,Approved,Ataxic disorder,[ICD-11: 8A03]
T88505,NFE2L2,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T88505,NFE2L2,INDICATI,Phase 2,Glaucoma,[ICD-11: 9C61]
T88505,NFE2L2,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T88505,NFE2L2,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T88505,NFE2L2,INDICATI,Phase 1/2,Melanoma,[ICD-11: 2C30]
T88505,NFE2L2,INDICATI,Clinical trial,Mental/behavioural/neurodevelopmental disorder,[ICD-11: 6E20-6E8Z]
T88505,NFE2L2,INDICATI,Preclinical,Motor neuron disease,[ICD-11: 8B60]
T88505,NFE2L2,INDICATI,Preclinical,Multiple sclerosis,[ICD-11: 8A40]
T88505,NFE2L2,INDICATI,Phase 1,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T88505,NFE2L2,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
T88505,NFE2L2,INDICATI,Phase 2,Subarachnoid haemorrhage,[ICD-11: 8B01]
T88505,NFE2L2,INDICATI,Phase 2,Urinary system clinical sympton,[ICD-11: MF8Y]
,#N/A,,,,
T88531,GPR39,TARGETID,T88531,,
T88531,GPR39,TARGNAME,G-protein coupled receptor 39 (GPR39),,
T88531,GPR39,INDICATI,Investigative,Acute diabete complication,[ICD-11: 5A2Y]
,#N/A,,,,
T88537,#N/A,TARGETID,T88537,,
T88537,#N/A,TARGNAME,Mitochondrial protein unspecific (MP),,
T88537,#N/A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T88537,#N/A,INDICATI,Phase 1/2,Ataxic disorder,[ICD-11: 8A03]
T88537,#N/A,INDICATI,Phase 1/2,Muscular dystrophy,[ICD-11: 8C70]
T88537,#N/A,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T88547,#N/A,TARGETID,T88547,,
T88547,#N/A,TARGNAME,HUMAN opioid receptor sigma 1 (OPRS1),,
T88547,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T88547,#N/A,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T88569,IDH1,TARGETID,T88569,,
T88569,IDH1,TARGNAME,Mutated oxalosuccinate decarboxylase (mIDH1),,
T88569,IDH1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T88569,IDH1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T88595,#N/A,TARGETID,T88595,,
T88595,#N/A,TARGNAME,MERS-CoV spike glycoprotein (S),,
T88595,#N/A,INDICATI,Phase 2/3,COVID-19,[ICD-11: 1D6Y]
T88595,#N/A,INDICATI,Discontinued in Phase 1,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T88595,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T88637,#N/A,TARGETID,T88637,,
T88637,#N/A,TARGNAME,Myosin (MYO),,
T88637,#N/A,INDICATI,Approved,Cardiomyopathy,[ICD-11: BC43]
,#N/A,,,,
T88656,NOTCH2,TARGETID,T88656,,
T88656,NOTCH2,TARGNAME,Notch-2 receptor (NOTCH2),,
T88656,NOTCH2,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T88656,NOTCH2,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T88697,ANGPTL3,TARGETID,T88697,,
T88697,ANGPTL3,TARGNAME,ANGPTL3 messenger RNA (ANGPTL3 mRNA),,
T88697,ANGPTL3,INDICATI,Phase 2,Dyslipidemia,[ICD-11: 5C80-5C81]
T88697,ANGPTL3,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T88697,ANGPTL3,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T88697,ANGPTL3,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T88714,ADORA1,TARGETID,T88714,,
T88714,ADORA1,TARGNAME,ADORA1 messenger RNA (ADORA1 mRNA),,
T88714,ADORA1,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T88714,ADORA1,INDICATI,Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T88729,UCP1,TARGETID,T88729,,
T88729,UCP1,TARGNAME,Mitochondrial uncoupling protein 1 (UCP1),,
T88729,UCP1,INDICATI,Phase 2,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T88752,RAC1,TARGETID,T88752,,
T88752,RAC1,TARGNAME,Ras-related C3 botulinum toxin substrate 1 (RAC1),,
T88752,RAC1,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T88806,ITGA5-ITGB1,TARGETID,T88806,,
T88806,ITGA5-ITGB1,TARGNAME,Integrin alpha-5/beta-1 (ITGA5/B1),,
T88806,ITGA5-ITGB1,INDICATI,Terminated,Herpes simplex infection,[ICD-11: 1F00]
T88806,ITGA5-ITGB1,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T88806,ITGA5-ITGB1,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T88806,ITGA5-ITGB1,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
,#N/A,,,,
T88847,DMD,TARGETID,T88847,,
T88847,DMD,TARGNAME,Dystrophin messenger RNA (DMD mRNA),,
T88847,DMD,INDICATI,Approved,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T88887,Stap-coc rpoB,TARGETID,T88887,,
T88887,Stap-coc rpoB,TARGNAME,Staphylococcus Plastid RNA polymerase beta (Stap-coc rpoB),,
T88887,Stap-coc rpoB,INDICATI,Approved,Bowel habit change,[ICD-11: ME05]
T88887,Stap-coc rpoB,INDICATI,Phase 3,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T88975,PDE3A,TARGETID,T88975,,
T88975,PDE3A,TARGNAME,Phosphodiesterase 3A (PDE3A),,
T88975,PDE3A,INDICATI,Approved,Arterial occlusive disease,[ICD-11: BD40]
T88975,PDE3A,INDICATI,Approved,Asthma,[ICD-11: CA23]
T88975,PDE3A,INDICATI,Discontinued in Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T88975,PDE3A,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T88975,PDE3A,INDICATI,Approved,Thrombocytosis,[ICD-11: 3B63]
,#N/A,,,,
T89034,PLG,TARGETID,T89034,,
T89034,PLG,TARGNAME,Plasminogen (PLG),,
T89034,PLG,INDICATI,Phase 2/3,Alzheimer disease,[ICD-11: 8A20]
T89034,PLG,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T89034,PLG,INDICATI,Approved,Bleeding disorder,[ICD-11: GA20-GA21]
T89034,PLG,INDICATI,Investigative,Cerebral ischaemia,[ICD-11: 8B1Z]
T89034,PLG,INDICATI,Phase 3,Cerebral ischaemic stroke,[ICD-11: 8B11]
T89034,PLG,INDICATI,Phase 2,Cerebral ischaemic stroke,ICD-11: 8B11
T89034,PLG,INDICATI,Approved,Menopausal disorder,[ICD-11: GA30]
T89034,PLG,INDICATI,Investigative,Menstrual cycle bleeding disorder,[ICD-11: GA20]
T89034,PLG,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T89034,PLG,INDICATI,Clinical trial,Otitis media,[ICD-11: AA80-AB0Z]
T89034,PLG,INDICATI,Approved,Procedure injury,[ICD-11: NE81]
T89034,PLG,INDICATI,Approved,Pulmonary thromboembolism,[ICD-11: BB00]
T89034,PLG,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T89034,PLG,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T89034,PLG,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T89039,#N/A,TARGETID,T89039,,
T89039,#N/A,TARGNAME,HUMAN sigma intracellular receptor 2 (TMEM97),,
T89039,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T89039,#N/A,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T89041,CYP17A1,TARGETID,T89041,,
T89041,CYP17A1,TARGNAME,Steroid 17-alpha-monooxygenase (S17AH),,
T89041,CYP17A1,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T89041,CYP17A1,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T89055,MAP2K2,TARGETID,T89055,,
T89055,MAP2K2,TARGNAME,ERK activator kinase 2 (MEK2),,
T89055,MAP2K2,INDICATI,Investigative,Cardiac arrest,[ICD-11: MC82]
T89055,MAP2K2,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T89055,MAP2K2,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T89055,MAP2K2,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T89055,MAP2K2,INDICATI,Phase 3,Thyroid cancer,[ICD-11: 2D10]
,#N/A,,,,
T89083,#N/A,TARGETID,T89083,,
T89083,#N/A,TARGNAME,HUMAN toll-like receptor 2 (TLR2),,
T89083,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T89086,#N/A,TARGETID,T89086,,
T89086,#N/A,TARGNAME,Toxic reactive metabolite (TRM),,
T89086,#N/A,INDICATI,Approved,Nasopharyngitis,[ICD-11: CA00]
,#N/A,,,,
T89147,SOD2,TARGETID,T89147,,
T89147,SOD2,TARGNAME,Superoxide dismutase Mn (SOD Mn),,
T89147,SOD2,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T89176,CD gyrA; CD gyrB,TARGETID,T89176,,
T89176,CD gyrA; CD gyrB,TARGNAME,Clostridium difficile DNA gyrase (CD gyr),,
T89176,CD gyrA; CD gyrB,INDICATI,Phase 1,Clostridium difficile enterocolitis,[ICD-11: 1A04]
,#N/A,,,,
T89213,NPY1R,TARGETID,T89213,,
T89213,NPY1R,TARGNAME,Neuropeptide Y receptor type 1 (NPY1R),,
T89213,NPY1R,INDICATI,Terminated,Binge eating disorder,[ICD-11: 6B82]
T89213,NPY1R,INDICATI,Discontinued in Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T89213,NPY1R,INDICATI,Preclinical,Heart disease,[ICD-11: BA41-BA42]
T89213,NPY1R,INDICATI,Preclinical,Hypertension,[ICD-11: BA00-BA04]
T89213,NPY1R,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T89234,C5,TARGETID,T89234,,
T89234,C5,TARGNAME,C5 messenger RNA (C5 mRNA),,
T89234,C5,INDICATI,Phase 2,Haemolytic anemia,[ICD-11: 3A20-3A2Z]
,#N/A,,,,
T89251,BAX,TARGETID,T89251,,
T89251,BAX,TARGNAME,Apoptosis regulator BAX (BAX),,
T89251,BAX,INDICATI,Phase 2/3,Ovarian dysfunction,[ICD-11: 5A80]
,#N/A,,,,
T89360,IMPDH2,TARGETID,T89360,,
T89360,IMPDH2,TARGNAME,Inosine-5'-monophosphate dehydrogenase 2 (IMPDH2),,
T89360,IMPDH2,INDICATI,Investigative,Immune system disease,[ICD-11: 4A01-4B41]
T89360,IMPDH2,INDICATI,Phase 3,Pemphigus,[ICD-11: EB40]
T89360,IMPDH2,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T89361,CDK6,TARGETID,T89361,,
T89361,CDK6,TARGNAME,Cyclin-dependent kinase 6 (CDK6),,
T89361,CDK6,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T89361,CDK6,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T89361,CDK6,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T89361,CDK6,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T89361,CDK6,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
T89361,CDK6,INDICATI,Terminated,Schizophrenia,[ICD-11: 6A20]
T89361,CDK6,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T89415,#N/A,TARGETID,T89415,,
T89415,#N/A,TARGNAME,HUMAN toll-like receptor 6 (TLR6),,
T89415,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T89458,SLC2A1,TARGETID,T89458,,
T89458,SLC2A1,TARGNAME,HepG2 glucose transporter (SLC2A1),,
T89458,SLC2A1,INDICATI,Preclinical,Skin disease,[ICD-11: EA00-EM0Z]
,#N/A,,,,
T89515,PDF,TARGETID,T89515,,
T89515,PDF,TARGNAME,Polypeptide deformylase (PDF),,
T89515,PDF,INDICATI,Approved,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T89515,PDF,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T89515,PDF,INDICATI,Investigative,Gram-positive bacterial infection,[ICD-11: 1B74-1F40]
T89515,PDF,INDICATI,Phase 2/3,Indeterminate colitis,[ICD-11: DD72]
T89515,PDF,INDICATI,Withdrawn from market,Leukaemia,[ICD-11: 2A60-2B33]
T89515,PDF,INDICATI,Discontinued in Phase 1,Liver vascular disorder,[ICD-11: DB98]
T89515,PDF,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
T89515,PDF,INDICATI,Approved,Mature T-cell lymphoma,[ICD-11: 2A90]
T89515,PDF,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
T89515,PDF,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T89515,PDF,INDICATI,Approved,Toxoplasmosis,[ICD-11: 1F57]
,#N/A,,,,
T89529,PTPN1,TARGETID,T89529,,
T89529,PTPN1,TARGNAME,PTPN1 messenger RNA (PTPN1 mRNA),,
T89529,PTPN1,INDICATI,Phase 2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T89529,PTPN1,INDICATI,Approved,Ophthalmic devices/implants/grafts injury,[ICD-11: PK97]
T89529,PTPN1,INDICATI,Approved,Postoperative inflammation,[ICD-11: 1A00-CA43]
T89529,PTPN1,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T89534,ESR1,TARGETID,T89534,,
T89534,ESR1,TARGNAME,Estrogen receptor (ESR),,
T89534,ESR1,INDICATI,Approved,Acne vulgaris,[ICD-11: ED80]
T89534,ESR1,INDICATI,Approved,Acquired prion disease,[ICD-11: 8E01]
T89534,ESR1,INDICATI,Approved,Adrenal cancer,[ICD-11: 2D11]
T89534,ESR1,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T89534,ESR1,INDICATI,Preclinical,Atrophy,[ICD-11: 9A2Y-9C40]
T89534,ESR1,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T89534,ESR1,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T89534,ESR1,INDICATI,Phase 2,Breast in situ carcinoma,[ICD-11: 2E65]
T89534,ESR1,INDICATI,Approved,Contraceptive management,[ICD-11: QA21]
T89534,ESR1,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T89534,ESR1,INDICATI,Discontinued in Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T89534,ESR1,INDICATI,Approved,Dyspareunia,[ICD-11: GA12]
T89534,ESR1,INDICATI,Phase 3,Endometriosis,[ICD-11: GA10]
T89534,ESR1,INDICATI,Discontinued in Phase 2,Eye disorder,[ICD-11: 9A01-9A0Z]
T89534,ESR1,INDICATI,Phase 3,Female genital tract noninflammatory disorder,[ICD-11: GA1Y]
T89534,ESR1,INDICATI,Approved,Female infertility,[ICD-11: GA31]
T89534,ESR1,INDICATI,Phase 3,Female pelvic pain,[ICD-11: GA34]
T89534,ESR1,INDICATI,Phase 3,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T89534,ESR1,INDICATI,Withdrawn from market,Irregularities,[ICD-11: N.A.]
T89534,ESR1,INDICATI,Preclinical,Joint pain,[ICD-11: ME82]
T89534,ESR1,INDICATI,Investigative,Leukaemia,[ICD-11: 2A60-2B33]
T89534,ESR1,INDICATI,Approved,Low bone mass disorder,[ICD-11: FB83]
T89534,ESR1,INDICATI,Approved,Male infertility,[ICD-11: GB04]
T89534,ESR1,INDICATI,Approved,Menopausal disorder,[ICD-11: GA30]
T89534,ESR1,INDICATI,Approved,Menstrual cycle bleeding disorder,[ICD-11: GA20]
T89534,ESR1,INDICATI,Phase 1,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T89534,ESR1,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T89534,ESR1,INDICATI,Discontinued in Phase 3,Pain,[ICD-11: MG30-MG3Z]
T89534,ESR1,INDICATI,Phase 1/2,Parkinsonism,[ICD-11: 8A00]
T89534,ESR1,INDICATI,Approved,Pituitary gland disorder,[ICD-11: 5A60-5A61]
T89534,ESR1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T89534,ESR1,INDICATI,Preclinical,Sexual dysfunction,[ICD-11: HA00-HA01]
T89534,ESR1,INDICATI,Approved,Skeletal anomaly,[ICD-11: LD24]
T89534,ESR1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T89534,ESR1,INDICATI,Discontinued in Phase 1,Thrombocytopenia,[ICD-11: 3B64]
T89534,ESR1,INDICATI,Withdrawn from market,Trematode disease,[ICD-11: 1F8Y]
T89534,ESR1,INDICATI,Approved,Vaginitis,[ICD-11: GA02]
T89534,ESR1,INDICATI,Discontinued in Phase 1,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T89573,Stap-coc srtA,TARGETID,T89573,,
T89573,Stap-coc srtA,TARGNAME,Staphylococcus Sortase A (Stap-coc srtA),,
T89573,Stap-coc srtA,INDICATI,Preclinical,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T89592,#N/A,TARGETID,T89592,,
T89592,#N/A,TARGNAME,MERS-CoV 3C-like proteinase (3CLpro),,
T89592,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T89592,#N/A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T89592,#N/A,INDICATI,Phase 2/3,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T89592,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T89636,#N/A,TARGETID,T89636,,
T89636,#N/A,TARGNAME,MERS-CoV helicase (Hel),,
T89636,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T89636,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T89658,#N/A,TARGETID,T89658,,
T89658,#N/A,TARGNAME,MERS-CoV RNA-directed RNA polymerase (RdRp),,
T89658,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T89658,#N/A,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T89658,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T89658,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T89697,IDO1,TARGETID,T89697,,
T89697,IDO1,TARGNAME,"Indoleamine 2,3-dioxygenase 1 (IDO1)",,
T89697,IDO1,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T89697,IDO1,INDICATI,Phase 1,B-cell lymphoma,[ICD-11: 2A86]
T89697,IDO1,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T89697,IDO1,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T89697,IDO1,INDICATI,Approved,Depression,[ICD-11: 6A70-6A7Z]
T89697,IDO1,INDICATI,Phase 1,Head and neck cancer,[ICD-11: 2D42]
T89697,IDO1,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T89697,IDO1,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T89697,IDO1,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T89697,IDO1,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T89697,IDO1,INDICATI,Phase 1,Neuroendocrine carcinoma,[ICD-11: 2C34]
T89697,IDO1,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T89697,IDO1,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T89697,IDO1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T89697,IDO1,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T89697,IDO1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T89697,IDO1,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
T89697,IDO1,INDICATI,Phase 3,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T89736,#N/A,TARGETID,T89736,,
T89736,#N/A,TARGNAME,SARS-CoV papain-like proteinase (PL-PRO),,
T89736,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T89736,#N/A,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T89736,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T89736,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
T89736,#N/A,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T89747,ABL1,TARGETID,T89747,,
T89747,ABL1,TARGNAME,ABL messenger RNA (ABL mRNA),,
T89747,ABL1,INDICATI,Discontinued in Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T89772,SLC18A3,TARGETID,T89772,,
T89772,SLC18A3,TARGNAME,Vesicular acetylcholine transporter (SLC18A3),,
T89772,SLC18A3,INDICATI,Discontinued in Phase 2,Motor neuron disease,[ICD-11: 8B60]
,#N/A,,,,
T89826,#N/A,TARGETID,T89826,,
T89826,#N/A,TARGNAME,SARS-CoV 3C-like protease (3CLpro),,
T89826,#N/A,INDICATI,Investigative,COVID-19,[ICD-11: 1D6Y]
T89826,#N/A,INDICATI,Approved,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T89826,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T89826,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T89846,#N/A,TARGETID,T89846,,
T89846,#N/A,TARGNAME,Herpesvirus DNA polymerase (KSHV DNAP),,
T89846,#N/A,INDICATI,Discontinued in Phase 2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T89873,FTH1,TARGETID,T89873,,
T89873,FTH1,TARGNAME,Ferritin (FTH1),,
T89873,FTH1,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
,#N/A,,,,
T89879,#N/A,TARGETID,T89879,,
T89879,#N/A,TARGNAME,SARS-CoV RNA-directed RNA polymerase (RdRp),,
T89879,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T89879,#N/A,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T89879,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T89879,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T89883,#N/A,TARGETID,T89883,,
T89883,#N/A,TARGNAME,Ryanodine receptor (RYR),,
T89883,#N/A,INDICATI,Approved,Fever,[ICD-11: MG26]
T89883,#N/A,INDICATI,Phase 1,Muscular dystrophy,[ICD-11: 8C70]
,#N/A,,,,
T89917,#N/A,TARGETID,T89917,,
T89917,#N/A,TARGNAME,SARS-CoV helicase (Hel),,
T89917,#N/A,INDICATI,Preclinical,Coronavirus infection,[ICD-11: 1D92]
T89917,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T89917,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T89918,GART,TARGETID,T89918,,
T89918,GART,TARGNAME,Glycinamide ribonucleotide formyltransferase (GART),,
T89918,GART,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T89950,#N/A,TARGETID,T89950,,
T89950,#N/A,TARGNAME,Calcitonin gene-related peptide (CALC),,
T89950,#N/A,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T89950,#N/A,INDICATI,Approved,Migraine,[ICD-11: 8A80]
,#N/A,,,,
T89988,CCR2,TARGETID,T89988,,
T89988,CCR2,TARGNAME,C-C chemokine receptor type 2 (CCR2),,
T89988,CCR2,INDICATI,Investigative,Alzheimer disease,[ICD-11: 8A20]
T89988,CCR2,INDICATI,Terminated,Arterial occlusive disease,[ICD-11: BD40]
T89988,CCR2,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T89988,CCR2,INDICATI,Phase 2,Chronic obstructive pulmonary disease,[ICD-11: CA22]
T89988,CCR2,INDICATI,Phase 1,Chronic pain,[ICD-11: MG30]
T89988,CCR2,INDICATI,Investigative,General pain disorder,[ICD-11: 8E43]
T89988,CCR2,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T89988,CCR2,INDICATI,Discontinued in Phase 2,Insulin-resistance syndrome,[ICD-11: 5A44]
T89988,CCR2,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T89988,CCR2,INDICATI,Phase 2,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T89988,CCR2,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T89988,CCR2,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T89988,CCR2,INDICATI,Terminated,Postoperative inflammation,[ICD-11: 1A00-CA43]
T89988,CCR2,INDICATI,Phase 1,Retinopathy,[ICD-11: 9B71]
T89988,CCR2,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T89988,CCR2,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T89988,CCR2,INDICATI,Terminated,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T90035,#N/A,TARGETID,T90035,,
T90035,#N/A,TARGNAME,MERS-CoV spike glycoprotein S2 subunit (S S2),,
T90035,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
,#N/A,,,,
T90038,#N/A,TARGETID,T90038,,
T90038,#N/A,TARGNAME,HUMAN MYD88NF-kappa-B proinflammatory pathway (MYD88-NFKB pathway),,
T90038,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T90038,#N/A,INDICATI,Approved,Hyperlipidemia,[ICD-11: 5C80]
,#N/A,,,,
T90048,#N/A,TARGETID,T90048,,
T90048,#N/A,TARGNAME,HUMAN interleukin-1 receptor 1 (IL1R1),,
T90048,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T90048,#N/A,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T90070,#N/A,TARGETID,T90070,,
T90070,#N/A,TARGNAME,HUMAN interleukin 8 (IL8),,
T90070,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T90286,FGFR3-TACC3,TARGETID,T90286,,
T90286,FGFR3-TACC3,TARGNAME,Fusion protein FGFR3-TACC3 (FGFR3-TACC3),,
T90286,FGFR3-TACC3,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
,#N/A,,,,
T90391,CYP3A4,TARGETID,T90391,,
T90391,CYP3A4,TARGNAME,CYP3A4 messenger RNA (CYP3A4 mRNA),,
T90391,CYP3A4,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
,#N/A,,,,
T90457,CD274,TARGETID,T90457,,
T90457,CD274,TARGNAME,CD274 messenger RNA (CD274 mRNA),,
T90457,CD274,INDICATI,Phase 1,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T90553,MARK3,TARGETID,T90553,,
T90553,MARK3,TARGNAME,Microtubule affinity regulating kinase 3 (MARK3),,
T90553,MARK3,INDICATI,Phase 1/2,Peritoneal cancer,[ICD-11: 2C51]
T90553,MARK3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T90572,IGF2,TARGETID,T90572,,
T90572,IGF2,TARGNAME,Insulin-like growth factor-II (IGF2),,
T90572,IGF2,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T90572,IGF2,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T90628,CHM,TARGETID,T90628,,
T90628,CHM,TARGNAME,Rab proteins geranylgeranyltransferase component A 1 (CHM),,
T90628,CHM,INDICATI,Phase 3,Choroidal dystrophy,ICD-11: 9B61
T90628,CHM,INDICATI,Phase 1/2,Choroidal dystrophy,[ICD-11: 9B61]
,#N/A,,,,
T90648,BRAF,TARGETID,T90648,,
T90648,BRAF,TARGNAME,B-Raf messenger RNA (BRAF mRNA),,
T90648,BRAF,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T90648,BRAF,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T90648,BRAF,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T90665,DLG4-NOS1,TARGETID,T90665,,
T90665,DLG4-NOS1,TARGNAME,PSD95-nNOS interaction (PSD95-nNOS PPI),,
T90665,DLG4-NOS1,INDICATI,Investigative,Anxiety disorder,[ICD-11: 6B00-6B0Z]
,#N/A,,,,
T90672,LGR4,TARGETID,T90672,,
T90672,LGR4,TARGNAME,G-protein coupled receptor 48 (LGR4),,
T90672,LGR4,INDICATI,Preclinical,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T90695,#N/A,TARGETID,T90695,,
T90695,#N/A,TARGNAME,PI3K/AKT/mTOR pathway (PAm pathway),,
T90695,#N/A,INDICATI,Discontinued in Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T90695,#N/A,INDICATI,Phase 1/2,Hydrocephalus,[ICD-11: 8D64]
T90695,#N/A,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T90695,#N/A,INDICATI,Phase 1,Radiation effect,[ICD-11: NF00]
T90695,#N/A,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T90768,#N/A,TARGETID,T90768,,
T90768,#N/A,TARGNAME,Human immunodeficiency virus Trans-activation response element (HIV TAR RNA element),,
T90768,#N/A,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T90782,P2RY6,TARGETID,T90782,,
T90782,P2RY6,TARGNAME,P2Y purinoceptor 6 (P2RY6),,
T90782,P2RY6,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T90782,P2RY6,INDICATI,Discontinued in Phase 3,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T90828,IL5RA,TARGETID,T90828,,
T90828,IL5RA,TARGNAME,Interleukin 5 receptor alpha (IL5RA),,
T90828,IL5RA,INDICATI,Approved,Asthma,[ICD-11: CA23]
T90828,IL5RA,INDICATI,Phase 3,Chronic obstructive pulmonary disease,[ICD-11: CA22]
,#N/A,,,,
T90835,IL1R1; IL1R2,TARGETID,T90835,,
T90835,IL1R1; IL1R2,TARGNAME,Interleukin-1 receptor (IL1R),,
T90835,IL1R1; IL1R2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T90848,#N/A,TARGETID,T90848,,
T90848,#N/A,TARGNAME,HGF/Met signaling pathway (HGF/Met pathway),,
T90848,#N/A,INDICATI,Phase 2/3,Alzheimer disease,[ICD-11: 8A20]
T90848,#N/A,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T90848,#N/A,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T90848,#N/A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T90935,DHCR24,TARGETID,T90935,,
T90935,DHCR24,TARGNAME,Delta(24)-sterol reductase (DHCR24),,
T90935,DHCR24,INDICATI,Preclinical,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T90985,BRDT,TARGETID,T90985,,
T90985,BRDT,TARGNAME,Bromodomain testis-specific protein (BRDT),,
T90985,BRDT,INDICATI,Phase 1,Testicular cancer,[ICD-11: 2C80]
,#N/A,,,,
T90989,FGFR4,TARGETID,T90989,,
T90989,FGFR4,TARGNAME,Fibroblast growth factor receptor 4 (FGFR4),,
T90989,FGFR4,INDICATI,Phase 1/2,Liver cancer,[ICD-11: 2C12]
T90989,FGFR4,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T91023,RSPO1,TARGETID,T91023,,
T91023,RSPO1,TARGNAME,Roof plate-specific spondin-1 (RSPO1),,
T91023,RSPO1,INDICATI,Phase 1,Digestive system disease,[ICD-11: DE2Z]
,#N/A,,,,
T91286,STEAP1,TARGETID,T91286,,
T91286,STEAP1,TARGNAME,Metalloreductase STEAP1 (STEAP1),,
T91286,STEAP1,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T91331,FGFR3,TARGETID,T91331,,
T91331,FGFR3,TARGNAME,Fibroblast growth factor receptor 3 (FGFR3),,
T91331,FGFR3,INDICATI,Phase 1/2,Alzheimer disease,[ICD-11: 8A20]
T91331,FGFR3,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T91331,FGFR3,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T91331,FGFR3,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T91331,FGFR3,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T91331,FGFR3,INDICATI,Approved,Liver cancer,[ICD-11: 2C12]
T91331,FGFR3,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T91331,FGFR3,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T91331,FGFR3,INDICATI,Phase 4,Myocardial infarction,[ICD-11: BA41-BA43]
T91331,FGFR3,INDICATI,Phase 3,Renal cell carcinoma,[ICD-11: 2C90]
T91331,FGFR3,INDICATI,Terminated,Retina cancer,[ICD-11: 2D02]
T91331,FGFR3,INDICATI,Phase 2,Skeletal anomaly,[ICD-11: LD24]
T91331,FGFR3,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T91331,FGFR3,INDICATI,Phase 1,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T91390,Stap-coc crtN,TARGETID,T91390,,
T91390,Stap-coc crtN,TARGNAME,Staphylococcus Dehydrosqualene desaturase (Stap-coc crtN),,
T91390,Stap-coc crtN,INDICATI,Investigative,Staphylococcal/streptococcal disease,[ICD-11: 1B5Y]
,#N/A,,,,
T91435,ROR2,TARGETID,T91435,,
T91435,ROR2,TARGNAME,Neurotrophic tyrosine kinase ROR2 (ROR2),,
T91435,ROR2,INDICATI,Phase 2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T91435,ROR2,INDICATI,Phase 1/2,Renal cell carcinoma,[ICD-11: 2C90]
,#N/A,,,,
T91442,VZV ORF28,TARGETID,T91442,,
T91442,VZV ORF28,TARGNAME,Varicella-zoster virus DNA polymerase (VZV ORF28),,
T91442,VZV ORF28,INDICATI,Phase 3,Herpes simplex infection,[ICD-11: 1F00]
T91442,VZV ORF28,INDICATI,Approved,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T91450,#N/A,TARGETID,T91450,,
T91450,#N/A,TARGNAME,Poly-N-acetyl glucosamine (PNAG),,
T91450,#N/A,INDICATI,Phase 2,Unspecific infection,[ICD-11: 1H0Z]
,#N/A,,,,
T91451,UBE2T,TARGETID,T91451,,
T91451,UBE2T,TARGNAME,E2 ubiquitin-conjugating enzyme T (UBE2T),,
T91451,UBE2T,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T91451,UBE2T,INDICATI,Phase 2,Rectum cancer,[ICD-11: 2B92]
,#N/A,,,,
T91480,ABCC8,TARGETID,T91480,,
T91480,ABCC8,TARGNAME,ATP-binding cassette transporter C8 (ABCC8),,
T91480,ABCC8,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T91480,ABCC8,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T91480,ABCC8,INDICATI,Phase 3,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T91480,ABCC8,INDICATI,Investigative,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T91480,ABCC8,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T91558,TRPC4,TARGETID,T91558,,
T91558,TRPC4,TARGNAME,Short transient receptor potential channel 4 (TRPC4),,
T91558,TRPC4,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
,#N/A,,,,
T91661,ADK,TARGETID,T91661,,
T91661,ADK,TARGNAME,Adenosine kinase (ADK),,
T91661,ADK,INDICATI,Phase 1,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T91661,ADK,INDICATI,Terminated,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T91696,FN1,TARGETID,T91696,,
T91696,FN1,TARGNAME,Fibronectin (FN1),,
T91696,FN1,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T91696,FN1,INDICATI,Approved,Vitreous body disorder,[ICD-11: 9B8Z]
,#N/A,,,,
T91761,ITK,TARGETID,T91761,,
T91761,ITK,TARGNAME,T-cell-specific kinase (ITK),,
T91761,ITK,INDICATI,Phase 1,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T91761,ITK,INDICATI,Phase 1,Mature T-cell lymphoma,[ICD-11: 2A90]
T91761,ITK,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T91761,ITK,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T91894,MAS1,TARGETID,T91894,,
T91894,MAS1,TARGNAME,Proto-oncogene Mas (MAS),,
T91894,MAS1,INDICATI,Phase 3,Diabetic foot ulcer,[ICD-11: BD54]
T91894,MAS1,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T91894,MAS1,INDICATI,Phase 2,Muscular dystrophy,[ICD-11: 8C70]
T91894,MAS1,INDICATI,Phase 2,Nausea/vomiting,[ICD-11: MD90]
T91894,MAS1,INDICATI,Phase 3,Sarcoma,[ICD-11: 2A60-2C35]
,#N/A,,,,
T92030,REG3A,TARGETID,T92030,,
T92030,REG3A,TARGNAME,Regenerating human pro-islet peptide (REG3A),,
T92030,REG3A,INDICATI,Phase 2,Liver disease,[ICD-11: DB90-DB9Z]
T92030,REG3A,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
T92030,REG3A,INDICATI,Phase 1,Type-1/2 diabete,[ICD-11: 5A10-5A11]
,#N/A,,,,
T92035,#N/A,TARGETID,T92035,,
T92035,#N/A,TARGNAME,Hepatitis C virus Internal ribosome entry site messenger RNA (HCV IRES mRNA),,
T92035,#N/A,INDICATI,Discontinued in Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T92042,GFRA3,TARGETID,T92042,,
T92042,GFRA3,TARGNAME,GDNF receptor alpha-3 (GFRA3),,
T92042,GFRA3,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T92057,ERBB4,TARGETID,T92057,,
T92057,ERBB4,TARGNAME,Erbb4 tyrosine kinase receptor (Erbb-4),,
T92057,ERBB4,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T92057,ERBB4,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
T92057,ERBB4,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T92057,ERBB4,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T92057,ERBB4,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T92057,ERBB4,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T92072,ADORA1,TARGETID,T92072,,
T92072,ADORA1,TARGNAME,Adenosine A1 receptor (ADORA1),,
T92072,ADORA1,INDICATI,Discontinued in Phase 1,Acute diabete complication,[ICD-11: 5A2Y]
T92072,ADORA1,INDICATI,Discontinued in Phase 2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T92072,ADORA1,INDICATI,Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T92072,ADORA1,INDICATI,Discontinued in Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T92072,ADORA1,INDICATI,Discontinued in Phase 3,Diabetes mellitus,[ICD-11: 5A10]
T92072,ADORA1,INDICATI,Discontinued in Phase 2,General pain disorder,[ICD-11: 8E43]
T92072,ADORA1,INDICATI,Phase 1/2,Glaucoma,[ICD-11: 9C61]
T92072,ADORA1,INDICATI,Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
T92072,ADORA1,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T92072,ADORA1,INDICATI,Discontinued in Phase 2,Hypertension,[ICD-11: BA00-BA04]
T92072,ADORA1,INDICATI,Preclinical,Ischaemic heart disease,[ICD-11: BA6Z]
T92072,ADORA1,INDICATI,Phase 1,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T92072,ADORA1,INDICATI,Discontinued in Phase 2,Kidney failure,[ICD-11: GB60-GB6Z]
T92072,ADORA1,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T92072,ADORA1,INDICATI,Terminated,Multiple sclerosis,[ICD-11: 8A40]
T92072,ADORA1,INDICATI,Approved,Orthostatic hypotension,[ICD-11: BA21]
T92072,ADORA1,INDICATI,Phase 1,Parkinsonism,[ICD-11: 8A00]
T92072,ADORA1,INDICATI,Investigative,Sepsis,[ICD-11: 1G40-1G41]
T92072,ADORA1,INDICATI,Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
,#N/A,,,,
T92076,CASR,TARGETID,T92076,,
T92076,CASR,TARGNAME,Extracellular calcium-sensing receptor (CASR),,
T92076,CASR,INDICATI,Preclinical,Cerebral ischaemia,[ICD-11: 8B1Z]
T92076,CASR,INDICATI,Approved,Hyper-parathyroidism,[ICD-11: 5A51]
T92076,CASR,INDICATI,Phase 3,Hypo-parathyroidism,ICD-11: 5A50
T92076,CASR,INDICATI,Phase 2,Low bone mass disorder,[ICD-11: FB83]
T92076,CASR,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T92076,CASR,INDICATI,Phase 3,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T92078,DPYSL2,TARGETID,T92078,,
T92078,DPYSL2,TARGNAME,Dihydropyrimidinase related protein 2 (DPYSL2),,
T92078,DPYSL2,INDICATI,Approved,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T92078,DPYSL2,INDICATI,Phase 3,Neuropathy,[ICD-11: 8C0Z]
,#N/A,,,,
T92124,TNFRSF4,TARGETID,T92124,,
T92124,TNFRSF4,TARGNAME,OX40L receptor (CD134),,
T92124,TNFRSF4,INDICATI,Phase 3,Atopic eczema,[ICD-11: EA80]
T92124,TNFRSF4,INDICATI,Phase 2,Metastatic malignant neoplasm,[ICD-11: 2D50-2E09]
T92124,TNFRSF4,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T92124,TNFRSF4,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T92138,#N/A,TARGETID,T92138,,
T92138,#N/A,TARGNAME,Phosphodiesterase (PDE),,
T92138,#N/A,INDICATI,Terminated,Acute diabete complication,[ICD-11: 5A2Y]
T92138,#N/A,INDICATI,Phase 3,Angina pectoris,[ICD-11: BA40]
T92138,#N/A,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T92138,#N/A,INDICATI,Investigative,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T92138,#N/A,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
T92138,#N/A,INDICATI,Discontinued in Phase 3,Heart failure,[ICD-11: BD10-BD1Z]
T92138,#N/A,INDICATI,Discontinued in Phase 2,Postoperative inflammation,[ICD-11: 1A00-CA43]
T92138,#N/A,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T92138,#N/A,INDICATI,Discontinued in Phase 1,Sepsis,[ICD-11: 1G40-1G41]
,#N/A,,,,
T92144,TEK,TARGETID,T92144,,
T92144,TEK,TARGNAME,Angiopoietin 1 receptor (TEK),,
T92144,TEK,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T92144,TEK,INDICATI,Phase 2,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T92144,TEK,INDICATI,Investigative,Ischemia,[ICD-11: 8B10-8B11]
T92144,TEK,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T92144,TEK,INDICATI,Discontinued in Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T92144,TEK,INDICATI,Phase 1/2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T92144,TEK,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T92144,TEK,INDICATI,Discontinued in Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T92144,TEK,INDICATI,Investigative,Sepsis,[ICD-11: 1G40-1G41]
T92144,TEK,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T92185,ADCYAP1R1,TARGETID,T92185,,
T92185,ADCYAP1R1,TARGNAME,PACAP type I receptor (PAC1R),,
T92185,ADCYAP1R1,INDICATI,Phase 2,Migraine,[ICD-11: 8A80]
T92185,ADCYAP1R1,INDICATI,Investigative,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T92281,NPTX2,TARGETID,T92281,,
T92281,NPTX2,TARGNAME,Neuronal pentraxin-2 (NPTX2),,
T92281,NPTX2,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T92281,NPTX2,INDICATI,Phase 2,Myeloproliferative neoplasm,[ICD-11: 2A20]
T92281,NPTX2,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T92281,NPTX2,INDICATI,Phase 2,Thrombocytosis,[ICD-11: 3B63]
,#N/A,,,,
T92308,#N/A,TARGETID,T92308,,
T92308,#N/A,TARGNAME,DNA [cytosine-5]-methyltransferase (DNMT),,
T92308,#N/A,INDICATI,Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T92308,#N/A,INDICATI,Approved,Myelodysplastic syndrome,[ICD-11: 2A37]
T92308,#N/A,INDICATI,Phase 3,Myeloproliferative neoplasm,[ICD-11: 2A20]
T92308,#N/A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T92328,RYR1,TARGETID,T92328,,
T92328,RYR1,TARGNAME,Ryanodine receptor 1 (RYR1),,
T92328,RYR1,INDICATI,Discontinued in Phase 2,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T92403,SLC9A3,TARGETID,T92403,,
T92403,SLC9A3,TARGNAME,Sodium/hydrogen exchanger 3 (SLC9A3),,
T92403,SLC9A3,INDICATI,Discontinued in Phase 2,Angina pectoris,[ICD-11: BA40]
T92403,SLC9A3,INDICATI,Phase 2,Breathing abnormality,[ICD-11: MD11]
T92403,SLC9A3,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T92403,SLC9A3,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T92403,SLC9A3,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T92403,SLC9A3,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T92403,SLC9A3,INDICATI,Phase 2,Urinary system disease,[ICD-11: GC2Z]
,#N/A,,,,
T92424,ITGAV-ITGB5,TARGETID,T92424,,
T92424,ITGAV-ITGB5,TARGNAME,Integrin alpha-V/beta-5 (ITGAV/B5),,
T92424,ITGAV-ITGB5,INDICATI,Terminated,Herpes simplex infection,[ICD-11: 1F00]
T92424,ITGAV-ITGB5,INDICATI,Discontinued in Phase 1,Low bone mass disorder,[ICD-11: FB83]
,#N/A,,,,
T92458,CYP24A1,TARGETID,T92458,,
T92458,CYP24A1,TARGNAME,Cytochrome P450 24 (CYP24A1),,
T92458,CYP24A1,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T92463,RIPK2,TARGETID,T92463,,
T92463,RIPK2,TARGNAME,RIP2 messenger RNA (RIP2 mRNA),,
T92463,RIPK2,INDICATI,Phase 1,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T92463,RIPK2,INDICATI,Phase 1,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T92494,EEF2K,TARGETID,T92494,,
T92494,EEF2K,TARGNAME,Eukaryotic elongation factor 2 kinase (eEF-2K),,
T92494,EEF2K,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T92609,ADRA1A,TARGETID,T92609,,
T92609,ADRA1A,TARGNAME,Adrenergic receptor alpha-1A (ADRA1A),,
T92609,ADRA1A,INDICATI,Discontinued in Phase 2,Abnormal micturition,[ICD-11: MF50]
T92609,ADRA1A,INDICATI,Discontinued in Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T92609,ADRA1A,INDICATI,Terminated,Genetic cardiac arrhythmia,[ICD-11: BC65]
T92609,ADRA1A,INDICATI,Terminated,Glaucoma,[ICD-11: 9C61]
T92609,ADRA1A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T92609,ADRA1A,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T92609,ADRA1A,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
T92609,ADRA1A,INDICATI,Preclinical,Post-traumatic stress disorder,[ICD-11: 6B40]
T92609,ADRA1A,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T92609,ADRA1A,INDICATI,Discontinued in Phase 2,Prostate disease,[ICD-11: GA91]
T92609,ADRA1A,INDICATI,Approved,Prostate hyperplasia,[ICD-11: GA90]
T92609,ADRA1A,INDICATI,Investigative,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T92640,LPAR1,TARGETID,T92640,,
T92640,LPAR1,TARGNAME,Lysophosphatidic acid receptor 1 (LPAR1),,
T92640,LPAR1,INDICATI,Phase 2,Fibrosis,[ICD-11: GA14-GC01]
T92640,LPAR1,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T92640,LPAR1,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T92640,LPAR1,INDICATI,Phase 2,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T92653,#N/A,TARGETID,T92653,,
T92653,#N/A,TARGNAME,Neuropeptide Y receptor (NPYR),,
T92653,#N/A,INDICATI,Discontinued in Phase 1,Mood disorder,[ICD-11: 6A60-6E23]
,#N/A,,,,
T92678,MALT1,TARGETID,T92678,,
T92678,MALT1,TARGNAME,MALT lymphoma-associated translocation (MALT1),,
T92678,MALT1,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T92678,MALT1,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T92687,ATP4A; ATP4B,TARGETID,T92687,,
T92687,ATP4A; ATP4B,TARGNAME,Gastric H(+)/K(+) ATPase (Proton pump),,
T92687,ATP4A; ATP4B,INDICATI,Phase 2,Digestive system disease,[ICD-11: DE2Z]
T92687,ATP4A; ATP4B,INDICATI,Phase 2,Duodenal ulcer,[ICD-11: DA63]
T92687,ATP4A; ATP4B,INDICATI,Phase 3,Gastric ulcer,[ICD-11: DA60]
T92687,ATP4A; ATP4B,INDICATI,Approved,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T92687,ATP4A; ATP4B,INDICATI,Approved,Helicobacter infection,[ICD-11: DA42-DA63]
T92687,ATP4A; ATP4B,INDICATI,Approved,Oesophageal ulcer,[ICD-11: DA25]
T92687,ATP4A; ATP4B,INDICATI,Approved,Peptic ulcer,[ICD-11: DA61]
T92687,ATP4A; ATP4B,INDICATI,Discontinued in Preregistration,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T92689,P2RY11,TARGETID,T92689,,
T92689,P2RY11,TARGNAME,P2Y purinoceptor 11 (P2RY11),,
T92689,P2RY11,INDICATI,Discontinued in Phase 3,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T92750,CFI,TARGETID,T92750,,
T92750,CFI,TARGNAME,Complement factor I (CFI),,
T92750,CFI,INDICATI,Terminated,Cerebral ischaemia,[ICD-11: 8B1Z]
,#N/A,,,,
T92777,MGAM,TARGETID,T92777,,
T92777,MGAM,TARGNAME,Intestinal maltase-glucoamylase (MGAM),,
T92777,MGAM,INDICATI,Approved,Acute diabete complication,[ICD-11: 5A2Y]
T92777,MGAM,INDICATI,Investigative,Blood chemistry clinical sympton,[ICD-11: MA18]
T92777,MGAM,INDICATI,Phase 3,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T92777,MGAM,INDICATI,Phase 1/2,Dengue fever,[ICD-11: 1D2Z]
T92777,MGAM,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T92777,MGAM,INDICATI,Approved,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
T92777,MGAM,INDICATI,Phase 3,Muscle disorder,[ICD-11: FB32-FB3Z]
T92777,MGAM,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T92803,DYRK1A,TARGETID,T92803,,
T92803,DYRK1A,TARGNAME,Dual-specificity tyrosine-phosphorylation regulated kinase 1A (DYRK1A),,
T92803,DYRK1A,INDICATI,Investigative,Cytomegaloviral disease,[ICD-11: 1D82]
,#N/A,,,,
T92828,EDNRB,TARGETID,T92828,,
T92828,EDNRB,TARGNAME,Endothelin B receptor (EDNRB),,
T92828,EDNRB,INDICATI,Discontinued in Phase 2,Cardiac arrhythmia,[ICD-11: BC9Z]
T92828,EDNRB,INDICATI,Approved,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T92828,EDNRB,INDICATI,Phase 3,Encephalopathy,[ICD-11: 8E47]
T92828,EDNRB,INDICATI,Phase 2,Hypertension,[ICD-11: BA00-BA04]
T92828,EDNRB,INDICATI,Phase 3,Kidney failure,[ICD-11: GB60-GB6Z]
T92828,EDNRB,INDICATI,Phase 1/2,Melanoma,[ICD-11: 2C30]
T92828,EDNRB,INDICATI,Phase 3,Myasthenia gravis,[ICD-11: 8C6Y]
T92828,EDNRB,INDICATI,Phase 3,Neuromyelitis optica,[ICD-11: 8A43]
T92828,EDNRB,INDICATI,Approved,Pulmonary hypertension,[ICD-11: BB01]
T92828,EDNRB,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T92963,NPR3,TARGETID,T92963,,
T92963,NPR3,TARGNAME,Natriuretic peptide receptor (NPR3),,
T92963,NPR3,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
,#N/A,,,,
T93026,#N/A,TARGETID,T93026,,
T93026,#N/A,TARGNAME,Quinone reductase (NQO),,
T93026,#N/A,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T93026,#N/A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T93061,DDX5,TARGETID,T93061,,
T93061,DDX5,TARGNAME,Phosphorylated p68 RNA helicase (pDDX5),,
T93061,DDX5,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T93061,DDX5,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T93062,ABCB4,TARGETID,T93062,,
T93062,ABCB4,TARGNAME,Multidrug resistance protein 3 (ABCB4),,
T93062,ABCB4,INDICATI,Discontinued in Phase 3,Acute myeloid leukaemia,[ICD-11: 2A60]
T93062,ABCB4,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T93062,ABCB4,INDICATI,Discontinued in Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T93092,#N/A,TARGETID,T93092,,
T93092,#N/A,TARGNAME,Serine/threonine PP2A (PP2A),,
T93092,#N/A,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T93092,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T93105,PSEN1,TARGETID,T93105,,
T93105,PSEN1,TARGNAME,Presenilin 1 (PSEN1),,
T93105,PSEN1,INDICATI,Preregistration,Osteoarthritis,[ICD-11: FA00-FA05]
T93105,PSEN1,INDICATI,Preregistration,Shoulder lesion,[ICD-11: FB53]
T93105,PSEN1,INDICATI,Preregistration,Soft tissue disorder,[ICD-11: FB56]
,#N/A,,,,
T93121,ETS2,TARGETID,T93121,,
T93121,ETS2,TARGNAME,Protein C-ets-2 (ETS2),,
T93121,ETS2,INDICATI,Phase 1,Ewing sarcoma,[ICD-11: 2B52]
,#N/A,,,,
T93122,BDNF,TARGETID,T93122,,
T93122,BDNF,TARGNAME,Brain-derived neurotrophic factor (BDNF),,
T93122,BDNF,INDICATI,Phase 2,Dissociative neurological symptom disorder,[ICD-11: 6B60]
,#N/A,,,,
T93145,#N/A,TARGETID,T93145,,
T93145,#N/A,TARGNAME,Pyruvate dehydrogenase kinase (PDHK),,
T93145,#N/A,INDICATI,Phase 1,Heart failure,[ICD-11: BD10-BD1Z]
T93145,#N/A,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
T93145,#N/A,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T93262,PRKCE,TARGETID,T93262,,
T93262,PRKCE,TARGNAME,PKC-epsilon messenger RNA (PRKCE mRNA),,
T93262,PRKCE,INDICATI,Investigative,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T93283,ACPP,TARGETID,T93283,,
T93283,ACPP,TARGNAME,Prostatic acid phosphatase (ACPP),,
T93283,ACPP,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T93344,SQLE,TARGETID,T93344,,
T93344,SQLE,TARGNAME,Squalene monooxygenase (SQLE),,
T93344,SQLE,INDICATI,Terminated,Coronary atherosclerosis,[ICD-11: BA80]
T93344,SQLE,INDICATI,Approved,Dermatophytosis,[ICD-11: 1F28]
T93344,SQLE,INDICATI,Phase 3,Hepatic fibrosis/cirrhosis,[ICD-11: DB93]
T93344,SQLE,INDICATI,Terminated,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T93344,SQLE,INDICATI,Approved,Skin fungal infection disorder,[ICD-11: EA60]
,#N/A,,,,
T93430,#N/A,TARGETID,T93430,,
T93430,#N/A,TARGNAME,ATP-binding cassette transporter (ABCA),,
T93430,#N/A,INDICATI,Phase 2,Insulin-resistance syndrome,[ICD-11: 5A44]
,#N/A,,,,
T93440,IL6R; IL6ST,TARGETID,T93440,,
T93440,IL6R; IL6ST,TARGNAME,Interleukin 6 receptor (IL6R),,
T93440,IL6R; IL6ST,INDICATI,Phase 3,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T93440,IL6R; IL6ST,INDICATI,Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T93440,IL6R; IL6ST,INDICATI,Phase 2,Diabetes mellitus,[ICD-11: 5A10]
T93440,IL6R; IL6ST,INDICATI,Phase 3,Encephalopathy,[ICD-11: 8E47]
T93440,IL6R; IL6ST,INDICATI,Phase 3,Inflammatory spondyloarthritis,[ICD-11: FA92]
T93440,IL6R; IL6ST,INDICATI,Phase 3,Juvenile idiopathic arthritis,[ICD-11: FA24]
T93440,IL6R; IL6ST,INDICATI,Phase 2,Lupus erythematosus,[ICD-11: 4A40]
T93440,IL6R; IL6ST,INDICATI,Terminated,Melanoma,[ICD-11: 2C30]
T93440,IL6R; IL6ST,INDICATI,Investigative,Multiple myeloma,[ICD-11: 2A83]
T93440,IL6R; IL6ST,INDICATI,Phase 3,Neuromyelitis optica,[ICD-11: 8A43]
T93440,IL6R; IL6ST,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
T93440,IL6R; IL6ST,INDICATI,Phase 3,Vasculitis,[ICD-11: 4A44]
,#N/A,,,,
T93450,IL24,TARGETID,T93450,,
T93450,IL24,TARGNAME,Interleukin-24 (IL24),,
T93450,IL24,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T93480,UGT1A1,TARGETID,T93480,,
T93480,UGT1A1,TARGNAME,UDP-glucuronosyltransferase 1A1 (UGT1A1),,
T93480,UGT1A1,INDICATI,Phase 1/2,Inborn porphyrin/heme metabolism error,[ICD-11: 5C58]
,#N/A,,,,
T93485,#N/A,TARGETID,T93485,,
T93485,#N/A,TARGNAME,Hepatitis B virus Reverse transcriptase priming/DNA synthesis (HBV RTP/DS),,
T93485,#N/A,INDICATI,Phase 1/2,Virus infection,[ICD-11: 1A24-1D9Z]
,#N/A,,,,
T93509,CALCA,TARGETID,T93509,,
T93509,CALCA,TARGNAME,Calcitonin gene-related peptide 1 (CALCA),,
T93509,CALCA,INDICATI,Phase 2,General pain disorder,[ICD-11: 8E43]
,#N/A,,,,
T93515,P2RY2,TARGETID,T93515,,
T93515,P2RY2,TARGNAME,P2Y purinoceptor 2 (P2RY2),,
T93515,P2RY2,INDICATI,Phase 2,Cystic fibrosis,[ICD-11: CA25]
T93515,P2RY2,INDICATI,Investigative,Irritable bowel syndrome,[ICD-11: DD91]
T93515,P2RY2,INDICATI,Discontinued in Phase 3,Lung cancer,[ICD-11: 2C25]
T93515,P2RY2,INDICATI,Phase 3,Visual system disease,[ICD-11: 9E1Z]
,#N/A,,,,
T93548,ITGAV-ITGB8,TARGETID,T93548,,
T93548,ITGAV-ITGB8,TARGNAME,Integrin alpha-V/beta-8 (ITGAV/B8),,
T93548,ITGAV-ITGB8,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T93566,ALOX5,TARGETID,T93566,,
T93566,ALOX5,TARGNAME,LOX-5 messenger RNA (ALOX5 mRNA),,
T93566,ALOX5,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T93566,ALOX5,INDICATI,Discontinued in Phase 2,Pain,[ICD-11: MG30-MG3Z]
T93566,ALOX5,INDICATI,Terminated,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T93627,HIV gag,TARGETID,T93627,,
T93627,HIV gag,TARGNAME,Human immunodeficiency virus GAG protein (HIV gag),,
T93627,HIV gag,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T93653,CTSV,TARGETID,T93653,,
T93653,CTSV,TARGNAME,Cathepsin V (CTSV),,
T93653,CTSV,INDICATI,Patented,Bone cancer,[ICD-11: 2B5Z]
T93653,CTSV,INDICATI,Patented,Chronic pain,[ICD-11: MG30]
,#N/A,,,,
T93661,SMAD7,TARGETID,T93661,,
T93661,SMAD7,TARGNAME,Smad7 messenger RNA (Smad7 mRNA),,
T93661,SMAD7,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T93661,SMAD7,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T93662,#N/A,TARGETID,T93662,,
T93662,#N/A,TARGNAME,Hyaluronidase (HYAL),,
T93662,#N/A,INDICATI,Phase 1,Cholelithiasis,[ICD-11: DC11]
T93662,#N/A,INDICATI,Approved,Immunodeficiency,[ICD-11: 4A00-4A85]
T93662,#N/A,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T93662,#N/A,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T93662,#N/A,INDICATI,Approved,Schizophrenia,[ICD-11: 6A20]
T93662,#N/A,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T93703,#N/A,TARGETID,T93703,,
T93703,#N/A,TARGNAME,Cytokine unspecific (CYK),,
T93703,#N/A,INDICATI,Phase 1,Atopic eczema,[ICD-11: EA80]
T93703,#N/A,INDICATI,Phase 1,Vasomotor/allergic rhinitis,[ICD-11: CA08]
,#N/A,,,,
T93711,RHBDF2,TARGETID,T93711,,
T93711,RHBDF2,TARGNAME,Inactive rhomboid protein 2 (RHBDF2),,
T93711,RHBDF2,INDICATI,Investigative,Skin disease,[ICD-11: EA00-EM0Z]
T93711,RHBDF2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T93783,HIV tat,TARGETID,T93783,,
T93783,HIV tat,TARGNAME,Human immunodeficiency virus Tat protein (HIV tat),,
T93783,HIV tat,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T93783,HIV tat,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T93788,GPR119,TARGETID,T93788,,
T93788,GPR119,TARGNAME,Glucose-dependent insulinotropic receptor (GPR119),,
T93788,GPR119,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
T93788,GPR119,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T93788,GPR119,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
T93788,GPR119,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T93798,CNGA1,TARGETID,T93798,,
T93798,CNGA1,TARGNAME,Cyclic nucleotide-gated channel alpha-1 (CNGA1),,
T93798,CNGA1,INDICATI,Clinical trial,Myelopathy,[ICD-11: 8B42]
,#N/A,,,,
T93878,SLC12A1,TARGETID,T93878,,
T93878,SLC12A1,TARGNAME,Solute carrier family 12 member 1 (SLC12A1),,
T93878,SLC12A1,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T93878,SLC12A1,INDICATI,Approved,Essential hypertension,[ICD-11: BA00]
T93878,SLC12A1,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T93878,SLC12A1,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T93878,SLC12A1,INDICATI,Approved,Hypo-kalaemia,[ICD-11: 5C77]
T93878,SLC12A1,INDICATI,Approved,Oedema,[ICD-11: MG29]
,#N/A,,,,
T93903,CASP9,TARGETID,T93903,,
T93903,CASP9,TARGNAME,Caspase-9 (CASP9),,
T93903,CASP9,INDICATI,Clinical trial,Cystic fibrosis,[ICD-11: CA25]
T93903,CASP9,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T93923,TNFRSF9,TARGETID,T93923,,
T93923,TNFRSF9,TARGNAME,Co-stimulatory molecule 4-1BB (CD137),,
T93923,TNFRSF9,INDICATI,Phase 1/2,Acute myeloid leukaemia,[ICD-11: 2A60]
T93923,TNFRSF9,INDICATI,Phase 1/2,B-cell lymphoma,[ICD-11: 2A86]
T93923,TNFRSF9,INDICATI,Investigative,Immune system disease,[ICD-11: 4A01-4B41]
T93923,TNFRSF9,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T93923,TNFRSF9,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T93923,TNFRSF9,INDICATI,Phase 1/2,Mature B-cell lymphoma,[ICD-11: 2A85]
T93923,TNFRSF9,INDICATI,Phase 2,Melanoma,[ICD-11: 2C30]
T93923,TNFRSF9,INDICATI,Phase 1/2,Non-small-cell lung cancer,[ICD-11: 2C25]
T93923,TNFRSF9,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T93955,Asperg mpdA,TARGETID,T93955,,
T93955,Asperg mpdA,TARGNAME,Aspergillus Mannitol-1-phosphate 5-dehydrogenase (Asperg mpdA),,
T93955,Asperg mpdA,INDICATI,Approved,Bronchiectasis,[ICD-11: CA24]
T93955,Asperg mpdA,INDICATI,Approved,Kidney failure,[ICD-11: GB60-GB6Z]
,#N/A,,,,
T93995,NEDD8,TARGETID,T93995,,
T93995,NEDD8,TARGNAME,Ubiquitin-like protein Nedd8 (NEDD8),,
T93995,NEDD8,INDICATI,Phase 2,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T93995,NEDD8,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T93995,NEDD8,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
T93995,NEDD8,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T94033,F2,TARGETID,T94033,,
T94033,F2,TARGNAME,Coagulation factor IIa (F2),,
T94033,F2,INDICATI,Phase 2,Angina pectoris,[ICD-11: BA40]
T94033,F2,INDICATI,Terminated,Asthma,[ICD-11: CA23]
T94033,F2,INDICATI,Discontinued in Phase 2,Atopic eczema,[ICD-11: EA80]
T94033,F2,INDICATI,Approved,Bleeding disorder,[ICD-11: GA20-GA21]
T94033,F2,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T94033,F2,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T94033,F2,INDICATI,Approved,Coagulation defect,[ICD-11: 3B10]
T94033,F2,INDICATI,Phase 2/3,Coronary thrombosis,[ICD-11: BA43]
T94033,F2,INDICATI,Discontinued in Phase 1,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T94033,F2,INDICATI,Discontinued in Phase 1,Genetic cardiac arrhythmia,[ICD-11: BC65]
T94033,F2,INDICATI,Approved,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T94033,F2,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T94033,F2,INDICATI,Approved,Myocardial infarction,[ICD-11: BA41-BA43]
T94033,F2,INDICATI,Approved,Nutritional deficiency,[ICD-11: 5B50-5B71]
T94033,F2,INDICATI,Discontinued in Phase 1,Pregnancy/childbirth/puerperium maternal infection,[ICD-11: JB63]
T94033,F2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T94033,F2,INDICATI,Discontinued in Phase 2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T94033,F2,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
T94033,F2,INDICATI,Approved,Thrombosis,[ICD-11: DB61-GB90]
T94033,F2,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T94085,RARA,TARGETID,T94085,,
T94085,RARA,TARGNAME,Retinoic acid receptor alpha (RARA),,
T94085,RARA,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T94085,RARA,INDICATI,Phase 2/3,Alzheimer disease,[ICD-11: 8A20]
T94085,RARA,INDICATI,Investigative,Colorectal cancer,[ICD-11: 2B91]
T94085,RARA,INDICATI,Discontinued in Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T94085,RARA,INDICATI,Phase 3,Mature T-cell lymphoma,[ICD-11: 2A90]
T94085,RARA,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T94085,RARA,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T94119,#N/A,TARGETID,T94119,,
T94119,#N/A,TARGNAME,HUMAN PI3-kinase delta (PIK3CD),,
T94119,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T94119,#N/A,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
,#N/A,,,,
T94131,#N/A,TARGETID,T94131,,
T94131,#N/A,TARGNAME,HUMAN PI3-kinase gamma (PIK3CG),,
T94131,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T94131,#N/A,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
,#N/A,,,,
T94201,SRPK1,TARGETID,T94201,,
T94201,SRPK1,TARGNAME,SRSF protein kinase 1 (SRPK1),,
T94201,SRPK1,INDICATI,Preclinical,Retinopathy,[ICD-11: 9B71]
,#N/A,,,,
T94307,#N/A,TARGETID,T94307,,
T94307,#N/A,TARGNAME,HUMAN interferon gamma (IFNG),,
T94307,#N/A,INDICATI,Approved,Adaptive immunity immunodeficiency,[ICD-11: 4A01]
T94307,#N/A,INDICATI,Phase 2/3,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T94309,PNLIP,TARGETID,T94309,,
T94309,PNLIP,TARGNAME,Pancreatic triacylglycerol lipase (PNLIP),,
T94309,PNLIP,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T94309,PNLIP,INDICATI,Phase 3,Cystic fibrosis,[ICD-11: CA25]
T94309,PNLIP,INDICATI,Approved,Obesity,[ICD-11: 5B80-5B81]
T94309,PNLIP,INDICATI,Phase 1/2,Pancreas disease,[ICD-11: DC35-DC3Z]
T94309,PNLIP,INDICATI,NDA filed,Pancreatic malfunction,[ICD-11: DC30-DC3Z]
,#N/A,,,,
T94324,HDAC10,TARGETID,T94324,,
T94324,HDAC10,TARGNAME,Histone deacetylase 10 (HDAC10),,
T94324,HDAC10,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T94429,CMV TRM1,TARGETID,T94429,,
T94429,CMV TRM1,TARGNAME,Cytomegalovirus Terminase UL56 (CMV TRM1),,
T94429,CMV TRM1,INDICATI,Approved,Cytomegaloviral disease,[ICD-11: 1D82]
,#N/A,,,,
T94444,AOX1,TARGETID,T94444,,
T94444,AOX1,TARGNAME,Aldehyde oxidase (AOX1),,
T94444,AOX1,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T94444,AOX1,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T94444,AOX1,INDICATI,Approved,Vitamin deficiency,[ICD-11: 5B55-5B5F]
,#N/A,,,,
T94471,#N/A,TARGETID,T94471,,
T94471,#N/A,TARGNAME,HUMAN complement C5 protein (C5),,
T94471,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T94471,#N/A,INDICATI,Approved,Neuromyelitis optica,[ICD-11: 8A43]
T94471,#N/A,INDICATI,Approved,Paroxysmal nocturnal haemoglobinuria,[ICD-11: 3A21]
,#N/A,,,,
T94479,RPS6KB1,TARGETID,T94479,,
T94479,RPS6KB1,TARGNAME,Ribosomal protein S6 kinase beta-1 (S6K1),,
T94479,RPS6KB1,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T94479,RPS6KB1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T94479,RPS6KB1,INDICATI,Clinical trial,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T94482,IL20,TARGETID,T94482,,
T94482,IL20,TARGNAME,Interleukin-20 (IL20),,
T94482,IL20,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T94493,#N/A,TARGETID,T94493,,
T94493,#N/A,TARGNAME,Human immunodeficiency virus Adenovector Ad35 (HIV Ad35),,
T94493,#N/A,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T94501,#N/A,TARGETID,T94501,,
T94501,#N/A,TARGNAME,HUMAN complement C5 alpha (C5A),,
T94501,#N/A,INDICATI,Phase 2/3,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T94514,#N/A,TARGETID,T94514,,
T94514,#N/A,TARGNAME,HUMAN colony-stimulating factor (GM-CSF),,
T94514,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T94514,#N/A,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T94549,#N/A,TARGETID,T94549,,
T94549,#N/A,TARGNAME,HUMAN angiopoietin-2 (ANG-2),,
T94549,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T94692,LDLR,TARGETID,T94692,,
T94692,LDLR,TARGNAME,Low-density lipoprotein receptor (LDL-R),,
T94692,LDLR,INDICATI,Approved,Lung cancer,[ICD-11: 2C25]
,#N/A,,,,
T94695,SMAD7,TARGETID,T94695,,
T94695,SMAD7,TARGNAME,Mothers against decapentaplegic homolog 7 (SMAD7),,
T94695,SMAD7,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T94695,SMAD7,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T94718,LAG3,TARGETID,T94718,,
T94718,LAG3,TARGNAME,Lymphocyte activation gene 3 protein (LAG3),,
T94718,LAG3,INDICATI,Phase 1/2,Allergic/hypersensitivity disorder,[ICD-11: 4A80-4A8Z]
T94718,LAG3,INDICATI,Phase 1,Autoimmune disease,[ICD-11: 4A40-4A45]
T94718,LAG3,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T94718,LAG3,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T94718,LAG3,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T94718,LAG3,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T94718,LAG3,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T94718,LAG3,INDICATI,Phase 2/3,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T94718,LAG3,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T94718,LAG3,INDICATI,Phase 1,Psoriasis,[ICD-11: EA90]
T94718,LAG3,INDICATI,Phase 2,Renal cell carcinoma,[ICD-11: 2C90]
T94718,LAG3,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T94718,LAG3,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T94781,HRSV N mRNA,TARGETID,T94781,,
T94781,HRSV N mRNA,TARGNAME,HRSV Nucleoprotein messenger RNA (HRSV N mRNA),,
T94781,HRSV N mRNA,INDICATI,Phase 2,Respiratory infection,[ICD-11: CA07-CA4Z]
T94781,HRSV N mRNA,INDICATI,Phase 2,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T94879,#N/A,TARGETID,T94879,,
T94879,#N/A,TARGNAME,HUMAN phosphodiesterase type 5 (PDE5),,
T94879,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T94879,#N/A,INDICATI,Approved,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T94880,TYRO3,TARGETID,T94880,,
T94880,TYRO3,TARGNAME,TYRO3 tyrosine kinase receptor (TYRO3),,
T94880,TYRO3,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T94912,#N/A,TARGETID,T94912,,
T94912,#N/A,TARGNAME,HUMAN C5a receptor (C5aR),,
T94912,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T94918,#N/A,TARGETID,T94918,,
T94918,#N/A,TARGNAME,COVID-19 RNA-directed RNA polymerase (RdRp),,
T94918,#N/A,INDICATI,Phase 1,African trypanosomiasis,[ICD-11: 1F51]
T94918,#N/A,INDICATI,Approved,Candidosis,[ICD-11: 1F23]
T94918,#N/A,INDICATI,Approved,COVID-19,[ICD-11: 1D6Y]
T94918,#N/A,INDICATI,Phase 1,Filovirus disease,[ICD-11: 1D60]
T94918,#N/A,INDICATI,Approved,Herpes simplex infection,[ICD-11: 1F00]
T94918,#N/A,INDICATI,Approved,Influenza,[ICD-11: 1E30-1E32]
T94918,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T94918,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T94933,#N/A,TARGETID,T94933,,
T94933,#N/A,TARGNAME,HUMAN basigin (BSG),,
T94933,#N/A,INDICATI,Phase 1/2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T94977,CTF1,TARGETID,T94977,,
T94977,CTF1,TARGNAME,Cardiotrophin-1 (CTF1),,
T94977,CTF1,INDICATI,Phase 1,Acute/subacute hepatic failure,[ICD-11: DB91]
,#N/A,,,,
T95108,HLA-G,TARGETID,T95108,,
T95108,HLA-G,TARGNAME,MHC class I antigen G (HLA-G),,
T95108,HLA-G,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T95139,#N/A,TARGETID,T95139,,
T95139,#N/A,TARGNAME,Cysteine protease (CYP),,
T95139,#N/A,INDICATI,Approved,Trypanosomiasis,[ICD-11: 1D51-1F53]
,#N/A,,,,
T95183,USP2,TARGETID,T95183,,
T95183,USP2,TARGNAME,Ubiquitin carboxyl-terminal hydrolase 2 (USP2),,
T95183,USP2,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T95212,#N/A,TARGETID,T95212,,
T95212,#N/A,TARGNAME,Streptococcus Diphtheria protein (Stre DIPP),,
T95212,#N/A,INDICATI,Approved,Otitis media,[ICD-11: AA80-AB0Z]
T95212,#N/A,INDICATI,Discontinued in Phase 2,Ulcer,[ICD-11: CA02-CB40]
,#N/A,,,,
T95241,#N/A,TARGETID,T95241,,
T95241,#N/A,TARGNAME,Calcium-activated potassium channel KCa2 (KCNN),,
T95241,#N/A,INDICATI,Phase 1/2,Ataxic disorder,[ICD-11: 8A03]
T95241,#N/A,INDICATI,Phase 1/2,Supraventricular tachyarrhythmia,[ICD-11: BC81]
T95241,#N/A,INDICATI,Phase 1,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T95286,MAG,TARGETID,T95286,,
T95286,MAG,TARGNAME,Myelin-associated glycoprotein (MAG),,
T95286,MAG,INDICATI,Phase 2,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
,#N/A,,,,
T95289,#N/A,TARGETID,T95289,,
T95289,#N/A,TARGNAME,Retinoic acid receptor RXR (RXR),,
T95289,#N/A,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T95289,#N/A,INDICATI,Phase 1,Lung cancer,[ICD-11: 2C25]
T95289,#N/A,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T95289,#N/A,INDICATI,Phase 1,Prostate cancer,[ICD-11: 2C82]
T95289,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T95302,MC5R,TARGETID,T95302,,
T95302,MC5R,TARGNAME,Melanocortin receptor 5 (MC5R),,
T95302,MC5R,INDICATI,Phase 2,Acne vulgaris,[ICD-11: ED80]
T95302,MC5R,INDICATI,Phase 2,Sebaceous gland disorder,[ICD-11: ED91]
T95302,MC5R,INDICATI,Investigative,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T95339,#N/A,TARGETID,T95339,,
T95339,#N/A,TARGNAME,Beta-hematin formation (BHF),,
T95339,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T95371,IFNAR1,TARGETID,T95371,,
T95371,IFNAR1,TARGNAME,Interferon alpha/beta receptor 1 (IFNAR1),,
T95371,IFNAR1,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T95371,IFNAR1,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T95379,#N/A,TARGETID,T95379,,
T95379,#N/A,TARGNAME,Selectin (SEL),,
T95379,#N/A,INDICATI,Phase 3,Asthma,[ICD-11: CA23]
T95379,#N/A,INDICATI,Phase 3,Circulatory system disease,[ICD-11: BE2Z]
,#N/A,,,,
T95385,IL12B,TARGETID,T95385,,
T95385,IL12B,TARGNAME,Interleukin-12 beta (IL12B),,
T95385,IL12B,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T95385,IL12B,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T95385,IL12B,INDICATI,Approved,Conduction disorder,[ICD-11: BC63]
T95385,IL12B,INDICATI,Discontinued in Phase 2,Crohn disease,[ICD-11: DD70]
T95385,IL12B,INDICATI,Phase 2,Fallopian tube cancer,[ICD-11: 2C74]
T95385,IL12B,INDICATI,Phase 1,Indeterminate colitis,[ICD-11: DD72]
T95385,IL12B,INDICATI,Phase 1/2,Melanoma,[ICD-11: 2C30]
T95385,IL12B,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T95385,IL12B,INDICATI,Phase 2,Peritoneal cancer,[ICD-11: 2C51]
T95385,IL12B,INDICATI,Phase 3,Psoriasis,[ICD-11: EA90]
T95385,IL12B,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T95385,IL12B,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T95399,PYGM,TARGETID,T95399,,
T95399,PYGM,TARGNAME,Myophosphorylase (PYGM),,
T95399,PYGM,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T95399,PYGM,INDICATI,Discontinued in Phase 3,Mature B-cell leukaemia,[ICD-11: 2A82]
T95399,PYGM,INDICATI,Discontinued in Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T95400,FCER1G,TARGETID,T95400,,
T95400,FCER1G,TARGNAME,Immunoglobulin epsilon Fc receptor gamma (FCERG),,
T95400,FCER1G,INDICATI,Approved,Asthma,[ICD-11: CA23]
T95400,FCER1G,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T95400,FCER1G,INDICATI,Phase 2,Spontaneous urticaria,[ICD-11: EB00]
,#N/A,,,,
T95410,#N/A,TARGETID,T95410,,
T95410,#N/A,TARGNAME,Aspergillus Dihydroorotate dehydrogenase (Aspergillus DHODH),,
T95410,#N/A,INDICATI,Phase 2,Fungal infection,[ICD-11: 1F29-1F2F]
,#N/A,,,,
T95446,POR,TARGETID,T95446,,
T95446,POR,TARGNAME,Cytochrome P450 reductase (P450),,
T95446,POR,INDICATI,Terminated,Eczema,[ICD-11: EA80-EA89]
T95446,POR,INDICATI,Terminated,Pruritus,[ICD-11: EC90]
T95446,POR,INDICATI,Discontinued in Phase 2,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T95479,SST,TARGETID,T95479,,
T95479,SST,TARGNAME,Somatostatin (SST),,
T95479,SST,INDICATI,Approved,Amino acid absorption/transport disorder,[ICD-11: 5C60]
,#N/A,,,,
T95488,#N/A,TARGETID,T95488,,
T95488,#N/A,TARGNAME,Interleukin-1 (IL1),,
T95488,#N/A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T95498,#N/A,TARGETID,T95498,,
T95498,#N/A,TARGNAME,NFE2-related factor 2 pathway (Nrf2 pathway),,
T95498,#N/A,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T95515,KRT6A,TARGETID,T95515,,
T95515,KRT6A,TARGNAME,Keratin 6A messenger RNA (KRT6A mRNA),,
T95515,KRT6A,INDICATI,Phase 1,Nail plate acquired deformity,[ICD-11: EE10]
T95515,KRT6A,INDICATI,Phase 2,Viral encephalitis,[ICD-11: 1C80]
,#N/A,,,,
T95558,DGAT2,TARGETID,T95558,,
T95558,DGAT2,TARGNAME,Diacylglycerol O-acyltransferase 2 (DGAT2),,
T95558,DGAT2,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T95558,DGAT2,INDICATI,Phase 2,Dyslipidemia,[ICD-11: 5C80-5C81]
T95558,DGAT2,INDICATI,Phase 2,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T95558,DGAT2,INDICATI,Approved,Inborn lipid metabolism error,[ICD-11: 5C52]
T95558,DGAT2,INDICATI,Phase 2,Non-alcoholic fatty liver disease,[ICD-11: DB92]
,#N/A,,,,
T95616,ITGAM,TARGETID,T95616,,
T95616,ITGAM,TARGNAME,Integrin alpha-M (ITGAM),,
T95616,ITGAM,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T95678,Influ M,TARGETID,T95678,,
T95678,Influ M,TARGNAME,Influenza M2 protein (Influ M),,
T95678,Influ M,INDICATI,Approved,Influenza,[ICD-11: 1E30-1E32]
,#N/A,,,,
T95695,SMN1,TARGETID,T95695,,
T95695,SMN1,TARGNAME,SMN1 messenger RNA (SMN1 mRNA),,
T95695,SMN1,INDICATI,Approved,Muscular atrophy,[ICD-11: 8B61]
,#N/A,,,,
T95860,FOXO4-TP53,TARGETID,T95860,,
T95860,FOXO4-TP53,TARGNAME,FOXO4-P53 interaction (FOXO4-P53 PPI),,
T95860,FOXO4-TP53,INDICATI,Preclinical,Pituitary gland disorder,[ICD-11: 5A60-5A61]
,#N/A,,,,
T95878,RPS6KA6,TARGETID,T95878,,
T95878,RPS6KA6,TARGNAME,Ribosomal protein S6 kinase alpha-6 (RSK6),,
T95878,RPS6KA6,INDICATI,Preclinical,Mature B-cell leukaemia,[ICD-11: 2A82]
,#N/A,,,,
T95899,CLU,TARGETID,T95899,,
T95899,CLU,TARGNAME,Clusterin messenger RNA (Clusterin mRNA),,
T95899,CLU,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T95899,CLU,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T95899,CLU,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T95913,PIK3CG,TARGETID,T95913,,
T95913,PIK3CG,TARGNAME,PI3-kinase gamma (PIK3CG),,
T95913,PIK3CG,INDICATI,Phase 1,Adrenal cancer,[ICD-11: 2D11]
T95913,PIK3CG,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T95913,PIK3CG,INDICATI,Investigative,Bacterial infection,[ICD-11: 1A00-1C4Z]
T95913,PIK3CG,INDICATI,Phase 1,B-cell lymphoma,[ICD-11: 2A86]
T95913,PIK3CG,INDICATI,Phase 1/2,BCR-ABL1-negative chronic myeloid leukaemia,[ICD-11: 2A41]
T95913,PIK3CG,INDICATI,Phase 2,Bladder cancer,[ICD-11: 2C94]
T95913,PIK3CG,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T95913,PIK3CG,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T95913,PIK3CG,INDICATI,Terminated,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T95913,PIK3CG,INDICATI,Phase 1,Central nervous system disease,[ICD-11: 8A04-8D87]
T95913,PIK3CG,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T95913,PIK3CG,INDICATI,Phase 3,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T95913,PIK3CG,INDICATI,Phase 2,Endometrial cancer,[ICD-11: 2C76]
T95913,PIK3CG,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
T95913,PIK3CG,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T95913,PIK3CG,INDICATI,Phase 1/2,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T95913,PIK3CG,INDICATI,Phase 1,Liver cancer,[ICD-11: 2C12]
T95913,PIK3CG,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T95913,PIK3CG,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T95913,PIK3CG,INDICATI,Approved,Mature B-cell leukaemia,[ICD-11: 2A82]
T95913,PIK3CG,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T95913,PIK3CG,INDICATI,Phase 2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T95913,PIK3CG,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T95913,PIK3CG,INDICATI,Phase 1/2,Myocardial infarction,[ICD-11: BA41-BA43]
T95913,PIK3CG,INDICATI,Phase 1,Pain,[ICD-11: MG30-MG3Z]
T95913,PIK3CG,INDICATI,Phase 1,Peritoneal cancer,[ICD-11: 2C51]
T95913,PIK3CG,INDICATI,Phase 1,Pleural mesothelioma,[ICD-11: 2C26]
T95913,PIK3CG,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T95913,PIK3CG,INDICATI,Investigative,Prostate cancer,[ICD-11: 2C82]
T95913,PIK3CG,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T95913,PIK3CG,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T95913,PIK3CG,INDICATI,Discontinued in Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T95923,LPAR3,TARGETID,T95923,,
T95923,LPAR3,TARGNAME,Lysophosphatidate-3 receptor (LPAR3),,
T95923,LPAR3,INDICATI,Phase 2,Fibrosis,[ICD-11: GA14-GC01]
T95923,LPAR3,INDICATI,Phase 2,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T95947,ASIC3,TARGETID,T95947,,
T95947,ASIC3,TARGNAME,Acid-sensing ion channel 3 (ASIC3),,
T95947,ASIC3,INDICATI,Investigative,Chronic pain,[ICD-11: MG30]
T95947,ASIC3,INDICATI,Investigative,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T95998,PCYT1B,TARGETID,T95998,,
T95998,PCYT1B,TARGNAME,Cholinephosphate cytidylyltransferase (PCYT1B),,
T95998,PCYT1B,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T96079,CXCR4,TARGETID,T96079,,
T96079,CXCR4,TARGNAME,C-X-C chemokine receptor type 4 (CXCR4),,
T96079,CXCR4,INDICATI,Phase 2,Acute myeloid leukaemia,[ICD-11: 2A60]
T96079,CXCR4,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T96079,CXCR4,INDICATI,Investigative,Chronic arterial occlusive disease,[ICD-11: BD4Z]
T96079,CXCR4,INDICATI,Investigative,Diabetes mellitus,[ICD-11: 5A10]
T96079,CXCR4,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T96079,CXCR4,INDICATI,Phase 3,Innate/adaptive immunodeficiency,[ICD-11: 4A00]
T96079,CXCR4,INDICATI,Preclinical,Kaposi sarcoma,[ICD-11: 2B57]
T96079,CXCR4,INDICATI,Approved,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T96079,CXCR4,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T96079,CXCR4,INDICATI,Investigative,Mature B-cell lymphoma,[ICD-11: 2A85]
T96079,CXCR4,INDICATI,Phase 1/2,Melanoma,[ICD-11: 2C30]
T96079,CXCR4,INDICATI,Phase 1,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T96079,CXCR4,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T96079,CXCR4,INDICATI,Phase 2,Myelodysplastic syndrome,[ICD-11: 2A37]
T96079,CXCR4,INDICATI,Phase 1/2,Neuroendocrine carcinoma,[ICD-11: 2C34]
T96079,CXCR4,INDICATI,Phase 1,Neutropenia,[ICD-11: 4B00]
T96079,CXCR4,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T96079,CXCR4,INDICATI,Investigative,Psoriasis,[ICD-11: EA90]
T96079,CXCR4,INDICATI,Phase 1/2,Renal cell carcinoma,[ICD-11: 2C90]
T96079,CXCR4,INDICATI,Phase 1/2,Respiratory infection,[ICD-11: CA07-CA4Z]
T96079,CXCR4,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T96079,CXCR4,INDICATI,Phase 1/2,Sarcoma,[ICD-11: 2A60-2C35]
T96079,CXCR4,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T96079,CXCR4,INDICATI,Discontinued in Phase 1,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T96144,TOP2A; TOP2B,TARGETID,T96144,,
T96144,TOP2A; TOP2B,TARGNAME,DNA topoisomerase II (TOP2),,
T96144,TOP2A; TOP2B,INDICATI,Approved,Acute myeloid leukaemia,[ICD-11: 2A60]
T96144,TOP2A; TOP2B,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T96144,TOP2A; TOP2B,INDICATI,Approved,Anogenital warts,[ICD-11: 1A95]
T96144,TOP2A; TOP2B,INDICATI,Phase 1,Asthma,[ICD-11: CA23]
T96144,TOP2A; TOP2B,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T96144,TOP2A; TOP2B,INDICATI,Approved,Bladder cancer,[ICD-11: 2C94]
T96144,TOP2A; TOP2B,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T96144,TOP2A; TOP2B,INDICATI,Approved,Breast cancer,[ICD-11: 2C60-2C6Y]
T96144,TOP2A; TOP2B,INDICATI,Approved,Chemoprotection,[ICD-11: N.A.]
T96144,TOP2A; TOP2B,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T96144,TOP2A; TOP2B,INDICATI,Approved,Common warts,[ICD-11: 1E80]
T96144,TOP2A; TOP2B,INDICATI,Phase 3,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T96144,TOP2A; TOP2B,INDICATI,Terminated,Endocarditis,[ICD-11: BB40-BA42]
T96144,TOP2A; TOP2B,INDICATI,Phase 3,Follicular lymphoma,[ICD-11: 2A80]
T96144,TOP2A; TOP2B,INDICATI,Approved,Gonococcal infection,[ICD-11: 1A70-1A7Z]
T96144,TOP2A; TOP2B,INDICATI,Approved,HIV-infected patients with tuberculosis,[ICD-11: 1B10-1B14]
T96144,TOP2A; TOP2B,INDICATI,Phase 3,Kaposi sarcoma,[ICD-11: 2B57]
T96144,TOP2A; TOP2B,INDICATI,Terminated,Leukaemia,[ICD-11: 2A60-2B33]
T96144,TOP2A; TOP2B,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T96144,TOP2A; TOP2B,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T96144,TOP2A; TOP2B,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T96144,TOP2A; TOP2B,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T96144,TOP2A; TOP2B,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T96144,TOP2A; TOP2B,INDICATI,Discontinued in Phase 1,Metastatic lung neoplasm,[ICD-11: 2D70]
T96144,TOP2A; TOP2B,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
T96144,TOP2A; TOP2B,INDICATI,Approved,Otitis externa,[ICD-11: AA00-AA13]
T96144,TOP2A; TOP2B,INDICATI,Approved,Otitis media,[ICD-11: AA80-AB0Z]
T96144,TOP2A; TOP2B,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T96144,TOP2A; TOP2B,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T96144,TOP2A; TOP2B,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T96144,TOP2A; TOP2B,INDICATI,Investigative,Respiratory system disease,[ICD-11: CB40-CB7Z]
T96144,TOP2A; TOP2B,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T96144,TOP2A; TOP2B,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
T96144,TOP2A; TOP2B,INDICATI,Approved,Syphilis,[ICD-11: 1A61-1A6Z]
T96144,TOP2A; TOP2B,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
T96144,TOP2A; TOP2B,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T96215,Malaria gdh,TARGETID,T96215,,
T96215,Malaria gdh,TARGNAME,Plasmodium Glutamate dehydrogenase (Malaria gdh),,
T96215,Malaria gdh,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T96235,GRIA4,TARGETID,T96235,,
T96235,GRIA4,TARGNAME,Glutamate receptor AMPA 4 (GRIA4),,
T96235,GRIA4,INDICATI,Approved,Neuropathy,[ICD-11: 8C0Z]
T96235,GRIA4,INDICATI,Discontinued in Phase 3,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T96257,#N/A,TARGETID,T96257,,
T96257,#N/A,TARGNAME,Haemophilus influenzae CRM197 (Hae-influ CRM197),,
T96257,#N/A,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T96257,#N/A,INDICATI,Phase 2,Pneumococcal infection,[ICD-11: CA00-CA40]
,#N/A,,,,
T96281,#N/A,TARGETID,T96281,,
T96281,#N/A,TARGNAME,Hepatitis C virus Envelope glycoprotein (HCV Env),,
T96281,#N/A,INDICATI,Terminated,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T96299,#N/A,TARGETID,T96299,,
T96299,#N/A,TARGNAME,Wnt protein (WNT),,
T96299,#N/A,INDICATI,Phase 1,Ovarian cancer,[ICD-11: 2C73]
T96299,#N/A,INDICATI,Terminated,Sarcoidosis,[ICD-11: 4B20]
,#N/A,,,,
T96321,#N/A,TARGETID,T96321,,
T96321,#N/A,TARGNAME,Bacillus poly-gamma-d-glutamic acid (Bacillus PGA),,
T96321,#N/A,INDICATI,Preclinical,Anthrax,[ICD-11: 1B97]
,#N/A,,,,
T96413,GUSB,TARGETID,T96413,,
T96413,GUSB,TARGNAME,Beta-glucuronidase (GUSB),,
T96413,GUSB,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
T96413,GUSB,INDICATI,Phase 2,Periodontal disease,[ICD-11: DA0C]
,#N/A,,,,
T96476,Malaria MSP-1,TARGETID,T96476,,
T96476,Malaria MSP-1,TARGNAME,Plasmodium Merozoite surface protein 1 (Malaria MSP-1),,
T96476,Malaria MSP-1,INDICATI,Phase 1/2,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T96592,#N/A,TARGETID,T96592,,
T96592,#N/A,TARGNAME,Phosphoric monoester hydrolase (PMH),,
T96592,#N/A,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T96623,HSP90AB1,TARGETID,T96623,,
T96623,HSP90AB1,TARGNAME,Heat shock protein 90 beta (HSP90B),,
T96623,HSP90AB1,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T96623,HSP90AB1,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T96623,HSP90AB1,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T96623,HSP90AB1,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T96623,HSP90AB1,INDICATI,Phase 1,Myeloproliferative neoplasm,[ICD-11: 2A20]
T96623,HSP90AB1,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T96623,HSP90AB1,INDICATI,Phase 1,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T96627,CXCL2,TARGETID,T96627,,
T96627,CXCL2,TARGNAME,C-X-C motif chemokine 2 (CXCL2),,
T96627,CXCL2,INDICATI,Phase 3,Multiple sclerosis,[ICD-11: 8A40]
,#N/A,,,,
T96685,HK2,TARGETID,T96685,,
T96685,HK2,TARGNAME,Hexokinase-2 (HK2),,
T96685,HK2,INDICATI,Phase 2,Epidermal dysplasias,[ICD-11: EK90]
,#N/A,,,,
T96721,#N/A,TARGETID,T96721,,
T96721,#N/A,TARGNAME,Vascular endothelial growth factor (VEGF),,
T96721,#N/A,INDICATI,Phase 3,Colorectal cancer,[ICD-11: 2B91]
T96721,#N/A,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T96721,#N/A,INDICATI,Phase 2,Macular degeneration,[ICD-11: 9B75]
T96721,#N/A,INDICATI,Investigative,Multiple myeloma,[ICD-11: 2A83]
T96721,#N/A,INDICATI,Phase 3,Non-small-cell lung cancer,[ICD-11: 2C25]
T96721,#N/A,INDICATI,Approved,Retinopathy,[ICD-11: 9B71]
T96721,#N/A,INDICATI,Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T96723,SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6,TARGETID,T96723,,
T96723,SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6,TARGNAME,SF3b complex (SF3b),,
T96723,SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T96723,SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6,INDICATI,Phase 1,Chronic myelomonocytic leukaemia,[ICD-11: 2A40]
T96723,SF3B1-SF3B2-SF3B3-SF3B4-SF3B5-SF3B6,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
,#N/A,,,,
T96736,RHOA,TARGETID,T96736,,
T96736,RHOA,TARGNAME,Transforming protein RhoA (RHOA),,
T96736,RHOA,INDICATI,Discontinued in Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T96747,#N/A,TARGETID,T96747,,
T96747,#N/A,TARGNAME,Galactosyltransferase (GALT),,
T96747,#N/A,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T96760,GDF5,TARGETID,T96760,,
T96760,GDF5,TARGNAME,Growth/differentiation factor 5 (GDF-5),,
T96760,GDF5,INDICATI,Phase 2,Periodontal disease,[ICD-11: DA0C]
,#N/A,,,,
T96788,ERBB2,TARGETID,T96788,,
T96788,ERBB2,TARGNAME,ERBB2 messenger RNA (HER2 mRNA),,
T96788,ERBB2,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T96788,ERBB2,INDICATI,Phase 2,Chronic pain,[ICD-11: MG30]
T96788,ERBB2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T96816,Malaria ESPS,TARGETID,T96816,,
T96816,Malaria ESPS,TARGNAME,Plasmodium Enopyruvyl shikimate phosphate synthase (Malaria ESPS),,
T96816,Malaria ESPS,INDICATI,Investigative,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T96837,NIE,TARGETID,T96837,,
T96837,NIE,TARGNAME,Immunoglobulin gamma-1 heavy NIE (NIE),,
T96837,NIE,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T96837,NIE,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T96845,IL37,TARGETID,T96845,,
T96845,IL37,TARGNAME,Interleukin-37 (IL37),,
T96845,IL37,INDICATI,Approved,Psoriasis,[ICD-11: EA90]
,#N/A,,,,
T96876,COL7A1,TARGETID,T96876,,
T96876,COL7A1,TARGNAME,Collagen VII (COL7A1),,
T96876,COL7A1,INDICATI,Phase 3,Epidermolysis bullosa,[ICD-11: EC3Z]
,#N/A,,,,
T96892,MELK,TARGETID,T96892,,
T96892,MELK,TARGNAME,Maternal embryonic leucine zipper kinase (MELK),,
T96892,MELK,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T96892,MELK,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T96892,MELK,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T96892,MELK,INDICATI,Phase 1,Mature B-cell lymphoma,[ICD-11: 2A85]
T96892,MELK,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T96892,MELK,INDICATI,Phase 1,Myeloproliferative neoplasm,[ICD-11: 2A20]
,#N/A,,,,
T96894,LIFR,TARGETID,T96894,,
T96894,LIFR,TARGNAME,Leukemia inhibitory factor receptor (LIFR),,
T96894,LIFR,INDICATI,Phase 1/2,Male infertility,[ICD-11: GB04]
,#N/A,,,,
T96914,Malaria gyrase,TARGETID,T96914,,
T96914,Malaria gyrase,TARGNAME,Plasmodium DNA gyrase (Malaria gyrase),,
T96914,Malaria gyrase,INDICATI,Approved,Bacterial infection,[ICD-11: 1A00-1C4Z]
T96914,Malaria gyrase,INDICATI,Approved,Skin and skin-structure infection,[ICD-11: 1F28-1G0Z]
,#N/A,,,,
T96916,DKK3,TARGETID,T96916,,
T96916,DKK3,TARGNAME,Dickkopf-related protein 3 (DKK3),,
T96916,DKK3,INDICATI,Phase 1/2,Prostate cancer,[ICD-11: 2C82]
,#N/A,,,,
T97008,MAT2A,TARGETID,T97008,,
T97008,MAT2A,TARGNAME,S-adenosylmethionine synthase type-2 (MAT2A),,
T97008,MAT2A,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T97008,MAT2A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97035,TYR,TARGETID,T97035,,
T97035,TYR,TARGNAME,Tyrosinase (TYR),,
T97035,TYR,INDICATI,Approved,Acquired hypermelanosis,[ICD-11: ED60]
T97035,TYR,INDICATI,Approved,Acquired hypomelanotic disorder,[ICD-11: ED63]
T97035,TYR,INDICATI,Patented,Acquired melanotic macule/lentigine,[ICD-11: ED61]
T97035,TYR,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T97035,TYR,INDICATI,Patented,Mineral absorption/transport disorder,[ICD-11: 5C64]
T97035,TYR,INDICATI,Investigative,Rheumatoid arthritis,[ICD-11: FA20]
T97035,TYR,INDICATI,Patented,Skin pigmentation genetic disorder,[ICD-11: EC23]
,#N/A,,,,
T97036,AHSG,TARGETID,T97036,,
T97036,AHSG,TARGNAME,Connecting peptide (C-peptide),,
T97036,AHSG,INDICATI,Phase 2,Acute diabete complication,[ICD-11: 5A2Y]
,#N/A,,,,
T97071,FOLH1,TARGETID,T97071,,
T97071,FOLH1,TARGNAME,Glutamate carboxypeptidase II (GCPII),,
T97071,FOLH1,INDICATI,Phase 2,Adenocarcinoma,[ICD-11: 2D40]
T97071,FOLH1,INDICATI,Phase 1/2,Bladder cancer,[ICD-11: 2C94]
T97071,FOLH1,INDICATI,Phase 1/2,Cervical cancer,[ICD-11: 2C77]
T97071,FOLH1,INDICATI,Approved,Diagnostic imaging,[ICD-11: N.A.]
T97071,FOLH1,INDICATI,Phase 1,General pain disorder,[ICD-11: 8E43]
T97071,FOLH1,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
T97071,FOLH1,INDICATI,Investigative,Intracranial injury,[ICD-11: NA07]
T97071,FOLH1,INDICATI,Phase 1,Non-small-cell lung cancer,[ICD-11: 2C25]
T97071,FOLH1,INDICATI,Approved,Prostate cancer,[ICD-11: 2C82]
T97071,FOLH1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97111,CD37,TARGETID,T97111,,
T97111,CD37,TARGNAME,Leukocyte antigen CD37 (CD37),,
T97111,CD37,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T97111,CD37,INDICATI,Preclinical,Leukaemia,[ICD-11: 2A60-2B33]
T97111,CD37,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T97111,CD37,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T97111,CD37,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T97111,CD37,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97136,MKNK1,TARGETID,T97136,,
T97136,MKNK1,TARGNAME,MAPK signal-integrating kinase 1 (MKNK1),,
T97136,MKNK1,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T97136,MKNK1,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T97136,MKNK1,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T97136,MKNK1,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T97136,MKNK1,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97141,MYLK,TARGETID,T97141,,
T97141,MYLK,TARGNAME,Myosin light kinase (MYLK),,
T97141,MYLK,INDICATI,Phase 2,Duodenal ulcer,[ICD-11: DA63]
,#N/A,,,,
T97155,ATR,TARGETID,T97155,,
T97155,ATR,TARGNAME,Serine/threonine-protein kinase ATR (FRP1),,
T97155,ATR,INDICATI,Phase 2,Lung cancer,[ICD-11: 2C25]
T97155,ATR,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T97155,ATR,INDICATI,Phase 1,Mature B-cell leukaemia,[ICD-11: 2A82]
T97155,ATR,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97174,M6PR,TARGETID,T97174,,
T97174,M6PR,TARGNAME,Mannose-6-phosphate receptor (M6PR),,
T97174,M6PR,INDICATI,Approved,Inborn carbohydrate metabolism error,[ICD-11: 5C51]
,#N/A,,,,
T97196,ATM,TARGETID,T97196,,
T97196,ATM,TARGNAME,ATM serine/threonine kinase (ATM),,
T97196,ATM,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T97196,ATM,INDICATI,Clinical trial,Lung cancer,[ICD-11: 2C25]
T97196,ATM,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97257,TGFB1,TARGETID,T97257,,
T97257,TGFB1,TARGNAME,Transforming growth factor beta 1 (TGFB1),,
T97257,TGFB1,INDICATI,Phase 2/3,Arterial occlusive disease,[ICD-11: BD40]
T97257,TGFB1,INDICATI,Phase 1/2,Brain cancer,[ICD-11: 2A00]
T97257,TGFB1,INDICATI,Approved,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T97257,TGFB1,INDICATI,Discontinued in Phase 2,Lesion,[ICD-11: 8A00-8C12]
T97257,TGFB1,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T97257,TGFB1,INDICATI,Phase 2/3,Lung cancer,[ICD-11: 2C25]
T97257,TGFB1,INDICATI,Investigative,Osteoarthritis,[ICD-11: FA00-FA05]
T97257,TGFB1,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T97257,TGFB1,INDICATI,Phase 2,Retinopathy,[ICD-11: 9B71]
T97257,TGFB1,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
T97257,TGFB1,INDICATI,IND submitted,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T97257,TGFB1,INDICATI,Phase 1,Systemic sclerosis,[ICD-11: 4A42]
,#N/A,,,,
T97353,ITGA2-ITGB1,TARGETID,T97353,,
T97353,ITGA2-ITGB1,TARGNAME,Integrin alpha-2/beta-1 (ITGA2/B1),,
T97353,ITGA2-ITGB1,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T97353,ITGA2-ITGB1,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T97353,ITGA2-ITGB1,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97388,UPP1; UPP2,TARGETID,T97388,,
T97388,UPP1; UPP2,TARGNAME,Uridine phosphorylase (UPP),,
T97388,UPP1; UPP2,INDICATI,Investigative,Nasopharyngitis,[ICD-11: CA00]
,#N/A,,,,
T97413,BRS3,TARGETID,T97413,,
T97413,BRS3,TARGNAME,Bombesin-like receptor 3 (BRS3),,
T97413,BRS3,INDICATI,Investigative,Obesity,[ICD-11: 5B80-5B81]
,#N/A,,,,
T97553,#N/A,TARGETID,T97553,,
T97553,#N/A,TARGNAME,Serine/threonine-protein kinase (STK),,
T97553,#N/A,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T97553,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T97553,#N/A,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97587,ITGA4,TARGETID,T97587,,
T97587,ITGA4,TARGNAME,Integrin alpha-4 (ITGA4),,
T97587,ITGA4,INDICATI,Phase 2,Asthma,[ICD-11: CA23]
T97587,ITGA4,INDICATI,Phase 2,Cerebral ischaemic stroke,[ICD-11: 8B11]
T97587,ITGA4,INDICATI,Approved,Crohn disease,[ICD-11: DD70]
T97587,ITGA4,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T97587,ITGA4,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T97587,ITGA4,INDICATI,Phase 2,Indeterminate colitis,[ICD-11: DD72]
T97587,ITGA4,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T97587,ITGA4,INDICATI,Approved,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T97589,MAP3K5,TARGETID,T97589,,
T97589,MAP3K5,TARGNAME,Apoptosis signal-regulating kinase 1 (MAP3K5),,
T97589,MAP3K5,INDICATI,Phase 2,Chronic kidney disease,[ICD-11: GB61]
T97589,MAP3K5,INDICATI,Phase 2,Pulmonary hypertension,[ICD-11: BB01]
,#N/A,,,,
T97592,AURKC,TARGETID,T97592,,
T97592,AURKC,TARGNAME,Aurora kinase C (AURKC),,
T97592,AURKC,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T97592,AURKC,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T97592,AURKC,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97613,MTNR1A,TARGETID,T97613,,
T97613,MTNR1A,TARGNAME,Melatonin receptor type 1A (MTNR1A),,
T97613,MTNR1A,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T97613,MTNR1A,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T97613,MTNR1A,INDICATI,Terminated,Circadian rhythm sleep disorder,[ICD-11: 7A60-7A65]
T97613,MTNR1A,INDICATI,Phase 2,Dementia,[ICD-11: 6D80-6D8Z]
T97613,MTNR1A,INDICATI,Withdrawn from market,Depression,[ICD-11: 6A70-6A7Z]
T97613,MTNR1A,INDICATI,Approved,Insomnia,[ICD-11: 7A00-7A0Z]
T97613,MTNR1A,INDICATI,Terminated,Sleep-wake disorder,[ICD-11: 7A00-7B2Z]
,#N/A,,,,
T97617,#N/A,TARGETID,T97617,,
T97617,#N/A,TARGNAME,Sphingosine-1 phosphate receptor (S1PR),,
T97617,#N/A,INDICATI,Phase 2,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T97617,#N/A,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T97617,#N/A,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T97617,#N/A,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T97621,CFTR,TARGETID,T97621,,
T97621,CFTR,TARGNAME,cAMP-dependent chloride channel F508 deletion (CFTR del F508),,
T97621,CFTR,INDICATI,Approved,Cystic fibrosis,[ICD-11: CA25]
T97621,CFTR,INDICATI,Approved,Intrathoracic organs injury,[ICD-11: NB32]
,#N/A,,,,
T97632,Fung HOS2,TARGETID,T97632,,
T97632,Fung HOS2,TARGNAME,Fungal Probable histone deacetylase HOS2 (Fung HOS2),,
T97632,Fung HOS2,INDICATI,Phase 2,Candidosis,[ICD-11: 1F23]
,#N/A,,,,
T97655,ADCY2,TARGETID,T97655,,
T97655,ADCY2,TARGNAME,Adenylate cyclase type 2 (ADCY2),,
T97655,ADCY2,INDICATI,Investigative,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T97701,#N/A,TARGETID,T97701,,
T97701,#N/A,TARGNAME,Voltage-gated T-type calcium channel (T-CaC),,
T97701,#N/A,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T97701,#N/A,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T97701,#N/A,INDICATI,Phase 2,Tremor-related disorder,[ICD-11: 8A04]
,#N/A,,,,
T97713,PPAT,TARGETID,T97713,,
T97713,PPAT,TARGNAME,Amidophosphoribosyltransferase (PPAT),,
T97713,PPAT,INDICATI,Phase 4,Crohn disease,[ICD-11: DD70]
T97713,PPAT,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T97713,PPAT,INDICATI,Approved,Transplant rejection,[ICD-11: NE84]
,#N/A,,,,
T97719,#N/A,TARGETID,T97719,,
T97719,#N/A,TARGNAME,HUMAN bruton tyrosine kinase (BTK),,
T97719,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T97719,#N/A,INDICATI,Approved,Leukaemia,[ICD-11: 2A60-2B33]
,#N/A,,,,
T97725,#N/A,TARGETID,T97725,,
T97725,#N/A,TARGNAME,Virus Replication (Viru Repli),,
T97725,#N/A,INDICATI,Phase 3,Common warts,[ICD-11: 1E80]
T97725,#N/A,INDICATI,Phase 2,Herpes simplex infection,[ICD-11: 1F00]
T97725,#N/A,INDICATI,Phase 2,Influenza,[ICD-11: 1E30-1E32]
,#N/A,,,,
T97729,#N/A,TARGETID,T97729,,
T97729,#N/A,TARGNAME,HUMAN two pore channel subtype 2 (TPC2),,
T97729,#N/A,INDICATI,Phase 2/3,COVID-19,[ICD-11: 1D6Y]
T97729,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
T97729,#N/A,INDICATI,Approved,Ventricular tachyarrhythmia,[ICD-11: BC71]
,#N/A,,,,
T97740,PPT1,TARGETID,T97740,,
T97740,PPT1,TARGNAME,Palmitoyl-protein thioesterase 1 (PPT1),,
T97740,PPT1,INDICATI,Phase 1/2,Lysosomal disease,ICD-11: 5C56
T97740,PPT1,INDICATI,Phase 2,Mature T-cell lymphoma,[ICD-11: 2A90]
T97740,PPT1,INDICATI,Phase 3,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T97747,#N/A,TARGETID,T97747,,
T97747,#N/A,TARGNAME,HUMAN C-C chemokine receptor 5 (CCR5),,
T97747,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
T97752,EV VP24 mRNA,TARGETID,T97752,,
T97752,EV VP24 mRNA,TARGNAME,Ebola virus VP24 messenger RNA (EV VP24 mRNA),,
T97752,EV VP24 mRNA,INDICATI,Phase 1,Filovirus disease,[ICD-11: 1D60]
,#N/A,,,,
T97759,HCV NS1,TARGETID,T97759,,
T97759,HCV NS1,TARGNAME,Hepatitis C virus Envelope glycoprotein E2 (HCV NS1),,
T97759,HCV NS1,INDICATI,Phase 2,Hepatitis virus infection,[ICD-11: 1E50-1E51]
,#N/A,,,,
T97765,CCL3,TARGETID,T97765,,
T97765,CCL3,TARGNAME,Macrophage inflammatory protein 1-alpha (CCL3),,
T97765,CCL3,INDICATI,Phase 1,Transplanted organ/tissue,[ICD-11: QB63]
,#N/A,,,,
T97766,CD47,TARGETID,T97766,,
T97766,CD47,TARGNAME,Leukocyte surface antigen CD47 (CD47),,
T97766,CD47,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T97766,CD47,INDICATI,Phase 1,B-cell lymphoma,[ICD-11: 2A86]
T97766,CD47,INDICATI,Phase 1/2,Colorectal cancer,[ICD-11: 2B91]
T97766,CD47,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T97766,CD47,INDICATI,Phase 1,Leukaemia,[ICD-11: 2A60-2B33]
T97766,CD47,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T97766,CD47,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T97766,CD47,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T97766,CD47,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T97766,CD47,INDICATI,Phase 1,Mycosis fungoides,[ICD-11: 2B01]
T97766,CD47,INDICATI,Phase 3,Myelodysplastic syndrome,[ICD-11: 2A37]
T97766,CD47,INDICATI,Phase 1,Neuroendocrine carcinoma,[ICD-11: 2C34]
T97766,CD47,INDICATI,Phase 1,Non-small-cell lung cancer,[ICD-11: 2C25]
T97766,CD47,INDICATI,Phase 1/2,Ovarian cancer,[ICD-11: 2C73]
T97766,CD47,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T97766,CD47,INDICATI,Phase 1,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
T97766,CD47,INDICATI,Phase 2/3,Stomach cancer,ICD-11: 2B72
,#N/A,,,,
T97822,#N/A,TARGETID,T97822,,
T97822,#N/A,TARGNAME,Prostaglandin synthetase (PGS),,
T97822,#N/A,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
,#N/A,,,,
T97873,CCR9,TARGETID,T97873,,
T97873,CCR9,TARGNAME,C-C chemokine receptor type 9 (CCR9),,
T97873,CCR9,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T97873,CCR9,INDICATI,Phase 1,Sjogren syndrome,[ICD-11: 4A43]
T97873,CCR9,INDICATI,Phase 1,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T97917,FPR2,TARGETID,T97917,,
T97917,FPR2,TARGNAME,FMLP-related receptor I (FPR2),,
T97917,FPR2,INDICATI,Preclinical,Alzheimer disease,[ICD-11: 8A20]
,#N/A,,,,
T97947,GUCY2C,TARGETID,T97947,,
T97947,GUCY2C,TARGNAME,Guanylyl cyclase C (GUCY2C),,
T97947,GUCY2C,INDICATI,Approved,Chronic pancreatitis,[ICD-11: DC32]
T97947,GUCY2C,INDICATI,Phase 3,Crohn disease,[ICD-11: DD70]
T97947,GUCY2C,INDICATI,Approved,Irritable bowel syndrome,[ICD-11: DD91]
T97947,GUCY2C,INDICATI,Phase 2,Malignant digestive organ neoplasm,[ICD-11: 2C11]
T97947,GUCY2C,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T97947,GUCY2C,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T97982,#N/A,TARGETID,T97982,,
T97982,#N/A,TARGNAME,HUMAN cyclophilin D (CYP3),,
T97982,#N/A,INDICATI,Approved,Graft-versus-host disease,[ICD-11: 4B24]
T97982,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T97982,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T98015,#N/A,TARGETID,T98015,,
T98015,#N/A,TARGNAME,Sodium/potassium transport (Na/K trans),,
T98015,#N/A,INDICATI,Phase 3,Essential hypertension,[ICD-11: BA00]
,#N/A,,,,
T98022,CPB2,TARGETID,T98022,,
T98022,CPB2,TARGNAME,Carboxypeptidase B2 (CPB2),,
T98022,CPB2,INDICATI,Phase 1,Cerebral ischaemia,[ICD-11: 8B1Z]
T98022,CPB2,INDICATI,Phase 1,Cerebral ischaemic stroke,[ICD-11: 8B11]
T98022,CPB2,INDICATI,Phase 1,Thrombosis,[ICD-11: DB61-GB90]
,#N/A,,,,
T98034,CDK19,TARGETID,T98034,,
T98034,CDK19,TARGNAME,Cyclin-dependent kinase 19 (CDK19),,
T98034,CDK19,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T98034,CDK19,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
,#N/A,,,,
T98052,SLAMF7,TARGETID,T98052,,
T98052,SLAMF7,TARGNAME,SLAM family member 7 SLAMF7 (CS1),,
T98052,SLAMF7,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T98052,SLAMF7,INDICATI,Approved,Multiple myeloma,[ICD-11: 2A83]
T98052,SLAMF7,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T98062,PYGM,TARGETID,T98062,,
T98062,PYGM,TARGNAME,Glycogen phosphorylase muscle form (GP),,
T98062,PYGM,INDICATI,Phase 2,Metabolic disorder,[ICD-11: 5C50-5D2Z]
T98062,PYGM,INDICATI,Discontinued in Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T98091,GPR84,TARGETID,T98091,,
T98091,GPR84,TARGNAME,Inflammation-related GPCR EX33 (GPR84),,
T98091,GPR84,INDICATI,Phase 2,Idiopathic interstitial pneumonitis,[ICD-11: CB03]
T98091,GPR84,INDICATI,Phase 1,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T98092,#N/A,TARGETID,T98092,,
T98092,#N/A,TARGNAME,HUMAN cyclophilin A (CYPA),,
T98092,#N/A,INDICATI,Phase 3,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T98092,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T98092,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T98157,ARSA,TARGETID,T98157,,
T98157,ARSA,TARGNAME,Cerebroside-sulfatase (ARSA),,
T98157,ARSA,INDICATI,Approved,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T98179,COASY,TARGETID,T98179,,
T98179,COASY,TARGNAME,Phosphopantetheine adenylyltransferase (PPAT),,
T98179,COASY,INDICATI,Terminated,Bacterial infection,[ICD-11: 1A00-1C4Z]
,#N/A,,,,
T98196,MOCS1,TARGETID,T98196,,
T98196,MOCS1,TARGNAME,Cyclic pyranopterin monophosphate synthase (MOCS1),,
T98196,MOCS1,INDICATI,Phase 2/3,Mineral deficiency,[ICD-11: 5B5K]
,#N/A,,,,
T98234,MELTF,TARGETID,T98234,,
T98234,MELTF,TARGNAME,Melanotransferrin (MELTF),,
T98234,MELTF,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T98269,CASP1,TARGETID,T98269,,
T98269,CASP1,TARGNAME,Caspase-1 (CASP1),,
T98269,CASP1,INDICATI,Patented,Contact dermatitis,[ICD-11: EK00-EK0Z]
T98269,CASP1,INDICATI,Phase 2,Epilepsy/seizure,[ICD-11: 8A61-8A6Z]
T98269,CASP1,INDICATI,Phase 2,Fibrosis,[ICD-11: GA14-GC01]
T98269,CASP1,INDICATI,Patented,Fragrance/cosmetics phototoxic reaction,[ICD-11: EK20]
T98269,CASP1,INDICATI,Patented,Irritant contact dermatitis,[ICD-11: EK02]
T98269,CASP1,INDICATI,Phase 2,Rheumatoid arthritis,[ICD-11: FA20]
T98269,CASP1,INDICATI,Phase 2,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T98271,#N/A,TARGETID,T98271,,
T98271,#N/A,TARGNAME,HUMAN adaptor-associated kinase 1 (AAK1),,
T98271,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T98271,#N/A,INDICATI,Approved,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T98278,#N/A,TARGETID,T98278,,
T98278,#N/A,TARGNAME,HUMAN type-1 angiotensin II receptor (AGTR1),,
T98278,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T98278,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T98293,PAK4,TARGETID,T98293,,
T98293,PAK4,TARGNAME,PAK-4 protein kinase (PAK4),,
T98293,PAK4,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T98293,PAK4,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T98311,#N/A,TARGETID,T98311,,
T98311,#N/A,TARGNAME,HUMAN angiotensin-converting enzyme (ACE),,
T98311,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T98311,#N/A,INDICATI,Approved,Heart failure,[ICD-11: BD10-BD1Z]
T98311,#N/A,INDICATI,Approved,Hypertension,[ICD-11: BA00-BA04]
,#N/A,,,,
T98390,#N/A,TARGETID,T98390,,
T98390,#N/A,TARGNAME,HUMAN angiotensin-converting enzyme 2 (ACE2),,
T98390,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T98390,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T98397,TYMS,TARGETID,T98397,,
T98397,TYMS,TARGNAME,Thymidylate synthase (TYMS),,
T98397,TYMS,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T98397,TYMS,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T98430,IDUA,TARGETID,T98430,,
T98430,IDUA,TARGNAME,Alpha-L-iduronidase (IDUA),,
T98430,IDUA,INDICATI,Phase 1/2,Lysosomal disease,[ICD-11: 5C56]
,#N/A,,,,
T98494,GALR1; GALR2; GALR3,TARGETID,T98494,,
T98494,GALR1; GALR2; GALR3,TARGNAME,Galanin receptor (GAL-R),,
T98494,GALR1; GALR2; GALR3,INDICATI,Phase 1/2,Mild neurocognitive disorder,[ICD-11: 6D71]
,#N/A,,,,
T98642,PBK,TARGETID,T98642,,
T98642,PBK,TARGNAME,PDZ binding kinase (PBK),,
T98642,PBK,INDICATI,Investigative,Nasopharyngeal cancer,[ICD-11: 2B6B]
,#N/A,,,,
T98691,#N/A,TARGETID,T98691,,
T98691,#N/A,TARGNAME,HUMAN cathepsin L (CTSL),,
T98691,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T98691,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T98708,PTH,TARGETID,T98708,,
T98708,PTH,TARGNAME,Parathyroid hormone (PTH),,
T98708,PTH,INDICATI,Phase 2,Low bone mass disorder,[ICD-11: FB83]
T98708,PTH,INDICATI,Phase 2,Musculoskeletal system/connective tissue disease,[ICD-11: FC0Z]
T98708,PTH,INDICATI,Terminated,Parathyroid disease,[ICD-11: 5A50-5A5Z]
T98708,PTH,INDICATI,Discontinued in Phase 2,Psoriasis,[ICD-11: EA90]
T98708,PTH,INDICATI,Approved,Skeletal anomaly,[ICD-11: LD24]
,#N/A,,,,
T98798,SLC34A2,TARGETID,T98798,,
T98798,SLC34A2,TARGNAME,Sodium/phosphate cotransporter 2B (SLC34A2),,
T98798,SLC34A2,INDICATI,Phase 1/2,Lung cancer,[ICD-11: 2C25]
T98798,SLC34A2,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
,#N/A,,,,
T98896,ADAMTS5,TARGETID,T98896,,
T98896,ADAMTS5,TARGNAME,Aggrecanase (ADAMTS5),,
T98896,ADAMTS5,INDICATI,Phase 1,Osteoarthritis,[ICD-11: FA00-FA05]
,#N/A,,,,
T98906,#N/A,TARGETID,T98906,,
T98906,#N/A,TARGNAME,Polymerase unspecific (POL),,
T98906,#N/A,INDICATI,Discontinued in Phase 3,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T98913,CSF3R,TARGETID,T98913,,
T98913,CSF3R,TARGNAME,Granulocyte colony-stimulating factor receptor (G-CSF-R),,
T98913,CSF3R,INDICATI,Phase 2,Cardiovascular disease,[ICD-11: BA00-BE2Z]
T98913,CSF3R,INDICATI,Phase 1,Diabetes mellitus,[ICD-11: 5A10]
T98913,CSF3R,INDICATI,Investigative,Leukaemia,[ICD-11: 2A60-2B33]
T98913,CSF3R,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T98913,CSF3R,INDICATI,Approved,Neutropenia,[ICD-11: 4B00]
T98913,CSF3R,INDICATI,Phase 1,Pancreatic cancer,[ICD-11: 2C10]
T98913,CSF3R,INDICATI,Investigative,Postoperative inflammation,[ICD-11: 1A00-CA43]
T98913,CSF3R,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T98917,MRM2,TARGETID,T98917,,
T98917,MRM2,TARGNAME,Mitochondrial rRNA methyltransferase 2 (MRM2),,
T98917,MRM2,INDICATI,Approved,Bronchitis,[ICD-11: CA20]
T98917,MRM2,INDICATI,Phase 3,Pancreatic cancer,[ICD-11: 2C10]
T98917,MRM2,INDICATI,Approved,Prostate disease,[ICD-11: GA91]
T98917,MRM2,INDICATI,Approved,Urinary tract infection,[ICD-11: GC08]
,#N/A,,,,
T98933,THRB,TARGETID,T98933,,
T98933,THRB,TARGNAME,Thyroid hormone receptor beta (THRB),,
T98933,THRB,INDICATI,Approved,Hyper-lipoproteinaemia,[ICD-11: 5C80]
T98933,THRB,INDICATI,Phase 2,Hypo-thyroidism,[ICD-11: 5A00]
T98933,THRB,INDICATI,Phase 1,Inborn lipid metabolism error,[ICD-11: 5C52]
T98933,THRB,INDICATI,Phase 1,Peroxisomal disease,ICD-11: 5C57
T98933,THRB,INDICATI,Clinical trial,Skin postprocedural disorder,[ICD-11: EL8Y]
T98933,THRB,INDICATI,Investigative,Thyrotoxicosis,[ICD-11: 5A02]
,#N/A,,,,
T98945,#N/A,TARGETID,T98945,,
T98945,#N/A,TARGNAME,HUMAN dibasic-processing enzyme (Furin),,
T98945,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
,#N/A,,,,
T99009,#N/A,TARGETID,T99009,,
T99009,#N/A,TARGNAME,HUMAN dihydroorotate dehydrogenase (DHODH),,
T99009,#N/A,INDICATI,Phase 2/3,COVID-19,[ICD-11: 1D6Y]
T99009,#N/A,INDICATI,Preclinical,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T99009,#N/A,INDICATI,Approved,Multiple sclerosis,[ICD-11: 8A40]
T99009,#N/A,INDICATI,Preclinical,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T99031,#N/A,TARGETID,T99031,,
T99031,#N/A,TARGNAME,ERK activator kinase (MEK),,
T99031,#N/A,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T99031,#N/A,INDICATI,Phase 2,Phakomatoses/hamartoneoplastic syndrome,ICD-11: LD2D
T99031,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99041,#N/A,TARGETID,T99041,,
T99041,#N/A,TARGNAME,HUMAN dipeptidyl peptidase 4 (DPP-4),,
T99041,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T99041,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T99041,#N/A,INDICATI,Approved,Type 2 diabetes mellitus,[ICD-11: 5A11]
,#N/A,,,,
T99057,#N/A,TARGETID,T99057,,
T99057,#N/A,TARGNAME,HUMAN ERK activator kinase 1 (MEK1),,
T99057,#N/A,INDICATI,Approved,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T99057,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T99057,#N/A,INDICATI,Approved,Phakomatoses/hamartoneoplastic syndrome,[ICD-11: LD2D]
T99057,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T99089,BRAF,TARGETID,T99089,,
T99089,BRAF,TARGNAME,Serine/threonine-protein kinase B-raf (BRAF),,
T99089,BRAF,INDICATI,Approved,Melanoma,[ICD-11: 2C30]
T99089,BRAF,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99149,#N/A,TARGETID,T99149,,
T99149,#N/A,TARGNAME,HUMAN ERK activator kinase 2 (MEK2),,
T99149,#N/A,INDICATI,Approved,Metastatic tumour,[ICD-11: 2D50-2E2Z]
T99149,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T99149,#N/A,INDICATI,Approved,Phakomatoses/hamartoneoplastic syndrome,[ICD-11: LD2D]
T99149,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T99160,MKNK2,TARGETID,T99160,,
T99160,MKNK2,TARGNAME,MAP kinase signal-integrating kinase 2 (MKNK2),,
T99160,MKNK2,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T99160,MKNK2,INDICATI,Phase 2,Colorectal cancer,[ICD-11: 2B91]
T99160,MKNK2,INDICATI,Phase 2,Liver cancer,[ICD-11: 2C12]
T99160,MKNK2,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T99160,MKNK2,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99189,SLC10A1,TARGETID,T99189,,
T99189,SLC10A1,TARGNAME,Sodium/bile acid cotransporter (SLC10A1),,
T99189,SLC10A1,INDICATI,Phase 2,Autoimmune liver disease,[ICD-11: DB96]
T99189,SLC10A1,INDICATI,Phase 2,Gallbladder/bile ducts/liver structural developmental anomaly,[ICD-11: LB20]
T99189,SLC10A1,INDICATI,Approved,Hepatitis virus infection,[ICD-11: 1E50-1E51]
T99189,SLC10A1,INDICATI,Phase 2,Inborn porphyrin/heme metabolism error,[ICD-11: 5C58]
,#N/A,,,,
T99204,PSEN2,TARGETID,T99204,,
T99204,PSEN2,TARGNAME,Presenilin 2 (PSEN2),,
T99204,PSEN2,INDICATI,Preregistration,Osteoarthritis,[ICD-11: FA00-FA05]
T99204,PSEN2,INDICATI,Preregistration,Shoulder lesion,[ICD-11: FB53]
T99204,PSEN2,INDICATI,Preregistration,Soft tissue disorder,[ICD-11: FB56]
,#N/A,,,,
T99313,RGMA,TARGETID,T99313,,
T99313,RGMA,TARGNAME,Repulsive guidance molecule A (RGMA),,
T99313,RGMA,INDICATI,Phase 2,Multiple sclerosis,[ICD-11: 8A40]
T99313,RGMA,INDICATI,Phase 2,Spine/trunk injury,[ICD-11: ND51]
,#N/A,,,,
T99338,TMEM173,TARGETID,T99338,,
T99338,TMEM173,TARGNAME,Stimulator of interferon genes protein (TMEM173),,
T99338,TMEM173,INDICATI,Phase 2,Head and neck cancer,[ICD-11: 2D42]
T99338,TMEM173,INDICATI,Investigative,Inborn purine/pyrimidine/nucleotide metabolism error,[ICD-11: 5C55]
T99338,TMEM173,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T99338,TMEM173,INDICATI,Phase 1,Melanoma,[ICD-11: 2C30]
T99338,TMEM173,INDICATI,Phase 2,Metastatic lymph node neoplasm,[ICD-11: 2D60]
T99338,TMEM173,INDICATI,Phase 1/2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99340,RIPK1,TARGETID,T99340,,
T99340,RIPK1,TARGNAME,Receptor-interacting protein 1 (RIPK1),,
T99340,RIPK1,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T99340,RIPK1,INDICATI,Phase 2,Cutaneous lupus erythematosus,[ICD-11: EB50-EB5Z]
T99340,RIPK1,INDICATI,Investigative,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T99340,RIPK1,INDICATI,Phase 2,Motor neuron disease,[ICD-11: 8B60]
T99340,RIPK1,INDICATI,Phase 1,Nervous system paraneoplastic/autoimmune disorder,[ICD-11: 8E4A]
T99340,RIPK1,INDICATI,Investigative,Non-alcoholic fatty liver disease,[ICD-11: DB92]
T99340,RIPK1,INDICATI,Phase 1/2,Pancreatic cancer,[ICD-11: 2C10]
T99340,RIPK1,INDICATI,Preclinical,Postoperative inflammation,[ICD-11: 1A00-CA43]
T99340,RIPK1,INDICATI,Phase 2,Psoriasis,[ICD-11: EA90]
T99340,RIPK1,INDICATI,Phase 1,Rheumatoid arthritis,[ICD-11: FA20]
T99340,RIPK1,INDICATI,Phase 2,Ulcerative colitis,[ICD-11: DD71]
,#N/A,,,,
T99347,GRM5,TARGETID,T99347,,
T99347,GRM5,TARGNAME,Metabotropic glutamate receptor 5 (mGluR5),,
T99347,GRM5,INDICATI,Phase 1,Alzheimer disease,[ICD-11: 8A20]
T99347,GRM5,INDICATI,Phase 2,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T99347,GRM5,INDICATI,Phase 2,Autism spectrum disorder,[ICD-11: 6A02]
T99347,GRM5,INDICATI,Investigative,Central nervous system disease,[ICD-11: 8A04-8D87]
T99347,GRM5,INDICATI,Discontinued in Phase 2,Chronic pain,[ICD-11: MG30]
T99347,GRM5,INDICATI,Discontinued in Phase 2,Depression,[ICD-11: 6A70-6A7Z]
T99347,GRM5,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T99347,GRM5,INDICATI,Phase 2/3,Fragile X chromosome,[ICD-11: LD55]
T99347,GRM5,INDICATI,Patented,Gastro-oesophageal reflux disease,[ICD-11: DA22]
T99347,GRM5,INDICATI,Terminated,General pain disorder,[ICD-11: 8E43]
T99347,GRM5,INDICATI,Terminated,Migraine,[ICD-11: 8A80]
T99347,GRM5,INDICATI,Phase 2,Mood disorder,[ICD-11: 6A60-6E23]
T99347,GRM5,INDICATI,Phase 2/3,Parkinsonism,[ICD-11: 8A00]
T99347,GRM5,INDICATI,Phase 1,Schizophrenia,[ICD-11: 6A20]
T99347,GRM5,INDICATI,Phase 1,Sensation disturbance,[ICD-11: MB40]
T99347,GRM5,INDICATI,Phase 2,Tonus and reflex abnormality,[ICD-11: MB47]
,#N/A,,,,
T99379,THPO,TARGETID,T99379,,
T99379,THPO,TARGNAME,Thrombopoietin (THPO),,
T99379,THPO,INDICATI,Phase 1,Ischaemic/haemorrhagic stroke,[ICD-11: 8B20]
T99379,THPO,INDICATI,Phase 1,Myocardial infarction,[ICD-11: BA41-BA43]
T99379,THPO,INDICATI,IND submitted,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T99394,TNFRSF13B,TARGETID,T99394,,
T99394,TNFRSF13B,TARGNAME,Transmembrane activator and CAML interactor (TNFRSF13B),,
T99394,TNFRSF13B,INDICATI,Phase 1/2,Multiple myeloma,[ICD-11: 2A83]
,#N/A,,,,
T99397,VDAC1,TARGETID,T99397,,
T99397,VDAC1,TARGNAME,Voltage-dependent anion-selective channel 1 (VDAC1),,
T99397,VDAC1,INDICATI,Phase 2,Epidermal dysplasias,[ICD-11: EK90]
,#N/A,,,,
T99402,GRM4,TARGETID,T99402,,
T99402,GRM4,TARGNAME,Metabotropic glutamate receptor 4 (mGluR4),,
T99402,GRM4,INDICATI,Investigative,Anxiety disorder,[ICD-11: 6B00-6B0Z]
T99402,GRM4,INDICATI,Investigative,Dissociative neurological symptom disorder,[ICD-11: 6B60]
T99402,GRM4,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
,#N/A,,,,
T99455,#N/A,TARGETID,T99455,,
T99455,#N/A,TARGNAME,HUMAN fusion protein Bcr-Abl (Bcr-Abl),,
T99455,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T99455,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T99455,#N/A,INDICATI,Approved,Myeloproliferative neoplasm,[ICD-11: 2A20]
T99455,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T99524,TAAR1,TARGETID,T99524,,
T99524,TAAR1,TARGNAME,Trace amine-associated receptor-1 (TAAR1),,
T99524,TAAR1,INDICATI,Approved,Attention deficit hyperactivity disorder,[ICD-11: 6A05]
T99524,TAAR1,INDICATI,Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T99524,TAAR1,INDICATI,Approved,Focal/segmental autonomic disorder,[ICD-11: 8D8A]
T99524,TAAR1,INDICATI,Approved,Narcolepsy,[ICD-11: 7A20]
T99524,TAAR1,INDICATI,Phase 2,Parkinsonism,[ICD-11: 8A00]
T99524,TAAR1,INDICATI,Phase 3,Schizophrenia,[ICD-11: 6A20]
,#N/A,,,,
T99557,TRBC1,TARGETID,T99557,,
T99557,TRBC1,TARGNAME,T-cell receptor beta constant 1 (TRBC1),,
T99557,TRBC1,INDICATI,Phase 1/2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T99557,TRBC1,INDICATI,Phase 1/2,Mature T-cell lymphoma,[ICD-11: 2A90]
,#N/A,,,,
T99566,#N/A,TARGETID,T99566,,
T99566,#N/A,TARGNAME,Free radical (FRD),,
T99566,#N/A,INDICATI,Phase 1,Brain cancer,[ICD-11: 2A00]
T99566,#N/A,INDICATI,Phase 3,Ischemia,[ICD-11: 8B10-8B11]
T99566,#N/A,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T99566,#N/A,INDICATI,Phase 2,Lymphoma,[ICD-11: 2A80-2A86]
T99566,#N/A,INDICATI,Phase 2,Ovarian cancer,[ICD-11: 2C73]
T99566,#N/A,INDICATI,Phase 2/3,Pancreatic cancer,[ICD-11: 2C10]
T99566,#N/A,INDICATI,Phase 2,Prostate cancer,[ICD-11: 2C82]
T99566,#N/A,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T99566,#N/A,INDICATI,Phase 2,Stomach cancer,[ICD-11: 2B72]
,#N/A,,,,
T99582,#N/A,TARGETID,T99582,,
T99582,#N/A,TARGNAME,HUMAN interleukin 6 (IL6),,
T99582,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T99582,#N/A,INDICATI,Approved,Idiopathic multicentric Castlemans disease,[ICD-11: 2A81]
T99582,#N/A,INDICATI,Phase 3,Rheumatoid arthritis,[ICD-11: FA20]
,#N/A,,,,
T99616,Trypano TPR,TARGETID,T99616,,
T99616,Trypano TPR,TARGNAME,Trypanosoma Trypanothione reductase (Trypano TPR),,
T99616,Trypano TPR,INDICATI,Investigative,Kinetoplastids,[ICD-11: 1F61-1G2Z]
T99616,Trypano TPR,INDICATI,Approved,Light sensitivity impairment,[ICD-11: 9D45]
T99616,Trypano TPR,INDICATI,Approved,Thrombocytopenia,[ICD-11: 3B64]
,#N/A,,,,
T99641,ALDH1A1; ALDH2; ALDH1B1,TARGETID,T99641,,
T99641,ALDH1A1; ALDH2; ALDH1B1,TARGNAME,Acetaldehyde dehydrogenase (ALDH),,
T99641,ALDH1A1; ALDH2; ALDH1B1,INDICATI,Approved,Substance abuse,[ICD-11: 6C40]
,#N/A,,,,
T99685,#N/A,TARGETID,T99685,,
T99685,#N/A,TARGNAME,HUMAN mammalian target of rapamycin (mTOR),,
T99685,#N/A,INDICATI,Approved,Advanced/metastatic breast cancer,[ICD-11: 2C60]
T99685,#N/A,INDICATI,Phase 2,Breast cancer,[ICD-11: 2C60-2C6Y]
T99685,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T99685,#N/A,INDICATI,Approved,Lymphangioleiomyomatosis,[ICD-11: CB07]
T99685,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T99685,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T99704,VSIR,TARGETID,T99704,,
T99704,VSIR,TARGNAME,V-set immunoregulatory receptor (VSIR),,
T99704,VSIR,INDICATI,Phase 1,Lymphoma,[ICD-11: 2A80-2A86]
T99704,VSIR,INDICATI,Phase 1,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99727,#N/A,TARGETID,T99727,,
T99727,#N/A,TARGNAME,Hyperpolarization cyclic nucleotide-gated channel (HCN),,
T99727,#N/A,INDICATI,Approved,Angina pectoris,[ICD-11: BA40]
T99727,#N/A,INDICATI,Phase 1,Cardiac arrhythmia,[ICD-11: BC9Z]
T99727,#N/A,INDICATI,Phase 2,Pain,[ICD-11: MG30-MG3Z]
,#N/A,,,,
T99732,FGF18,TARGETID,T99732,,
T99732,FGF18,TARGNAME,Fibroblast growth factor-18 (FGF18),,
T99732,FGF18,INDICATI,Phase 2,Arthropathy,[ICD-11: FA11-FA5Z]
,#N/A,,,,
T99740,MYB,TARGETID,T99740,,
T99740,MYB,TARGNAME,Myb messenger RNA (MYB mRNA),,
T99740,MYB,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
,#N/A,,,,
T99765,SUMO1; SUMO2; SUMO3; SUMO4; SUMO1P1,TARGETID,T99765,,
T99765,SUMO1; SUMO2; SUMO3; SUMO4; SUMO1P1,TARGNAME,Small ubiquitin-related modifier (SUMO),,
T99765,SUMO1; SUMO2; SUMO3; SUMO4; SUMO1P1,INDICATI,Preclinical,Acute myeloid leukaemia,[ICD-11: 2A60]
,#N/A,,,,
T99799,BCHE,TARGETID,T99799,,
T99799,BCHE,TARGNAME,Cholinesterase (BCHE),,
T99799,BCHE,INDICATI,Phase 3,Alzheimer disease,[ICD-11: 8A20]
T99799,BCHE,INDICATI,Phase 1,Eexposure to noxious substances harmful effect,[ICD-11: NE61]
T99799,BCHE,INDICATI,Phase 3,Mild neurocognitive disorder,[ICD-11: 6D71]
T99799,BCHE,INDICATI,Approved,Pain,[ICD-11: MG30-MG3Z]
T99799,BCHE,INDICATI,Approved,Tonus and reflex abnormality,[ICD-11: MB47]
T99799,BCHE,INDICATI,Investigative,Toxicity,[ICD-11: N.A.]
T99799,BCHE,INDICATI,Investigative,Unspecific substance harmful effect,[ICD-11: NE6Z]
,#N/A,,,,
T99816,GRPR,TARGETID,T99816,,
T99816,GRPR,TARGNAME,Gastrin-releasing peptide receptor (GRPR),,
T99816,GRPR,INDICATI,Phase 1,Breast cancer,[ICD-11: 2C60-2C6Y]
T99816,GRPR,INDICATI,Phase 2,Irritable bowel syndrome,[ICD-11: DD91]
T99816,GRPR,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99818,#N/A,TARGETID,T99818,,
T99818,#N/A,TARGNAME,HUMAN sodium pump subunit alpha-1 (ATP1A1),,
T99818,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
,#N/A,,,,
T99834,#N/A,TARGETID,T99834,,
T99834,#N/A,TARGNAME,HUMAN toll-like receptor 3 (TLR3),,
T99834,#N/A,INDICATI,Phase 1/2,COVID-19,[ICD-11: 1D6Y]
T99834,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T99834,#N/A,INDICATI,phase 3,Postviral fatigue syndrome,[ICD-11: 8E49]
,#N/A,,,,
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,TARGETID,T99840,,
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,TARGNAME,Gamma-secretase (GS),,
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Phase 2,Alzheimer disease,[ICD-11: 8A20]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Discontinued in Phase 2,Asthma,[ICD-11: CA23]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Approved,Desmoid tumour,[ICD-11: 2F7C]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Phase 3,General pain disorder,[ICD-11: 8E43]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Phase 2,Mild neurocognitive disorder,[ICD-11: 6D71]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Phase 1,Mineral absorption/transport disorder,[ICD-11: 5C64]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Preregistration,Osteoarthritis,[ICD-11: FA00-FA05]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Phase 3,Parkinsonism,[ICD-11: 8A00]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Preclinical,Sexual dysfunction,[ICD-11: HA00-HA01]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Preregistration,Shoulder lesion,[ICD-11: FB53]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Preregistration,Soft tissue disorder,[ICD-11: FB56]
T99840,APH1A; APH1B; NCSTN; PSENEN; PSEN1,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99884,#N/A,TARGETID,T99884,,
T99884,#N/A,TARGNAME,HUMAN toll-like receptor 7/9 signalling pathway (TLR7/9 pathway),,
T99884,#N/A,INDICATI,Phase 3,COVID-19,[ICD-11: 1D6Y]
T99884,#N/A,INDICATI,Approved,Malaria,[ICD-11: 1F40-1F45]
,#N/A,,,,
T99907,#N/A,TARGETID,T99907,,
T99907,#N/A,TARGNAME,Human immunodeficiency virus Maturation (HIV Mat),,
T99907,#N/A,INDICATI,Phase 2,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
,#N/A,,,,
T99908,#N/A,TARGETID,T99908,,
T99908,#N/A,TARGNAME,HUMAN transmembrane protease serine 2 (TMPRSS2),,
T99908,#N/A,INDICATI,Phase 2,COVID-19,[ICD-11: 1D6Y]
T99908,#N/A,INDICATI,Investigative,Middle East Respiratory Syndrome,[ICD-11: 1D64]
T99908,#N/A,INDICATI,Investigative,Severe acute respiratory syndrome,[ICD-11: 1D65]
,#N/A,,,,
T99909,HSPA9,TARGETID,T99909,,
T99909,HSPA9,TARGNAME,Mortalin (HSPA9),,
T99909,HSPA9,INDICATI,Phase 2,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99912,KYNU,TARGETID,T99912,,
T99912,KYNU,TARGNAME,Kynureninase (KYNU),,
T99912,KYNU,INDICATI,Preclinical,Bacterial infection,[ICD-11: 1A00-1C4Z]
T99912,KYNU,INDICATI,Preclinical,Breast cancer,[ICD-11: 2C60-2C6Y]
,#N/A,,,,
T99935,#N/A,TARGETID,T99935,,
T99935,#N/A,TARGNAME,GPCR unspecific (GPCR),,
T99935,#N/A,INDICATI,Terminated,Alzheimer disease,[ICD-11: 8A20]
T99935,#N/A,INDICATI,Discontinued in Phase 1,Depression,[ICD-11: 6A70-6A7Z]
T99935,#N/A,INDICATI,Discontinued in Phase 1,Functional bladder disorder,[ICD-11: GC50]
T99935,#N/A,INDICATI,Discontinued in Phase 1,Nausea/vomiting,[ICD-11: MD90]
T99935,#N/A,INDICATI,Terminated,Prostate hyperplasia,[ICD-11: GA90]
T99935,#N/A,INDICATI,Discontinued in Phase 2,Sexual dysfunction,[ICD-11: HA00-HA01]
,#N/A,,,,
T99948,CD274,TARGETID,T99948,,
T99948,CD274,TARGNAME,Programmed cell death 1 ligand 1 (PD-L1),,
T99948,CD274,INDICATI,Phase 1,Acute myeloid leukaemia,[ICD-11: 2A60]
T99948,CD274,INDICATI,Phase 2,Biliary tract cancer,[ICD-11: 2C17]
T99948,CD274,INDICATI,Phase 3,Bladder cancer,[ICD-11: 2C94]
T99948,CD274,INDICATI,Phase 2,Brain cancer,[ICD-11: 2A00]
T99948,CD274,INDICATI,Phase 3,Breast cancer,[ICD-11: 2C60-2C6Y]
T99948,CD274,INDICATI,Phase 3,Colon cancer,[ICD-11: 2B90]
T99948,CD274,INDICATI,Phase 1,Colorectal cancer,[ICD-11: 2B91]
T99948,CD274,INDICATI,Phase 2,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T99948,CD274,INDICATI,Phase 1,Follicular lymphoma,[ICD-11: 2A80]
T99948,CD274,INDICATI,Phase 3,Head and neck cancer,[ICD-11: 2D42]
T99948,CD274,INDICATI,Phase 1,Human immunodeficiency virus disease,[ICD-11: 1C60-1C62]
T99948,CD274,INDICATI,Patented,Inflammatory liver disease,[ICD-11: DB97]
T99948,CD274,INDICATI,Phase 3,Liver cancer,[ICD-11: 2C12]
T99948,CD274,INDICATI,Phase 3,Lung cancer,[ICD-11: 2C25]
T99948,CD274,INDICATI,Phase 1/2,Lymphoma,[ICD-11: 2A80-2A86]
T99948,CD274,INDICATI,Phase 1,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T99948,CD274,INDICATI,Phase 3,Mature T-cell lymphoma,ICD-11: 2A90
T99948,CD274,INDICATI,Phase 3,Melanoma,[ICD-11: 2C30]
T99948,CD274,INDICATI,Phase 1,Multiple myeloma,[ICD-11: 2A83]
T99948,CD274,INDICATI,Phase 1,Myelodysplastic syndrome,[ICD-11: 2A37]
T99948,CD274,INDICATI,Phase 3,Nasopharyngeal cancer,[ICD-11: 2B6B]
T99948,CD274,INDICATI,Approved,Neuroendocrine carcinoma,[ICD-11: 2C34]
T99948,CD274,INDICATI,Approved,Non-small-cell lung cancer,[ICD-11: 2C25]
T99948,CD274,INDICATI,Phase 3,Ovarian cancer,[ICD-11: 2C73]
T99948,CD274,INDICATI,Phase 2,Pancreatic cancer,[ICD-11: 2C10]
T99948,CD274,INDICATI,Phase 2,Pleomorphic sarcoma,[ICD-11: 2B54]
T99948,CD274,INDICATI,Patented,Postoperative inflammation,[ICD-11: 1A00-CA43]
T99948,CD274,INDICATI,Phase 3,Prostate cancer,[ICD-11: 2C82]
T99948,CD274,INDICATI,Phase 3,Renal cell carcinoma,[ICD-11: 2C90]
T99948,CD274,INDICATI,Approved,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
T99948,CD274,INDICATI,Phase 3,Squamous cell carcinoma,[ICD-11: 2B60-2D01]
T99948,CD274,INDICATI,Phase 3,Stomach cancer,[ICD-11: 2B72]
T99948,CD274,INDICATI,Phase 2,Testicular cancer,[ICD-11: 2C80]
T99948,CD274,INDICATI,Phase 0,Ulcer,[ICD-11: CA02-CB40]
T99948,CD274,INDICATI,Approved,Ureteral cancer,[ICD-11: 2C92]
,#N/A,,,,
T99954,PTGIR,TARGETID,T99954,,
T99954,PTGIR,TARGNAME,Prostacyclin receptor (PTGIR),,
T99954,PTGIR,INDICATI,Approved,Abortion,[ICD-11: JA00]
T99954,PTGIR,INDICATI,Discontinued in Phase 3,Arterial occlusive disease,[ICD-11: BD40]
T99954,PTGIR,INDICATI,Discontinued in Preregistration,Asthma,[ICD-11: CA23]
T99954,PTGIR,INDICATI,Discontinued in Phase 3,Chronic kidney disease,[ICD-11: GB61]
T99954,PTGIR,INDICATI,Phase 4,Coronary atherosclerosis,[ICD-11: BA80]
T99954,PTGIR,INDICATI,Phase 3,Gout,[ICD-11: FA25]
T99954,PTGIR,INDICATI,Discontinued in Phase 2,Hypertension,[ICD-11: BA00-BA04]
T99954,PTGIR,INDICATI,Approved,Pulmonary hypertension,[ICD-11: BB01]
T99954,PTGIR,INDICATI,Terminated,Solid tumour/cancer,[ICD-11: 2A00-2F9Z]
,#N/A,,,,
T99989,CSNK1E,TARGETID,T99989,,
T99989,CSNK1E,TARGNAME,Casein kinase I epsilon (CSNK1E),,
T99989,CSNK1E,INDICATI,Phase 2/3,Diffuse large B-cell lymphoma,[ICD-11: 2A81]
T99989,CSNK1E,INDICATI,Approved,Follicular lymphoma,[ICD-11: 2A80]
T99989,CSNK1E,INDICATI,Phase 2,Malignant haematopoietic neoplasm,[ICD-11: 2B33]
T99989,CSNK1E,INDICATI,Phase 2,Mature B-cell leukaemia,[ICD-11: 2A82]
T99989,CSNK1E,INDICATI,Approved,Mature B-cell lymphoma,[ICD-11: 2A85]
T99989,CSNK1E,INDICATI,Preclinical,Pancreatic cancer,[ICD-11: 2C10]
,#N/A,,,,
T99993,#N/A,TARGETID,T99993,,
T99993,#N/A,TARGNAME,HUMAN vascular endothelial growth factor (VEGF),,
T99993,#N/A,INDICATI,Approved,Colorectal cancer,[ICD-11: 2B91]
T99993,#N/A,INDICATI,Phase 2/3,COVID-19,[ICD-11: 1D6Y]
,#N/A,,,,
,#N/A,,,,
